<SEC-DOCUMENT>0001739614-20-000014.txt : 20201113
<SEC-HEADER>0001739614-20-000014.hdr.sgml : 20201113
<ACCEPTANCE-DATETIME>20201113160924
ACCESSION NUMBER:		0001739614-20-000014
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201113
DATE AS OF CHANGE:		20201113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inhibrx, Inc.
		CENTRAL INDEX KEY:			0001739614
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				824257312
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39452
		FILM NUMBER:		201311564

	BUSINESS ADDRESS:	
		STREET 1:		11025 N. TORREY PINES ROAD, SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 795-4220

	MAIL ADDRESS:	
		STREET 1:		11025 N. TORREY PINES ROAD, SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>inhibrx-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:3fe0b274-dc64-47fa-9492-4cc4ecb00ef6,g:c0dac7ab-748b-42c9-8c2a-26a240098d0f,d:ee91b9a90f804077b237584160b9370a--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:inhibrx="http://inhibrx.namespace.com/20200930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>inhibrx-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY18xLTEtMS0xLTc4OA_5be7b270-7ee0-45ca-b6a8-202f82209faa">12/31</ix:nonNumeric><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY18yLTEtMS0xLTc4OA_20f0d45c-acd4-4066-8577-8955ac584e05">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY18zLTEtMS0xLTc4OA_6ebcfff2-568e-4446-9d92-bc0e9a81af0a">0001739614</ix:nonNumeric><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY180LTEtMS0xLTc4OA_2fc9ae49-b572-4d0b-acdb-927b9660b023">2020</ix:nonNumeric><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY181LTEtMS0xLTc4OA_f0d801b4-c0bb-4fb1-ae18-85cfebdb0705">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ifba32dd833574402ada1e36890f6561a_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i6f274e94611f454abf5e4027b0746f28_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i6fe512cd41a649b5b6c7acf1a99ef3f0_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430">P4Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie5731faed81f4f03a3bb8f76c85c0064_D20200811-20200811" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xNDc5L2ZyYWc6N2NjYzIwNDk2MDc0NGYwM2E2MjRkNDJiMzZjNzFjODEvdGFibGU6ZjkxNjViMDk3MjI5NDdkMWE2YzQ5M2IzOWM5YTQxYTkvdGFibGVyYW5nZTpmOTE2NWIwOTcyMjk0N2QxYTZjNDkzYjM5YzlhNDFhOV8xLTEtMS0xLTgzMzI_8ffe4950-368f-4f15-884d-470636e92803">0.5753</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="inhibrx-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idbf3661972cb42c9b5609ea4cbd7cb26_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1a502282910747c9aac74a5847fac525_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2815584d6b3449bae058364571557b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2eec07eda2401383326e716774ff76_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieadc553907f04aea9984cc210e0af52f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17fce0905feb4ca0a6d436f23bdb5a51_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic597294d6b05480f9b87cfc8e153db62_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8caa9dd3e98483facac392f2f26d651_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820a8e2822d74bbd82ecbf86ba928b9c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34e5f2d63b64f9ab8bdc6574f9e7285_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000ce15b89d840528ca0541bc84717e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac975841c0c4eee8d4575323136a11b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f21270f21874db1b0bbfb358bb4a78a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d17755e65848568a5814eb7e92fa96_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603a3e22a39e4c3f84a33bd10c4b7461_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb47a5672584355b7d05652419f4135_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8c696851984b19adde3434ae473fe3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846daf89fc2b40ff9276e0309f8bc49b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15a549f5d7c49ba8413651379bcbb4b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b03bb902a94c8785ee943f02414084_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5228ec7bd82b4d18aa5c78ca560be27f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab8209e132d4d49885fdd7a39a220b4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6aba7f28dc64367a0eece71a35d9fb9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad3866ecff24d2bb1c1621c08c1e65d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0a954ba6d54755911e36150df70447_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ac8459a45944d89bd8d8c502750883_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43ea9fc9a3749ca8aec69153be4824b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e3380af6394476b9fb41f80b54569d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72f396661b64960a85d478129870552_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eee8e0a5aa64149a5e9678da896aa09_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2e22b91c8f4c61bc620f632b4e3aa3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868602c6c8094dfe8c35ccb6d3bf5389_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c3d1c7115344cf87b4e8072fb23023_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e8f3fe84bb4c7c80b0765347fb47fe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia490249b50314ffeb9819be68dddeff5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfaf63fd5be43bd94a1aa0e5f1b9ed8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59bd56e946e5445bae234daf9abde8e6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968c5b21c23d497c885a34db4e9dcc82_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93804641103b457fad36e34238434091_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80eeafcebb44eda80d0e0ab4cb21502_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6437dc22b9a1413a83a988950e6b212f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b810262bba4b218699272e9d863800_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad639b97919472cb19836f0f20c8578_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5b516dbf8534c51a8a187a321b5ff02_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17c4099b42e47cdb2c7b8aaaa29181c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb446db2851407d98c475b4a9496a9b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fd70b3e3724e78bbd68fad24152716_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib639469f8e6f46fe9e906ab1f8a23c3c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c148e447dd4a72b3fb1401d56a109a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i832575ad734f4ac68adc394981e0dd95_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3ee615da3341d98188126debd31173_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33fdbec7cbe14bb58d66b46ff6a32efb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aba2096009b41df80c66bfd01ec2c58_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad87a43bcfd47718c0aa0291e455eef_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2000034bdf45109c782f320cd6a01d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dacf172bede47d8a24654bfb96d5b2e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f99f3c856b4015a5874dbe44c7d459_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8760e90a1ba450cadb660bb033f985c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf47f3d3e3c429eb534fb4774e9f5cf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i935c025cf0be4f52aa328da8cd08cdbc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73dbd07a8a064245beef5a5cd1785fc5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa3b845869d4942a592437637e60ccb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d63e6b69ff48ee80954424e39ed256_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae97d8956ab04cc2adbd33a7853f81d6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e35846453d49108af294a83527115a_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716fae2ef5ce4494a59333e61122850c_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e5ed6c9480459caa6ba643143e71bb_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e33ca65d2942a182ef960398078928_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8dadc7ef039420eaa7b0c92264e86ca_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba32dd833574402ada1e36890f6561a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3feb5c4ab8444992aad253b0eb3aac6c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f274e94611f454abf5e4027b0746f28_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31329f709cd646a1985943678e052e84_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe512cd41a649b5b6c7acf1a99ef3f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b2ff8ae24b4a848877e3577572b4fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>inhibrx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i678ba84787b74c33aaa1dabda2391b12_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97607866f6cc41cc94cca89d10cf6bdc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dbaed7d7d47475091f2e4ab91488da7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c38f2ed7fa44b4a81fe1f1eed88df2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica2104115bc94b9fa8ac3b4e7d8a5952_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inhibrx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f268e0f7dca45f9b9332914738e6f74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac814f782c3b45af984e9c168fd5b2c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9257d69f32004657829030276365dab2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inhibrx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34eb3903a88c4cf4a2c174b773b1619b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d33748b115443b382ab613199d390b0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i853b5ffb64fa4b6c9270743f860795a1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inhibrx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48577e54c534c9cb159d018b57d9192_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ac33289ae142bd80d836a856c99abf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ce0cd624534b4fb3a651217b134e1e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b460d94a844e52ade7a0f2b9ab1b9f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0f30e90da64a8baa297d499a8884ff_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbde3532e59e43b4a2a437f33e108ffd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06bcfbe172b34cf880f671de4e455fd8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f7d4dd51b19431eb1b4a19269978732_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced870049b9c4af8a2a71c8e3372f3bd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34ba14de47a44d4bbeebf803e29fcda_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6dd439011c4044a8417377d85ed8ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>inhibrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie5731faed81f4f03a3bb8f76c85c0064_D20200811-20200811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7dd225fb7244d46a1448835a24eedc8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4771026d5c3c40319d148f5c1fcdb3cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099bcc18560648f6b4af3ed81b2359f0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc99fb23a741432181c70887a43007ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55cc14d646e5495391d1f2b7134f4a82_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575d68e93bc24286964f7a4a6a71af6d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f581b24f01849d48dc4babb1fee7e16_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa0ca10369144789935f71aa0d4b1c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6863d5d7e63541b0a3f1be858bc15d80_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1492990af4cd4609ab13680229c0d787_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2dbb72e83b64adc8434cf549fd94175_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12196a7c26a24c34983264cd528c02a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2e8e28f6944a6cad3e341eddbd124d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a938740c8f41d98cdd5977f98ba01d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="loan"><xbrli:measure>inhibrx:loan</xbrli:measure></xbrli:unit><xbrli:context id="i73adcaf6ee1947b18f6562d5ec941caf_I20150315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1128b89e97354edab268af53bdbb2cfc_I20150315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968d197dbe54493980d0c6601895286d_I20150315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedc8c75d167c4002ae62b4656fc8dc96_I20150315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc18af2d45e5429aa46b9f3c1c60dacf_I20150315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if717d2bbf6df424fbf967687e556c917_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a2211031b8411a97f1eedd40de2aea_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bd4629e345403594bc83286802f27d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib431edb342fd4664ae233fef94fbc459_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inhibrx:ProfitInterestUnitPIUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-15</xbrli:startDate><xbrli:endDate>2015-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44998013bed488a89c12a2bbbf5d413_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inhibrx:ProfitInterestUnitPIUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b1864cd5ba4d82ad35132d3bf4651c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5bfebe16ba4d42b9420939d6abd37e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if576809f1ef74d2dae834e212f4c787a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b1c64897a0450b8b676d88f5779c65_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id069de05c44b419a8bc04341e87faf34_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-15</xbrli:startDate><xbrli:endDate>2020-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifab34d6750ef4bf6b880aa50a8da757b_D20200715-20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-15</xbrli:startDate><xbrli:endDate>2020-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802d90f694e04e9cbc8a950326d54eca_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i080025cf9ef84898b13a4a46dd987fa0_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fc4b9c1f869452c886e27fd8cb739ca_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2314b9fb755947e4ab7ad70f16e7a771_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0a3edbbf394e39ac9b8b95852e4df9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515b22595f7847ed9dff1e886916e38f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2815bc314c46819698b119c61f9104_D20200511-20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-11</xbrli:startDate><xbrli:endDate>2020-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4662b14824724021a2692a483eecb043_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41bc12ffbb534f18a23e536d4dde5a2c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818e609617104ca8b6c8c4969ac1e906_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26693951deed4303a7da2ddadc8ee05f_I20190520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77d30165eef43de82b4519b6e11aabd_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5faa4978633f459b997f876d04a34424_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80dd5d72484a4344aea558884246a977_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bbe316909104cd2b78167b976ed7a0b_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32241f5d4454450aa87c2b3c1c404b87_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83317f913e354c4c8e1ec68bfd7bd8e5_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181595e7e07c4d178483c8e330544e15_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60dcc587e93f4a8496bb9b4c5c8fe5fb_I20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a4b8eb0b864a8f9f9048637d3d5001_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i654fca3b7c5d415bb115995496918fd5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28a1239656045f886b00a040931a4d9_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91870e5d313147eaa4bfc0c02c210fe7_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06dc05837124fb486c25738d89fd171_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d02369269bd4bd19d7ac96425d902f6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd0edf54fa0f44648f71f8021664a663_D20190501-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87def4161b5741d0a3372af759a43214_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0d84dc7c03423189234b747382592d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2a8d92980b45cd86a9a0e569b171a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c0ec15d63b4c9c9db72a0042d9233b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9230559c947e4bdfbd7d8718f81613a0_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>inhibrx:plan</xbrli:measure></xbrli:unit><xbrli:context id="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e89d479cc1c49dcac81106f1a23036d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291c0d139a404246b0f7fca420127e86_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc0db1dedb64652bed03e473906f250_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9043b1e7d94f868faef2ed4ddb4eda_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b90f3cbd93444a8e502d826cbbe51f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia387c26a722e4699b6595d2f733a93c1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e933df6d96c4e25a0e01262d530c949_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd8eff35edb7419e9932c5f914758304_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1cec1573a81491f8627da20eab3bf7a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16757954c1044691837622036e587d62_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c7d40392014b9993d7e113b2eac17c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd02944395c4cd4867b8652d51a714a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i910bafb21fde4c9d995b95ae87cf63a5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54757ed54df14bceb415fb75f4faf788_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41c0b142c464e41bb151ae9a392ab96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5230b6435fd4ceb84a6af9831cd457c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92744c9c477a4e4ba89940a3d753b3b3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4373a79ed10e41d296ee0962058ceb18_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab658b65d2b4e509ba7e6fbedd7ea7f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca21b8ec7ba4cbbb974b0a2ed21beea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120f8c853b1845998a75889f0c5bcfe9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf43c32005f4158b0a144b53515e8f4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie739eb4e2f9d498a802def60014528b5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356cf52c8b484b40b183fa4c374dd895_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45dd132e1b3a439c9b1a6235d9bb85e2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0911529fc304f48ba356122d24789d2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe55a942de0426eba7b59eec3f142f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa06f7d2b0c24a02ae94a2059ca88a36_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d8c3a4a6fb430e9f1f76dd0683680a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b8a55eee8e1430987c756c531fd2f92_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd65ea0d77dd4536bd5211b76ed0f786_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd2973e2e9248cd84da19d0ec58f321_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f4401ebc2846b4ae91adeae6e806d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40770b8bf174b6f8619cbc166946dc4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46e3791b92d409bb00978ee31d2cbf5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f87004b4c11448b93df28c2392164ca_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieacc3e428d0f429ba6530cfe19d2e300_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cdcea5a7ee042059428f8230d335a2f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835a732af4b24c559cab997e0fc7e788_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf8e3ff3da7b46a4ad695b6d2fdeaf72_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e44a5c0664414894b59ef342a25530_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6529f0b04b94b0bbe8a4aa98b0cca04_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67731484d5f24597939db7a05b45c3e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a8d9ba96ce4164a0a1f5e705ce4880_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d81ecc28084fcdbc1204e113833fc8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257bc2317ed94a5281a528a81b5b8d35_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16213d344cb4afaa96412b15c0eedb6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac09946014a4214af25c0e06ce6c6f6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c5f5eb489b4481b39ec65ca48ebfce_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id880884b9ea94b869fb5816f6510e211_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2e9de97d974ecc9e2ee333fb3c25e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9b775d892046ed8cff1e30bad6547b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81510c3679774fff8f396fc3ab77fb74_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ebc7d152324a9ea5b0b3b86ab48f78_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd19c4f689a94a488fadc52fb549283a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b52c38a8c44d49a69c3fcc734f8f2d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce2eacccd9044d788db421fc7a18c46_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43aed1ced8c04ca78d779f9c16210fa8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113089823357421ab17799b937585703_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822e016bcba04e979cf25eaaedefc7a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5301fb930f5846abbe1ac0d7088d390c_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de109f4840c4e22aafdac033f63ff7e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>inhibrx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:unit id="compound"><xbrli:measure>inhibrx:compound</xbrli:measure></xbrli:unit><xbrli:context id="i86854d401efc41658a1f7cabc6fbf75f_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2312287da4844f98353e533084710b1_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4f3ab77c814395bd909a08f8cdbd8b_I20181220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>inhibrx:program</xbrli:measure></xbrli:unit><xbrli:context id="if0630b88591a432fb950d54e0c58af38_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3240262b0c843ab948e2324834e8f4a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementAdditionalProgramsAuthorizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e132a26c12432e9177650608108558_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedProgramOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9075aabe3384589aa3de96de0cec785_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedProgramTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ec1ec2abba44ff94474aa6f6a83271_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15bf51c282994899a1f5ce5fa7ed4e9e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="license"><xbrli:measure>inhibrx:license</xbrli:measure></xbrli:unit><xbrli:context id="i51e4a311ac19416ebf4f8e8ba3195ba7_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d316a27f564f6c9455708922cd2566_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ab1c4748ac4b588b54989d44e542db_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7827c4c605f403c95b605cbe15393e7_I20190819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0531016c866d4a068e2358c8f73b0f39_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c3ddd258264ea38d9e7f8ee2affbb4_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75bd7c4152884c68b92109e363fdde3e_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4aef1c0a3941d986e5b4bf56476cf9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia81f4833f5a946919ea5fac5c81bd331_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530e97d213314faf9adf351089af9dca_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a2e84dab1f45e3bb160edd91676c7a_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cd4816ef076457ea37eb5b862932984_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ef54ae4f554e239587b8661dc8a3c4_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id25843c5c03943bca5950d2498fcf7fc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4443a6f4f1e84d38b14ec1c139ca5267_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d4b7b4251d42058175aaa32b17035e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08c3ccad96d44bea3c92b45810c37f3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9dc418ead24b64bb8341e1299808f8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0bac45fcb24762a17738da0331eeb2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d67a9e6f56b4ed58267e24b66936168_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd3c6489f044c5f983e14ec05aca582_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c665a21a67f4bba8893929943f5f8d3_I20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0c1f1f0a744b53a8d4ea48cd955591_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe47e6db9f494550ba03c3a1ee101b76_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0b1022232b4f71b8972eb5887adc42_D20171001-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13e3186ca28469286c7cee39c4a772a_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36fb85c03c24ea8a91837247d809173_D20180901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7c69c38154458b921c096178efb2ad_D20180901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie752799339b24161bced2a3798bf9a4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:LAVSummitLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf1efa19e3548d48a2df125b2ba8d78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:LAVSummitLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bd613f072f461db198c9f9f272863d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabfd8187536c4daf96510c57f57bade2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36cb4e41c5bb48e89203d72ff7e9ad71_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief513a4e2d6b4dff83e12409769524ba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1debe51ec3e946f19e9ced16e42dc5e1_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id456e841f6ea429782b9752a0983fce5_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec507b082f8043d7944a7cd34a09a823_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i9382d50f269442c59ff29a8133e54f76_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29539df2bfdf4e7080d49e945e09a68a_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i434a60e482d64431a96e2d34a17d0b06_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4a4c41e60c471987fc84b082722cf4_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTranchesBAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11ebf603f344bfeb2b655dcddb72921_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48109ca4da0c44b1b47c9c968a9d401d_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i893ad457259b4931a5c0ce26c8fb0c92_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749adb0c10a241f59042990471fbddfe_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b6adb629804b27bc064abbdf18bbbb_D20200715-20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-15</xbrli:startDate><xbrli:endDate>2020-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc414bff1c84c9089ef103ad34b6d98_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6760108879a84be9ad67b709f7c52557_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76849810b9be4460b784e44f45823ceb_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iee91b9a90f804077b237584160b9370a_1"></div><div style="min-height:18pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549 </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzYzYmQ5MmFlOGY5NDUyNmEwNDBjYTcxMmZhYjM0Y2YvdGFibGVyYW5nZTo3NjNiZDkyYWU4Zjk0NTI2YTA0MGNhNzEyZmFiMzRjZl8zLTEtMS0xLTU5NTQvdGV4dHJlZ2lvbjplMzFlYzliZTljMjY0MDViYTJmYjAwYmFlODk0Y2RmNl8zODQ4MjkwNjk3MjM3_e8640c14-5940-4c27-a35c-f38289dd7ba0">10-Q</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark one)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDcyMTc5_b64e29bd-1039-4d06-9183-3bbeadb95a1b">&#9746;</ix:nonNumeric> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF85MzQ1ODQ4ODU4MTEx_41c825fd-f4e2-46d8-8541-63abf5e91195">September&#160;30, 2020</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDcyMTgz_cb54caa6-e6c9-44e3-8163-5407a18a22af">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDkxNDE2_1b742a3f-f3c7-4806-b814-8462d9e98026">001-39452</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:28pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8xLTAtMS0xLTYyOTU_9f1ae1f5-c59e-47f3-9cd3-89395ae3c79d">INHIBRX, INC.</ix:nonNumeric> </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) &#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8wLTAtMS0xLTY5Mw_afc7c526-4f2d-4465-9f9e-8849118969d4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8wLTItMS0xLTY5Ng_f0042ac5-c4e9-44a7-bc39-fb789057b30f">82-4257312</ix:nonNumeric></span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification Number)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8zLTAtMS0xLTUxNjAvdGV4dHJlZ2lvbjo4MTNjYjdkMGIyMzE0ODUwYjU0MTI5N2U3N2VlMzczZF8zODQ4MjkwNjk3Mjg1_e3651cf1-3314-458b-b1a2-c1a4f0126442">11025 N. Torrey Pines Road</ix:nonNumeric>, <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8zLTAtMS0xLTUxNjAvdGV4dHJlZ2lvbjo4MTNjYjdkMGIyMzE0ODUwYjU0MTI5N2U3N2VlMzczZF8zODQ4MjkwNjk3Mjk3_e4ed35ef-abfb-472a-ac97-9db428cfcffe">Suite 200</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF80LTAtMS0xLTUxNzQvdGV4dHJlZ2lvbjpmYjlhMDIxMjIyYTU0YWU5YTM4NzVhOGI1YWYzMzBmYl8zODQ4MjkwNjk3MjQ4_22b052a1-34bc-44ee-8aac-f3667497df53">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF80LTAtMS0xLTUxNzQvdGV4dHJlZ2lvbjpmYjlhMDIxMjIyYTU0YWU5YTM4NzVhOGI1YWYzMzBmYl8zODQ4MjkwNjk3Mjc0_12a988a1-7a14-4aa0-923f-58441fbcc55a">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF80LTItMS0xLTEwODU_8f238b09-6e9c-45b0-9dc9-8e80905f5539">92037</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8xMi0xLTEtMS01OTYxL3RleHRyZWdpb246ZGI0ZDVmYjZjN2I3NDcyYWExZjNmZjUyNTQ5NDlmZDVfMzg0ODI5MDY5NzIzOQ_8ed3cde1-9396-4bfe-930f-eb8c3b161bcd">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8xMi0xLTEtMS01OTYxL3RleHRyZWdpb246ZGI0ZDVmYjZjN2I3NDcyYWExZjNmZjUyNTQ5NDlmZDVfMzg0ODI5MDY5NzI1MA_b83eb5ac-9c66-4a61-80fb-88438c5d5e93">795-4220</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:571.50pt"><tr><td style="width:1.0pt"></td><td style="width:193.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:27.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:27.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6Y2M1ZmFhYzc0NmUxNGQxNWE5OGJlNzFlMmNjZWYyOTcvdGFibGVyYW5nZTpjYzVmYWFjNzQ2ZTE0ZDE1YTk4YmU3MWUyY2NlZjI5N18xLTAtMS0xLTczNQ_aec2ce4e-18cb-48d6-bc52-87a9442afd94">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6Y2M1ZmFhYzc0NmUxNGQxNWE5OGJlNzFlMmNjZWYyOTcvdGFibGVyYW5nZTpjYzVmYWFjNzQ2ZTE0ZDE1YTk4YmU3MWUyY2NlZjI5N180LTItMS0xLTc4MDk_a1c18646-d05f-49f1-b6eb-d09e74f708da">INBX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6Y2M1ZmFhYzc0NmUxNGQxNWE5OGJlNzFlMmNjZWYyOTcvdGFibGVyYW5nZTpjYzVmYWFjNzQ2ZTE0ZDE1YTk4YmU3MWUyY2NlZjI5N18xLTItMS0xLTczOQ_e3c23a23-9ab4-4398-9087-863791ddd175">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes &#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDc5MTIz_462db13c-df10-46e9-9a94-54fb28207b6a">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDkxNDE3_2b2163d7-8b9a-4ebf-bf09-de9d2ea5163c">Yes</ix:nonNumeric> &#160;&#9746;&#160;&#160;&#160;&#160;No &#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:564.75pt"><tr><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:24.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:265.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:24.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large&#160;Accelerated&#160;Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzIwZDIwZDM0MTk2NGUzNmIzMTAxNzVlMGNkYzRiYzYvdGFibGVyYW5nZTo3MjBkMjBkMzQxOTY0ZTM2YjMxMDE3NWUwY2RjNGJjNl8xLTAtMS0xLTgxMzI_17c7a663-8513-4d6b-88fd-09b89b25dbc3">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzIwZDIwZDM0MTk2NGUzNmIzMTAxNzVlMGNkYzRiYzYvdGFibGVyYW5nZTo3MjBkMjBkMzQxOTY0ZTM2YjMxMDE3NWUwY2RjNGJjNl8xLTMtMS0xLTc0Ng_27f8f733-a2cf-4b7c-bf05-47f106c7404d">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzIwZDIwZDM0MTk2NGUzNmIzMTAxNzVlMGNkYzRiYzYvdGFibGVyYW5nZTo3MjBkMjBkMzQxOTY0ZTM2YjMxMDE3NWUwY2RjNGJjNl8yLTMtMS0xLTc0OA_148f6037-f705-46c9-b654-1bacd479e737">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;&#160;&#160;&#160;&#160;      <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yMTk5MDIzMjc4ODc1_fa0afa17-9bb8-45e3-ada6-5681d1961c71">&#9746;</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;Yes &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDkyNjc2_ab952e22-f065-4f06-bfd0-114c269a2c34">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No &#9746;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;31, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="idbf3661972cb42c9b5609ea4cbd7cb26_I20201031" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8zODQ4MjkwNzE5MjI2_906ef3f6-1499-4b9b-8844-d27c4cb27cae">37,712,390</ix:nonFraction> shares of common stock outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;design,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our research and development programs as well as our preclinical studies and clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance therapeutic candidates into, and successfully complete, clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our interpretation of initial, interim or preliminary data from our clinical trials, including interpretations regarding disease control and disease response; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of our therapeutic candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing, coverage and reimbursement of our therapeutic candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize our technology platform to generate and advance additional therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, strategic plans for our business and therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully manufacture our therapeutic candidates for clinical trials and commercial use, if approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into strategic partnerships and the potential benefits of such partnerships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, capital requirements and needs for additional financing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the COVID-19 pandemic on our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our third party partners and service providers&#8217; ability to continue operations and advance our therapeutic candidates through clinical trials and the ability of our third party manufacturers to provide the required raw materials, antibodies and other biologics for our preclinical research and clinical trials in light of the COVID-19 pandemic and the recent political developments in Hong Kong;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry.</span></div><div><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to new information, actual results or to changes in our expectations, except as required by law. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report and the documents that we file with the Securities and Exchange Commission, with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_13">Part I. Financial Information</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_16">Item 1. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_19">Condensed Consolidated Balance Sheets (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_22">Condensed Consolidated Statements of Operations (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25">Condensed Consolidated Statements of Convertible Preferred Stock</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25">, and Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25">Equity (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25">Deficit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25">)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_28">Condensed Consolidated Statements of Cash Flows (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_31">Notes to the Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_76">Item 2. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_76">Management&#8217;s Discussion And Analysis Of Financial Condition And Results Of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_76">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_118">Item 3. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_118">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_118">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_121">Item 4. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_121">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_121">51</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_124">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_124">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_127">Item 1. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_127">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_130">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_130">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_151">Item 2. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_151">Unregistered Sales of Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_151">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_154">Item 3. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_154">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_154">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_157">Item 4. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_157">Mine Safety Disclosure </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_157">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_160">Item 5. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_160">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_160">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_163">Item 6. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_163">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_163">104</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_166">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_166">105</a></span></div></td></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_13"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I &#8212; Financial Information</span></div><div id="iee91b9a90f804077b237584160b9370a_16"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="iee91b9a90f804077b237584160b9370a_19"></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc. <br/>Condensed Consolidated Balance Sheets <br/>(In thousands, except share data and par value)&#160;</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNS0zLTEtMS0w_7474eb4e-5834-4ca0-8f94-8414f0689703">127,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNi01LTEtMS0xMTE_563cb6f1-c70c-4f37-8a74-1ba5f639468d">11,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNi0zLTEtMS0w_a2852c94-9e11-467e-8e24-fe4a8e3f458b">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNy01LTEtMS0xMTE_4c3fd38c-62cf-44f7-99b9-edb370dabbcc">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNy0zLTEtMS0w_e4ca8fca-d3b6-44fc-a665-a56def7ff585">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfOC01LTEtMS0xMTE_511badd9-d1f5-4f1a-a470-388a7b93a003">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfOC0zLTEtMS0w_a9610077-a2d5-48d8-a444-bd803c1f1c8d">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfOS01LTEtMS0xMTE_f929582f-d935-4555-b2b6-00aacf821e7d">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTEtMS0xLTEtNzkx_8a8662e8-67a3-4db0-a97a-6f709a62271a">131,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTEtMy0xLTEtNzkx_7da03550-5950-4c76-b6c0-d9983843c414">15,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTEtMy0xLTEtMA_3512c135-faf8-4c06-9745-3942051d64fa">3,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTItNS0xLTEtMTEx_bb7ad0a8-30a3-4cb0-b6e1-4fd323b37755">3,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTItMy0xLTEtMA_4e6b33b6-7ade-4fb1-a0b5-1bc8998825ee">8,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTMtNS0xLTEtMTEx_f67a582d-fdc5-4a03-a8a2-3d530ce8560e">7,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTMtMy0xLTEtMA_59365a4b-dadf-426c-8e32-7dff4186916a">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTQtNS0xLTEtMTEx_1bb4e793-a7c7-4954-9d9e-23e76bcda727">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTUtMS0xLTEtNzkx_5b95007f-4144-445e-ae26-f34a1d050806">143,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTUtMy0xLTEtNzkx_fbb19c65-2f5d-4ab0-98a5-846bfed5cd83">26,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTctMy0xLTEtMA_9d1ec870-289a-468e-aaaa-c721e26aa287">15,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTgtNS0xLTEtMTEx_fa66f9c4-bbf0-4dad-ad15-9eca4ec3dc20">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTgtMy0xLTEtMA_87d0034d-2dcb-43eb-9cd2-4af2a3e5ff8a">11,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTktNS0xLTEtMTEx_5ab422f3-7442-469f-87d4-a912c2d8ee79">4,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTktMy0xLTEtMA_0e2d4c29-6bd0-4c8c-bcb6-ad5cecb8d80c">5,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjAtNS0xLTEtMTEx_9d60f2f1-65fd-4dba-a343-b906d1581b4a">7,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjAtMy0xLTEtMA_cfe7f91d-e83b-414e-b116-2ce02f8233c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjEtNS0xLTEtMTEx_fb1b4d78-ef45-4a54-b060-67e6053c8897">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjEtMy0xLTEtMA_ceca362f-19f9-48e1-ab1e-7b47326ca39c">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItNS0xLTEtMTEx_cb29e51d-e068-4975-99a4-b0dd3b26a1b7">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItMS0xLTEtOTQ4NQ_b1a5e648-ecc3-46b9-9797-51ae2ced878f">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItMy0xLTEtOTQ4OQ_d3da89e9-af5a-4a10-8c5a-7cf1339ad89e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItMy0xLTEtMA_a24f36c5-59c4-4a2f-bd52-28d0b07082b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjMtNS0xLTEtMTEx_25b4f170-01d9-417e-bb72-bffa98930b8a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtMS0xLTEtNzkx_ecf4fe95-056f-4c5b-9d4c-759a85d9fa03">34,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtMy0xLTEtNzkx_f80ae461-6e77-4469-8d52-b9f38a8b7b01">20,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes, net of discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtMy0xLTEtMA_65305bb5-5dd1-476c-9ba3-b9d87f002b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtNS0xLTEtMA_133ccb66-6f10-464f-907a-8c80686625a8">30,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjUtMy0xLTEtMA_9de21aa0-2dc5-4867-aab6-b602b5285b66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjUtNS0xLTEtMA_b51ce19a-ac8b-471d-baf5-be24ca0008e3">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjctMS0xLTEtMTUzMDc_54805ad3-82b9-4c81-ae02-e8f35939b9fb">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjctMy0xLTEtMTUzMDc_13bfa51a-685f-4a1a-abf5-b8203109e7cd">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and including final payment fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjYtMy0xLTEtMA_46e9af2f-ab45-4995-862b-113c989e7fb6">9,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:SecuredLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjctNS0xLTEtMTEx_a8e1a7d4-cb1b-4e47-9153-c46d933c2163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjgtMy0xLTEtMA_585c2eb0-d9ce-4897-958a-3f3af513513c">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjktNS0xLTEtMTEx_9d4d9bd4-5582-4e1f-ba77-f406a48db6d1">6,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzItMS0xLTEtNzkx_05f442c6-3603-4c63-8832-adbb91e57665">51,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzItMy0xLTEtNzkx_5253b32e-9e53-44b4-aafb-8e04ebb38c1f">60,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtMS0xLTEtNzk0_9cea63d8-67cd-421f-b7a5-4f997a349993"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtMy0xLTEtNzk0_2e7fed83-3827-4f2a-8934-f176631d865d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzczMA_2bb5df64-1b5f-4bab-836e-8353dd1011ea"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzczMA_d532c34b-9b69-4a4a-a7ad-b832054bae0b">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzYzMw_135e2ee9-1747-4362-aae5-503adbbdbd93">no</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzYyNg_f91ed079-86f2-4ed1-b956-61efe4016262">25,765,000</ix:nonFraction> shares authorized at September&#160;30, 2020 and December&#160;31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY1Mw_251ffd73-bf0d-438d-b7c9-7aaefc008fef"><ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY1Mw_ada3dde4-4f6a-4644-ae4c-db51a7a62d98">no</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY0Ng_7e539d67-fbfc-4948-9724-abbde12b1e92"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY0Ng_8489fa48-67ff-4a32-8e7e-6f8177b6f5c7">12,534,331</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2020 and December&#160;31, 2019 respectively; liquidation preferences of $<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfNjA0NzMxMzk1MzI4Ng_c962ff0d-5714-4dfa-a43e-85eee0eba731">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-5" name="us-gaap:TemporaryEquityLiquidationPreference" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY2OA_0dbb4621-4eeb-4b7b-a5c0-e94c6b0b3d4c">87.5</ix:nonFraction> million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtMy0xLTEtMA_1bc1e2a3-6253-43d3-9220-45b884705039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtNS0xLTEtMA_f37a3dd0-b231-46e9-ad2e-eaea50a82e3f">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock,  $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzQ2Mg_03e09db4-0962-489e-a8aa-a6ff492c8500"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzQ2Mg_a6be608e-4f79-40f8-a7bf-80e2360b7aac">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM3OQ_e727cd30-fdb6-4c9f-a852-6c52954977fb">15,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4NA_b3e7a1ca-2e95-41a0-ae91-d322dece7390">no</ix:nonFraction> shares authorized at September&#160;30, 2020 and December&#160;31, 2019; <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_1b7736fd-a90d-48c6-ae03-b7647aa5eb2b"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_6ae5ff53-fc56-4980-a466-3ec1634ad022"><ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_d700027e-21e1-4854-902c-4ec6dd0992ab"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_f5f3ec80-08d9-4a6f-91c3-ce67d62d6298">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzUtMS0xLTEtMzIzMw_46bad8ec-8206-4681-914f-29a2ed0e6054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzUtMy0xLTEtMzIzMw_30b93087-93f5-4c39-9add-5f96586ada9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU1NA_7f7b0e00-dc75-4745-b108-2d78a901905d"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU1NA_f03edf4f-5738-4fdb-9595-30cd0ee3589c">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU2OA_f429b00e-97ef-44f4-b43f-10498e3c9c51">120,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU4MQ_3600fa5e-a1a6-4d77-a7d6-33bbb28bdf65">65,000,000</ix:nonFraction> shares authorized as of September&#160;30, 2020 and December&#160;31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzYwMg_8b51a87c-cd39-4076-8276-3265ed1da154"><ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzYwMg_cdd86e22-48dd-4d04-9d69-1fac4da9d8a4">37,710,190</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU5NA_af2fb6ea-88eb-4233-870f-ab6552405040"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU5NA_bf7db5da-77c2-4680-bd76-804c57c6150a">18,154,119</ix:nonFraction></ix:nonFraction> issued and outstanding as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMy0xLTEtMA_ff897333-046d-41df-a8a6-78b8e598d6a6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtNS0xLTEtMA_c6d1cd14-21c7-4f12-98ad-d00d87a3c866">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMy0xLTEtMA_98b3ac61-e6dd-4c05-95e9-97dbf1c179b5">219,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctNS0xLTEtMA_9d4a3d73-d49b-4f82-9948-d7c58b8081cd">24,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzgtMy0xLTEtMA_8d327fad-e00f-499f-811a-7ea2aa58bb08">127,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzgtNS0xLTEtMA_4ecf845c-13ae-4869-9202-606142fac776">69,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNDAtMS0xLTEtNzkx_1861ddfb-d851-4cef-883a-533db8614b77">91,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzktNS0xLTEtMA_39354300-6b56-48b6-a2e7-6b2021de4e0c">93,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNDEtMS0xLTEtNzkx_11a8d184-8465-4a87-871d-4f1d511d6446">143,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNDEtMy0xLTEtNzkx_e912b660-94ba-4d1b-9a38-126758f2827a">26,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_22"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc. <br/>Condensed Consolidated Statements of Operations <br/>(In thousands, except per share data)<br/>(Unaudited)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a502282910747c9aac74a5847fac525_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0xLTEtMS0yMjc_0b4b4f96-baa0-47d3-9fec-c21b41033ce3">5,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2815584d6b3449bae058364571557b3_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0zLTEtMS0yMzM_d347081b-3fd3-4b95-89c3-439cbd472802">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2eec07eda2401383326e716774ff76_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0xLTEtMS0w_5e361cd5-385d-4a4b-9c73-21af01b240ed">10,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieadc553907f04aea9984cc210e0af52f_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0zLTEtMS0w_480f6a9f-9bf8-4129-b55c-56478524b777">8,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fce0905feb4ca0a6d436f23bdb5a51_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0xLTEtMS0yMjc_e21112d8-7d35-4951-bbaf-d03051fa0ff3">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic597294d6b05480f9b87cfc8e153db62_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0zLTEtMS0yMzM_1aa1d1dd-4bf7-43c6-a49b-cb0c598e04b2">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8caa9dd3e98483facac392f2f26d651_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0xLTEtMS0w_2a5b73bd-4258-4fcf-a67e-04dde1e95bfe">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820a8e2822d74bbd82ecbf86ba928b9c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0zLTEtMS0w_4bcd2156-ccd1-4877-a356-a88beb07199b">4,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0xLTEtMS04MTEy_76a6c765-60f5-4ede-a8f2-173fe8f028ce">5,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0zLTEtMS04MTEy_e50d4ecf-ff91-4f29-8b61-d1901d19c083">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNy01LTEtMS04NzA_e1a7c995-00f1-441a-8f48-fd21c726c340">10,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNy03LTEtMS04NzA_da35267e-f81e-4f58-8775-53cb1eb91835">12,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0xLTEtMS0yMjc_90b4861a-8018-4059-8e70-cd32fb2f700a">19,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0zLTEtMS0yMzM_290ba575-0b92-4b55-8479-4fa2c2a43711">12,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0xLTEtMS0w_30517347-bd0e-4de2-9c2f-69a6bcaffe1c">55,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0zLTEtMS0w_e0e15fa2-c99b-4a0b-8b7e-8ec6b03014ef">35,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMS0xLTEtMjI3_a277f802-5564-4060-8926-a5ebef7645e3">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMy0xLTEtMjMz_7ad353e6-faee-4a8b-9841-a3fa1f7019c2">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMS0xLTEtMA_fb5d31cc-5ffc-44f4-9112-f57d96056b73">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMy0xLTEtMA_b210547b-1193-4954-9ebf-db5f807d4682">4,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTEtMS0xLTEtODExMg_6cd4429a-156d-4897-84f5-a8838dd4e8c7">21,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTEtMy0xLTEtODExMg_36272f16-9d26-4ba3-a968-b5c84706adf3">14,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItNS0xLTEtODcw_fd4318cf-2b82-4478-93ed-66ec50ab8622">60,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItNy0xLTEtODcw_3beded05-a1d8-4799-84d3-29fe3ef3fb26">40,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItMS0xLTEtODExMg_69546b07-e428-47d1-8142-39f304330061">15,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItMy0xLTEtODExMg_35340932-8c1f-4284-a73f-e5fc504f8f4a">13,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTMtNS0xLTEtODcw_8d367e43-9062-4c30-ba0e-8c972c6303df">50,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTMtNy0xLTEtODcw_aafb924e-ee19-45f7-87d6-9a64b8ad1e41">27,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMS0xLTEtMjI3_9066589d-7b3a-4ac5-bd6c-2e4525ce5979">4,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMy0xLTEtMjMz_da041efc-0df5-40c5-aae8-bcc32457abea">2,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMS0xLTEtMA_9725ed85-6f79-419f-98fb-fdbc4ccbb446">10,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMy0xLTEtMA_266f81a7-4649-432c-9d46-a5d3b1878e39">3,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMS0xLTEtMjI3_ce839b07-dec7-4cb6-8b09-3328abd1cb8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMy0xLTEtMjMz_4a49e1ab-97a2-4de7-9ee2-5508b79cb2a5">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMS0xLTEtMA_ae28e9f8-7f8c-44a7-bc04-e0ac12e27c68">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMy0xLTEtMA_6d574caa-1700-47a1-b013-6dde7f63b23e">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMS0xLTEtODYwNg_d27b277c-789f-4087-b3df-d70c33773f29">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMy0xLTEtODYzMQ_7b53d842-939b-475f-accb-a75f68775c7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtNS0xLTEtODYzNQ_ebc9a9e0-2a62-4347-b818-9d2a68add14d">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtNy0xLTEtODYzOQ_ab2da79e-497a-4554-b77a-3755462cfb1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMS0xLTEtMjI3_1e6dc09d-4103-414f-a073-45ea0cb868b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMy0xLTEtMjMz_aa29cefa-66a6-4b07-b204-9e96ab54850a">3,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMS0xLTEtMA_0b472413-798c-426c-8848-db558e630eb2">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMy0xLTEtMA_d8723d67-34e0-4dee-ad04-2cfd8069dba4">3,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMS0xLTEtODExMg_d6e0d379-142b-481b-af52-2ee62e694858">4,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMy0xLTEtODExMg_df8e8397-4936-4a80-8271-a3f8bcf189b7">6,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtNS0xLTEtODcw_fe1f9160-08f6-4990-989e-9d69bb0b24b0">7,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtNy0xLTEtODcw_cec8495c-c175-4871-882d-470b2402f085">6,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtMS0xLTEtODExMg_bf757c5b-c4a1-4434-9579-ac669d44d2fd">20,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtMy0xLTEtODExMg_34ddd9e0-ca7b-4580-b5a8-cd8478f44ac4">19,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTktNS0xLTEtODcw_2894667c-76fe-41dc-a75f-e611a9718999">57,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTktNy0xLTEtODcw_f4725b0b-fa1b-4cc4-a1a5-60b40d8d0142">34,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMS0xLTEtMjI3_ab8ec992-567c-467b-9f68-2c53cd9a9b85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMy0xLTEtMjMz_fc5d129e-e725-492d-8099-d2cdf28e0d78">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMS0xLTEtMA_a742b21e-dffc-4104-a08d-8938542dbc51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMy0xLTEtMA_a228642e-bf34-41f9-85a4-b7004075f715">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMS0xLTEtMTQwNzQ_c87dbb97-70b1-4ace-9d17-5402d0dd627a">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMy0xLTEtMTQwNzg_aa75574b-f3f5-465c-8745-e4607c50ce02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtNS0xLTEtMTQwODI_5d902b45-8b3e-43ce-96d8-18f6292a8a4a">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtNy0xLTEtMTQwOTI_9eceb72c-38eb-4259-bb44-ff5c9ed97107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjQtMS0xLTEtMjI3_724e8c64-02ab-4fa4-83e8-a896d08c93cf">20,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMy0xLTEtODExMg_eda1bc13-35ca-4404-97ee-8c94daaab81a">20,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjQtNS0xLTEtMjM5_5b58f4ac-a5ef-4628-838f-970004957f8d">58,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjQtMy0xLTEtMA_680e4ac1-4283-4a74-9ae5-c51149a95568">35,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMS0xLTEtODExMg_26d28a34-dd36-44ae-8507-4af676e45f55">0.77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMy0xLTEtODExMg_b44d8d68-bb6e-46cd-9c29-955619da89eb">1.11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjUtNS0xLTEtODcw_119eeb00-6ec4-44ff-840e-65d5beb920b3">2.78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjUtNy0xLTEtODcw_f136fef9-3e83-40be-9bd8-e13be123e1ae">1.93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMS0xLTEtMjI3_f3975d95-5031-468d-9923-20c51503c482">26,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMy0xLTEtMjMz_49bc19ad-4893-45c1-a97f-2c63c3d14572">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMS0xLTEtMA_db47ec77-dff0-4074-a735-272a406d8297">21,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMy0xLTEtMA_f42fcf58-e09b-4e70-9db2-714afdabe4f5">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_25"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc.<br/>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) <br/>(In thousands)<br/>(Unaudited)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">CONVERTIBLE PREFERRED STOCK<br/>(SHARES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">CONVERTIBLE PREFERRED STOCK<br/>(AMOUNT)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">COMMON<br/>STOCK<br/>(SHARES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">COMMON<br/>STOCK<br/>(AMOUNT)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">ADDITIONAL<br/>PAID-IN<br/>CAPITAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">TOTAL STOCKHOLDERS&#8217;<br/>EQUITY<br/>(DEFICIT)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xLTEtMS0zMzgx_89db3911-11cc-4cf2-916f-e63325e8e8c8">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0zLTEtMS0zMzgx_f3562153-4345-475e-8ae2-2208653a4cbd">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie34e5f2d63b64f9ab8bdc6574f9e7285_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi02LTEtMS0zMzgx_4a7a6e31-89c0-4cc1-83b0-bc75a4dce754">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie34e5f2d63b64f9ab8bdc6574f9e7285_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi04LTEtMS0zMzgx_81accdee-fc9a-48ac-bd6b-5119661dddf4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i000ce15b89d840528ca0541bc84717e8_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xMC0xLTEtMzM4MQ_2f7eff0a-0c90-47bc-8a0e-1526d7281c90">24,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ac975841c0c4eee8d4575323136a11b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xMi0xLTEtMzM4MQ_039fd78f-1c88-40d6-98d6-d1d1b4f9f022">69,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xNC0xLTEtMzM4MQ_928aa4e8-96c3-43f8-b8ce-255bacbffb68">93,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f21270f21874db1b0bbfb358bb4a78a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xMC0xLTEtMzM4MQ_4891b416-c8e5-4c99-a1b4-1afe2fb0af94">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d17755e65848568a5814eb7e92fa96_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xNC0xLTEtMzM4MQ_1f107dbe-fe2d-4cdf-8063-d974c006f64b">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i603a3e22a39e4c3f84a33bd10c4b7461_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xMi0xLTEtOTUyNg_6d7fffce-180f-434a-bf4b-56a174fa8741">20,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d17755e65848568a5814eb7e92fa96_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xNC0xLTEtOTg4MQ_11765ecb-0e01-4877-91f2-8ac7b60c9ef0">20,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cb47a5672584355b7d05652419f4135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xLTEtMS05ODYz_c4880ca9-47a5-48f4-ad76-d55f1d08dedc">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb47a5672584355b7d05652419f4135_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0zLTEtMS05ODY1_31e9d3bc-6be6-40bc-a706-0407c9717cf9">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd8c696851984b19adde3434ae473fe3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC02LTEtMS05ODY3_564461e3-f924-4052-8018-7c389d1fe401">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8c696851984b19adde3434ae473fe3_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC04LTEtMS05ODY5_cd0bbff2-8053-4b39-b5fc-9c3418ce48cf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i846daf89fc2b40ff9276e0309f8bc49b_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xMC0xLTEtOTg3MQ_effa46c9-4302-4ecb-b109-2a2e3af31f51">23,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib15a549f5d7c49ba8413651379bcbb4b_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xMi0xLTEtOTg3MQ_3126f68e-57ba-4bd2-ab46-4e2a09a268ea">89,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cb47a5672584355b7d05652419f4135_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xNC0xLTEtOTg3MQ_1b622775-3760-45ce-a5ae-1131363cb720">112,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b03bb902a94c8785ee943f02414084_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xMC0xLTEtOTUzMw_e6949e40-afe0-483a-945a-c0c6d2152235">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5228ec7bd82b4d18aa5c78ca560be27f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xNC0xLTEtOTg3OA_92a4f73c-c0c7-46e2-ac67-1c4924a8ddbd">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Notes - beneficial conversion feature</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab8209e132d4d49885fdd7a39a220b4_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xMC0xLTEtMzM4MQ_f3129006-134a-45ce-8533-f5ee24a0985c">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6aba7f28dc64367a0eece71a35d9fb9_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xNC0xLTEtMzM4MQ_4663ff81-657d-48eb-b899-13939fe8d573">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idad3866ecff24d2bb1c1621c08c1e65d_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNy0xMi0xLTEtOTU0NA_2d84ca93-6e13-4771-a0e3-aef77f39b163">17,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5228ec7bd82b4d18aa5c78ca560be27f_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNy0xNC0xLTEtOTg4MQ_c707e825-955e-425e-be71-b574a0ef4064">17,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide0a954ba6d54755911e36150df70447_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xLTEtMS05ODYz_e58b7ffd-b6a8-4862-9b6a-af80a836aaa5">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0a954ba6d54755911e36150df70447_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0zLTEtMS05ODY1_6294b367-1a5e-418a-bc03-09842d66b7d2">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29ac8459a45944d89bd8d8c502750883_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC02LTEtMS05ODY3_a8e53f0e-76a9-4bee-91b7-359db97e2f61">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ac8459a45944d89bd8d8c502750883_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC04LTEtMS05ODY5_13615504-4ae3-493c-bcaa-40ab692f97f3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib43ea9fc9a3749ca8aec69153be4824b_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xMC0xLTEtOTg3MQ_f9b6356e-4b63-49e3-802c-cffb12b063ad">19,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06e3380af6394476b9fb41f80b54569d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xMi0xLTEtOTg3MQ_6d8bdc0e-d880-41f3-8b5f-932927289dd6">107,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide0a954ba6d54755911e36150df70447_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xNC0xLTEtOTg3MQ_58a8c96c-1e8e-4891-83f7-eda5bc48c3a6">126,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xMC0xLTEtOTU4Nw_8d3504e6-dfef-4b7c-a892-7742ae323571">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xNC0xLTEtOTg3OA_5e9eb465-fefb-4d60-8129-6a8066539e75">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xMC0xLTEtMzM5OA_c5033f51-69f2-4baf-907d-f22a698a2a60">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xNC0xLTEtMzM5OA_f9496baa-259e-47e4-ba8d-cbe34c5a02a8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares in IPO, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eee8e0a5aa64149a5e9678da896aa09_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC02LTEtMS0zMzk4_8fa10d64-e0a3-4cd2-addc-cc7415a439a4">8,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eee8e0a5aa64149a5e9678da896aa09_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC04LTEtMS0zMzk4_dbb71fd3-78b2-46ce-a532-ed3bacfd17a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xMC0xLTEtMzM5OA_0afdb991-86d3-419b-b548-a4052908bd76">125,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xNC0xLTEtMzM5OA_32c56da8-ce6f-4041-8a20-6b3ca254f818">125,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares in conversion of preferred shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xLTEtMS0zMzk4_70722386-b829-4b02-a65d-4fdce46cb5a1">12,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0zLTEtMS0zMzk4_f168c028-dbc9-4a9d-a8cf-e53e0516b6c5">59,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e22b91c8f4c61bc620f632b4e3aa3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS02LTEtMS0zMzk4_fa64131a-6b8d-4af6-9b5d-9e8692c216ca">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e22b91c8f4c61bc620f632b4e3aa3_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS04LTEtMS0zMzk4_e7366959-f00d-4348-93ca-8cdc00ae0db8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868602c6c8094dfe8c35ccb6d3bf5389_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xMC0xLTEtMzM5OA_1163e6f9-2ec6-4c25-8f58-e47dd15b1a03">59,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c3d1c7115344cf87b4e8072fb23023_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xNC0xLTEtMzM5OA_af25808f-63d6-4ed4-bb76-dff0a777b7b5">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares in conversion of the 2019 Note the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00e8f3fe84bb4c7c80b0765347fb47fe_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTAtNi0xLTEtMzM5OA_c76133d9-2ada-4994-8272-f317feccc4da">4,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia490249b50314ffeb9819be68dddeff5_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTAtMTAtMS0xLTMzOTg_0c5f2127-ff1e-41b1-8b93-5d29c2f132db">59,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfaf63fd5be43bd94a1aa0e5f1b9ed8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTAtMTQtMS0xLTMzOTg_33df8db6-3b0f-4272-b0e6-8a6c789101e2">59,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of unamortized BCF on the 2019 Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59bd56e946e5445bae234daf9abde8e6_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTItMTAtMS0xLTMzOTg_135a7997-ea7b-4263-9df4-31880c2a73eb">5,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i968c5b21c23d497c885a34db4e9dcc82_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTItMTQtMS0xLTMzOTg_fabce598-79c6-4939-b1d1-ac8cd760fbb4">5,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of unamortized BCF on the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93804641103b457fad36e34238434091_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTMtMTAtMS0xLTMzOTg_a6fc7f47-6f8f-4da1-9670-7cdef44ea019">2,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if80eeafcebb44eda80d0e0ab4cb21502_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTMtMTQtMS0xLTMzOTg_e8da162d-fec8-4f75-802a-a89f6debabd9">2,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTYtMTAtMS0xLTk2MzM_ed56674c-2281-46a2-91a2-54e95253af55">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTYtMTQtMS0xLTEwNjY1_fdf9f7d3-4b50-46d1-b977-8411dcad52fa">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6437dc22b9a1413a83a988950e6b212f_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xMi0xLTEtMzM4MQ_df61f425-afa0-49e8-98d6-64baec48db1e">20,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xNC0xLTEtMzM4MQ_803138ef-f49e-472e-82d8-bf6e1ff2a712">20,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xLTEtMS0zMzgx_a2660cc3-ea6d-4739-83a4-88b83b1d14a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0zLTEtMS0zMzgx_80ad0c07-7a54-4936-a1fb-b95ca1104203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98b810262bba4b218699272e9d863800_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi02LTEtMS0zMzgx_ecf26888-5c9a-4114-a6f5-e6170433b7a0">37,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b810262bba4b218699272e9d863800_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi04LTEtMS0zMzgx_df513592-3d04-49ef-8150-0dfb4223bc59">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad639b97919472cb19836f0f20c8578_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xMC0xLTEtMzM4MQ_d38e7217-cc10-4eef-9885-7053980cbd64">219,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5b516dbf8534c51a8a187a321b5ff02_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xMi0xLTEtMzM4MQ_5805f7a3-c5bc-4792-8bb5-d59257c0462a">127,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xNC0xLTEtMzM4MQ_39eaacfb-b832-4490-a4e9-030231f2792e">91,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">CONVERTIBLE PREFERRED STOCK<br/>(SHARES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">CONVERTIBLE PREFERRED STOCK<br/>(AMOUNT)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">COMMON<br/>STOCK<br/>(SHARES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">COMMON<br/>STOCK<br/>(AMOUNT)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">ADDITIONAL<br/>PAID-IN<br/>CAPITAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.7pt;font-weight:700;line-height:100%">TOTAL STOCKHOLDERS&#8217;<br/>EQUITY<br/>(DEFICIT)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2018 </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xLTEtMS0xNTUxNg_172a94c9-e8d2-40f9-bc9f-3fcbac05ce9c">10,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0zLTEtMS0xNTUxNg_7739000a-a3d3-4898-b05d-2c6a23dd7b2f">47,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie17c4099b42e47cdb2c7b8aaaa29181c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC02LTEtMS0xNTUxNg_e049f970-835a-49be-918d-af12b8f7725a">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17c4099b42e47cdb2c7b8aaaa29181c_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC04LTEtMS0xNTUxNg_4861f759-4def-41f5-8849-3936b9f08528">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb446db2851407d98c475b4a9496a9b_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xMC0xLTEtMTU1MTY_02075267-2884-4703-9d35-b90643b227a1">39,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3fd70b3e3724e78bbd68fad24152716_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xMi0xLTEtMTU1MTY_8262c800-b762-47d8-aec5-51910439afa0">17,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xNC0xLTEtMTU1MTY_c03756a8-2c06-41ee-85ae-454da1476a27">57,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib639469f8e6f46fe9e906ab1f8a23c3c_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMS0xMC0xLTEtMTU1MTg_f70d3a04-5930-4e70-bb99-1920735e6d3a">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMS0xNC0xLTEtMTU1MTg_307d7590-fd02-41fc-9c6e-5d3752181a61">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Mezzanine Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMi0xLTEtMS0xNTUyMA_76d89a59-8cb8-4fb6-aba0-b6c52e329a6c">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMi0zLTEtMS0xNTUyMw_9913d92b-0cbe-4dd6-a206-b90b2316e829">11,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c148e447dd4a72b3fb1401d56a109a_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMy0xMi0xLTEtMTU1MjU_2edabac1-a79c-4ae8-b1c4-0b84162c4749">3,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMy0xNC0xLTEtMTU1MjU_b21f288f-77a8-475b-8e58-c22c81137d91">3,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xLTEtMS0xNTUyNw_7424f1bf-3be3-4919-a1e8-188183ced73f">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0zLTEtMS0xNTUyNw_118d3424-fcc7-4901-b80f-2afa9a6fd93e">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i832575ad734f4ac68adc394981e0dd95_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC02LTEtMS0xNTUyNw_2a0d27a7-cbe1-47d8-8e76-3b3a7ba73c61">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i832575ad734f4ac68adc394981e0dd95_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC04LTEtMS0xNTUyNw_27bb3636-0470-477b-98d7-37b33cd40f23">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f3ee615da3341d98188126debd31173_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xMC0xLTEtMTU1Mjc_adb97f8d-e7c9-4b38-87cc-ecfb911e902b">38,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33fdbec7cbe14bb58d66b46ff6a32efb_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xMi0xLTEtMTU1Mjc_0ab92b25-6ddc-4e24-9451-c347e928fa1f">21,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xNC0xLTEtMTU1Mjc_d1fadb71-eea4-43fa-b3a1-a1ef0e3f3f78">60,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aba2096009b41df80c66bfd01ec2c58_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNS0xMC0xLTEtMTU1Mjk_26366a8b-5090-4e47-8513-a2baa6c5a5aa">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNS0xNC0xLTEtMTU1Mjk_1b8a6051-a379-43c2-bb1e-8a92dd5536e9">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019 Note - beneficial conversion feature</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aba2096009b41df80c66bfd01ec2c58_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNi0xMC0xLTEtMTU1NDE_ecd593b9-ac48-4828-8f5e-b0f505ede70f">11,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNi0xNC0xLTEtMTU1NDE_7c550501-6fe8-4217-aee5-04ad5253b72a">11,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ad87a43bcfd47718c0aa0291e455eef_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNy0xMi0xLTEtMTU1MzE_b42aefeb-3021-44d2-bd71-ed6c73e331b0">11,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNy0xNC0xLTEtMTU1MzE_770ae365-b4f2-4d6e-948c-4f3cdbb30462">11,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c2000034bdf45109c782f320cd6a01d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xLTEtMS0xNTUzMw_a33abb28-d43b-4f99-8ef2-4e21f4b020ec">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2000034bdf45109c782f320cd6a01d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0zLTEtMS0xNTUzMw_101e38a2-a7ed-4ce2-896a-f8d336e4b5c3">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dacf172bede47d8a24654bfb96d5b2e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC02LTEtMS0xNTUzMw_96a2cb47-7b2f-4e57-a23e-0da33e119872">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dacf172bede47d8a24654bfb96d5b2e_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC04LTEtMS0xNTUzMw_ff5894a1-a0f7-4c86-987e-cc48282fa25e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89f99f3c856b4015a5874dbe44c7d459_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xMC0xLTEtMTU1MzM_5b3d3584-cce6-4f83-8d18-438d41736e53">26,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8760e90a1ba450cadb660bb033f985c_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xMi0xLTEtMTU1MzM_ff848105-bcf8-4695-bc79-11c0f423c1d9">32,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c2000034bdf45109c782f320cd6a01d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xNC0xLTEtMTU1MzM_6477c2fa-36b2-4eb9-82f0-b5b9e75c9ef5">59,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf47f3d3e3c429eb534fb4774e9f5cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOS0xMC0xLTEtMTU1MzU_016db425-b21c-4657-bd89-4004b5d1d9b5">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOS0xNC0xLTEtMTU1MzU_b5e7796f-b7c2-4c2e-b21f-7593cd254836">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i935c025cf0be4f52aa328da8cd08cdbc_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTAtMTItMS0xLTE1NTM3_9d51861d-1fae-4582-90f6-2bbd7ff189d1">20,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTAtMTQtMS0xLTE1NTM3_c59278cc-ace7-4d54-9d63-164d972be904">20,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMS0xLTEtMTU1Mzk_df7b34c2-59cd-4233-ab4e-8272fbffdf97">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMy0xLTEtMTU1Mzk_79fd2287-8e52-4bed-85f8-0c63429180dc">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fa3b845869d4942a592437637e60ccb_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtNi0xLTEtMTU1Mzk_64cef673-209f-4ce3-9c64-b079b52c04b0">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa3b845869d4942a592437637e60ccb_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtOC0xLTEtMTU1Mzk_45403cfa-b7bd-45b5-b007-c6fc84d1268b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3d63e6b69ff48ee80954424e39ed256_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMTAtMS0xLTE1NTM5_7777486c-ebdb-4786-bc0c-baf0a415ef9c">25,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae97d8956ab04cc2adbd33a7853f81d6_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMTItMS0xLTE1NTM5_5ec1d201-d2a6-43fc-8914-78510b5ecc41">52,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMTQtMS0xLTE1NTM5_ebe5933f-843c-4702-bd09-0139af5674a1">78,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_28"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc.<br/>Condensed Consolidated Statements of Cash Flows<br/>(In thousands)<br/>(Unaudited)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNC0xLTEtMS0zNjc_51deb2b4-bb0f-4fec-aaab-a31b5d6dd1c8">58,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNS0xLTEtMS0w_c73b741b-5293-4c78-b32b-fd99dfae55a5">35,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNi0xLTEtMS0zNjc_8eb46c8b-79b1-4ca2-b81c-09a046aaa9ec">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNy0xLTEtMS0w_6755105a-135c-468c-b501-9fe06250e064">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of debt discount and non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNy0xLTEtMS0zNjc_7899f75a-9361-4573-82be-1d3de0ae6500">10,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOC0xLTEtMS0w_5381ab0e-0793-4725-9257-7009ae85358c">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOC0xLTEtMS0zNjc_407f8931-84d3-46c4-8670-1b08430c95ad">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOS0xLTEtMS0w_b795f1c4-f60c-4fa9-ae32-21b893cce948">2,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:NoncashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOS0xLTEtMS0zNjc_ff5e9fa6-0ccb-47c9-98ad-99adf6afc15a">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:NoncashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMS0xLTEtMA_f69d22fd-9aba-4199-b4a6-a713f36b9c1c">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMS0xLTEtMzY3_48f335c1-5ed8-4f27-bbf2-ab9b7a111436">2,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMS0xLTEtMA_bd12f0c5-20d4-4b33-a8e1-5d9842bc6a37">3,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMS0xLTEtODcwMA_53ebeb16-31f0-45d3-883a-45de05be9977">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMy0xLTEtODcwNA_adf31b74-4445-42ef-9eb7-fabbfdb093dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMS0xLTEtMTQxMTE_541bf981-4f42-45f4-ae7f-c203704cbb16">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMy0xLTEtMTQxMTU_347b21a4-45e4-4bd9-aa9b-6ef2cdecdfb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMS0xLTEtMzY3_26ee9a50-4298-463f-b78e-94cab55bcf63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTItMS0xLTEtMA_56dd6107-33c8-4687-9708-3c9a7304b33f">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTQtMS0xLTEtMzY3_62128632-5d9d-47df-b204-72a7c075a7c3">482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTUtMS0xLTEtMA_0ff6d18d-03e5-4716-9114-ba5c061f9201">1,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTUtMS0xLTEtMzY3_66920f71-21e7-4d76-9eff-97594b657cdb">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTYtMS0xLTEtMA_faa09047-fdc2-4576-8c3f-eb215cbd2290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTYtMS0xLTEtMzY3_9eb13f7d-071d-45a8-848e-2e1679bf451b">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTctMS0xLTEtMA_01962807-bf49-4ea3-84bb-0d2319303813">848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTgtMS0xLTEtMzY3_e9f60d56-d810-4c79-a97b-9741c058e624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTktMS0xLTEtMA_4fb5dfb0-897a-4eec-80fc-bab7983b51d4">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTktMS0xLTEtMzY3_6a92e611-51fe-4183-8cfc-872d05334603">11,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjAtMS0xLTEtMA_b4f48a94-6f29-4498-908e-6e8126d89eca">3,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjAtMS0xLTEtMzY3_c5cf6b54-a75b-4ba5-ae37-0438145e95bd">6,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjEtMS0xLTEtMA_e255b91e-4e78-4532-8445-9fc7940bac6d">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjEtMS0xLTEtMzY3_6fa74411-a530-4d4a-b5ac-ea4de135738b">995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjItMS0xLTEtMA_e159dc63-ad1b-49f2-9d33-3a1fc94aa9ac">746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="inhibrx:IncreaseDecreaseContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjItMS0xLTEtMzY3_1217ad6e-bfe0-4f44-8255-8811b5fc342c">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:IncreaseDecreaseContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjMtMS0xLTEtMA_32257a70-f9ef-4cc2-9196-97550e2675cd">8,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, non-current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" name="inhibrx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjMtMS0xLTEtMzY3_653ece35-662d-4ab5-98ec-e1e9950335bf">830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjQtMS0xLTEtMA_afc768eb-51b6-4285-b494-189deef397b4">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjQtMS0xLTEtMzY3_a4b6ab33-e5bd-41d7-b68b-7e20bfb2716c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjUtMS0xLTEtMA_26deab64-6394-47c9-b9f9-1673ab1879bc">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjUtMS0xLTEtMzY3_3e094887-b29c-4fa0-bf7d-136175238250">32,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjYtMS0xLTEtMA_1ead2cc9-e653-45ce-97de-a788d466c8e1">20,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjctMS0xLTEtMzY3_8606b4d1-d02b-492c-8638-b1defd6e3f15">752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjgtMS0xLTEtMA_bbd877e2-f2c4-4c19-a576-c2716e7345e1">1,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjgtMS0xLTEtMzY3_910101ed-65be-4ee6-a217-5f6d0299a02f">752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjktMS0xLTEtMA_b6ef5f20-739e-4e77-808d-0fa8b2757cf4">1,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from initial public offering, gross</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMS0xLTEtODcyMw_b779037d-5f43-401b-aaa9-9ed65f28d232">136,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMy0xLTEtODcyNw_e32bff17-4fdf-4763-9c7f-a56f27b7caf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs associated with initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMS0xLTEtODcyMw_2c00cccd-35fb-4f1d-bcf6-995f51c5a9f5">10,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMy0xLTEtODcyNw_1d9ed9eb-40be-4df0-a6a8-8cd1b3d143e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred offering costs paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="inhibrx:PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMS0xLTEtMTMxNjY_c313ec9b-bd35-4950-9517-8766a8b67310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMy0xLTEtMTMxNjY_6f09c714-9dd8-4c80-8c5f-a40e0924041d">1,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMS0xLTEtMTMxNzQ_1cfe9c59-6ec5-46b1-9669-d99297695e94">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMy0xLTEtMTMxNzQ_3e69a09b-91c5-47e2-83a5-89d91675ae21">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs associated with the issuance of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="inhibrx:PaymentsOfDebtIssuanceCostsConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtMTMxODI_30decdd9-cd7c-4411-8d72-3c61f06faa00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:PaymentsOfDebtIssuanceCostsConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMy0xLTEtMTMxODI_2675fb08-35f4-4376-be18-3da410d5c4d3">2,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtMTMxNTQ_7d92b788-3994-4f97-b341-1f0c56a81dee">9,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMy0xLTEtMTMxNTQ_57d902c1-f885-46e3-b53e-af131016bce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of fees associated with debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:PaymentsOfDebtIssuanceCostsSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMS0xLTEtMTMxNTQ_a7023103-19ba-474c-948e-7a1065381379">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:PaymentsOfDebtIssuanceCostsSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMy0xLTEtMTMxNTQ_8ce5cd7b-c243-49e0-8eae-ac1f7bca267e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzctMS0xLTEtMTMxOTc_6fe57ec8-1561-4cd2-b723-dac302e0c780">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzctMy0xLTEtMTMxOTc_5dcc704a-160e-411d-9926-082370c637e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of principal on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzgtMS0xLTEtMTMxOTI_b2d96bf9-0fd0-45b3-aae0-180f1f9b8f68">2,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzgtMy0xLTEtMTMxOTI_b4757442-9b8f-4d25-8f40-5d38bcae24fa">4,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Final payment on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:RepaymentsOfSecuredDebtFinalBalloonPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzktMS0xLTEtMTMxOTI_36f8eb6c-d4ca-4684-89c2-8dc4c0e5351c">1,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:RepaymentsOfSecuredDebtFinalBalloonPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzktMy0xLTEtMTMxOTI_1cb40791-5e33-4092-9bc8-1cdfd462e86f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtODcyMw_4a98a05f-6ecc-4a0f-bf7b-91820a070ce9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMy0xLTEtODcyNw_3260933b-a7c8-43a6-8c4b-594a0fde72c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtMzY3_a4a76626-57ed-4200-aaac-8ba2ac6d3aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMS0xLTEtMA_7e568b35-dcf0-4432-8875-5b32a0490ada">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs associated with the issuance of preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="inhibrx:PaymentsOfStockIssuanceCostsConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMS0xLTEtMzY3_e8331616-fabb-4827-ac52-34c67d10356f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="inhibrx:PaymentsOfStockIssuanceCostsConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzYtMS0xLTEtMA_ad53968b-8313-4ffa-b825-aa132fb941d9">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDEtMS0xLTEtMzY3_3927fdaf-929f-4046-b6e8-5b55f72c259c">149,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDItMS0xLTEtMA_de309ff6-aef8-483e-8ed0-505563ea45e5">43,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDItMS0xLTEtMzY3_31dd0f80-d046-4fd2-bf32-fdcd8452bd06">116,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDMtMS0xLTEtMA_5d9b02f9-1fb3-4edd-aeaa-cf3c503e8308">22,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDMtMS0xLTEtMzY3_da0b6ee9-83a5-4153-b5a3-044db581d6a7">11,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDQtMS0xLTEtMA_9de4b936-4e74-498f-a7ee-f6788d8e8b86">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDQtMS0xLTEtOTM3_b06c9e4c-0300-4cc2-9386-3d234e444cb4">127,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDQtMy0xLTEtOTM3_2dbdb661-f287-4e9e-8972-952135d9b52d">24,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDctMS0xLTEtMzY3_506e1732-a5e3-45f1-b576-ab6ba34d4eb9">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDgtMS0xLTEtMA_992d93dd-95e7-4bd0-94ef-0388178c68f6">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDgtMS0xLTEtMzY3_650af386-e166-4d78-9aec-4e94a0b7d401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDktMS0xLTEtMA_68bd038b-1090-46ff-a7af-3481c051091a">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMS0xLTEtMTM1Mzg_2212e7e1-2cac-432a-8927-16d347c7c7d2">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMy0xLTEtMTM1Mzg_73fbaf5b-f459-486a-9eaf-eb4ba1d4b5d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of the 2019 Note and the 2020 Notes to common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjEtMS0xLTEtMTM1Mzg_a0caf5be-8e2f-4746-972c-b9ba520b4473">53,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjEtMy0xLTEtMTM1Mzg_3ab490b9-2879-4341-b43b-3b8a750666a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMS0xLTEtMTM1NTI_cef893a8-0bf4-484a-a283-1aba6b468dce">4,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="inhibrx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMy0xLTEtMTM1NTI_fc768870-2b4b-4090-a20a-a2fa96be467c">11,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMS0xLTEtOTc2Mw_1b3b2099-778e-4043-bfa1-356fc819a1fd">1,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMy0xLTEtOTc2Mw_800d3961-139a-425a-8c9e-8ce4fdb99111">8,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMS0xLTEtODc1Nw_c7b44e24-8d23-489a-9604-059b70470234">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="inhibrx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMy0xLTEtODc1Nw_4c95873f-563d-4c37-b67e-9c4c170622c9">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount related to derivative liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTctMS0xLTEtMzY3_9edbe2f5-b6fc-412a-9f4d-834718e6bbdd">735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTgtMS0xLTEtMA_371b5c96-2791-4287-b50f-24d775e5e490">900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:NonCashEstablishmentOfEquityMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzItMS0xLTEtMTM1OTY_2d01ec7d-c4cb-4169-95d4-ba7a0a2e443f">487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:NonCashEstablishmentOfEquityMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzItMy0xLTEtMTM1OTY_4c3e9dd3-da7c-413e-91aa-fe4ff62188eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial public offering costs included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzMtMS0xLTEtMTM2MDE_b01968fb-b002-4f58-bc87-86320de58c64">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="inhibrx:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzMtMy0xLTEtMTM2MDE_785610a2-972a-4a0d-9e1b-9952a1c335de">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities to equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:ReclassificationOfWarrantLiabilitiesToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTgtMS0xLTEtMzY3_a0578206-0e87-4f42-b365-cd11924eefe0">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:ReclassificationOfWarrantLiabilitiesToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTktMS0xLTEtMA_c712552b-7ff6-4d6e-adeb-087f32be3005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzUtMS0xLTEtMTM1Nzk_477fd667-6f98-4d36-99cb-c6c4d2bd2c46">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzUtMy0xLTEtMTM1Nzk_1f74b9c7-b63c-45f2-b272-fda47211be4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount related to warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="inhibrx:DebtInstrumentUnamortizedDiscountWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjUtMS0xLTEtODc0OQ_2ecd0d65-c57c-4088-b4eb-9cb76d0e3397">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="inhibrx:DebtInstrumentUnamortizedDiscountWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjUtMy0xLTEtODc1Mw_be7530a2-96c0-4609-a8e6-365546c1704f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payable for purchase of fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjYtMS0xLTEtODc0OQ_f56899f3-0a20-4214-8360-e191b1efa720">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjYtMy0xLTEtODc1Mw_1ce15ece-9d26-4ba1-804f-6dd90c143df1">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc.<br/>Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div id="iee91b9a90f804077b237584160b9370a_34"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NjUzNg_fe7f7410-ad58-4e84-bae4-3a84dff6f1f4" continuedAt="i3b7150ed00e84e9b85ff1ec3cc96bd05" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i3b7150ed00e84e9b85ff1ec3cc96bd05" continuedAt="i492bdcbc403e47baab98357693b6161f"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc. (the &#8220;Company&#8221; or &#8220;Inhibrx&#8221;) is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines a deep understanding of target biology with innovative protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design highly differentiated therapeutic candidates. The Company&#8217;s current pipeline is focused on oncology and orphan diseases. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;21, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) in which it sold <ix:nonFraction unitRef="shares" contextRef="i59e35846453d49108af294a83527115a_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDY0Nw_e1a76260-72c5-4322-aa12-a744f2631cc1">8,050,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i716fae2ef5ce4494a59333e61122850c_I20200821" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDY1OQ_826119da-a7f9-458a-a18d-fdfb617ba84a">17.00</ix:nonFraction> per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs were $<ix:nonFraction unitRef="usd" contextRef="i59e35846453d49108af294a83527115a_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDYxMQ_f3a3ff75-3422-4a54-a243-d27f738be75e">125.9</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of the following occurred in connection with the completion of the IPO:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of the 2019 Note and the 2020 Notes (each as defined below) into <ix:nonFraction unitRef="shares" contextRef="id7e5ed6c9480459caa6ba643143e71bb_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0NzU2Mg_1c771f04-064d-4a32-b7ed-8eec8f9659e1">4,294,603</ix:nonFraction> shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of all outstanding convertible preferred stock into <ix:nonFraction unitRef="shares" contextRef="i55e33ca65d2942a182ef960398078928_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0NzU2Ng_f52b7d97-d81f-49c0-a4fa-ccc8be3fbb1c">7,211,086</ix:nonFraction> shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0NzU3MA_c2ae56d8-78d5-499a-9800-b7c933ed6611">7,354</ix:nonFraction> shares of the Company&#8217;s common stock; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amendment and restatement of the Company&#8217;s certificate of incorporation, authorizing <ix:nonFraction unitRef="shares" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDYyNQ_e47d228a-2e15-4488-bc70-b9865daeec4a">120.0</ix:nonFraction> million shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDYzNQ_b87910b3-fec9-4717-8b74-317186a2ae3c">15.0</ix:nonFraction> million shares of preferred stock.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2020 the Company effected a&#160;one-for-1.7382&#160;reverse stock split of the Company&#8217;s common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion prices of the convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjM0Ng_8149dd62-0240-4c84-90db-8d578d6d6536" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) related to an interim report on the Form 10-Q. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.&#160;All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company&#8217;s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 19, 2020 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i492bdcbc403e47baab98357693b6161f" continuedAt="i3e79a207ea47495f9aa402c4818abe09"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="inhibrx:LiquidityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjQ3Mw_38b20353-8550-4829-bfe6-a8f179fabc5c" continuedAt="idd9aa0b8b9b34f12ae5607b99201e75f" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNjA0NzMxNDA0ODkwNA_59f84f40-c6aa-4f8b-a27e-fc6ba92dc2bf">127.7</ix:nonFraction> million and cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNjA0NzMxNDA0ODk0NQ_78cd1816-1e64-410e-b9f3-5face790cac1">127.7</ix:nonFraction> million. From its inception and through September&#160;30, 2020, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd9aa0b8b9b34f12ae5607b99201e75f">The Company believes that existing cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date of the filing of this Form 10-Q. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjUxNg_7b251fba-041d-4e2d-94ac-c6ee833491d2" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features within convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease, and valuation allowances for the Company&#8217;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjU3Mw_c3c6f19b-1a8e-4ba7-bd43-aa4af4261956" continuedAt="ie747985aad5149c3a61cc195273c62fa" escape="true">Fair Value of Financial Instruments </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie747985aad5149c3a61cc195273c62fa">The Company&#8217;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its current loan and security agreement (the &#8220;2020 Loan Agreement&#8221;) with Oxford Finance LLC (&#8220;Oxford&#8221;) and its former loan and security agreement, as amended (the &#8220;2015 Loan Agreement&#8221;), which has been terminated, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense and convertible notes approximate their related fair values due to the short-term nature of these instruments. The Company&#8217;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjU4NQ_5a7caa47-bdac-4829-b959-c9a5c576e6df" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i3e79a207ea47495f9aa402c4818abe09" continuedAt="i2ba3eb0bd7cb4458b8d0e5a9984d14e9"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjY4Nw_bb97d654-aa69-4b5a-b755-5bc4a62c5e77" continuedAt="ida0ff360fd2342ada503604f5edf4df4" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institution in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of September&#160;30, 2020 and December&#160;31, 2019, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida0ff360fd2342ada503604f5edf4df4">The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, (&#8220;WuXi Biologics&#8221;) pursuant to which the Company agreed, for <ix:nonNumeric contextRef="ie8dadc7ef039420eaa7b0c92264e86ca_D20200801-20200831" format="ixt-sec:durwordsen" name="inhibrx:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NDQzNA_d02a90ce-fc0b-46f9-93f7-a76e4387083c">three years</ix:nonNumeric> and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. The Company does not control the manufacturing processes of the contract development and manufacturing organizations (&#8220;CDMOs&#8221;) with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations (such as current Good Manufacturing Practices, &#8220;cGMP&#8221;), which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2Mjc4Mw_5e6e18f5-3041-4199-978b-43ac4ad86799" continuedAt="i2259909c365c42788126138ed134f85f" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has never declared or paid any dividends on its common stock. The Company currently intends to retain available cash for funding operations; therefore, it does not expect to pay any dividends in the foreseeable future. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2259909c365c42788126138ed134f85f">Additionally, the 2020 Loan Agreement with Oxford, limits, among other things, the Company&#8217;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2Mjg3OQ_554c6403-eb0c-44cb-b8c4-e09737856e0a" continuedAt="ie6788ad7f3ef4cffbd1afab2bd596ab0" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">machinery and equipment: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b">three</span> to <ix:nonNumeric contextRef="i3feb5c4ab8444992aad253b0eb3aac6c_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzY4Nw_ee642007-89a2-453b-946b-dc9eee28913c">five years</ix:nonNumeric>; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture and fixtures: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18">three</span> to <ix:nonNumeric contextRef="i31329f709cd646a1985943678e052e84_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzY4OQ_f8f1089b-dfda-47f7-98ba-8849d3ded290">five years</ix:nonNumeric>; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430">four</span> to <ix:nonNumeric contextRef="i87b2ff8ae24b4a848877e3577572b4fd_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDA4OQ_ed40d4ff-1720-4dfa-b21f-589aadb9ede6">five years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie6788ad7f3ef4cffbd1afab2bd596ab0">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzE1OQ_107c25b6-3ec6-499e-95ae-92c374a837cf" continuedAt="ieaeb41139be24358903cb0fbd95ccea1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i2ba3eb0bd7cb4458b8d0e5a9984d14e9" continuedAt="i08131eedc8b3467ea462e85e66c22ebd"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieaeb41139be24358903cb0fbd95ccea1">based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its condensed consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzE2MQ_cd13de4f-7a33-40b9-b095-7ba7454c67e5" continuedAt="i0df74bd1409147dcbd036a463690b9dd" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:NumberOfOperatingLeasesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE3ODAzOA_8d97d483-f415-4376-9bce-a988fc87cbee">two</ix:nonFraction> existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#8217;s facilities, which commenced in January 2020. This amendment is accounted for as a separate lease. Leases are reviewed and classified as operating or financing leases at commencement. The Company&#8217;s existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its condensed consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its condensed consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the condensed consolidated statements of operations for all periods presented. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0df74bd1409147dcbd036a463690b9dd">Agreements are reviewed at inception to determine if they contain a lease.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NDQ0Ng_2b3f90c0-7c2d-4702-bdca-38632f416f38" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 8, the Company received an equity investment in the form of a <ix:nonFraction unitRef="number" contextRef="i678ba84787b74c33aaa1dabda2391b12_I20200731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NjU0MQ_1679b6bd-7996-4565-b4e3-a8d15db70072">10</ix:nonFraction>% equity interest as consideration in a series of agreements with Phylaxis BioScience, LLC (&#8220;Phylaxis&#8221;), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the condensed consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. As of September&#160;30, 2020, the Company&#8217;s equity method investment has been written down to <ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI2Mzg1OQ_bd696a96-0e8c-4146-8cb0-962e3bbcc124">zero</ix:nonFraction> as a result of the allocation of the Company&#8217;s share of losses of the investee.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzIzMg_cb4beb87-3412-4ddd-986c-058242b76acb" continuedAt="ibda34040bc024d88948b4e4d6ae69258" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, the convertible promissory note (the &#8220;2019 Note&#8221;) issued in May 2019 to DRAGSA 50, LLC, an entity affiliated with Viking Global Investors LP (&#8220;Viking&#8221;) and the convertible promissory notes (the &#8220;2020 Notes&#8221;) issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#8217;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determined certain of the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i08131eedc8b3467ea462e85e66c22ebd" continuedAt="ic49bc39b3d874d1bbd72169b87b8ad5f"><ix:continuation id="ibda34040bc024d88948b4e4d6ae69258"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock. As of September&#160;30, 2020, the derivative liabilities no longer exist.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="inhibrx:WarrantLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTU5NDI5MTg3MTE0OTc_9eac04b8-5fd4-48c7-94da-cbddf4cb1bc3" continuedAt="id7f91267c90f44009156226ac1e35650" escape="true">Warrant Liabilities</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7f91267c90f44009156226ac1e35650">As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#8217;s IPO, the warrants were deemed to be issued for the purchase of common stock and were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the condensed consolidated statements of operations during the three and nine months ended September&#160;30, 2020.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzM0MA_b9494d33-6e2c-4945-a47a-3a5f32717f2d" continuedAt="ib4d1c02ac44f4558bae1493bd04372be" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific&#160;to the asset or liability. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib4d1c02ac44f4558bae1493bd04372be" continuedAt="i96397cf9ef394ea1841639aeb1411b09">The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 5). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020 and as of September&#160;30, 2020, the derivative liabilities and warrant liabilities no longer existed.</ix:continuation> <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzUwNw_7a2d9914-e8b4-4cae-8a6e-a8a6eb483d4e" continuedAt="iaf01051370274596a401570c3ba24c2d" escape="true">The following table presents the Company&#8217;s financial liability that was measured at fair value as of December&#160;31, 2019 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><ix:continuation id="iaf01051370274596a401570c3ba24c2d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97607866f6cc41cc94cca89d10cf6bdc_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy0xLTEtMS00MTU1_dc8afaca-ec62-4b1a-a9bd-f42d584ae471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbaed7d7d47475091f2e4ab91488da7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy0zLTEtMS00MTU1_f0c45eac-e42d-4972-98c5-f8b5ee348bbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c38f2ed7fa44b4a81fe1f1eed88df2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy01LTEtMS0w_327cb2ec-c029-49d1-8291-63eac5e206d8">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy03LTEtMS00MTU1_4eea1d9e-0a70-486f-b41e-3b122b9e1929">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i96397cf9ef394ea1841639aeb1411b09" continuedAt="i00bb5b1b0c134c129e92dc2d14d92c1a">Prior to the completion of the IPO in August 2020, the Company&#8217;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement.</ix:continuation> <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1NA_aad7b531-7d57-49ba-abbc-44e055f1dfbf" continuedAt="id0cc4f8a35b34df8be9d4c61fea4ac5a" escape="true">The following table provides a </ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="ic49bc39b3d874d1bbd72169b87b8ad5f" continuedAt="ied40312b3dc84817851c2df268719460"><ix:continuation id="id0cc4f8a35b34df8be9d4c61fea4ac5a"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the nine months ended September 30, 2020 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2104115bc94b9fa8ac3b4e7d8a5952_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfMi0xLTEtMS0w_7c55e233-ae57-4dd1-8495-8aadc553ac82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2019 Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f268e0f7dca45f9b9332914738e6f74_D20190101-20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfMy0xLTEtMS0w_cdc4ff4a-ff96-4c10-94d1-1cb157480db3">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac814f782c3b45af984e9c168fd5b2c1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNC0xLTEtMS0w_d2b821f6-3993-4aa4-8c8d-a5f0be9adabd">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9257d69f32004657829030276365dab2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNS0xLTEtMS0w_fe4cb552-88b3-49ef-9880-53f095f1f8d1">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34eb3903a88c4cf4a2c174b773b1619b_D20200101-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNi0xLTEtMS0w_99ba6879-fbe9-4953-bd28-7b2f8ccfa09b">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of warrant liabilities on the 2020 Loan Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNy0xLTEtMS05MTgy_1d2cdc84-d62d-4733-963c-2d3a941c636d">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities on the 2019 and 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d33748b115443b382ab613199d390b0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNy0xLTEtMS0w_061f5847-ddcd-4728-ab81-28a2d670a069">2,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfOS0xLTEtMS05MTg2_4f84f214-9348-4dab-b2f6-63cc828146dc">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930" decimals="-3" name="inhibrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfMTAtMS0xLTEtOTE5MA_c67400e9-f826-4925-bfb5-eeb2eef054b8">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853b5ffb64fa4b6c9270743f860795a1_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfOC0xLTEtMS0w_83cc2edc-9bac-4a28-877f-2c4f7b09c60c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00bb5b1b0c134c129e92dc2d14d92c1a">The fair value of the Company&#8217;s derivative liabilities categorized in Level 3 of the fair value hierarchy as of December&#160;31, 2019 was determined based upon an independent third-party valuation report which used a lattice model. The valuation report utilized unobservable inputs, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s 2019 Note and the 2020 Notes (as discussed in Note 5), such as an IPO, financing, or extraordinary event, and the current valuation of the Company through an independent third-party valuation report. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of September&#160;30, 2020, the derivative liabilities <ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfOTg5NTYwNDc1ODUxNA_f24ac222-09ce-4288-b759-7375d12de94a">no</ix:nonFraction> longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon Qualified IPO. Additionally, as of September&#160;30, 2020, the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#8217;s IPO.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1Mw_5219bd6e-3184-4e26-b40d-f6c720c514bb" continuedAt="i04ac34967ccf48e5b4e19a943e14a328" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the condensed consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i04ac34967ccf48e5b4e19a943e14a328">Legal, accounting, and filing fees related directly to the Company&#8217;s IPO were capitalized as deferred IPO costs to be offset against proceeds upon the consummation of the IPO within stockholders&#8217; equity (deficit). In August 2020, the Company completed its IPO and offset $<ix:nonFraction unitRef="usd" contextRef="ic48577e54c534c9cb159d018b57d9192_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0Nzg0OA_c029622b-63b1-47fc-a90f-9b7dd293c7db">11.0</ix:nonFraction>&#160;million of IPO costs against the proceeds. As of September&#160;30, 2020 and December&#160;31, 2019, no deferred IPO costs were capitalized on the Company&#8217;s condensed consolidated balance sheets.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1NQ_26e4152a-3acc-42d5-928a-4735d607bd95" continuedAt="i6aeb8450e8894b339149e0aab36e22fb" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies such as the National Institutes of Health (&#8220;NIH&#8221;) and the Congressionally Directed Medical Research Program (&#8220;CDMRP&#8221;) funded through the Department of Defense (&#8220;DoD&#8221;), as well as from private not-for-profit organizations including Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#8220;CARB-X&#8221;). Payments received from customers are included in deferred revenue, allocated between current and non-current, on the condensed consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="ied40312b3dc84817851c2df268719460" continuedAt="i2467706849d84bf9a37c0abb7350be01"><ix:continuation id="i6aeb8450e8894b339149e0aab36e22fb" continuedAt="i483b36ccc514480ea01c42b44952bf30"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;). The Company&#8217;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has been awarded multiple grants from the NIH, one grant from the CDMRP funded through the DoD, as well as one grant from CARB-X. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the&#160;condensed consolidated&#160;statements of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#8220;customer&#8221; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. Since the Company has concluded that these </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i2467706849d84bf9a37c0abb7350be01" continuedAt="i6acf2deef9f74adaad0b990632bf1f28"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i483b36ccc514480ea01c42b44952bf30" continuedAt="ie205801f5ce844d387b99a10c3a5dea2">grants do meet the definition of a contribution and are indeed non-reciprocal transactions, the adoption of ASC Topic 606 had no impact on the Company&#8217;s accounting for grant revenue from governmental agencies or private institutions not considered customers. </ix:continuation></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie205801f5ce844d387b99a10c3a5dea2">Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1Ng_7ce4d320-8c6a-4f31-a470-fe946a004193" continuedAt="if1ca645ef29b4a65b8510ed82154b129" escape="true">Research and Development and Clinical Trial Accruals </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if1ca645ef29b4a65b8510ed82154b129">Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed by third party contract research organizations (&#8220;CROs&#8221;) and/or clinical investigators. The Company also engages with CDMOs for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1Nw_28ec5f78-c081-4c44-9896-e81feb6e46b0" continuedAt="i470c267a6a4844758061431e323dc96c" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i470c267a6a4844758061431e323dc96c">The utilization of unused federal and state net operating losses (&#8220;NOLs&#8221;) and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended (&#8220;IRC&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1OA_75d725ec-b527-44ca-a951-dc744ed14f2d" continuedAt="i4d7105566e8b4bed84738a2c900cc25c" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i6acf2deef9f74adaad0b990632bf1f28" continuedAt="iee885147d7384d0e81ef0cc437dae6f7"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4d7105566e8b4bed84738a2c900cc25c">For purposes of the diluted net loss per share calculation, the convertible preferred stock, convertible notes, warrants for purchase of common stock, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the three and nine months ended September 30, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</ix:continuation></span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1OQ_3788b7b2-3ede-44ba-bf15-60deacd43d8d" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities that could potentially decrease net loss per share in the future were not included in the determination of diluted loss per share as their effect is anti-dilutive (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0ac33289ae142bd80d836a856c99abf_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfMy0xLTEtMS0xMjMyOA_b2475061-a0f4-45f9-b543-8bd5ea02637d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ce0cd624534b4fb3a651217b134e1e_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfMy0zLTEtMS0xMjMyOA_a06c715e-7265-4293-b86f-818447593ccf">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1b460d94a844e52ade7a0f2b9ab1b9f_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNC0xLTEtMS0xMjMyOA_fd8e473d-674a-4ff4-81b8-caab9a53c9ba">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0f30e90da64a8baa297d499a8884ff_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNC0zLTEtMS0xMjMyOA_ad49c613-bc32-471c-8b98-8e1a5128f04e">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbde3532e59e43b4a2a437f33e108ffd_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNS0xLTEtMS0xMjMyOA_ff790e6c-9441-4251-84d4-1351d3801306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06bcfbe172b34cf880f671de4e455fd8_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNS0zLTEtMS0xMjMyOA_78726cb7-2d72-4b3b-949a-2508a562476f">2,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f7d4dd51b19431eb1b4a19269978732_D20200101-20200930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNi0xLTEtMS0xMjMyOA_27caa30e-c8e6-478d-918d-2d819d1094b3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iced870049b9c4af8a2a71c8e3372f3bd_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNi0zLTEtMS0xMjMyOA_d7951b6b-bac8-4c87-baf1-7901213a68e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNy0xLTEtMS0xMjMyOA_a5a6537b-309d-4fee-bc83-c1eb3645377a">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNy0zLTEtMS0xMjMyOA_180553cd-47a4-4f37-8511-13acb63cfb47">12,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  The conversion of the convertible notes into common stock assumes a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib34ba14de47a44d4bbeebf803e29fcda_I20200930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI1MzM5MA_8fbb0af8-8c35-41fb-9ad8-f298c0f65512">14.35</ix:nonFraction> per share for the 2019 Note and $<ix:nonFraction unitRef="usdPerShare" contextRef="ifd6dd439011c4044a8417377d85ed8ee_I20200930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI1MzQyNg_96020c96-a350-41c2-86a7-8d30b490b2ce">12.56</ix:nonFraction> per share for the 2020 Notes, and includes the conversion of the principal balance and all accrued interest as of the stated date (see Note 5).</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NzIxMw_69b4ac43-18e8-4691-b300-59b47d07829b" continuedAt="i0a4f1beea2564cd1a4863ba64134a0b0" escape="true">Fair Value of Stock-Based Awards </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a4f1beea2564cd1a4863ba64134a0b0">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NzI0Nw_897820c2-922f-409c-b1a7-f70af61a6092" continuedAt="if56817fb04604638ada53b8076bead2f" escape="true">Other Comprehensive Income </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if56817fb04604638ada53b8076bead2f">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NzI0OA_ca8e20f7-da6d-4c8f-94a9-4cb000024064" continuedAt="i36127c711c014bddb1f65d592dd1422e" escape="true">Segment Information </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i36127c711c014bddb1f65d592dd1422e">The Company operates under <ix:nonFraction unitRef="segment" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE3ODA0OQ_cc79d5ac-aba6-48a1-8e7e-8dee930f6113">one</ix:nonFraction> segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.</ix:continuation> </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE3NTU0OA_f01854f0-b692-4021-8604-f8e9e555a02d" continuedAt="i6dbe4968933b4cbfabf94ce8bdf28361" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its condensed consolidated financial condition or results of operations upon adoption. The Company has irrevocably elected not to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act of 2012, as amended (&#8220;JOBS Act&#8221;), for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, which includes amendments intended to improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and affects companies that are required to </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="iee885147d7384d0e81ef0cc437dae6f7"><ix:continuation id="i6dbe4968933b4cbfabf94ce8bdf28361"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include fair value measurement disclosures. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company adopted this guidance as of January 1, 2020, which did not result in a material impact on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard will be effective for the Company on January 1, 2023 or at such time where it is no longer a smaller reporting company. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the potential impact that the adoption of ASU 2019-12 may have on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted, but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the potential impact that the adoption of ASU 2020-01 may have on its condensed consolidated financial statements and related disclosures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Subtopic 470-20) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 815-40): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its condensed consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMTU5NDI5MTg2MDQzNjI_6de4bdfa-5aec-4720-ad7c-b82b102758ba" continuedAt="i2a2dc0a3ab18430f832e6ca3ff35497c" escape="true">OTHER FINANCIAL INFORMATION </ix:nonNumeric></span></div><ix:continuation id="i2a2dc0a3ab18430f832e6ca3ff35497c" continuedAt="i2a3fb2f618c84280aba38640503488b7"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMjc0ODc3OTA3MTAxMw_d82d5d24-8b0b-46a0-b7db-4607ae26cfd1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNC0xLTEtMS0w_cbfb8b6f-6683-4b42-b329-53ef960f574e">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNC0zLTEtMS0w_f7c1bdd8-2005-471f-bb8b-1cb18d76a7ca">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNi0xLTEtMS0w_6759d638-cda2-4e29-bda0-65b87ea89d6e">972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNi0zLTEtMS0w_2e03d537-5efd-4137-ad98-7e41a9199364">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNy0xLTEtMS00Njk1_26b69d08-3415-482d-8e52-934d1645014a">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNy0zLTEtMS00Njk1_6491d7e0-6ef3-4f35-8582-2fca235f04bf">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMjc0ODc3OTA3MTAxNA_23d39ee4-224f-4a33-9d5c-a47a52a880be" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7dd225fb7244d46a1448835a24eedc8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNC0xLTEtMS0w_77cce2fe-6213-4c0f-a974-7cde1ffc5606">5,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4771026d5c3c40319d148f5c1fcdb3cd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNC0zLTEtMS0w_67dc4e88-ba7b-42f3-9e76-dc3eabffff64">4,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099bcc18560648f6b4af3ed81b2359f0_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNS0xLTEtMS0w_50d53b31-9585-4aaf-9cc7-a79500206553">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc99fb23a741432181c70887a43007ec_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNS0zLTEtMS0w_782b6c7f-f758-4a04-992e-d1a9f8e9474a">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55cc14d646e5495391d1f2b7134f4a82_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNi0xLTEtMS0w_f97462a3-2664-49b6-bdbd-1dd000bb3981">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575d68e93bc24286964f7a4a6a71af6d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNi0zLTEtMS0w_978c011b-a1af-473a-9028-0460404ab895">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f581b24f01849d48dc4babb1fee7e16_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNy0xLTEtMS0w_3b07abd9-03ea-4b4e-932e-8117e5b74c67">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa0ca10369144789935f71aa0d4b1c5_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNy0zLTEtMS0w_515fe0b7-045b-4935-b83d-1f7c8741fab6">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOC0xLTEtMS00NjU4_8b3e2925-dc66-4917-8ddd-6260206f3ff3">6,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOC0zLTEtMS00NjU4_98710976-b2d5-49fc-b3e5-bbc772dafb93">5,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOS0xLTEtMS0w_99510fc6-54ff-4001-a2f5-a615ae1deff0">3,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOS0zLTEtMS0w_918565d8-143d-4a7a-b862-415960ccd666">2,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfMTAtMS0xLTEtNDY1OA_449a655a-67b3-41e3-8c37-521b6587d274">3,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfMTAtMy0xLTEtNDY1OA_b2520ca5-03d1-4e79-be59-fa013ea7a1e7">3,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDQ3MA_b687af23-b87b-4d69-958e-783628790fc6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDQ3OQ_1ab0589b-94d8-4a2b-b7e8-eba733448351">0.5</ix:nonFraction> million for the three months ended September 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDM2MA_1ab28182-afe1-4d09-a591-ddef7ba53925">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDM1MQ_0e2a30c8-45b4-4650-8b42-d193a388e754">0.9</ix:nonFraction> million for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMjc0ODc3OTA3MTAxNQ_9d6b3746-c25d-4983-9730-876a7054caa2" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:AccruedResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNC0xLTEtMS0w_a8f4dd7f-bd8c-46f3-be1c-e26beaa31916">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:AccruedResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNC0zLTEtMS0w_dc56ddf4-9d62-426a-bf39-aebe47d25852">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0xLTEtMS0xMzQzOA_98031ae4-0cec-494b-80f5-da0f15c27c66">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0zLTEtMS0xMzQzOA_29275bb9-b932-4d10-add3-e9db8a4146cf">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0xLTEtMS0w_369f6fd2-fcaa-4058-a47b-b5620654254b">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0zLTEtMS0w_6ff8bcc0-3285-40cb-9582-1891aae709db">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOC0xLTEtMS0w_eb1a7c6b-306f-4dfc-8efd-e28dbb953b65">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOC0zLTEtMS0w_40560a59-a647-40d5-a2f5-cbbabbbfe836">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOS0xLTEtMS00NzM0_064a38cf-ee06-43bc-b66e-22c5d04ea795">11,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOS0zLTEtMS00NzM2_48356660-b7e2-40b5-ab74-f7f784fc8859">4,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a3fb2f618c84280aba38640503488b7">The amount accrued for research and development expense relates primarily to the Company&#8217;s increased usage of third-party CROs and CDMOs for preclinical, clinical and development efforts as its therapeutic candidates progress. See Note 1 for further discussion of the components of research and development.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTMxOA_fc9539cf-cb49-4bec-9e45-2742dfd0bd8e" continuedAt="i687e1c52c929410cb1142ca490907f49" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="i687e1c52c929410cb1142ca490907f49" continuedAt="i193616096d534f1f817dc17ec719a488"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts owed pursuant to the 2019 Note, the 2020 Notes, and the PPP Loan (defined below), the Company&#8217;s debt balance as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following under the 2015 Loan Agreement and the 2020 Loan Agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had no outstanding balances under the 2015 Loan Agreement. As of March 31, 2020, the Company had repaid its Oxford Term Loans under the 2015 Loan Agreement in full, including all principal balances, accrued interest, and the $<ix:nonFraction unitRef="usd" contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NDQyNA_4f7ef53f-c507-48eb-85dc-b651c8778338">1.4</ix:nonFraction> million final payment. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTMyMA_98d730ac-e40f-4586-83d8-da9f8536ed65" continuedAt="i2dc335b336194c63b4a5128a63a66020" escape="true">As of December&#160;31, 2019, the Company&#8217;s outstanding debt balance under the 2015 Loan Agreement consisted of the following (in thousands).</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><ix:continuation id="i2dc335b336194c63b4a5128a63a66020" continuedAt="ib55839557ede4654915e403acb2b7d73"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.849%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1492990af4cd4609ab13680229c0d787_I20191231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfMy0zLTEtMS0w_f8525306-631f-49b3-a7ea-4bc75b5ba7d1">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dbb72e83b64adc8434cf549fd94175_I20191231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNC0zLTEtMS0w_e6c59945-a0f8-475a-bd90-295c7c202b2f">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12196a7c26a24c34983264cd528c02a4_I20191231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNS0zLTEtMS0w_d5441467-8210-4714-8bc6-3fcb8b3d48f8">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2e8e28f6944a6cad3e341eddbd124d_I20191231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNi0zLTEtMS0w_1de62404-0c64-4a9b-ac3a-e09fd2a84941">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNy0zLTEtMS0w_90be6f6b-b165-4c03-88ea-286fc20bd961">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfOC0xLTEtMS02NTY0_4fc08ef2-950d-4849-9590-8c7d074c3b9b">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfOS0zLTEtMS0w_47c708be-29c2-437c-a09b-2a495d69fc6d">3,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfMTAtMS0xLTEtNjU3NQ_23fbccb2-748a-4185-b6b7-ac7bf6a2b9ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;15, 2015, the Company entered into the 2015 Loan Agreement, pursuant to which Oxford agreed, subject to certain conditions, to make term loans to the Company in <ix:nonFraction unitRef="loan" contextRef="i73adcaf6ee1947b18f6562d5ec941caf_I20150315" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:DebtInstrumentNumberOfTermLoans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTExMDI2OA_6dfbd30a-c061-4897-b46d-63aabcd6faeb">four</ix:nonFraction> $<ix:nonFraction unitRef="usd" contextRef="i1128b89e97354edab268af53bdbb2cfc_I20150315" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_0406a27b-a3ad-43c5-b1e1-c10a9fa70856"><ix:nonFraction unitRef="usd" contextRef="i968d197dbe54493980d0c6601895286d_I20150315" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_2080eabf-b369-405a-b4ab-c5482725c50a"><ix:nonFraction unitRef="usd" contextRef="iedc8c75d167c4002ae62b4656fc8dc96_I20150315" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_b5a600a9-8640-4a80-b8b7-bd49da03b093"><ix:nonFraction unitRef="usd" contextRef="icc18af2d45e5429aa46b9f3c1c60dacf_I20150315" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_ddb5b468-51ac-4e59-bd9d-d6306e7d95fe">5.0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million installments for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i73adcaf6ee1947b18f6562d5ec941caf_I20150315" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTE3_626ff745-bff1-45c9-9c04-66d0dad0062d">20.0</ix:nonFraction> million. The term loans were made on the following dates: (1) Term A: March&#160;31, 2015; (2) Term B: September&#160;9, 2016; (3) Term C: December&#160;22, 2016; and (4) Term D: December&#160;22, 2016. The proceeds from these loans were designated for working capital and general business purposes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2015 Loan Agreement, Oxford had a senior-secured lien on all of the Company&#8217;s current and future assets, other than its intellectual property. Oxford also had the right to declare the term loan immediately due and payable in an event of default under the 2015 Loan Agreement, which includes, among other things, a material adverse change in the Company&#8217;s business, operations, or financial condition or a material impairment in the prospect of repayment of the term loan. Throughout the life of the 2015 Loan Agreement, the Company was in compliance with all covenants under the 2015 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each term loan bore interest at the following annual rate: (1) Term A: <ix:nonFraction unitRef="number" contextRef="if717d2bbf6df424fbf967687e556c917_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTU1Ng_486d5b08-1e51-47fa-a16c-16c1d9743a05">8.0</ix:nonFraction>%; (2) Term B: <ix:nonFraction unitRef="number" contextRef="ib7a2211031b8411a97f1eedd40de2aea_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTU3Mg_6b398089-770f-4956-9b93-0645bcedd271">8.6</ix:nonFraction>%; (3) Term C: <ix:nonFraction unitRef="number" contextRef="i39bd4629e345403594bc83286802f27d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTU4OA_7908fcc8-612b-454d-a5d1-867553088cb9">8.7</ix:nonFraction>%; and (4) Term D: <ix:nonFraction unitRef="number" contextRef="ib431edb342fd4664ae233fef94fbc459_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTYwOA_0dd60c04-b1b7-4d7a-865e-053f783abd3c">8.7</ix:nonFraction>%. The repayment schedule provided for interest-only payments in arrears until May 2016, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date, which was March&#160;31, 2020 (the &#8220;Maturity Date&#8221;) for all four term loans. The Company had the option to prepay the outstanding balance of the term loans in full prior to the Maturity Date, subject to a prepayment fee of up to&#160;<ix:nonFraction unitRef="number" contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331" decimals="INF" name="inhibrx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjAyMQ_3d3bf1fc-192b-4eca-84ec-471cdddf03a2">3.0</ix:nonFraction>%. Upon repayment of each term loan, the Company was also required to make a final payment to Oxford equal to&#160;<ix:nonFraction unitRef="number" contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331" decimals="INF" name="inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjEzMg_ddb9098d-eb08-4fcd-9562-c1bb95474903">7.0</ix:nonFraction>%&#160;of the original principal amount of each term loan. This final payment of $<ix:nonFraction unitRef="usd" contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjIwOQ_4f7ef53f-c507-48eb-85dc-b651c8778338">1.4</ix:nonFraction> million was accreted over the life of the 2015 Loan Agreement using the effective interest method. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s issuance of its first and second tranches of debt, Oxford also received <ix:nonFraction unitRef="shares" contextRef="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjQxMA_a6223e19-ebc9-4550-824c-5279a4abc1c3">33,650</ix:nonFraction> profit interest units (&#8220;PIUs&#8221;), which had a per unit value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjQ0OQ_c8914edf-3764-4b2f-a400-939a38c41380">3.50</ix:nonFraction>, for a total value of $<ix:nonFraction unitRef="usd" contextRef="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjQ3NA_b0611b2d-fbe1-4aa5-9453-0d8602148aca">0.1</ix:nonFraction> million. This was recorded as a debt discount and is being amortized using the effective interest method. The PIUs issued to Oxford were converted into <ix:nonFraction unitRef="shares" contextRef="ia44998013bed488a89c12a2bbbf5d413_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjYyMQ_b1261ee0-c2aa-45f8-a83f-6b9c5c02b589">33,889</ix:nonFraction> shares of the Company&#8217;s common stock in connection with the Company&#8217;s merger with various affiliated entities in April 2018, in which the Company was the surviving corporation. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i193616096d534f1f817dc17ec719a488" continuedAt="i55f3c95d623d47b987d730eedf821f3d"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest expense related to the Oxford term loans for the three months ended September 30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i75b1864cd5ba4d82ad35132d3bf4651c_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTEwMTEzMA_6eabc866-a704-4975-aeea-4ee9f1e8af9d">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9a5bfebe16ba4d42b9420939d6abd37e_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY1Mw_7ba5b521-899f-42d0-beea-79e009eaeb33">0.1</ix:nonFraction> million, respectively, and for the nine months ended September 30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="if576809f1ef74d2dae834e212f4c787a_D20200101-20200930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE0ODcwNQ_a42f0a2d-d411-461b-9ade-2a3a68c5fdb5">0.04</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie8b1c64897a0450b8b676d88f5779c65_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY2MA_0a55c0f0-0ebc-4167-8277-91c8f8ca75fa">0.6</ix:nonFraction> million, respectively. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><ix:continuation id="ib55839557ede4654915e403acb2b7d73"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company&#8217;s outstanding debt balance under the 2020 Loan Agreement consisted of the following (in thousands).</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.849%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfMy0xLTEtMS02NjA5_749a47cc-c3cc-4689-aab1-814e84975efa">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNC0xLTEtMS02NjA5_b4b77a21-da19-4908-9db3-7989936e93a6">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNS0xLTEtMS02NjA5_f56f3dc3-d77e-46c2-9457-7b6c9ae9373e">9,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNi0xLTEtMS02NjA5_52b12f86-693b-4166-86b9-2d89614fdef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNy0xLTEtMS02NjA5_c0790c89-8124-4259-833e-dedd7366a9eb">9,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTExMDI3Nw_7eb074ce-8c2e-4b80-b538-8779e2a87462" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the total future minimum payments, which consist of the future contractual principal and final fee payments, on the Company&#8217;s debt are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.849%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfMy0xLTEtMS0xNTIwNg_fce48a0e-e2a3-45b5-b787-f5d1d800c771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNC0xLTEtMS0xNTIwNg_f702a611-bb62-4e90-b98d-73c00c9ff438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNS0xLTEtMS0xNTIwNg_d289a6bf-8cdc-4343-985c-d8df48648fdf">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNi0xLTEtMS0xNTIwNg_191f8b78-d1c5-4604-afaf-d7969ba442f7">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNy0xLTEtMS0xNTIwNg_c514c17e-2a91-4535-81c9-2b633793c914">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfOC0xLTEtMS0xNTU2MA_8a1f5f12-5fe5-4732-a303-a09425501b95">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfMTItMS0xLTEtMTUyMTE_554305e7-4b3d-46de-8cef-aa8da61f501e">879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id069de05c44b419a8bc04341e87faf34_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfMTAtMS0xLTEtMTU1NjA_e09acd98-d850-401d-9564-ff3b64d8dfa1">9,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;15, 2020, the Company entered into the 2020 Loan Agreement with Oxford, pursuant to which it received&#160;$<ix:nonFraction unitRef="usd" contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY4Ng_2b0b7475-15ec-4f6a-a6ef-6f65198ca208">10.0</ix:nonFraction> million&#160;in gross proceeds, net of $<ix:nonFraction unitRef="usd" contextRef="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY5NA_97fb80db-e3dc-4eb6-9d73-541bfcb36d5d">0.1</ix:nonFraction> million of debt issuance costs (the &#8220;Term Loan&#8221;). The outstanding Term Loan will mature on August 1, 2024 (the &#8220;Maturity Date&#8221;) and bears interest at a floating per annum rate equal to (1)&#160;<ix:nonFraction unitRef="number" contextRef="ifab34d6750ef4bf6b880aa50a8da757b_D20200715-20200715" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDcwMQ_0b8ebc55-83b4-4a97-814d-7488979918b8">8.95</ix:nonFraction>%&#160;plus (2) the greater of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715" decimals="INF" name="inhibrx:DebtInstrumentVariableRateFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDcwNQ_8f8f2107-fda5-481b-9eca-de16c5b5bc2d">1.00</ix:nonFraction>%. The repayment schedule provides for interest-only payments beginning on September&#160;1, 2020 and continuing for <ix:nonNumeric contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715" format="ixt-sec:durmonth" name="inhibrx:DebtInstrumentInterestOnlyPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTEwMTM3Nw_c423847a-2378-493a-9847-1df606017fc1">24</ix:nonNumeric> months thereafter. The interest-only period is followed by <ix:nonNumeric contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715" format="ixt-sec:durmonth" name="inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTEwMTE4NQ_12b22213-588e-4643-bbc3-83d686208ad8">24</ix:nonNumeric> months of equal payments of principal and interest. Upon the Maturity Date, a final payment of <ix:nonFraction unitRef="number" contextRef="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715" decimals="INF" name="inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDczNA_01f715ef-804f-4f37-be4c-38dbf9da72a3">7.0</ix:nonFraction>% of the original principal amount will be due to Oxford. This final payment of $<ix:nonFraction unitRef="usd" contextRef="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3OTY4OA_07f364c1-80d4-4035-93e4-2045949844b2">0.7</ix:nonFraction> million will be accreted over the life of the 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the Term Loan in full prior to the Maturity Date, subject to a prepayment fee ranging from <ix:nonFraction unitRef="number" contextRef="i802d90f694e04e9cbc8a950326d54eca_I20200715" decimals="INF" name="inhibrx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTM0Mw_18e58670-759b-4518-9c7f-34f6d07ac317">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i080025cf9ef84898b13a4a46dd987fa0_I20200715" decimals="INF" name="inhibrx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTM0OQ_f4ddf713-2afb-419a-976f-eb2c77d0301f">3.0</ix:nonFraction>%, depending on the timing of the prepayment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to use the proceeds from the Term Loan solely for working capital and to fund its general business requirements. Its obligations under the Loan Agreement are secured by a first priority security interest of substantially all of the Company&#8217;s assets, other than its intellectual property. The 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding Term Loan. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance, the Company issued to Oxford warrants to purchase shares of the Company&#8217;s capital stock equal to <ix:nonFraction unitRef="number" contextRef="i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715" decimals="INF" name="inhibrx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjUxOA_78d8ecf3-72d3-48a9-bb79-f514684a2e50">1.25</ix:nonFraction>% of the funded amount, or $<ix:nonFraction unitRef="usd" contextRef="i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:WarrantsAndRightsOutstandingLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjUyOQ_b5e472bd-88ea-4453-a1c0-7e826b657af2">125,000</ix:nonFraction>. Upon issuance, the warrants were exercisable for preferred stock and were classified as liabilities pursuant to Topic ASC 480 at their fair value of $<ix:nonFraction unitRef="usd" contextRef="i2fc4b9c1f869452c886e27fd8cb739ca_I20200715" decimals="-4" format="ixt:numdotdecimal" name="inhibrx:WarrantsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjY1Ng_5e682ef6-b26e-4106-9a35-a1f4fb025f36">0.12</ix:nonFraction> million. Upon </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55f3c95d623d47b987d730eedf821f3d" continuedAt="if63067bba0704e3b97aeb423045a164d">the consummation of the Company&#8217;s IPO in August 2020, the Company remeasured the warrants and determined a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i2314b9fb755947e4ab7ad70f16e7a771_I20200831" decimals="-4" format="ixt:numdotdecimal" name="inhibrx:WarrantsLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjY3Mg_1e8eda32-0712-4b82-ac9f-9d448ddb1bbb">0.14</ix:nonFraction> million. The change in fair value was recorded as a change in fair value of warrant liabilities within other income in the Company&#8217;s condensed consolidated statements of operations. As of September&#160;30, 2020, the warrants are equity-classified and are exercisable for <ix:nonFraction unitRef="shares" contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NzEwMQ_3ccf5b0d-fc3c-4208-aaf4-10c3cc441101">7,354</ix:nonFraction> shares of common stock of the Company at $<ix:nonFraction unitRef="usdPerShare" contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NzExMA_d9f755a5-7f08-45b1-ab13-9adcd32ceeaa">17.00</ix:nonFraction> per share.</ix:continuation></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if63067bba0704e3b97aeb423045a164d">The Company&#8217;s interest expense related to the Term Loan for the three and nine months ended September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i0c0a3edbbf394e39ac9b8b95852e4df9_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDgwMQ_73d3ecf8-3e30-4fa8-9848-55e33b1d3355"><ix:nonFraction unitRef="usd" contextRef="i515b22595f7847ed9dff1e886916e38f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDgwMQ_ad7ef048-5e3f-43be-858e-51ff9421f190">0.3</ix:nonFraction></ix:nonFraction> million for each period. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment.</ix:continuation> </span></div><div id="iee91b9a90f804077b237584160b9370a_43"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfMjc0ODc3OTA3MzY4Mg_416de980-6ac7-40eb-92f3-8fb5eb1d999b" continuedAt="i85f802a0f1004bebabfe64bb1c7fd3be" escape="true">PPP LOAN</ix:nonNumeric></span></div><ix:continuation id="i85f802a0f1004bebabfe64bb1c7fd3be"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;). The CARES Act includes a provision for a Paycheck Protection Program (&#8220;PPP&#8221;) administered by the U.S. Small Business Administration (&#8220;SBA&#8221;) and further amended by the Paycheck Protection Program Flexibility Act of 2020 (&#8220;PPP Flexibility Act&#8221;), which was enacted on June 5, 2020. See Note 11 for further details regarding other provisions of the CARES Act.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PPP, the Company was approved for a loan pursuant to the PPP program (the &#8220;PPP Loan&#8221;) in the amount of $<ix:nonFraction unitRef="usd" contextRef="iab2815bc314c46819698b119c61f9104_D20200511-20200511" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTcy_6e667974-0ed0-449c-8c5e-499ab3474127">1.9</ix:nonFraction> million and received the funds on May&#160;11, 2020. The application for these funds required the Company to certify in good faith that current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. The Company was also required to certify that the loan funds would be used to retain workers and maintain payroll or make mortgage payments, lease payments, and utility payments. The PPP Loan has a&#160;two-year&#160;term and bears interest at a rate of 1.0% per annum. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CARES Act, the Company was eligible to apply for and be granted forgiveness for all or a portion of the PPP Loan. Such forgiveness, if any, would have been determined, subject to limitations, based on the use of loan proceeds for payroll costs, rent and utility costs and provided that only a portion of the use of proceeds are for non-payroll&#160;costs. The unforgiven portion of the PPP Loan was eligible to be repaid by the Company at any time prior to maturity with no prepayment penalty. Loan recipients may elect an eight week or 24 week forgiveness period and the repayment period begins on the date which the amount of forgiveness is determined. In the event that a loan recipient has not applied for forgiveness within 10 months of the end of its covered forgiveness period, the loan recipient must begin making principal and interest payments on that date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, the Company determined that it would not seek forgiveness of the PPP Loan and would repay the loan in full during the fourth quarter of 2020. As a result, as of September&#160;30, 2020, the full amount of the PPP Loan of $<ix:nonFraction unitRef="usd" contextRef="i4662b14824724021a2692a483eecb043_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTQ5NzU1ODE0MzE4NQ_59be5fec-9d1c-47d3-88e4-1390a49b7959">1.9</ix:nonFraction> million was classified as current debt within the Company&#8217;s condensed consolidated balance sheets. Interest expense related to the PPP loan for the three and nine months ended September&#160;30, 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i41bc12ffbb534f18a23e536d4dde5a2c_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTQ5NzU1ODE0MzE1MQ_7822e2eb-352e-4478-968c-42c6e672345f">4,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i818e609617104ca8b6c8c4969ac1e906_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTQ5NzU1ODE0MzE0OA_b288be38-2048-46c6-ba2e-60caf5f42b67">7,000</ix:nonFraction>, respectively. Interest expense was calculated using the effective interest method. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;2, 2020, the Company repaid the loan in full plus all interest accrued during the period outstanding. See Note 12 for further details regarding the repayment.</span></div></ix:continuation><div id="iee91b9a90f804077b237584160b9370a_46"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjU1Ng_be17aaec-ac4e-4320-a9c5-a7fe4ca01a79" continuedAt="i530f1707b5154c47bd3056d493cc137c" escape="true">CONVERTIBLE PROMISSORY NOTES </ix:nonNumeric></span></div><ix:continuation id="i530f1707b5154c47bd3056d493cc137c" continuedAt="i826032a959744a49902894498ef8700a"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company issued the 2019 Note in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i26693951deed4303a7da2ddadc8ee05f_I20190520" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0ODkxMA_961abb3c-a5a8-470b-9218-9097ef9e07ad">40.0</ix:nonFraction> million to Viking in a private placement transaction. The 2019 Note began to accrue interest in February 2020 at a rate of <ix:nonFraction unitRef="number" contextRef="ic77d30165eef43de82b4519b6e11aabd_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0OTQ2OA_f557155e-ccfa-4f77-8edf-b02bf4f2cbd6">1.5</ix:nonFraction>% per month. In April 2020, the Company issued the 2020 Notes in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i5faa4978633f459b997f876d04a34424_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0OTU2Mg_f74abe43-abfa-44b2-8a78-c563ec0e5f45">15.0</ix:nonFraction> million to Viking and certain other investors in a private placement transaction. Upon issuance, the 2020 Notes accrued interest at a rate of <ix:nonFraction unitRef="number" contextRef="i5faa4978633f459b997f876d04a34424_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0OTY4NA_a57d570b-ee23-4457-bd3e-56d335e0f7d3">1.0</ix:nonFraction>% per month. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Note and the 2020 Notes were to mature on the earlier of (1) March&#160;31, 2022; (2) upon the consummation of certain potential settlement events (each as defined in the 2019 Note and the 2020 Notes); or (3) the time at which the balance of the 2019 Note and the 2020 Notes is due and payable upon an Event of Default (the &#8220;Maturity Date&#8221;). </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i826032a959744a49902894498ef8700a" continuedAt="i725979a825e443608d03284f696ca808"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Upon Qualified IPO</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company completed a qualified IPO, which was defined as the completion of an IPO with a Company valuation above $<ix:nonFraction unitRef="usd" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" format="ixt:numdotdecimal" name="inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjU1OA_710d6bec-2264-4f2c-a6b3-44e616f10ddf">400.0</ix:nonFraction>&#160;million (&#8220;Qualified IPO&#8221;). As defined, a Qualified IPO triggered the automatic conversion and settlement of the aggregate outstanding principal amount plus accrued interest to date under the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock at the lesser of (i) a conversion price equal to <ix:nonFraction unitRef="number" contextRef="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821" decimals="INF" name="inhibrx:DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjU3NA_dd4c68ad-4aef-4413-96e6-fc64ecccfd0b">90</ix:nonFraction>% of the IPO price per share and (ii) a fixed price based on a specified valuation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the conversion date, accrued interest expense for the 2019 Note and the 2020 Notes was $<ix:nonFraction unitRef="usd" contextRef="i80dd5d72484a4344aea558884246a977_I20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQyNA_58385107-51de-4ccc-b029-5587941cba48">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQzNA_04ab5cd9-ae57-4955-a02b-f01fa3da9b13">0.7</ix:nonFraction> million, respectively for an aggregate total balance of $<ix:nonFraction unitRef="usd" contextRef="i80dd5d72484a4344aea558884246a977_I20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ0NA_e5898ae4-0c52-43b2-b8f1-6fa109a45081">43.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ1NA_b730835a-c38a-439f-82c1-681946095571">15.7</ix:nonFraction> million, respectively. Based on a $<ix:nonFraction unitRef="usd" contextRef="i32241f5d4454450aa87c2b3c1c404b87_I20200821" decimals="INF" format="ixt:numdotdecimal" name="inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfMjc0ODc3OTA5ODk0NQ_1d0c78ee-7437-4f0f-91b1-5f188d6b09ba">400.0</ix:nonFraction>&#160;million valuation, the 2019 Note converted at the fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i80dd5d72484a4344aea558884246a977_I20200821" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ2OA_1251761f-9409-493a-92a4-f746b458afc1">14.35</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i83317f913e354c4c8e1ec68bfd7bd8e5_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ4Mg_b3aa1d21-5ffc-4abc-85c3-4cbd44608259">3,046,467</ix:nonFraction> shares of common stock to the holder. Based on a $<ix:nonFraction unitRef="usd" contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821" decimals="INF" format="ixt:numdotdecimal" name="inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfMjc0ODc3OTA5ODk2MQ_69540c3b-2284-4276-bba0-13159d6048ff">350.0</ix:nonFraction>&#160;million valuation, the 2020 Notes converted at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ4OA_ac839135-fc8a-44f8-b88a-311f6668d1ce">12.56</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i181595e7e07c4d178483c8e330544e15_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ5Mg_9900239c-f5e1-4b79-bede-cfb224c2479e">1,248,136</ix:nonFraction> shares of common stock to the holders.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of the 2019 Note and the 2020 Notes were evaluated for contingent beneficial conversion features (&#8220;BCF&#8221;) under ASC Topic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt With Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the effective conversion prices of both the 2019 Note and the 2020 Notes exceeded the relative fair value of the price per share at the commitment date of the 2019 Note and the 2020 Notes, including the paid-in-kind interest, there was no intrinsic value within the conversion feature. As a result, no additional BCF was recorded upon conversion of the 2019 and the 2020 Notes.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2019 Note and the 2020 Notes contained alternative conversion options to the Qualified IPO upon the consummation of certain events, each of which had its own conversion prices and terms. For instance, upon a maturity date conversion, upon the election of the holder, the note would have converted and settled into shares of the Company&#8217;s then-most senior equity securities at the time of such maturity date conversion at the lesser of (i) a conversion price equal to <ix:nonFraction unitRef="number" contextRef="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821" decimals="INF" name="inhibrx:DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjY2NQ_597bcaf5-1abb-4934-a0ad-a364e2487c60">90</ix:nonFraction>% of the price per share to be received by the then-most senior equity securities and (ii) a fixed price based on a specified valuation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of each of the 2019 Note and the 2020 Notes and prior to conversion under the IPO, the Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under ASC Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine if it required bifurcation as a derivative instrument. The Company determined certain settlement features qualified as conversion features not meeting the requirements for separate accounting as embedded derivatives, while others qualified as redemption features meeting the requirements for separate accounting which were accounted for as derivative instruments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2019 Note on May&#160;20, 2019, the estimated fair value of the bifurcated compound liability was approximately $<ix:nonFraction unitRef="usd" contextRef="i26693951deed4303a7da2ddadc8ee05f_I20190520" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNDkxMA_15e7285e-acc0-4501-a2f7-cebb2b1200ba">0.9</ix:nonFraction> million, which was recorded as a derivative liability with a corresponding reduction to the debt discount on the condensed consolidated balance sheets. The 2019 Note was amended during April 2020 to align the maturity date and certain other provisions with the 2020 Notes. During the second quarter of 2020, the Company assessed the amendment and determined it should be treated as a modification. Since there was no change in the fair value of the embedded conversion options as of the modification date, no change in the carrying amount of the convertible debt instrument was recognized.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2020 Notes on April&#160;6, 2020, the estimated fair value of the bifurcated compound liability was approximately $<ix:nonFraction unitRef="usd" contextRef="i60dcc587e93f4a8496bb9b4c5c8fe5fb_I20200406" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTU2MQ_40c46354-4ed7-4c56-af4d-dc3e1cd0c3fc">0.7</ix:nonFraction> million, which was recorded as a derivative liability with a corresponding reduction to the debt discount on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engaged a third-party valuation specialist in order to assess the fair value of the derivative liability as of December 31, 2019, which was determined based upon significant inputs not observable in the market, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s notes, such as an IPO, financing or extraordinary event, as well as the current valuation of the Company as determined by an independent third-party&#8217;s valuation report. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability at December 31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2NDc4Mw_ed0727d4-4bc4-4a1d-b38b-d0b651dd55d5">1.9</ix:nonFraction> million. Changes in the probability of each embedded redemption feature drove changes in the fair value of the derivative liabilities and had a corresponding impact on the Company&#8217;s net loss. During the second quarter of 2020, the fair value of the derivative was </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i725979a825e443608d03284f696ca808"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined to be <ix:nonFraction unitRef="usd" contextRef="ie9a4b8eb0b864a8f9f9048637d3d5001_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfMjc0ODc3OTEwMTI0MA_ecba16b7-c0a8-45ba-87db-690d2230bd18">zero</ix:nonFraction> based upon the expected conversion of the notes via an embedded conversion feature which did not meet the definition of a derivative. Upon conversion of the 2019 Note and the 2020 Notes in August 2020 upon completion of the Company&#8217;s IPO, the derivative liabilities were extinguished. No additional expense was recorded at extinguishment since the derivative liabilities had already been assessed to have zero value. During the  nine months ended September 30, 2020, the Company recorded other income $<ix:nonFraction unitRef="usd" contextRef="i654fca3b7c5d415bb115995496918fd5_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2NDc5OA_bc0b031e-7504-4429-b33d-77315e379cef">2.7</ix:nonFraction> million related to changes in fair value of derivative liabilities in the condensed consolidated statements of operations. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Discount </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to conversion, the Company also evaluated the 2019 Note and the 2020 Notes for BCFs under ASC Topic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt With Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined that the maturity date conversion feature met the definition of a BCF since the embedded conversion option was in-the-money at inception and was fixed and determinable upon execution. Upon issuance of the 2019 Note during the second quarter of 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ie28a1239656045f886b00a040931a4d9_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODAyOA_ebdc7356-e88b-43f3-8fd8-7d74f27d7620">11.5</ix:nonFraction> million as a debt discount with a corresponding entry to additional paid-in-capital on its condensed consolidated balance sheet to record the BCF the 2019 Note. Additionally, at issuance in May 2019, the Company recorded a debt discount which consisted of $<ix:nonFraction unitRef="usd" contextRef="i91870e5d313147eaa4bfc0c02c210fe7_I20190531" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:DebtIssuanceCostsNetDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODI3Mg_8048b6a8-b442-4a2a-9c8f-fdd5ed34e321">0.9</ix:nonFraction> million related to the establishment of the derivative liability and $<ix:nonFraction unitRef="usd" contextRef="i91870e5d313147eaa4bfc0c02c210fe7_I20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODMzNg_77012ac1-fb01-4a2c-b5d7-0b9857a54659">2.5</ix:nonFraction> million related to debt issuance costs on the 2019 Note. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2020 Notes during the second quarter of 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if06dc05837124fb486c25738d89fd171_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODQ3Nw_b56179a7-35ad-4cdc-96b8-7a91f19db4b2">2.7</ix:nonFraction> million as a debt discount with a corresponding entry to additional paid-in-capital on its condensed consolidated balance sheets to record the BCF on the 2020 Notes. Additionally, the Company recorded a debt discount of $<ix:nonFraction unitRef="usd" contextRef="i1d02369269bd4bd19d7ac96425d902f6_I20200630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:DebtIssuanceCostsNetDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODY4NQ_38f6203b-f0d3-428e-bce3-cab873632d06">0.7</ix:nonFraction> million related to the establishment of the derivative liability on the 2020 Notes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to conversion, the debt discounts were amortized over the life of the notes. Amortization of the debt discount from inception of the 2019 Note until conversion of the Notes upon IPO was $<ix:nonFraction unitRef="usd" contextRef="ifd0edf54fa0f44648f71f8021664a663_D20190501-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUwMA_8b0aff44-9072-4897-8beb-2bc9bce88c2d">8.7</ix:nonFraction>&#160;million. At the time of conversion, the 2019 and the 2020 Notes had unamortized discounts of $<ix:nonFraction unitRef="usd" contextRef="i80dd5d72484a4344aea558884246a977_I20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUxMg_05655b6d-2bde-4b4c-9c8d-8db4acc92409">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUyOQ_27e3ec67-6f6c-40bd-b02b-061bd4a03c2d">2.7</ix:nonFraction>&#160;million, respectively.   </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the 2019 Note and the 2020 Notes, the Company remeasured the intrinsic value of the BCFs which resulted in a reversal of the remaining unamortized discounts associated with the BCFs, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUzOQ_cca91103-ad7e-454e-97b9-b7f3734dcb7a">7.4</ix:nonFraction>&#160;million impact to additional paid-in-capital. Additionally, the Company accelerated the unamortized debt discounts related to the debt issuance costs and the derivative liabilities, resulting in a $<ix:nonFraction unitRef="usd" contextRef="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODU1Ng_4284da4b-2c80-4763-9293-4f2266854f2e">2.2</ix:nonFraction>&#160;million charge to interest expense.</span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjc0Mw_ae0e5bfc-559b-4dae-801f-1fbfbca8d560" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company&#8217;s 2019 Note and the 2020 Notes balance, net of discount, consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RhYmxlOmUwOTE4MjdjMGU0MTQ3NTY4ODI0ZGRlYmUzNDBlMWE2L3RhYmxlcmFuZ2U6ZTA5MTgyN2MwZTQxNDc1Njg4MjRkZGViZTM0MGUxYTZfMy0zLTEtMS0w_d142d966-71a6-4801-90a9-6ce61eee5302">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RhYmxlOmUwOTE4MjdjMGU0MTQ3NTY4ODI0ZGRlYmUzNDBlMWE2L3RhYmxlcmFuZ2U6ZTA5MTgyN2MwZTQxNDc1Njg4MjRkZGViZTM0MGUxYTZfNC0zLTEtMS0w_dc02d49d-bd73-4d80-a1e8-c32b7d9a9d33">9,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RhYmxlOmUwOTE4MjdjMGU0MTQ3NTY4ODI0ZGRlYmUzNDBlMWE2L3RhYmxlcmFuZ2U6ZTA5MTgyN2MwZTQxNDc1Njg4MjRkZGViZTM0MGUxYTZfNi0zLTEtMS02ODk3_adf93e28-ff3e-4a90-9018-3266bd3ca0da">30,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iee91b9a90f804077b237584160b9370a_49"></div><div style="margin-bottom:4pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjc0ODc3OTA5NzYxNQ_b6015395-e5a5-4ba1-8267-eb87635eb2c2" continuedAt="ie853ab7108c14b72a48d345cc3c6a39a" escape="true">STOCKHOLDERS&#8217; EQUITY (DEFICIT) </ix:nonNumeric></span></div><ix:continuation id="ie853ab7108c14b72a48d345cc3c6a39a"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020 upon completion of the IPO, the Company&#8217;s certificate of incorporation was amended and restated to authorize <ix:nonFraction unitRef="shares" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM0OA_8879475b-9ab3-43ac-b888-ba7b272fba0a">120,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM1Mg_05b08e1c-eb2b-4310-baf8-773e2a4a5e81">15,000,000</ix:nonFraction> shares of preferred stock, each with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM0NA_8009b996-d75d-4e41-896b-f8bffba49f54"><ix:nonFraction unitRef="usdPerShare" contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM0NA_9d8f2385-785e-4c9c-b3ef-faff087d2cd7">0.0001</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to its conversion to common stock in connection with the Company&#8217;s IPO, the convertible preferred stock was classified as temporary, or mezzanine, equity on the accompanying condensed consolidated balance sheets since the shares contained certain redemption features that were not solely within the control of the Company. The Company had not previously accreted the convertible preferred stock to its redemption value since the shares were not redeemable and redemption was not deemed to be probable. </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjc0ODc3OTA5Mjg4Mw_d9197884-360f-4ff4-b286-d54cde9d44f3" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock authorized and issued as of December&#160;31, 2019 consisted of the following (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.943%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Liquidation Preference</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Mezzanine 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy0xLTEtMS0yMTc5_4d2cec47-22cc-4eda-8586-59d1c3bc9fab">4,299,319</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy0zLTEtMS03NzMw_9bd18570-9baf-4ea9-b3b7-819d98c12753"><ix:nonFraction unitRef="shares" contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy0zLTEtMS03NzMw_f1d59ac5-8596-47eb-b11a-bb54a661614c">4,299,319</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy03LTEtMS03NzMx_9d6784d1-a9df-4b13-a9b4-b88b4fb4c91f">6.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy05LTEtMS0yMTg5_b18db894-1491-4397-b90c-19c8b14c550f">30,009.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Mezzanine 2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87def4161b5741d0a3372af759a43214_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC0xLTEtMS0yMTgy_7f11fab1-4c28-4609-bbf8-441e70677f5c">21,465,681</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87def4161b5741d0a3372af759a43214_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC0zLTEtMS03NzMw_9b6e6b89-b45d-4da5-99be-a4e2031a943f"><ix:nonFraction unitRef="shares" contextRef="i87def4161b5741d0a3372af759a43214_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC0zLTEtMS03NzMw_d94cc2f3-fd91-4c91-b71f-f4412ab84ee7">8,235,012</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87def4161b5741d0a3372af759a43214_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC03LTEtMS03NzMx_94c4fcd8-9a71-462e-a551-2f1330e50ad8">6.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87def4161b5741d0a3372af759a43214_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC05LTEtMS0yMTkz_e69fb1ac-b913-48ad-93f5-f84fc58e1590">57,480.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS0xLTEtMS03NzI4_d28138a7-acea-479f-ad0e-b8e49a4cae6b">25,765,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS0zLTEtMS03NzMw_12bdbbf7-b87d-4274-85df-c025b600dc37"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS0zLTEtMS03NzMw_5ef45ddb-260e-41da-849c-986ca56766a0">12,534,331</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS05LTEtMS03NzM0_e8282029-6818-44c3-8611-cfc378779dae">87,489.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i4c0d84dc7c03423189234b747382592d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM1Ng_5b6f80d7-fa61-4606-9416-5a294945cf09">1.7</ix:nonFraction> million shares of Series Mezzanine 2 Preferred Stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i87def4161b5741d0a3372af759a43214_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM2Mw_ef51e640-ffda-4921-8bb3-ad2784517aaf">6.98</ix:nonFraction> per share, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i4c0d84dc7c03423189234b747382592d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfOTg5NTYwNDY3MzQ4OA_64919482-1d72-4728-a45a-9d82202710fb">12.0</ix:nonFraction>&#160;million, after deducting offering expenses. <ix:nonFraction unitRef="shares" contextRef="i1b2a8d92980b45cd86a9a0e569b171a7_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjE5OTAyMzI3OTAwOQ_94fdb3e4-486b-48c5-83cd-f0d312d69b54"><ix:nonFraction unitRef="shares" contextRef="ia8c0ec15d63b4c9c9db72a0042d9233b_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjE5OTAyMzI3OTAwOQ_edb8bd00-62e8-4829-b8c3-09d7ccfd6289">No</ix:nonFraction></ix:nonFraction> shares of Series Mezzanine 1 Preferred Stock and Series Mezzanine 2 Preferred Stock were issued during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the Company&#8217;s IPO in August 2020, all of the outstanding shares of convertible preferred stock were converted into <ix:nonFraction unitRef="shares" contextRef="i9230559c947e4bdfbd7d8718f81613a0_D20200821-20200821" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM2Nw_dffe0366-6c20-4b90-9da1-59fd0482df49">7,211,086</ix:nonFraction> shares of the Company&#8217;s common stock.  </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, the Company issued warrants to Oxford concurrently with the 2020 Loan Agreement. Upon the consummation of the Company&#8217;s IPO in August 2020, the warrants are exercisable for <ix:nonFraction unitRef="shares" contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2NDMwNA_3ccf5b0d-fc3c-4208-aaf4-10c3cc441101">7,354</ix:nonFraction> shares of common stock of the Company at $<ix:nonFraction unitRef="usdPerShare" contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2NDM0OQ_d9f755a5-7f08-45b1-ab13-9adcd32ceeaa">17.00</ix:nonFraction> per share. As of September&#160;30, 2020, the warrants are equity-classified and reflected in additional paid-in-capital at $<ix:nonFraction unitRef="usd" contextRef="i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2NDc2Nw_2419e833-7d3c-486c-a98c-f9704cc8a823">0.14</ix:nonFraction> million. The fair value of the warrants was determined using the Black-Scholes model on the date of conversion. No subsequent remeasurement is required for equity-classified warrants.</span></div></ix:continuation><div id="iee91b9a90f804077b237584160b9370a_52"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDg5NA_c171f10b-7f19-42ff-a83c-dcf899bc3a2d" continuedAt="ic9ee64de1af14674b3258a39064f7f61" escape="true">EQUITY COMPENSATION PLANS </ix:nonNumeric></span></div><ix:continuation id="ic9ee64de1af14674b3258a39064f7f61" continuedAt="i4faa54e2192547ba82ee3ce487518ab1"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="plan" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:ShareBasedCompensationNumberOfPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MTkwMw_77f6b857-ac22-4868-8dfd-16b6d0ee6d00">one</ix:nonFraction> share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of September&#160;30, 2020, an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNjU5NzA2OTc3OTA4NQ_b636da48-1509-4824-864a-456171335931">3.0</ix:nonFraction> million shares of common stock were reserved for issuance under the 2017 Plan, of which <ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNjU5NzA2OTc3OTA5Mg_94f861e3-dce3-4198-b40e-6029d7f2e69f">0.6</ix:nonFraction> million were available. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. The options are subject to <ix:nonNumeric contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNzY5NjU4MTQwNTkyNg_a7601782-9629-4029-ad56-42784fc754e2">four-year</ix:nonNumeric> vesting with a <ix:nonNumeric contextRef="i8e89d479cc1c49dcac81106f1a23036d_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNzY5NjU4MTQwNTk0Mw_b6830872-5d06-43d9-83f7-aec990de7e52">one-year</ix:nonNumeric> cliff and have a contractual term of <ix:nonNumeric contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDkwOA_3e00e6c7-cb2f-4a1a-99e7-ad97495d1b34">10</ix:nonNumeric> years. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i4faa54e2192547ba82ee3ce487518ab1" continuedAt="i19dd2bed8d924161a4bb0416ab18008c"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDkxNA_29aea8e4-ab94-4076-b32e-bd99fb659586" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2017 Plan for the nine months ended September 30, 2020 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF SHARES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE EXERCISE PRICE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (IN YEARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGGREGATE INTRINSIC VALUE</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS0xLTEtMS03Nzk5_4fefaca2-971e-449c-9f82-c701899ed387">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS0zLTEtMS0w_1437779a-8f60-48ea-aa64-5504499ad271">10.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i291c0d139a404246b0f7fca420127e86_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS01LTEtMS0w_79f7a89f-5efb-44d1-a742-f8bb6e30d197">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS03LTEtMS0w_69d29aeb-417a-4c19-87a0-3c45a45157b7">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNy0xLTEtMS0w_d57572cc-4c59-4f84-a93c-d9469466aca9">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNy0zLTEtMS0w_abfd71ce-1d77-4bb2-af83-06d89ef5df3f">12.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:duryear" name="inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNi01LTEtMS05OTcx_86cbaaae-0637-4142-866f-294aef94d965">9.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNi03LTEtMS05OTc5_98d82ebd-c79c-4950-9379-31a92879c6fb">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0xLTEtMS03Nzk5_985f16d4-59dd-4679-824c-e3041cb9bddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0zLTEtMS04NDIw_dc1bcc14-29b0-4736-80ce-eb4267a66d2d">10.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0xLTEtMS0w_f9be75dc-1d2b-4f1b-924f-f4529c0b1e24">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0zLTEtMS0w_d8921c51-051b-4f60-8206-3cb41986b2e4">11.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtMS0xLTEtNzc5OQ_5b18f653-a8c0-4d10-9442-0c12d1d7e287">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOS0zLTEtMS0w_dde2eccc-9d2f-495b-b796-83dbe819b898">11.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOS01LTEtMS0w_7c43871a-1561-4397-a903-a297cb0ac447">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOS03LTEtMS0w_4511823b-0127-4800-8411-78dad40288de">16,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and exercisable as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtMS0xLTEtMA_77f8c1a2-abd7-4c5f-b061-9b02b1270563">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtMy0xLTEtMA_ddaa99d2-d398-4916-b3da-ca28e0dee2dc">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtNS0xLTEtMA_5f41a61e-39b9-49a0-885d-64bfdf86c166">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtNy0xLTEtMA_d42301cb-35d7-4fc9-b563-c6552dce42d6">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. The Company recognizes forfeitures as they occur. </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDkxNQ_5705342d-3561-4078-a938-4c565e44eeb0" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.803%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNC03LTEtMS0w_c122f316-000d-4243-a752-7595f698eba5">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNC05LTEtMS0w_d47401fc-9943-4e21-9cce-148a018d002b">2.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNS03LTEtMS0w_8e926ca3-704e-45b1-8cc4-f0ed08548642">97.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNS05LTEtMS0w_0ce87f13-a8d8-4c28-9afa-b21d598ce442">87.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNi03LTEtMS0w_14da663a-cb68-44d6-ba8b-535f4fa99a91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNi05LTEtMS0w_8decbe8c-8410-46ed-95d2-4db8c3c8b0dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNy03LTEtMS0w_cf0d9173-bef1-4e40-9422-dc71cb129d4c">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNy05LTEtMS0w_e9ac9ed8-90a8-44b5-9ae3-d60455576d66">6.08</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfOS03LTEtMS0w_706a1319-c284-4e8b-b594-0b99a1eeff69">9.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfOS05LTEtMS0w_967006cb-3e92-408e-bfd9-ed33494f8705">9.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i19dd2bed8d924161a4bb0416ab18008c" continuedAt="ie0ad1d9a27f14633a8dd6f8172b8a3b3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, given the absence of a public trading market for the Company&#8217;s common stock, its board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company&#8217;s common stock underlying the stock options, such as: contemporaneous valuations performed by independent third-party specialists, its stage of development, including the status of its research and development efforts of its therapeutic candidates and the material risks related to its business and industry, its results of operations and financial condition, including its levels of capital resources, the prices at which its sold shares of its convertible preferred stock, the rights, preferences and privileges of its convertible preferred stock relative to those of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as recently completed mergers and acquisitions of peer companies, the likelihood of achieving a liquidity event for the holders of its common stock or convertible preferred stock, such as an IPO or a sale of the Company given prevailing market conditions, trends and developments in its industry, external market conditions affecting the life sciences and biotechnology sectors, and the lack of liquidity of its common stock, among other factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price. The Company&#8217;s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNzY5NjU4MTQwNTkwOA_6da5268c-df5d-4a15-b187-a1bed27dc9b7" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9043b1e7d94f868faef2ed4ddb4eda_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC0xLTEtMS0w_08ae7fad-e983-4f00-976a-49271031e4c8">1,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b90f3cbd93444a8e502d826cbbe51f_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC0zLTEtMS0w_782eb724-4f6b-4dbd-b53b-addeea02f35b">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia387c26a722e4699b6595d2f733a93c1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC01LTEtMS0w_25261637-3c19-4179-8b05-0e1a3f804158">3,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e933df6d96c4e25a0e01262d530c949_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC03LTEtMS0w_592e767e-9196-41b4-a455-7536f5b2b9e6">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8eff35edb7419e9932c5f914758304_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS0xLTEtMS0w_23e65c89-b5d4-4b78-8b38-f2158ee8af89">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cec1573a81491f8627da20eab3bf7a_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS0zLTEtMS0w_5bbc6725-8cec-42c4-a9e0-7cebf887ecf8">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16757954c1044691837622036e587d62_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS01LTEtMS0w_52e48ea3-888c-47e9-a4ad-462669a4dbd8">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c7d40392014b9993d7e113b2eac17c_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS03LTEtMS0w_220af98e-e51a-497f-b468-135c36c152f8">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd02944395c4cd4867b8652d51a714a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS0xLTEtMS04NDI5_4d7b1a6c-63a6-4b6f-bbca-733235a6ba4a">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910bafb21fde4c9d995b95ae87cf63a5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNi0zLTEtMS01MDA_a11f5507-11f9-4214-a70a-fb6ce8326e7b">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNi01LTEtMS01MjE_0c2dcd08-f84f-4da7-aab3-5a38a23fc7ee">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNi03LTEtMS0w_5eb0e1e5-4944-4b9e-87b8-3796393d11be">2,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0ad1d9a27f14633a8dd6f8172b8a3b3">As of September&#160;30, 2020 and December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="i54757ed54df14bceb415fb75f4faf788_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE0OQ_71750d84-e43b-4c8a-8ac7-f3889f44c273">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id41c0b142c464e41bb151ae9a392ab96_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE1OQ_caa7fa58-c473-4e50-833d-b5de55da4c29">12.2</ix:nonFraction> million, respectively, of total unrecognized stock-based compensation expense related to its stock options, which it expected to recognize over a weighted-average period of <ix:nonNumeric contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE5Nw_5d5e80f2-eacd-4961-95f8-d65e87de32ec">2.4</ix:nonNumeric> and <ix:nonNumeric contextRef="ib5230b6435fd4ceb84a6af9831cd457c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE5Mw_d2becc01-0f39-44be-b3e2-13a0f286234b">2.9</ix:nonNumeric> years, respectively.</ix:continuation> </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="inhibrx:LicenseAndGrantRevenueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDE0Nw_b0b011f6-0664-4209-9736-84d993f9c222" continuedAt="ia671c246b1884227abce933ad388a25e" escape="true">LICENSE AND GRANT REVENUES </ix:nonNumeric></span></div><ix:continuation id="ia671c246b1884227abce933ad388a25e" continuedAt="i0e0473697bc74451b7dec35e77e781ac"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="inhibrx:ScheduleOfLicenseAndGrantRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDMwNA_828099be-6c44-48f3-abeb-3b1b02ad1946" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s condensed consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from affiliates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcenta Holding, Ltd.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92744c9c477a4e4ba89940a3d753b3b3_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS0xLTEtMS0w_7ed00c99-b243-4a88-9219-49f9d7d0bdc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4373a79ed10e41d296ee0962058ceb18_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS0zLTEtMS0w_bb95535e-678f-49af-b377-171cf3f151ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab658b65d2b4e509ba7e6fbedd7ea7f_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS01LTEtMS0w_c431438f-b6fa-49b7-8e97-0cd9a041432d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca21b8ec7ba4cbbb974b0a2ed21beea_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS03LTEtMS0w_2fadd8bb-b480-4ee3-b94e-dad4b7f6145c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elpiscience Biopharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120f8c853b1845998a75889f0c5bcfe9_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0xLTEtMS0w_d336bdd3-a93d-4393-bd84-fe7d5c5aecd2">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf43c32005f4158b0a144b53515e8f4_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0zLTEtMS0w_378d5d54-6a2e-4921-8d6d-ad8daf9bfb43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie739eb4e2f9d498a802def60014528b5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi01LTEtMS0w_aaf609ab-8c71-428e-9eb4-83fd168eb8df">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356cf52c8b484b40b183fa4c374dd895_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi03LTEtMS0w_a1adad45-19b9-4ec8-b8aa-3c67da17f99c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from affiliates</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dd132e1b3a439c9b1a6235d9bb85e2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0xLTEtMS04MTg3_ef79e3ea-0fb5-4513-9e9d-e0c972cc698e">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0911529fc304f48ba356122d24789d2_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0zLTEtMS04MTg3_5ce002d6-672d-4457-82e1-4b50444a0e05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe55a942de0426eba7b59eec3f142f0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi01LTEtMS03ODgw_f99fb79b-a996-4eb1-bfce-0d16834a4b26">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa06f7d2b0c24a02ae94a2059ca88a36_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi03LTEtMS03ODgy_a2649741-f998-4e33-9ae8-f840d17649fe">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from non-affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d8c3a4a6fb430e9f1f76dd0683680a_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC0xLTEtMS0xMDE4NA_b909b037-8c61-48fc-b50f-ea70f8591d75">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8a55eee8e1430987c756c531fd2f92_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC0zLTEtMS0xMDE4NA_93cec983-d635-4604-9c5e-16476891b769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd65ea0d77dd4536bd5211b76ed0f786_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC01LTEtMS0xMDE4NA_6290d890-2a4c-48d1-af4e-427f10ba80c7">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd2973e2e9248cd84da19d0ec58f321_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC03LTEtMS0xMDE4NA_780aa69a-506a-4741-a242-7ad0d34a2b76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bluebird bio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f4401ebc2846b4ae91adeae6e806d4_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS0xLTEtMS0w_06fc1d23-72d4-4a14-81ae-dae51a7edd61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib40770b8bf174b6f8619cbc166946dc4_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS0zLTEtMS0w_f6607a99-2426-42f5-9a90-695ff1d87a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46e3791b92d409bb00978ee31d2cbf5_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS01LTEtMS0w_80906745-972d-4941-94ab-84433846b362">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f87004b4c11448b93df28c2392164ca_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS03LTEtMS0w_5a29e00a-9fc0-47a9-9e3e-f5ccbc204c23">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieacc3e428d0f429ba6530cfe19d2e300_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtMS0xLTEtMA_31420796-72fa-4aad-a337-30388df63011">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdcea5a7ee042059428f8230d335a2f_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtMy0xLTEtMA_56dab255-fdcf-418d-908f-442de8081187">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835a732af4b24c559cab997e0fc7e788_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtNS0xLTEtMA_5362c046-6018-4da2-b4b2-f6e0a8c1ade2">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8e3ff3da7b46a4ad695b6d2fdeaf72_D20190101-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtNy0xLTEtMA_c2f0a8b9-5326-42ac-83ef-9c8220d3702d">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license revenues from non-affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e44a5c0664414894b59ef342a25530_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtMS0xLTEtMA_56bd66b8-05ee-4d93-8a12-1a80e9b415d0">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6529f0b04b94b0bbe8a4aa98b0cca04_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtMy0xLTEtMA_f04ec5f3-0fc0-49a8-b989-3c7037eea362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67731484d5f24597939db7a05b45c3e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtNS0xLTEtMA_e350832c-7299-4f7f-98d6-5765a0091e87">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a8d9ba96ce4164a0a1f5e705ce4880_D20190101-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtNy0xLTEtMA_8008aac5-20cf-4489-b320-45635551f1c8">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from non-affiliates</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d81ecc28084fcdbc1204e113833fc8_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItMS0xLTEtODE4Nw_a34b8360-27ac-48fe-a691-20e3ec498450">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257bc2317ed94a5281a528a81b5b8d35_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItMy0xLTEtODE4Nw_3d7cbc52-fe14-49bf-a926-55201e1a6452">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16213d344cb4afaa96412b15c0eedb6_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItNS0xLTEtNzg4NA_f560baa5-e330-42c8-9742-c62540e4c629">8,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac09946014a4214af25c0e06ce6c6f6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItNy0xLTEtNzg4Ng_3865e8b9-d3a7-4cae-ab71-2be2773d5d46">7,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Institutes of Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c5f5eb489b4481b39ec65ca48ebfce_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtMS0xLTEtMA_4ddfe3c8-020f-4b35-8b3e-5e6adf863d13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id880884b9ea94b869fb5816f6510e211_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtMy0xLTEtMA_0b700b75-a149-4e2b-a100-ad005d4c5bcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2e9de97d974ecc9e2ee333fb3c25e3_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtNS0xLTEtMA_9ee09f2a-294b-4dc2-aa71-f264fd5d9b5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9b775d892046ed8cff1e30bad6547b_D20190101-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtNy0xLTEtMA_9a441bd2-501f-4dd2-968d-cc4dc6ecb066">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combating Antibiotic Resistant Bacteria Accelerator</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81510c3679774fff8f396fc3ab77fb74_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtMS0xLTEtMA_fd205bf2-ee38-4374-8b87-a728c626f2fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ebc7d152324a9ea5b0b3b86ab48f78_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtMy0xLTEtMA_5fdf76ae-2939-4167-b6cb-ef486825a7d6">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd19c4f689a94a488fadc52fb549283a_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtNS0xLTEtMA_d1e80d79-5d4a-4ee9-b631-ed5269210b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5b52c38a8c44d49a69c3fcc734f8f2d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtNy0xLTEtMA_84630c09-d13c-45fe-9315-ed1a5098a639">3,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce2eacccd9044d788db421fc7a18c46_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtMS0xLTEtMA_67a474e7-dd9b-44e7-8934-7b3bcbaac3e6">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43aed1ced8c04ca78d779f9c16210fa8_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtMy0xLTEtMA_e892ccfb-1249-4d35-a7aa-69605ea7d352">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113089823357421ab17799b937585703_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtNS0xLTEtMA_168f754d-dd79-4557-bdac-e3f8f1e102aa">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822e016bcba04e979cf25eaaedefc7a6_D20190101-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtNy0xLTEtMA_ed7b3c90-996c-4587-9258-00868d17f0d0">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fce0905feb4ca0a6d436f23bdb5a51_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctMS0xLTEtODE4Nw_7eb9d612-0da9-4523-b64c-b364fdfe22d8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic597294d6b05480f9b87cfc8e153db62_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctMy0xLTEtODE4Nw_0287522c-4f93-4fb6-b84c-9c57e928ab15">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8caa9dd3e98483facac392f2f26d651_D20200101-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctNS0xLTEtNzg4OA_867034bb-1903-4507-8a38-2f96e0ed4a7c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820a8e2822d74bbd82ecbf86ba928b9c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctNy0xLTEtNzg5MA_f008466e-350a-4211-b77a-196542d906a1">4,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtMS0xLTEtODE4Nw_4e48fa0c-09df-4abb-a14a-c5512e89447d">5,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtMy0xLTEtODE4Nw_2015ffa5-2b9e-43d4-8745-1248c9fd4620">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtNS0xLTEtNzg4OA_4023e3cb-dbef-42cf-bcbc-e671579b527d">10,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtNy0xLTEtNzg5MA_9098492e-8a80-4fff-b83d-7aa4b524b6df">12,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phylaxis Agreements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis BioScience, LLC (&#8220;Phylaxis&#8221;). In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement (collectively the &#8220;Phylaxis Agreements&#8221;), pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. Upon closing, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i5301fb930f5846abbe1ac0d7088d390c_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY2OA_612532a7-37b6-499d-9897-970806cc16ec">2.5</ix:nonFraction>&#160;million nonrefundable, upfront payment from Phylaxis under the Master Services Agreement (&#8220;MSA&#8221;). The Company is also entitled to an additional $<ix:nonFraction unitRef="usd" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementAdditionalPaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY3NQ_220be591-7ede-4f3d-bbe2-68c13d497daf">2.5</ix:nonFraction>&#160;million payable within <ix:nonNumeric contextRef="i6de109f4840c4e22aafdac033f63ff7e_D20200101-20200930" format="ixt-sec:durday" name="inhibrx:CollaborativeArrangementAdditionalPaymentReceivablePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDE3Nw_b3bc01df-a4cc-47e7-84b6-fc4d31063fa5">180</ix:nonNumeric> days from closing under the MSA. Upon closing, the Company received a <ix:nonFraction unitRef="number" contextRef="i678ba84787b74c33aaa1dabda2391b12_I20200731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY5MA_37037b3d-aa98-44d9-8994-a02c9c9f6049">10</ix:nonFraction>% equity interest in Phylaxis as consideration for the contribution of the license of the Company&#8217;s intellectual property and know-how and is entitled to receive an additional <ix:nonFraction unitRef="number" contextRef="i678ba84787b74c33aaa1dabda2391b12_I20200731" decimals="2" name="inhibrx:EquityMethodInvestmentAdditionalOwnershipEntitled" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY5NA_dd2f6739-0bec-42e0-82da-e318a39d26ab">5</ix:nonFraction>% based on the achievement of certain milestones. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY5OA_9f2d3f88-0884-49e6-8549-3fdb2633e396">225.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementCommercializationMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTcwNg_16689415-2bc8-4ca7-9bd7-de74c8e14b60">175.0</ix:nonFraction>&#160;million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the fair value of the equity interest in Phylaxis, the Company engaged a third-party valuation specialist. The valuation report utilized a market approach to establish the total equity value of Phylaxis using inputs not observable in the market, including the discount rate. The fair value of the equity interest was $<ix:nonFraction unitRef="usd" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTcxNA_ceabf088-c9be-4a62-98b0-6988b0af7e28">0.5</ix:nonFraction>&#160;million, which has been accounted for under the equity method. The fair value of the equity interest upon the execution of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i0e0473697bc74451b7dec35e77e781ac" continuedAt="ideb160260839485eb4e17e20c9960e68"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the agreements has been included in the transaction price, along with the $<ix:nonFraction unitRef="usd" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementPaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTcyNg_ae02d6c3-bfaf-4fbc-9ba7-f4ce86bbfd35">5.0</ix:nonFraction>&#160;million of payments due pursuant to the MSA.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the transfer of the exclusive licenses for, and performance of, development services to modify the first and second compounds as <ix:nonFraction unitRef="performanceobligation" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NzczOA_be6f9313-2e1b-4a15-8c94-9cf7ea949655">one</ix:nonFraction> performance obligation and allocated the transaction price evenly between the <ix:nonFraction unitRef="compound" contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:RevenueRecognitionNumberOfCompounds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1Nzc0Ng_371ea12d-662e-4fcf-b153-a4efe96097fe">two</ix:nonFraction> compounds. Revenue related to the performance obligation will be recognized over time as services are performed, based on the Company&#8217;s progress to satisfy the performance obligation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="ib0d8c3a4a6fb430e9f1f76dd0683680a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTczOA_1374a2b4-29ad-4188-b81d-b47730dea939"><ix:nonFraction unitRef="usd" contextRef="ifd65ea0d77dd4536bd5211b76ed0f786_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTczOA_80367917-f905-47a6-bcb1-9706ebd35543">0.8</ix:nonFraction></ix:nonFraction>&#160;million of revenue related to this performance obligation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bluebird</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2018, the Company entered into a License Agreement with bluebird bio, Inc. (&#8220;bluebird&#8221;) whereby the Company granted bluebird the exclusive, worldwide rights to develop, manufacture, and commercialize certain cell therapy products containing binders. In January 2019, the Company received a non-refundable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i86854d401efc41658a1f7cabc6fbf75f_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMDg4NQ_5ea82066-907b-493c-9bfc-f04cfabf977e">7.0</ix:nonFraction> million from bluebird for this exclusive license. As part of the Company&#8217;s performance obligations to bluebird, it transferred certain know-how to bluebird, the completion of which occurred in March&#160;2019. As a result, the Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ie2312287da4844f98353e533084710b1_D20190301-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMTEyNg_e3263c6e-a38a-4310-a40d-e5c7407fba5e">7.0</ix:nonFraction> million upfront payment as license fee revenue during March 2019 upon completion of all performance obligations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to receive specified development milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0f4f3ab77c814395bd909a08f8cdbd8b_I20181220" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMTM0Mg_5ae63757-ba2f-4ba0-8d23-cda57a378427">51.5</ix:nonFraction> million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Option and License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a separate Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide development licenses to develop binders and cell therapy products containing sdAbs directed to specified targets, consisting of <ix:nonFraction unitRef="program" contextRef="if0630b88591a432fb950d54e0c58af38_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI1NA_57f76f32-bf5d-4b61-9ddb-f2772f88c85c">two</ix:nonFraction> initial programs and up to an additional <ix:nonFraction unitRef="program" contextRef="ic3240262b0c843ab948e2324834e8f4a_I20200630" decimals="INF" name="inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI1Mg_d61e0df7-d9f7-4c4e-8f7e-b6b960504bd2">8</ix:nonFraction> programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company received a non-refundable upfront option fee of $<ix:nonFraction unitRef="usd" contextRef="i65e132a26c12432e9177650608108558_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMjQyNQ_a147fc77-4daa-4852-8efd-becce7e775ca"><ix:nonFraction unitRef="usd" contextRef="ia9075aabe3384589aa3de96de0cec785_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMjQyNQ_b98a36cd-8385-4015-baee-437cebe4c7a0">0.2</ix:nonFraction></ix:nonFraction> million in connection with each of the <ix:nonFraction unitRef="program" contextRef="if0630b88591a432fb950d54e0c58af38_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MTQ3NQ_48374c26-afeb-4e55-8906-91bf8803a1ca">two</ix:nonFraction> initial programs, or $<ix:nonFraction unitRef="usd" contextRef="i91ec1ec2abba44ff94474aa6f6a83271_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMjQ4NQ_c49599b3-78c9-4cfc-82c1-b0f13023f000">0.4</ix:nonFraction> million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. The Company also granted to bluebird an option to acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which bluebird exercises its option, bluebird will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions for each option bluebird chooses to exercise. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i15bf51c282994899a1f5ce5fa7ed4e9e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMzE5NA_c98df41a-794e-4d04-9517-16f28b4187b2">51.5</ix:nonFraction> million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the agreement, the Company identified <ix:nonFraction unitRef="performanceobligation" contextRef="if0630b88591a432fb950d54e0c58af38_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMxMw_3481b11c-2831-4273-b057-6d35852059fd">one</ix:nonFraction> performance obligation, which was the transfer of the exclusive development license to bluebird for the <ix:nonFraction unitRef="program" contextRef="if0630b88591a432fb950d54e0c58af38_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI2MA_848d77e1-b692-4144-8b26-6bd5262de192">two</ix:nonFraction> initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the <ix:nonFraction unitRef="program" contextRef="ic3240262b0c843ab948e2324834e8f4a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI2Ng_8ab1b579-1cf8-4aec-b009-15e4eb6c38cd">eight</ix:nonFraction> programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company will reassess its performance obligations and transaction price accordingly.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="ideb160260839485eb4e17e20c9960e68" continuedAt="ic8d8549793b140efb59b8c0f47182c59"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the total transaction price of the contract at execution was $<ix:nonFraction unitRef="usd" contextRef="i91ec1ec2abba44ff94474aa6f6a83271_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzNDUyNQ_662bd949-276f-46f7-9d13-2dddc63afc8d">0.4</ix:nonFraction> million for the transfer of the <ix:nonFraction unitRef="license" contextRef="i15bf51c282994899a1f5ce5fa7ed4e9e_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:CollaborativeAgreementExclusiveDevelopmentLicenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI3NA_73035365-f503-49da-a605-ed3edd00ca84">two</ix:nonFraction> exclusive development licenses. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i51e4a311ac19416ebf4f8e8ba3195ba7_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzNDYxMg_03b6d8e1-07ee-42ef-852b-3e197ed56485">0.4</ix:nonFraction> million of revenue related to this agreement at the point in time in which the exclusive development licenses were transferred to bluebird, which occurred upon execution of the agreement in June 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chiesi</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into an Option Agreement (as amended by the First Amendment to Option Agreement, dated August 19, 2019, the &#8220;Chiesi Option Agreement&#8221;) with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $<ix:nonFraction unitRef="usd" contextRef="if6d316a27f564f6c9455708922cd2566_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzOTk3Ng_e5c66099-9a2d-42a5-903a-2439528c5766">10.0</ix:nonFraction> million in August 2019. If Chiesi chooses to exercise its option under the Chiesi Option Agreement, then Chiesi must pay the Company a one-time, non-refundable fee of $<ix:nonFraction unitRef="usd" contextRef="i47ab1c4748ac4b588b54989d44e542db_I20190831" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementAdditionalPaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc0NQ_48f5b1fe-ab27-42f6-9d71-5418c655edf4">12.5</ix:nonFraction> million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, the Company may be entitled to receive specified milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i47ab1c4748ac4b588b54989d44e542db_I20190831" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementMilestonePaymentsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzNTcyNA_63bd12a0-4a3f-4dbf-83eb-110586835b7b">122.5</ix:nonFraction> million, as well as royalties on future product sales.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1Nzc1NA_6b66b8da-c7b5-480c-a377-73395cdb62d9">The Company has identified <ix:nonFraction unitRef="performanceobligation" contextRef="if7827c4c605f403c95b605cbe15393e7_I20190819" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMxOQ_f7daf4c3-15e0-407a-aee3-56bcff666b82">one</ix:nonFraction> performance obligation as of the effective date of this agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#8217;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration (&#8220;FDA&#8221;) scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive parallel EMA-HTA scientific advice meeting conducted following completion of such Phase I Clinical Trial.</ix:nonNumeric> The Company has determined that the option to grant a license in the future is not a material right.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="if6d316a27f564f6c9455708922cd2566_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc1Mg_65b10ce3-2dff-47e3-8de3-b5d7f9eaa166">10.0</ix:nonFraction> million upfront payment has been allocated to the single performance obligation. Revenue will be recognized over time as services are performed during the option period, based on the Company&#8217;s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the three months ended September 30, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ieacc3e428d0f429ba6530cfe19d2e300_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc2Nw_3ad27990-af0b-4746-9125-2bebdc8ed547">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cdcea5a7ee042059428f8230d335a2f_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc4MQ_5fd9598b-0e58-4de2-9439-d5486b80b9ed">0.8</ix:nonFraction> million, respectively, in revenue related to this agreement. During the nine months ended September 30, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i835a732af4b24c559cab997e0fc7e788_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc4NQ_15df77a7-bf72-41e5-8b66-20fe77adc6ee">5.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf8e3ff3da7b46a4ad695b6d2fdeaf72_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc5NA_045bf867-0b70-42c9-ac82-8764dfbf8abd">0.8</ix:nonFraction> million, respectively, in revenue related to this agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elpiscience</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has entered into <ix:nonFraction unitRef="program" contextRef="i0531016c866d4a068e2358c8f73b0f39_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="inhibrx:NumberOfLicenseAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI5NA_6734d2a2-788a-40e9-8998-dbe72c105974">two</ix:nonFraction> different License Agreements with Elpiscience Biopharmaceuticals, Inc. (&#8220;Elpiscience&#8221;). Each agreement is a standalone license of a distinct and differentiated protein therapeutic candidate with a separate biological target, providing a unique benefit. Neither the license nor the asset is reliant upon the other. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PD-L1 and 4-1BB Program </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a License Agreement (the &#8220;PD-L1 and 4-1BB License Agreement&#8221;) with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s bi-specific therapeutic candidate designed to target PD-L1 and 4-1BB (also referred to as &#8220;INBRX-105&#8221;). This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as to manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-105, including process development and manufacturing data and information necessary to develop INBRX-105. In the PD-L1 and 4-1BB License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-105 for its development in China, Hong Kong, Macau and Taiwan. The Company is eligible to receive specified developmental and commercial milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i83c3ddd258264ea38d9e7f8ee2affbb4_I20180228" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementMilestonePaymentsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxOTY2Mg_8d05aefe-3945-40ca-b656-953ea6495ceb">100.0</ix:nonFraction> million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="ic8d8549793b140efb59b8c0f47182c59" continuedAt="ifb76d06cb3ae47cc9227a488112600e1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PD-L1 and 4-1BB License Agreement, the Company is entitled to reimbursement for certain toxicology study costs and chemistry, manufacturing and controls (&#8220;CMC&#8221;) costs. Elpiscience paid the Company $<ix:nonFraction unitRef="usd" contextRef="i75bd7c4152884c68b92109e363fdde3e_I20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMDM4MA_73a129c4-95ae-41c2-a239-bb63e4be8721">3.0</ix:nonFraction> million in March 2018 for certain costs in relation to the development of INBRX-105. The payment received in advance of the work to be completed was recorded to other current liabilities upon receipt and, since the Company was acting as an agent on behalf of Elpiscience, the Company recorded it as a contra-expense against research and development as the relevant work was completed. During the three and nine months ended September 30, 2019, the Company derecognized approximately $<ix:nonFraction unitRef="usd" contextRef="i1f4aef1c0a3941d986e5b4bf56476cf9_D20190701-20190930" decimals="-5" name="inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTgxNA_9e2b13a4-0d1f-4d70-8aaf-f8e1e09d8562">0</ix:nonFraction>  and $<ix:nonFraction unitRef="usd" contextRef="ia81f4833f5a946919ea5fac5c81bd331_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTgxOQ_7b4cfda1-ebf8-4769-9a18-ce43b2bf5331">0.7</ix:nonFraction> million of liabilities related to this agreement, respectively. As of September&#160;30, 2019, the Company had completed all relevant work on this program and had <ix:nonFraction unitRef="usd" contextRef="i530e97d213314faf9adf351089af9dca_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjE5OTAyMzM0Mjg1Ng_4c9a057b-2465-4e74-a8e4-d7af43bde217">no</ix:nonFraction> remaining liabilities related to the reimbursement under the PD-L1 and 4-1BB License Agreement. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OX40 Program </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into a separate License Agreement (the &#8220;OX40 License Agreement&#8221;) with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s multivalent protein therapeutic directed to the biological target OX40 (also referred to as &#8220;INBRX-106&#8221;). This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-106, including process development and manufacturing data and information necessary to develop INBRX-106. In the OX40 License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-106 for its development in Mainland China, Hong Kong Macau and Taiwan. The Company is eligible to receive certain developmental and commercial milestones of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="id7a2e84dab1f45e3bb160edd91676c7a_I20180430" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementMilestonePaymentsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMjA1Mg_a4e1c8c0-1758-4690-8fe3-5dff457860c7">100.0</ix:nonFraction> million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company achieved a milestone under the contract for $<ix:nonFraction unitRef="usd" contextRef="i3cd4816ef076457ea37eb5b862932984_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTgzMw_ec6f095e-d206-46c3-8818-10182d64a575">2.0</ix:nonFraction>&#160;million, which was received during September 2020. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie739eb4e2f9d498a802def60014528b5_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg0Mg_010cc48a-574e-4a63-a6c6-de3d63c1603d"><ix:nonFraction unitRef="usd" contextRef="i120f8c853b1845998a75889f0c5bcfe9_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg0Mg_441c9d75-0273-49cc-8c92-1b41f4539e8e">2.0</ix:nonFraction></ix:nonFraction>&#160;million during the three and nine months ended September 30, 2020 related to this agreement. <ix:nonFraction unitRef="usd" contextRef="i5bf43c32005f4158b0a144b53515e8f4_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MTQ2NQ_017ad484-b671-4e96-a443-a35c05dbbc92"><ix:nonFraction unitRef="usd" contextRef="i356cf52c8b484b40b183fa4c374dd895_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MTQ2NQ_8df9bfc4-341f-471b-b68f-8e4ccea310d0">No</ix:nonFraction></ix:nonFraction> revenue was recognized related to this agreement during the three and nine months ended September 30, 2019.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OX40 License Agreement, the Company is entitled to reimbursement for certain toxicology study costs and CMC costs. Elpiscience paid the Company $<ix:nonFraction unitRef="usd" contextRef="i24ef54ae4f554e239587b8661dc8a3c4_D20180801-20180831" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementExpenseReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMjczMg_68e2d5e0-e479-41d4-b1a4-19573f539819">3.4</ix:nonFraction> million in August 2018 for certain costs incurred in relation to the development and production of INBRX-106. The payment received in advance of the work to be completed was recorded to other current liabilities upon receipt and since the Company was acting as an agent on behalf of Elpiscience, the Company recorded it as a contra-expense against research and development as the relevant work was completed. As of September&#160;30, 2020, the Company has $<ix:nonFraction unitRef="usd" contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMzE2NA_28842dcd-0b35-4649-bd92-ba898fd0df5b">0.2</ix:nonFraction> million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. As of September&#160;30, 2020 and December 31, 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="i4443a6f4f1e84d38b14ec1c139ca5267_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMzOQ_b7697360-cc3f-4cd5-9630-747fe4d4afe7"><ix:nonFraction unitRef="usd" contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMzOQ_f25256e4-3aa6-4a4d-a3f4-190ffd028575">no</ix:nonFraction></ix:nonFraction> liabilities outstanding related to this agreement. During the three and nine months ended September 30, 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i48d4b7b4251d42058175aaa32b17035e_D20200701-20200930" decimals="-5" name="inhibrx:CollaborativeArrangementExpenseReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg2Mg_100312a3-6985-4c85-b18e-2ca62fd53738">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id08c3ccad96d44bea3c92b45810c37f3_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementExpenseReimbursement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg2Nw_b8a7d68e-970e-4831-9797-3e6d58f58850">0.2</ix:nonFraction> million in reimbursements for expenses already incurred, respectively. During the three and nine months ended September 30, 2019, the Company derecognized approximately $<ix:nonFraction unitRef="usd" contextRef="i3a9dc418ead24b64bb8341e1299808f8_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg4MA_c4d57adc-28ba-4e19-85ac-5da2bf2c3978">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ife0bac45fcb24762a17738da0331eeb2_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg4NA_1f96c3fe-173d-4e21-a176-49443e7f6ec8">1.3</ix:nonFraction> million of liabilities related to this reimbursement, respectively. Additional reimbursements of $<ix:nonFraction unitRef="usd" contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementAdditionalPaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg5Mw_21318be1-b33f-4ce1-9bfa-4770613b6646">0.1</ix:nonFraction> million related to multi-year stability studies are expected to be recognized and paid upon completion.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transcenta</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company entered into a License Agreement with Transcenta Holding, Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), (&#8220;Transcenta&#8221;) (the &#8220;Transcenta License Agreement&#8221;), whereby the Company granted Transcenta exclusive, non-transferable rights to develop, manufacture, and sell its products containing the Company&#8217;s protein therapeutic candidate, designed to target DR5 (also referred to as &#8220;INBRX-109&#8221;), or a derivative thereof, within mainland China, Hong Kong, Macau and Taiwan and agreed to provide Transcenta with the intellectual property and materials, including assays and cell lines, necessary to develop the therapeutic candidate. In addition, pursuant to the Transcenta License Agreement, the Transcenta License Agreement granted the Company a royalty-free, worldwide, non-exclusive research license to intellectual property created by Transcenta that </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="ifb76d06cb3ae47cc9227a488112600e1" continuedAt="i51b032d949e3406cbee7b07ec9c48e3b"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporates intellectual property licensed to Transcenta. In June 2019, the Company achieved a milestone under the contract for $<ix:nonFraction unitRef="usd" contextRef="i8d67a9e6f56b4ed58267e24b66936168_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxMTk4OA_bc728cb8-fa5a-44ea-84d3-b5ba6c219e4f">1.0</ix:nonFraction> million, which was received during August 2019, net of $<ix:nonFraction unitRef="usd" contextRef="i8d67a9e6f56b4ed58267e24b66936168_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementForeignTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxMjAzOQ_dffd129a-e130-4914-a876-d788cdb0e86e">0.1</ix:nonFraction> million in foreign tax withholding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Transcenta License Agreement, the Company is also eligible to receive certain developmental and commercial milestone payments of up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i9bd3c6489f044c5f983e14ec05aca582_I20170630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementMilestonePaymentsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxMjI0Ng_4786d37e-d776-45d1-9f9e-8043b8d890ec">100.0</ix:nonFraction> million, as well as percentage tiered royalties on future product sales with rates ranging between the high single-digits to the low teens. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2012, the Company entered into a Development and Option agreement with Celgene whereby the Company granted Celgene an option to exclusively license certain intellectual property rights relating to the Company&#8217;s CD47 checkpoint inhibitor . Upon grant of the Development and Option agreement, Celgene made a non-refundable upfront option payment for the exclusive license. In June 2013, Celgene opted to exercise its right to license the intellectual property rights associated with the Company&#8217;s CD47 therapeutic. The Company is also eligible to receive certain developmental and commercial milestones of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i2c665a21a67f4bba8893929943f5f8d3_I20130630" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:CollaborativeArrangementMilestonePaymentsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMTg0NDY_4d93cf5c-6c07-4fae-8b3f-abe56e9ef591">934.1</ix:nonFraction> million, assuming the achievement of all potential milestones in the agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens. The Company is obligated to pay <ix:nonFraction unitRef="number" contextRef="i2c665a21a67f4bba8893929943f5f8d3_I20130630" decimals="INF" name="inhibrx:CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDMwMQ_5506b78c-ed46-4583-b6d4-d55f54e5ae27">2</ix:nonFraction>% of future amounts received under the Development and Option Agreement to advisors who assisted the Company with the negotiation and other matters in connection with the Development and Option agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was recognized in accordance with the Company&#8217;s stated methodology discussed in Note 1.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NIH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2017, the Company was awarded a grant by the NIH in the amount of $<ix:nonFraction unitRef="usd" contextRef="iaa0c1f1f0a744b53a8d4ea48cd955591_I20170831" decimals="INF" format="ixt:numdotdecimal" name="inhibrx:GrantValuedAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMTk0ODE_47ffdd12-7764-494a-94f0-11ab5ea565b0">1.0</ix:nonFraction> million for the continued development of multi-specific antibodies for the treatment of Pseudomonas aeruginosa infection, all of which has been recognized as revenue upon completion in June 2019.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this NIH grant was based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue was recognized when the Company incurred these covered expenses related to the grant&#8217;s continued progression. The Company submitted invoices to the NIH for only those expenses which had been incurred by the Company in each period, resulting in reimbursement in arrears. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CARB-X Subaward Agreement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July 2017, the Company was awarded a grant by Boston University in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ibe47e6db9f494550ba03c3a1ee101b76_I20170731" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:GrantValuedAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjA2MDQ_4cf6c4e9-551f-4ab8-9f56-e8fe246581fa">4.6</ix:nonFraction> million. The program, Combating Antibiotic Resistant Bacteria Accelerator (&#8220;CARB-X&#8221;), is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. The Company received this award in relation to its program aimed at the development of novel antimicrobial therapeutics using multiple mechanisms of action to circumvent the development of resistance, and in the case of this grant, specifically for pseudomonas. The payment structure of this grant was a cost share, where <ix:nonFraction unitRef="number" contextRef="ibe47e6db9f494550ba03c3a1ee101b76_I20170731" decimals="INF" name="inhibrx:GrantAwardedPaymentStructurePercentageReimbursedBySponsor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjExNjI_79529fcc-bf05-4779-bb14-47f4657426bd">70</ix:nonFraction>% of costs were reimbursed by the sponsor, or Boston University, and the remaining <ix:nonFraction unitRef="number" contextRef="ibe47e6db9f494550ba03c3a1ee101b76_I20170731" decimals="INF" name="inhibrx:GrantAwardedPaymentStructurePercentageCoveredByCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjEyNDY_91727c77-4203-4c98-96a0-8f20929b4f6c">30</ix:nonFraction>% of costs are covered by the Company. The work under this grant began in October 2017 and was discontinued during the third quarter of 2019 based on the uncertainty within the applicable regulatory environment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this grant was based upon internal costs incurred by the Company that were specifically covered by the grant as well as certain specified overhead expenses. Revenue was recognized when the Company incurred these covered expenses related to the grant&#8217;s continued progression. The Company submitted invoices to Boston University for only those expenses which had been incurred by the Company in each period, resulting in reimbursement in arrears. Prior to discontinuation of the work on this grant, $<ix:nonFraction unitRef="usd" contextRef="i1e0b1022232b4f71b8972eb5887adc42_D20171001-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjE5Mjc_acd59cd6-59a0-4d94-af26-99a0a7c4ba7d">4.0</ix:nonFraction> million in revenue was recognized, all of which has been received in cash from Boston University. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i51b032d949e3406cbee7b07ec9c48e3b"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CDMRP funded through the DoD </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2018, the Company was awarded a grant by the CDMRP funded through the DoD by the U.S. Army Medical Research Acquisition Activity in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ia13e3186ca28469286c7cee39c4a772a_I20180930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:GrantValuedAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjIyMzM_58023eec-9f55-490d-8433-66f4415ec3dd">0.3</ix:nonFraction> million for the continued development of multi-specific antibodies for the treatment against Acinetobacter baumannii infection by circumventing development of bacterial resistance. The work under this grant began in December 2018 and was completed in September 2020. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this grant is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant&#8217;s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. As of September&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="ia36fb85c03c24ea8a91837247d809173_D20180901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg5OQ_69df0616-e37a-4bb7-bea6-f505704739dd">0.3</ix:nonFraction> million in revenue has been recognized under this grant, $<ix:nonFraction unitRef="usd" contextRef="i8c7c69c38154458b921c096178efb2ad_D20180901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTkwOA_ec4b6d7a-3758-4c57-a2f2-e341dfea102e">0.2</ix:nonFraction>&#160;million of which has been received in cash from the DoD.</span></div></ix:continuation><div id="iee91b9a90f804077b237584160b9370a_58"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4MA_191f978e-7e52-40ee-b42b-1888c3563346" continuedAt="i37d744d1cb3841f2990f0f22743e7ecc" escape="true">RELATED PARTY TRANSACTIONS </ix:nonNumeric></span></div><ix:continuation id="i37d744d1cb3841f2990f0f22743e7ecc" continuedAt="if954671a9c0c4cadae9d93d33461210a"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company&#8217;s Board of Directors or a committee thereof pursuant to policy.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LAV Summit Limited </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LAV Summit Limited (&#8220;LAV SL&#8221;), a limited company, is a principal shareholder owning more than <ix:nonFraction unitRef="number" contextRef="ie752799339b24161bced2a3798bf9a4d_I20200930" decimals="2" name="inhibrx:RelatedPartyEquityInterestInCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzQyMw_4da1f390-b24a-4243-9981-91c041c53669"><ix:nonFraction unitRef="number" contextRef="i3cf1efa19e3548d48a2df125b2ba8d78_I20191231" decimals="2" name="inhibrx:RelatedPartyEquityInterestInCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzQyMw_9673b8f2-6be7-47d8-bde7-cc63642c7509">5</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s outstanding equity interest as of September&#160;30, 2020 and December&#160;31, 2019. Due to this equity ownership, LAV SL is considered a related party. Moreover, Judith Li, a former member of the Company&#8217;s board of directors, is a Partner at LAV SL&#8217;s General Partner, Lilly Asia Ventures (&#8220;LAV&#8221;), a biomedical venture capital firm. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company entered into the Transcenta License Agreement. LAV, through one of its funds, holds a significant equity ownership position in Transcenta. During the three and nine months ended September 30, 2019, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i4373a79ed10e41d296ee0962058ceb18_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1Njg3OA_73f16ea5-e3ad-4ddd-bd16-ff1e99c3a409">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2ca21b8ec7ba4cbbb974b0a2ed21beea_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1Njg4Ng_a0616272-8aaf-4e8d-bc18-571e4cefb853">1.0</ix:nonFraction>&#160;million related to this agreement. During the three and nine months ended September 30, 2020, the Company recorded <ix:nonFraction unitRef="usd" contextRef="ifab658b65d2b4e509ba7e6fbedd7ea7f_D20200101-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mw_5e8ece35-518d-412b-88fb-779ce818065d"><ix:nonFraction unitRef="usd" contextRef="i92744c9c477a4e4ba89940a3d753b3b3_D20200701-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mw_9db28a13-1a28-49fe-8433-832978aca804">no</ix:nonFraction></ix:nonFraction> revenue related to this agreement. See Note 8 for further discussion of this agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into the PD-L1 and 4-1BB License Agreement with Elpiscience. LAV, through one of its funds, holds a significant equity ownership position in Elpiscience and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identifies Elpiscience as a related party. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred for which Elpiscience has paid the Company $<ix:nonFraction unitRef="usd" contextRef="if8bd613f072f461db198c9f9f272863d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ExpensesReimbursedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMTczMg_55ac770f-15ef-4e58-8bbb-22be30ccb562"><ix:nonFraction unitRef="usd" contextRef="iabfd8187536c4daf96510c57f57bade2_I20200930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ExpensesReimbursedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMTczMg_56fc0241-8503-4b4d-9106-62e047fdf880">4.7</ix:nonFraction></ix:nonFraction> million to date as of September&#160;30, 2020 and December&#160;31, 2019. During the three and nine months ended September 30, 2020 and 2019, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i36cb4e41c5bb48e89203d72ff7e9ad71_D20200101-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_25f0f351-fb56-4e28-91e5-2f482ab44aca"><ix:nonFraction unitRef="usd" contextRef="ia81f4833f5a946919ea5fac5c81bd331_D20190101-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_783dbcec-6a1c-44de-8af4-736b33f637ec"><ix:nonFraction unitRef="usd" contextRef="i1f4aef1c0a3941d986e5b4bf56476cf9_D20190701-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_db611474-33ab-4661-a533-8e458f3aae15"><ix:nonFraction unitRef="usd" contextRef="ief513a4e2d6b4dff83e12409769524ba_D20200701-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_f425d0b3-56d4-471a-bab2-b2ad6336e537">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue related to this agreement. See Note 8 for further discussion of this agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into the OX40 License Agreement with Elpiscience. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred for which Elpiscience has paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ExpensesReimbursedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE0NTg3Mg_3cbca1e8-4ed6-4bfb-88aa-1fa12bd6474d">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4443a6f4f1e84d38b14ec1c139ca5267_I20191231" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:ExpensesReimbursedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjMyNQ_83ce0898-090e-49e1-895b-92ad26764422">4.9</ix:nonFraction> million to date as of September&#160;30, 2020 and December&#160;31, 2019, respectively. During the three and nine months ended September 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i48d4b7b4251d42058175aaa32b17035e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1NzAxNA_41ad8471-8a50-4d75-ad20-98f88c0e1c35"><ix:nonFraction unitRef="usd" contextRef="id08c3ccad96d44bea3c92b45810c37f3_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1NzAxNA_f34f627b-4d36-4c30-8c3e-65806bc69c4b">2.0</ix:nonFraction></ix:nonFraction>&#160;million of revenue related to this agreement. During the three and nine months ended September 30, 2019, the Company recorded <ix:nonFraction unitRef="usd" contextRef="ife0bac45fcb24762a17738da0331eeb2_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM5Mg_3c8e9f48-451d-4a78-8c33-9efa35292541"><ix:nonFraction unitRef="usd" contextRef="i3a9dc418ead24b64bb8341e1299808f8_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM5Mg_b9f15e22-a36f-4925-8c95-59f882bfaa52">no</ix:nonFraction></ix:nonFraction> revenue related to this agreement. See Note 8 for further discussion of this agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics Healthcare Venture</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if954671a9c0c4cadae9d93d33461210a">WuXi Biologics Healthcare Venture (&#8220;WuXi Bio HV&#8221;) is a corporate venture arm of WuXi Biologics, with whom the Company has an existing Exclusivity Agreement. In January 2019, WuXi Bio HV purchased <ix:nonFraction unitRef="shares" contextRef="i1debe51ec3e946f19e9ced16e42dc5e1_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1MDU2Ng_c24a0bbb-1303-40fe-b12a-65bbe3049fc2">1.7</ix:nonFraction> million shares of the Company&#8217;s Series Mezzanine 2 Preferred Stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id456e841f6ea429782b9752a0983fce5_I20190131" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1NzAwNg_0b23ae3c-1c58-4d0a-bc52-05a56b69a150">6.98</ix:nonFraction> per share, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i1debe51ec3e946f19e9ced16e42dc5e1_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1MDgxNw_2b646a99-10a8-413a-95e6-395ac288c13d">12.0</ix:nonFraction> million. These shares converted to common stock upon the consummation of the Company&#8217;s IPO in August 2020. See Note 6 for further discussion of Preferred Stock transactions.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU0NA_49395d05-5ebc-44fd-b97f-c90e10cb1d2c" continuedAt="i46c637cabd1a41b0832240f7db6d0845" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="i46c637cabd1a41b0832240f7db6d0845" continuedAt="icea402dd04e94d31bc91e4845d88ca04"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a <ix:nonNumeric contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU2MQ_92c97c9c-ed04-4deb-a943-45c0a8026ce2">seven-year</ix:nonNumeric> lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:LesseeOperatingLeaseSquareFootage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMTE0_4459481e-dd36-4258-ad88-89a6ad3f3bab">34,000</ix:nonFraction> square feet as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional <ix:nonNumeric contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU3Ng_15406a38-0f61-4555-a043-3bd99303d94f">five years</ix:nonNumeric>. The lease contained an initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930" decimals="-5" format="ixt:numdotdecimal" name="inhibrx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMzE4_6f95ff40-e878-43fc-84ec-badfd1681b7c">0.1</ix:nonFraction> million per month with <ix:nonFraction unitRef="number" contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930" decimals="INF" name="inhibrx:LesseeOperatingLeaseAnnualEscalations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMzM2_18e6e481-1083-4df7-9922-c906165262ec">2</ix:nonFraction>% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company executed an amendment to its lease agreement to expand its facilities by approximately <ix:nonFraction unitRef="sqft" contextRef="i9382d50f269442c59ff29a8133e54f76_I20190531" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:LesseeOperatingLeaseSquareFootageExpansion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNjUx_fc63a6ff-6ebd-41ea-8b7e-3e595a67fdaa">9,000</ix:nonFraction> square feet and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="i9382d50f269442c59ff29a8133e54f76_I20190531" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfODMx_566a078b-080a-48be-80fd-cb63f1473fd8">30,000</ix:nonFraction> per month with <ix:nonFraction unitRef="number" contextRef="i9382d50f269442c59ff29a8133e54f76_I20190531" decimals="INF" name="inhibrx:LesseeOperatingLeaseAnnualEscalations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfODQ5_1a34c3ea-bf0d-423c-8bdb-60ad087923c1">2</ix:nonFraction>% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. </span></div><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="inhibrx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU0NQ_5fdec110-6589-49df-b137-8484b74ba083" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset and operating lease liability as of September&#160;30, 2020 and December&#160;31, 2019 are as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfMi0xLTEtMS01MzYz_f6bb3754-b251-4220-8f3f-d86694b08454">8,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfMi0zLTEtMS01Mzc5_d6f48d8c-8694-49a7-89cd-7e3ca479b03e">7,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNS0xLTEtMS01MzY2_ff3ca329-ade2-4dc1-85dc-dfebb4cf24e3">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNS0zLTEtMS01Mzg1_9d0a76a7-8c7a-465b-9a7a-68903ce71eff">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNi0xLTEtMS01MzY2_a0280763-ed36-48b7-b0a2-140e59d87aee">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNi0zLTEtMS01Mzg1_325ec6c6-c6c7-4a9c-b0d2-c57c33dbc586">6,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfOS0xLTEtMS04NDMz_92d2c090-a252-4940-92a2-44b25d1d4221">8,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfOS0zLTEtMS04NDMz_d3dcdf5d-0522-4d97-b2e0-aa77a31bc1e3">7,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020 and 2019, the Company recognized operating lease expense of $<ix:nonFraction unitRef="usd" contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjAzMg_d26581f4-bebf-4c19-989d-158335575b44">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjA0MQ_567a773e-f854-4f2f-af74-daa3eb5353d8">0.6</ix:nonFraction>&#160;million, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized operating lease expense of $<ix:nonFraction unitRef="usd" contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjA0NQ_0612b8fe-89ed-4c2c-bcda-1dea689b6831">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjA0OQ_e5cf5da9-a2c8-4186-8976-ec7a517e9d8f">1.7</ix:nonFraction>&#160;million, respectively. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s operating lease had a remaining term of <ix:nonNumeric contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0MTU4MQ_417b043d-c8bb-4af6-b267-9fe335875691">4.8</ix:nonNumeric> and <ix:nonNumeric contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0MTU4NQ_675ae60b-a150-48ed-8900-5c73532a23a5">5.5</ix:nonNumeric> years, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0MTU5Mg_b0aab395-5369-4d4e-b2ab-83f81d87dcb8">8.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMTk2Mg_bd1e8f36-72f3-492d-816b-edcbf3a58186">8.0</ix:nonFraction>% as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="icea402dd04e94d31bc91e4845d88ca04"><ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU0Ng_ef75d4ed-250a-41d4-bbee-d68cd45d5518" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating leases are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.849%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (3 months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMy0yLTEtMS0w_d4f55dd1-5335-413f-ba0e-d81a3fe921a9">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNC0yLTEtMS0w_621a97c0-29ee-4970-a3dd-cb8e214ff2ad">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNS0yLTEtMS0w_d2cbc6af-a02a-484b-96ec-e7699c133094">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNi0yLTEtMS0w_116f0f6b-eece-408e-9783-55ed2c54cc64">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNy0yLTEtMS0w_9430be79-1984-4f66-8309-31fe52ee8179">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="inhibrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfOC0yLTEtMS0w_acdd707b-e160-4650-b153-14969177fa5f">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTAtMS0xLTEtODQ1Nw_4c4c8ec1-e0f2-486d-9ef0-a5211d44b000">10,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTAtMi0xLTEtMA_81d89591-581b-43b3-b67b-70b45b4b8046">1,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTItMS0xLTEtODQ1Nw_86d04d80-ffd9-423a-ab29-688e7d6ac22f">8,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTItMi0xLTEtMA_5d7b6e28-e4ec-4e44-8de0-82e9177daa01">1,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTQtMS0xLTEtODQ1Nw_71b30faa-7e33-4f7c-be30-324c8f388dc6">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s condensed consolidated balance sheets, condensed consolidated statements of operations, or condensed consolidated statements of cash flows.</span></div></ix:continuation><div id="iee91b9a90f804077b237584160b9370a_70"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83MC9mcmFnOmUwOTI3YmM1YjJlMDRjZmY5ZGU2YzY0NGQ0YTFkZmU3L3RleHRyZWdpb246ZTA5MjdiYzViMmUwNGNmZjlkZTZjNjQ0ZDRhMWRmZTdfNzY5NjU4MTM5NzA4Ng_bd9a0f2a-aa85-44d2-9803-f39772f79f71" continuedAt="i4ea592304eaa4246b50be852f97f4262" escape="true">COVID-19</ix:nonNumeric></span></div><ix:continuation id="i4ea592304eaa4246b50be852f97f4262" continuedAt="i4f7e9f02e9a24a1a889b20d9020e5c0d"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of the COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&#8217;s therapeutic candidates and the conduct of future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the FDA which could result in delays in meetings, reviews and approvals, including with respect to any of the Company&#8217;s therapeutic candidates. For example, as a result of the COVID-19 pandemic patient travel restrictions, the Company temporarily suspended patient enrollment for its trial for INBRX-101 during the second and third quarters of 2020. Additionally, while the potential economic </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><ix:continuation id="i4f7e9f02e9a24a1a889b20d9020e5c0d" continuedAt="i58d44f882a23473880060ae7983364df"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or future clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s business, financial condition, results of operations and prospects, and those of the third parties relied upon by the Company.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i58d44f882a23473880060ae7983364df">On March 27, 2020, the U.S. federal government enacted the CARES Act, which includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;The CARES Act also includes provisions for PPP loans administered by the SBA. The Company applied for and received PPP funds. See Note 4 and Note 12 for further discussion of the Company&#8217;s PPP loan. The Company will continue to examine and evaluate any impacts the CARES Act and associated subsequent legislation may have on its business and taxes.</ix:continuation> </span></div><div id="iee91b9a90f804077b237584160b9370a_73"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTA4NDg3Nw_e69f67a6-6e0e-4da8-bb68-a1b4b7fe079f" continuedAt="i2d8036c3b5bd4fc8a10f5f470eeca12e" escape="true">SUBSEQUENT EVENTS </ix:nonNumeric></span></div><ix:continuation id="i2d8036c3b5bd4fc8a10f5f470eeca12e" continuedAt="i586db7050d454c17b8af841e468a5257"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the unaudited condensed consolidated financial statements as of September&#160;30, 2020, the Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these condensed consolidated financial statements, other than disclosures related to those outlined below. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Loan Repayment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after receiving proceeds from its IPO, the Company repaid its PPP Loan in full. As of the repayment date, the Company had accrued approximately $<ix:nonFraction unitRef="usd" contextRef="i29539df2bfdf4e7080d49e945e09a68a_I20201031" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfNTQ5NzU1ODE2MTI4Ng_20846723-e2f0-4563-ab0e-f3f1a57140ff">7,400</ix:nonFraction> of interest, for a total repayment of $<ix:nonFraction unitRef="usd" contextRef="i434a60e482d64431a96e2d34a17d0b06_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfNTQ5NzU1ODE2MTMxNA_516278aa-8821-48ee-a41b-4ccc850b1ce9">1.9</ix:nonFraction>&#160;million. As discussed in Note 4, there were no prepayment penalties associated with the payment of the loan prior to maturity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the 2020 Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, the Company entered into the First Amendment to the 2020 Loan Agreement with Oxford (the &#8220;2020 Loan Amendment&#8221;). The 2020 Loan Amendment provides for two additional tranches of term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ifb4a4c41e60c471987fc84b082722cf4_I20201112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjE5OTAyMzI4ODQ1OA_5604152a-eaaa-4d69-b983-f01f3d4a0883">40.0</ix:nonFraction>&#160;million, as follows: (a) the second tranche in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic11ebf603f344bfeb2b655dcddb72921_I20201112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTM5Ng_76e367d9-3e33-45f8-b584-3c72b785bd77">20.0</ix:nonFraction>&#160;million, funded upon the closing of the 2020 Loan Amendment (&#8220;Tranche B&#8221;), and (b) the third tranche in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i48109ca4da0c44b1b47c9c968a9d401d_I20201112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQxMQ_acfce076-50ab-478d-b20d-ab74dd2da748">20.0</ix:nonFraction>&#160;million to fund on or before September 30, 2021, subject to the initiation of a registration-enabling trial for the Company&#8217;s therapeutic candidate, INBRX-109, in chondrosarcoma, pursuant to the terms of the 2020 Loan Amendment (&#8220;Tranche C&#8221;). Tranche B and Tranche C are in addition to the first tranche of term loans in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i893ad457259b4931a5c0ce26c8fb0c92_I20200715" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjE5OTAyMzI4ODQ0Mw_bcce83f1-bd04-4ce4-8b08-2d51b553f5a2">10.0</ix:nonFraction>&#160;million, which was funded on July 15, 2020. In accordance with the 2020 Loan Amendment, the Company paid a one-time first amendment fee of $<ix:nonFraction unitRef="usd" contextRef="i749adb0c10a241f59042990471fbddfe_D20201112-20201112" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQyNg_a1c04360-6b03-4e1c-943e-216d9ca5b687">0.7</ix:nonFraction>&#160;million. The terms of the first tranche under the 2020 Loan Agreement were modified to align with Tranche B pursuant to the 2020 Loan Amendment.</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i586db7050d454c17b8af841e468a5257">The outstanding term loan will mature on November 1, 2025 (the &#8220;Amended Maturity Date&#8221;) and bears interest at a floating per annum rate equal to the greater of (1)&#160;<ix:nonFraction unitRef="number" contextRef="i893ad457259b4931a5c0ce26c8fb0c92_I20200715" decimals="INF" name="inhibrx:DebtInstrumentInterestRateFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQ3NA_f413b1dd-84da-403d-941b-c04185c0a91a">7.96</ix:nonFraction>%&#160;and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii)&#160;<ix:nonFraction unitRef="number" contextRef="ie0b6adb629804b27bc064abbdf18bbbb_D20200715-20200715" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQ4MQ_23919aac-e05c-4dc4-9a8b-33a4b81f6119">7.80</ix:nonFraction>%. The repayment schedule provides for interest-only payments until January 1, 2024. Upon funding of Tranche C, the interest-only payments may be extended by <ix:nonNumeric contextRef="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112" format="ixt-sec:durmonth" name="inhibrx:DebtInstrumentInterestOnlyPaymentsExtendedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTUyNw_9f8fb70b-483c-46e1-be5c-bc2c0f2bb017">12</ix:nonNumeric> months to January 1, 2025. The interest-only period is followed by <ix:nonNumeric contextRef="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112" format="ixt-sec:durmonth" name="inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTUwNw_5e5352a9-f9db-4f25-84b0-2f500e2af6f9">23</ix:nonNumeric> months of equal payments of principal and interest, or if the interest-only period is extended, by <ix:nonNumeric contextRef="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112" format="ixt-sec:durmonth" name="inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTU0Nw_38751572-cb22-4870-b6f4-e9b86c875708">11</ix:nonNumeric> months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of <ix:nonFraction unitRef="number" contextRef="i1dc414bff1c84c9089ef103ad34b6d98_I20201112" decimals="INF" name="inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQ4OA_69c1746b-b96a-479e-9102-3597e47226bb">9.0</ix:nonFraction>% of the original principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from <ix:nonFraction unitRef="number" contextRef="i6760108879a84be9ad67b709f7c52557_I20201112" decimals="INF" name="inhibrx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMjMxMQ_a6fbe717-0b3c-467b-8547-abc509dfaa5e">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i76849810b9be4460b784e44f45823ceb_I20201112" decimals="INF" name="inhibrx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMjMxNw_8a3b6bea-8799-42fc-9cd8-6ba6711b2539">3.0</ix:nonFraction>%, depending on the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION <br/>AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q, or Quarterly Report, and our final prospectus for our initial public offering, or IPO, filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, or the Securities Act, with the Securities and Exchange Commission, or SEC. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the section of this Quarterly Report titled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div id="iee91b9a90f804077b237584160b9370a_79"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using our protein engineering expertise and proprietary single domain antibody, or sdAb, platform. Our sdAb platform allows us to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Highly modular, our sdAbs can be combined with precise valencies and multiple specificities, creating therapeutic candidates designed to be capable of enhanced cell signaling, conditional activation or combined synergistic functions. We currently have four programs in ongoing Phase 1 clinical trials, three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency, or AATD. Our most advanced therapeutic candidate, INBRX-109,&#160;is a tetravalent death receptor 5, or DR5, agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma, two difficult-to-treat cancers. INBRX-106 is a hexavalent OX40 agonist currently being investigated in patients with locally advanced or metastatic solid tumors. Both INBRX-109 and INBRX-106 programs are designed to achieve target agonism through precise control of therapeutic valency. INBRX&#8209;105 targets two proteins, each of which can lead to an enhanced anti-tumor immune response; it is engineered with the goal of improving safety through conditional target agonism. Based on preclinical mechanistic data, INBRX-106 and INBRX-105 may have the potential to be used in combination with, or in place of, currently approved checkpoint inhibitors. Our fourth program, INBRX-101, is an optimized, recombinant alpha 1 antitrypsin, or AAT, augmentation therapy for AATD. We anticipate additional data releases from all four of our clinical programs by the end of 2021.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have had significant operating losses. Our net losses were $58.5 million and $35.1 million for the nine months ended September 30, 2020 and 2019, respectively. During August 2020, we completed an IPO in which we sold 8,050,000 shares of common stock at an offering price of $17.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions and offering costs, were $125.9&#160;million. As of September&#160;30, 2020, we had an accumulated deficit of $127.7 million and cash and cash equivalents of $127.7 million. Since our inception, we have devoted substantially all of our efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of our therapeutic candidates, hiring to support our research and development activities and financial reporting capabilities, establishing our intellectual property portfolio, and raising capital to support and expand these activities. Our primary use of cash has been to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative, or G&amp;A, expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, G&amp;A expenses and capital expenditures will continue to increase. In particular, we expect our expenses and losses to increase as we continue our development of, and seek regulatory approvals for, our therapeutic candidates (especially as we move more candidates from preclinical to clinical development as well as study candidates in later stages of clinical development), and begin to commercialize any approved products, if ever. We also expect our expenses and losses to increase as we hire additional personnel and incur increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs and as we incur increased costs from investor and public relations expenses associated with operating as a public company. Our net losses may fluctuate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our current business plan, we believe that our existing cash and cash equivalents, including the net proceeds from our IPO, will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months. To date, we have not had any therapeutics approved for sale and have not generated any revenue from the commercial sale of approved therapeutic products. We do not expect to generate any revenue from therapeutic product sales unless and until we, or our collaboration partners, successfully complete development and obtain regulatory approval for one or more of our therapeutic candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaboration or other similar agreements. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our intellectual property on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations, financial condition, and prospects. We do not own or operate manufacturing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies, and other biologics for our preclinical research, clinical trials, and if and when applicable, commercial product and employ internal resources to manage our manufacturing relationships with these third parties. </span></div><div id="iee91b9a90f804077b237584160b9370a_85"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Agreement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;28, 2018, we entered into the Amended and Restated Master Services Agreement, as amended by Amendment No. 1 to Amended and Restated Master Services Agreement dated December 11, 2019, or the WuXi Agreement, with WuXi Biologics (Hong Kong) Limited, or WuXi, pursuant to which we agreed, for three years and subject to certain conditions, to exclusively use WuXi to manufacture our therapeutic candidates for which we plan to first initiate clinical studies outside of China. Under the WuXi Agreement, WuXi and certain of its affiliates will provide biologics development and manufacturing services on a&#160;project-by-project&#160;basis. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the WuXi Agreement, we will own all intellectual property created, developed or reduced to practice by WuXi in the course of providing services to us; provided that, certain intellectual property created or developed by WuXi may be owned exclusively by WuXi if this intellectual property (i)&#160;relates to generally applicable experimental methods, (ii)&#160;relates to generally applicable manufacturing processes, developed solely at WuXi&#8217;s expense, or (iii)&#160;is derivative of WuXi&#8217;s&#160;pre-existing&#160;intellectual property.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the WuXi Agreement, fees will be mutually agreed upon on a&#160;project-by-project&#160;basis. We also may be eligible to receive discounts in the&#160;low-&#160;to&#160;mid-single&#160;digits for certain projects and services per the terms of the WuXi Agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">bluebird bio Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2018, we entered into an exclusive license agreement with bluebird bio, Inc., or bluebird, to research, develop and commercialize chimeric antigen receptor, or CAR, T-cell therapies using our proprietary sdAb platform. Under the terms of this license agreement we will provide bluebird the exclusive worldwide rights to develop, manufacture and commercialize certain cell therapy products containing sdAbs directed to various cancer targets.&#160;In January 2019, we received a $7.0 million payment and pursuant to the license agreement, we are entitled to receive developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single digits. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, we entered into an option and license agreement, or the 2020 bluebird Agreement, with bluebird, pursuant to which we granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets, consisting of two initial programs and up to an additional 8 programs. Inhibrx retains all rights to the specific sdAbs outside of the cell therapy field. We received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and we are entitled to an upfront option fee for each additional program. We also granted to bluebird an option to acquire an exclusive license with respect to all binders and cell therapy products developed under the 2020 bluebird Agreement, which entitles us to additional fees upon exercise of the option. We are also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaboration Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these contracts, we have entered into strategic collaborations with other third parties, including Chiesi, Phylaxis, Transcenta Holding Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), or Transcenta, and Elpiscience Biopharmaceuticals, Inc., or Elpiscience. For more information regarding these agreements, refer to Note 8 to the condensed consolidated financial statements.</span></div><div id="iee91b9a90f804077b237584160b9370a_88"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all of our revenue has been derived from licenses with collaboration partners and grant awards. We have not generated any revenue from the commercial sale of approved therapeutic products, and we expect our revenue for the next several years will be derived primarily from payments under our current and any future grant awards and agreements with our collaboration partners. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to research activities, including our discovery efforts, and preclinical and clinical development and the manufacturing of our therapeutic candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track our internal research and development expenses on a&#160;program-by-program&#160;basis as they primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">External expenses, consisting of:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses incurred in connection with the preclinical development of our programs; </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials of our therapeutic candidates, including under agreements with third parties, such as consultants and contract research organizations, or CROs; </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with manufacturing our contract development and manufacturing therapeutic candidates including under agreements with contract development and manufacturing organizations, or CDMOs; and</span></div><div style="margin-bottom:9.5pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other external expenses, such as laboratory services related to our discovery and development programs and other shared services, and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Internal expenses, consisting of:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities; and</span></div><div style="margin-bottom:9.5pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other internal expenses, such as laboratory supplies and other shared research and development costs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development, support our preclinical programs, and continue to discover new therapeutic candidates, as well as increase our headcount. In particular, clinical development of our therapeutic candidates, as opposed to preclinical development, generally has higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Moreover, the costs associated with our CDMOs to manufacture our therapeutic candidates and future commercial products is also much more costly as compared to early stage preclinical development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each therapeutic candidate&#8217;s commercial potential. We will need substantial additional capital in the future to support these efforts. In addition, we cannot forecast which therapeutic candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development costs may vary significantly based on factors such as: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">per patient trial costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of trials required for approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the countries in which the trials are conducted </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the length of time required to enroll eligible patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients that participate in the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of doses that patients receive; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the drop-out or discontinuation rates of patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional safety monitoring requested by regulatory agencies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of patient participation in the trials and follow-up; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of manufacturing of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the phase and development of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety profile of our therapeutic candidates; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties related to the COVID-19 pandemic. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses consist primarily of: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in G&amp;A functions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with accounting and audit services, legal services, business development and investor relations as well as consulting expense under agreements with third parties, such as consultants and contractors; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities, insurance and supplies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our G&amp;A expenses will continue to increase over the next several years as we incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company and as we increase our headcount. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense) </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest expense on our debt from Oxford and prior to conversion, interest expense related to the amortization of the debt discount related to the 2019 Note and the 2020 Notes, and gains or losses on the change in fair value of derivative liabilities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2020 and 2019 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated results of operations for each of the periods indicated (in thousands, except percentages): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,558)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,047)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,497)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,163)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fee revenue increased by $5.0 million to $5.8 million during the three months ended September 30, 2020 from $0.8 million during the three months ended September 30, 2019. Approximately $2.0 million of license fee revenue recognized during the three months ended September 30, 2020 was related to our effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period under our option agreement with Chiesi. During the three months ended September 30, 2020, we achieved a milestone under our agreement with Elpiscience and recognized $2.0 million of revenue related to this agreement. Additionally, we recognized $0.8 million of revenue under our agreements with Phylaxis, and $1.1 million related to other license revenue from non-affiliates. The $0.8 million of license fee revenue earned during the three months ended September 30, 2019 was earned related to our option agreement with Chiesi.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue decreased to $75,000 during the three months ended September 30, 2020 from $425,000 during the nine months ended September 30, 2019. Grant revenue during the three months ended September 30, 2020 consisted of revenue earned under the DoD grant of $75,000. Grant revenue during the three months ended September 30, 2019 consisted of approximately $364,000 of revenue earned under the CARB-X grant and $61,000 under the DoD grant. Our grants with the NIH and CARB-X were completed or terminated prior to 2020.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">External expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preclinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other external research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $7.0 million to $19.8 million during the three months ended September 30, 2020 from $12.8 million during the three months ended September 30, 2019. The overall increase was primarily due to the following factors:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing expense increased by $8.2 million, which was primarily attributable to work performed by our CDMO partners for the formulation and manufacturing of our INBRX-101 and INBRX-109 therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial expense increased by $0.7 million, which was primarily attributable to increased CRO costs from the progression of our Phase 1 trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical expense decreased by $0.9 million, which was primarily attributable to the completion of preclinical development of our four clinical programs as they progress through the pipeline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expense decreased by $0.1 million, which was attributable to a decrease in our headcount; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities expense increased by $0.3 million, which was attributable to additional rent payments under an amended lease, which commenced in January 2020. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G&amp;A Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expense increased by $0.1&#160;million to $1.6&#160;million during the three months ended September 30, 2020 from $1.5&#160;million during the three months ended September 30, 2019. During the three months ended September 30, 2020, personnel expenses increased $0.3 million as compared to the same period in the prior year, related to an increase in headcount and an increase in discretionary bonuses. This increase was offset by a decrease of $0.2 million in legal expense related to patents, as we initiated several new patents during the three months ended September 30, 2019.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, increased by $1.7 million to $4.4 million during the three months ended September 30, 2020 from $2.7 million during the three months ended September 30, 2019. During the three months ended September 30, 2020, we incurred interest expense of $2.0 million related to the amortization of the 2019 Note and the 2020 Notes through their conversion date. Upon the IPO and the notes conversion, we accelerated amortization of the debt discounts for an additional $2.2 million of expense. Additionally, during the three months ended September 30, 2020, we recorded $0.3 million of interest related to interest paid and the amortization of debt discounts related to the 2020 Loan Agreement with Oxford. During the three months ended September 30, 2019, we recorded $2.6 million of interest expense related to amortization of the 2019 Note and $0.1 million of interest expense related to the 2015 Loan Agreement with Oxford related to interest paid and the amortization of debt discounts.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of derivative liabilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we recorded no gain or loss related to the change in fair value of derivative liabilities, as they were already written down to zero at the beginning of the period. During the three months ended September 30, 2019, we recognized a loss of $3.5 million related to the change in fair value of derivative liabilities upon the revaluation of the derivative based upon a decreased likelihood of IPO at the end of the period.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on equity method investment during the three months ended September 30, 2020 of $0.5 million consists of our share of losses from our investment in Phylaxis, which reduced our equity investment to zero. The equity investment was established during the third quarter of 2020. As a result, no gains or losses were recognized during the three months ended September 30, 2019.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2020 and 2019 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our condensed consolidated results of operations for each of the periods indicated (in thousands, except percentages): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,836)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,076)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,475)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,095)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,380)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fee revenue increased by $1.2 million to $10.0 million during the nine months ended September 30, 2020 from $8.8 million during the nine months ended September 30, 2019. Approximately $5.8 million of license fee revenue recognized during the nine months ended September 30, 2020 was related to our effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period under our option agreement with Chiesi. During the nine months ended September 30, 2020, we achieved a milestone under our agreement with Elpiscience and recognized $2.0 million of revenue related to this agreement. Additionally, we recognized $0.8 million of revenue under our agreements with Phylaxis, $0.4 million under our 2020 Option and License Agreement with bluebird, and another $1.1 million related to other license revenue from non-affiliates. Approximately $0.8 million of license fee revenue recognized during the nine months ended September 30, 2019 was related to our option agreement with Chiesi. During the nine months ended September 30, 2019, we earned revenue under our 2018 bluebird Agreement, which consisted of a $7.0 million payment received and recognized as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the third quarter of 2019, as well as a milestone achieved under our agreement with Transcenta, resulting in a payment of $1.0 million during June 2019. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue decreased by $4.0 million during the nine months ended September 30, 2020 to $0.1 million from $4.1 million during the nine months ended September 30, 2019. During the nine months ended September 30, 2020, we earned revenue of $0.1 million related to work on the DoD grant. Grant revenue during the nine months ended September 30, 2019 consisted of $0.9 million from the NIH, $3.1 million from CARB-X, and $0.1 million from the DoD. Our grants with the NIH and CARB-X were completed or terminated prior to 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">External expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preclinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other external research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $20.2 million to $55.8 million during the nine months ended September 30, 2020 from $35.6 million during the nine months ended September 30, 2019. The overall increase in was primarily due to the following factors:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing expense increased by $24.4 million, which was primarily attributable to work performed by our CDMO partners for the formulation and manufacturing of our INBRX-101 and INBRX-109 therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials expense increased by $2.1 million, which was primarily attributable to CRO costs from the progression of our Phase 1 trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical expense decreased by $6.8 million, which was primarily attributable to the completion of preclinical development of our four clinical programs as they progressed through the pipeline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expense increased by $1.4 million, which was primarily attributable to an overall increase in our headcount during the period; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities-related expense increased by $0.7 million, which was primarily attributable to additional rent payments under an amended lease, which commenced in January 2020. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G&amp;A Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expense was consistent at $4.6&#160;million during each of the nine months ended September 30, 2020 and the nine months ended September 30, 2019. Personnel expense remained consistent over each period. Facilities expense increased by $0.2 million as a result of additional rent payments under an amended lease that commenced in January 2020, which was offset by a decrease in external professional services of $0.2 million.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense) </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, increased by $6.9 million to $10.3 million during the nine months ended September 30, 2020 from $3.4 million during the nine months ended September 30, 2019. During the nine months </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September 30, 2020, we incurred interest expense of $7.8 million related to the 2019 Note and the 2020 Notes prior to conversion into equity. Upon the IPO and the conversion of the notes, we recorded accelerated amortization of $2.2 million. During the nine months ended September 30, 2020, we recorded interest expense of $43,000 related to our 2015 Loan Agreement with Oxford and $0.3 million related to our 2020 Loan Agreement with Oxford, both of which consisted of cash payments of interest and amortization of debt discounts. During the nine months ended September 30, 2019, we issued the 2019 Note and began to incur interest expense for a total of $3.0 million. We recorded $0.6 million of interest expense related to our 2015 Loan Agreement with Oxford. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of derivative liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the nine months ended September 30, 2020, we recorded a gain of $2.7 million to change in fair value of derivative liabilities as a result of the revaluation of the derivative liabilities on the 2019 Note and the 2020 Notes. This change was recorded during the second quarter of 2020 and was due to our impending IPO and its impact on our probability assessment of expected conversion scenarios. During the nine months ended September 30, 2019, we recorded a loss of $3.5 million related to the change in fair value of derivative liabilities upon the revaluation of the derivative based upon a decreased likelihood of IPO at the end of the period.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on equity method investment during the nine months ended September 30, 2020 of $0.5 million consists of our share of losses from our investment in Phylaxis, which reduced our equity investment to zero. The equity investment was established during the third quarter of 2020. As a result, no gains or losses were recognized during the nine months ended September 30, 2019.</span></div><div id="iee91b9a90f804077b237584160b9370a_94"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Financial Condition </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed our IPO of 8,050,000 shares of our common stock at a price to the public of $17.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,050,000 additional shares of our common stock. Our aggregate net proceeds from the offering were $125.9&#160;million, net of underwriting discounts, commissions and offering costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO and through September&#160;30, 2020, other sources of capital raised to fund our operations were comprised of the sale of equity securities, payments received from commercial partners for licensing rights to our therapeutic candidates under development and grants, borrowings under loan and security agreements with Oxford including $10.0 million of gross proceeds borrowed under the 2020 Loan Agreement in July 2020, and proceeds from the sale and issuance of the 2019 Note and the 2020 Notes.&#160;</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash and cash equivalents of $127.7 million. Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future liquidity and capital funding requirements will depend on numerous factors, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, costs and timing of preclinical studies and clinical trials for our current or future therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and when we are able to obtain regulatory approval to market any of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize any therapeutic candidates that receive regulatory approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence and effect of competing or complementary therapeutics or therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any strategic licensing, collaboration or other similar agreement that we have or may establish; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repay, refinance or restructure our indebtedness when payment is due, including in the event such indebtedness is accelerated;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of our capital stock; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing or future effects of the COVID-19 pandemic and related uncertainties on capital and financial markets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to require additional funding in order to complete the development of our therapeutic candidates and commercialize our therapies, if approved. Until such time, if ever, in which we can generate substantial product revenue, we expect to continue to fund our operations and capital funding needs through potential future equity offerings, debt financings or other capital sources, including strategic licensing, collaboration, or other similar arrangement. However, we may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms or at all. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our intellectual property on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations, financial condition, and prospects. </span></div><div id="iee91b9a90f804077b237584160b9370a_97"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the net cash flow activity for each of the periods indicated&#160;(in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(32,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(20,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">149,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">116,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $32.6 million during the nine months ended September 30, 2020 and consisted primarily of a net loss of $58.5 million, adjusted for non-cash items including accretion on our debt discount and the non-cash portion of interest expense related to our debt of $10.0 million, stock-based compensation expense of $3.7 million, depreciation and amortization of $0.8 million, non-cash lease expense of $1.0 million, the change in fair value of derivative liabilities of $2.7 million, and loss on equity method investment of $0.5 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, primarily related to increases in accounts payable of $11.6 million and to accrued expenses and other current liabilities of $6.2 million due to an overall higher volume of clinical activity and contract manufacturing work performed by our CDMO partners, offset in part by a decrease in deferred revenue of $4.1 million and a decrease in the operating lease liability of $1.0 million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $20.1 million during the nine months ended September 30, 2019&#160;and consisted primarily of a net loss of $35.1 million, adjusted for non-cash items such as stock-based compensation expense of $2.9 million, non-cash lease expense of $1.1 million, depreciation and amortization expense of $0.9 million, accretion on our debt discount and the non-cash portion of interest expense related to our debt of $3.2 million, and a change in fair value of derivative liability of $3.5 million. Changes in operating assets and liabilities </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also contributed to the cash used in operating activities, primarily related to decreases in accounts payable of $3.0 million, other liabilities of $0.4 million, prepaid expenses and other current assets of $0.8 million, and decreases in the operating lease liability of $0.7 million. Additionally, increases in accrued expenses and current liabilities of $1.0 million due to an overall higher volume of preclinical and clinical activity, and increases in deferred revenue of $9.2 million were offset by an increase in accounts receivable of $1.7&#160;million due to the timing of cash collections on revenue earned during the nine months ended September 30, 2019. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.8 million and $1.5 million during the nine months ended September 30, 2020 and 2019, respectively, and was related to capital purchases, including laboratory equipment and the expansion of our facility in La Jolla, California. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $149.5 million during the nine months ended September 30, 2020 and consisted primarily of the gross proceeds $136.9 million from our IPO during August 2020, which was partially offset by the payment of offering costs of $10.6 million. Additionally, the Company received proceeds of $15.0 million from the sale and issuance of the 2020 Notes, $10.0 million in proceeds from the issuance of the 2020 Loan Agreement with Oxford, and $1.9 million in borrowings from the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act, or PPP Loan. These proceeds were offset in part by repayments of $3.6 million on our 2015 Loan Agreement with Oxford, which consisted of the remaining principal payments and the final payment under that agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $43.8 million during the nine months ended September 30, 2019 consisted primarily of the gross proceeds of $12.0 million from the issuance of convertible preferred stock and the gross proceeds of $40.0 million from the issuance of the 2019 Note, partially offset by $2.5 million in issuance costs related to the 2019 Note, the repayment of debt principal of $4.6 million, and the payment of deferred IPO costs of $1.2 million.</span></div><div id="iee91b9a90f804077b237584160b9370a_100"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any&#160;off-balance&#160;sheet arrangements, as defined in the rules and regulations of the SEC. </span></div><div id="iee91b9a90f804077b237584160b9370a_106"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act: Emerging Growth Company Status; Smaller Reporting Company Status </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to take advantage of this extended transition period and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For so long as we are an emerging growth company we expect we will: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avail ourselves of the exemption from the requirement to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide less extensive disclosure about our executive compensation arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company for up to five years, although we will cease to be an &#8220;emerging growth company&#8221; upon the earliest of: (i)&#160;the last day of the fiscal year following the fifth anniversary of our IPO; (ii)&#160;the last day of the first fiscal year in which our annual revenue is $1.07&#160;billion or more; (iii)&#160;the date on which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have, during the previous rolling three-year period, issued more than $1&#160;billion in non-convertible debt securities; and (iv)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies, including that we will present no more than two years of audited financial statements and no more than two years of related management&#8217;s discussion and analysis of financial condition and results of operations. We may be a smaller reporting company even after we are no longer an emerging growth company.</span></div><div id="iee91b9a90f804077b237584160b9370a_109"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 to our condensed consolidated financial statements included elsewhere in this Form 10-Q for a discussion of recent accounting pronouncements and their effect, if any, on us. </span></div><div id="iee91b9a90f804077b237584160b9370a_112"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations and commitments from those disclosed in our financial statements and the related notes and other financial information included in our Prospectus for our IPO filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on August 18, 2020.</span></div><div id="iee91b9a90f804077b237584160b9370a_115"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates and Policies </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of financial statements requires us to make estimates and judgements that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are reflected in reported results for the period in which they become known. Actual results could differ significantly from the estimates made by our management.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates from those disclosed in our financial statements and the related notes and other financial information included in our Prospectus for our IPO filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on August 18, 2020.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risks.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were designed and operating effectively at the reasonable assurance level.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended September&#160;30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and our Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II &#8212; Other Information</span></div><div id="iee91b9a90f804077b237584160b9370a_127"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="iee91b9a90f804077b237584160b9370a_130"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report, including our consolidated financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results, financial condition, and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment.</span></div><div id="iee91b9a90f804077b237584160b9370a_133"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need for Additional Capital </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable, or if we achieve profitability, we may not be able to sustain it. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company. To date, we have financed our operations through equity and debt financings, license and milestone revenue and grants. We have incurred significant recurring operating losses since our inception. Our net loss for the nine months ended September 30, 2020 was $58.5 million. As of September&#160;30, 2020, we had an accumulated deficit of $127.7 million. We expect to incur additional losses in future years as we execute our plan to continue our discovery, research and development activities, including the manufacturing of and ongoing and planned preclinical and clinical development of our therapeutic candidates, and as we incur the additional costs of operating as a public company. We are unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources and efforts to developing our therapeutic candidates, identifying potential therapeutic candidates and conducting preclinical studies and clinical trials. We are still in the early stages of developing our therapeutic candidates, and we have not yet demonstrated an ability to successfully conduct or complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had more experience developing therapeutic candidates. We previously entered into an option agreement, dated August 19, 2019, by and between Chiesi Farmaceutici S.p.A., or Chiesi, and us, or the Chiesi Option Agreement, and a license agreement, or the Celgene Agreement, with Celgene Corporation, a Bristol-Myers Squibb Company, or Celgene. Our ability to generate revenue and achieve profitability, including any revenue we may receive pursuant to the Chiesi Option Agreement or the Celgene Agreement, depends in large part on our ability, alone or with license partners, to achieve milestones and to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize, our therapeutic candidates. For example,while we believe it is possible Celgene may incorporate our proprietary CD47 binding domain, or the Celgene Licensed Intellectual Property, into a multispecific format with another antibody for future development pursuant to the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Celgene Agreement, this may not occur. We believe it is unlikely we will receive additional milestone payments pursuant to the Celgene Agreement unless Celgene develops a therapeutic candidate under the Celgene Agreement and advances that therapeutic candidate beyond Phase 1 clinical trials. Even if we achieve development or commercial milestones, generate product royalties or generate product sales, including any milestones and royalties we may be eligible to receive pursuant to the Celgene Agreement or the Chiesi Option Agreement, we may never achieve or sustain profitability on a quarterly or annual basis. We do not anticipate generating revenue from sales of products for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our and our collaborators&#8217; success in: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing clinical trials through all phases of clinical development of our current therapeutic candidates, including INBRX-109, INBRX-106, INBRX-105, and INBRX-101; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancing our preclinical therapeutic candidates into clinical development; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining marketing approvals for our therapeutic candidates that successfully complete clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining satisfactory acceptance, formulary placement coverage and adequate reimbursement for our approved products from third-party payors, including private health insurers, managed care providers and governmental payor programs, including Medicare and Medicaid; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing products for which we obtain marketing approval, with a collaborator or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of any approved products by physicians, patients, third-party payors and the medical community; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting, expanding and enforcing our intellectual property portfolio; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementing additional internal systems and infrastructure, as needed; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the United States Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other comparable foreign authorities to perform preclinical studies or clinical trials in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our therapeutic candidates, our expenses could increase and revenue could be further delayed. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect we will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee this additional funding will be available on acceptable terms or at all. Failure to obtain this funding when needed may force us to delay, limit or terminate our development efforts and, if any of our therapeutic candidates are approved, our commercialization efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had $127.7 million in cash. We expect our expenses to increase in future years as we execute our plan to continue our discovery, research and development activities, including the ongoing and planned preclinical and clinical development of our therapeutic candidates, and as we incur the additional costs of operating as a public company. Identifying potential therapeutic candidates and conducting preclinical testing and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we, or our collaborators, may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our therapeutic candidates, if approved, may not achieve commercial success. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the net proceeds from the IPO consummated in August 2020, together with our existing cash and cash equivalents, will be sufficient to fund our planned operations through at least the 12 month period following the date of this Quarterly Report. However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. For example, our current and our planned preclinical studies and clinical trials for our current therapeutic candidates or other therapeutic candidates we may seek to develop may encounter technical, enrollment or other issues that could cause our development costs to increase more than we expect, or we could expand our clinical trials to additional indications which could increase clinical trial expenses. Because successful development of our therapeutic candidates is uncertain, we are unable to estimate the actual </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funds we will require to complete research and development and commercialize our therapeutic candidates. Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. In addition, our ability to obtain future funding when needed through equity financings, debt financings or strategic collaborations may be particularly challenging in light of the uncertainties and circumstances regarding the COVID-19 pandemic (as defined below).</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or clinical therapeutic candidates, or we may be unable to take advantage of future business opportunities. In addition, any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital by issuing equity or debt securities may cause dilution to existing stockholders, and raising funds through lending and licensing or collaboration agreements may restrict our operations or require us to relinquish proprietary rights. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic collaborations and license and development agreements. We do not have any committed external source of funds. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures or declaring dividends. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants therein, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely affect our ability to conduct our business. Additionally, in July 2020 and November 2020, we borrowed from Oxford $10.0 million and $40.0 million, respectively, under the 2020 Loan Agreement as amended by the 2020 Loan Amendment, which, as further described below, also has covenants restricting our ability to declare dividends or incur additional indebtedness.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through collaborations, strategic alliances or third-party licensing agreements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or therapeutics candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital through equity or debt financings when needed (including if we are unable to do so as a result of the COVID-19 pandemic), we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market therapeutic candidates that we would otherwise develop and market ourselves. </span></div><div id="iee91b9a90f804077b237584160b9370a_136"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we, or our collaborators, are unable to advance our therapeutic candidates through clinical development, obtain regulatory approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our development efforts, with only four therapeutic candidates currently in clinical trials (INBRX-109, INBRX-106, INBRX-105 and INBRX-101). We have no products on the market and our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing our therapeutic candidates, either alone or with our collaborators. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we, or our collaborators, must conduct extensive preclinical tests and clinical trials to demonstrate sufficient safety and efficacy of our therapeutic candidates in patients. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. As a result, we may not have the financial resources to continue development of, or to modify existing or to enter into </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new license or collaboration for, a therapeutic candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our therapeutic candidates, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials, the clinical trials of our collaborators or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic-related side effects experienced by participants in our clinical trials, the clinical trials of our collaborators or by individuals using drugs or therapeutic biologics similar to our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting Investigational New Drug applications, or INDs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling research subjects or high drop-out rates of research subjects enrolled in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in our clinical trials due to quarantines or other restrictions resulting from the COVID-19 pandemic, including further delays or suspensions in enrollment in our Phase 1 clinical trial for INBRX-101; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or the manufacturing location(s) for a therapeutic candidate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of therapeutic candidate clinical material or other raw materials or supplies necessary for the conduct of our clinical trials or the clinical trials of our collaborators; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in the development or approval of companion diagnostic tests for our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight for human clinical testing generally or with respect to our technology in particular; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The therapeutic candidates we or our collaborators pursue may not demonstrate the necessary safety or efficacy requirements for regulatory approval. Further, a clinical trial may be suspended or terminated by us, our collaborators, the Institutional Review Boards of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations, administrative actions or lack of adequate funding to continue the clinical trial. Clinical holds may be placed prior to a clinical trial even beginning, in order to address potential safety and risk concerns of regulatory authorities, and partial or complete clinical holds can be imposed at any time during a trial. Furthermore, we expect to rely on contract research organizations, or CROs, and clinical trial sites to ensure proper and timely conduct of our clinical trials and while we expect to enter into and have entered into agreements governing those CROs&#8217; committed activities, we have limited influence over their actual performance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates will be harmed, and our ability to generate product revenue or receive royalties from any of these therapeutic candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. If we were to cancel the development of any of our therapeutic candidates, we may still be required to pay certain non-cancellable commitments to our CROs under the terms of our various CRO contracts. Our approach to protein engineering is novel and unproven, and as such, the cost, time needed to develop and likelihood of success of our therapeutic candidates may be more uncertain than if we employed more established drug development approaches. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early stage clinical trials of our therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial results or observations in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical studies and early clinical trials does not ensure that later and pivotal clinical trials will generate the same results, or otherwise provide adequate data to demonstrate the safety and efficacy of a therapeutic candidate. Frequently, therapeutic candidates that have shown promising results in preclinical studies or early clinical trials have subsequently suffered significant setbacks in later or pivotal clinical trials. The initiation of registration-enabling trials for INBRX-109 (in 2021 or otherwise), or for any of our other therapeutic candidates, is and would be predicated on positive Phase 1 trial results. Our therapeutic candidates in clinical trials, including INBRX-109, INBRX-106, INBRX-105 and INBRX-101, may ultimately fail to show the desired safety and efficacy in clinical trials despite having progressed through preclinical studies and despite any initial observations of single agent activity, stable disease or partial responses. There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development, including development in registration-enabling trials, of any of our therapeutic candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any of these setbacks in our clinical development could have a material adverse effect on our business and operating results. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our therapeutic candidates could cause us, our collaborators or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Results of our clinical trials or the clinical trials of our collaborators could reveal a high and unacceptable severity of adverse side effects and it is possible that patients enrolled in these clinical trials could respond in unexpected ways. For instance, INBRX-109, INBRX-106, and INBRX-105 are all therapeutic candidates targeting oncology indications that are clinically evaluated in very sick populations, and INBRX-101 is a therapeutic candidate focused on Alpha-1 Antitrypsin Deficiency, or AATD, a rare disease with a relatively small patient population. It may be difficult to establish safety and efficacy in these types of patient populations. Further, we intend to develop certain of our therapeutic candidates in combination with one or more cancer therapies. This combination may have additional side effects that were not present in preclinical studies or clinical trials of our therapeutic candidates conducted as a monotherapy or in combination with other cancer therapies. The uncertainty resulting from the use of our therapeutic candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our clinical trials or the clinical trials of our collaborators reveal adverse side effects, our trials or the clinical trials of our collaborators could be suspended or terminated and the FDA or comparable foreign regulatory authorities could impose a clinical hold, order us to cease further development of or deny approval of our therapeutic candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, clinical trials by their nature utilize a sample of the potential patient population. Rare and severe side effects of our therapeutic candidates may only be uncovered with a significantly larger number of patients exposed to our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our therapeutic candidates receives regulatory approval and we, our collaborators or others identify undesirable side effects caused by a product or any other similar therapeutics, any of the following adverse events could occur: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of safety-related labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients or to implement other aspects of a risk evaluation and mitigation strategy, or REMS, such as a restricted distribution program or educational programs for prescribers; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse side effects caused by any therapeutics that may be similar in nature to our therapeutic candidates could delay or prevent regulatory approval of our therapeutic candidates, limit the commercial profile of an approved label for our therapeutic candidates, or result in significant negative consequences for our therapeutic candidates following marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of the above described events could prevent us from achieving or maintaining market acceptance of our therapeutic candidates, if approved, and could delay, impede and/or substantially increase the costs of commercializing our therapeutic candidates thus significantly impacting our ability to successfully commercialize our therapeutic candidates and generate revenue. Any of the above described occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to develop certain of our therapeutic candidates in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop certain of our therapeutic candidates in combination with one or more approved or investigational cancer therapies.&#160;Even if any therapeutic candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our therapeutic candidates are replaced as the standard of care for the indications we choose for any of our therapeutic candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may evaluate our therapeutic candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell any therapeutic candidate we develop in combination with an unapproved cancer therapy if that unapproved cancer therapy does not ultimately obtain marketing approval. In addition, unapproved cancer therapies face the same risks described with respect to our therapeutic candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination our therapeutic candidates, we may be unable to obtain approval of or market any such therapeutic candidate. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our therapeutic candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. We may have particular difficulty enrolling patients for our clinical trials for INBRX-101. In particular, patients with AATD are particularly susceptible to COVID-19 and the physicians acting as clinical investigators for our clinical sites are otherwise engaged with treating COVID-19 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients. For instance, as a result of the COVID-19 pandemic, we temporarily suspended enrollment for our trial for INBRX-101 during the second and third quarters of 2020. Should any competitors have ongoing clinical trials for therapeutic candidates treating the same indications as our therapeutic candidates, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by other factors including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria for the study in question; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the therapeutic candidate under study; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our payments for conducting clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for any of our clinical trials could result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our therapeutic candidates and in delays to commercially launching our therapeutic candidates, if approved, which would materially harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our therapeutic candidates may be delayed, and our business will be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have provided, and will continue to provide, a number of timing estimates regarding the initiation of clinical trials and clinical development milestones, and the expected availability of data resulting from these trials for certain of our therapeutic candidates. We expect to continue to estimate the timing of these types of development milestones and our expected timing for the accomplishment of various other scientific, clinical, regulatory and other product development objectives. From time to time, we may publicly announce the expected timing of some of these events. However, the achievement of many of these milestones and events may be outside of our control. All of these timing estimations are based on a variety of assumptions we make, which may cause the actual timing of these events to differ from the timing we expect, including </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our available capital resources and our ability to obtain additional funding as needed; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress, costs and results of our clinical trials and research and development activities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of clinical trial approvals by the FDA, EMA and other regulatory authorities and the timing of these approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts of our collaborators and licensees, including Celgene, with respect to the commercialization of our therapeutics;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the securing of, costs related to, and timing issues associated with, manufacturing our therapeutic candidates and, if any of our therapeutic candidates are approved, associated with sales and marketing activities and the commercial manufacture of our therapeutic candidates; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">circumstances arising from or relating to the COVID-19 pandemic, including potential effects on the global supply chain, our manufacturers and the availability of raw materials needed for the research and development of our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to achieve announced milestones in the timeframes we expect, the future marketing approval and commercialization of any of our therapeutic candidates may be delayed, and our business, financial condition, results of operations, and prospects may be harmed and our stock price may decline. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial, interim, topline and preliminary data from our clinical trials that we may announce, observe or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect from time to time, to publish initial, interim, topline or preliminary data from our clinical trials. In particular, we previously reported observed signs of partial responses and stable disease in initial and interim data from our Phase 1 clinical trial for INRBRX-109 and noted observed signs of partial responses, disease control and tumor regression in initial data from our Phase 1 clinical trial for INBRX-106. Our clinical trials are also conducted as &#8220;open-label&#8221; trials. An open-label trial is one where both the patient and investigator know whether the patient is receiving the therapeutic candidate and where we (as the sponsor) have access to trial data on an ongoing basis during the trial.&#160;These initial and interim data from INBRX-109 and INBRX-106 and other initial, interim, topline and preliminary data from our clinical trials that we may publish from time to time or that we may observe on an ongoing basis in our open-label trials may change as more patient data become available and, accordingly, they are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available and we issue our final clinical trial report. Initial, interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim, topline and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for any current or future therapeutic candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized as first-, second-, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to initially seek approval of certain of our therapeutic candidates as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that therapeutic candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future therapeutic candidates may be limited, if and when approved. Even if we obtain significant market share for any therapeutic candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect to continue our current clinical trials and expect to initiate clinical trials in the near term for many of our therapeutic candidates, we do not have the ability to independently conduct clinical trials. As such, we currently rely and intend to continue to rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to help us design, conduct, supervise and monitor clinical trials of our therapeutic candidates. As a result, we will have less control over the timing, quality and other aspects of our clinical trials than we would have had we conducted them on our own. There is a limited number of third party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs or investigators or to do so on commercially reasonable terms. Further, these investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials. These third parties may also be susceptible to disruption as a result of health crises such as the COVID-19 pandemic or periods of societal unrest. For example, we currently retain CROs located in Hong Kong. These CROs may be negatively affected by, or subject to disruption arising from, the societal unrest and regulatory regime change related to China&#8217;s recent passage of a national&#160;security law exerting additional control by mainland China over activities in Hong Kong. If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy the legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines for any reason, our clinical development programs could be delayed and otherwise adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the relevant study or trial. The FDA requires preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, or GCPs, including practices and requirements for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on Celgene for the successful development, manufacture and commercialization of the Celgene Licensed Intellectual Property. If Celgene does not devote sufficient resources to the development, manufacture and commercialization of the Celgene Licensed Intellectual Property, is unsuccessful in its efforts, or chooses to terminate the Celgene Agreement with us, we may not receive any further proceeds from the Celgene Agreement and our business could be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Celgene Agreement, we have exclusively licensed (even as to us) to Celgene the right to develop, manufacture and commercialize the Celgene Licensed Intellectual Property. Celgene is obligated to use commercially reasonable efforts to clinically develop and commercialize the Celgene Licensed Intellectual Property. However, Celgene may ultimately determine it is not commercially reasonable to continue development of the Celgene Licensed Intellectual Property. This outcome could occur for many reasons, including internal business reasons or because of unfavorable regulatory feedback. Further, on review of any safety and efficacy data then available for potential candidates relating to the Celgene Licensed Intellectual Property, the FDA may impose requirements on a clinical trial program that would render the program commercially nonviable. In the event of any such decision, we would be unable to advance such program ourselves. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the Celgene Agreement, Celgene has full control and authority over the development and commercialization of the Celgene Licensed Intellectual Property. We may disagree with Celgene about the development strategy it employs, but we will have limited rights to impose our preferred development strategy on Celgene. Celgene may elect to discontinue the development of the Celgene Licensed Intellectual Property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Celgene Licensed Intellectual Property may not be scientifically or commercially successful for us due to a number of important factors, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene has wide discretion in determining the efforts and resources that it will apply to its development, manufacture and commercialization of the Celgene Licensed Intellectual Property. The timing and amount of any development milestones, regulatory milestones and royalties that we may receive under the Celgene Agreement will depend on, among other things, Celgene&#8217;s efforts, allocation of resources and successful development and commercialization of the Celgene Licensed Intellectual Property and the other antibodies that are the subject of the Celgene Agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene may terminate the Celgene Agreement without cause and for circumstances outside of our control, which could make it difficult for us to attract new strategic partners or adversely affect how we are perceived in scientific and financial communities; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene may develop or commercialize the Celgene Licensed Intellectual Property in such a way as to elicit litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential liability; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene may not comply with all applicable regulatory requirements, or may fail to report safety data in accordance with all applicable regulatory requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Celgene were to breach the Celgene Agreement, we may need to enforce our right to terminate the Celgene Agreement in legal proceedings, which could be costly and cause delay in our ability to receive our rights back to develop and commercialize the Celgene Licensed Intellectual Property. If we were to terminate the Celgene Agreement due to Celgene&#8217;s breach or if Celgene terminated the Celgene Agreement without cause upon 30 days&#8217; written notice, the development and commercialization of the Celgene Licensed Intellectual Property could be delayed, curtailed or terminated. Additionally, even if the Celgene Agreement is terminated, we may not be able to dispose of the Celgene Licensed Intellectual Property in a strategic transaction without Celgene&#8217;s consent. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Celgene became a Bristol-Myers Squibb Company in November 2019. Bristol-Myers Squibb Company may again enter into one or more transactions with third parties, including other mergers, consolidations, reorganizations, sale of substantial assets, sales of substantial stock or other changes in control involving Celgene. These types of transactions could divert the attention of Celgene&#8217;s management and adversely affect Celgene&#8217;s ability to retain and motivate key personnel who are important to the continued development of the Celgene Licensed Intellectual Property. In addition, the third party to any such transaction could determine to reprioritize Celgene&#8217;s development programs such that Celgene ceases to diligently pursue the development of the Celgene Licensed Intellectual Property, and/or cause the Celgene Agreement to terminate. If Celgene does not devote sufficient resources to the development, manufacture and commercialization of the Celgene Licensed Intellectual Property, is unsuccessful in its efforts, or chooses to terminate the Celgene Agreement with us, we may not receive any further proceeds from the Celgene Agreement and our business could be materially harmed.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently party to license agreements with Elpiscience and Transcenta for the development and, if approved, commercialization of INBRX-105 and INBRX-106, and INBRX-109, respectively. We may in the future enter into additional collaborations with third parties to develop our therapeutic candidates, including collaborations with Chiesi if Chiesi exercises its option pursuant to the Chiesi Option Agreement. If these collaborations are not successful, our business could be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to two different license agreements, or the Elpiscience Agreements, with Elpiscience Biopharmaceuticals, Inc., or Elpiscience, pursuant to which we granted Elpiscience exclusive licenses for the development and, if approved, commercialization of INBRX-105 and INBRX-106 in China, Hong Kong, Macau and Taiwan. We are also party to a license agreement, or the Transcenta License Agreement, with Transcenta Holding, Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), or Transcenta, pursuant to which we granted Transcenta an exclusive license for the development and, if approved, commercialization of INBRX-109 in China, Hong Kong, Macau and Taiwan. Ultimately, Chiesi may not exercise its option pursuant to the Chiesi Agreement. If Chiesi does not exercise its option under the Chiesi Agreement, we could incur additional expenses for the development, and if approved, the commercialization of INBRX-101. We may enter into additional collaborations with third parties in the future, including collaborations with Chiesi if Chiesi exercises its option pursuant to the Chiesi Option Agreement. Any collaborations that we are party to may pose several risks, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical trials conducted as part of these collaborations may not be successful; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any therapeutic candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a therapeutic candidate, repeat or conduct new clinical trials or require a new formulation of a therapeutic candidate for clinical testing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding therapeutic candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our therapeutic candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own therapeutic candidates or products, which may cause collaborators to cease to devote, or limit, resources to the commercialization of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our therapeutic candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such therapeutic candidate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may have disagreements with these collaborators, including disagreements over proprietary rights, collaborator performance, contract interpretation or the preferred course of development of any therapeutic candidates. Any disagreement we may have with our collaborators may cause delays or termination of the research, development or commercialization of our therapeutic candidates pursuant to the applicable agreement, may lead to additional responsibilities for us with respect to our therapeutic candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive and which would likely divert the attention of our management from our core research and development activities. These types of disputes could materially harm our financial condition and our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, or otherwise fail to comply with their contractual obligations, the development or commercialization of our therapeutic candidates could be delayed or stopped. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have found that our sdAb-based therapeutic candidates can be readily manufactured at high yields with established processes used to produce therapeutic proteins, the manufacture of biotechnology products is generally complex and requires significant expertise and capital investment. We and our contract manufacturers must comply with current Good Manufacturing Practices, or cGMP, regulations and guidelines for clinical trial product manufacture and for commercial product manufacture. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up, addressing product quality, product comparability, validating production processes and mitigating potential sources of contamination. These problems include difficulties with raw material procurement, production costs and yields, quality control, product quality, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our therapeutics or in the manufacturing facilities in which our therapeutics are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that manufacturing problems, including supply chain disruptions of any of our therapeutic candidates or products will not occur in the future. Any delay or interruption in the supply of preclinical or clinical trial supplies, including any delays arising from circumstances related to the COVID-19 pandemic, could delay the completion of these trials, increase the costs associated with maintaining these trial programs and, depending upon the period of delay, require us to commence new trials at additional expense or terminate trials completely. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for any of our therapeutic candidates or future approved products, if any, we seek to commercialize, we could experience delays in our research or planned clinical studies or be forced to stop our development or commercialization efforts. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, would significantly delay our clinical studies and the commercialization of our therapeutics, if approved, which would materially adversely affect our business, prospects, financial condition and results of operation.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to supply and manufacture our therapeutic candidates, and we expect to continue to rely on third parties to manufacture and supply our therapeutics, if approved. The development of therapeutic candidates and the commercialization of any therapeutic candidates, if approved, could be stopped, delayed or made less profitable if any of these third parties fail to provide us with sufficient quantities of therapeutic candidates or therapeutics, fail to do so at acceptable quality levels or prices, or fail to maintain or achieve satisfactory regulatory compliance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to develop and manufacture our therapeutic candidates for use in the conduct of our trials or for commercial supply, if our therapeutics are approved. Instead, we rely on, and expect to continue to rely on third-party providers to manufacture the supplies for our preclinical studies and clinical trials. We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies, other biologics for our preclinical research and clinical trials, as well as for the manufacture of supplies for our therapeutic candidates. To the extent any of our manufacturing partners is unable to fulfill these obligations in a timely manner, including as a result of circumstances relating to the COVID-19 pandemic or circumstances related to China&#8217;s implementation of its recently adopted security law to exert additional control over activities in Hong Kong, our clinical trials may be delayed and our business may be adversely affected. In general, reliance on third party providers may expose us to more risk than if we were to manufacture our therapeutic candidates ourselves. We do not control the operational processes of the contract manufacturing organizations with whom we contract and are dependent on these third parties for the production of our therapeutic candidates in accordance with relevant regulations (such as cGMP), which include, among other things, quality control and the maintenance of records and documentation. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party manufacturers may be unable to successfully scale up manufacturing of our therapeutic candidates in sufficient quality and quantity, which would delay or prevent us from developing our therapeutic candidates and commercializing any approved therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing partners may be unable to successfully increase the manufacturing capacity for our therapeutic candidates in a timely or cost-effective manner, or at all, as needed for our development efforts or, if our therapeutic candidates are approved, our commercialization efforts. Quality issues may also arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our therapeutic candidates in sufficient quality and quantity, the development, testing, and clinical trials of our therapeutic candidates may be delayed or infeasible, and regulatory approval or future commercial launch of any resulting therapeutic may be delayed or not obtained, which could significantly harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully identify, develop and commercialize additional therapeutics or therapeutic candidates could impair our ability to grow. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our therapeutic candidates in our current pipeline, we expect to continue to innovate and potentially expand our portfolio. Because we have limited financial and managerial resources, research programs to identify therapeutic candidates may require substantial additional technical, financial and human resources, whether or not </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any new potential therapeutic candidates are ultimately identified. Our success may depend in part upon our ability to identify, select and develop promising therapeutic candidates and therapeutics. We may expend resources and ultimately fail to discover and generate additional therapeutic candidates suitable for further development. All therapeutic candidates are prone to risks of failure typical of biotechnology product development, including the possibility that a therapeutic candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics indicating that it is unlikely to receive approval by the FDA, the EMA and other comparable foreign regulatory authorities or to achieve market acceptance. If we do not successfully develop and commercialize new therapeutic candidates we have identified and explored, our business, prospects, financial condition and results of operations could be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of biotechnology treatments of any therapeutic candidates for which we or our collaborators may conduct clinical trials. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing any approved products, these claims could result in an FDA investigation of the safety and effectiveness of our future commercial products, our manufacturing processes and facilities (or the manufacturing processes and facilities of our third-party manufacturers) or our marketing programs, a recall of our products or more serious enforcement action, limitations on the approved indications for which the product may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to clinical trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by potential product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities. While we have marketing and commercialization agreements in place for certain territories with our collaborators, we will still need to develop our own internal sales, marketing and distribution capabilities to commercialize our approved therapeutic candidates, if any, in the United States and other remaining worldwide territories, or will need to enter into collaborations with third parties to perform these services. Any internal effort would be expensive and time-consuming, and we would need to commit significant financial and managerial resources to develop an internal marketing and sales force with technical expertise and the related supporting distribution, administration and compliance capabilities. If we were to rely on additional third parties with these capabilities to market our future therapeutics or were to decide to co-promote products with any of our current or future collaborators, we would need to establish and maintain or revise existing marketing and distribution arrangements with these partners, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. Any revenue we receive in connection with third-party license, marketing or distribution arrangements, including the Celgene Agreement, the Chiesi Option Agreement and license agreements with our licensing partners in China, will depend upon the efforts of these third parties, and there can be no assurance these third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The future commercial success of our therapeutic candidates will depend on the degree of market acceptance of our therapeutic candidates among physicians, patients, healthcare payors and the medical community. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates are in early stages of development, and many of our therapeutic candidates are still in preclinical development; we may never have an approved product that is commercially successful. Due to the inherent risk in the development of biotechnology products, it is probable that not all or none of the therapeutic candidates in our pipeline, including any that are or may be licensed to third parties, will successfully complete development and be commercialized. Furthermore, even when available on the market, our products may not achieve an adequate level of acceptance by physicians, patients and the medical community, and we may not become profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of any approved products by physicians, patients and healthcare payors will depend on a number of factors, many of which are beyond our control, including, but not limited to: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for any approved product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">wording in the FDA- or EMA-approved prescribing information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales, marketing and distribution support; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, patients and healthcare payors of each product as safe, effective and cost-effective; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience, ease of use, ease of administration and other perceived advantages over alternative products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of adverse events or publicity; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment with our therapeutics in relation to alternative treatments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which products are approved for inclusion and adequately reimbursed on formularies of hospitals and third-party payors, including managed care organizations; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our products are designated in the label, under physician treatment guidelines or under reimbursement guidelines as a first, second, third or last line therapy. </span></div><div id="iee91b9a90f804077b237584160b9370a_139"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Organization and Operations </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive. We are currently developing therapeutic candidates that will compete, if approved, with other products and therapies that currently exist or are being developed. Our primary competitors fall into the following groups:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Alligator Bioscience AB, Camel-IDS N.V., Crescendo Biologics Ltd., GlaxoSmithKline plc, IGM Biosciences, Inc., Molecular Partners AG, Pieris Pharmaceuticals, Inc., Sanofi S.A. and VHsquared Ltd.; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Adimab&#160;LLC, Genmab A/S, Macrogenics, Inc., Merus&#160;N.V., MorphoSys AG, Numab Therapeutics AG, TeneoBio, Inc., Xencor&#160;Inc., Zymeworks Inc.; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing therapeutics designed to treat AATD, including CSL Limited, Grifols, S.A., Kamada Ltd., Takeda Pharmaceutical Company Limited and Vertex Pharmaceuticals, Inc. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors also include large pharmaceutical and biotechnology companies who may be developing therapeutic candidates with mechanisms similar to or targeting the same indications as our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to&#160;in-license&#160;novel compounds that could make the therapeutic candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the therapeutic candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our therapeutic candidates obsolete, less competitive or not economical. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, the conduct of our clinical trials, results of operations, financial condition, and prospects may be adversely affected by the widespread outbreak of an illness or any other communicable disease, or any other public health crisis, including the coronavirus disease (COVID-19) pandemic.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by widespread outbreak of illness or other communicable diseases, health epidemics, or any other public health crisis. On January 30, 2020, the World Health Organization, or the WHO, announced a global health emergency because of a novel strain of coronavirus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or novel coronavirus, which causes coronavirus disease 2019, or COVID-19, originating in Wuhan, China. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, COVID-19 has spread to most regions of the world, including California, where our primary office and laboratory space is located.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are, with our partners, conducting clinical trials and other research in geographies that are affected by the COVID-19 pandemic. Potential impacts of the COVID-19 pandemic on our various clinical trials may include delays related to patient enrollment, dosing and study monitoring due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions. They may also be impacted by the prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trials, interruption or delays in the operations of the FDA, or other reasons related to the pandemic. For example, we temporarily suspended </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enrollment for our INBRX-101 Phase 1 clinical trial as a direct result of the COVID-19 pandemic during the second and third quarters of 2020. While our oncology-related clinical trials have not been materially impacted to date, it is possible that these programs may be negatively impacted in the future. If the COVID-19 pandemic continues, other aspects of our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment, further or additional delays in enrollment, availability of clinical trial materials, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our trials. It is unknown how long these suspension, pauses or disruptions could continue. FDA has issued a guidance for industry, &#8220;FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards,&#8221; which is being periodically updated to continue clarifying for affected stakeholders to ensure the safety of clinical trial participants, maintain compliance with good clinical practices (GCPs), and minimize risks to trial and clinical data integrity. We intend to follow FDA&#8217;s recommendations in order to address unavoidable protocol deviations due to COVID-19 illness or COVID-19 control measures, as appropriate.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on third parties to, among other things, manufacture raw materials, manufacture our therapeutic candidates, ship investigational drugs and clinical samples, perform quality testing and supply other goods and services to run our business. If any third party in our supply chain for materials are adversely impacted by restrictions resulting from the COVID-19 pandemic, including as a result of staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to conduct our research and development operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have requested that our employees, including all of our administrative employees, work remotely and have restricted on-site staff to only those personnel who must perform essential on-site activities such as activities in our research and development laboratories. Our increased reliance on employees working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees conducting research and development activities may be more limited in their ability to access our laboratories for an extended period of time as a result of the rigorous workplace policies and guidelines implemented as a result of the COVID-19 pandemic. Additionally, it is possible that governmental authorities will further modify current restrictions. As a result, this could delay timely completion of our research and development efforts and further delay our INBRX-101 trial efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health regulatory agencies globally may experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our therapeutic candidates. For example, regulatory authorities may require that we not distribute a therapeutic candidate lot until the relevant agency authorizes its release. Such release authorization may be delayed as a result of the COVID-19 pandemic and could result in delays to our clinical trials.</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading prices for biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common shares in future offerings or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common shares. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Mark P. Lappe, our Chief Executive Officer, Brendan P. Eckelman, Ph.D., our Chief Scientific Officer, Klaus W. Wagner, M.D., Ph.D., our Chief Medical Officer, and Kelly D. Deck, our Chief Financial Officer, who are all employed at will and for whom we do not have &#8220;key man&#8221; insurance coverage. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and technologies and the specialized nature of the regulatory approval process. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations (many of whom have substantially greater financial resources than us), and we might not be able to attract or retain these key employees on conditions that are economically acceptable. Our inability to attract and retain these key employees could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a significant amount of debt which may affect our ability to operate our business and secure additional financing in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we borrowed $10.0 million under the 2020 Loan Agreement with Oxford and in November 2020, we borrowed an additional $40.0 million under the First Amendment to the 2020 Loan Agreement. Our obligations under the 2020 Loan Agreement, as amended, are secured by substantially all of our assets, other than our intellectual property. The 2020 Loan Agreement, as amended, requires us, and any debt arrangements or instruments we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete mergers or acquisitions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur or guarantee indebtedness; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell or encumber certain assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends or make other distributions to holders of our capital stock, including by way of certain stock buybacks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make specified investments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in different lines of business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change certain key management personnel; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain transactions with our affiliates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may make it difficult to operate our business. A failure by us to comply with the covenants could result in an event of default, which could adversely affect our ability to respond to changes in our business and manage our operations. Upon the occurrence of an event of default, including the occurrence of a material adverse change, the lender could elect to declare all amounts outstanding to be due and payable and exercise other remedies. If the indebtedness were to be accelerated, our future financial condition could be materially adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The instruments governing such indebtedness could contain provisions that are as, or more, restrictive than our existing debt instruments. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against any collateral granted to them to secure such indebtedness or force us into bankruptcy or liquidation. Further, if our business is subject to liquidation, the right to repayment of Oxford and any other holders of indebtedness would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees and independent contractors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees or independent contractors. Misconduct by these parties could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish for our therapeutic candidates, comply with federal and state data privacy, security, fraud and abuse, and other healthcare laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain marketing approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development and regulatory affairs, as well as sales and marketing to the extent any of our therapeutic candidates approach receipt of marketing authorization. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to integrate efficiently or achieve the expected benefits of any acquisitions of complementary businesses, therapeutic candidates or technologies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we in the future acquire any complementary business, therapeutic candidates or technologies, our ability to integrate and manage acquired businesses, therapeutic candidates or technologies effectively will depend upon a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of factors including the size of the acquired business, the complexity of any therapeutic candidate or technology and the resulting difficulty of integrating the acquired business&#8217;s operations, if any. Our relationship with current employees or employees of any acquired business may become impaired. We may also be subject to unexpected claims and liabilities arising from such acquisitions. These claims and liabilities could be costly to defend, could be material to our financial condition and might exceed either the limitations of any applicable indemnification provisions or the financial resources of the indemnifying parties. There can also be no assurance that we will be able to assess ongoing profitability and identify all actual or potential liabilities of a business, therapeutic candidate or technology prior to its acquisition. If we acquire businesses, therapeutic candidates or technologies that result in assuming unforeseen liabilities in respect of which it has not obtained contractual protections or for which protection is not available, this could materially adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected as a result of computer system failures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the internal computer systems belonging to us or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our partners&#8217; or collaborators&#8217; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability, our development programs and competitive position may be adversely affected and the further development of our therapeutic candidates may be delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information. We face a number of threats to our networks from unauthorized access, accidental acts or omissions that expose vulnerabilities, security breaches and other system disruptions. As noted above, certain of our employees are presently and may in the future be working remotely as a result of the COVID-19 pandemic. We may face additional cybersecurity risks as a result of these circumstances and despite our security measures, our infrastructure may be vulnerable to attacks by hackers or vulnerable to other disruptive problems. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and dissemination of data. Some of these federal, state and foreign government requirements include obligations of companies to notify individuals and others of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information, it may also subject us to significant fines, penalties or liabilities for any noncompliance with certain privacy and security laws. A cybersecurity breach could adversely affect our reputation and could result in other negative consequences, including disruption of our internal operations, increased cybersecurity protection costs, lost revenue or litigation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes, medical epidemics or pandemics, or other natural disasters. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in our facilities in La Jolla, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents, including the COVID-19 pandemic, that results in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. Earthquakes, medical epidemics or pandemics, including the COVID-19 pandemic, or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, pandemic, including the COVID-19 pandemic, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or if similar events occurred elsewhere effecting the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material and adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div id="iee91b9a90f804077b237584160b9370a_142"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce patent protection for our technologies or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, patents and patent applications protecting, or seeking to protect, our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. Our patent estate includes various issued Unit States patents, United States pending non-provisional patent applications, United States pending provisional applications, pending Patent Cooperation Treaty, or PCT, applications, issued foreign patents, and foreign patent applications currently pending in various foreign jurisdictions.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will endeavor to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining, maintaining, and enforcing patents is time-consuming, expensive and sometimes unpredictable, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to any patents we may license to or from third parties. Therefore, such patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to provide meaningful protection from any competitors. Our competitors may be able to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumvent our patents by developing similar or alternative therapeutic candidates in a non-infringing manner. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which non-compliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the subject of much litigation. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., due to a determination that the claims are invalid or unenforceable. In addition, there can be no assurance that: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not or will not be able to legally make, use or sell products or therapeutic candidates that are the same as or similar to our therapeutic candidates despite the claims of the patents that we own or license; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our collaborators are the first to file patent applications covering certain aspects of our inventions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any issued patents that we own or have licensed will provide us with any competitive advantage; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining valid and enforceable issued or granted patents covering our therapeutic candidates in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors or third parties may use our technology to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Third-party or competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could provoke third parties to assert claims against us, and, whether or not successful, could result in substantial cost and divert our efforts and attention from other aspects of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the PCT is usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, Europe, Japan, Australia and Canada and, depending on the individual case, also in one, several or all of Brazil, China, India, Israel, Mexico, New Zealand, Russia or Eurasian Patent Organization, Singapore, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a patent is granted by a regional patent office (e.g., Europe or Eurasia), the patent must be validated in individual countries in order to be in effect in those countries. We may decide not to validate regional patents in every available country or at all in any country in the region. In addition, we may decide to abandon national and regional patent applications before or after grant. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or any licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions in which we file patent applications could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. In contrast, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, assuming that other requirements for patentability were met. Furthermore, United States patent law under the America Invents Act allows for post issuance challenges to United States patents, including ex parte reexaminations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews and post grant oppositions. If our United States patents are challenged using such procedures, we may not prevail, possibly resulting in altered or diminished claim scope or loss of patent rights altogether. Similarly, some countries, notably members of the European Union, also have post grant opposition proceedings that can result in changes in scope and/or cancellation of patent claims. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Supreme Court has also ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non compliance with these requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO, the European Patent Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. For example, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO, the European Patent Office and foreign patent agencies in several stages over the lifetime of the patent. Some jurisdictions also require payment of annuity fees during pendency of a patent application. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our therapeutic candidates, our competitors might better be able to enter the market, which would have an adverse effect on our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to reduce the scope of our intellectual property due to intellectual property claims included in the patents or patent applications of others. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may have filed, and may in the future file, patent applications covering technology similar to ours. It is also possible that we have failed to identify relevant third-party patents or applications. For example, United States applications filed before November&#160;29, 2000 and certain United States applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with this earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutic candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover any future approved products or our therapeutic candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies, if possible, or block us from practicing certain aspects of our technology if we are unable to successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed prior to March&#160;16, 2013, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. Similarly, if another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed after March&#160;16, 2013, we may have to participate in a derivation proceeding to determine whether that party derived the claimed invention from an inventor listed on our application and then filed the third-party application without authorization. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our United States patent position with respect to such inventions. In addition, an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Further, changes enacted on March&#160;15, 2013 to the United States patent laws under the America Invents Act resulted in the United States changing from a &#8220;first to invent&#8221; country to a &#8220;first to file&#8221; country. As a result, we may lose the ability to obtain a patent if a third party files with the USPTO first and could become involved in proceedings before the USPTO to resolve disputes related to inventorship. We may also become involved in similar proceedings in other jurisdictions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, licensees or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. We or our licensors, licensees or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries including patent infringement lawsuits, interferences, derivations, oppositions and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future therapeutic candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If we, our licensees or our licensors, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we, our licensees or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give any competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, the holders of any such patents may be able to block us, our licensees or our collaborators from marketing therapeutic candidates based on our technology until such patents expire, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our technology. This loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property licensed to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements under which we are granted rights to third-party intellectual property, and we expect that we may need to enter into additional license agreements in the future. License agreements may impose various development obligations, payment of royalties and fees based on achieving certain milestones, as well as other obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. The termination of any license agreements or failure to adequately protect such license agreements could prevent us from commercializing therapeutic candidates covered by the licensed intellectual property or otherwise adversely affect our business. Our license agreements may involve sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we would rely on our licensor to comply with its obligations under the primary license agreements, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which we may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize any of our therapeutic candidates incorporating the relevant intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborator; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property agreements with our licensors, licensees, collaborators and third parties may be subject to disagreements over contract interpretation, which could narrow the scope of, or result in termination of, our rights to the relevant intellectual property or technology or increase our financial or other obligations to such third parties, or reduce the financial or other obligations our licensees have to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. For example, we may disagree with our licensors, licensees or collaborators regarding whether, when and to what extent various obligations under these agreements apply to certain of our/their therapeutic candidates and products, including various payment, development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement. In either case, such disagreement could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self executing or may be breached, and we may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable, generally expensive, time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material and adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. Trade secrets and confidential know-how are difficult to maintain as confidential. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, partners, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if relevant agreements are entered into, despite these efforts, any of these parties may breach the agreements and unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Moreover, a competitor who independently develops substantially equivalent proprietary information may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. Under certain circumstances, we may also decide to publish some know-how to attempt to prevent others from obtaining patent rights covering such know-how. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or biotechnology companies, including potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Our trademarks may not be approved by one or more governmental trademark offices or may not be approved for use on our products by regulatory agencies, such as the FDA. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our patent terms expire before or soon after our therapeutic candidates are approved, or if manufacturers of biosimilar drugs successfully challenge our patents, our business may be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our therapeutic candidates, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive medications, including biosimilar medications. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our therapeutic candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act and similar legislation in the European Union. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner than we expect. Also, the scope of our right to exclude during any patent term extension period may be limited or may not cover a competitor&#8217;s product or product use. As a result, our revenue from applicable therapeutic candidates, if approved, could be reduced, possibly materially. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our patents and patent applications may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of biosimilar drugs may challenge the scope, validity, or enforceability of our patents in court or before a patent office, and we may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any potential sales of that product. Upon the expiration of our issued patents or patents that may issue from our pending patent applications, we will not be able to assert such patent rights against potential competitors and our business, financial condition, results of operations, and prospects may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business nor permit us to maintain our competitive advantage. The following examples are illustrative: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may be able to make therapeutic candidates that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or may have exclusively licensed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not develop additional technologies that are patentable. </span></div><div id="iee91b9a90f804077b237584160b9370a_145"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our collaborators may be unable to obtain regulatory approval for any product that we or a collaborator may develop and the regulatory approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time-consuming and inherently unpredictable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we or our collaborators may attempt to develop, manufacture or market in the United States will be subject to extensive regulation by the FDA, including regulations relating to development, preclinical testing, performance of clinical trials, manufacturing and post-approval commercialization. Preclinical testing, clinical trials and manufacturing, among other activities, will be subjected to an extensive review process before a new therapeutic product may be sold in the United States. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays, including delays arising from the COVID-19 pandemic. The time required to obtain FDA&#160;approval, and any other required approvals for biological products is unpredictable but typically requires several years and may never be obtained. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we or our collaborators may wish to develop, manufacture or market in countries other than the United States will also be subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing, pricing and third-party reimbursement among other things in such countries. The foreign regulatory approval process includes all of the risks and uncertainties associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in such foreign jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, obtaining marketing approval for biological products requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process, and in many cases the inspection of manufacturing, processing, and packaging facilities by the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use, or there may be deficiencies in cGMP compliance by us or by our CDMOs that could result in the candidate not being approved. Moreover, we have not obtained regulatory approval for any therapeutic candidate in any jurisdiction and it is possible that none of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our existing therapeutic candidates or any therapeutic candidates we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates could fail to receive, or could be delayed in receiving, regulatory approval for many reasons, including any one or more of the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for marketing approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate or may identify other GCP deficiencies related to the trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA, EMA or comparable foreign regulatory authorities; or&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medical standard of care or the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of the therapeutic candidates we or our collaborators may develop will obtain the marketing approvals necessary for us or our collaborators to sell the products either in the United States or any other country. Furthermore, approval by the FDA of a therapeutic product does not assure approval by regulatory authorities outside the United States or vice versa. Even if approval for a therapeutic product is obtained, such approval may be subject to limitations on the indicated uses or appropriate patient population that could result in a significantly reduced potential market size for the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators fail to obtain the appropriate regulatory approvals necessary for us or our collaborators to sell our therapeutic candidates, or if the approvals are more limited than those that we intend to seek, our business, financial condition and results of operations would be materially harmed. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to stringent domestic and foreign therapeutic and drug regulation with respect to any potential products. Even if we receive regulatory approval for any of our therapeutic candidates, we will still be subject to ongoing regulatory obligations and continued review, which may result in significant additional expense. If we fail to comply with United States and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties. Any unfavorable regulatory action may materially and adversely affect our future financial condition and business operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive marketing and commercialization approval for a therapeutic candidate, we will be subject to continuing post-marketing regulatory requirements. Our potential products, further development activities and manufacturing and distribution of a future product, once developed and determined, will be subject to extensive and rigorous regulation by numerous government agencies, including the FDA and comparable foreign agencies. To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and the safety and effectiveness of our therapeutic candidates and, if approved, our future products. The process of obtaining marketing approval or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clearance from the FDA and comparable foreign bodies for new products, or for enhancements, expansion of the indications or modifications to existing products, could: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant, indeterminate amount of time; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous preclinical and clinical testing, and possibly post-market surveillance; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require design changes of our potential products; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in our never being granted the regulatory approval we seek. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may cause our operations or potential for success to suffer, harm our competitive standing and result in further losses that adversely affect our financial condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as well as its foreign regulatory counterparts, also have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. Additionally, the FDA regulates the promotional claims that may be made about prescription products, such as our products, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, we may share truthful and not misleading information with healthcare providers and payors that is otherwise consistent with the product&#8217;s FDA approved labeling. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will have ongoing responsibilities under these and other FDA and international regulations, both before and after a product is approved and commercially released. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign regulatory agencies. If we or our collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, adverse regulatory inspection finding, holds on clinical trials, delay of approval or refusal by the FDA or applicable authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, exclusion of eligibility from government contracts, injunctions, civil penalties or criminal prosecution. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively commercializing our potential products and harm our business. In addition, negative publicity and product liability claims resulting from any adverse regulatory action could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted outside of their respective jurisdictions. While we currently have partnerships in China designed to provide access to patient populations outside of the United States and in the future may conduct clinical trials in other foreign jurisdictions, there can be no assurance these data will be accepted by the FDA or EMA or other comparable foreign regulatory authorities as a basis for a product&#8217;s regulatory approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To augment our U.S.-centric clinical strategy, we have formed partnerships in China designed to provide access patient populations for clinical trials not readily available in the United States and to facilitate rapid patient enrollment with the goal of generating more robust early clinical data from patients in China. We may in the future pursue partnerships to conduct other clinical trials outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, any foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, including any trials conducted in China. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partnerships in China subject us to risks and uncertainties relating to the laws and regulations of China and the changes in relations between the United States and China. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its current leadership, the government of China has been pursuing economic reform policies, including by encouraging foreign trade and investment. However, there is no assurance that the Chinese government will continue to pursue such policies, that such policies will be successfully implemented, that such policies will not be significantly altered, or that such policies will be beneficial to our partnerships in China. China&#8217;s system of laws can be unpredictable, especially with respect to foreign investment and foreign trade. The United States government has called for substantial changes to foreign trade policy with China and has raised, and has proposed to further raise in the future, tariffs on several Chinese goods. China has retaliated with increased tariffs on United States goods. Moreover, China&#8217;s legislature has recently adopted a national&#160;security law to substantially change the way&#160;Hong Kong&#160;has been governed since the territory was handed over by the United Kingdom to China in 1997. This law increases the power of the central government in Beijing over&#160;Hong Kong, limit the civil liberties of residents of&#160;Hong Kong&#160;and could restrict the ability of businesses in Hong Kong to continue to conduct business or to continue to with business as previously conducted. The U.S. State Department has indicated that the United States no longer considers&#160;Hong Kong&#160;to have significant autonomy from China and President Trump signed an executive order and the Hong Kong Autonomy Act to remove Hong Kong&#8217;s preferential trade status. The United States may impose the same tariffs and other trade restrictions on exports from&#160;Hong Kong&#160;that it places on goods from mainland China. Any further changes in United States trade policy could trigger retaliatory actions by affected countries, including China, resulting in trade wars. Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations affecting biopharmaceutical companies are also unpredictable. Any regulatory changes and changes in United States and China relations may have a material adverse effect on our partnerships in China which could materially harm our business and financial condition. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives could harm our business in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing pressure on biotechnology companies to reduce healthcare costs. In the United States, these pressures come from a variety of sources, such as managed care groups and institutional and government purchasers. Increased purchasing power of entities that negotiate on behalf of federal healthcare programs and private sector beneficiaries could increase pricing pressures in the future. Such pressures may also increase the risk of litigation or investigation by the government regarding pricing calculations. The biotechnology industry will likely face greater regulation and political and legal actions in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse pricing limitations may hinder our ability to recoup our investment in one or more future therapeutic candidates, even if our future therapeutic candidates obtain regulatory approval. Adverse pricing limitations prior to approval will also adversely affect us by reducing our commercial potential. Our ability to commercialize any potential products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments becomes available from third-party payors, including government health administration authorities, private health insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize in the future and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval in the future. If reimbursement is not available or is available only </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to limited levels, we may not be able to successfully commercialize any therapeutic candidate that we successfully develop. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for approved products could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize potential products and our overall financial condition. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material and adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our therapeutic candidates, if we obtain regulatory approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive or set a price that we believe is fair for our products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act, or collectively the ACA, was enacted, which includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers in the United States. It also included the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The ACA continues to significantly impact the United States&#8217; pharmaceutical industry. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and as a result certain sections of the ACA have not been fully implemented or effectively repealed. In particular, in December of 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act, effective January 1, 2019. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether other reforms enacted as part of the ACA but not specifically related to the individual mandate or health insurance, including the provisions comprising the BPCIA, could be severed from the rest of the ACA so as not to be declared invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case and has allocated one hour for oral arguments, which are scheduled to occur on November 10, 2020, with a decision likely to follow in spring 2021. It is unclear how such litigation and other efforts to repeal and replace the ACA will </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact the ACA and our business. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which was signed into law on March 27, 2020 and was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. In addition, the Trump administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out-of-pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in September 2020, the FDA finalized a rulemaking to establish a system whereby state governmental entities could lawfully import and distribute prescription drugs sourced from Canada. Those new regulations become effective on November 30, 2020, although the impact of such future programs is uncertain. While some of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Notably, on July 24, 2020, President Trump announced four executive orders related to prescription drug pricing that attempt to implement several of the Administration&#8217;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS (which has since been finalized, as noted above) and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for plans, pharmacies, and pharmaceutical benefit managers after HHS confirms that the action is not projected to increase federal spending, Medicare beneficiary premiums, or patients&#8217; total out-of-pocket costs; and one that reduces costs of insulin and epinephrine auto-injectors to patients of Federally Qualified Health Centers. President Trump issued another executive order on September 13, 2020 that directs HHS to undertake rulemaking in order to test an international reference pricing model for prescription drug products. The probability of success of these newly announced policies and their impact on the U.S. prescription drug marketplace is unknown. There are likely to be political and legal challenges associated with implementing these reforms as they are currently envisioned. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our therapeutic candidates, if approved. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Our future products, if any, might not be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, an adequate level of reimbursement might not be available for such products and third-party payors&#8217; reimbursement policies might adversely affect our ability to sell any future products profitably. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biologic therapeutics. For example, on December 20, 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019, or the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products to deny generic and biosimilar product developers access to samples of brand products. Whether and how generic and biosimilar product developers will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on the U.S. biopharmaceutical industry are unknown. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our therapeutic candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-approval testing and other requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our therapeutic candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors and customers expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the U.S. federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and the civil monetary penalties laws, which prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. federal False Claims Act; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes obligations on certain healthcare providers, health plans, and healthcare clearinghouse, known as covered entities, as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of individually identifiable health information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to HHS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors and, beginning in 2022 for payments and other transfers of value provided in the previous year, certain advanced non-physician healthcare practitioners) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgements, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations, any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug status for one or more of our therapeutic candidates, but even if it is granted, we may be unable to maintain any benefits associated with orphan drug status, including market exclusivity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for a disease or condition will be recovered from sales in the United States for that drug or biologic. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full Biologics License Application, or a BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek orphan drug status for one or more of our therapeutic candidates, but the FDA may not approve any such request. Even if the FDA grants orphan drug status to one or more of our therapeutic candidates, exclusive marketing rights in the United States may be limited if we seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally, any therapeutic candidate that initially receives orphan drug status designation may lose such designation if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, others may obtain orphan drug status for products addressing the same diseases or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant period of time. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek fast-track designation for our therapeutic candidates. Even if received, fast-track designation may not actually lead to a faster review process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to benefit from the FDA&#8217;s fast track and priority review processes. However, our therapeutic candidates may not receive an FDA fast-track designation or priority review. Without fast-track designation, submitting a BLA and getting through the regulatory process to gain marketing approval is a lengthier process. Under fast-track designation, the FDA may initiate a rolling review of sections of a fast-track drug&#8217;s BLA before the application is complete. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the BLA is submitted. Additionally, the fast-track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. Under the FDA policies, a drug candidate is eligible for priority review, or review within a six-month time frame from the time a complete BLA is accepted for filing, if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. A fast-track designated drug candidate would ordinarily meet the FDA&#8217;s criteria for priority review. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fast-track designation for our therapeutic candidates, if obtained, may not actually lead to a faster review process and a delay in the review process or in the approval of our potential products will delay revenue from their potential sales and will increase the capital necessary to fund these product development programs. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates for which we intend to seek approval may face competition sooner than anticipated.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving regulatory approval to commercialize a therapeutic candidate ahead of our competitors, our future therapeutic candidates may face direct competition from biosimilar products. In the United States, our therapeutic candidates are regulated by the FDA as biological products and we intend to seek approval for these therapeutic candidates pursuant to the BLA pathway. The BPCIA created an abbreviated pathway for the FDA approval of biosimilar biological products based on a previously licensed innovator, or reference, biological product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12&#160;years after the original reference biological product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our therapeutic candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our therapeutic candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA, potentially creating the opportunity for follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only so-called &#8220;interchangeable&#8221; biosimilar products are considered substitutable for the reference biological product without the intervention of the healthcare provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient&#8217;s specific medical needs, healthcare providers are not restricted from prescribing biosimilar products in an off-label manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own preclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our therapeutic candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our therapeutic candidates may have received approval.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face regulation and potential liability related to the privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory environment surrounding information security, data collection and privacy is increasingly demanding. We are subject to numerous U.S. federal and state laws and non-U.S. regulations governing the protection of personal and confidential information of our clinical subjects, clinical investigators, employees and vendors/business contacts, including in relation to medical records, credit card data and financial information. For example, on May&#160;25, 2018, the European General Data Protection Regulation, or the GDPR, went into effect, significantly increasing fining levels of up to 4% total worldwide annual turnover or up to &#8364;20&#160;million (whichever is higher) for non-compliance with its requirements. We will be subject to the GDPR where we have a European Union presence or &#8220;establishment&#8221; (e.g. European Union based subsidiary or operations), when conducting clinical trials with European Union based data subjects (whether the trials are conducted directly by us or through a clinical vendor or partner) or offering approved products or services (if relevant) to European Union based data subjects (regardless of whether involving our European Union based subsidiary or operations). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR sets out a number of requirements that must be complied with when handling the personal data of such European Union based data subjects including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g. access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual are all classified as &#8220;special category&#8221; data under the GDPR and afford greater protection and require additional compliance obligations. Further, European Union member states have a broad right to impose additional conditions&#8212;including restrictions&#8212;on these data categories. This is because the GDPR allows European Union member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes). As the European Union states continue to reframe their national legislation to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harmonize with the GDPR, we will need to monitor compliance with all relevant European Union member states&#8217; laws and regulations, including where permitted derogations from the GDPR are introduced. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be subject to evolving European Union laws on data export, where we transfer data outside the European Union to group companies or third parties. The GDPR only permits exports of data outside the European Union where there is a suitable data transfer solution in place to safeguard personal data (e.g. the European Union Commission approved Standard Contractual Clauses). On July 16, 2020, the Court of Justice of the European Union or the CJEU, issued a landmark opinion in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maximilian Schrems vs. Facebook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Case C-311/18), called </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This decision (a) calls into question certain data transfer mechanisms as between the European Union member states and the U.S. (such as the Standard Contractual Clauses) and (b) invalidates the EU-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the U.S. The CJEU is the highest court in Europe and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of European Union data protection authorities are difficult to predict at the early date. Consequently, there is some risk of any of our data transfers from the European Union being halted.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where we rely on third parties to carry out a number of services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse impact on our reputation and business. Any contractual arrangements requiring the transfer of personal data from the European Union to us in the United States will require greater scrutiny and assessments as required under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, while the Data Protection Act of 2018, that &#8220;implements&#8221; and complements the GDPR achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area to the United Kingdom will remain lawful under GDPR. During the period of &#8220;transition&#8221; (i.e., until December 31, 2020), European Union law will continue to apply in the United Kingdom, including the GDPR, after which the GDPR will be converted into United Kingdom law. Beginning in 2021, the United Kingdom will be a &#8220;third country&#8221; under the GDPR. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act and California Consumer Privacy Act of 2018, or CCPA), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators, and the privacy regulatory area is in constant flux. The state of California, for example, has adopted the CCPA, which went into effect beginning in January 2020. The CCPA has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the GDPR. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for residents of the State of California, imposing special rules on the collection of personal information from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. An initiative called the California Privacy Rights Act, or CCPA 2.0, will be voted on in California on November 2, 2020 and its future application could impact our operations or that of our collaborators. Other states have been considering legislation similar to the CCPA, and several federal privacy proposals are under consideration in the current session of Congress.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, U.S. and European lawmakers and regulators have expressed concern over electronic marketing. In the European Union, marketing is defined broadly to include any promotional material and the rules specifically on e-marketing are currently set out in the ePrivacy Directive which will be replaced by a new ePrivacy Regulation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the ePrivacy Regulation was originally intended to be adopted on May&#160;25, 2018 (alongside the GDPR), it is still going through the European legislative process and commentators now expect it to be adopted in 2021. The current draft of the ePrivacy Regulation imposes strict opt-in e-marketing rules with limited exceptions to business to business communications and significantly increases fining powers to the same levels as GDPR (see above). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may find it necessary or desirable to join self-regulatory bodies or other privacy-related organizations, particularly relating to biopharmacy and/or scientific research that may require compliance with their rules pertaining to privacy and data security. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of the GDPR, and any resultant changes in European Union member states&#8217; national laws and regulations and the ePrivacy Regulation, will increase our compliance obligations and will necessitate the review and implementation of policies and processes relating to our collection and use of data. This increase in compliance obligations could also lead to an increase in compliance costs which may have an adverse impact on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any person, including any of our employees, clinical vendors or partners or those with whom we share such information, negligently disregards or intentionally breaches our established controls with respect to our clinical subject, clinical investigator or employee data, or otherwise mismanages or misappropriates that data, we could be subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution in one or more jurisdictions. As above, under the GDPR there are significant new punishments for non-compliance which could result in a penalty of up to 4% of a firm&#8217;s global annual revenue.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. If we become liable under laws or regulations applicable to us, we could be required to pay significant fines and penalties, our reputation may be harmed and we may be forced to change the way we operate. That could require us to incur significant expenses or to discontinue certain services, which could negatively affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including in certain cases allowing office-based employees in the United States to work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies. A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack. Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. Further, a data breach could result in negative publicity which could damage our reputation and have an adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.&#160;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160;We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160;We may engage third parties to sell our products sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&#160;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our application for the PPP Loan could in the future be determined to have been impermissible which could result in damage to our reputation or adversely impact our business.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we received proceeds of approximately $1.9 million from a loan under the Paycheck Protection Program, or the PPP Loan,&#160;of the CARES Act and was repaid in full in October 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying for the PPP Loan, we were required to certify, among other things, that the then current economic uncertainty made the PPP Loan necessary to support our ongoing operations and that we did not, together with our affiliates, then employ more than 500 employees. We made these certifications in good faith after analyzing, among other things, our current business activity and our ability to access other sources of liquidity sufficient to support our ongoing operations in a manner that would not be significantly detrimental to our business. We believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan was consistent with the broad objectives of the PPP&#160;of the CARES Act. The certification regarding necessity described above did not at the time contain any objective criteria and continues to be subject to interpretation. If, despite our good-faith belief that we satisfied all eligibility requirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us in connection with the PPP Loan, such as the False Claims Act, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to civil, criminal and administrative penalties. Any violations or alleged violations may result in adverse publicity and damage to our reputation, a review or audit by the U.S. Small Business Administration or other government entity, or claims under the False Claims Act.  These events could consume significant financial and management resources and could have a material adverse effect on our business, results of operations,  financial condition, and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of net operating loss carryforwards may be limited and U.S. federal income tax reform could adversely affect us.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our net operating loss, or NOL, carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes. Corresponding rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from the IPO or other transactions, or any resulting limitations, if any, on our ability to utilize our NOL carryforwards and other tax attributes. Even if there is no limitation on utilization of our NOL carryforwards as the result of an ownership change, the utilization of NOL carryforwards originating from a loss incurred in a year after 2017 is limited and may reduce taxable income in any post-2020 year by no more than 80% of the pre-NOL taxable income in such year. If we earn taxable income in a future year, such limitations on utilization of NOL carryforwards could result in increased future tax liability to us and our future cash flows could be adversely affected.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. We cannot predict the timing or extent of such tax-related developments which could have a negative impact on our financial results. United States federal legislation affecting the tax laws was enacted in December 2017 (the Tax Cuts and Jobs Act, or TCJA), March 2020 (the Families First Coronavirus Response Act), and again in March 2020 (the CARES Act). We cannot estimate how the changes in tax law from this legislation will affect our tax liability in future years, but we have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits from those assets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we use our best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause actual financial results to deviate from previous estimates.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain quantities of various flammable and toxic chemicals in our facilities in La Jolla, California required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these hazardous materials in our La Jolla facilities comply with the relevant guidelines of La Jolla, the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Any insurance coverage we have may not be sufficient to cover these liabilities. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations which would adversely affect our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize our therapeutic candidates, if approved, in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our therapeutic candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our therapeutic candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our therapeutic candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our therapeutic candidates and ultimately commercialize our therapeutic candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements and the reduced protection of intellectual property rights in some foreign countries. We may need to rely on third parties to market, distribute and sell our products in foreign markets. </span></div><div id="iee91b9a90f804077b237584160b9370a_148"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not know whether an active, liquid and orderly trading market will continue for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO in August 2020, there was no public market for shares of our common stock. Shares of our common stock only recently began trading on the Nasdaq Global Market, but we can provide no assurance that we will be able to sustain an active trading market for our shares. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our stock price may fluctuate significantly. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of shares of our common stock may be highly volatile and could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of our clinical trials and preclinical studies or those of our competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to our therapeutic candidates or development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; actual or anticipated fluctuations in our financial condition and operating results; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our partners or our competitors of new therapeutics or therapeutic candidates, significant contracts, strategic partnerships, joint ventures, collaborations, commercial relationships or capital commitments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of new or updated research or reports by securities analysts or recommendations for our stock; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing disputes or delays; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any future sales of our common stock or other securities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any change to the composition of the board of directors or key personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expiration of contractual lock-up agreements with our executive officers, directors and security holders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional debt or equity financing efforts; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">circumstances and market conditions relating to the COVID-19 pandemic. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance. In addition, the stock market in general, and life science companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have on occasion instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and holders of more than 5% of our capital stock own a significant percentage of our stock and will be able to exercise significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, our executive officers, directors and holders of more than 5% of our capital stock beneficially owned approximately 55.0% of our shares of common stock outstanding. Accordingly, this group of stockholders will continue to have significant control over our operations. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock in the public market could cause our stock price to fall. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we had 37,710,190 shares of common stock outstanding. Of these shares, the 8,050,000 shares sold in our IPO are freely tradable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, unless held by our &#8220;affiliates,&#8221; as that term is defined in Rule&#160;144 under the Securities Act, or Rule 144. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the remaining 29,660,190 shares of common stock, or 78.7% of our outstanding shares of common stock, are currently prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by our stockholders with us or lock-up agreements entered into by our stockholders with the underwriters. The lock-up agreements will expire 180 days from the date of the prospectus for our IPO (or February 14, 2021), subject to earlier release of all or a portion of the shares subject to such agreements by our underwriters in their sole discretion. These shares will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting and the 180-day lock-up agreements described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have filed a registration statement on Form S-8 under the Securities Act registering the issuance of 3,000,000 shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under the registration statement on Form S-8 can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lockup agreements described above, and, in the case of our affiliates, the restrictions of Rule 144.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, our stock price and trading volume could decline. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts who cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the public markets, which could cause our stock price or trading volume to decline. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Nasdaq Stock Market may delist our securities from its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading restrictions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market. We cannot assure you that, in the future, our securities will meet the continued listing requirements to be listed on the Nasdaq Global Market. If the Nasdaq Stock Market delists our common stock, we could face significant material adverse consequences, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. The 2020 Loan Agreement and future debt financing agreements may require us to have the lender&#8217;s permission before declaring dividends on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial statements and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning in the year following the first required annual report. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended, or the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that there will not be material weaknesses or significant deficiencies identified in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. In the future, if we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigations by The Nasdaq Stock Market, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we lose our status as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, and once we become an &#8220;accelerated filer&#8221; as defined in the Exchange Act our independent registered public accounting firm will be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. We could be an &#8220;emerging growth company&#8221; for up to five years from the closing of our initial public offering. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We intend to take advantage of this legislation, but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance as compared to when we operated as a privately held company. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221;, and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and a &#8220;smaller reporting company&#8221; under SEC regulations. For so long as we remain an emerging growth company or smaller reporting company, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies&#8221; or &#8220;smaller reporting companies.&#8221; These exemptions include reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As long as we remain an emerging growth company (and thereafter for so long as we remain a non-accelerated filer), these exemptions also include an exemption from the auditor attestation requirements of Section&#160;404. In addition, Section&#160;107 of the JOBS Act also </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result of our emerging growth company election and smaller reporting company status, investors may view our financial statements as not comparable to some other public companies. We cannot predict if investors will find our common stock less attractive because we may rely on certain of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company or a smaller reporting company. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenue of $1.07&#160;billion or more; (ii)&#160;the last day of our fiscal year following the fifth anniversary of the date of the completion of our IPO (December 31, 2025); (iii)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. In addition, we will continue to be a smaller reporting company as long as we (a) have less than $250 million in public float (based on our common equity) measured as of the last business day of our most recently completed second fiscal quarter, or (b) have annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available and have no public float or public float of less than $700 million (based on our common equity). </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions contained in our restated certificate of incorporation and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation, restated bylaws and Delaware law contain provisions which could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing our board of directors to issue up to 15,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as our board of directors may determine; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specifying that special meetings of our stockholders can be called only by our board of directors, the chairman of our board of directors or our Chief Executive Officer and that our stockholders may not act by written consent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that our board of directors may create new directorships and that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing that our board of directors is divided into three classes&#8212;Class&#160;I, Class&#160;II, and Class&#160;III&#8212;with each class serving staggered three-year terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that our board of directors may amend our restated bylaws without stockholder approval; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring a super-majority of votes to amend certain of the above-mentioned provisions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Delaware corporation, we are also subject to provisions of Delaware law, including Section&#160;203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware, or the Chancery Court, or the federal district court for the District of Delaware, or the District Court of Delaware, or the other federal district courts of the United States as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation requires, unless we otherwise consent, that the Chancery Court will, to the fullest extent permitted by law, be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law (subject to the Chancery Court having personal jurisdiction over the indispensable parties named as defendants): (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers or employees of the Company , arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Chancery Court, or (vi) any action or proceeding asserting a claim against us, or our directors, officers or employees, governed by the internal affairs doctrine. If the Chancery Court does not have jurisdiction for these actions or proceedings, then the actions or proceedings must be brought in a state court located in the State of Delaware. If these state courts also do not have jurisdiction, these actions or proceedings must be brought in the District Court of Delaware. These limitations in our amended and restated certificate of incorporation will not apply to actions brought to enforce a duty or liability created by the Securities Act, the Exchange Act or to any claim for which the federal courts have exclusive jurisdiction. However, our amended and restated certificate of incorporation also provides that, unless we otherwise consent in writing, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. In addition, any person holding, owning or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. These Delaware and federal court choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Chancery Court or the District Court of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Chancery Court or the District Court of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2020, the Delaware Supreme Court ruled that provisions of a Delaware corporation&#8217;s certificate of incorporation that designate a federal forum for securities claims brought pursuant to the Securities Act, or federal forum provisions, are valid and enforceable under Delaware law, or the March 2020 Ruling. Various U.S. Supreme Court cases offer support for the argument that federal forum provisions do not violate federal policy. However, the March 2020 Ruling applies only to claims brought in Delaware state courts, and it is not binding on any other state court or the federal courts. Therefore, we are unable to predict whether a state court in any other state or a federal court would enforce a federal forum provision such as the one set forth in our amended and restated certificate of incorporation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth information regarding all unregistered securities sold from July 1, 2020 (share and per share amounts give effect to a one-for-1.7382 reverse stock split, effected on August 11, 2020) through September 30, 2020:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) We granted stock options to purchase an aggregate of 52,641 common shares at a weighted average exercise price of $19.98 per share to employees under our 2017 Equity Incentive Plan and to directors pursuant to our Non-Employee Director Compensation Policy. These were granted in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or the exemption set forth in Section 4(a)(2) under the Securities Act and Rule 506 promulgated thereunder as a transaction not involving any public offering.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) On August 21, 2020, immediately prior to and in connection with the completion of our IPO, all shares of our then-outstanding convertible preferred stock automatically converted into 7,211,086 shares of our common stock. The common stock was issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 3(a)(9) or Section 4(a)(2) of the Securities Act.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) On August 21, 2020, immediately prior to and in connection with the completion of our IPO, all of our then-outstanding convertible notes automatically converted into 4,294,603 shares of our common stock. The common stock was issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 3(a)(9) or Section 4(a)(2) of the Securities Act.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) On August 21, 2020, immediately prior to and in connection with the completion of our IPO, our outstanding warrants issued to Oxford for purchase of our preferred stock automatically converted into warrants for purchase of 7,354 shares of our common stock. These were granted in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or the exemption set forth in Section 4(a)(2) under the Securities Act and Rule 506 promulgated thereunder as a transaction not involving any public offering.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Use of Proceeds</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2020, the SEC declared effective our registration statement on Form S-1 (File No. 333-240135), as amended, filed in connection with our IPO. Our IPO closed on August 21, 2020, and we issued and sold 8,050,000 shares of our common stock at a price to the public of $17.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from our IPO of $136.9&#160;million, before deducting underwriting discounts, commissions and offering costs of $11.0&#160;million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint book-running managing underwriters of the offering were Jefferies LLC, Evercore Group L.L.C. and Credit Suisse Securities (USA) LLC, with LifeSci Capital as Co-Manager.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank deposits and money market funds. Through September 30, 2020, we have used a portion of the net proceeds from our IPO for general corporate purposes, including the preclinical and clinical development of our programs. There has been no material change in the planned use of proceeds from our IPO from those disclosed in the Prospectus.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Loan Repayment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after receiving proceeds from its IPO, the Company repaid its PPP Loan in full. As of the repayment date, the Company had accrued approximately $7,400 of interest, for a total repayment of $1.9&#160;million. As discussed in Note 4, there were no prepayment penalties associated with the payment of the loan prior to maturity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the 2020 Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, the Company entered into the First Amendment to the 2020 Loan Agreement with Oxford (the &#8220;2020 Loan Amendment&#8221;). The 2020 Loan Amendment provides for two additional tranches of term loans in an aggregate principal amount of up to $40.0 million, as follows: (a) the second tranche in an aggregate principal amount of $20.0&#160;million, funded upon the closing of the 2020 Loan Amendment (&#8220;Tranche B&#8221;), and (b) the third tranche in an aggregate principal amount of $20.0&#160;million to fund on or before September 30, 2021, subject to the initiation of a registration-enabling trial for the Company&#8217;s therapeutic candidate, INBRX-109, in chondrosarcoma, pursuant to the terms of the 2020 Loan Amendment (&#8220;Tranche C&#8221;). Tranche B and Tranche C are in addition to the first tranche of term loans in an aggregate principal amount of $10.0 million, which was funded on July 15, 2020. In accordance with the 2020 Loan Amendment, the Company paid a one-time first amendment fee of $0.7&#160;million. The terms of the first tranche under the 2020 Loan Agreement were modified to align with Tranche B pursuant to the 2020 Loan Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding term loan will mature on November 1, 2025 (the &#8220;Amended Maturity Date&#8221;) and bears interest at a floating per annum rate equal to the greater of (1)&#160;7.96%&#160;and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii)&#160;7.80%. The repayment schedule provides for interest-only payments until January 1, 2024. Upon funding of Tranche C, the interest-only payments may be extended by 12 months to January 1, 2025. The interest-only period is followed by 23 months of equal payments of principal and interest, or if the interest-only period is extended, by 11 months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding. </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_163"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Exhibits. </span></div><div style="margin-bottom:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EXHIBIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NO.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">DESCRIPTION OF EXHIBIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FILED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">HEREWITH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE FILE NO.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">DATE FILED</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012979/exhibit318-k.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/21/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012979/exhibit328-k.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/21/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex41.htm">Form of Common Stock Certificate of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/3/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit46s-1.htm">Form of Warrant to Purchase Stock by and between the Registrant and Oxford Finance LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit101s-1.htm">Form of Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012466/exhibit1013s-1a1xamendedan.htm">Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (effective upon completion of the initial public offering)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex109.htm">Form of Stock Option Grant Notice under the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (effective upon completion of the initial public offering)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/3/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1010.htm">Form of Restricted Stock Agreement under the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (effective upon completion of the initial public offering)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/3/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit1031s-1.htm">Non-Employee Director Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012466/exhibit103s-1a1xamendedand.htm">Amended and Restated Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Mark Lappe</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012466/exhibit105s-1a1xamendedand.htm">Amended and Restated Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Klaus Wagner, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012466/exhibit107s-1a1xamendedand.htm">Amended and Restated Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Brendan Eckelman, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012466/exhibit108s-1a1xexecutivee.htm">Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Kelly Deck</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit1028s-1.htm">Loan and Security Agreement, dated July 15, 2020, by and between the Registrant and Oxford Finance LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1011-firstamend.htm">First Amendment to Loan and Security Agreement, dated November 12, 2020, by and between the Registrant and Oxford Finance LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#94;&#160;&#160;&#160;&#160;Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#916;&#160;&#160;&#160;&#160;Management Compensation Plan or arrangement.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="iee91b9a90f804077b237584160b9370a_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee91b9a90f804077b237584160b9370a_7">Table of Contents</a></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:454.50pt"><tr><td style="width:1.0pt"></td><td style="width:223.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:223.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INHIBRX, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;13, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark P. Lappe</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;13, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kelly D. Deck</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div id="iee91b9a90f804077b237584160b9370a_1493"></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>exhibit1011-firstamend.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie488c1425277482ca3c9dfac73422387_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.11</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS FIRST AMENDMENT to Loan and Security Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entered into as of November 12, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (&#8220;Oxford&#8221;), as collateral agent (in such capacity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and INHIBRX, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of July 15, 2020 (as amended, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement entered into pursuant to the Loan Agreement as provided herein and subject to the terms and conditions set forth herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 2.2(a) of the Loan Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower on the Effective Date in an aggregate amount of Ten Million Dollars ($10,000,000.00) according to each Lender&#8217;s Term A Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term A Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  After repayment, no Term A Loan may be re borrowed.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, on the First Amendment Date, to make term loans to Borrower in an aggregate amount of Twenty Million Dollars ($20,000,000) according to each Lender&#8217;s Term B Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term&#160;B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term B Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  After repayment, no Term B Loan may be re borrowed.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period, to make term loans to Borrower in an aggregate amount of Twenty Million Dollars ($20,000,000) according to each Lender&#8217;s Term C Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term&#160;C Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term C Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#59; each Term&#160;A Loan, Term B Loan or Term&#160;C Loan is hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term&#160;A Loans, Term B Loans and Term C Loans are</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  After repayment, no Term C Loan may be re borrowed.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 2.2(b) is hereby amended and restated as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Repayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date.  Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof.  Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon&#58; (1) the amount of such Lender&#8217;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (i) twenty-three (23) months, if the Term C Loans are not made hereunder or (ii) eleven (11) months, if the Term C Loans are made hereunder.  All unpaid principal and accrued and unpaid interest with respect to the Term Loans is due and payable in full on the Maturity Date.  The Term Loans may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 2.5 of the Loan Agreement is hereby amended by deleting the word &#8220;and&#8221; at the end of Section 2.5(d), replacing &#8220;.&#8221; at the end of Section 2.5(e) with &#8220;&#59; and&#8221; and adding the following Section 2.5(f) thereto&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Amendment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  A non-refundable first amendment fee in the amount of Seven Hundred Thousand Dollars ($700,000.00) which shall become fully-earned, due and payable on the First Amendment Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 3.1 of the Loan Agreement is hereby amended by replacing every occurrence of the text &#8220;Term Loan&#8221; therein with &#8220;Term A Loan.&#8221;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is (i) January 1, 2024, if the Term C Loans are not made hereunder, or (ii)&#160;January 1, 2025, if the Term C Loans are made hereunder.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is with respect to any Term Loan, the per annum rate of interest (based on a year of three hundred sixty (360) days) equal to the greater of (a) Seven and Ninety-Six Hundredths percent (7.96%) and (b) the sum of (i) thirty (30) day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last Business Day of the month that immediately precedes the month in which the interest will accrue, plus (ii) Seven and Eighty hundredths percent (7.80%).  Furthermore, notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a LIBOR Transition Event, Collateral Agent may amend this Agreement to replace the Basic Rate with a LIBOR Replacement Rate. Any such amendment with respect to a LIBOR Transition Event will become effective at 5&#58;00 p.m. (Eastern Standard Time) on the third Business Day after Collateral Agent has notified Borrower of such amendment.  Any determination, decision or election that may be made by Collateral Agent pursuant hereto will be conclusive and binding absent manifest error and may be made in Collateral Agent&#8217;s sole discretion and without consent from any other party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Final Payment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is Nine percent (9.00%).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is November 1, 2025.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory (other than in accordance with Section 6.5 hereof) or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;for a prepayment made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such Term Loan, three percent (3.00%) of the principal amount of such Term Loan prepaid&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the first anniversary of the Funding Date of such Term Loan through and including the second anniversary of the Funding Date of such Term Loan, two percent (2.00%) of the principal amount of such Term Loan prepaid&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the second anniversary of the Funding Date of such Term Loan and prior to the Maturity Date of such Term Loan, one percent (1.00%) of the principal amount of such Term Loan prepaid.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything herein to the contrary, the Funding Date of Term A Loan, strictly for the purposes of calculation of the Prepayment Fee shall be deemed to be the First Amendment Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is defined in Section 2.2(a)(iii).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 13.1 of the Loan Agreement is hereby further amended by adding the following definition thereto in alphabetical order&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is that certain First Amendment to this Agreement, entered into by and among Borrower, Collateral Agent and Lenders on the First Amendment Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is November 12, 2020.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration Study Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is the commencement of the registration study of INBRX-109 in chondrosarcoma on or before September 30, 2021, which study must be designed and intended to obtain sufficient data and results to support the filing of an application for the final regulatory approval for commercialization of INBRX-109 for use in chondrosarcoma. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is defined in Section 2.2(a)(i).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is defined in Section 2.2(a)(ii).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term C Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is defined in Section 2.2(a)(iii).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is the period commencing on the date of the occurrence of the Registrational Study Event and ending on the earliest of (i) September 30, 2021, (ii) the date that is forty-five (45) days immediately after the occurrence of the Registration Study Event and (iii) the occurrence of an Event of Default&#59; provided, however, that the Third Draw Period shall not commence if on the date of the occurrence of the Registration Study Event an Event of Default has occurred and is continuing</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 13.1 of the Loan Agreement is hereby further amended by deleting the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I&#47;O Extension Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Amortization Table attached to the Disbursement Letter entered into on the Effective Date is hereby amended and restated in its entirety as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Loan Agreement is hereby amended and restated as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Schedule 1.1 to the Loan Agreement is hereby amended and restated as set forth on Schedule 1.1 attached hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Collateral Agent hereby acknowledges receipt of an amount of $50,000 from Borrower on or about October 7, 2020, which amount shall be applied towards the Lenders&#8217; Expenses due under Section 2.5(e) of the Loan Agreement that have been incurred through the First Amendment Date, with the balance, if any, to be refunded to Borrower.  For the purposes of clarity, Borrower shall be responsible for the entire amount of the Lenders&#8217; Expenses payable under Section 2.5(e) of the Loan Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Limitation of Amendment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing&#59; </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The execution, delivery and performance by Borrower of this Amendment and the Loan Agreement as amended by this Amendment have been duly authorized&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect&#59;  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The execution, delivery and performance by Borrower of this Amendment have been duly authorized, and do not (i) conflict with any of Borrower&#8217;s organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower, or any of its property or assets may be bound or affected&#59; or (iv) constitute an event of default under any material agreement by which Borrower or any of its property, is bound&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any action by, filing, registration, or qualification with, or Governmental Approval from, any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to Section 6.1(b) of the Loan Agreement&#59; and </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(&#8220;Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity (other than claims relating to fraud), which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof and through the date hereof.  Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest&#58; (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents&#59; (b) any provision of this Amendment or the Loan Documents&#59; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">This Amendment shall be deemed effective as of the First Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto, (b) receipt by Collateral Agent of Perfection Certificates from Borrower and each of its Subsidiaries that are current as of the First Amendment Date and acceptable to Collateral Agent in its discretion, (c) Borrower&#8217;s payment of the first amendment fee in accordance with Section 2.5(f) of the Loan Agreement and (d) Borrower&#8217;s payment of all Lenders&#8217; Expenses incurred through the date hereof, which may be debited (or ACH&#8217;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ie488c1425277482ca3c9dfac73422387_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the parties hereto have caused this First Amendment to the Loan Agreement to be executed as of the date first set forth above.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INHIBRX, INC.</font></div><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Kelly Deck</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Kelly Deck</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; CFO</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COLLATERAL AGENT AND LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Colette H. Featherly</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Colette H. Featherly</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ie488c1425277482ca3c9dfac73422387_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE&#160;1.1</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lenders and Commitments</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term&#160;A Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10,000,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$10,000,000</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100.00%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term B Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20,000,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$20,000,000</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100.00%</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term C Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20,000,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$20,000,000</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100.00%</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate (all Term Loans)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50,000,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$50,000,000</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100.00%</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ie488c1425277482ca3c9dfac73422387_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Amortization Table</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;see attached&#93; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ie488c1425277482ca3c9dfac73422387_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Form of Secured Promissory Note</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;see attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ie488c1425277482ca3c9dfac73422387_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURED PROMISSORY NOTE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Term&#160;&#91;B&#93;&#91;C&#93; Loan)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$____________________&#160;&#160;&#160;&#160;Dated&#58;  &#91;DATE&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR VALUE RECEIVED, the undersigned, INHIBRX, INC., a Delaware corporation with an office located at with an office located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), HEREBY PROMISES TO PAY to the order of OXFORD FINANCE LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the principal amount of &#91;___________&#93; MILLION DOLLARS ($______________) or such lesser amount as shall equal the outstanding principal balance of the Term &#91;B&#93;&#91;C&#93; Loan made to Borrower by Lender, plus interest on the aggregate unpaid principal amount of such Term &#91;B&#93;&#91;C&#93; Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated July 15, 2020 by and among Borrower, Lender, Oxford Finance LLC, as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  If not sooner paid, the entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement.  Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal, interest and all other amounts due with respect to the Term &#91;B&#93;&#91;C&#93; Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Secured Promissory Note (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement, among other things, (a)&#160;provides for the making of a secured Term &#91;B&#93;&#91;C&#93; Loan by Lender to Borrower, and (b)&#160;contains provisions for acceleration of the maturity hereof upon the happening of certain stated events.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Note may not be prepaid except as set forth in Section&#160;2.2(c)&#160;and Section&#160;2.2(d)&#160;of the Loan Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Note and the obligation of Borrower to repay the unpaid principal amount of the Term &#91;B&#93;&#91;C&#93; Loan, interest on the Term &#91;B&#93;&#91;C&#93; Loan and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Note are hereby waived.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrower shall pay all reasonable fees and expenses, including, without limitation, reasonable and documented attorneys&#8217; fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower&#8217;s obligations hereunder not performed when due.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent.  Notwithstanding anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an interest in the obligation.  Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Note on the part of any other person or entity.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#91;Balance of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><div id="ie488c1425277482ca3c9dfac73422387_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BORROWER&#58;</font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INHIBRX, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _______________________________________</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; _____________________________________</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; ______________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:19.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scheduled</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment Amount</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notation By</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idbeb7ae626004b9ea81658f94789f3d0_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark P. Lappe, certify that&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Inhibrx, Inc&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;13, 2020</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if1f9be4b856c4d72ac6ddafe639c56eb_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kelly D. Deck, certify that&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Inhibrx, Inc&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;13, 2020</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly D. Deck</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia7749086a10d4f2ba692f48f442b9dad_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inhibrx, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark P. Lappe, Chief Executive Officer and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;13, 2020</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9facc1765d4e4130b98961de55f1e4ba_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inhibrx, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kelly D. Deck, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;13, 2020</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly D. Deck</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>inhibrx-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:3fe0b274-dc64-47fa-9492-4cc4ecb00ef6,g:c0dac7ab-748b-42c9-8c2a-26a240098d0f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:inhibrx="http://inhibrx.namespace.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://inhibrx.namespace.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inhibrx-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inhibrx-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inhibrx-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inhibrx-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://inhibrx.namespace.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2303301 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails">
        <link:definition>2404401 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2405402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails">
        <link:definition>2406403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails">
        <link:definition>2407404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails">
        <link:definition>2408405 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>2109102 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>2310302 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails">
        <link:definition>2411406 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails">
        <link:definition>2412407 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccruedExpensesDetails" roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails">
        <link:definition>2413408 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://inhibrx.namespace.com/role/DEBT">
        <link:definition>2114103 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://inhibrx.namespace.com/role/DEBTTables">
        <link:definition>2315303 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTOutstandingDebtBalance2015LoanAgreementDetails" roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails">
        <link:definition>2416409 - Disclosure - DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTOutstandingDebtBalance2015LoanAgreementDetails_1" roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1">
        <link:definition>2416409 - Disclosure - DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://inhibrx.namespace.com/role/DEBTNarrativeDetails">
        <link:definition>2417410 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTOutstandingDebtBalance2020LoanAgreementDetails" roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails">
        <link:definition>2418411 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTFutureMinimumPaymentsDetails" roleURI="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails">
        <link:definition>2419412 - Disclosure - DEBT - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPLOAN" roleURI="http://inhibrx.namespace.com/role/PPPLOAN">
        <link:definition>2120104 - Disclosure - PPP LOAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPLOANDetails" roleURI="http://inhibrx.namespace.com/role/PPPLOANDetails">
        <link:definition>2421413 - Disclosure - PPP LOAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEPROMISSORYNOTES" roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES">
        <link:definition>2122105 - Disclosure - CONVERTIBLE PROMISSORY NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEPROMISSORYNOTESTables" roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables">
        <link:definition>2323304 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEPROMISSORYNOTESNarrativeDetails" roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails">
        <link:definition>2424414 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails">
        <link:definition>2425415 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Notes Balance, Net of Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2126106 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>2327305 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITDetails" roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails">
        <link:definition>2428416 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANS" roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS">
        <link:definition>2129107 - Disclosure - EQUITY COMPENSATION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSTables" roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables">
        <link:definition>2330306 - Disclosure - EQUITY COMPENSATION PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSNarrativeDetails" roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails">
        <link:definition>2431417 - Disclosure - EQUITY COMPENSATION PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails">
        <link:definition>2432418 - Disclosure - EQUITY COMPENSATION PLANS - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails">
        <link:definition>2433419 - Disclosure - EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails">
        <link:definition>2434420 - Disclosure - EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUES" roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES">
        <link:definition>2135108 - Disclosure - LICENSE AND GRANT REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESTables" roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables">
        <link:definition>2336307 - Disclosure - LICENSE AND GRANT REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESRevenueSummaryDetails" roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails">
        <link:definition>2437421 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails">
        <link:definition>2438422 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESGovernmentGrantsDetails" roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails">
        <link:definition>2439423 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2140109 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2441424 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2142110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>2343308 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2444425 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails">
        <link:definition>2445426 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails">
        <link:definition>2446427 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1" roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1">
        <link:definition>2446427 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COVID19" roleURI="http://inhibrx.namespace.com/role/COVID19">
        <link:definition>2147111 - Disclosure - COVID-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS">
        <link:definition>2148112 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2449428 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="inhibrx_LAVSummitLimitedMember" abstract="true" name="LAVSummitLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" abstract="false" name="RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="inhibrx_A2015OxfordTermLoansMember" abstract="true" name="A2015OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_NumberOfOperatingLeasesHeld" abstract="false" name="NumberOfOperatingLeasesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_A2020OxfordTermLoansMember" abstract="true" name="A2020OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_NoncashOperatingLeaseExpense" abstract="false" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CelgeneMember" abstract="true" name="CelgeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_NonCashEstablishmentOfEquityMethodInvestment" abstract="false" name="NonCashEstablishmentOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" abstract="false" name="CollaborativeArrangementMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_RevenueRecognitionNumberOfCompounds" abstract="false" name="RevenueRecognitionNumberOfCompounds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_WuXiBiologicsHealthcareVentureMember" abstract="true" name="WuXiBiologicsHealthcareVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_LicenseAffiliateOX40LicenseAgreementMember" abstract="true" name="LicenseAffiliateOX40LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_WarrantsIssuedUponConsummationOfIPOMember" abstract="true" name="WarrantsIssuedUponConsummationOfIPOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_ChiesiFarmaceuticiSpAMember" abstract="true" name="ChiesiFarmaceuticiSpAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_GrantValuedAwarded" abstract="false" name="GrantValuedAwarded" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_LesseeOperatingLeaseSquareFootage" abstract="false" name="LesseeOperatingLeaseSquareFootage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="inhibrx_DebtInstrumentNumberOfTermLoans" abstract="false" name="DebtInstrumentNumberOfTermLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" abstract="false" name="ContractWithCustomerLiabilityDerecognizedDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="inhibrx_BluebirdBioIncMember" abstract="true" name="BluebirdBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_A2020OxfordTermLoansTrancheBMember" abstract="true" name="A2020OxfordTermLoansTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" abstract="true" name="WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" abstract="false" name="PaymentsOfDebtIssuanceCostsConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_RelatedPartyEquityInterestInCompany" abstract="false" name="RelatedPartyEquityInterestInCompany" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_LesseeOperatingLeaseSquareFootageExpansion" abstract="false" name="LesseeOperatingLeaseSquareFootageExpansion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="inhibrx_DebtIssuanceCostsNetDerivativeLiability" abstract="false" name="DebtIssuanceCostsNetDerivativeLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" abstract="false" name="RepaymentsOfSecuredDebtFinalBalloonPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_WarrantsLiability" abstract="false" name="WarrantsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" abstract="false" name="OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_NationalInstitutesOfHealthMember" abstract="true" name="NationalInstitutesOfHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" abstract="true" name="BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" abstract="false" name="CollaborativeArrangementAdditionalPaymentReceivablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" abstract="true" name="LicenseAffiliatePDL1And41BBLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" abstract="false" name="CollaborativeAgreementExclusiveDevelopmentLicenses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" abstract="false" name="DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" abstract="false" name="OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" abstract="false" name="ScheduleOfLicenseAndGrantRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="inhibrx_ProfitInterestUnitPIUMember" abstract="true" name="ProfitInterestUnitPIUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_A2015OxfordTermLoansTermCMember" abstract="true" name="A2015OxfordTermLoansTermCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_LicenseNonAffiliateMember" abstract="true" name="LicenseNonAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_A2019ConvertiblePromissoryNoteMember" abstract="true" name="A2019ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" abstract="false" name="DebtInstrumentInterestOnlyPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" abstract="false" name="IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" abstract="false" name="PaymentsOfStockIssuanceCostsConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" abstract="false" name="ClassOfWarrantOrRightPercentageOfFundedAmountIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" abstract="false" name="GrantAwardedPaymentStructurePercentageCoveredByCompany" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="inhibrx_A2015OxfordTermLoansTermAMember" abstract="true" name="A2015OxfordTermLoansTermAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_SeriesMezzanine1PreferredStockMember" abstract="true" name="SeriesMezzanine1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_A2020OxfordTermLoansTranchesBAndCMember" abstract="true" name="A2020OxfordTermLoansTranchesBAndCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementExpenseReimbursement" abstract="false" name="CollaborativeArrangementExpenseReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" abstract="false" name="PaymentsOfDebtIssuanceCostsSecuredDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" abstract="true" name="LicenseAgreementAdditionalProgramsAuthorizedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" abstract="false" name="CollaborativeAgreementNumberOfRelatedProgramsToAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" abstract="false" name="PaymentsOfStockIssuanceCostsInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_A2020ConvertiblePromissoryNoteMember" abstract="true" name="A2020ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_ShareBasedCompensationNumberOfPlans" abstract="false" name="ShareBasedCompensationNumberOfPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_WarrantsAndRightsOutstandingLiability" abstract="false" name="WarrantsAndRightsOutstandingLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_DebtInstrumentInterestRateFloor" abstract="false" name="DebtInstrumentInterestRateFloor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_DebtInstrumentVariableRateFloor" abstract="false" name="DebtInstrumentVariableRateFloor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_A2020OxfordTermLoansFirstTrancheMember" abstract="true" name="A2020OxfordTermLoansFirstTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" abstract="false" name="QualifiedCompanyValuationForInitialPublicOfferingIPO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_LesseeOperatingLeaseAnnualEscalations" abstract="false" name="LesseeOperatingLeaseAnnualEscalations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" abstract="false" name="CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" abstract="false" name="GrantAwardedPaymentStructurePercentageReimbursedBySponsor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" abstract="false" name="CollaborativeArrangementCommercializationMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" abstract="false" name="CollaborativeArrangementDevelopmentMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_SeriesMezzanine2PreferredStockMember" abstract="true" name="SeriesMezzanine2PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_ExpensesReimbursedToDate" abstract="false" name="ExpensesReimbursedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_NumberOfLicenseAgreements" abstract="false" name="NumberOfLicenseAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" abstract="false" name="EquityMethodInvestmentAdditionalOwnershipEntitled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_WarrantAndDerivativeLiabilitiesMember" abstract="true" name="WarrantAndDerivativeLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_PhylaxisBioScienceLLCMember" abstract="true" name="PhylaxisBioScienceLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_A2019And2020ConvertiblePromissoryNotesMember" abstract="true" name="A2019And2020ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementForeignTaxWithholding" abstract="false" name="CollaborativeArrangementForeignTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementPaymentReceivable" abstract="false" name="CollaborativeArrangementPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" abstract="false" name="DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_DebtInstrumentPrepaymentFee" abstract="false" name="DebtInstrumentPrepaymentFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" abstract="false" name="DebtInstrumentUnamortizedDiscountWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" abstract="false" name="ReclassificationOfWarrantLiabilitiesToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_A2020OxfordTermLoansTrancheCMember" abstract="true" name="A2020OxfordTermLoansTrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_StockIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_LicenseAffiliateMember" abstract="true" name="LicenseAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_A2015OxfordTermLoansTermBMember" abstract="true" name="A2015OxfordTermLoansTermBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_OtherCustomersNotSeparatelyDisclosedMember" abstract="true" name="OtherCustomersNotSeparatelyDisclosedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" abstract="false" name="DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" abstract="false" name="IncreaseDecreaseContractWithCustomerLiabilityCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_WarrantLiabilitiesPolicyTextBlock" abstract="false" name="WarrantLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" abstract="false" name="CollaborativeArrangementAdditionalPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_ElpiscienceBiopharmaceuticalsIncMember" abstract="true" name="ElpiscienceBiopharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" abstract="false" name="LesseeOperatingLeaseInitialBaseRentExpensePerMonth" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" abstract="false" name="CollaborativeArrangementNonrefundableUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" abstract="true" name="CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" abstract="false" name="DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedProgramOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" abstract="false" name="PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inhibrx_TranscentaHoldingLtdMember" abstract="true" name="TranscentaHoldingLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" abstract="true" name="DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" abstract="false" name="DebtInstrumentInterestOnlyPaymentsExtendedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inhibrx_A2015OxfordTermLoansTermDMember" abstract="true" name="A2015OxfordTermLoansTermDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="inhibrx_LicenseAndGrantRevenueTextBlock" abstract="false" name="LicenseAndGrantRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" abstract="false" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>inhibrx-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:3fe0b274-dc64-47fa-9492-4cc4ecb00ef6,g:c0dac7ab-748b-42c9-8c2a-26a240098d0f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/Cover" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_417ca308-93c7-46bc-bdc4-5404b073310d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_8fead585-c6e0-4893-be4c-7d193f2d3094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_417ca308-93c7-46bc-bdc4-5404b073310d" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_8fead585-c6e0-4893-be4c-7d193f2d3094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c7fbaef-399f-4189-9d25-1db6118939e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_417ca308-93c7-46bc-bdc4-5404b073310d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c7fbaef-399f-4189-9d25-1db6118939e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f01fb6cd-2893-491f-b443-dfb3a895f70b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_417ca308-93c7-46bc-bdc4-5404b073310d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f01fb6cd-2893-491f-b443-dfb3a895f70b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb3fb598-36da-4868-8953-933c62a429ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_417ca308-93c7-46bc-bdc4-5404b073310d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb3fb598-36da-4868-8953-933c62a429ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f52c8e7a-8d08-40a2-bd7b-6c5257c14031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f52c8e7a-8d08-40a2-bd7b-6c5257c14031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_0ed754eb-77b7-4a0e-b790-f323040e3b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_0ed754eb-77b7-4a0e-b790-f323040e3b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6c25e600-a6fa-4290-943f-3da9d2075f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6c25e600-a6fa-4290-943f-3da9d2075f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_430bfde2-07f3-4fb6-bed2-fbccd0e42b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_430bfde2-07f3-4fb6-bed2-fbccd0e42b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e7dec91b-6a1e-494a-a611-62849313f613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:to="loc_us-gaap_LiabilitiesCurrent_e7dec91b-6a1e-494a-a611-62849313f613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_890047e7-ce4f-44e1-b946-65fa0d2442f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_66fa66c6-2271-40e7-868e-a5fb5089a589" xlink:to="loc_us-gaap_SecuredLongTermDebt_890047e7-ce4f-44e1-b946-65fa0d2442f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9a5b5fe0-4d94-4d9e-941f-f0a8fd5d2798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_LongTermDebtCurrent_9a5b5fe0-4d94-4d9e-941f-f0a8fd5d2798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_82a33fb1-c7b8-4953-b63f-e9cc6d3330ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_82a33fb1-c7b8-4953-b63f-e9cc6d3330ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d513123f-0179-47b4-bef8-69eab2b1df26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_AccountsPayableCurrent_d513123f-0179-47b4-bef8-69eab2b1df26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e267a577-fae3-4ec6-ad59-66c91ce388d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e267a577-fae3-4ec6-ad59-66c91ce388d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_66a0c071-ec03-4401-97fd-1124eed62efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_66a0c071-ec03-4401-97fd-1124eed62efe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca155b79-8c6f-4a9a-afcf-09c2c4afada4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca155b79-8c6f-4a9a-afcf-09c2c4afada4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_5d220979-0798-43b2-a118-e95f8e5ab448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_83717892-3c7e-4f02-8976-1e71c7ae8dc0" xlink:to="loc_us-gaap_ShortTermBorrowings_5d220979-0798-43b2-a118-e95f8e5ab448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9961bfce-4c81-47a2-a178-c14834ef070f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2bbc92b6-dd37-46d5-8046-d9c3a25ff1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9961bfce-4c81-47a2-a178-c14834ef070f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2bbc92b6-dd37-46d5-8046-d9c3a25ff1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_95e0c0d7-b4b1-481b-8fd8-197185f2bdc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9961bfce-4c81-47a2-a178-c14834ef070f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_95e0c0d7-b4b1-481b-8fd8-197185f2bdc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c482223d-7191-43bd-85a2-5bcaa824c365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9961bfce-4c81-47a2-a178-c14834ef070f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c482223d-7191-43bd-85a2-5bcaa824c365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c7d49889-cdc6-4ce8-8688-c4ba05cf9be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9961bfce-4c81-47a2-a178-c14834ef070f" xlink:to="loc_us-gaap_AssetsCurrent_c7d49889-cdc6-4ce8-8688-c4ba05cf9be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad0b52f-1360-42d8-84a2-91320d787119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0d6594e3-c602-4dcd-977b-5c9df21dbb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad0b52f-1360-42d8-84a2-91320d787119" xlink:to="loc_us-gaap_Liabilities_0d6594e3-c602-4dcd-977b-5c9df21dbb6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c61200a-83c9-4f6b-bc9b-f13cd7856509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad0b52f-1360-42d8-84a2-91320d787119" xlink:to="loc_us-gaap_StockholdersEquity_9c61200a-83c9-4f6b-bc9b-f13cd7856509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d5959b9-c8d6-4f0b-a8d5-eb16814a6623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad0b52f-1360-42d8-84a2-91320d787119" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d5959b9-c8d6-4f0b-a8d5-eb16814a6623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_35ab134c-5c4b-4526-8d76-86b6c12c2603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad0b52f-1360-42d8-84a2-91320d787119" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_35ab134c-5c4b-4526-8d76-86b6c12c2603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0096c1d6-432c-49ce-8a1c-a7d7fcbb64f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_323cd210-5ae3-4213-82ca-36b952894e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0096c1d6-432c-49ce-8a1c-a7d7fcbb64f8" xlink:to="loc_us-gaap_PreferredStockValue_323cd210-5ae3-4213-82ca-36b952894e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce94b681-7086-400a-83ce-62c0be553a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0096c1d6-432c-49ce-8a1c-a7d7fcbb64f8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce94b681-7086-400a-83ce-62c0be553a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5c20e116-518d-4c44-806c-e6f7a4a46bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0096c1d6-432c-49ce-8a1c-a7d7fcbb64f8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5c20e116-518d-4c44-806c-e6f7a4a46bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_617db89b-001b-4550-a3e9-5221facbdf74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0096c1d6-432c-49ce-8a1c-a7d7fcbb64f8" xlink:to="loc_us-gaap_CommonStockValue_617db89b-001b-4550-a3e9-5221facbdf74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8515306e-8fc9-49d6-9bbe-b4b7b9c72f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9d7e4e69-5c09-403b-a801-9a4e5f0bdbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8515306e-8fc9-49d6-9bbe-b4b7b9c72f93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9d7e4e69-5c09-403b-a801-9a4e5f0bdbe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_98ddd419-0534-451f-a4f1-a39b5247e78c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8515306e-8fc9-49d6-9bbe-b4b7b9c72f93" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_98ddd419-0534-451f-a4f1-a39b5247e78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_37a914a2-54f4-4018-8dde-e30338d68ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8515306e-8fc9-49d6-9bbe-b4b7b9c72f93" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_37a914a2-54f4-4018-8dde-e30338d68ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0b3cf430-ed04-4d7c-922e-59c6ca9a69ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7928915b-5d18-4117-87af-acf6181bec61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0b3cf430-ed04-4d7c-922e-59c6ca9a69ed" xlink:to="loc_us-gaap_OperatingExpenses_7928915b-5d18-4117-87af-acf6181bec61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c96c1071-5aab-481b-b9b7-6eda8cea86b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0b3cf430-ed04-4d7c-922e-59c6ca9a69ed" xlink:to="loc_us-gaap_Revenues_c96c1071-5aab-481b-b9b7-6eda8cea86b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_68127d9e-1c07-48cc-aac6-c258d11531fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5d728100-866f-4a28-b8fe-b13bdeef34e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68127d9e-1c07-48cc-aac6-c258d11531fb" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5d728100-866f-4a28-b8fe-b13bdeef34e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_080ebcfb-082c-4f08-bc79-ac94f03a1915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68127d9e-1c07-48cc-aac6-c258d11531fb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_080ebcfb-082c-4f08-bc79-ac94f03a1915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6f48580c-6c57-4ba8-93c6-010ef637abba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68127d9e-1c07-48cc-aac6-c258d11531fb" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6f48580c-6c57-4ba8-93c6-010ef637abba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e96232ea-0e6d-4255-b4d5-92232b442042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68127d9e-1c07-48cc-aac6-c258d11531fb" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e96232ea-0e6d-4255-b4d5-92232b442042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_38248e9c-30a8-445f-a45e-925bda77aa7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e46d6a72-3559-4135-9f0e-15e89de74559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_38248e9c-30a8-445f-a45e-925bda77aa7e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e46d6a72-3559-4135-9f0e-15e89de74559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d3c74027-b159-446f-a910-4f5a1e9c06c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_38248e9c-30a8-445f-a45e-925bda77aa7e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d3c74027-b159-446f-a910-4f5a1e9c06c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8ca16e48-ad16-4540-b33f-9af21671b7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a29275ac-5efb-4a93-aa58-ceb01b759dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8ca16e48-ad16-4540-b33f-9af21671b7f5" xlink:to="loc_us-gaap_OperatingIncomeLoss_a29275ac-5efb-4a93-aa58-ceb01b759dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e4363fed-ec3d-4d4c-a1f1-5f0aa9129bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8ca16e48-ad16-4540-b33f-9af21671b7f5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e4363fed-ec3d-4d4c-a1f1-5f0aa9129bac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NoncashOperatingLeaseExpense_6abc4629-b2c4-4be6-96d3-a4dddf35de96" xlink:href="inhibrx-20200930.xsd#inhibrx_NoncashOperatingLeaseExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_inhibrx_NoncashOperatingLeaseExpense_6abc4629-b2c4-4be6-96d3-a4dddf35de96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f3824bba-93ee-4b6b-b19a-dca3b27b5ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f3824bba-93ee-4b6b-b19a-dca3b27b5ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_8e9d3c37-0d27-47c2-8dba-6f35331357a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_8e9d3c37-0d27-47c2-8dba-6f35331357a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_91459506-0ec8-4674-976e-a4beb695e916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_91459506-0ec8-4674-976e-a4beb695e916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4126729f-3ed9-4cc2-87ad-0b25ab989720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4126729f-3ed9-4cc2-87ad-0b25ab989720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7bf675d1-8b29-4798-96a4-74ab2f840005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7bf675d1-8b29-4798-96a4-74ab2f840005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_dda60c41-14bf-438c-883e-ba6d2e0da15d" xlink:href="inhibrx-20200930.xsd#inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_dda60c41-14bf-438c-883e-ba6d2e0da15d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c4604132-6fb7-4d26-862c-d9c6b9be1f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_ShareBasedCompensation_c4604132-6fb7-4d26-862c-d9c6b9be1f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77e914ba-e939-495a-a9bc-40fc44c0ddf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77e914ba-e939-495a-a9bc-40fc44c0ddf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ae399c2a-4f1b-46d5-9afc-997a0a9cb523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ae399c2a-4f1b-46d5-9afc-997a0a9cb523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ebb71c8a-a17b-4942-822b-79c4b4467dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_OperatingLeasePayments_ebb71c8a-a17b-4942-822b-79c4b4467dd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a6852f22-781a-47ea-a604-a5d82b5ed1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a6852f22-781a-47ea-a604-a5d82b5ed1ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_44612331-f68c-499e-8fa3-7b5ba6798ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_44612331-f68c-499e-8fa3-7b5ba6798ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a2d6e9d-7932-40fb-9c56-c6221269935a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_NetIncomeLoss_2a2d6e9d-7932-40fb-9c56-c6221269935a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_464a36d6-2f79-4def-9edb-5367b860f6a4" xlink:href="inhibrx-20200930.xsd#inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_464a36d6-2f79-4def-9edb-5367b860f6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_65e2a503-bb3b-41e6-9c52-2206617210b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_65e2a503-bb3b-41e6-9c52-2206617210b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_ddab6d8b-6e27-4cc6-89b6-e35ba4a31cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_ddab6d8b-6e27-4cc6-89b6-e35ba4a31cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ef87413b-8b54-431f-a16d-27eb1693b042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ef87413b-8b54-431f-a16d-27eb1693b042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_995008af-bdff-48ec-b6da-827bc863a962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8199939f-1db9-49b4-bd66-3ea152d4f12b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_995008af-bdff-48ec-b6da-827bc863a962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7149728-cf48-4ab1-9399-8b2d3f779d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16396aeb-2728-4889-8979-1972ffbf7556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7149728-cf48-4ab1-9399-8b2d3f779d0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16396aeb-2728-4889-8979-1972ffbf7556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77c5943f-44d4-434d-9ea2-8ba905d5b302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7149728-cf48-4ab1-9399-8b2d3f779d0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77c5943f-44d4-434d-9ea2-8ba905d5b302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d56324e-a59d-4e0b-9f9b-ec0b63547bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7149728-cf48-4ab1-9399-8b2d3f779d0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d56324e-a59d-4e0b-9f9b-ec0b63547bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e6d5f01-4211-477d-a707-b3f680f7a3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19b4e905-f669-40dc-a7b4-5089cb95eb16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e6d5f01-4211-477d-a707-b3f680f7a3a6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19b4e905-f669-40dc-a7b4-5089cb95eb16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_3d834a8f-0acb-4a1f-acae-9d36f935b179" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_3d834a8f-0acb-4a1f-acae-9d36f935b179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_41b74025-5856-4002-b9c6-14ddada466d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_41b74025-5856-4002-b9c6-14ddada466d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_09de62fc-e108-410c-a73d-2a5fc9747510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_09de62fc-e108-410c-a73d-2a5fc9747510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_4152d12b-8813-43cf-b976-2c4d03fc0afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_4152d12b-8813-43cf-b976-2c4d03fc0afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_f6ce43f9-32a9-4982-955c-82ca83ea4e03" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_f6ce43f9-32a9-4982-955c-82ca83ea4e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_7e1d0383-ffee-4dee-903b-ca5afa42877c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_7e1d0383-ffee-4dee-903b-ca5afa42877c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_d317a430-71a0-448a-93fd-7321a20fac92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_d317a430-71a0-448a-93fd-7321a20fac92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a72a71a4-5b1d-48ea-96e3-27a32c4317b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a72a71a4-5b1d-48ea-96e3-27a32c4317b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_f5fbe923-cb88-445a-9a03-9f1a5d4e2348" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_f5fbe923-cb88-445a-9a03-9f1a5d4e2348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6acc70eb-862f-412c-a58b-006409047f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6acc70eb-862f-412c-a58b-006409047f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_6e73d89d-f731-4fbb-a7d5-13ffdd8bad81" xlink:href="inhibrx-20200930.xsd#inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_6e73d89d-f731-4fbb-a7d5-13ffdd8bad81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_8d94919f-e43c-4c65-ada8-2292dfd932e8" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_8d94919f-e43c-4c65-ada8-2292dfd932e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_e994f292-54fe-415d-8bbb-a3e019458756" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab07d76c-2b65-4803-b949-5b664c8164e3" xlink:to="loc_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_e994f292-54fe-415d-8bbb-a3e019458756" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATION"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_935c757b-15ad-4dd7-a7a7-35ad70ca48e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_05170f78-ef2e-49ac-8903-f175de0b194d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_935c757b-15ad-4dd7-a7a7-35ad70ca48e3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_05170f78-ef2e-49ac-8903-f175de0b194d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cff75cb3-bc5a-43c9-b3db-4a4e204a28fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_935c757b-15ad-4dd7-a7a7-35ad70ca48e3" xlink:to="loc_us-gaap_OtherAssetsCurrent_cff75cb3-bc5a-43c9-b3db-4a4e204a28fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_01994610-fc1c-4f8d-a82c-5c82060b08e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_737b044e-be39-4e06-8307-8b5bc4d480a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_01994610-fc1c-4f8d-a82c-5c82060b08e9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_737b044e-be39-4e06-8307-8b5bc4d480a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2d9d9ebb-b833-4f6e-bd01-f310dcb6caca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_01994610-fc1c-4f8d-a82c-5c82060b08e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2d9d9ebb-b833-4f6e-bd01-f310dcb6caca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c601a621-9141-498c-9312-faca8000a22e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65ab74f9-db67-4014-a6b9-9f0a236f9ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c601a621-9141-498c-9312-faca8000a22e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65ab74f9-db67-4014-a6b9-9f0a236f9ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1415cd1c-7e64-4e64-8bbd-36b028a9e55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c601a621-9141-498c-9312-faca8000a22e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1415cd1c-7e64-4e64-8bbd-36b028a9e55f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9d956edd-f630-4628-b9f5-17b3b623df3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c601a621-9141-498c-9312-faca8000a22e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9d956edd-f630-4628-b9f5-17b3b623df3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_AccruedResearchAndDevelopmentCurrent_38381d6a-b9b6-4e9a-bc40-2a9858be73e2" xlink:href="inhibrx-20200930.xsd#inhibrx_AccruedResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c601a621-9141-498c-9312-faca8000a22e" xlink:to="loc_inhibrx_AccruedResearchAndDevelopmentCurrent_38381d6a-b9b6-4e9a-bc40-2a9858be73e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBT" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBT"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBT" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2015LoanAgreementDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1aebec50-b43a-4909-8bd6-52e5936bacd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b313fc01-0f2d-4659-b6de-89c53703fb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1aebec50-b43a-4909-8bd6-52e5936bacd9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b313fc01-0f2d-4659-b6de-89c53703fb7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ef71f45c-295c-4e0a-9d04-aa64818d70fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1aebec50-b43a-4909-8bd6-52e5936bacd9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ef71f45c-295c-4e0a-9d04-aa64818d70fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2015LoanAgreementDetails_1"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e01060ec-2467-4a9c-a557-84b5e7a0cf2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4116d4c8-e646-4241-a251-eefb5534d0ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e01060ec-2467-4a9c-a557-84b5e7a0cf2c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4116d4c8-e646-4241-a251-eefb5534d0ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_58e38b23-06f7-48c7-b0c1-2d6adad587e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e01060ec-2467-4a9c-a557-84b5e7a0cf2c" xlink:to="loc_us-gaap_LongTermDebtCurrent_58e38b23-06f7-48c7-b0c1-2d6adad587e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTNarrativeDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBTNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_acb633ac-3ad7-4d80-83fc-aa4f840270d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_bc89b8e9-a213-49cf-a56e-05a690fd52c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_acb633ac-3ad7-4d80-83fc-aa4f840270d2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_bc89b8e9-a213-49cf-a56e-05a690fd52c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4f3ec6a2-b07c-4e70-9129-ef99cb271f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_acb633ac-3ad7-4d80-83fc-aa4f840270d2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4f3ec6a2-b07c-4e70-9129-ef99cb271f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6343b1a8-0214-4322-bf92-81b9c3afc63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_acb633ac-3ad7-4d80-83fc-aa4f840270d2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6343b1a8-0214-4322-bf92-81b9c3afc63f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cb99a249-d692-49cd-ac8d-4f041395ebe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_acb633ac-3ad7-4d80-83fc-aa4f840270d2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cb99a249-d692-49cd-ac8d-4f041395ebe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9976d66-7a17-49bf-b0bf-98ee26480c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_acb633ac-3ad7-4d80-83fc-aa4f840270d2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9976d66-7a17-49bf-b0bf-98ee26480c8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/PPPLOAN" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#PPPLOAN"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/PPPLOAN" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/PPPLOANDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#PPPLOANDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/PPPLOANDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTES"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANS"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUES"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESRevenueSummaryDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESGovernmentGrantsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_de347d2c-f8a6-4db6-ad82-d775c0c3931e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_de347d2c-f8a6-4db6-ad82-d775c0c3931e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e035403-ae2a-4158-ba3e-c531b5424e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e035403-ae2a-4158-ba3e-c531b5424e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_774a17f0-0cb8-4a5b-9f62-16b1d08b04cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_774a17f0-0cb8-4a5b-9f62-16b1d08b04cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3ff84ed-55b2-4cdb-9771-901cbae984e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3ff84ed-55b2-4cdb-9771-901cbae984e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc9b9588-bd86-4e0d-80d5-b938bc6945c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc9b9588-bd86-4e0d-80d5-b938bc6945c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7ecc8ba3-9772-425c-8f2e-d8a77a3a44bb" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f5e251-9dca-4fb1-905a-dc05916e42ad" xlink:to="loc_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7ecc8ba3-9772-425c-8f2e-d8a77a3a44bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4a616e1d-d729-4add-8fec-67fd1593199b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d198e6f-2444-4b72-912d-11eae0c72268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4a616e1d-d729-4add-8fec-67fd1593199b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d198e6f-2444-4b72-912d-11eae0c72268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e64b16b1-ff01-4a17-9bc4-6dfd08754b40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4a616e1d-d729-4add-8fec-67fd1593199b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e64b16b1-ff01-4a17-9bc4-6dfd08754b40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bebc823-72ba-42ae-bd5f-35acfc5fc60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_477cf025-a089-4b5f-a52f-1e3ed522e773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bebc823-72ba-42ae-bd5f-35acfc5fc60b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_477cf025-a089-4b5f-a52f-1e3ed522e773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0d16302b-dd90-4239-9840-812c197c674a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bebc823-72ba-42ae-bd5f-35acfc5fc60b" xlink:to="loc_us-gaap_OperatingLeaseLiability_0d16302b-dd90-4239-9840-812c197c674a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COVID19" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COVID19"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/COVID19" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#SUBSEQUENTEVENTS"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>inhibrx-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:3fe0b274-dc64-47fa-9492-4cc4ecb00ef6,g:c0dac7ab-748b-42c9-8c2a-26a240098d0f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/Cover" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/Cover" xlink:type="extended" id="iac14649f843f46d5959e4d1a10c205c3_Cover"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i6a58f5ae4cc74dd7a269964ef181ab0d_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i68a6440cd3954281acfe7e54b554acac_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="id8edb7bcdb134e4ca58de9f49931c8e6_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bc451cc0-dbea-4695-b27d-a74e619d82dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_RevenuesAbstract_bc451cc0-dbea-4695-b27d-a74e619d82dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_100326fa-8de1-42e8-b161-c4938f133c77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_bc451cc0-dbea-4695-b27d-a74e619d82dd" xlink:to="loc_us-gaap_Revenues_100326fa-8de1-42e8-b161-c4938f133c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bef98ccb-fb57-4e38-af2c-1dae4130ed66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bef98ccb-fb57-4e38-af2c-1dae4130ed66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5281f1fc-0e7f-46c5-aa00-a159980a87c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5281f1fc-0e7f-46c5-aa00-a159980a87c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_afc4855c-412d-4eaf-9b35-c3997f62f2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:to="loc_us-gaap_OperatingExpenses_afc4855c-412d-4eaf-9b35-c3997f62f2a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b1df7109-2a8f-477b-b911-baaabb34de26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_OperatingIncomeLoss_b1df7109-2a8f-477b-b911-baaabb34de26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bf24d231-033d-463e-a15d-96f7b80f640c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bf24d231-033d-463e-a15d-96f7b80f640c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5be07a46-6482-44bb-aeec-d8d6b68ebd32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5be07a46-6482-44bb-aeec-d8d6b68ebd32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_157bde45-47d8-429b-b323-815bc413e5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_157bde45-47d8-429b-b323-815bc413e5f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5ef04f71-566b-42c3-90da-1e32440c1ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5ef04f71-566b-42c3-90da-1e32440c1ad9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_359e3f39-6275-4fb0-adf9-1fed3c375bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_359e3f39-6275-4fb0-adf9-1fed3c375bd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_443359bc-deb2-499a-8f04-fb58ebc59b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_443359bc-deb2-499a-8f04-fb58ebc59b6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ba8faac4-fc9b-4141-80b4-cf65f91636b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ba8faac4-fc9b-4141-80b4-cf65f91636b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cc226d64-3944-4acd-908a-1d88bd5d2db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cc226d64-3944-4acd-908a-1d88bd5d2db9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5778dc74-aac9-4950-afc8-e0f1b752e3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_NetIncomeLoss_5778dc74-aac9-4950-afc8-e0f1b752e3f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6e2d6f44-a368-404b-8747-950c55be45da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6e2d6f44-a368-404b-8747-950c55be45da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_034dad10-13cd-44bd-9179-264c877b7747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_034dad10-13cd-44bd-9179-264c877b7747" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:to="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d8e5b3fc-8fb1-4d29-be99-e35eb151435d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:to="loc_srt_ProductsAndServicesDomain_d8e5b3fc-8fb1-4d29-be99-e35eb151435d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:to="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_99732c26-34e8-4c10-b4b3-f5c8898985ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:to="loc_us-gaap_LicenseMember_99732c26-34e8-4c10-b4b3-f5c8898985ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_1ce61fb1-57a2-4eb9-95d5-5738c940e78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:to="loc_us-gaap_GrantMember_1ce61fb1-57a2-4eb9-95d5-5738c940e78b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i1d907db49833406b86b49fef7d47742a_CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_27328859-6d63-49a5-8149-bcbf41a9aca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_27328859-6d63-49a5-8149-bcbf41a9aca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7400a5bd-6773-4372-a6bb-1e5759669755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7400a5bd-6773-4372-a6bb-1e5759669755" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3bf1a5bf-1c8c-4c08-9e54-b6dcf3136a96" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3bf1a5bf-1c8c-4c08-9e54-b6dcf3136a96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_561d4cdc-2c2b-4555-a52d-4fbc4eced90e" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_561d4cdc-2c2b-4555-a52d-4fbc4eced90e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_03bdf561-3537-4aa5-8e4c-74e3f59a6fb4" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_03bdf561-3537-4aa5-8e4c-74e3f59a6fb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d10309ae-013f-4f2d-a0d0-72fc2bf56581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d10309ae-013f-4f2d-a0d0-72fc2bf56581" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_18caf402-d681-466c-9cbb-5f6ba0077dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_992c9161-03a4-4094-8617-cec3246c70a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b9c42f21-ac28-49dc-868c-709907d2e74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b9c42f21-ac28-49dc-868c-709907d2e74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d16648-00b2-419e-9628-4b20b0de0d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d16648-00b2-419e-9628-4b20b0de0d37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_606ce0b7-099c-488b-bcc4-34f14dfd2356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_606ce0b7-099c-488b-bcc4-34f14dfd2356" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_100975fe-9d3c-4af9-a6bb-d4cea1df2900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_100975fe-9d3c-4af9-a6bb-d4cea1df2900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86cdc86a-55b2-44e3-b43e-64b58308a21e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86cdc86a-55b2-44e3-b43e-64b58308a21e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a2cf9d33-2d0f-41cf-9af6-881e0b809e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a2cf9d33-2d0f-41cf-9af6-881e0b809e29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3da8aebf-1456-4d34-bcdc-a42d6713a551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3da8aebf-1456-4d34-bcdc-a42d6713a551" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2fe48ef8-4001-4339-8b82-988fb3274420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2fe48ef8-4001-4339-8b82-988fb3274420" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8a9b4a1a-3d8e-42a0-b243-ea459dabfb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8a9b4a1a-3d8e-42a0-b243-ea459dabfb02" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_27bfeb1e-4dd1-4095-96fd-254910e07fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_27bfeb1e-4dd1-4095-96fd-254910e07fb2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20aa52ee-ad7c-4068-a822-1db9319cbb80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_NetIncomeLoss_20aa52ee-ad7c-4068-a822-1db9319cbb80" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_713bc223-9d49-45d8-9e67-88f0eef69b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7402ae6b-0ae5-42da-9e77-034c9e58fbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:to="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0cb15454-255a-4be0-8d00-a7500b4de647_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:to="loc_us-gaap_EquityComponentDomain_0cb15454-255a-4be0-8d00-a7500b4de647_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:to="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2c113ae9-60ce-4b68-b798-61983402b7c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:to="loc_us-gaap_CommonStockMember_2c113ae9-60ce-4b68-b798-61983402b7c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_90955493-72a6-4565-8e69-43cb4edc5ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_90955493-72a6-4565-8e69-43cb4edc5ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ec3be5cc-58f2-4b25-b75e-4ce6d949851a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:to="loc_us-gaap_RetainedEarningsMember_ec3be5cc-58f2-4b25-b75e-4ce6d949851a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4c809e7-b949-4347-9e76-e10e2e55e6ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4c809e7-b949-4347-9e76-e10e2e55e6ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_4302459b-b115-4ff3-8d5e-076de2e37659" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:to="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_4302459b-b115-4ff3-8d5e-076de2e37659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_11d4fd6d-693e-435f-85e0-3db45134ae2f" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_11d4fd6d-693e-435f-85e0-3db45134ae2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_ca7ce27d-fb5e-4daf-aaa1-c2eaa71c5379" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_ca7ce27d-fb5e-4daf-aaa1-c2eaa71c5379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79121da2-2b25-4195-9d98-0671d08e6d7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:to="loc_us-gaap_ClassOfStockDomain_79121da2-2b25-4195-9d98-0671d08e6d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ac1c56e-02a2-4e5b-a075-d9d876a2b97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:to="loc_us-gaap_ClassOfStockDomain_4ac1c56e-02a2-4e5b-a075-d9d876a2b97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_18ecd370-e231-4f0e-b033-e4619cbc6ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ac1c56e-02a2-4e5b-a075-d9d876a2b97d" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_18ecd370-e231-4f0e-b033-e4619cbc6ac6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="if171bd6c8a344d3d931d45d04faa50fb_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i713c488cf96240b1857f9140b89a2a88_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i9e579f8f52014682be451d32f6efbf93_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended" id="ic000a1ef8084404287fde1182de9e186_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="extended" id="i1010c2d4421749e5869e047b41c5df86_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a689bc08-8ebe-433e-897d-8cdeb16a48a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a689bc08-8ebe-433e-897d-8cdeb16a48a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cbb9da31-0836-40b5-8c74-e3ef2fca709e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cbb9da31-0836-40b5-8c74-e3ef2fca709e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_60006bd5-22b8-4628-9c89-a88ef34ae634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_60006bd5-22b8-4628-9c89-a88ef34ae634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4cae9160-8be3-4015-9af9-9982316c93bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4cae9160-8be3-4015-9af9-9982316c93bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5d27427b-4c8d-406c-8ae1-9ce12ca433c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5d27427b-4c8d-406c-8ae1-9ce12ca433c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a91b35d2-260b-48e9-9cf5-00af6f12ac71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a91b35d2-260b-48e9-9cf5-00af6f12ac71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_eeec71e7-34be-43e5-b11b-2bcaf00aa6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_eeec71e7-34be-43e5-b11b-2bcaf00aa6c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_575ee88d-1340-45b8-92ad-1c395578521e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_575ee88d-1340-45b8-92ad-1c395578521e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db9144d2-32b2-47f0-a047-19c5e01f958a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db9144d2-32b2-47f0-a047-19c5e01f958a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96df2451-ac4d-4ebd-9584-6927fc69bdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96df2451-ac4d-4ebd-9584-6927fc69bdea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4982dffb-1165-453d-bedd-680afd6c857f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96df2451-ac4d-4ebd-9584-6927fc69bdea" xlink:to="loc_us-gaap_IPOMember_4982dffb-1165-453d-bedd-680afd6c857f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b4023925-bf1d-41c6-a504-8b920bc28f43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b4023925-bf1d-41c6-a504-8b920bc28f43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e16f150-2c14-49a2-8a17-d51a456546fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e16f150-2c14-49a2-8a17-d51a456546fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_51a3c375-ac3e-4f2f-9986-e1d7c244d788" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e16f150-2c14-49a2-8a17-d51a456546fa" xlink:to="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_51a3c375-ac3e-4f2f-9986-e1d7c244d788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b63c348f-2f1b-4f81-8bff-8c3994709767_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b63c348f-2f1b-4f81-8bff-8c3994709767_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f7558e3-0fbd-4009-98a2-073cee550e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f7558e3-0fbd-4009-98a2-073cee550e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_3b3f2b8b-73de-48b6-80de-506a7384d820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6f7558e3-0fbd-4009-98a2-073cee550e7b" xlink:to="loc_us-gaap_ConvertibleDebtMember_3b3f2b8b-73de-48b6-80de-506a7384d820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_deea5c5f-523d-48ca-95cf-07e7f54665fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:to="loc_us-gaap_ClassOfStockDomain_deea5c5f-523d-48ca-95cf-07e7f54665fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7ad42c6-09e2-4255-91c5-17ec709b4aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:to="loc_us-gaap_ClassOfStockDomain_c7ad42c6-09e2-4255-91c5-17ec709b4aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_34670231-daab-49c5-becb-5c048f1776fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c7ad42c6-09e2-4255-91c5-17ec709b4aae" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_34670231-daab-49c5-becb-5c048f1776fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e5ff2d0a-12c0-416c-99b6-554a88e16fb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:to="loc_us-gaap_EquityComponentDomain_e5ff2d0a-12c0-416c-99b6-554a88e16fb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e289e35-a56d-4b48-8363-c3b1cc49ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:to="loc_us-gaap_EquityComponentDomain_9e289e35-a56d-4b48-8363-c3b1cc49ef3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c3ff9ad-6412-4858-b25d-5b022bcb9c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9e289e35-a56d-4b48-8363-c3b1cc49ef3d" xlink:to="loc_us-gaap_CommonStockMember_6c3ff9ad-6412-4858-b25d-5b022bcb9c8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i1713d83bc4e34a3ebe653e54d536d408_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementTerm_30021c12-1a38-440a-94fc-2252557010e9" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:to="loc_inhibrx_CollaborativeArrangementTerm_30021c12-1a38-440a-94fc-2252557010e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a00a73fb-6316-42cd-ab01-53c5b40560d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a00a73fb-6316-42cd-ab01-53c5b40560d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_91ef348f-93f9-4963-93ef-94126729dc60_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:to="loc_srt_RangeMember_91ef348f-93f9-4963-93ef-94126729dc60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:to="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cd6a1cc-e598-45b3-b6ac-007054a5858c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:to="loc_srt_MinimumMember_5cd6a1cc-e598-45b3-b6ac-007054a5858c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fde1b1e0-0083-4b7c-8ba6-48ce68ceb06f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:to="loc_srt_MaximumMember_fde1b1e0-0083-4b7c-8ba6-48ce68ceb06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_119ef176-96e0-448e-a9ae-7f2f6069b96c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_119ef176-96e0-448e-a9ae-7f2f6069b96c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_dd35c098-806e-497f-b432-e0736534950f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_dd35c098-806e-497f-b432-e0736534950f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_602514fd-5427-4618-86ff-96f23ad2d276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_602514fd-5427-4618-86ff-96f23ad2d276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e863aa11-3c36-4580-96ac-deb58f32557b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e863aa11-3c36-4580-96ac-deb58f32557b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7e528c6f-9e0d-4e5e-acb9-b54709c41b29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:to="loc_us-gaap_RelatedPartyDomain_7e528c6f-9e0d-4e5e-acb9-b54709c41b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_70b2b0e2-496f-47bd-b226-0e2742e4f865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:to="loc_us-gaap_RelatedPartyDomain_70b2b0e2-496f-47bd-b226-0e2742e4f865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_39baccd6-81a3-4c90-8717-488432316a19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_70b2b0e2-496f-47bd-b226-0e2742e4f865" xlink:to="loc_srt_AffiliatedEntityMember_39baccd6-81a3-4c90-8717-488432316a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4ba4242-ea3a-4a59-b018-1414e78d1d90_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4ba4242-ea3a-4a59-b018-1414e78d1d90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cd41963-18d7-4a69-ab47-cc589564cd97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cd41963-18d7-4a69-ab47-cc589564cd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_b798d725-94c4-48f5-982e-ce9c0a15afe6" xlink:href="inhibrx-20200930.xsd#inhibrx_WuXiBiologicsHealthcareVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cd41963-18d7-4a69-ab47-cc589564cd97" xlink:to="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_b798d725-94c4-48f5-982e-ce9c0a15afe6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" xlink:type="extended" id="i700859748f984c638691daa785f9761d_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8e06158-7cf5-44ba-a68d-e0e4e5cb78ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c50bc3bb-5fa9-4ce0-a6db-e695d8357607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8e06158-7cf5-44ba-a68d-e0e4e5cb78ac" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c50bc3bb-5fa9-4ce0-a6db-e695d8357607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8e06158-7cf5-44ba-a68d-e0e4e5cb78ac" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f823a775-9e06-46a0-a446-021be491f5df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f823a775-9e06-46a0-a446-021be491f5df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_66032ef4-2b0f-4bbd-b052-2e7be5f7a665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_66032ef4-2b0f-4bbd-b052-2e7be5f7a665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f016f089-05b6-4076-bb0a-bc2470fa54c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f016f089-05b6-4076-bb0a-bc2470fa54c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_55b12eea-5896-4937-b1c6-7478038d4711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_55b12eea-5896-4937-b1c6-7478038d4711" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended" id="i2b37f4d179ff4852b3e9310119282dd6_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_88225418-fe73-4be1-9e39-0a61d7c255f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_88225418-fe73-4be1-9e39-0a61d7c255f1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3c6089d-d8eb-4c93-b052-e3bc7ed1ee98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3c6089d-d8eb-4c93-b052-e3bc7ed1ee98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9fe0462-1244-4be8-a327-00739bda7e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9fe0462-1244-4be8-a327-00739bda7e09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bb6e82bd-e51e-493c-992b-4a1729e45512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bb6e82bd-e51e-493c-992b-4a1729e45512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_dcff1ad8-39da-4457-bff4-51e471c92ef2" xlink:href="inhibrx-20200930.xsd#inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_dcff1ad8-39da-4457-bff4-51e471c92ef2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74c3a32e-f8aa-4cb0-a8c7-48be6f2d30c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_88225418-fe73-4be1-9e39-0a61d7c255f1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:to="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_40178fce-6386-44a0-ab7a-d6f963d623d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_40178fce-6386-44a0-ab7a-d6f963d623d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_1b91d56d-9d59-4f68-8887-148979f487aa" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_1b91d56d-9d59-4f68-8887-148979f487aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_a50c9756-3ffc-4bc7-b7e4-7851d4140d9f" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_a50c9756-3ffc-4bc7-b7e4-7851d4140d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_0462979e-3923-4bfd-9d73-9061d1198c8d" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:to="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_0462979e-3923-4bfd-9d73-9061d1198c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8295aa99-2283-42e1-84c1-ec08672ead90_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8295aa99-2283-42e1-84c1-ec08672ead90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantAndDerivativeLiabilitiesMember_2516ee56-430c-455a-8b73-ed6c10d2b3f3" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantAndDerivativeLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:to="loc_inhibrx_WarrantAndDerivativeLiabilitiesMember_2516ee56-430c-455a-8b73-ed6c10d2b3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_ecaf8982-1115-4d55-9489-05b4d38721ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:to="loc_us-gaap_DerivativeMember_ecaf8982-1115-4d55-9489-05b4d38721ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_34d2fe36-661f-4f3d-bc52-3c65e362ce53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:to="loc_us-gaap_WarrantMember_34d2fe36-661f-4f3d-bc52-3c65e362ce53" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="extended" id="i370809a233984af49ff6f8590f10210e_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ae38440-28df-4390-b2fc-645d96e2e86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ae38440-28df-4390-b2fc-645d96e2e86a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7de18f02-07bf-4e92-9544-eb620306a3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7de18f02-07bf-4e92-9544-eb620306a3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93ceb563-ce8e-49a4-be7e-000799e7b1f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93ceb563-ce8e-49a4-be7e-000799e7b1f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_6294619e-3086-4582-9a72-6dc009107006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_6294619e-3086-4582-9a72-6dc009107006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d0a05fd8-5284-4a0b-acb9-712a0e5fee0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d0a05fd8-5284-4a0b-acb9-712a0e5fee0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_bf527006-6a88-4ed1-99be-5af3e7487b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_bf527006-6a88-4ed1-99be-5af3e7487b78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d6144fbd-2713-420e-8ac1-be46c36de332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_WarrantMember_d6144fbd-2713-420e-8ac1-be46c36de332" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5857a15-4966-4b92-af18-778e7274f6e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5857a15-4966-4b92-af18-778e7274f6e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_25577293-da7f-4cc2-a37e-bf03eeea6a6f" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_25577293-da7f-4cc2-a37e-bf03eeea6a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_95b9514f-f368-4168-8d83-cc7a22a27a61" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_95b9514f-f368-4168-8d83-cc7a22a27a61" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATION"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended" id="ie4b951f2d1a84789ae8874731508cc49_OTHERFINANCIALINFORMATION"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended" id="i001d6a35eef1488ba2c5bebe73d44d88_OTHERFINANCIALINFORMATIONTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended" id="i4f2dd3b105514308a5fd13d54c4a4908_OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="extended" id="id50c6b021ef6471aa875d5298f852153_OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_55a7bcd3-d300-4a4d-b5aa-dfc646823334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_55a7bcd3-d300-4a4d-b5aa-dfc646823334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93a3f668-2879-4737-b7c0-b635bf45acae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93a3f668-2879-4737-b7c0-b635bf45acae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_255f5532-f514-4787-9a25-5f6cea06bd2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_255f5532-f514-4787-9a25-5f6cea06bd2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_25eddfa3-e113-49cb-a45b-e91ac4cfe1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_25eddfa3-e113-49cb-a45b-e91ac4cfe1c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15f1b143-085a-498c-907f-04c5e672294a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15f1b143-085a-498c-907f-04c5e672294a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6c5e493e-8eaa-4e43-a21c-c7a0510a6215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6c5e493e-8eaa-4e43-a21c-c7a0510a6215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_48a6476e-6f69-49f6-97d5-67b3a5db76c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_48a6476e-6f69-49f6-97d5-67b3a5db76c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c8bd0004-a357-4098-96e9-13046343f41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c8bd0004-a357-4098-96e9-13046343f41b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6484beca-eae7-44fc-9340-36767b7f7706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_ConstructionInProgressMember_6484beca-eae7-44fc-9340-36767b7f7706" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="extended" id="i987a997ea46d44d082c0272f40fa2c1f_OTHERFINANCIALINFORMATIONAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBT" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBT"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/DEBT" xlink:type="extended" id="i9c02f4ecc75b401eb649e45a878c8fe2_DEBT"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/DEBTTables" xlink:type="extended" id="i7619a7a20a9e47b2b1ec7acc64c7d331_DEBTTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2015LoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails" xlink:type="extended" id="i62efe1b8380a4b3ea05e2915e01f91d0_DEBTOutstandingDebtBalance2015LoanAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_598c0439-686c-4367-a0dd-4f7f3e5886a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_598c0439-686c-4367-a0dd-4f7f3e5886a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_402d747c-4bc0-4923-b875-1090f1fc4989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_402d747c-4bc0-4923-b875-1090f1fc4989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f5ddc904-0c9f-4286-a987-9e8156d0af31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_LongTermDebt_f5ddc904-0c9f-4286-a987-9e8156d0af31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c7c8723f-de93-4d27-a97e-4763762ed20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_LongTermDebtCurrent_c7c8723f-de93-4d27-a97e-4763762ed20d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e2245f26-dbf1-4f8f-9127-2aa67289dd28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e2245f26-dbf1-4f8f-9127-2aa67289dd28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82ba5aa7-4ee4-455c-b464-68caee625812_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82ba5aa7-4ee4-455c-b464-68caee625812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_febdbcd8-81dc-40d6-840b-8654fce75f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_febdbcd8-81dc-40d6-840b-8654fce75f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_febdbcd8-81dc-40d6-840b-8654fce75f99" xlink:to="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermAMember_aadac70b-96fc-494b-a7c0-0967c2a99834" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermAMember_aadac70b-96fc-494b-a7c0-0967c2a99834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermBMember_cc1ef963-f237-4e8c-8011-eadca94a9c5c" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermBMember_cc1ef963-f237-4e8c-8011-eadca94a9c5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermCMember_ace9abf8-09b7-4c1b-a75b-9b8ef0f01dd6" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermCMember_ace9abf8-09b7-4c1b-a75b-9b8ef0f01dd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermDMember_5a6dfd00-5942-4e37-9c7f-44f352a6d796" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermDMember_5a6dfd00-5942-4e37-9c7f-44f352a6d796" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ca1c103-c4f7-4115-936e-ab487f62dae7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ca1c103-c4f7-4115-936e-ab487f62dae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68054320-658a-403e-87f1-264495f5d9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68054320-658a-403e-87f1-264495f5d9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c583ab9f-6718-4d21-9baf-1040008b7af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68054320-658a-403e-87f1-264495f5d9f5" xlink:to="loc_us-gaap_SecuredDebtMember_c583ab9f-6718-4d21-9baf-1040008b7af8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/DEBTNarrativeDetails" xlink:type="extended" id="i374f9ea6953240b6a1233d89f2d1911d_DEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentNumberOfTermLoans_bf3886c7-6dbb-4ea3-b725-c0583c6bbfe8" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentNumberOfTermLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentNumberOfTermLoans_bf3886c7-6dbb-4ea3-b725-c0583c6bbfe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0bad9548-f02a-4f0f-b53d-1ba3d4c5d0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0bad9548-f02a-4f0f-b53d-1ba3d4c5d0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8814be3d-ddd5-48e5-9fe1-4c92a9b9bada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8814be3d-ddd5-48e5-9fe1-4c92a9b9bada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPrepaymentFee_fac531b9-232a-4f1f-a6ac-5c2d7b199e82" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentPrepaymentFee_fac531b9-232a-4f1f-a6ac-5c2d7b199e82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_dfdfd825-e293-4905-aab7-c0ee870aceaa" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_dfdfd825-e293-4905-aab7-c0ee870aceaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_017569b5-9386-458f-af49-4c383c744310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_017569b5-9386-458f-af49-4c383c744310" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7886b05f-8dd7-4f75-a7b1-0721630b4f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7886b05f-8dd7-4f75-a7b1-0721630b4f59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5395b9c6-530e-414f-ae11-9210e379a5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5395b9c6-530e-414f-ae11-9210e379a5c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_5d0ea79a-b26a-4696-a22c-346d7d83df66" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_5d0ea79a-b26a-4696-a22c-346d7d83df66" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_e39e005f-2ce5-48f3-a319-e42b7e110806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_e39e005f-2ce5-48f3-a319-e42b7e110806" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_bb0f87be-4145-4433-9b03-73384879d76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_InterestExpenseDebt_bb0f87be-4145-4433-9b03-73384879d76d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_397b497a-2ddb-4c42-ac15-b6b5b4bd80a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_397b497a-2ddb-4c42-ac15-b6b5b4bd80a6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_28cdafeb-9e78-4f06-95e2-3a34bf3df643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_28cdafeb-9e78-4f06-95e2-3a34bf3df643" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44e482c1-2b3d-47c7-80fb-8a8017ac31ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44e482c1-2b3d-47c7-80fb-8a8017ac31ad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentVariableRateFloor_2f504c7a-7a6d-4f8b-994e-f00438e6d958" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentVariableRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentVariableRateFloor_2f504c7a-7a6d-4f8b-994e-f00438e6d958" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_23566b66-a5b3-4782-b614-6de1ea6ae291" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestOnlyPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_23566b66-a5b3-4782-b614-6de1ea6ae291" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_b47ef558-8dd3-492c-ac44-061a74ec3eba" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_b47ef558-8dd3-492c-ac44-061a74ec3eba" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_a77b0e1a-0a30-41f1-9312-43ec2aaa1cff" xlink:href="inhibrx-20200930.xsd#inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_a77b0e1a-0a30-41f1-9312-43ec2aaa1cff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsAndRightsOutstandingLiability_a758ec9f-78ba-48d6-bee2-90e9d6fde32a" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsAndRightsOutstandingLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_WarrantsAndRightsOutstandingLiability_a758ec9f-78ba-48d6-bee2-90e9d6fde32a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsLiability_5989c307-0c6e-4434-a69f-a57f8afad1e2" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_WarrantsLiability_5989c307-0c6e-4434-a69f-a57f8afad1e2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d5a31346-b8f1-4305-8794-de1faae8a3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d5a31346-b8f1-4305-8794-de1faae8a3fe" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6a763b93-78c0-4f2c-ac95-c7e5cb3c1f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6a763b93-78c0-4f2c-ac95-c7e5cb3c1f3c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_05c8960e-28b5-4428-b812-4ffe8eef31a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_05c8960e-28b5-4428-b812-4ffe8eef31a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:to="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermAMember_622d3a65-f9ac-42c7-8fba-e7fab14652ae" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermAMember_622d3a65-f9ac-42c7-8fba-e7fab14652ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermBMember_7a4b7634-3b3d-44bc-823b-9d338ec18f2e" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermBMember_7a4b7634-3b3d-44bc-823b-9d338ec18f2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermCMember_f142b571-edde-4b11-8d61-1cf3f8d91e79" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermCMember_f142b571-edde-4b11-8d61-1cf3f8d91e79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermDMember_73c40461-0ed3-4d9d-a469-386a9e56babc" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermDMember_73c40461-0ed3-4d9d-a469-386a9e56babc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_ffbaf1fe-58c5-472d-9daf-ced5160dfd67" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_ffbaf1fe-58c5-472d-9daf-ced5160dfd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fb5b09c-4450-4c2a-9dae-b5470ed801d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fb5b09c-4450-4c2a-9dae-b5470ed801d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c17613b2-6dff-44f4-b3bd-1dbb3bc5b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c17613b2-6dff-44f4-b3bd-1dbb3bc5b27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a097271f-c5f8-4da9-95f1-66d195d81b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c17613b2-6dff-44f4-b3bd-1dbb3bc5b27b" xlink:to="loc_us-gaap_SecuredDebtMember_a097271f-c5f8-4da9-95f1-66d195d81b0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a6594a1-65c5-4f55-8239-028f13470df5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a6594a1-65c5-4f55-8239-028f13470df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88496a7e-5cea-4ef6-985c-a44dc9562957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88496a7e-5cea-4ef6-985c-a44dc9562957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ProfitInterestUnitPIUMember_dff7029f-6234-4832-b94d-adb11f1cc963" xlink:href="inhibrx-20200930.xsd#inhibrx_ProfitInterestUnitPIUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88496a7e-5cea-4ef6-985c-a44dc9562957" xlink:to="loc_inhibrx_ProfitInterestUnitPIUMember_dff7029f-6234-4832-b94d-adb11f1cc963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5341888d-5561-4b96-bb6a-6a1f7b7922dc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:to="loc_srt_RangeMember_5341888d-5561-4b96-bb6a-6a1f7b7922dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:to="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c266bc2-87cc-4501-acd6-d82e44d9bee5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:to="loc_srt_MinimumMember_1c266bc2-87cc-4501-acd6-d82e44d9bee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b6fc3ad8-ccb7-4362-a183-e4c63acaaa7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:to="loc_srt_MaximumMember_b6fc3ad8-ccb7-4362-a183-e4c63acaaa7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ee1fca73-6529-4eb6-8d38-b4692d6c8806_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ee1fca73-6529-4eb6-8d38-b4692d6c8806_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_ef6b24be-f319-408e-a28b-c37884e3e5ad" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:to="loc_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_ef6b24be-f319-408e-a28b-c37884e3e5ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_99328ec5-e97b-4f76-a26c-fab8632d85ea" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:to="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_99328ec5-e97b-4f76-a26c-fab8632d85ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d73cd81f-404d-4920-9abc-61ddad70d094_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:to="loc_us-gaap_VariableRateDomain_d73cd81f-404d-4920-9abc-61ddad70d094_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_48682946-d466-473d-baf8-a19dc8eef32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:to="loc_us-gaap_VariableRateDomain_48682946-d466-473d-baf8-a19dc8eef32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7d87a009-ffef-4803-8528-1e8889ca0198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_48682946-d466-473d-baf8-a19dc8eef32d" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7d87a009-ffef-4803-8528-1e8889ca0198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47ac2f32-4d54-4abf-96e0-137444c58a74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:to="loc_us-gaap_EquityComponentDomain_47ac2f32-4d54-4abf-96e0-137444c58a74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:to="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_2b2227e2-f3b3-4866-9d31-9a4a77b16478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:to="loc_us-gaap_PreferredStockMember_2b2227e2-f3b3-4866-9d31-9a4a77b16478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7b2f38ef-9bd9-4207-851e-da54f248ecfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7b2f38ef-9bd9-4207-851e-da54f248ecfd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="extended" id="ibcb82f5ca146413382922ac67cf55018_DEBTOutstandingDebtBalance2020LoanAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d137765f-60c4-428a-b390-b804c295886b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d137765f-60c4-428a-b390-b804c295886b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8b0216c5-b4a2-44db-90a5-2b9c393bb46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8b0216c5-b4a2-44db-90a5-2b9c393bb46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5fda588e-b14c-46ed-9899-fae000b742e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_LongTermDebt_5fda588e-b14c-46ed-9899-fae000b742e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_aec6de69-f67c-48dc-b31b-a5cd6d552a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_LongTermDebtCurrent_aec6de69-f67c-48dc-b31b-a5cd6d552a5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f30a9b05-c40e-48c3-8c2b-7676973a4c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f30a9b05-c40e-48c3-8c2b-7676973a4c08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9fe834fa-abdd-4505-a8b5-93684a11b618_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9fe834fa-abdd-4505-a8b5-93684a11b618_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09fb29ed-7172-46a1-8204-2a4017f8deae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09fb29ed-7172-46a1-8204-2a4017f8deae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_3ad39a6c-52b7-49ba-a5bb-09b3804bb339" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09fb29ed-7172-46a1-8204-2a4017f8deae" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_3ad39a6c-52b7-49ba-a5bb-09b3804bb339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_721687f9-db97-46f2-b2e8-0c261e070655_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_721687f9-db97-46f2-b2e8-0c261e070655_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2cc649de-952f-4e56-a62f-c0e1081ab854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2cc649de-952f-4e56-a62f-c0e1081ab854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d4adeb03-2a5c-4d27-82af-e8310ef0a46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2cc649de-952f-4e56-a62f-c0e1081ab854" xlink:to="loc_us-gaap_SecuredDebtMember_d4adeb03-2a5c-4d27-82af-e8310ef0a46c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTFutureMinimumPaymentsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="extended" id="ie00a54c228ce42d0a61caa804fb8586c_DEBTFutureMinimumPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9e9e7b2d-1675-475c-871d-a94954b1b26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9e9e7b2d-1675-475c-871d-a94954b1b26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f238c031-8e84-46b6-908e-715e9cf8d89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f238c031-8e84-46b6-908e-715e9cf8d89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bfe098e5-6a0d-4943-b049-34ab745d5c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bfe098e5-6a0d-4943-b049-34ab745d5c13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7cc9df01-43c4-4881-9e27-68af17f71d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7cc9df01-43c4-4881-9e27-68af17f71d08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99318ae3-a4e3-4b25-bed6-84c5d8f05af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99318ae3-a4e3-4b25-bed6-84c5d8f05af6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1f0b4057-a9ac-405f-9475-9867a046ab55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1f0b4057-a9ac-405f-9475-9867a046ab55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f0b7829-2b40-4ba6-85b3-b82c24a30727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f0b7829-2b40-4ba6-85b3-b82c24a30727" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ae474ff8-bc5c-4089-b830-a8e656caad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebt_ae474ff8-bc5c-4089-b830-a8e656caad7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:to="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d68db88a-5fb4-4821-b10f-3e68039d1d53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d68db88a-5fb4-4821-b10f-3e68039d1d53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fd112647-1b8c-4ef5-85ce-b757ecab14f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fd112647-1b8c-4ef5-85ce-b757ecab14f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_1ce1f3b8-2b2a-4371-ba10-7a63fb210645" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd112647-1b8c-4ef5-85ce-b757ecab14f0" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_1ce1f3b8-2b2a-4371-ba10-7a63fb210645" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7aa1e773-f94d-49ff-a35f-a0562ec04ab9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7aa1e773-f94d-49ff-a35f-a0562ec04ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ceed4b5a-49e0-486f-be06-0ab3709234ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ceed4b5a-49e0-486f-be06-0ab3709234ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_94de080a-b98b-43c6-8335-fb6577ba524d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ceed4b5a-49e0-486f-be06-0ab3709234ea" xlink:to="loc_us-gaap_SecuredDebtMember_94de080a-b98b-43c6-8335-fb6577ba524d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/PPPLOAN" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#PPPLOAN"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/PPPLOAN" xlink:type="extended" id="i4b76b30fa91343c9ac9e4bcf83127bf6_PPPLOAN"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/PPPLOANDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#PPPLOANDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/PPPLOANDetails" xlink:type="extended" id="idb7b27f695df4ed78c996a5102c7021d_PPPLOANDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_d04204c4-aefc-476b-9f21-56ab3b1a65f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_d04204c4-aefc-476b-9f21-56ab3b1a65f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_40ad1907-9010-4a6e-9b83-2043e9fd6f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_ShortTermBorrowings_40ad1907-9010-4a6e-9b83-2043e9fd6f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8a5a1086-e385-49a5-ad24-0ce788ae868a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_InterestExpenseDebt_8a5a1086-e385-49a5-ad24-0ce788ae868a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:to="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4a00cc8a-f60f-426f-8cd0-fa6a4987683b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4a00cc8a-f60f-426f-8cd0-fa6a4987683b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_070663ec-4379-4dff-a93c-47946135386c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_070663ec-4379-4dff-a93c-47946135386c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaycheckProtectionProgramCARESActMember_54a548cb-f584-4cfc-87d2-97fa55d4ba0b" xlink:href="inhibrx-20200930.xsd#inhibrx_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_070663ec-4379-4dff-a93c-47946135386c" xlink:to="loc_inhibrx_PaycheckProtectionProgramCARESActMember_54a548cb-f584-4cfc-87d2-97fa55d4ba0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_fb6eb71c-0498-4c74-baf4-956667c3fbc4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_fb6eb71c-0498-4c74-baf4-956667c3fbc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6282c8e6-0042-40f6-96d8-93cb6ca1bb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6282c8e6-0042-40f6-96d8-93cb6ca1bb2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f16a5697-b3c4-4a85-b22b-3e9dc63c18aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6282c8e6-0042-40f6-96d8-93cb6ca1bb2e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f16a5697-b3c4-4a85-b22b-3e9dc63c18aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTES"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES" xlink:type="extended" id="i7564764bbe3f48dcbf2140295855ab67_CONVERTIBLEPROMISSORYNOTES"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables" xlink:type="extended" id="ibcda4c0afdc64a61b97b8794aa982e30_CONVERTIBLEPROMISSORYNOTESTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails" xlink:type="extended" id="i6a1b867f05fd464ab1a485da0ecefcc5_CONVERTIBLEPROMISSORYNOTESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e8147ac4-153c-4942-8ca0-903c67da33be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e8147ac4-153c-4942-8ca0-903c67da33be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1cf5836-251b-498f-8c3f-b3438be9d055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1cf5836-251b-498f-8c3f-b3438be9d055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_71f1d36e-00dd-4ce0-8d44-ef589d5e3310" xlink:href="inhibrx-20200930.xsd#inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_71f1d36e-00dd-4ce0-8d44-ef589d5e3310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_d938492b-6bb7-4277-ac94-bd2a59f85ce3" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_d938492b-6bb7-4277-ac94-bd2a59f85ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c478c1ea-5dcc-445c-9049-1ca3538cda71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_InterestPayableCurrent_c478c1ea-5dcc-445c-9049-1ca3538cda71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_85cf5e71-b5c2-4a1f-a995-99f2eef03e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_LongTermDebt_85cf5e71-b5c2-4a1f-a995-99f2eef03e55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_69b04745-a0d0-4c74-86db-df689c4e4e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_69b04745-a0d0-4c74-86db-df689c4e4e20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_073588f4-490b-4c55-a70c-78a8256f737e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_073588f4-490b-4c55-a70c-78a8256f737e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_bf1492ec-2fa9-427f-9b16-bd7d4b00652f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_bf1492ec-2fa9-427f-9b16-bd7d4b00652f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_413d7594-1f42-4b1f-81da-e4e478605e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DerivativeLiabilities_413d7594-1f42-4b1f-81da-e4e478605e39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ccb07dbb-fea4-4d10-a75e-a6bd5c93fef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ccb07dbb-fea4-4d10-a75e-a6bd5c93fef0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ce3638dc-7cbe-45db-88c3-5b29f2639585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ce3638dc-7cbe-45db-88c3-5b29f2639585" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtIssuanceCostsNetDerivativeLiability_0e9c382b-fc6c-4770-ae1c-5d9c4526eebd" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtIssuanceCostsNetDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_inhibrx_DebtIssuanceCostsNetDerivativeLiability_0e9c382b-fc6c-4770-ae1c-5d9c4526eebd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_01cdf9cc-d701-4803-a557-b428f76c2473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_01cdf9cc-d701-4803-a557-b428f76c2473" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0beaa3ca-2bcd-40c7-a600-c2d79c66375c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0beaa3ca-2bcd-40c7-a600-c2d79c66375c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_659f6366-600b-4b7f-b638-d39e5c08768f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_659f6366-600b-4b7f-b638-d39e5c08768f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ab8acf45-5af5-486e-969d-a5fac3dfc56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ab8acf45-5af5-486e-969d-a5fac3dfc56f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7fd4eabb-f2e8-453e-9f49-3393b7860bea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7fd4eabb-f2e8-453e-9f49-3393b7860bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_e0d3a24b-5194-4733-aa27-2fb698ca3352" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_e0d3a24b-5194-4733-aa27-2fb698ca3352" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_7f839550-cfe7-40a1-9e36-eebbaf10f16c" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_7f839550-cfe7-40a1-9e36-eebbaf10f16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5de769a0-345c-4580-a7b6-32a18b68f129_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5de769a0-345c-4580-a7b6-32a18b68f129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b5643df9-55e7-41ba-b5d0-9d3e37d5b828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b5643df9-55e7-41ba-b5d0-9d3e37d5b828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a4092c40-1e6b-45ca-8567-d736ce5f867d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b5643df9-55e7-41ba-b5d0-9d3e37d5b828" xlink:to="loc_us-gaap_ConvertibleDebtMember_a4092c40-1e6b-45ca-8567-d736ce5f867d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9cc549c9-618e-4214-8eb2-de8daddf6ef6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:to="loc_us-gaap_EquityComponentDomain_9cc549c9-618e-4214-8eb2-de8daddf6ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac2dbae3-b75d-4df9-8af2-0dcbc2c9cd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:to="loc_us-gaap_EquityComponentDomain_ac2dbae3-b75d-4df9-8af2-0dcbc2c9cd57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5dbe5bcf-9b9c-4d74-b647-3def97c356b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ac2dbae3-b75d-4df9-8af2-0dcbc2c9cd57" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5dbe5bcf-9b9c-4d74-b647-3def97c356b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" xlink:type="extended" id="i19ddc04adfee4bf1875786922e6431bb_CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_706957d4-c49a-45ab-bb98-77da9c535a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_706957d4-c49a-45ab-bb98-77da9c535a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3d4c057-92b9-4c66-8228-3e66a687ae10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3d4c057-92b9-4c66-8228-3e66a687ae10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6fac5a23-d9d8-4907-ace0-ca73684c3c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_LongTermDebt_6fac5a23-d9d8-4907-ace0-ca73684c3c8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4622699d-56c5-4cd5-a350-d5f8a9acfb3e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4622699d-56c5-4cd5-a350-d5f8a9acfb3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_193c0af4-339a-4700-a007-202199639206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_193c0af4-339a-4700-a007-202199639206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a69a1bac-0deb-4b23-8419-3390a500557e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_193c0af4-339a-4700-a007-202199639206" xlink:to="loc_us-gaap_ConvertibleDebtMember_a69a1bac-0deb-4b23-8419-3390a500557e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="ia278eaf5f81b4ed9948cf904cb62a9a9_STOCKHOLDERSEQUITYDEFICIT"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended" id="i32ff529cd3be43259eb442373350501c_STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended" id="i2c49dd8c3c2940e79d064ae54c29e578_STOCKHOLDERSEQUITYDEFICITDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3c3737a2-3351-44a8-b9a9-0e0dad9a5513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3c3737a2-3351-44a8-b9a9-0e0dad9a5513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_36c08158-f117-416f-8762-5dd8453d85d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_36c08158-f117-416f-8762-5dd8453d85d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_99cefb65-c17f-45c5-8d64-f447c24be097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_99cefb65-c17f-45c5-8d64-f447c24be097" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_52211585-84d5-42e6-b4f0-404395525f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_52211585-84d5-42e6-b4f0-404395525f22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_94b616c2-31f1-44cd-9dbe-add38ef950b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_94b616c2-31f1-44cd-9dbe-add38ef950b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_02f32813-3f1d-4c27-bf21-b30853ad878f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_02f32813-3f1d-4c27-bf21-b30853ad878f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6f69d70f-c779-4524-8dd3-a9771b54b2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6f69d70f-c779-4524-8dd3-a9771b54b2ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3b9bb7be-71f6-4211-aa4c-a4334856fa7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_SharePrice_3b9bb7be-71f6-4211-aa4c-a4334856fa7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_8c355e64-0301-47ce-bd58-1bbeabbfbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_8c355e64-0301-47ce-bd58-1bbeabbfbce0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0e403c2-b54d-4b9d-971d-017392e8dd64" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0e403c2-b54d-4b9d-971d-017392e8dd64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a0a2b664-edfd-4233-8240-e1dec926bddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a0a2b664-edfd-4233-8240-e1dec926bddc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ee8f9f6b-0d8e-49b0-a115-f9334c094de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ee8f9f6b-0d8e-49b0-a115-f9334c094de6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8371c277-0a68-4ade-b704-c4aa4beac026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8371c277-0a68-4ade-b704-c4aa4beac026" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b39c80d-056f-4526-9562-ee62b631dd44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b39c80d-056f-4526-9562-ee62b631dd44" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_43804640-5f76-4ede-a839-9e271a8dfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_43804640-5f76-4ede-a839-9e271a8dfa38" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1c1d1a39-78fb-4932-a36c-8d17f48effff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:to="loc_us-gaap_ClassOfStockDomain_1c1d1a39-78fb-4932-a36c-8d17f48effff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:to="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine1PreferredStockMember_248bfcb1-3ee4-4e08-99f8-943dade4c7f0" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:to="loc_inhibrx_SeriesMezzanine1PreferredStockMember_248bfcb1-3ee4-4e08-99f8-943dade4c7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine2PreferredStockMember_c0ee1bdc-b7ba-445a-a00b-4a8690b88eaf" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine2PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:to="loc_inhibrx_SeriesMezzanine2PreferredStockMember_c0ee1bdc-b7ba-445a-a00b-4a8690b88eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1ce4b52-b653-4b81-a9d2-7859d8260b14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:to="loc_us-gaap_EquityComponentDomain_f1ce4b52-b653-4b81-a9d2-7859d8260b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:to="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d0b32a64-dc73-455d-aa04-96e81c040576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:to="loc_us-gaap_CommonStockMember_d0b32a64-dc73-455d-aa04-96e81c040576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41063370-d736-44b5-a3ae-1b972f239d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41063370-d736-44b5-a3ae-1b972f239d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d98fe136-c311-4f44-b73a-a8f5d37e1c39_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d98fe136-c311-4f44-b73a-a8f5d37e1c39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2be8e64-bf68-4a9a-832d-0fba0f286807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2be8e64-bf68-4a9a-832d-0fba0f286807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_78438a24-b2c1-4538-8425-5330c0aaf2ae" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2be8e64-bf68-4a9a-832d-0fba0f286807" xlink:to="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_78438a24-b2c1-4538-8425-5330c0aaf2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba30aafc-8141-42a6-8e3d-daba9901f539_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba30aafc-8141-42a6-8e3d-daba9901f539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_17c931cc-0252-4089-98ac-f1d579ed5874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_17c931cc-0252-4089-98ac-f1d579ed5874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_93d11dfa-4764-4324-9ee1-9417c9295307" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_17c931cc-0252-4089-98ac-f1d579ed5874" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_93d11dfa-4764-4324-9ee1-9417c9295307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_72769f69-93fe-4650-ab2d-b5a2b454491b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_72769f69-93fe-4650-ab2d-b5a2b454491b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5e7f44c-6ce9-4afe-b56f-4de0e3919c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5e7f44c-6ce9-4afe-b56f-4de0e3919c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_31450a93-76b2-4514-ae1e-c9cf14911fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d5e7f44c-6ce9-4afe-b56f-4de0e3919c1b" xlink:to="loc_us-gaap_SecuredDebtMember_31450a93-76b2-4514-ae1e-c9cf14911fce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANS"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="extended" id="ie7428649389d4b5e8b6ed41342bdd6d7_EQUITYCOMPENSATIONPLANS"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="extended" id="i7e35f3d825534c719e5cc481774d73b2_EQUITYCOMPENSATIONPLANSTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="extended" id="i03e3d6ab001a4186a317291a8b193968_EQUITYCOMPENSATIONPLANSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationNumberOfPlans_acf908bd-f7a7-4111-8d22-efa07d96b0fb" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationNumberOfPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_inhibrx_ShareBasedCompensationNumberOfPlans_acf908bd-f7a7-4111-8d22-efa07d96b0fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_95b164b9-ab15-4eac-aaad-11883e6c3a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_95b164b9-ab15-4eac-aaad-11883e6c3a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8ac87d7f-33aa-4ed6-8901-c26970d8ff5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8ac87d7f-33aa-4ed6-8901-c26970d8ff5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_998b6317-841c-44a3-bfd3-7065894a8f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_998b6317-841c-44a3-bfd3-7065894a8f31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_69d9ea1d-0552-4bc1-8d67-6d372b4d5cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_69d9ea1d-0552-4bc1-8d67-6d372b4d5cdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bedbff-df8b-4524-97c0-12b14f1a98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bedbff-df8b-4524-97c0-12b14f1a98f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9d79890b-3617-48d9-83e9-824012961d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9d79890b-3617-48d9-83e9-824012961d42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:to="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_81c1887c-aa33-4e03-8985-542989661781_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:to="loc_us-gaap_VestingDomain_81c1887c-aa33-4e03-8985-542989661781_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f57a5422-ae36-4b6f-af90-904249dde2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:to="loc_us-gaap_VestingDomain_f57a5422-ae36-4b6f-af90-904249dde2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a2b7ab52-8761-41b1-a8ea-5c558b227445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f57a5422-ae36-4b6f-af90-904249dde2c4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a2b7ab52-8761-41b1-a8ea-5c558b227445" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:to="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3a021b-bafa-4fe5-8a4c-83daece0aa58_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3a021b-bafa-4fe5-8a4c-83daece0aa58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67c847ba-19ad-49ae-9043-4e9473f42d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67c847ba-19ad-49ae-9043-4e9473f42d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_640c7de8-c155-49d4-9371-778f05de3476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67c847ba-19ad-49ae-9043-4e9473f42d88" xlink:to="loc_us-gaap_EmployeeStockOptionMember_640c7de8-c155-49d4-9371-778f05de3476" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="extended" id="ia2bee88d4ac540ec82077ec2d8f35615_EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="extended" id="idbc8ca0cd52d4ddbbe69002b080b32c6_EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34185745-d7f7-4b02-a71c-88eb0cae6605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34185745-d7f7-4b02-a71c-88eb0cae6605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee6ad9f4-da33-4d97-82ab-5df801639a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee6ad9f4-da33-4d97-82ab-5df801639a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6c74439-740f-4abd-b0bc-66d8217ef026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6c74439-740f-4abd-b0bc-66d8217ef026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc94c15-9a1f-4628-978b-cc2d13ff9e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc94c15-9a1f-4628-978b-cc2d13ff9e3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa7355f-8563-4302-be92-39d6c96fc2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa7355f-8563-4302-be92-39d6c96fc2dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:to="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fed0ad57-a0cf-4f1d-af24-e30207c1f494_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fed0ad57-a0cf-4f1d-af24-e30207c1f494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b520d69-b294-430d-baea-3fa675dfec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b520d69-b294-430d-baea-3fa675dfec3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_745262a0-e897-451f-a876-9069a7bd26c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b520d69-b294-430d-baea-3fa675dfec3f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_745262a0-e897-451f-a876-9069a7bd26c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="extended" id="i1216e81043134706ac03d42b2d64c8cf_EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4882659b-c94d-4277-bd0d-b6304fe701ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f330464-6bff-43fa-ae2b-83099342f0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4882659b-c94d-4277-bd0d-b6304fe701ac" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f330464-6bff-43fa-ae2b-83099342f0b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4882659b-c94d-4277-bd0d-b6304fe701ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b1eaab57-dd55-46b1-958a-0d8660123a54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b1eaab57-dd55-46b1-958a-0d8660123a54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0f7e1031-4560-4882-8487-c7b133d6efd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0f7e1031-4560-4882-8487-c7b133d6efd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dbb50a7b-7db8-46cd-b116-2b1f4ad5d023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dbb50a7b-7db8-46cd-b116-2b1f4ad5d023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:to="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_799b3d45-818c-45c3-9024-7db92d27b060_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_799b3d45-818c-45c3-9024-7db92d27b060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dd548fa-2fa3-48d8-aa11-6e642b38ccdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dd548fa-2fa3-48d8-aa11-6e642b38ccdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5d82cc1d-ad57-4094-b65a-cd0c5109f754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dd548fa-2fa3-48d8-aa11-6e642b38ccdb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5d82cc1d-ad57-4094-b65a-cd0c5109f754" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUES"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES" xlink:type="extended" id="i19797222fa0044d48ec1f1e0a6f16c00_LICENSEANDGRANTREVENUES"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="extended" id="i95e64ef675054597a0333a6d51812636_LICENSEANDGRANTREVENUESTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESRevenueSummaryDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="extended" id="idb79b3ac82e9408aaf19535024d963b9_LICENSEANDGRANTREVENUESRevenueSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aac611d5-200b-44d4-968f-dfabed4bbe24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8394d94f-5fbf-48f1-86fc-dcf2f24bdda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aac611d5-200b-44d4-968f-dfabed4bbe24" xlink:to="loc_us-gaap_Revenues_8394d94f-5fbf-48f1-86fc-dcf2f24bdda7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aac611d5-200b-44d4-968f-dfabed4bbe24" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:to="loc_srt_ProductsAndServicesDomain_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:to="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember_ae0e77e2-e1b7-4d80-894b-bf1d409ec8c8" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:to="loc_inhibrx_LicenseAffiliateMember_ae0e77e2-e1b7-4d80-894b-bf1d409ec8c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseNonAffiliateMember_c85f862f-d79c-4122-8c11-eddb608bbf9d" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:to="loc_inhibrx_LicenseNonAffiliateMember_c85f862f-d79c-4122-8c11-eddb608bbf9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_23a77973-dd68-4afe-9c7a-83248fac6213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:to="loc_us-gaap_GrantMember_23a77973-dd68-4afe-9c7a-83248fac6213" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d602b9aa-761e-4de4-a86f-bf0cedc26ab2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:to="loc_srt_NameOfMajorCustomerDomain_d602b9aa-761e-4de4-a86f-bf0cedc26ab2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:to="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember_e1ad625a-a8d1-4d94-b504-0baff1d0cf79" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_TranscentaHoldingLtdMember_e1ad625a-a8d1-4d94-b504-0baff1d0cf79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_a4bf3cd2-9038-48cb-a8e6-322b8ff76c63" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_a4bf3cd2-9038-48cb-a8e6-322b8ff76c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember_79bf3152-fcce-4b41-ab3e-fa1a93da9506" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_PhylaxisBioScienceLLCMember_79bf3152-fcce-4b41-ab3e-fa1a93da9506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BluebirdBioIncMember_7a421fb8-f11a-4086-bd98-0fb7786837df" xlink:href="inhibrx-20200930.xsd#inhibrx_BluebirdBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_BluebirdBioIncMember_7a421fb8-f11a-4086-bd98-0fb7786837df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ChiesiFarmaceuticiSpAMember_aea566b3-ad5b-4461-9bed-1b655604e21b" xlink:href="inhibrx-20200930.xsd#inhibrx_ChiesiFarmaceuticiSpAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_ChiesiFarmaceuticiSpAMember_aea566b3-ad5b-4461-9bed-1b655604e21b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_9a93e09e-bac1-430b-9df1-22a898b4c103" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherCustomersNotSeparatelyDisclosedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_9a93e09e-bac1-430b-9df1-22a898b4c103" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7ac031d-379d-4923-a681-65b122bed7c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7ac031d-379d-4923-a681-65b122bed7c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NationalInstitutesOfHealthMember_19b1f3c2-57bb-4756-95cc-66a4a3010529" xlink:href="inhibrx-20200930.xsd#inhibrx_NationalInstitutesOfHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:to="loc_inhibrx_NationalInstitutesOfHealthMember_19b1f3c2-57bb-4756-95cc-66a4a3010529" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_ae497f2e-072d-4835-a87c-03bf9803ec19" xlink:href="inhibrx-20200930.xsd#inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:to="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_ae497f2e-072d-4835-a87c-03bf9803ec19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_8ce92b0b-ee9d-4274-936b-eafc268dcf52" xlink:href="inhibrx-20200930.xsd#inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:to="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_8ce92b0b-ee9d-4274-936b-eafc268dcf52" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="extended" id="i3accd369a5084a0b9583ac9aeead6dde_LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_7a17b4f7-d064-4f55-aa8d-4393ef361fff" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_7a17b4f7-d064-4f55-aa8d-4393ef361fff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_5052b1f9-cb36-47a2-8c0b-c9a5585a7055" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementAdditionalPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_5052b1f9-cb36-47a2-8c0b-c9a5585a7055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_987d0210-353c-40f7-b79d-80031440170d" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_987d0210-353c-40f7-b79d-80031440170d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3bb95a20-dd8a-42c2-befb-713dec7154ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3bb95a20-dd8a-42c2-befb-713dec7154ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_9c43878c-e760-4745-97a3-0b587a3889af" xlink:href="inhibrx-20200930.xsd#inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_9c43878c-e760-4745-97a3-0b587a3889af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_2324861c-ceff-4eb4-9b98-74cfe5b3e30e" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_2324861c-ceff-4eb4-9b98-74cfe5b3e30e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_9990712f-96f1-47f8-856f-cc98c122f1c1" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_9990712f-96f1-47f8-856f-cc98c122f1c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c9e785a2-b44e-4c85-b19c-87f0d83447cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_EquityMethodInvestments_c9e785a2-b44e-4c85-b19c-87f0d83447cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementPaymentReceivable_98bec887-c1cb-4c61-8a11-34092db8c52c" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementPaymentReceivable_98bec887-c1cb-4c61-8a11-34092db8c52c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfPerformanceObligations_1ce2f400-2011-42bd-8562-26f1902a733d" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_NumberOfPerformanceObligations_1ce2f400-2011-42bd-8562-26f1902a733d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RevenueRecognitionNumberOfCompounds_582d0453-338b-4763-b13f-22681c77334a" xlink:href="inhibrx-20200930.xsd#inhibrx_RevenueRecognitionNumberOfCompounds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_RevenueRecognitionNumberOfCompounds_582d0453-338b-4763-b13f-22681c77334a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f21475c6-acf4-42aa-8fe2-0e26cd08c383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f21475c6-acf4-42aa-8fe2-0e26cd08c383" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_609d103f-5e8e-427e-8a07-deb383f725be" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_609d103f-5e8e-427e-8a07-deb383f725be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_d801519f-98d9-486d-a2b1-da0d2c739657" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_d801519f-98d9-486d-a2b1-da0d2c739657" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf6d70e5-9d82-4a3d-9358-e0bc98ce355a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_Revenues_cf6d70e5-9d82-4a3d-9358-e0bc98ce355a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_fc8d8eca-98cb-4ca9-b568-a4d87aa61cbd" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_fc8d8eca-98cb-4ca9-b568-a4d87aa61cbd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_42f02c78-cf56-44ba-b594-47f3d4865bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_42f02c78-cf56-44ba-b594-47f3d4865bfe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfLicenseAgreements_7f1237db-91a3-481a-9498-5577788985fa" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_NumberOfLicenseAgreements_7f1237db-91a3-481a-9498-5577788985fa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementExpenseReimbursement_49fe7ca8-9031-4c5b-b6c6-66aba52e2ca8" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementExpenseReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementExpenseReimbursement_49fe7ca8-9031-4c5b-b6c6-66aba52e2ca8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d7a3a1ea-50fc-423f-a3b6-34643bab7776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d7a3a1ea-50fc-423f-a3b6-34643bab7776" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_59d98e0e-69a2-43b8-9adc-19c9dbd5d8c7" xlink:href="inhibrx-20200930.xsd#inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_59d98e0e-69a2-43b8-9adc-19c9dbd5d8c7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_21acaf73-ba70-4b8c-8885-ebb82790fcf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_21acaf73-ba70-4b8c-8885-ebb82790fcf4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementForeignTaxWithholding_863c5be6-51ce-49cf-98c5-0822ac6c92b9" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementForeignTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementForeignTaxWithholding_863c5be6-51ce-49cf-98c5-0822ac6c92b9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_77e8eb03-8c6c-4829-9b48-b62fa05172d9" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_77e8eb03-8c6c-4829-9b48-b62fa05172d9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_290bcf25-6386-4d98-b3b0-db2b1aa12241_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:to="loc_srt_NameOfMajorCustomerDomain_290bcf25-6386-4d98-b3b0-db2b1aa12241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:to="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember_5e214378-f07b-42de-948b-350b38b4f0dc" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_PhylaxisBioScienceLLCMember_5e214378-f07b-42de-948b-350b38b4f0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BluebirdBioIncMember_01475fcc-b481-4c0e-a2c6-8cc5d6055409" xlink:href="inhibrx-20200930.xsd#inhibrx_BluebirdBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_BluebirdBioIncMember_01475fcc-b481-4c0e-a2c6-8cc5d6055409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ChiesiFarmaceuticiSpAMember_33596b16-d2fa-4540-950b-c4fafb2d9e58" xlink:href="inhibrx-20200930.xsd#inhibrx_ChiesiFarmaceuticiSpAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_ChiesiFarmaceuticiSpAMember_33596b16-d2fa-4540-950b-c4fafb2d9e58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_60b93b54-34c2-4c13-bc73-64fb0304ddea" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_60b93b54-34c2-4c13-bc73-64fb0304ddea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember_ce7acb9f-8d99-4863-9441-552c96d4cdd1" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_TranscentaHoldingLtdMember_ce7acb9f-8d99-4863-9441-552c96d4cdd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CelgeneMember_0e736880-7548-4f6d-8070-149dfeb857ef" xlink:href="inhibrx-20200930.xsd#inhibrx_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_CelgeneMember_0e736880-7548-4f6d-8070-149dfeb857ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0388b4f1-a837-467f-b1b9-a31d41b43bbc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0388b4f1-a837-467f-b1b9-a31d41b43bbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_76b78ca7-d09c-47ac-8633-d71c46356da5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_76b78ca7-d09c-47ac-8633-d71c46356da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember_96c8d7ae-e764-4a40-8e56-03a1e1587f76" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_76b78ca7-d09c-47ac-8633-d71c46356da5" xlink:to="loc_inhibrx_PhylaxisBioScienceLLCMember_96c8d7ae-e764-4a40-8e56-03a1e1587f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_060ae547-8954-4242-9bca-27bf3973af25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_060ae547-8954-4242-9bca-27bf3973af25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:to="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_a6e35c5b-60a7-43a4-8224-9f89437b99f5" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:to="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_a6e35c5b-60a7-43a4-8224-9f89437b99f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_798253b4-52a9-4acc-8968-eec2be97c9ef" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:to="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_798253b4-52a9-4acc-8968-eec2be97c9ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_b45476d3-807d-4602-865f-963062cf69a7" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:to="loc_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_b45476d3-807d-4602-865f-963062cf69a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9cbf643d-3d28-4cd2-809f-86b3f3801813_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:to="loc_srt_ProductsAndServicesDomain_9cbf643d-3d28-4cd2-809f-86b3f3801813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:to="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseNonAffiliateMember_90fbd76e-5f9f-462d-ba5e-c539d37a60e7" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:to="loc_inhibrx_LicenseNonAffiliateMember_90fbd76e-5f9f-462d-ba5e-c539d37a60e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:to="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_8398dcd2-c522-4332-886c-cc8a23a10f4c" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:to="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_8398dcd2-c522-4332-886c-cc8a23a10f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_16043cfc-4b87-41e4-ade9-7e1cca8151dd" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:to="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_16043cfc-4b87-41e4-ade9-7e1cca8151dd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESGovernmentGrantsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="extended" id="ie2647a087d824c6199ec9d1717e5a5d4_LICENSEANDGRANTREVENUESGovernmentGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantValuedAwarded_97ffc188-6af2-452d-ace3-49995b029360" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantValuedAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_inhibrx_GrantValuedAwarded_97ffc188-6af2-452d-ace3-49995b029360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_be278da6-5435-430f-8186-8a60f5029fd7" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_be278da6-5435-430f-8186-8a60f5029fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_1b5fb786-dffc-4666-85e4-45554490b181" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_1b5fb786-dffc-4666-85e4-45554490b181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_569dcad3-9362-46c5-b10c-d7be5bb4bb81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_us-gaap_Revenues_569dcad3-9362-46c5-b10c-d7be5bb4bb81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:to="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1bc76264-f291-4863-9e4e-c974be1b9b58_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:to="loc_srt_ProductsAndServicesDomain_1bc76264-f291-4863-9e4e-c974be1b9b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fcab63ee-da3b-44b8-ad4f-1267c270656b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:to="loc_srt_ProductsAndServicesDomain_fcab63ee-da3b-44b8-ad4f-1267c270656b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_79d2f846-2399-4d86-8f7c-651d3befed19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fcab63ee-da3b-44b8-ad4f-1267c270656b" xlink:to="loc_us-gaap_GrantMember_79d2f846-2399-4d86-8f7c-651d3befed19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:to="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ebddb0f-0115-468f-bdd5-d40bfcd42440_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ebddb0f-0115-468f-bdd5-d40bfcd42440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NationalInstitutesOfHealthMember_2dad472d-10f1-4df7-b989-9ce5f8e006d6" xlink:href="inhibrx-20200930.xsd#inhibrx_NationalInstitutesOfHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_NationalInstitutesOfHealthMember_2dad472d-10f1-4df7-b989-9ce5f8e006d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_439f4798-27d5-4e62-b172-7dd8238eda62" xlink:href="inhibrx-20200930.xsd#inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_439f4798-27d5-4e62-b172-7dd8238eda62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_e2ebaaff-c7ad-4e84-ace9-3fb086e4ffbb" xlink:href="inhibrx-20200930.xsd#inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_e2ebaaff-c7ad-4e84-ace9-3fb086e4ffbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_0dc3d070-ef7a-48db-a463-a64fc8270654" xlink:href="inhibrx-20200930.xsd#inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_0dc3d070-ef7a-48db-a463-a64fc8270654" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended" id="ib8102a1f5cad405ba840b3970f712494_RELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i6e82d0dd93924d9aa35f0b2263ffd385_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RelatedPartyEquityInterestInCompany_9f01e685-a779-4da0-a5d6-0af209a2dcc6" xlink:href="inhibrx-20200930.xsd#inhibrx_RelatedPartyEquityInterestInCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_inhibrx_RelatedPartyEquityInterestInCompany_9f01e685-a779-4da0-a5d6-0af209a2dcc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ebb8b647-f682-4b39-98b8-b267829bb95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_Revenues_ebb8b647-f682-4b39-98b8-b267829bb95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ExpensesReimbursedToDate_b219eab3-115a-4a13-a7d1-8d9b981e65f9" xlink:href="inhibrx-20200930.xsd#inhibrx_ExpensesReimbursedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_inhibrx_ExpensesReimbursedToDate_b219eab3-115a-4a13-a7d1-8d9b981e65f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_cf7b41d4-ac38-4de0-bb6d-a7d6c6626c12" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_cf7b41d4-ac38-4de0-bb6d-a7d6c6626c12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bcaa8ea5-0ccc-4383-a8d4-5c8255b2427c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_SharePrice_bcaa8ea5-0ccc-4383-a8d4-5c8255b2427c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c16c5816-1ff3-4c45-890c-df9b5a1ba905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c16c5816-1ff3-4c45-890c-df9b5a1ba905" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_08f634c5-06b7-4014-8741-95b2ce7668d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:to="loc_us-gaap_RelatedPartyDomain_08f634c5-06b7-4014-8741-95b2ce7668d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24384ae4-6ef3-43b8-94f1-3ade800e7863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:to="loc_us-gaap_RelatedPartyDomain_24384ae4-6ef3-43b8-94f1-3ade800e7863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b29b19d9-3c56-4560-bf92-d4e3b202c1b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_24384ae4-6ef3-43b8-94f1-3ade800e7863" xlink:to="loc_srt_AffiliatedEntityMember_b29b19d9-3c56-4560-bf92-d4e3b202c1b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2e11369-4be9-468e-9163-7458dfcc153b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2e11369-4be9-468e-9163-7458dfcc153b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LAVSummitLimitedMember_1d503d61-1058-4dda-9ae7-9b83f836d9c5" xlink:href="inhibrx-20200930.xsd#inhibrx_LAVSummitLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:to="loc_inhibrx_LAVSummitLimitedMember_1d503d61-1058-4dda-9ae7-9b83f836d9c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_0ed91f7c-27d4-4ab9-af8b-c78e872eff8d" xlink:href="inhibrx-20200930.xsd#inhibrx_WuXiBiologicsHealthcareVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:to="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_0ed91f7c-27d4-4ab9-af8b-c78e872eff8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_69901fa3-7208-43b5-a7cf-b51db96a8819_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:to="loc_srt_NameOfMajorCustomerDomain_69901fa3-7208-43b5-a7cf-b51db96a8819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:to="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember_77083d2a-9348-419b-94c7-4ce818e198f1" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:to="loc_inhibrx_TranscentaHoldingLtdMember_77083d2a-9348-419b-94c7-4ce818e198f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_f31a755f-d6c7-4467-9ef3-be087d91eb59" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:to="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_f31a755f-d6c7-4467-9ef3-be087d91eb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_443a8192-3ba6-42f1-9d97-8085b149cf5a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:to="loc_srt_ProductsAndServicesDomain_443a8192-3ba6-42f1-9d97-8085b149cf5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:to="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember_4cb491c2-4ba7-441c-9511-99b0043ecc46" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:to="loc_inhibrx_LicenseAffiliateMember_4cb491c2-4ba7-441c-9511-99b0043ecc46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_9671915b-50e7-4ae4-b2e8-73eef88c851a" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:to="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_9671915b-50e7-4ae4-b2e8-73eef88c851a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_ff6a6bab-a3bc-47fc-b7d6-0562bf17d115" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:to="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_ff6a6bab-a3bc-47fc-b7d6-0562bf17d115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ea6a4a43-341f-4c40-9292-42e0f6b883e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:to="loc_us-gaap_ClassOfStockDomain_ea6a4a43-341f-4c40-9292-42e0f6b883e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_058f1a4c-cb5c-418b-9749-35291a38513b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:to="loc_us-gaap_ClassOfStockDomain_058f1a4c-cb5c-418b-9749-35291a38513b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine2PreferredStockMember_5d17cde7-0f84-40b3-9ce9-a17d324338b6" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine2PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_058f1a4c-cb5c-418b-9749-35291a38513b" xlink:to="loc_inhibrx_SeriesMezzanine2PreferredStockMember_5d17cde7-0f84-40b3-9ce9-a17d324338b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i1c2ea62c406449d2bb60371c20183cf4_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended" id="i5da7715f0e3c4b92aacc6b66f39e0745_COMMITMENTSANDCONTINGENCIESTables"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ib85ec59773644d209362baf873d920d1_COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="extended" id="ic84608d12ceb47c4b55a6adb0e243d74_COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended" id="iff7d4b15c36941d3bb46b3adae51e885_COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COVID19" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COVID19"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/COVID19" xlink:type="extended" id="i8f22f4232b5f40919d3e705826c2afde_COVID19"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#SUBSEQUENTEVENTS"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS" xlink:type="extended" id="ic439bf86eb3f4baf93893a4dae8cf881_SUBSEQUENTEVENTS"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i01eaba9f12e64b69a12a6e63f8126ba7_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_a0e88b00-c77c-4a0c-ab3a-0d4b378a4a48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_InterestPayableCurrent_a0e88b00-c77c-4a0c-ab3a-0d4b378a4a48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_6660620e-7081-4a3f-922d-e754abfc3d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_6660620e-7081-4a3f-922d-e754abfc3d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8a397eb2-85d8-44c6-a4d7-dc0ead991496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8a397eb2-85d8-44c6-a4d7-dc0ead991496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_933ed5b6-45cb-40b1-b92e-8165d7c7edf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_933ed5b6-45cb-40b1-b92e-8165d7c7edf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestRateFloor_d19d5b7d-aacc-4e22-b1ba-80a0040d3674" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentInterestRateFloor_d19d5b7d-aacc-4e22-b1ba-80a0040d3674" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_40c992a9-310e-4b53-a71f-a950c7eef0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_40c992a9-310e-4b53-a71f-a950c7eef0fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_e2edb4d3-e58f-4481-a9cf-db15033babcd" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_e2edb4d3-e58f-4481-a9cf-db15033babcd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_d9d0fa3c-ed81-482f-94d5-9448ea8b7ea0" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_d9d0fa3c-ed81-482f-94d5-9448ea8b7ea0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_b0b62002-bc29-4b9b-a080-65aeef2e2788" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_b0b62002-bc29-4b9b-a080-65aeef2e2788" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_30a9febf-c8c8-4685-93cb-c0375578b5fd" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_30a9febf-c8c8-4685-93cb-c0375578b5fd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPrepaymentFee_5c4f8b78-c4fd-451d-a9bd-d603183ac6fa" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentPrepaymentFee_5c4f8b78-c4fd-451d-a9bd-d603183ac6fa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f4874c34-c6ba-45b6-a33b-850fe291240b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f4874c34-c6ba-45b6-a33b-850fe291240b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a6529caf-7765-4cd3-9d40-9d3e9d1c2f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a6529caf-7765-4cd3-9d40-9d3e9d1c2f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_63d1ea6e-3e5c-4c99-ae88-eb72b79b2b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a6529caf-7765-4cd3-9d40-9d3e9d1c2f97" xlink:to="loc_us-gaap_SubsequentEventMember_63d1ea6e-3e5c-4c99-ae88-eb72b79b2b49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_0a03db76-bffe-4383-8efe-bdda9891ce50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_0a03db76-bffe-4383-8efe-bdda9891ce50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7f890fbd-50a7-4b64-90ff-efb9a2c73b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7f890fbd-50a7-4b64-90ff-efb9a2c73b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_d311c49b-8737-495a-90b3-9c9fc299f5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7f890fbd-50a7-4b64-90ff-efb9a2c73b54" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_d311c49b-8737-495a-90b3-9c9fc299f5da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b9fb90a0-aac6-4443-badf-a12f1ea2a66d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b9fb90a0-aac6-4443-badf-a12f1ea2a66d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94379f90-8227-401e-8625-33f248ede893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94379f90-8227-401e-8625-33f248ede893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b43f8782-cefc-4d6d-acb0-c192915cd602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_94379f90-8227-401e-8625-33f248ede893" xlink:to="loc_us-gaap_SecuredDebtMember_b43f8782-cefc-4d6d-acb0-c192915cd602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4ee63d05-513e-4550-8ed6-b158f75c2fad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4ee63d05-513e-4550-8ed6-b158f75c2fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaycheckProtectionProgramCARESActMember_d6fe824f-cc82-43dc-9b0d-cade2f6b6a06" xlink:href="inhibrx-20200930.xsd#inhibrx_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:to="loc_inhibrx_PaycheckProtectionProgramCARESActMember_d6fe824f-cc82-43dc-9b0d-cade2f6b6a06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_b187f447-f628-45a9-9118-04736bb75743" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTranchesBAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_b187f447-f628-45a9-9118-04736bb75743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTrancheBMember_9cf437d7-3ca8-483a-aff5-40ee14c22399" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansTrancheBMember_9cf437d7-3ca8-483a-aff5-40ee14c22399" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTrancheCMember_e3562a6e-7f42-489a-b681-e3ba141a2c5c" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansTrancheCMember_e3562a6e-7f42-489a-b681-e3ba141a2c5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansFirstTrancheMember_9f7bb47d-5f82-4a00-b1ca-1dd9744346d8" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansFirstTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansFirstTrancheMember_9f7bb47d-5f82-4a00-b1ca-1dd9744346d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6cb50d17-329e-4796-8e52-d2e2df102a82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:to="loc_us-gaap_VariableRateDomain_6cb50d17-329e-4796-8e52-d2e2df102a82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b35f93b0-10ca-4fdd-84bd-d1eb29ab8065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:to="loc_us-gaap_VariableRateDomain_b35f93b0-10ca-4fdd-84bd-d1eb29ab8065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2680578c-0664-4125-962a-687b7970e7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b35f93b0-10ca-4fdd-84bd-d1eb29ab8065" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2680578c-0664-4125-962a-687b7970e7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60f75807-6c83-4923-bf87-3d02048ad8fd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:to="loc_srt_RangeMember_60f75807-6c83-4923-bf87-3d02048ad8fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:to="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65dc86ab-62f4-4462-ac4a-50b0b0fa52e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:to="loc_srt_MinimumMember_65dc86ab-62f4-4462-ac4a-50b0b0fa52e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_16818c2e-0a9f-42d0-8baf-5ca1f7424f70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:to="loc_srt_MaximumMember_16818c2e-0a9f-42d0-8baf-5ca1f7424f70" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>inhibrx-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:3fe0b274-dc64-47fa-9492-4cc4ecb00ef6,g:c0dac7ab-748b-42c9-8c2a-26a240098d0f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_13bda14d-301a-454f-8f95-49e03a3a145a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_eaec8fe4-4d4f-4c4d-bd75-d57b82f5a642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4fc711ff-944b-44bd-acd4-43ada2033e80_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_865a7314-d5d5-4259-8116-a251eb1a6400_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGGREGATE INTRINSIC VALUE</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f605a4cf-fdf5-45cf-8c5f-0e237b5b9fd8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_55ede042-a392-42f2-a154-5af686690c8a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17c1d65e-c370-46f6-bb13-deb590bda9c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5f530e7-445f-4fa5-987f-285fb5fd6f94_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_e7cc7361-fd3a-4704-9b98-7e30df2dd635_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount related to derivative liabilities</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_08a67b2b-8a9e-4455-baa1-35c0972dcc90_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_fc13903f-bd45-4ddd-9753-73acfc94e343_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_715c9085-ab25-49bc-8672-5e27e81cb1ec_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment receivable period</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable Period</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:to="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_RevenueRecognitionNumberOfCompounds_f8f582d5-3a5d-47bb-b3e4-3f44f7297fd1_terseLabel_en-US" xlink:label="lab_inhibrx_RevenueRecognitionNumberOfCompounds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of compounds</link:label>
    <link:label id="lab_inhibrx_RevenueRecognitionNumberOfCompounds_label_en-US" xlink:label="lab_inhibrx_RevenueRecognitionNumberOfCompounds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Number Of Compounds</link:label>
    <link:label id="lab_inhibrx_RevenueRecognitionNumberOfCompounds_documentation_en-US" xlink:label="lab_inhibrx_RevenueRecognitionNumberOfCompounds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Number Of Compounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RevenueRecognitionNumberOfCompounds" xlink:href="inhibrx-20200930.xsd#inhibrx_RevenueRecognitionNumberOfCompounds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_RevenueRecognitionNumberOfCompounds" xlink:to="lab_inhibrx_RevenueRecognitionNumberOfCompounds" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementExpenseReimbursement_38edecf8-0464-49c4-8fc9-c332f76f1efd_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement expenses</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementExpenseReimbursement_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expense Reimbursement</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementExpenseReimbursement_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expense Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementExpenseReimbursement" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementExpenseReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementExpenseReimbursement" xlink:to="lab_inhibrx_CollaborativeArrangementExpenseReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_30560c85-3cd9-4431-8879-718930903c4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_29f0fd60-db99-4745-89cc-6f592ae28287_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of bifurcated compound liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_752930c7-beaa-456f-9bf2-5a49861e60a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_b14edb8f-eab4-42de-8e5c-f3d488a47c8a_terseLabel_en-US" xlink:label="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 and 2020 Notes</link:label>
    <link:label id="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_label_en-US" xlink:label="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 And 2020 Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_documentation_en-US" xlink:label="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 And 2020 Convertible Promissory Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember" xlink:to="lab_inhibrx_A2019And2020ConvertiblePromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_0b0348d7-88ad-442b-89e5-743f3aafc456_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage due to advisors</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay Advisors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:to="lab_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a3dabfd1-1f7c-42fa-adb7-2b7cd01b44a6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb3cd18f-24a1-487a-a7a1-726fc9115d28_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76bd3930-84cf-449a-9bed-e4151050fd48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_AccruedResearchAndDevelopmentCurrent_754d7f23-1e77-4b2d-9107-0f286841dc0a_terseLabel_en-US" xlink:label="lab_inhibrx_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development</link:label>
    <link:label id="lab_inhibrx_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_inhibrx_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:label id="lab_inhibrx_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_inhibrx_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_AccruedResearchAndDevelopmentCurrent" xlink:href="inhibrx-20200930.xsd#inhibrx_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_inhibrx_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8828e21b-cd07-40c2-9109-db15c27b3bde_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_d525f4ea-2265-47a7-9d89-d0b7bbfb6f9d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_40413412-7571-4d59-95ab-c2d79383cb8f_terseLabel_en-US" xlink:label="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_label_en-US" xlink:label="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Derivative Liabilities Incurred</link:label>
    <link:label id="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_documentation_en-US" xlink:label="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Derivative Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:to="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c066e330-f4a4-4ef2-81a6-21008082a1c9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_d8213087-0c97-4675-a885-6ecf3c3d63a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c48bbd30-4d31-466b-8793-46af58b7dfef_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b0355188-fb07-4619-a8ff-f6654f878e73_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_385ef0c5-b504-492e-a477-1ef6dddd46d4_terseLabel_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ac603c23-ac85-4bc2-93b8-8e7094d3443c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_48111d4b-b373-43ad-bbfe-9460d1ee0216_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ecce3eba-7a60-419e-af0a-401a73543643_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_669728bd-c500-4c1d-82e4-9ed5bec379f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9210c35f-68d8-477a-8af9-da8397bb3eac_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a9252b73-b8c1-417c-a195-57faa0530edc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2f218787-3b35-4d97-8bd1-d6e1e6d8b206_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b76fc56-e122-4ef2-a215-a0bed67d0556_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a482cc6-7059-41b9-a8d1-2a31db0fc696_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3c12c022-8087-4e39-8a75-26f2e0e04e25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_19531863-94ee-49aa-803f-2669794b23a6_terseLabel_en-US" xlink:label="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Current</link:label>
    <link:label id="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_documentation_en-US" xlink:label="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:href="inhibrx-20200930.xsd#inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:to="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_602dbf15-cf2a-4c08-b714-a4fef5826c66_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, net of discount</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_65d251cd-b760-4cf9-b9bc-7c1c24cf0e19_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_967109a7-4357-45e8-9a5f-8b310218ce68_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_733c198c-2d57-4d82-80a0-625a865fe8b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c0317ed9-9b9f-4801-9ea6-7fd982e9f72e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_6f9e29de-7da5-460d-b758-4015ae2a219e_negatedLabel_en-US" xlink:label="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of fees associated with debt</link:label>
    <link:label id="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_label_en-US" xlink:label="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs, Secured Debt</link:label>
    <link:label id="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_documentation_en-US" xlink:label="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs, Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:to="lab_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e86a61f4-882c-4e93-a654-68f0e38b41ab_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_50f56d6b-f71c-41bd-a9b7-3e2025b768b4_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PD-L1 and 4-1BB License Agreement</link:label>
    <link:label id="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_label_en-US" xlink:label="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate - PD-L1 And 4-1BB License Agreement [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate - PD-L1 And 4-1BB License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" xlink:to="lab_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_ddcb4fc5-b5b5-4c9c-b7f3-00808d88f37a_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Mezzanine Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_cc5c0d08-9894-49fd-965b-a73397dd097f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_0464b67f-b00c-4b0e-ab20-8b210463b545_terseLabel_en-US" xlink:label="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Upon Consummation of IPO</link:label>
    <link:label id="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_label_en-US" xlink:label="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Upon Consummation Of IPO [Member]</link:label>
    <link:label id="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_documentation_en-US" xlink:label="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Upon Consummation Of IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember" xlink:to="lab_inhibrx_WarrantsIssuedUponConsummationOfIPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1a608ea0-8a07-412c-bf38-426bbc5fa17a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1216080b-4591-49b4-903e-2af83691a472_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2020ConvertiblePromissoryNoteMember_78ae3c90-6385-4e54-8c5f-48f0a6714f94_terseLabel_en-US" xlink:label="lab_inhibrx_A2020ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Note</link:label>
    <link:label id="lab_inhibrx_A2020ConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_inhibrx_A2020ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_inhibrx_A2020ConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_inhibrx_A2020ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2020ConvertiblePromissoryNoteMember" xlink:to="lab_inhibrx_A2020ConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WarrantsAndRightsOutstandingLiability_c3e9ee8b-ba37-466c-a836-865b3047b982_terseLabel_en-US" xlink:label="lab_inhibrx_WarrantsAndRightsOutstandingLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued, amount</link:label>
    <link:label id="lab_inhibrx_WarrantsAndRightsOutstandingLiability_label_en-US" xlink:label="lab_inhibrx_WarrantsAndRightsOutstandingLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding, Liability</link:label>
    <link:label id="lab_inhibrx_WarrantsAndRightsOutstandingLiability_documentation_en-US" xlink:label="lab_inhibrx_WarrantsAndRightsOutstandingLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsAndRightsOutstandingLiability" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsAndRightsOutstandingLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WarrantsAndRightsOutstandingLiability" xlink:to="lab_inhibrx_WarrantsAndRightsOutstandingLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_fa29d637-a03d-4a5c-98b2-fa2a5b93904e_terseLabel_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of awards issued</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_label_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Value Of Shares Issued</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_documentation_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Value Of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" xlink:to="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermCMember_241912f3-d3db-4260-acc1-a9171dae15c3_terseLabel_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermCMember_label_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term C [Member]</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermCMember_documentation_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermCMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2015OxfordTermLoansTermCMember" xlink:to="lab_inhibrx_A2015OxfordTermLoansTermCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee3852b9-67cd-4c1e-bc77-6a8b31a47f7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_be479096-c601-42a7-b220-26755f20d4c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8e916555-5cf0-4186-b905-81392990edfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b80e58a-5b65-434e-98d6-3357fa5c023f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7cb4ac3c-fd15-43c0-b93f-6adc4e2d5069_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_36f32660-ffb2-4a06-b659-526e0d950c86_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted_2ef7a96d-5873-4903-bf2e-120a6762aec8_terseLabel_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Granted</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted_label_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term, Granted</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted_documentation_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" xlink:to="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_5adcc564-774f-4217-b21f-6f55fb194b1b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d83b761c-1937-47ac-9ff8-bc876b3f7c62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c5dca097-b194-4eeb-b747-c23b83e199b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 15,000,000 and no shares authorized at September&#160;30, 2020 and December&#160;31, 2019; no shares issued or outstanding.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c6e59c65-78a7-4ae8-a527-de8eb2e997e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_33534bf9-de95-42d8-8926-bebdbd8c27f3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2d8247c2-c040-4922-ab70-dae8f8ba292a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_97d79529-ef2c-4aa0-9a77-6416c60c89bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_4e8734f1-32f1-462c-9ac6-8f67c7d1c535_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equal payments of principal and interest period</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Equal Payments Of Principal And Interest Period</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Equal Payments Of Principal And Interest Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" xlink:to="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c9588457-d4bd-4781-9b4e-e21dc709292e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability_6683729b-417d-434b-9eeb-62f963f2361e_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount related to warrant liabilities</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Warrant Liability</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" xlink:to="lab_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMember_0ed21578-01f4-442b-a5c0-1bd9855ec9d3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeMember_label_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMember" xlink:to="lab_us-gaap_DerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_1d9e2f25-0208-4c33-b07c-50512e4404fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_ba5f0fbe-ad22-4ee0-b6ab-88f443d4b548_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentNumberOfTermLoans_03e87beb-57a8-4fb3-9778-5ce3a8b08912_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentNumberOfTermLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of term loans</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentNumberOfTermLoans_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentNumberOfTermLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Term Loans</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentNumberOfTermLoans_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentNumberOfTermLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentNumberOfTermLoans" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentNumberOfTermLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentNumberOfTermLoans" xlink:to="lab_inhibrx_DebtInstrumentNumberOfTermLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_15bc2ca3-e061-47cd-b433-246b064b9be1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, liquidation preferences</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1f92ccae-8e1f-4b00-854b-61b7480d3ddd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_cde650b0-c535-4b7e-97ba-0168aeb67cf0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_26321de0-778c-45cc-9ec3-b892fc3324a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_326789ca-8e37-4294-b372-1d9a9550927a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7d8e5c85-b818-40d5-a321-cc869d9851ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_17f12648-cce9-416b-81fe-b91e048f5ed2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_a7643be4-30ee-40a7-bf77-7ece914cbecd_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cb1bf08b-19dc-4bb9-8ae2-372288359c74_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_18fe92e1-6e8b-42a0-82bc-bebf9d566f42_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_5c2bb4a2-06c2-4630-b356-ef5443228743_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTrancheCMember_40067941-7e59-462d-a044-8e3e72b2dce0_terseLabel_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche C</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTrancheCMember_label_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, Tranche C [Member]</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTrancheCMember_documentation_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, Tranche C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTrancheCMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTrancheCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2020OxfordTermLoansTrancheCMember" xlink:to="lab_inhibrx_A2020OxfordTermLoansTrancheCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f3bcd4e9-cc8e-4aec-8187-855684aca7a5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_e4b19eb7-ded2-4f17-954e-a749b1937f00_terseLabel_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second and Third Tranches</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_label_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, Tranches B And C [Member]</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_documentation_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, Tranches B And C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTranchesBAndCMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTranchesBAndCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2020OxfordTermLoansTranchesBAndCMember" xlink:to="lab_inhibrx_A2020OxfordTermLoansTranchesBAndCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_5173a6c9-571e-4229-b5a9-29f5f17e4045_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature (reversal of unamortized BCF)</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_a8f4c51b-6b98-4d25-9387-0b44affb992e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_980d7091-be68-4e13-a604-def569e6b0ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_93dfd12c-d657-4caf-a40c-7c7830c79722_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Inhibrx, Inc., basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_513dece0-9d55-4220-b1fc-05781f2dec07_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_a3deb86e-9cc4-4df7-86a6-37c07938a2ac_terseLabel_en-US" xlink:label="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other license revenues from non-affiliates</link:label>
    <link:label id="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_label_en-US" xlink:label="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customers, Not Separately Disclosed [Member]</link:label>
    <link:label id="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_documentation_en-US" xlink:label="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customers, Not Separately Disclosed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherCustomersNotSeparatelyDisclosedMember" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherCustomersNotSeparatelyDisclosedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_OtherCustomersNotSeparatelyDisclosedMember" xlink:to="lab_inhibrx_OtherCustomersNotSeparatelyDisclosedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a72d2a9-802a-4106-9d36-6d235cd9d8ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_25c73760-8ca4-4f63-a046-1465ef0d076c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f2e7a40f-c6f7-4f8a-bdd1-ef3c1b7b1fb2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cc8a8f1-d2c4-474d-ac14-0bef549cecbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_9b5fb6bf-0183-4116-a65d-0b0cc55ee0d8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside research and development services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4469f636-b64b-4b2a-b3ce-53394c98cfc5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_df704f08-d5a1-4373-aa73-2459161d062a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a41d5786-a1a2-4de9-b6d4-38af4745dc9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2716c98d-5d11-4f46-938c-6132f814f98d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development and Clinical Trial Accrurals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_9f72cf26-6695-45c0-8d2a-568c5adf2634_terseLabel_en-US" xlink:label="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elpiscience</link:label>
    <link:label id="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_label_en-US" xlink:label="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elpiscience Biopharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elpiscience Biopharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember" xlink:to="lab_inhibrx_ElpiscienceBiopharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_49f938a4-de2c-48dd-9c2d-c0994c457023_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_37a344de-7130-4363-bfe0-bc3b8639d9c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_adf5937f-d3fa-46c9-8479-153b96a70ab2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b94cec3e-5f36-4cae-b17c-37a08a91f03a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansMember_6a75682c-5c5e-446a-9ff2-3c13d58145ba_terseLabel_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Loan Agreement</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansMember_label_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans [Member]</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansMember_documentation_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember" xlink:to="lab_inhibrx_A2015OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_3c86b32f-1926-4037-ab0c-082c99d8f9ca_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive development license</link:label>
    <link:label id="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_label_en-US" xlink:label="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Exclusive Development Licenses</link:label>
    <link:label id="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Exclusive Development Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:to="lab_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_84f0643f-27d3-43cb-ad60-999938f1882f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment_5f4b5e77-306e-4dfa-8e5e-5f0c9b3c1b01_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash equity method investment</link:label>
    <link:label id="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment_label_en-US" xlink:label="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Establishment Of Equity Method Investment</link:label>
    <link:label id="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Establishment Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NonCashEstablishmentOfEquityMethodInvestment" xlink:href="inhibrx-20200930.xsd#inhibrx_NonCashEstablishmentOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_NonCashEstablishmentOfEquityMethodInvestment" xlink:to="lab_inhibrx_NonCashEstablishmentOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_84acc889-f19a-4fa8-b2f1-80412efaa8f7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_1efeb545-e00f-478a-9811-cb71ee3043b2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8f88daeb-d700-46a3-acd5-df378e5e1a7f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c6570fec-05dd-410a-9c60-690a455d5ab9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_f7800fc0-93ae-4b1f-93e1-472a1a28472a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_8cf41306-1dbc-4aec-b627-844fe07e371b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_06ff3f4d-6b81-4a90-becf-b8313e3fce01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_4a9d4f82-0196-433f-a4d4-cf44d7f0bd45_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income related to changes in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_ec6cbf3a-9010-4944-b16d-43a8c44c8ab4_terseLabel_en-US" xlink:label="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional equity interest percentage entitled to receive</link:label>
    <link:label id="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_label_en-US" xlink:label="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Ownership Entitled</link:label>
    <link:label id="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_documentation_en-US" xlink:label="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Ownership Entitled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:href="inhibrx-20200930.xsd#inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:to="lab_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_e633d7d5-dcc6-4e46-bc0f-014aaf5789a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_229cb481-05b9-444f-96b7-145ec7110ba4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_283f4134-6dd9-479d-a8da-2df84465f742_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable for purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1da8c434-9b49-474c-81cd-9ee4c311531c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_0c7c4832-a39b-458f-80a5-d4ad1e414035_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_15c359f2-039f-4e8d-8dc6-12384494210a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_2c5a927c-15f9-4056-8263-7000d24b4e71_terseLabel_en-US" xlink:label="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program</link:label>
    <link:label id="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_label_en-US" xlink:label="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program [Member]</link:label>
    <link:label id="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_documentation_en-US" xlink:label="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:href="inhibrx-20200930.xsd#inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:to="lab_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_69b2661f-8e7f-495f-90ad-cff8b55e9104_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_BluebirdBioIncMember_35d19590-3e20-4fd8-a024-6a7451939307_terseLabel_en-US" xlink:label="lab_inhibrx_BluebirdBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bluebird bio, Inc.</link:label>
    <link:label id="lab_inhibrx_BluebirdBioIncMember_label_en-US" xlink:label="lab_inhibrx_BluebirdBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bluebird Bio, Inc. [Member]</link:label>
    <link:label id="lab_inhibrx_BluebirdBioIncMember_documentation_en-US" xlink:label="lab_inhibrx_BluebirdBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bluebird Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BluebirdBioIncMember" xlink:href="inhibrx-20200930.xsd#inhibrx_BluebirdBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_BluebirdBioIncMember" xlink:to="lab_inhibrx_BluebirdBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_5844c8eb-cec0-4a7b-ba09-88dcc8106072_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_9d90464c-86ab-4f90-8f28-7dc22a2a75d3_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with initial public offering</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_a47c8419-903d-489b-9b3b-366f13a3b0b7_terseLabel_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with initial public offering</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_label_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs, Initial Public Offering</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_documentation_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs, Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:to="lab_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_bf7b1367-685c-4a28-bf39-16f6d2fd9cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99a0c8ef-7fce-4d78-8060-028ef653bf4d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557babab-9608-451b-93e0-64902c770413_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermAMember_fed4e13a-01ee-42f7-85c3-09c186947083_terseLabel_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermAMember_label_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term A [Member]</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermAMember_documentation_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermAMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2015OxfordTermLoansTermAMember" xlink:to="lab_inhibrx_A2015OxfordTermLoansTermAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_388cd9f0-6cb9-4f6d-95bf-1fbea59eb81d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3f34e0f9-494d-4ce0-b9f1-21e451d373c7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a6e9a1ac-6972-4250-bc93-6b485d58ed8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_8a2e3276-be4f-4b0c-9927-f3df1433fe4f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb80f1cd-dbf1-446e-a157-7c2299f3a460_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f3381be2-df53-4a80-83bd-216fd7f434d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_81e5781f-24fd-4240-afdb-e3abb557e6b0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseSquareFootage_96cf81f9-2362-428d-8ee5-b8fd3060058f_terseLabel_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseSquareFootage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of lease agreement (in sq feet)</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseSquareFootage_label_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseSquareFootage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseSquareFootage_documentation_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseSquareFootage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseSquareFootage" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseSquareFootage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LesseeOperatingLeaseSquareFootage" xlink:to="lab_inhibrx_LesseeOperatingLeaseSquareFootage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_247a974a-3c48-445c-9291-c5a0ec0a85a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3a037017-cc3a-4280-984c-8531a4df4129_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_f098b283-35f1-4fa8-8d14-1d3b810cdb0a_negatedLabel_en-US" xlink:label="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the issuance of convertible notes</link:label>
    <link:label id="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_label_en-US" xlink:label="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs, Convertible Debt</link:label>
    <link:label id="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_documentation_en-US" xlink:label="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs, Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" xlink:to="lab_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f9c66881-f6d5-42d2-bc27-33c8bd5e5bf1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in IPO, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_8214abe0-c209-4dd1-b9db-b5c28c1bcd04_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_4d62ecb6-d946-4d44-b8f3-511bc4d79b1a_terseLabel_en-US" xlink:label="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Concurrently With 2020 Loan Agreement</link:label>
    <link:label id="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_label_en-US" xlink:label="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Concurrently With 2020 Loan Agreement [Member]</link:label>
    <link:label id="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_documentation_en-US" xlink:label="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Concurrently With 2020 Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:to="lab_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1116118a-eb65-48fe-a392-cf74623ffaa6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of the 2019 Note and the 2020 Notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ab7a69a6-a103-4ef3-9a3f-975d45ea2dfe_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b7db8e46-135d-4854-9c23-5d689f4f2876_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_68a523d5-1847-4458-a022-66f4b2994e17_terseLabel_en-US" xlink:label="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current portion</link:label>
    <link:label id="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_label_en-US" xlink:label="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Non-Current</link:label>
    <link:label id="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_documentation_en-US" xlink:label="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:href="inhibrx-20200930.xsd#inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:to="lab_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_6e4effae-7aa3-4995-9f54-4b32d487ab72_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_TranscentaHoldingLtdMember_ec05ab15-9f39-4613-95cd-fa25a92a04f2_terseLabel_en-US" xlink:label="lab_inhibrx_TranscentaHoldingLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transcenta Holding, Ltd.</link:label>
    <link:label id="lab_inhibrx_TranscentaHoldingLtdMember_label_en-US" xlink:label="lab_inhibrx_TranscentaHoldingLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transcenta Holding, Ltd. [Member]</link:label>
    <link:label id="lab_inhibrx_TranscentaHoldingLtdMember_documentation_en-US" xlink:label="lab_inhibrx_TranscentaHoldingLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transcenta Holding, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_TranscentaHoldingLtdMember" xlink:to="lab_inhibrx_TranscentaHoldingLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fde2e3ea-b176-4185-afc6-a1f53045fb94_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9c9396ed-3a68-4baf-ae8b-078d8fe5a68b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_06a088be-71a2-494e-8a42-11318c46e374_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock after conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c6c0367b-518d-420e-8716-272a6fe3c82a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_SeriesMezzanine1PreferredStockMember_50cb1bac-9ebb-471f-bb2f-3bdfaa89e602_terseLabel_en-US" xlink:label="lab_inhibrx_SeriesMezzanine1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Mezzanine 1</link:label>
    <link:label id="lab_inhibrx_SeriesMezzanine1PreferredStockMember_label_en-US" xlink:label="lab_inhibrx_SeriesMezzanine1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Mezzanine 1 Preferred Stock [Member]</link:label>
    <link:label id="lab_inhibrx_SeriesMezzanine1PreferredStockMember_documentation_en-US" xlink:label="lab_inhibrx_SeriesMezzanine1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Mezzanine 1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine1PreferredStockMember" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_SeriesMezzanine1PreferredStockMember" xlink:to="lab_inhibrx_SeriesMezzanine1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_e00953c2-ee04-4031-bac8-c9ab48a68999_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Programs</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_label_en-US" xlink:label="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Programs Authorized [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Programs Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:to="lab_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6e8553a8-0671-4e58-9e02-4654d9f42751_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3be5eec2-a1fa-46d1-a5fb-b1df75c2dcc7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_28985caa-c69d-4496-bc6e-ef397e796cec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7632f878-c18a-4d03-a791-32d56d376bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_42f3362f-dfc3-4779-8d16-21d954c0cb42_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_edf07c26-2374-4a84-a734-e6c1af75f25e_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the issuance of preferred stock</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_label_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stock Issuance Costs, Convertible Preferred Stock</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_documentation_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stock Issuance Costs, Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" xlink:to="lab_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember_aa04c8bc-1fbf-4c91-bed8-b77833d10a80_terseLabel_en-US" xlink:label="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Derivative Liabilities</link:label>
    <link:label id="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember_label_en-US" xlink:label="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Derivative Liabilities [Member]</link:label>
    <link:label id="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember_documentation_en-US" xlink:label="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantAndDerivativeLiabilitiesMember" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantAndDerivativeLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WarrantAndDerivativeLiabilitiesMember" xlink:to="lab_inhibrx_WarrantAndDerivativeLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_37146fae-faa2-443e-b3d7-c2a47c0a0d2c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1edb859d-076a-446f-9c02-b7dc0693e3dc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d5f45986-c745-4474-a52b-89cff070b203_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ba45761b-f9de-423b-9965-215fdbd2d49d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5d54166e-cd3e-4bbd-bec6-d7266e90cdb8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_969e192b-1ab0-4eaa-8a8c-e83586118655_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Temporary Equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3a4b9563-d778-4aa3-82a3-7eaec0dc5d96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_85ef3f8a-268d-48ed-b2e9-b7d311983fa3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d49f1553-27e5-4962-9623-85162fd1fd83_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1cc55a5d-ab65-41f1-bf20-6d5a79b3909a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4a968373-06e4-415c-9d57-d946ac693e89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_29d53843-f6e0-4bce-aa82-0303a6d7934b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_98325580-e43e-4f95-97f6-f7c3c094b4c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentVariableRateFloor_b0469c57-5c13-4b05-9473-c88f05496bfe_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentVariableRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate floor</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentVariableRateFloor_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentVariableRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Floor</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentVariableRateFloor_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentVariableRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentVariableRateFloor" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentVariableRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentVariableRateFloor" xlink:to="lab_inhibrx_DebtInstrumentVariableRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_NoncashOperatingLeaseExpense_d0908316-00a9-4023-b70d-36f769f87a2c_terseLabel_en-US" xlink:label="lab_inhibrx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_inhibrx_NoncashOperatingLeaseExpense_label_en-US" xlink:label="lab_inhibrx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:label id="lab_inhibrx_NoncashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_inhibrx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NoncashOperatingLeaseExpense" xlink:href="inhibrx-20200930.xsd#inhibrx_NoncashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_NoncashOperatingLeaseExpense" xlink:to="lab_inhibrx_NoncashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_a4a629be-297b-44f3-9568-e0fdb30e67a2_terseLabel_en-US" xlink:label="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company valuation</link:label>
    <link:label id="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_label_en-US" xlink:label="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Company Valuation For Initial Public Offering (IPO)</link:label>
    <link:label id="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_documentation_en-US" xlink:label="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Company Valuation For Initial Public Offering (IPO)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" xlink:href="inhibrx-20200930.xsd#inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" xlink:to="lab_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_127a4fec-b84c-443f-80fd-d95824afd78c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock_3712b27c-a10e-4954-84d4-d9a60e4ac6fd_terseLabel_en-US" xlink:label="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:label id="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantLiabilitiesPolicyTextBlock" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WarrantLiabilitiesPolicyTextBlock" xlink:to="lab_inhibrx_WarrantLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermBMember_def48cba-80d3-46e7-8dab-b42cf404af0d_terseLabel_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermBMember_label_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term B [Member]</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermBMember_documentation_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermBMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2015OxfordTermLoansTermBMember" xlink:to="lab_inhibrx_A2015OxfordTermLoansTermBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_60d9dce3-ef49-4f93-97a7-fad4e5a949f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cf5ca8e9-8c33-4ede-8a29-7ee3358e24c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_871c3905-3cac-47f2-92d7-cf6d78cec1fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ed54e312-1d8d-49f6-8321-ef14b62cc435_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d0b30763-629e-41ec-8c27-a4cccfb35514_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_59b06224-5a56-4fdb-b97d-7c3179adbfe8_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Programs, Program 1</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_label_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program One [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:to="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0e5b14b1-2b87-4509-a124-b64b06b902b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_64ea475c-755e-4ac6-b1d4-0e3510b429ea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LAVSummitLimitedMember_75bc25d2-15d7-4bfb-8e27-1760fbd8349d_terseLabel_en-US" xlink:label="lab_inhibrx_LAVSummitLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LAV Summit Limited</link:label>
    <link:label id="lab_inhibrx_LAVSummitLimitedMember_label_en-US" xlink:label="lab_inhibrx_LAVSummitLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LAV Summit Limited [Member]</link:label>
    <link:label id="lab_inhibrx_LAVSummitLimitedMember_documentation_en-US" xlink:label="lab_inhibrx_LAVSummitLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LAV Summit Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LAVSummitLimitedMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LAVSummitLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LAVSummitLimitedMember" xlink:to="lab_inhibrx_LAVSummitLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_4d54d9ed-2644-42ba-9c7c-e3f1946bb145_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_08ff1bfe-fd76-49e6-a941-b705b046586a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_32b3f0fd-f893-4d69-a662-c4460ddc640f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_97f9bb1e-7379-4600-a672-e146609a0bf0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4e3b68c1-2d50-48c5-83a6-360da67d8842_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_80c2e3af-ef0c-455e-ab99-3d4d727d762b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d1ae556b-daf0-4c2b-8cb5-b025388cbbb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_bc2a1563-48e5-4eed-b531-81567d95bde3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d1a6dd30-8502-4ea7-8a64-a6a66117c0cc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_5345fac5-fa96-4bf2-abc1-946c4a3a963d_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3b19a278-f4d1-4af2-9261-bf05387ab639_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce144c40-8648-4ace-9eae-c7667bd220be_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_761f1dd8-776f-4a1b-8ec6-455c8330a4d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0f5450a2-594a-4c63-9183-54a4ad34a656_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_76f054e6-81fd-4b4c-9a92-1a1afb902f29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_dfef7e1d-6d2c-4599-b959-dabfb0327257_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c5f91b2d-747d-4d78-b15e-bc34a8300f96_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_fd20dd4b-710e-42e6-a470-8b8d3bda05db_terseLabel_en-US" xlink:label="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_label_en-US" xlink:label="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</link:label>
    <link:label id="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_documentation_en-US" xlink:label="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:to="lab_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_10f6b639-92c8-40c9-a913-e3d8d498b736_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_92ea94c4-f29b-4ed5-95e5-1fb83a9549b1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations_a2e96aeb-1f15-4595-90d3-166d4ecf9adf_terseLabel_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual escalations</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations_label_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Escalations</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations_documentation_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Escalations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseAnnualEscalations" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseAnnualEscalations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LesseeOperatingLeaseAnnualEscalations" xlink:to="lab_inhibrx_LesseeOperatingLeaseAnnualEscalations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dc24350b-0df3-49de-834c-20b6191411a7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_62d9e75c-4cdc-4d95-bb5d-9059283cce0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fa473877-5c1c-40ef-8afd-35cd5071b187_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_0faf69d5-9ce4-48ec-8e9f-b64aae763844_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for debt restructuring costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_adfb890b-8731-44d0-98d0-189c01cbaae2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1f2bf34-8a44-40a0-ad34-a8b4b23a7196_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_201f3bc7-697f-4dd5-aed0-5d76d458362d_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1eb80a0-90bc-457e-be48-23ef385380b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e0a6aab5-46db-48fe-b32b-c5a1a69ef778_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e20b5edf-314a-4c14-bd1e-ac9e930fada5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_0fd9aa2f-4175-4b4e-9a40-87f317cdf150_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments Receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:to="lab_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PhylaxisBioScienceLLCMember_a320c5cf-6a2a-4d30-aa40-3dc3892fb0f6_terseLabel_en-US" xlink:label="lab_inhibrx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phylaxis BioScience, LLC</link:label>
    <link:label id="lab_inhibrx_PhylaxisBioScienceLLCMember_label_en-US" xlink:label="lab_inhibrx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phylaxis BioScience, LLC [Member]</link:label>
    <link:label id="lab_inhibrx_PhylaxisBioScienceLLCMember_documentation_en-US" xlink:label="lab_inhibrx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phylaxis BioScience, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PhylaxisBioScienceLLCMember" xlink:to="lab_inhibrx_PhylaxisBioScienceLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_69e3c720-f97f-4d42-b419-047897837c29_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12ccf33a-0142-4092-8b01-55b12283ca53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementPaymentReceivable_83b4ee6a-0cc3-4647-82c9-456b573e2e12_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments due pursuant to agreement</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementPaymentReceivable_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment Receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementPaymentReceivable_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementPaymentReceivable" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementPaymentReceivable" xlink:to="lab_inhibrx_CollaborativeArrangementPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_02e69ac6-b3d3-45bb-92dc-d15e79955bd5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1ca0910e-6aa0-4538-964d-40486ae10552_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_ea4d9a23-5848-49ce-97f1-f747b31ac61f_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementTerm_6e0cae8b-e382-4789-8c56-44ebb7127ad7_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementTerm" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementTerm" xlink:to="lab_inhibrx_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b28893d2-61bb-451c-84c0-6cd80f916298_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eebfac70-5504-4d39-93c6-cace144a39c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_74045d57-7712-4f10-a9dc-d59bd0987aa7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_5a76a432-be73-4b60-a2e4-174effab4e8a_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Programs, Program 2</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_label_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program Two [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:to="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_87334c2a-a684-4b42-9f85-e55f379648b9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_cfdc0737-6fe3-474c-977f-e68bad0b303d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONVERTIBLE PROMISSORY NOTES</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_b053f558-5d99-4152-9cfc-46cbfa4df6b1_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b3e79b00-9417-4935-970c-ba66195a7945_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_dad49de7-4366-43c9-99b6-74a16c4f2819_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability_ba266b28-d1d9-4755-a0eb-214f7bffda34_terseLabel_en-US" xlink:label="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount related to derivative liability</link:label>
    <link:label id="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability_label_en-US" xlink:label="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Derivative Liability</link:label>
    <link:label id="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability_documentation_en-US" xlink:label="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtIssuanceCostsNetDerivativeLiability" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtIssuanceCostsNetDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtIssuanceCostsNetDerivativeLiability" xlink:to="lab_inhibrx_DebtIssuanceCostsNetDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bb38eced-0d60-410b-8f06-34506fc91c51_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_RelatedPartyEquityInterestInCompany_683e5679-5d9a-4a89-b7d0-9c639001cedf_terseLabel_en-US" xlink:label="lab_inhibrx_RelatedPartyEquityInterestInCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest, more than</link:label>
    <link:label id="lab_inhibrx_RelatedPartyEquityInterestInCompany_label_en-US" xlink:label="lab_inhibrx_RelatedPartyEquityInterestInCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party , Equity Interest In Company</link:label>
    <link:label id="lab_inhibrx_RelatedPartyEquityInterestInCompany_documentation_en-US" xlink:label="lab_inhibrx_RelatedPartyEquityInterestInCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party , Equity Interest In Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RelatedPartyEquityInterestInCompany" xlink:href="inhibrx-20200930.xsd#inhibrx_RelatedPartyEquityInterestInCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_RelatedPartyEquityInterestInCompany" xlink:to="lab_inhibrx_RelatedPartyEquityInterestInCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b156e5a2-fd1b-4a48-b6c8-8e77b61427f4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_df5b93e5-076a-4736-9cb2-496cd1490886_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_f89d3cea-649d-4bb9-a5a1-edef5b522f6e_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_73c2514b-b72f-456b-b275-6cca33858802_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e76915a7-6c94-45a2-9b4a-ab67e5725651_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_54f40ee0-daae-40f2-aab5-3968a5c61077_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Beneficial Conversion Feature (Reversal) Of Beneficial Conversion Feature</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature Discount (Reversal) Of Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:to="lab_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTextBlock_30acfeab-0e1a-4790-a565-6110e11e95c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP LOAN</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_us-gaap_ShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c5533be0-e8b5-4d40-b2a8-eeb35af13db6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_GrantValuedAwarded_ca946791-301d-4b92-91fb-7edeb09b46a3_terseLabel_en-US" xlink:label="lab_inhibrx_GrantValuedAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant award</link:label>
    <link:label id="lab_inhibrx_GrantValuedAwarded_label_en-US" xlink:label="lab_inhibrx_GrantValuedAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Valued Awarded</link:label>
    <link:label id="lab_inhibrx_GrantValuedAwarded_documentation_en-US" xlink:label="lab_inhibrx_GrantValuedAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Valued Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantValuedAwarded" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantValuedAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_GrantValuedAwarded" xlink:to="lab_inhibrx_GrantValuedAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_NationalInstitutesOfHealthMember_c24f2ffb-605e-492a-978c-2f39005f12b5_terseLabel_en-US" xlink:label="lab_inhibrx_NationalInstitutesOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institutes of Health</link:label>
    <link:label id="lab_inhibrx_NationalInstitutesOfHealthMember_label_en-US" xlink:label="lab_inhibrx_NationalInstitutesOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:label id="lab_inhibrx_NationalInstitutesOfHealthMember_documentation_en-US" xlink:label="lab_inhibrx_NationalInstitutesOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institutes Of Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NationalInstitutesOfHealthMember" xlink:href="inhibrx-20200930.xsd#inhibrx_NationalInstitutesOfHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_NationalInstitutesOfHealthMember" xlink:to="lab_inhibrx_NationalInstitutesOfHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0f835fd8-3efb-41c8-80d0-ab25354b3204_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted_3cfcc140-5f32-4233-89d5-f8d0dd8970bb_terseLabel_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGGREGATE INTRINSIC VALUE, Granted</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted_label_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value, Granted</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted_documentation_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" xlink:to="lab_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f0686c21-43a0-4f41-a2dc-d6072299cb7f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_d8d4f95a-f321-441d-86d5-e44d691bb85c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_1acde666-649f-4072-a3ba-69ca5effba22_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_aaa1f50c-9e31-4187-9aba-1d1ee70ba9d9_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_048595f9-637b-43b4-aeeb-26291cafc813_terseLabel_en-US" xlink:label="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share, percentage covered by company</link:label>
    <link:label id="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_label_en-US" xlink:label="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Awarded, Payment Structure, Percentage Covered By Company</link:label>
    <link:label id="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_documentation_en-US" xlink:label="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Awarded, Payment Structure, Percentage Covered By Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" xlink:to="lab_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_477194d6-ef76-4e05-bec5-a49bd026812b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_0dc5d6fc-5031-4fc3-be35-a0c6bfb0059f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_18cda0e1-4bc8-45e3-afb1-59de0eaf5b2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_83b5aa1d-53d0-43a0-89d3-086ef5f1e8ec_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1d7fb0b9-a1ec-444b-aea3-b5d2000ca00e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic payment terms, final payment amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d65693ed-9cd6-4d74-9108-3ad384e6c9f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_39a04786-fd6d-45b9-b9aa-6ae550938094_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_fd825b94-ec38-4158-a516-f235907f87d1_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OX40 License Agreement</link:label>
    <link:label id="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_label_en-US" xlink:label="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate - OX40 License Agreement [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate - OX40 License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember" xlink:to="lab_inhibrx_LicenseAffiliateOX40LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTrancheBMember_0a69b0e9-b243-4a7b-af88-54672a3ca75e_terseLabel_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTrancheBMember_label_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, Tranche B [Member]</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansTrancheBMember_documentation_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTrancheBMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2020OxfordTermLoansTrancheBMember" xlink:to="lab_inhibrx_A2020OxfordTermLoansTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_1ba6ac86-8978-4c7b-be16-ef2d37af6811_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_34c01ec1-ac19-43a1-add0-0bd2148f48dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8338024e-d39d-41dc-8b47-c67501ec929f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseNonAffiliateMember_5d4e60b1-c3ae-463f-be49-4fd4daa40b16_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue, non-affiliates</link:label>
    <link:label id="lab_inhibrx_LicenseNonAffiliateMember_label_en-US" xlink:label="lab_inhibrx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Non-Affiliate [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseNonAffiliateMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Non-Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseNonAffiliateMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseNonAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseNonAffiliateMember" xlink:to="lab_inhibrx_LicenseNonAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_257cb2cf-f863-41dd-9664-0219e07e9a25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4951b7da-d918-4f19-91ba-9f3ae5aed1e0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermDMember_0dc5d0bb-756c-47d2-bd4e-a1dc295e9976_terseLabel_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term D</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermDMember_label_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term D [Member]</link:label>
    <link:label id="lab_inhibrx_A2015OxfordTermLoansTermDMember_documentation_en-US" xlink:label="lab_inhibrx_A2015OxfordTermLoansTermDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans, Term D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermDMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2015OxfordTermLoansTermDMember" xlink:to="lab_inhibrx_A2015OxfordTermLoansTermDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_91a36044-c306-4cc4-9b45-43fa12410c60_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bf95546f-2ce5-4efc-a036-e4109effc64f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bf932282-606e-4eef-bc34-96f980b41d48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock-Based Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5951b9f6-5bda-4f40-81e5-d9becb15cbd3_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_SeriesMezzanine2PreferredStockMember_4d1cd633-6490-42cc-8edc-ca44777964b8_terseLabel_en-US" xlink:label="lab_inhibrx_SeriesMezzanine2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Mezzanine 2</link:label>
    <link:label id="lab_inhibrx_SeriesMezzanine2PreferredStockMember_label_en-US" xlink:label="lab_inhibrx_SeriesMezzanine2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Mezzanine 2 Preferred Stock [Member]</link:label>
    <link:label id="lab_inhibrx_SeriesMezzanine2PreferredStockMember_documentation_en-US" xlink:label="lab_inhibrx_SeriesMezzanine2PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series Mezzanine 2 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine2PreferredStockMember" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine2PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_SeriesMezzanine2PreferredStockMember" xlink:to="lab_inhibrx_SeriesMezzanine2PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_85172666-bddd-4394-bedb-f618e526b9df_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0cdba0d9-8e83-4210-8721-a6c6bb7622cb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_1e195fe7-86ab-4ee6-9f39-2bd1be3ab9bf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d81cf8b6-f4d3-4692-ad70-2f6103e8eb0c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_4f88e085-e6b1-4260-b8cc-07921cd6baa0_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of liabilities into equity</link:label>
    <link:label id="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_label_en-US" xlink:label="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification</link:label>
    <link:label id="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_documentation_en-US" xlink:label="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:href="inhibrx-20200930.xsd#inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:to="lab_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_578da604-6ee9-4e19-9eb7-6c0694abcf99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_e993e251-a3f8-4ab6-911f-b25273c55bca_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_c9eaf02a-89d8-4ac8-ac59-409cf79d41d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bbb988e5-c734-42df-9d6d-c7e423b874e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE EXERCISE PRICE</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5c6c5344-19ff-4e53-8585-e3ba12d7d6be_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Mezzanine Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_3b40b28b-dd4a-4932-9d3e-c24e3b23856d_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_367d3eea-48d3-4875-a87a-85a140a72b14_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40d48658-6f5e-4b5e-b110-87cee11c7822_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of convertible securities</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_959cac6c-ffb3-4279-a79e-1734e7bde730_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9b02f5ca-e8c2-4ca5-80b8-7ea3147c945f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f66a5b3a-17a0-4b57-bb68-a86e76fd0e18_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ProfitInterestUnitPIUMember_e83fb70a-6bc5-4b5f-954f-f3dadf1d4f67_terseLabel_en-US" xlink:label="lab_inhibrx_ProfitInterestUnitPIUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Interest Unit (PIU)</link:label>
    <link:label id="lab_inhibrx_ProfitInterestUnitPIUMember_label_en-US" xlink:label="lab_inhibrx_ProfitInterestUnitPIUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Interest Unit (PIU) [Member]</link:label>
    <link:label id="lab_inhibrx_ProfitInterestUnitPIUMember_documentation_en-US" xlink:label="lab_inhibrx_ProfitInterestUnitPIUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Interest Unit (PIU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ProfitInterestUnitPIUMember" xlink:href="inhibrx-20200930.xsd#inhibrx_ProfitInterestUnitPIUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ProfitInterestUnitPIUMember" xlink:to="lab_inhibrx_ProfitInterestUnitPIUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_86f84e39-4774-4908-bfe1-92d648d01027_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_024d42d1-8eb0-48b1-b5f0-3a3d8ad15c63_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6761d123-888b-4a83-a29a-f8d59f4c8f2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3a6e53e2-b580-467b-93ab-d48e371faafa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of common stock outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0fe0b0b2-dcd4-4284-b420-09ea5b44e7df_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAffiliateMember_27acfa50-61c1-4bf8-a099-b9bd3d0cdc1a_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue, affiliates</link:label>
    <link:label id="lab_inhibrx_LicenseAffiliateMember_label_en-US" xlink:label="lab_inhibrx_LicenseAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAffiliateMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAffiliateMember" xlink:to="lab_inhibrx_LicenseAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3981f98-9d8c-4147-829a-e140695fca6e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_32896f9f-85ad-447e-8b62-88452cf5f30c_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantMember_92b0ddfc-6351-4aec-8e1e-71720ae2ba80_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1cc74632-8cc8-4d5f-8ae3-6491b932a52f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan aggregate amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a00c6ed0-024d-4028-b926-b06adfa930b9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e8f3494d-3099-4c63-9c08-f44731db2e3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_59c99ac8-3576-4d3a-a205-17a6f6b5fb3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e0604401-0cc1-4c09-bf25-3c371cf4aa2c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4d435ac7-51ff-429b-b2a1-6b1032f007fa_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e1bb2604-f616-470f-8758-73567ee5f59f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_1781f1db-bfca-48b2-91fd-85828af08e6c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_494369b0-f4d8-4197-8be5-70a32c3b9f23_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_6ca8c8e7-b915-47aa-97ca-6b4eea9c6642_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards converted to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_77dcd828-d183-4e59-8c43-14ac3b69a467_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_bd91befd-e703-4dfc-ac0b-8785f1926239_terseLabel_en-US" xlink:label="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combating Antibiotic Resistant Bacteria Accelerator</link:label>
    <link:label id="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_label_en-US" xlink:label="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston University - Combating Antibiotic Resistant Bacteria Accelerator [Member]</link:label>
    <link:label id="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_documentation_en-US" xlink:label="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston University - Combating Antibiotic Resistant Bacteria Accelerator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" xlink:href="inhibrx-20200930.xsd#inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" xlink:to="lab_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e7359921-cecc-4844-a431-1a44a6d94135_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_55c776f0-a4ae-45c2-8a47-d07e2b181e9c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5fecfbd9-52ac-472a-b9d5-fe40bcb752ab_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c1923f9e-4beb-4fe6-a1c6-f136744b2850_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5be13c05-a87b-48ac-a479-d199d0715b66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_81b208ec-425c-4285-8f0f-bf5f968eb9c5_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_506704c2-b487-472e-b069-4d5f15ea981d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding_b9536dc8-44c8-4658-ac0f-2d331bb3c95a_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax withholding</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Foreign Tax Withholding</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Foreign Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementForeignTaxWithholding" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementForeignTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementForeignTaxWithholding" xlink:to="lab_inhibrx_CollaborativeArrangementForeignTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_77535cf7-1b0c-47b9-a347-efdb3e540dcc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansMember_6cd50f84-d6d0-4f65-a6d9-02ea886c8520_terseLabel_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Loan Agreement</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansMember_label_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans [Member]</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansMember_documentation_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember" xlink:to="lab_inhibrx_A2020OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f8f41670-2966-4437-85e7-d55e52e78478_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_039141b3-3c52-42c3-ba68-04b97cf7e53a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ab6240aa-5333-4d90-a6f2-c7f954cb0211_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember_4f0968e8-e681-4ae0-a559-ccf44cdf24c1_terseLabel_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Tranche</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember_label_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, First Tranche [Member]</link:label>
    <link:label id="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember_documentation_en-US" xlink:label="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans, First Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansFirstTrancheMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansFirstTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2020OxfordTermLoansFirstTrancheMember" xlink:to="lab_inhibrx_A2020OxfordTermLoansFirstTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_fea09861-b2db-4172-9e26-adc0db62d9af_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a353077b-d217-4ca7-9912-3e1461158e0b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount and non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_98a43caa-500c-48c0-9e18-3832b4e7890e_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment on debt</link:label>
    <link:label id="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_label_en-US" xlink:label="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Secured Debt, Final Balloon Payment</link:label>
    <link:label id="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_documentation_en-US" xlink:label="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Secured Debt, Final Balloon Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:href="inhibrx-20200930.xsd#inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:to="lab_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAndGrantRevenueTextBlock_062cd4a4-2fdb-4e9f-9d72-77c61eb38020_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AND GRANT REVENUES</link:label>
    <link:label id="lab_inhibrx_LicenseAndGrantRevenueTextBlock_label_en-US" xlink:label="lab_inhibrx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Grant Revenue [Text Block]</link:label>
    <link:label id="lab_inhibrx_LicenseAndGrantRevenueTextBlock_documentation_en-US" xlink:label="lab_inhibrx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAndGrantRevenueTextBlock" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAndGrantRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAndGrantRevenueTextBlock" xlink:to="lab_inhibrx_LicenseAndGrantRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_75cc0f74-c2fa-47ca-8aef-8a48d8361739_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_cecc3b8a-915d-4d05-9f2d-3f61aa0b57b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity_72ef61c2-8f90-405f-bf90-64705ce99129_terseLabel_en-US" xlink:label="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liabilities to equity</link:label>
    <link:label id="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity_label_en-US" xlink:label="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liabilities To Equity</link:label>
    <link:label id="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity_documentation_en-US" xlink:label="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liabilities To Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:href="inhibrx-20200930.xsd#inhibrx_ReclassificationOfWarrantLiabilitiesToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:to="lab_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c6d4c298-35e2-487c-b1fa-a7f6973208ce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liabilities to equity</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c8dee054-1e65-49bf-a5d5-8682b6fd1c14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGGREGATE INTRINSIC VALUE, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_31ddc03f-f377-4d30-958c-cc274f8ec9a1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_10085f24-830a-4e73-a2d5-c6a55a9bfe4e_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization milestone payment receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercialization Milestone Receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercialization Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:to="lab_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_411cf0e3-d592-41ee-8d8f-c0a6420662c2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f9f8371a-f9e9-422f-81dd-e3c41632332a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 120,000,000 and 65,000,000 shares authorized as of September&#160;30, 2020 and December&#160;31, 2019, respectively; 37,710,190 and 18,154,119 issued and outstanding as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_0efd3d78-df8b-4923-91a3-512b2363a1eb_negatedTerseLabel_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs paid</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_label_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stock Issuance Costs, Abandoned IPO Attempt</link:label>
    <link:label id="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_documentation_en-US" xlink:label="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Stock Issuance Costs, Abandoned IPO Attempt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" xlink:to="lab_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_8cdb6597-901e-4b43-816a-1f850da564d6_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and including final payment fee</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a98b4164-334d-44b1-b1ff-2576acb4821b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_f8e1d7b7-8f6b-42a7-b87f-315127ddf559_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ChiesiFarmaceuticiSpAMember_b9a72a76-f4f9-4126-a777-e15ca4145e62_terseLabel_en-US" xlink:label="lab_inhibrx_ChiesiFarmaceuticiSpAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chiesi Farmaceutici S.p.A.</link:label>
    <link:label id="lab_inhibrx_ChiesiFarmaceuticiSpAMember_label_en-US" xlink:label="lab_inhibrx_ChiesiFarmaceuticiSpAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chiesi Farmaceutici S.p.A. [Member]</link:label>
    <link:label id="lab_inhibrx_ChiesiFarmaceuticiSpAMember_documentation_en-US" xlink:label="lab_inhibrx_ChiesiFarmaceuticiSpAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chiesi Farmaceutici S.p.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ChiesiFarmaceuticiSpAMember" xlink:href="inhibrx-20200930.xsd#inhibrx_ChiesiFarmaceuticiSpAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ChiesiFarmaceuticiSpAMember" xlink:to="lab_inhibrx_ChiesiFarmaceuticiSpAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_fb85abc7-7ba3-4422-bf6e-ee800d621574_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0931e390-60d1-401f-bc1e-226292cc74f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion, including debt discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ae797b8f-9741-4a82-bf05-3ee996188a85_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_58b4da99-71e7-405b-b908-7add954c474e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d5f7f245-1b1f-43e8-917c-3a0b80275b33_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_e6164c6a-fe56-4a47-98dc-54a811610335_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f200b237-19a4-4b91-b07b-bdef97d14832_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_80299562-19a4-4172-8b4f-e1c58ded2f6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1816353-8159-42e6-8351-60c5e20abe59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award issued, per unit value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_1c7c26de-f629-4065-932e-bed9e0cc3e23_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_03d319e8-1696-4402-b0c4-ab63c2fd1dce_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP loan</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5241b964-277e-442e-b9d7-b9f3a6a7ab9f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_27b3ab14-80bb-43c4-a267-1ff577310e99_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_792fdaf0-2b20-4616-a1ea-f72c80aaa22d_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3d2d3a14-c266-4860-8d93-ce7e371f3c9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f77e47d9-1eaf-457d-9ea1-3263ab8c0510_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_248d9b30-083d-42d4-9570-098d36ff25f1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_444ebc20-8657-49e0-ad12-d7bc874b5f50_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e3349c63-b6de-4301-9f98-f2d63ca418c4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including debt discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_NumberOfOperatingLeasesHeld_d83792a5-c95b-4182-abbb-783bee76f5e2_terseLabel_en-US" xlink:label="lab_inhibrx_NumberOfOperatingLeasesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases held</link:label>
    <link:label id="lab_inhibrx_NumberOfOperatingLeasesHeld_label_en-US" xlink:label="lab_inhibrx_NumberOfOperatingLeasesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases Held</link:label>
    <link:label id="lab_inhibrx_NumberOfOperatingLeasesHeld_documentation_en-US" xlink:label="lab_inhibrx_NumberOfOperatingLeasesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfOperatingLeasesHeld" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfOperatingLeasesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_NumberOfOperatingLeasesHeld" xlink:to="lab_inhibrx_NumberOfOperatingLeasesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_167c0e84-6049-4406-b056-082ed9a08be8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_98d752f0-42f6-4a0b-96c4-718e612fdde5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b46c651-333f-4fae-bad3-61e93ab13b4e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; no and 25,765,000 shares authorized at September&#160;30, 2020 and December&#160;31, 2019, respectively; no and 12,534,331 shares issued and outstanding at September&#160;30, 2020 and December&#160;31, 2019 respectively; liquidation preferences of $0 and $87.5 million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1e665a8e-af66-428e-98ef-6b9ed92f0972_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentInterestRateFloor_a91269e9-ec63-4cc8-bf0d-3d340d41fcb2_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual interest rate, floor</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentInterestRateFloor_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentInterestRateFloor_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestRateFloor" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentInterestRateFloor" xlink:to="lab_inhibrx_DebtInstrumentInterestRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f91f2749-ca0e-47cd-8573-9fbfcf9a9615_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_68264043-cc68-48ab-8738-2381db4fec8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4749c382-2861-41dc-9789-22e3b1661655_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fe72ad5-b095-4f90-ae34-472d31cdd6b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentPrepaymentFee_b8684ba1-7572-4664-b1e6-c2637de5ea37_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentPrepaymentFee_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentPrepaymentFee_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPrepaymentFee" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPrepaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentPrepaymentFee" xlink:to="lab_inhibrx_DebtInstrumentPrepaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WarrantsLiability_074e654d-4c88-476b-aa46-17962b26517d_terseLabel_en-US" xlink:label="lab_inhibrx_WarrantsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants liability</link:label>
    <link:label id="lab_inhibrx_WarrantsLiability_label_en-US" xlink:label="lab_inhibrx_WarrantsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Liability</link:label>
    <link:label id="lab_inhibrx_WarrantsLiability_documentation_en-US" xlink:label="lab_inhibrx_WarrantsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsLiability" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WarrantsLiability" xlink:to="lab_inhibrx_WarrantsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_901e1dfb-194c-4a43-9328-67bc06496477_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_6a0b512c-4a0a-4e91-9239-ef853918fea7_terseLabel_en-US" xlink:label="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share, percentage reimbursed by sponsor</link:label>
    <link:label id="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_label_en-US" xlink:label="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Awarded, Payment Structure, Percentage Reimbursed By Sponsor</link:label>
    <link:label id="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_documentation_en-US" xlink:label="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Awarded, Payment Structure, Percentage Reimbursed By Sponsor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" xlink:to="lab_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_60411971-fea8-4a03-ad81-1ceb46108197_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_0d38eb1f-9e0b-4e7e-a60a-b92fb04e2cac_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9cd804af-80f3-463c-a6ec-c0ddcb05528d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_49393b8d-1fd8-45f9-bbcc-88bc23bdcf4d_verboseLabel_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Mezzanine Preferred Stock (in shares)</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_a0f52470-53d2-44dc-bbc2-5ef12df9478b_terseLabel_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_59605e1b-9332-4123-a176-f542d76af0fd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e3aa4b26-65ce-4a8d-b79e-2b8d61c4cda8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0e355b07-9607-4732-b57b-7b7cd919fb2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7e4ba09a-07fe-4e8c-85da-40f996a8f137_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_362c3bdf-b30f-4c4e-abdd-f65fb9f817e2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_96d3f616-ab0b-4190-a3e0-d371beb3b571_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_7ab6846a-d639-4a4c-8f6d-503d2f423f63_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1d0a733c-4d8b-42aa-8a83-1e632b3819c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY COMPENSATION PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_79c7f81c-3803-4aa1-a661-bdeb1002175d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c993dcf7-3f62-4463-8db9-5b4075ebcbc6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb63666e-31b8-4d4a-af6a-3abda904d850_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e5bab965-76d4-48ba-8419-787dcca16fa4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_8da023ee-721a-4eda-a12d-46825e2c8f3b_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs related to collaborative agreement</link:label>
    <link:label id="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_label_en-US" xlink:label="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number Of Related Programs To Agreement</link:label>
    <link:label id="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number Of Related Programs To Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:to="lab_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c0cddcff-7a45-4af8-a98e-0d5da1f10848_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (3 months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9da95c52-7c56-4f45-aaad-acf2a6a7c203_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_780da625-a36c-4197-8341-418a7bbbf050_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_0f371cbe-670c-49ee-8717-8c8b66f36478_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_d92dcaeb-8ab3-4177-b7cc-209bad778027_terseLabel_en-US" xlink:label="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities derecognized from agreements</link:label>
    <link:label id="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_label_en-US" xlink:label="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Derecognized During Period</link:label>
    <link:label id="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_documentation_en-US" xlink:label="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Derecognized During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:href="inhibrx-20200930.xsd#inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:to="lab_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_98f75a69-51f2-4763-ba7f-ed1eeff39738_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-only payment period</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest-Only Payment Period</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest-Only Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestOnlyPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:to="lab_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_529dbb1b-c27a-4b43-b552-64989907d461_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid_1120aaa1-e213-4bbc-8eb0-61c19d74846c_terseLabel_en-US" xlink:label="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_StockIssuanceCostsIncurredButNotYetPaid" xlink:href="inhibrx-20200930.xsd#inhibrx_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_inhibrx_StockIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e9cb5b9b-f0e4-4f40-96b1-2a22db31eaa7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_312bc5ff-6909-440b-9587-fa589d99b2a3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_87285504-c0ae-43d1-8ab0-476b13019e7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ExpensesReimbursedToDate_8f247e89-ed93-40df-b839-b69484b510f2_terseLabel_en-US" xlink:label="lab_inhibrx_ExpensesReimbursedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for related party transaction expenses incurred to date</link:label>
    <link:label id="lab_inhibrx_ExpensesReimbursedToDate_label_en-US" xlink:label="lab_inhibrx_ExpensesReimbursedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Reimbursed To Date</link:label>
    <link:label id="lab_inhibrx_ExpensesReimbursedToDate_documentation_en-US" xlink:label="lab_inhibrx_ExpensesReimbursedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Reimbursed To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ExpensesReimbursedToDate" xlink:href="inhibrx-20200930.xsd#inhibrx_ExpensesReimbursedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ExpensesReimbursedToDate" xlink:to="lab_inhibrx_ExpensesReimbursedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_f9e25225-8760-44e6-9b5d-f4d68f5d528d_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable, upfront payment</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Upfront Payment</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:to="lab_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_a03d77a5-6ee3-485c-bdbc-5020c8ed3c98_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount for final payment</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:to="lab_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a9977187-4b07-4c15-a400-bc79007d2a15_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable for shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_476c3796-6e23-4097-b220-5cf1e78839e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NUMBER OF SHARES</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5b214a5c-ef58-4302-ad73-c3e9ce7f7ca3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_c6be7c0b-e5ea-4fb6-9f38-c50c8e925f27_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_c1b641b0-ce4d-411f-9f91-7d75bea46ea5_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest only payments, extended term</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Only Payments, Extended Term</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Only Payments, Extended Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" xlink:to="lab_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_a8c52a57-82f4-4572-b18e-54c547c44c9c_terseLabel_en-US" xlink:label="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of License and Grant Revenue</link:label>
    <link:label id="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_label_en-US" xlink:label="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License And Grant Revenue [Table Text Block]</link:label>
    <link:label id="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_documentation_en-US" xlink:label="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License And Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:href="inhibrx-20200930.xsd#inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:to="lab_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_cfa4c1e1-6dce-49fe-bd7e-ff1267bfc739_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_22cb4c69-a36b-4aab-89a1-777ba379ce74_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_399ea9b7-9bf6-444b-be6a-8bab27643183_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6e77a619-ae43-4f5d-a9e6-f8b52a286137_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f3eea480-6f64-4735-b7e6-d7b26cbdc562_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_bd719b25-d264-44d7-b797-b85117a1b789_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f59b4ac5-8368-4e84-8078-c2617f21ce95_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d27922d4-0a53-4cd5-bd09-7985f19593ea_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e682efdc-34b3-4d09-ab54-a3dfbdcbb286_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_87539bff-6b2c-4a2c-b204-df183900fd89_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equal payments of principal and interest, extended term</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Equal Payments Of Principal And Interest, Extended Term</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Equal Payments Of Principal And Interest, Extended Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" xlink:to="lab_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_2dae0b9f-660e-4261-9095-e787f202a21e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d0e9f573-c266-4db5-a1b0-8de3703f117c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_baba0da8-8854-496f-9881-b6f9634c968a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_798010a6-4ecb-4126-86aa-d7c8d4a112de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_42c0c0dc-9d35-4d43-8f52-9517bcc96285_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CelgeneMember_f1f7ff31-a396-4ec3-9061-c2c76e32f91c_terseLabel_en-US" xlink:label="lab_inhibrx_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:label id="lab_inhibrx_CelgeneMember_label_en-US" xlink:label="lab_inhibrx_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene [Member]</link:label>
    <link:label id="lab_inhibrx_CelgeneMember_documentation_en-US" xlink:label="lab_inhibrx_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CelgeneMember" xlink:href="inhibrx-20200930.xsd#inhibrx_CelgeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CelgeneMember" xlink:to="lab_inhibrx_CelgeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_58ba2f4c-796b-43b8-9a40-3eee674bcd0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5cdc05f-a8c5-4cd4-8c58-961e3ce7d993_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note monthly interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1d26d5d-82c5-4eff-920a-8de7ca12a81e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0a30084a-f8da-4cc6-acec-75c8d078b4e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_044a36d4-9122-424d-a0e2-32996fc22e33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_abcfc9b6-e544-4cc2-b087-2517d5a4b8f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_70ab5951-d218-4509-abef-77ad2b7b6d13_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized related to performance obligation</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4f48602e-6ecf-4e75-a8e9-0e53f70e2811_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d0505f6a-d1fc-4f12-8486-fb43e125c3b8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ShareBasedCompensationNumberOfPlans_fa2673aa-2479-4ef0-8081-4f314bf13f00_terseLabel_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share-based compensation plans</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationNumberOfPlans_label_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Number Of Plans</link:label>
    <link:label id="lab_inhibrx_ShareBasedCompensationNumberOfPlans_documentation_en-US" xlink:label="lab_inhibrx_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Number Of Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationNumberOfPlans" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ShareBasedCompensationNumberOfPlans" xlink:to="lab_inhibrx_ShareBasedCompensationNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5cc99807-94bb-4280-8f66-da3fde3b43c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5eb4c8bc-83f1-4241-864f-f2d91ed57396_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a2a3e289-f1e4-4025-8eed-f5604601a54e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b2d6aae4-7ba6-4b02-9a3f-90d96a0611fe_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_baf227dd-70c8-4032-b70a-408288a40861_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e689f296-da3a-433a-9d00-5c1c6cc6441c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40e067b0-fe92-4f11-a11a-cf61f5a36601_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e921f587-e92d-4c11-be93-669c369fdc31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8426e311-06a7-46e4-a4c6-740c69e43b52_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7eedd3e5-5a98-42f3-bc3c-06a027f55b34_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8b78b84b-a4bc-4deb-b502-78945216c234_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of outstanding warrants to purchase convertible preferred stock into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_6e477aca-ea7c-440e-b0d1-058aa0311dc6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e223fe4b-88f1-4966-9ec6-db4c03f48598_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_7d4585fa-30c4-4e31-b6e2-98cf4f3fe9cb_terseLabel_en-US" xlink:label="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program, Cash from DoD</link:label>
    <link:label id="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_label_en-US" xlink:label="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program, Cash From Department Of Defense [Member]</link:label>
    <link:label id="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_documentation_en-US" xlink:label="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program, Cash From Department Of Defense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" xlink:href="inhibrx-20200930.xsd#inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" xlink:to="lab_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_745bb5f2-084f-4f15-989f-4a3fa1bc1f10_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84b91fc8-2dee-478c-a4b0-7dfcfa0c9d32_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_85445002-9ca2-483b-99f9-39437211359f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion_0e70b2a9-d730-49fc-a930-9fdf0f5a2575_terseLabel_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of lease extension agreement (in sq feet)</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion_label_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage Expansion</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion_documentation_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage Expansion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseSquareFootageExpansion" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseSquareFootageExpansion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LesseeOperatingLeaseSquareFootageExpansion" xlink:to="lab_inhibrx_LesseeOperatingLeaseSquareFootageExpansion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_209a9ef4-b526-4006-bed2-bdeddd55cbc0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_582ac694-ec3b-489d-9044-87f837ec068a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_ebf94703-66aa-4606-a778-d4cd9bf5cd5a_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payment receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:to="lab_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_81ce18d8-d79d-4f31-a627-6ad35b6a2af2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_1c79a5be-c0e1-4249-b51d-3e9bae565171_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_f0bfaba5-26f9-43aa-9bab-4140a5c30972_terseLabel_en-US" xlink:label="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price, as a percentage of stock price</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_label_en-US" xlink:label="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Percentage Of Share Price</link:label>
    <link:label id="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_documentation_en-US" xlink:label="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Percentage Of Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" xlink:to="lab_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8339f514-c4bc-4462-8278-9daa6b43e138_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a3bc5379-4f4e-45b8-9aa5-8f737b36e15c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_PaycheckProtectionProgramCARESActMember_c8756a4e-8cff-42b5-9bd5-1c0308a3c27c_terseLabel_en-US" xlink:label="lab_inhibrx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:label id="lab_inhibrx_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_inhibrx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_inhibrx_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_inhibrx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaycheckProtectionProgramCARESActMember" xlink:href="inhibrx-20200930.xsd#inhibrx_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_PaycheckProtectionProgramCARESActMember" xlink:to="lab_inhibrx_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3beaac32-bf77-4dc2-a892-45c37ba68682_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3837b708-5c8e-41af-b692-31f77133d1c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95be3ee3-a4e6-4be5-aa47-4a3a372bd40f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9c6aca3d-5124-4075-8143-041185ef7a64_terseLabel_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of preferred shares (in shares)</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_eb30d40e-590c-4e5f-a72d-6b929ea2d6a7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8e0f8209-0fb5-4866-81e7-7c286494f2a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_a384b70a-bd48-4bd6-8a06-ce709588a0ff_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6075fb06-f92c-4cf9-844b-0b1a0098b24c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8eecf182-198f-459e-b112-e126dffe48e2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3be2e459-000d-4682-99ac-d5563327a1de_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_dc6b0aaa-93fd-4ace-87e9-820f50650356_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_914313ee-4c5f-4246-9485-f779da7bc12d_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_897ac0d0-0de5-4ed3-a191-562e1689628f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_98c0f24a-ebfc-440e-8d92-a4ee26af6a4e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d78b7b2c-ef24-4b8e-965e-c8e99d8dad11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff Vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c4156de8-5534-429a-9155-82c138f09e58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Notes Measured at Fair Value Using Level 3 Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b754071-7656-45f1-b7a9-9e63c85da40b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5726822a-be0c-46c9-83dd-dd182c1edcfb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_63550df4-d2d0-4529-9302-ef73cd99e242_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e91d8b72-7f36-4302-bb57-c1a0ad83b091_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_57eab62d-05f9-41a4-853e-175747472864_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7de42365-4eb2-47cb-9137-ca840c3e29df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_36b65f91-a622-400f-94d3-351262dca159_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_88ec9c8f-dd64-45f0-9c7e-b35190373ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to reimbursement of agreement</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1a617ccf-99ec-4370-a7dd-5fdf8ad3b28a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8b1d2175-9960-4967-8c88-9880fc2d7c04_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_91d76a35-29b4-4fc2-8cb0-ac105f01bf8f_terseLabel_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of preferred shares</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label id="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_b8cbe0c8-5d22-4dfb-9705-681d2822a275_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_8d406f11-f31b-48d8-9628-1899c5baa984_terseLabel_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial base rent per month</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_label_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Initial Base Rent Expense Per Month</link:label>
    <link:label id="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_documentation_en-US" xlink:label="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Initial Base Rent Expense Per Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:to="lab_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_78f8f08e-69c5-4db7-9dab-399a58dde415_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d36afb3-0325-440d-ac05-48befe636414_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LiquidityPolicyTextBlock_1500d15c-5873-44e0-8e20-bdad0e533981_terseLabel_en-US" xlink:label="lab_inhibrx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_inhibrx_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_inhibrx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_inhibrx_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_inhibrx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LiquidityPolicyTextBlock" xlink:href="inhibrx-20200930.xsd#inhibrx_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LiquidityPolicyTextBlock" xlink:to="lab_inhibrx_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_0faf49ce-68aa-4485-adc3-ad1f52e1e8c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_97d048fe-3fc7-47dc-869a-1b57391da07f_terseLabel_en-US" xlink:label="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common or preferred stock warrants issued as a percent of funded amount</link:label>
    <link:label id="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_label_en-US" xlink:label="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Percentage Of Funded Amount Issued</link:label>
    <link:label id="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_documentation_en-US" xlink:label="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Percentage Of Funded Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:href="inhibrx-20200930.xsd#inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:to="lab_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_A2019ConvertiblePromissoryNoteMember_d700030d-44be-4b8e-9588-52497eef30dd_terseLabel_en-US" xlink:label="lab_inhibrx_A2019ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Note</link:label>
    <link:label id="lab_inhibrx_A2019ConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_inhibrx_A2019ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_inhibrx_A2019ConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_inhibrx_A2019ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_A2019ConvertiblePromissoryNoteMember" xlink:to="lab_inhibrx_A2019ConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_06fff3e1-3b88-4b15-aa03-dd5c4c5167f9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge of amortized debt issuance costs to interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e8cbc0ef-500b-4ff0-bc60-88e83f6bfe59_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c045c7d6-cce2-40f6-97d1-c9917adf2adc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_f66bbc38-206f-4ed0-b0b5-6119b6db0778_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_461879cf-7b77-4ca6-9230-1984dcbfa1c9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8a1745e1-fe76-4cd4-9972-b7b13f59e8bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_578ec867-c252-409d-b658-dbfd646c6568_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ebc1eec3-51a0-45ec-a77d-6b7d0c5d959e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_47fd273e-b770-4f1f-bed3-11f88d400fd8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_NumberOfPerformanceObligations_c3f15532-063f-4443-aa68-16c2ff0e14bf_terseLabel_en-US" xlink:label="lab_inhibrx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_inhibrx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_inhibrx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_inhibrx_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_inhibrx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfPerformanceObligations" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_NumberOfPerformanceObligations" xlink:to="lab_inhibrx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3af8c1f-158e-47f9-809a-c8aac6581f77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fda9727-780a-4864-ba24-073b7c995976_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0355daed-c7ec-42d9-91c5-919e327b40f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_e675642f-f48d-4238-823f-a9cf7a800cf2_terseLabel_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Programs</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_label_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized [Member]</link:label>
    <link:label id="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_documentation_en-US" xlink:label="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:to="lab_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_196a0299-55f2-4321-b998-593d5ff6beee_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_85a7b7e7-cfc9-435d-b19f-2cf415c240f8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable for expenses incurred, not yet reimbursed</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_NumberOfLicenseAgreements_ad60251b-3366-4b8e-a42a-13927c097309_terseLabel_en-US" xlink:label="lab_inhibrx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements</link:label>
    <link:label id="lab_inhibrx_NumberOfLicenseAgreements_label_en-US" xlink:label="lab_inhibrx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:label id="lab_inhibrx_NumberOfLicenseAgreements_documentation_en-US" xlink:label="lab_inhibrx_NumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfLicenseAgreements" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_NumberOfLicenseAgreements" xlink:to="lab_inhibrx_NumberOfLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_WuXiBiologicsHealthcareVentureMember_ddc74dd6-2575-48b3-8271-6febe4d9b32a_terseLabel_en-US" xlink:label="lab_inhibrx_WuXiBiologicsHealthcareVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics Healthcare Venture</link:label>
    <link:label id="lab_inhibrx_WuXiBiologicsHealthcareVentureMember_label_en-US" xlink:label="lab_inhibrx_WuXiBiologicsHealthcareVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics Healthcare Venture [Member]</link:label>
    <link:label id="lab_inhibrx_WuXiBiologicsHealthcareVentureMember_documentation_en-US" xlink:label="lab_inhibrx_WuXiBiologicsHealthcareVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics Healthcare Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WuXiBiologicsHealthcareVentureMember" xlink:href="inhibrx-20200930.xsd#inhibrx_WuXiBiologicsHealthcareVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_WuXiBiologicsHealthcareVentureMember" xlink:to="lab_inhibrx_WuXiBiologicsHealthcareVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_0839965c-b85b-434f-9cc5-b5ca08ffe381_terseLabel_en-US" xlink:label="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease, by Balance Sheet Location</link:label>
    <link:label id="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_label_en-US" xlink:label="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset And Operating Lease Liability [Table Text Block]</link:label>
    <link:label id="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset And Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:href="inhibrx-20200930.xsd#inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:to="lab_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7807a1af-22b9-4a37-81df-af05c6193d39_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_43b81fa6-5952-48c5-9423-3c42757d96f6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_651ac8c7-1b54-4557-8d72-2a22b588a2b9_terseLabel_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payable due from agreement</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_label_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable</link:label>
    <link:label id="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_documentation_en-US" xlink:label="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementAdditionalPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:to="lab_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_05d5c6d3-7820-406a-bd02-2e8ffc7da68c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08229bc3-7327-40af-a658-aa742f7af39f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>inhibrx-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:3fe0b274-dc64-47fa-9492-4cc4ecb00ef6,g:c0dac7ab-748b-42c9-8c2a-26a240098d0f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/Cover" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eb2cdf70-566f-465d-8a20-71c79a39db9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_DocumentType_eb2cdf70-566f-465d-8a20-71c79a39db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6df4bea0-f565-4fb7-acf4-cdd48c0d6937" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_DocumentQuarterlyReport_6df4bea0-f565-4fb7-acf4-cdd48c0d6937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_411ba71b-eb0a-4258-ad90-1689237c2e76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_DocumentPeriodEndDate_411ba71b-eb0a-4258-ad90-1689237c2e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6bd16ef3-be52-48ae-bc95-e84dbef99a68" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_DocumentTransitionReport_6bd16ef3-be52-48ae-bc95-e84dbef99a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7733f0aa-f6a2-4b6f-ae31-ebe519769b76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityFileNumber_7733f0aa-f6a2-4b6f-ae31-ebe519769b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b9ed8d8d-c63a-42c4-aaa5-0b0dbebe42bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityRegistrantName_b9ed8d8d-c63a-42c4-aaa5-0b0dbebe42bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8797a40f-1bef-4987-b623-021b8e50c9cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8797a40f-1bef-4987-b623-021b8e50c9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dd28c3d5-422c-43f6-9af1-8aed7b1782aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityTaxIdentificationNumber_dd28c3d5-422c-43f6-9af1-8aed7b1782aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4969457c-2c35-4ce5-b67d-a868fc764578" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityAddressAddressLine1_4969457c-2c35-4ce5-b67d-a868fc764578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_359f16d5-e953-43a7-8720-b78b50037d6b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityAddressAddressLine2_359f16d5-e953-43a7-8720-b78b50037d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e7eaa067-81f4-4135-9ebb-b169a827588d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityAddressCityOrTown_e7eaa067-81f4-4135-9ebb-b169a827588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_05e1b457-aee8-4a24-aca6-8f5d371ad6fb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityAddressStateOrProvince_05e1b457-aee8-4a24-aca6-8f5d371ad6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_13339047-7076-4a05-b672-01836a100e53" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityAddressPostalZipCode_13339047-7076-4a05-b672-01836a100e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_90ce6ddf-6dc7-4cb0-9452-464deaa7da39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_CityAreaCode_90ce6ddf-6dc7-4cb0-9452-464deaa7da39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_760f7036-a5a8-416e-ba9c-1eec5c079c7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_LocalPhoneNumber_760f7036-a5a8-416e-ba9c-1eec5c079c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_45981496-0ee1-453f-91d1-73f5f01e9ef2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_Security12bTitle_45981496-0ee1-453f-91d1-73f5f01e9ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_779bfd89-fc96-44cd-9c2c-fae337c477af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_TradingSymbol_779bfd89-fc96-44cd-9c2c-fae337c477af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b91df3a9-4d7d-4587-a2bd-ccaf0c655c51" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_SecurityExchangeName_b91df3a9-4d7d-4587-a2bd-ccaf0c655c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2de21b6f-b00b-4380-939e-52715395882e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityCurrentReportingStatus_2de21b6f-b00b-4380-939e-52715395882e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a6546f56-01e2-401a-a336-7aaff247cdb4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityInteractiveDataCurrent_a6546f56-01e2-401a-a336-7aaff247cdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c402f6ae-0f96-4c64-b1d7-4b5c654b81ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityFilerCategory_c402f6ae-0f96-4c64-b1d7-4b5c654b81ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4e081e05-fe43-4299-9bbd-6c6b008cda70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntitySmallBusiness_4e081e05-fe43-4299-9bbd-6c6b008cda70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c853db77-0a1c-4644-a4bf-987ddea3b5e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityEmergingGrowthCompany_c853db77-0a1c-4644-a4bf-987ddea3b5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_4a293251-1cea-4707-bd0c-3e1ab4048c37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityExTransitionPeriod_4a293251-1cea-4707-bd0c-3e1ab4048c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9a783186-eca2-4eed-88a9-cad9fde40529" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityShellCompany_9a783186-eca2-4eed-88a9-cad9fde40529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cc74cce0-71bf-4d8f-bda4-da8002fd56bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cc74cce0-71bf-4d8f-bda4-da8002fd56bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c379592c-4e82-4193-b1c0-9f3f6d49d6f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_CurrentFiscalYearEndDate_c379592c-4e82-4193-b1c0-9f3f6d49d6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_345077c8-5e35-4101-948b-12e1ef353ff7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_AmendmentFlag_345077c8-5e35-4101-948b-12e1ef353ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bc72de4d-b21f-4600-b877-b9a6bb35132c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_EntityCentralIndexKey_bc72de4d-b21f-4600-b877-b9a6bb35132c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_68719e3f-77de-4ef0-8da4-3ea27ca1af24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_DocumentFiscalYearFocus_68719e3f-77de-4ef0-8da4-3ea27ca1af24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_13cd3eb0-f9d0-49ce-a6fb-2950b6e75e0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5786ad45-eb62-4bf0-8a1a-c81dea0b9e4e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_13cd3eb0-f9d0-49ce-a6fb-2950b6e75e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0a2dce1-b416-4a25-81e3-7b4c3567cb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0a2dce1-b416-4a25-81e3-7b4c3567cb05" xlink:to="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_219bc85e-e326-45a1-bd6c-236e70cc8bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_219bc85e-e326-45a1-bd6c-236e70cc8bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0b5eea03-ea34-4d2d-8190-de02c82adcff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0b5eea03-ea34-4d2d-8190-de02c82adcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_ec4a9402-9a5d-4973-a6be-4a01534a612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_ec4a9402-9a5d-4973-a6be-4a01534a612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9055684f-dfe5-479d-9071-6009d063b6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9055684f-dfe5-479d-9071-6009d063b6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a67626f1-ef5a-4ddc-82d2-f74e63338c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9244ed34-7467-45cf-a2b3-75042fb7ddee" xlink:to="loc_us-gaap_AssetsCurrent_a67626f1-ef5a-4ddc-82d2-f74e63338c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_836b27b3-0444-4336-a926-53f0cb5a8aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_836b27b3-0444-4336-a926-53f0cb5a8aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_79df9186-4e6f-4f14-ab5b-30a86869ff16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_79df9186-4e6f-4f14-ab5b-30a86869ff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9681b370-a2f7-4737-a8e7-628a24c5755c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9681b370-a2f7-4737-a8e7-628a24c5755c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39f441f4-3458-4581-a5f9-37238b8af38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d23fc3c-6d47-43f3-825e-bd16e94526b5" xlink:to="loc_us-gaap_Assets_39f441f4-3458-4581-a5f9-37238b8af38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0a2dce1-b416-4a25-81e3-7b4c3567cb05" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a05db8b5-e0aa-4ac4-ab0c-cc12af21ab43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_AccountsPayableCurrent_a05db8b5-e0aa-4ac4-ab0c-cc12af21ab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7a1e9356-643f-4172-907a-d75a4bd8e53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7a1e9356-643f-4172-907a-d75a4bd8e53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9dfea4b8-6f6d-4840-808f-bc33a6629175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9dfea4b8-6f6d-4840-808f-bc33a6629175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7c708370-40bb-4cb3-a4d0-cc592d0692b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_LongTermDebtCurrent_7c708370-40bb-4cb3-a4d0-cc592d0692b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f188127e-e4f7-4e28-a283-8d78e90b6876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f188127e-e4f7-4e28-a283-8d78e90b6876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_c8fc4579-d69b-4d0d-9c7f-5fdc8224794b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_ShortTermBorrowings_c8fc4579-d69b-4d0d-9c7f-5fdc8224794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4e189b96-4c1d-412b-ab37-4c17b0e94dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4e189b96-4c1d-412b-ab37-4c17b0e94dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_203ef687-5deb-4f37-919d-335f935b6af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f890ce40-ad92-441d-a243-fa44ac8609fb" xlink:to="loc_us-gaap_LiabilitiesCurrent_203ef687-5deb-4f37-919d-335f935b6af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_a534ffc5-c037-4092-905d-fb95a6a8cffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_a534ffc5-c037-4092-905d-fb95a6a8cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_481a717a-d9e4-4f74-9afc-fe2b0eac102c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_481a717a-d9e4-4f74-9afc-fe2b0eac102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_dee29101-63a1-4a93-bc83-551cf25adfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_dee29101-63a1-4a93-bc83-551cf25adfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_553869e7-88f5-44c0-b054-61781bdf745b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_SecuredLongTermDebt_553869e7-88f5-44c0-b054-61781bdf745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b1ee020-86eb-45f7-90a3-62045a2e43ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b1ee020-86eb-45f7-90a3-62045a2e43ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_82080521-9424-40dd-9d5e-6c8c82822d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_Liabilities_82080521-9424-40dd-9d5e-6c8c82822d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_16cb398e-4107-4c28-bd00-2a15282860b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_CommitmentsAndContingencies_16cb398e-4107-4c28-bd00-2a15282860b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8c585580-e40b-4a1c-bb66-bfb2bb8c98e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8c585580-e40b-4a1c-bb66-bfb2bb8c98e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0ef1d8c5-cf7d-4d13-91a9-5e970ad1eb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:to="loc_us-gaap_PreferredStockValue_0ef1d8c5-cf7d-4d13-91a9-5e970ad1eb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0ad0f4e0-5298-470f-ae7c-df4eeed958ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:to="loc_us-gaap_CommonStockValue_0ad0f4e0-5298-470f-ae7c-df4eeed958ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2b2c5cc5-e114-4051-a921-69fdaa05d67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2b2c5cc5-e114-4051-a921-69fdaa05d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57037245-6d3c-4d1a-9530-abc2566a6e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57037245-6d3c-4d1a-9530-abc2566a6e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b6aec24d-c4a5-403b-a7ac-47f8da738e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_baae1d91-fe8d-48f1-8660-049e2548a158" xlink:to="loc_us-gaap_StockholdersEquity_b6aec24d-c4a5-403b-a7ac-47f8da738e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5530e029-a01c-4e31-83b5-b89809ca7ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44a7b1e-4ce0-4a19-92c2-330d2b4c5893" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5530e029-a01c-4e31-83b5-b89809ca7ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_c894bd4c-764e-41e8-8fad-e8fd778e7c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_c894bd4c-764e-41e8-8fad-e8fd778e7c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_ac48a5ed-1236-4b03-abf6-a33599042fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_ac48a5ed-1236-4b03-abf6-a33599042fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_6a6b1445-2dab-4f21-a048-79b74eeeb6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_6a6b1445-2dab-4f21-a048-79b74eeeb6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b3c698ee-025a-4ea0-b599-61d027a7c23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_b3c698ee-025a-4ea0-b599-61d027a7c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_705bcd10-8794-4010-9aca-6a6282f4d182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_705bcd10-8794-4010-9aca-6a6282f4d182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2d9dd4b8-a21c-4372-9e12-345134449e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2d9dd4b8-a21c-4372-9e12-345134449e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bf68bda1-5d6d-458d-8494-ba27afa6a377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bf68bda1-5d6d-458d-8494-ba27afa6a377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5a3edfda-8e89-48a4-b4f3-28c704c681ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5a3edfda-8e89-48a4-b4f3-28c704c681ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_822a623a-f66b-4b91-8a6d-be3c14185d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_822a623a-f66b-4b91-8a6d-be3c14185d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a3b1703c-041a-493f-bb5f-4f8d8f63a9a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a3b1703c-041a-493f-bb5f-4f8d8f63a9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5ee074fd-bc64-4546-a3d6-1e141ba7d9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5ee074fd-bc64-4546-a3d6-1e141ba7d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b061e530-9017-42c3-b547-8096af97733d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_CommonStockSharesIssued_b061e530-9017-42c3-b547-8096af97733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a90475f7-1427-4b2b-8382-3a44605bc1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_74983642-102a-4f98-8345-055cb894d1ce" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a90475f7-1427-4b2b-8382-3a44605bc1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dd92092f-6327-496f-a3ca-93de93be178e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dd92092f-6327-496f-a3ca-93de93be178e" xlink:to="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:to="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d8e5b3fc-8fb1-4d29-be99-e35eb151435d" xlink:to="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_99732c26-34e8-4c10-b4b3-f5c8898985ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:to="loc_us-gaap_LicenseMember_99732c26-34e8-4c10-b4b3-f5c8898985ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_1ce61fb1-57a2-4eb9-95d5-5738c940e78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_de16ce02-35bb-49d8-89ee-e64463ab8761" xlink:to="loc_us-gaap_GrantMember_1ce61fb1-57a2-4eb9-95d5-5738c940e78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2c0a7f8b-9e07-4837-8636-81f1a83cb6ae" xlink:to="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bc451cc0-dbea-4695-b27d-a74e619d82dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_RevenuesAbstract_bc451cc0-dbea-4695-b27d-a74e619d82dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_100326fa-8de1-42e8-b161-c4938f133c77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bc451cc0-dbea-4695-b27d-a74e619d82dd" xlink:to="loc_us-gaap_Revenues_100326fa-8de1-42e8-b161-c4938f133c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bef98ccb-fb57-4e38-af2c-1dae4130ed66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bef98ccb-fb57-4e38-af2c-1dae4130ed66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5281f1fc-0e7f-46c5-aa00-a159980a87c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5281f1fc-0e7f-46c5-aa00-a159980a87c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_afc4855c-412d-4eaf-9b35-c3997f62f2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_11c9e065-a658-4ad9-8afd-29e31b8d6c76" xlink:to="loc_us-gaap_OperatingExpenses_afc4855c-412d-4eaf-9b35-c3997f62f2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b1df7109-2a8f-477b-b911-baaabb34de26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_OperatingIncomeLoss_b1df7109-2a8f-477b-b911-baaabb34de26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bf24d231-033d-463e-a15d-96f7b80f640c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bf24d231-033d-463e-a15d-96f7b80f640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5be07a46-6482-44bb-aeec-d8d6b68ebd32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5be07a46-6482-44bb-aeec-d8d6b68ebd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_157bde45-47d8-429b-b323-815bc413e5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_157bde45-47d8-429b-b323-815bc413e5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5ef04f71-566b-42c3-90da-1e32440c1ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5ef04f71-566b-42c3-90da-1e32440c1ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_359e3f39-6275-4fb0-adf9-1fed3c375bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b659e2df-1545-4ef3-897a-6db7b678f838" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_359e3f39-6275-4fb0-adf9-1fed3c375bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_443359bc-deb2-499a-8f04-fb58ebc59b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_443359bc-deb2-499a-8f04-fb58ebc59b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ba8faac4-fc9b-4141-80b4-cf65f91636b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ba8faac4-fc9b-4141-80b4-cf65f91636b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cc226d64-3944-4acd-908a-1d88bd5d2db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cc226d64-3944-4acd-908a-1d88bd5d2db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5778dc74-aac9-4950-afc8-e0f1b752e3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_NetIncomeLoss_5778dc74-aac9-4950-afc8-e0f1b752e3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6e2d6f44-a368-404b-8747-950c55be45da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6e2d6f44-a368-404b-8747-950c55be45da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_034dad10-13cd-44bd-9179-264c877b7747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b9654029-1ad6-4e2d-84da-39be42cfbdd4" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_034dad10-13cd-44bd-9179-264c877b7747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_abdc5877-1d95-4074-b533-275de3249ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_abdc5877-1d95-4074-b533-275de3249ba2" xlink:to="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0cb15454-255a-4be0-8d00-a7500b4de647" xlink:to="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2c113ae9-60ce-4b68-b798-61983402b7c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:to="loc_us-gaap_CommonStockMember_2c113ae9-60ce-4b68-b798-61983402b7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_90955493-72a6-4565-8e69-43cb4edc5ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_90955493-72a6-4565-8e69-43cb4edc5ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ec3be5cc-58f2-4b25-b75e-4ce6d949851a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0bff9cc2-1b33-4166-b2f8-392064e58625" xlink:to="loc_us-gaap_RetainedEarningsMember_ec3be5cc-58f2-4b25-b75e-4ce6d949851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4c809e7-b949-4347-9e76-e10e2e55e6ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_4302459b-b115-4ff3-8d5e-076de2e37659" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:to="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_4302459b-b115-4ff3-8d5e-076de2e37659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_11d4fd6d-693e-435f-85e0-3db45134ae2f" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_11d4fd6d-693e-435f-85e0-3db45134ae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_ca7ce27d-fb5e-4daf-aaa1-c2eaa71c5379" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ca5911-c73a-4999-a903-f3face0fa661" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_ca7ce27d-fb5e-4daf-aaa1-c2eaa71c5379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ac1c56e-02a2-4e5b-a075-d9d876a2b97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_79121da2-2b25-4195-9d98-0671d08e6d7d" xlink:to="loc_us-gaap_ClassOfStockDomain_4ac1c56e-02a2-4e5b-a075-d9d876a2b97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_18ecd370-e231-4f0e-b033-e4619cbc6ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ac1c56e-02a2-4e5b-a075-d9d876a2b97d" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_18ecd370-e231-4f0e-b033-e4619cbc6ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8914ca32-343d-4943-9b31-88e2b1aabf53" xlink:to="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_27328859-6d63-49a5-8149-bcbf41a9aca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_27328859-6d63-49a5-8149-bcbf41a9aca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7400a5bd-6773-4372-a6bb-1e5759669755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7400a5bd-6773-4372-a6bb-1e5759669755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3bf1a5bf-1c8c-4c08-9e54-b6dcf3136a96" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3bf1a5bf-1c8c-4c08-9e54-b6dcf3136a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_561d4cdc-2c2b-4555-a52d-4fbc4eced90e" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_561d4cdc-2c2b-4555-a52d-4fbc4eced90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_03bdf561-3537-4aa5-8e4c-74e3f59a6fb4" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_03bdf561-3537-4aa5-8e4c-74e3f59a6fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d10309ae-013f-4f2d-a0d0-72fc2bf56581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d10309ae-013f-4f2d-a0d0-72fc2bf56581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_18caf402-d681-466c-9cbb-5f6ba0077dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_18caf402-d681-466c-9cbb-5f6ba0077dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_992c9161-03a4-4094-8617-cec3246c70a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_72646dee-08f2-409a-a955-e6f6ba0d13a1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_992c9161-03a4-4094-8617-cec3246c70a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f5ba2fc-6ba5-4495-af82-05635c97e36f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b9c42f21-ac28-49dc-868c-709907d2e74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b9c42f21-ac28-49dc-868c-709907d2e74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d16648-00b2-419e-9628-4b20b0de0d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d16648-00b2-419e-9628-4b20b0de0d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_606ce0b7-099c-488b-bcc4-34f14dfd2356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_606ce0b7-099c-488b-bcc4-34f14dfd2356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_100975fe-9d3c-4af9-a6bb-d4cea1df2900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_100975fe-9d3c-4af9-a6bb-d4cea1df2900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86cdc86a-55b2-44e3-b43e-64b58308a21e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86cdc86a-55b2-44e3-b43e-64b58308a21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a2cf9d33-2d0f-41cf-9af6-881e0b809e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a2cf9d33-2d0f-41cf-9af6-881e0b809e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3da8aebf-1456-4d34-bcdc-a42d6713a551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3da8aebf-1456-4d34-bcdc-a42d6713a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2fe48ef8-4001-4339-8b82-988fb3274420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2fe48ef8-4001-4339-8b82-988fb3274420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8a9b4a1a-3d8e-42a0-b243-ea459dabfb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_8a9b4a1a-3d8e-42a0-b243-ea459dabfb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_27bfeb1e-4dd1-4095-96fd-254910e07fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_27bfeb1e-4dd1-4095-96fd-254910e07fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20aa52ee-ad7c-4068-a822-1db9319cbb80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_NetIncomeLoss_20aa52ee-ad7c-4068-a822-1db9319cbb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_713bc223-9d49-45d8-9e67-88f0eef69b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_713bc223-9d49-45d8-9e67-88f0eef69b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7402ae6b-0ae5-42da-9e77-034c9e58fbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_75f8b672-3022-4622-876d-eb29294d5687" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7402ae6b-0ae5-42da-9e77-034c9e58fbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2053a13-d05f-4d89-a3d8-c2b8fed35ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2053a13-d05f-4d89-a3d8-c2b8fed35ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f19d771e-e468-48ce-af98-6c4f2b2003f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2053a13-d05f-4d89-a3d8-c2b8fed35ff7" xlink:to="loc_us-gaap_NetIncomeLoss_f19d771e-e468-48ce-af98-6c4f2b2003f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2053a13-d05f-4d89-a3d8-c2b8fed35ff7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_18dd9db6-283a-459e-8957-36f8581c9cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_18dd9db6-283a-459e-8957-36f8581c9cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_67ccc20c-7061-406f-8664-c8b2b8f847f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_67ccc20c-7061-406f-8664-c8b2b8f847f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f2c2649b-837c-4012-b42e-bab796c3ca2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_ShareBasedCompensation_f2c2649b-837c-4012-b42e-bab796c3ca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NoncashOperatingLeaseExpense_6657ef07-b23b-4957-a1bd-dfdb0d1a667f" xlink:href="inhibrx-20200930.xsd#inhibrx_NoncashOperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_inhibrx_NoncashOperatingLeaseExpense_6657ef07-b23b-4957-a1bd-dfdb0d1a667f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f2eaa66b-5412-4ffa-a951-2c4a039c828a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f2eaa66b-5412-4ffa-a951-2c4a039c828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7e50f186-b485-4e36-9ba9-4bd677a08532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7e50f186-b485-4e36-9ba9-4bd677a08532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_07b48115-6bab-4d16-b77f-dfb835f375b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_07b48115-6bab-4d16-b77f-dfb835f375b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a46e13c7-4298-4fba-8685-7c4061e358d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a46e13c7-4298-4fba-8685-7c4061e358d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_31a49dd1-fdf4-40fc-868a-03ddcc56f69b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f34254e-b40c-4d55-890f-aa56f58236e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f34254e-b40c-4d55-890f-aa56f58236e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_18ed44ff-fbbd-4b51-845b-861698a0f7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_18ed44ff-fbbd-4b51-845b-861698a0f7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13da16e4-3c0c-4686-b60f-d0cfa9604ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13da16e4-3c0c-4686-b60f-d0cfa9604ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a0255721-979d-4c70-9c72-999a455678d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a0255721-979d-4c70-9c72-999a455678d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c2bc8f50-8f8c-40ce-ad05-d8911549632d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c2bc8f50-8f8c-40ce-ad05-d8911549632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e6e863c5-dd7f-40de-990e-78cfda3b0419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e6e863c5-dd7f-40de-990e-78cfda3b0419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a2f3904b-8e13-4289-b610-7dc35ad95aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_OperatingLeasePayments_a2f3904b-8e13-4289-b610-7dc35ad95aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_4ba17a2b-e0ea-4a46-addc-4539f0ee4560" xlink:href="inhibrx-20200930.xsd#inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_4ba17a2b-e0ea-4a46-addc-4539f0ee4560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_e50238ea-def8-40b9-8878-855ade819db8" xlink:href="inhibrx-20200930.xsd#inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_e50238ea-def8-40b9-8878-855ade819db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9e166677-9308-4941-b1bf-36d3c5d14244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c21915d0-1ec3-4acf-b27f-f330fc0accc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9e166677-9308-4941-b1bf-36d3c5d14244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51ba2139-ad99-401a-a5d7-37934ac13935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c2053a13-d05f-4d89-a3d8-c2b8fed35ff7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51ba2139-ad99-401a-a5d7-37934ac13935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_941a2056-9c44-423f-98e7-069ce105dac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_941a2056-9c44-423f-98e7-069ce105dac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_083faed7-8fa1-4b68-8dc0-0dbcf2c3299f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_941a2056-9c44-423f-98e7-069ce105dac7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_083faed7-8fa1-4b68-8dc0-0dbcf2c3299f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5012c147-286a-4a45-aa4c-eaa7033a530d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_941a2056-9c44-423f-98e7-069ce105dac7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5012c147-286a-4a45-aa4c-eaa7033a530d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c4d91ef6-35eb-4a19-8d91-2eb26a7fa774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c4d91ef6-35eb-4a19-8d91-2eb26a7fa774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_fdd23fcc-1bb6-436f-85a0-1df391ecf8f6" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_fdd23fcc-1bb6-436f-85a0-1df391ecf8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_9d75f8e2-1478-4a9c-8a2f-1ca0b3be2774" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt_9d75f8e2-1478-4a9c-8a2f-1ca0b3be2774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_56d998cd-899f-4df8-9bb8-634b79a09fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_56d998cd-899f-4df8-9bb8-634b79a09fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_f908424c-08d6-4467-a9ab-2d33a036d225" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt_f908424c-08d6-4467-a9ab-2d33a036d225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_3a6daeb8-7b9c-4a2e-877f-48340a19b1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_3a6daeb8-7b9c-4a2e-877f-48340a19b1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_10cac635-97bd-4627-b47d-936b11db78c9" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt_10cac635-97bd-4627-b47d-936b11db78c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_f5cf6778-793b-4497-9c98-f6bdd86f39cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_f5cf6778-793b-4497-9c98-f6bdd86f39cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_302e199f-8e9f-42d7-8db5-1990e42270be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_302e199f-8e9f-42d7-8db5-1990e42270be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_3bdd83b2-f91c-4e81-8a16-5416af6a02e1" xlink:href="inhibrx-20200930.xsd#inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment_3bdd83b2-f91c-4e81-8a16-5416af6a02e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_877fb908-d3b2-4aa2-8880-54eb02a00474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_877fb908-d3b2-4aa2-8880-54eb02a00474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_8982eb3a-d160-4e91-b999-8775510e6b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_8982eb3a-d160-4e91-b999-8775510e6b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_63d73a35-d6fb-4c21-b51c-b73870177987" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock_63d73a35-d6fb-4c21-b51c-b73870177987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7fdddd42-2a6a-4a87-a515-83072c22431a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c14b8ff-4ba3-47ac-8cd3-8f12f4147c3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7fdddd42-2a6a-4a87-a515-83072c22431a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_320690c2-858f-4f0d-b772-ca83563071b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_320690c2-858f-4f0d-b772-ca83563071b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddf1974-b628-487e-8813-a05c8df465b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddf1974-b628-487e-8813-a05c8df465b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_807bc8fa-50e6-4d90-b648-4618e219d450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_807bc8fa-50e6-4d90-b648-4618e219d450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cefea36-a48f-4de4-8150-b47ff5dc6726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cefea36-a48f-4de4-8150-b47ff5dc6726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_efdc3bd6-ad49-4939-a952-ccecc80c59de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cefea36-a48f-4de4-8150-b47ff5dc6726" xlink:to="loc_us-gaap_InterestPaidNet_efdc3bd6-ad49-4939-a952-ccecc80c59de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_447eea66-42f1-4e90-aae2-a180fb23a70a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0cefea36-a48f-4de4-8150-b47ff5dc6726" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_447eea66-42f1-4e90-aae2-a180fb23a70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_013ff677-6fa8-4f69-8284-2f8885152daf" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_2361f778-be98-4fc5-9a0f-274654779c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_2361f778-be98-4fc5-9a0f-274654779c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d948b44f-5d4b-45cc-aaaf-b982e7289e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d948b44f-5d4b-45cc-aaaf-b982e7289e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_5dd3ca61-5be0-4b49-9cfe-1da36a30cf3d" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_5dd3ca61-5be0-4b49-9cfe-1da36a30cf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3987d394-d17f-47f0-98db-887f4f184a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3987d394-d17f-47f0-98db-887f4f184a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_ea69ad34-fef9-4ed7-8529-6cffc54e83b2" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_ea69ad34-fef9-4ed7-8529-6cffc54e83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2c0dbc40-33ca-45f1-ac9c-1861c5552351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2c0dbc40-33ca-45f1-ac9c-1861c5552351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NonCashEstablishmentOfEquityMethodInvestment_f93a7f0b-4512-465f-80cf-c3b54fb6b3a5" xlink:href="inhibrx-20200930.xsd#inhibrx_NonCashEstablishmentOfEquityMethodInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_NonCashEstablishmentOfEquityMethodInvestment_f93a7f0b-4512-465f-80cf-c3b54fb6b3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_StockIssuanceCostsIncurredButNotYetPaid_d8ea5d85-be61-4f32-944b-ca0bd4273aed" xlink:href="inhibrx-20200930.xsd#inhibrx_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_StockIssuanceCostsIncurredButNotYetPaid_d8ea5d85-be61-4f32-944b-ca0bd4273aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity_485dc02e-7f7e-4eca-9181-0dddd5040d9d" xlink:href="inhibrx-20200930.xsd#inhibrx_ReclassificationOfWarrantLiabilitiesToEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity_485dc02e-7f7e-4eca-9181-0dddd5040d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_5f1de0f3-473b-42e2-809d-2c31bd47a95b" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_5f1de0f3-473b-42e2-809d-2c31bd47a95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability_e9cf2b90-65c2-46c1-8f2b-db07411d5ca0" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability_e9cf2b90-65c2-46c1-8f2b-db07411d5ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_63cb9f7d-4b45-4487-af0b-64fdd3f4889c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6b678394-c4b9-4d31-8c75-84d857c21585" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_63cb9f7d-4b45-4487-af0b-64fdd3f4889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83010a4a-21d0-4e83-9f05-f8c3b6f75049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6b6b7afe-8aa0-4491-aae4-ee7d1e2e9850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83010a4a-21d0-4e83-9f05-f8c3b6f75049" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6b6b7afe-8aa0-4491-aae4-ee7d1e2e9850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_78a28d60-774e-4567-bd5d-0abe62be4f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_78a28d60-774e-4567-bd5d-0abe62be4f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LiquidityPolicyTextBlock_ce951fa1-4541-4a76-9382-3ffbbccb9d2f" xlink:href="inhibrx-20200930.xsd#inhibrx_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_inhibrx_LiquidityPolicyTextBlock_ce951fa1-4541-4a76-9382-3ffbbccb9d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ee5f14e4-b41a-4aaf-8be1-27e9c7b4ca62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_UseOfEstimates_ee5f14e4-b41a-4aaf-8be1-27e9c7b4ca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_accad119-ad60-4837-a2ef-b716c05bd564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_accad119-ad60-4837-a2ef-b716c05bd564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e8ea0f48-7878-4282-a78e-4a17e6b16f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e8ea0f48-7878-4282-a78e-4a17e6b16f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_eab12b88-b868-4441-acb0-3151a2d6ad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_eab12b88-b868-4441-acb0-3151a2d6ad03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_aec2610e-e816-4cf9-b773-f1607bc22616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_aec2610e-e816-4cf9-b773-f1607bc22616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_75f12bf3-05b4-4949-8b6c-07e90a309b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_75f12bf3-05b4-4949-8b6c-07e90a309b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_29d61a86-79c3-4452-a4cf-17e09557f268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_29d61a86-79c3-4452-a4cf-17e09557f268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9a61ff75-b156-4138-a711-f1f9e39c9906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9a61ff75-b156-4138-a711-f1f9e39c9906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_6b0d3232-1607-4054-a6c1-89b902503533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_6b0d3232-1607-4054-a6c1-89b902503533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_48bef51f-5e2f-404a-a961-7bfa29320401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_48bef51f-5e2f-404a-a961-7bfa29320401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantLiabilitiesPolicyTextBlock_adab3acb-41b7-4617-b31a-51b652bf93f0" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_inhibrx_WarrantLiabilitiesPolicyTextBlock_adab3acb-41b7-4617-b31a-51b652bf93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_040ce800-528e-4b3e-a65c-bd46782d6765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_040ce800-528e-4b3e-a65c-bd46782d6765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_1459e9e5-0b33-40f6-be8f-90f000a4483d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_1459e9e5-0b33-40f6-be8f-90f000a4483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5ca997b4-b6b3-406a-9a85-74c4a5194751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5ca997b4-b6b3-406a-9a85-74c4a5194751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_62c382af-eea8-463c-a8ea-a61af3582e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_62c382af-eea8-463c-a8ea-a61af3582e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a05e81a6-d131-4d7b-9e78-2e17a6c61f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a05e81a6-d131-4d7b-9e78-2e17a6c61f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9f66677f-8825-469d-8330-1c519edfe5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9f66677f-8825-469d-8330-1c519edfe5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_04289a31-f0d8-4ef9-a41d-60a27d578665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_04289a31-f0d8-4ef9-a41d-60a27d578665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49dce5c3-deaa-4067-9774-dd6fc1c112be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49dce5c3-deaa-4067-9774-dd6fc1c112be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_38567258-9b8c-44fc-b32a-e4b93e94e03f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_38567258-9b8c-44fc-b32a-e4b93e94e03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04637c09-cf1b-4289-af2d-3b4d01df4ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e150908-0a95-4342-8367-1e93663a477f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04637c09-cf1b-4289-af2d-3b4d01df4ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f45d7e-da6e-4201-ab2c-1cac98ea23e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ee7833a4-7863-4de4-a8e1-646173b504de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f45d7e-da6e-4201-ab2c-1cac98ea23e2" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ee7833a4-7863-4de4-a8e1-646173b504de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ff3c0c54-a9f1-47c3-877b-c3debdb58d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f45d7e-da6e-4201-ab2c-1cac98ea23e2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ff3c0c54-a9f1-47c3-877b-c3debdb58d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_34042238-eedd-4f14-9225-eb18493e09d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f45d7e-da6e-4201-ab2c-1cac98ea23e2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_34042238-eedd-4f14-9225-eb18493e09d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2def6b22-3edc-4afa-b1b2-4eb903c059cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2def6b22-3edc-4afa-b1b2-4eb903c059cb" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96df2451-ac4d-4ebd-9584-6927fc69bdea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db9144d2-32b2-47f0-a047-19c5e01f958a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96df2451-ac4d-4ebd-9584-6927fc69bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4982dffb-1165-453d-bedd-680afd6c857f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_96df2451-ac4d-4ebd-9584-6927fc69bdea" xlink:to="loc_us-gaap_IPOMember_4982dffb-1165-453d-bedd-680afd6c857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e16f150-2c14-49a2-8a17-d51a456546fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b4023925-bf1d-41c6-a504-8b920bc28f43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e16f150-2c14-49a2-8a17-d51a456546fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_51a3c375-ac3e-4f2f-9986-e1d7c244d788" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9e16f150-2c14-49a2-8a17-d51a456546fa" xlink:to="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_51a3c375-ac3e-4f2f-9986-e1d7c244d788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f7558e3-0fbd-4009-98a2-073cee550e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b63c348f-2f1b-4f81-8bff-8c3994709767" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f7558e3-0fbd-4009-98a2-073cee550e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_3b3f2b8b-73de-48b6-80de-506a7384d820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6f7558e3-0fbd-4009-98a2-073cee550e7b" xlink:to="loc_us-gaap_ConvertibleDebtMember_3b3f2b8b-73de-48b6-80de-506a7384d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c7ad42c6-09e2-4255-91c5-17ec709b4aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_deea5c5f-523d-48ca-95cf-07e7f54665fb" xlink:to="loc_us-gaap_ClassOfStockDomain_c7ad42c6-09e2-4255-91c5-17ec709b4aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_34670231-daab-49c5-becb-5c048f1776fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c7ad42c6-09e2-4255-91c5-17ec709b4aae" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_34670231-daab-49c5-becb-5c048f1776fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e289e35-a56d-4b48-8363-c3b1cc49ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e5ff2d0a-12c0-416c-99b6-554a88e16fb6" xlink:to="loc_us-gaap_EquityComponentDomain_9e289e35-a56d-4b48-8363-c3b1cc49ef3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c3ff9ad-6412-4858-b25d-5b022bcb9c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9e289e35-a56d-4b48-8363-c3b1cc49ef3d" xlink:to="loc_us-gaap_CommonStockMember_6c3ff9ad-6412-4858-b25d-5b022bcb9c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25d71716-24e5-4f47-b041-187c70c2eeda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a689bc08-8ebe-433e-897d-8cdeb16a48a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a689bc08-8ebe-433e-897d-8cdeb16a48a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cbb9da31-0836-40b5-8c74-e3ef2fca709e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cbb9da31-0836-40b5-8c74-e3ef2fca709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_60006bd5-22b8-4628-9c89-a88ef34ae634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_60006bd5-22b8-4628-9c89-a88ef34ae634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4cae9160-8be3-4015-9af9-9982316c93bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4cae9160-8be3-4015-9af9-9982316c93bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5d27427b-4c8d-406c-8ae1-9ce12ca433c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5d27427b-4c8d-406c-8ae1-9ce12ca433c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a91b35d2-260b-48e9-9cf5-00af6f12ac71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a91b35d2-260b-48e9-9cf5-00af6f12ac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_eeec71e7-34be-43e5-b11b-2bcaf00aa6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_eeec71e7-34be-43e5-b11b-2bcaf00aa6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_575ee88d-1340-45b8-92ad-1c395578521e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6b8b3a01-67f0-4169-a5bd-c219e85f109f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_575ee88d-1340-45b8-92ad-1c395578521e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_91ef348f-93f9-4963-93ef-94126729dc60" xlink:to="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cd6a1cc-e598-45b3-b6ac-007054a5858c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:to="loc_srt_MinimumMember_5cd6a1cc-e598-45b3-b6ac-007054a5858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fde1b1e0-0083-4b7c-8ba6-48ce68ceb06f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d82c3bf-786f-43b9-bdb9-0a48db518de1" xlink:to="loc_srt_MaximumMember_fde1b1e0-0083-4b7c-8ba6-48ce68ceb06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_119ef176-96e0-448e-a9ae-7f2f6069b96c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_dd35c098-806e-497f-b432-e0736534950f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_dd35c098-806e-497f-b432-e0736534950f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_602514fd-5427-4618-86ff-96f23ad2d276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_602514fd-5427-4618-86ff-96f23ad2d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e863aa11-3c36-4580-96ac-deb58f32557b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d3ab5dd-9e25-40cd-b431-29a4d7494eb3" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e863aa11-3c36-4580-96ac-deb58f32557b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_70b2b0e2-496f-47bd-b226-0e2742e4f865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7e528c6f-9e0d-4e5e-acb9-b54709c41b29" xlink:to="loc_us-gaap_RelatedPartyDomain_70b2b0e2-496f-47bd-b226-0e2742e4f865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_39baccd6-81a3-4c90-8717-488432316a19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_70b2b0e2-496f-47bd-b226-0e2742e4f865" xlink:to="loc_srt_AffiliatedEntityMember_39baccd6-81a3-4c90-8717-488432316a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cd41963-18d7-4a69-ab47-cc589564cd97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c4ba4242-ea3a-4a59-b018-1414e78d1d90" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cd41963-18d7-4a69-ab47-cc589564cd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_b798d725-94c4-48f5-982e-ce9c0a15afe6" xlink:href="inhibrx-20200930.xsd#inhibrx_WuXiBiologicsHealthcareVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cd41963-18d7-4a69-ab47-cc589564cd97" xlink:to="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_b798d725-94c4-48f5-982e-ce9c0a15afe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2be10a5d-e531-4c88-943c-1495e3974bf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementTerm_30021c12-1a38-440a-94fc-2252557010e9" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:to="loc_inhibrx_CollaborativeArrangementTerm_30021c12-1a38-440a-94fc-2252557010e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a00a73fb-6316-42cd-ab01-53c5b40560d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5244094-aaad-4ca9-a05b-dfb79cda82d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a00a73fb-6316-42cd-ab01-53c5b40560d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_be466d43-19b4-469e-b56f-19d76d2c5e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_be466d43-19b4-469e-b56f-19d76d2c5e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6a718bf1-3e69-417b-bf2f-78de184e6cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6a718bf1-3e69-417b-bf2f-78de184e6cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fdf943c-d845-4fef-a64c-d752322dfd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fdf943c-d845-4fef-a64c-d752322dfd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfOperatingLeasesHeld_b01def25-c33e-4fdb-b623-030c1c63dcee" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfOperatingLeasesHeld"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_inhibrx_NumberOfOperatingLeasesHeld_b01def25-c33e-4fdb-b623-030c1c63dcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_38d3aff3-9665-418f-bb9c-54d903733e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_EquityMethodInvestments_38d3aff3-9665-418f-bb9c-54d903733e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b5e96b0c-4f12-4ef5-8cb4-ea250793e85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b5e96b0c-4f12-4ef5-8cb4-ea250793e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_35199cbd-e87d-4c51-94b9-d53b307c156e" xlink:href="inhibrx-20200930.xsd#inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering_35199cbd-e87d-4c51-94b9-d53b307c156e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6f952f41-1cbd-4f83-b897-f6963bc32a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_371536c1-7852-4806-afc7-74d363f9540d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6f952f41-1cbd-4f83-b897-f6963bc32a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3230ee08-3e40-4846-a607-c740713f6bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3230ee08-3e40-4846-a607-c740713f6bcf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f823a775-9e06-46a0-a446-021be491f5df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_66032ef4-2b0f-4bbd-b052-2e7be5f7a665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_66032ef4-2b0f-4bbd-b052-2e7be5f7a665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f016f089-05b6-4076-bb0a-bc2470fa54c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f016f089-05b6-4076-bb0a-bc2470fa54c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_55b12eea-5896-4937-b1c6-7478038d4711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748a3a28-208e-4ecf-aa98-ad4b72e546dd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_55b12eea-5896-4937-b1c6-7478038d4711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8e06158-7cf5-44ba-a68d-e0e4e5cb78ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8fd99b4b-29cd-4891-8fef-2b805bf15b75" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8e06158-7cf5-44ba-a68d-e0e4e5cb78ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c50bc3bb-5fa9-4ce0-a6db-e695d8357607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8e06158-7cf5-44ba-a68d-e0e4e5cb78ac" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c50bc3bb-5fa9-4ce0-a6db-e695d8357607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9382530-125e-40e4-95b7-be596c694086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9382530-125e-40e4-95b7-be596c694086" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:to="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_40178fce-6386-44a0-ab7a-d6f963d623d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_1b91d56d-9d59-4f68-8887-148979f487aa" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_1b91d56d-9d59-4f68-8887-148979f487aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_a50c9756-3ffc-4bc7-b7e4-7851d4140d9f" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_a50c9756-3ffc-4bc7-b7e4-7851d4140d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_0462979e-3923-4bfd-9d73-9061d1198c8d" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2478d843-5099-4c40-98c6-4bd20ca8854a" xlink:to="loc_inhibrx_A2019And2020ConvertiblePromissoryNotesMember_0462979e-3923-4bfd-9d73-9061d1198c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8295aa99-2283-42e1-84c1-ec08672ead90" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantAndDerivativeLiabilitiesMember_2516ee56-430c-455a-8b73-ed6c10d2b3f3" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantAndDerivativeLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:to="loc_inhibrx_WarrantAndDerivativeLiabilitiesMember_2516ee56-430c-455a-8b73-ed6c10d2b3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_ecaf8982-1115-4d55-9489-05b4d38721ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:to="loc_us-gaap_DerivativeMember_ecaf8982-1115-4d55-9489-05b4d38721ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_34d2fe36-661f-4f3d-bc52-3c65e362ce53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e962c795-f2be-4dd1-a816-801310042686" xlink:to="loc_us-gaap_WarrantMember_34d2fe36-661f-4f3d-bc52-3c65e362ce53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_88225418-fe73-4be1-9e39-0a61d7c255f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ab32fed2-db10-4959-bb81-17583424665f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_88225418-fe73-4be1-9e39-0a61d7c255f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_88225418-fe73-4be1-9e39-0a61d7c255f1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3c6089d-d8eb-4c93-b052-e3bc7ed1ee98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f3c6089d-d8eb-4c93-b052-e3bc7ed1ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9fe0462-1244-4be8-a327-00739bda7e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9fe0462-1244-4be8-a327-00739bda7e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bb6e82bd-e51e-493c-992b-4a1729e45512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bb6e82bd-e51e-493c-992b-4a1729e45512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_dcff1ad8-39da-4457-bff4-51e471c92ef2" xlink:href="inhibrx-20200930.xsd#inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_dcff1ad8-39da-4457-bff4-51e471c92ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74c3a32e-f8aa-4cb0-a8c7-48be6f2d30c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_49e390dc-c94f-4f7d-81de-4c25dbf68c0d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74c3a32e-f8aa-4cb0-a8c7-48be6f2d30c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef0e7213-7aaa-4c83-81fb-c77587594edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef0e7213-7aaa-4c83-81fb-c77587594edf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93ceb563-ce8e-49a4-be7e-000799e7b1f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_6294619e-3086-4582-9a72-6dc009107006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_6294619e-3086-4582-9a72-6dc009107006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d0a05fd8-5284-4a0b-acb9-712a0e5fee0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d0a05fd8-5284-4a0b-acb9-712a0e5fee0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_bf527006-6a88-4ed1-99be-5af3e7487b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_bf527006-6a88-4ed1-99be-5af3e7487b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d6144fbd-2713-420e-8ac1-be46c36de332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_688d1c81-ab94-4797-a0d1-73b8cec51461" xlink:to="loc_us-gaap_WarrantMember_d6144fbd-2713-420e-8ac1-be46c36de332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5857a15-4966-4b92-af18-778e7274f6e0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_25577293-da7f-4cc2-a37e-bf03eeea6a6f" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_25577293-da7f-4cc2-a37e-bf03eeea6a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_95b9514f-f368-4168-8d83-cc7a22a27a61" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f6a13f9-013c-4007-bf35-c724e16ff3f3" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_95b9514f-f368-4168-8d83-cc7a22a27a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc0d9fe0-c81d-4d8a-bb50-8b64226ce6fe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ae38440-28df-4390-b2fc-645d96e2e86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7ae38440-28df-4390-b2fc-645d96e2e86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7de18f02-07bf-4e92-9544-eb620306a3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b7d4f56-000e-4614-8bed-1d2fd493a401" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7de18f02-07bf-4e92-9544-eb620306a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c0742cc-a5cd-43a9-a9a9-d5a5d639be48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_390b2ecc-88ae-4cb0-9cab-ce182e7068f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c0742cc-a5cd-43a9-a9a9-d5a5d639be48" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_390b2ecc-88ae-4cb0-9cab-ce182e7068f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb3b1449-14e8-44bd-8ccd-a00df36f4106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_90aee1de-5ba0-419a-afc2-864026eb07c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb3b1449-14e8-44bd-8ccd-a00df36f4106" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_90aee1de-5ba0-419a-afc2-864026eb07c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d0fd3a75-620a-4c8b-94bc-448d232e7a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb3b1449-14e8-44bd-8ccd-a00df36f4106" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d0fd3a75-620a-4c8b-94bc-448d232e7a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3ad5f7e0-41db-468e-9eca-0f6d2e6782cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb3b1449-14e8-44bd-8ccd-a00df36f4106" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3ad5f7e0-41db-468e-9eca-0f6d2e6782cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c88fd7c-98e7-4ee1-bb33-5ce78423c241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a6523d42-d9d6-4c8f-a752-9e3a47599686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c88fd7c-98e7-4ee1-bb33-5ce78423c241" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a6523d42-d9d6-4c8f-a752-9e3a47599686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ded806c3-80e5-435d-923b-4c9a5f4e6846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c88fd7c-98e7-4ee1-bb33-5ce78423c241" xlink:to="loc_us-gaap_OtherAssetsCurrent_ded806c3-80e5-435d-923b-4c9a5f4e6846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ceff27d4-accf-4952-8c02-cb918afe1976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c88fd7c-98e7-4ee1-bb33-5ce78423c241" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ceff27d4-accf-4952-8c02-cb918afe1976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27ac38c7-ebff-462e-a18b-ac2c7a5bf6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27ac38c7-ebff-462e-a18b-ac2c7a5bf6f7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15f1b143-085a-498c-907f-04c5e672294a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6c5e493e-8eaa-4e43-a21c-c7a0510a6215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6c5e493e-8eaa-4e43-a21c-c7a0510a6215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_48a6476e-6f69-49f6-97d5-67b3a5db76c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_48a6476e-6f69-49f6-97d5-67b3a5db76c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c8bd0004-a357-4098-96e9-13046343f41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c8bd0004-a357-4098-96e9-13046343f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6484beca-eae7-44fc-9340-36767b7f7706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3667f4f7-6bb9-4dbf-96ff-6035082d9870" xlink:to="loc_us-gaap_ConstructionInProgressMember_6484beca-eae7-44fc-9340-36767b7f7706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fcd4ef2b-c933-462c-bf2a-8e9802c05244" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_55a7bcd3-d300-4a4d-b5aa-dfc646823334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_55a7bcd3-d300-4a4d-b5aa-dfc646823334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93a3f668-2879-4737-b7c0-b635bf45acae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93a3f668-2879-4737-b7c0-b635bf45acae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_255f5532-f514-4787-9a25-5f6cea06bd2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_255f5532-f514-4787-9a25-5f6cea06bd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_25eddfa3-e113-49cb-a45b-e91ac4cfe1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4137681d-b014-4d14-bc6c-2ee6ba79258a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_25eddfa3-e113-49cb-a45b-e91ac4cfe1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#OTHERFINANCIALINFORMATIONAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f66bccb-f7c1-41ce-b9f6-2bbcbd335c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_AccruedResearchAndDevelopmentCurrent_6b6a092c-1d3d-4696-821e-9cd324466062" xlink:href="inhibrx-20200930.xsd#inhibrx_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f66bccb-f7c1-41ce-b9f6-2bbcbd335c69" xlink:to="loc_inhibrx_AccruedResearchAndDevelopmentCurrent_6b6a092c-1d3d-4696-821e-9cd324466062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0c725424-c8ad-474c-9bab-32b518067230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f66bccb-f7c1-41ce-b9f6-2bbcbd335c69" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0c725424-c8ad-474c-9bab-32b518067230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b47b1156-10f3-4e9b-98e7-1143d7b24d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f66bccb-f7c1-41ce-b9f6-2bbcbd335c69" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b47b1156-10f3-4e9b-98e7-1143d7b24d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fec34889-c8a1-4b1f-925c-ce5a9f2afc87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f66bccb-f7c1-41ce-b9f6-2bbcbd335c69" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fec34889-c8a1-4b1f-925c-ce5a9f2afc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bf583c8c-1241-451d-a210-60a469da8fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f66bccb-f7c1-41ce-b9f6-2bbcbd335c69" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bf583c8c-1241-451d-a210-60a469da8fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBT" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5fccb8b3-914b-4389-aa6f-1d165f3b5bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3ccc655f-abbd-4f9c-8f37-2b96f57fe63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fccb8b3-914b-4389-aa6f-1d165f3b5bd9" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3ccc655f-abbd-4f9c-8f37-2b96f57fe63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89116a83-e446-4761-acc6-9c39e3cd2ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c1451e2b-d368-4f6a-b302-0063d0064829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89116a83-e446-4761-acc6-9c39e3cd2ee5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c1451e2b-d368-4f6a-b302-0063d0064829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5ede5356-eaec-41b1-ab50-aeb0793e27a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89116a83-e446-4761-acc6-9c39e3cd2ee5" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5ede5356-eaec-41b1-ab50-aeb0793e27a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2015LoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4f788ad7-81d6-4b34-958a-7e4492d80f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4f788ad7-81d6-4b34-958a-7e4492d80f14" xlink:to="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_febdbcd8-81dc-40d6-840b-8654fce75f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_82ba5aa7-4ee4-455c-b464-68caee625812" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_febdbcd8-81dc-40d6-840b-8654fce75f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_febdbcd8-81dc-40d6-840b-8654fce75f99" xlink:to="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermAMember_aadac70b-96fc-494b-a7c0-0967c2a99834" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermAMember_aadac70b-96fc-494b-a7c0-0967c2a99834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermBMember_cc1ef963-f237-4e8c-8011-eadca94a9c5c" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermBMember_cc1ef963-f237-4e8c-8011-eadca94a9c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermCMember_ace9abf8-09b7-4c1b-a75b-9b8ef0f01dd6" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermCMember_ace9abf8-09b7-4c1b-a75b-9b8ef0f01dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermDMember_5a6dfd00-5942-4e37-9c7f-44f352a6d796" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_ac1440c7-908a-4feb-a75a-5f370121e18a" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermDMember_5a6dfd00-5942-4e37-9c7f-44f352a6d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68054320-658a-403e-87f1-264495f5d9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ca1c103-c4f7-4115-936e-ab487f62dae7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68054320-658a-403e-87f1-264495f5d9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c583ab9f-6718-4d21-9baf-1040008b7af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68054320-658a-403e-87f1-264495f5d9f5" xlink:to="loc_us-gaap_SecuredDebtMember_c583ab9f-6718-4d21-9baf-1040008b7af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d490a11-d76b-45be-a3ea-83ec3d2caa0d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_598c0439-686c-4367-a0dd-4f7f3e5886a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_598c0439-686c-4367-a0dd-4f7f3e5886a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_402d747c-4bc0-4923-b875-1090f1fc4989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_402d747c-4bc0-4923-b875-1090f1fc4989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f5ddc904-0c9f-4286-a987-9e8156d0af31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_LongTermDebt_f5ddc904-0c9f-4286-a987-9e8156d0af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c7c8723f-de93-4d27-a97e-4763762ed20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_LongTermDebtCurrent_c7c8723f-de93-4d27-a97e-4763762ed20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e2245f26-dbf1-4f8f-9127-2aa67289dd28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0da71f9b-2581-4a9d-ae2e-a5d749bc8f5a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e2245f26-dbf1-4f8f-9127-2aa67289dd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2015LoanAgreementDetails_1"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7cf200c2-77e5-4456-9d9f-668b204d4835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7cf200c2-77e5-4456-9d9f-668b204d4835" xlink:to="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_05c8960e-28b5-4428-b812-4ffe8eef31a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:to="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermAMember_622d3a65-f9ac-42c7-8fba-e7fab14652ae" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermAMember_622d3a65-f9ac-42c7-8fba-e7fab14652ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermBMember_7a4b7634-3b3d-44bc-823b-9d338ec18f2e" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermBMember_7a4b7634-3b3d-44bc-823b-9d338ec18f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermCMember_f142b571-edde-4b11-8d61-1cf3f8d91e79" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermCMember_f142b571-edde-4b11-8d61-1cf3f8d91e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2015OxfordTermLoansTermDMember_73c40461-0ed3-4d9d-a469-386a9e56babc" xlink:href="inhibrx-20200930.xsd#inhibrx_A2015OxfordTermLoansTermDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2015OxfordTermLoansMember_2eb7f36f-04d2-48d5-96ed-b1feb3b01461" xlink:to="loc_inhibrx_A2015OxfordTermLoansTermDMember_73c40461-0ed3-4d9d-a469-386a9e56babc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_ffbaf1fe-58c5-472d-9daf-ced5160dfd67" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d219579a-3769-4201-9b4c-73219d9e7265" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_ffbaf1fe-58c5-472d-9daf-ced5160dfd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c17613b2-6dff-44f4-b3bd-1dbb3bc5b27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0fb5b09c-4450-4c2a-9dae-b5470ed801d9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c17613b2-6dff-44f4-b3bd-1dbb3bc5b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a097271f-c5f8-4da9-95f1-66d195d81b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c17613b2-6dff-44f4-b3bd-1dbb3bc5b27b" xlink:to="loc_us-gaap_SecuredDebtMember_a097271f-c5f8-4da9-95f1-66d195d81b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88496a7e-5cea-4ef6-985c-a44dc9562957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2a6594a1-65c5-4f55-8239-028f13470df5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88496a7e-5cea-4ef6-985c-a44dc9562957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ProfitInterestUnitPIUMember_dff7029f-6234-4832-b94d-adb11f1cc963" xlink:href="inhibrx-20200930.xsd#inhibrx_ProfitInterestUnitPIUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88496a7e-5cea-4ef6-985c-a44dc9562957" xlink:to="loc_inhibrx_ProfitInterestUnitPIUMember_dff7029f-6234-4832-b94d-adb11f1cc963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5341888d-5561-4b96-bb6a-6a1f7b7922dc" xlink:to="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c266bc2-87cc-4501-acd6-d82e44d9bee5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:to="loc_srt_MinimumMember_1c266bc2-87cc-4501-acd6-d82e44d9bee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b6fc3ad8-ccb7-4362-a183-e4c63acaaa7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df375c2b-58a9-4d82-a3b3-99348b7f97de" xlink:to="loc_srt_MaximumMember_b6fc3ad8-ccb7-4362-a183-e4c63acaaa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ee1fca73-6529-4eb6-8d38-b4692d6c8806" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_ef6b24be-f319-408e-a28b-c37884e3e5ad" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:to="loc_inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_ef6b24be-f319-408e-a28b-c37884e3e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_99328ec5-e97b-4f76-a26c-fab8632d85ea" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad4c0cc5-361a-4083-8fdf-8b04252e7c42" xlink:to="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_99328ec5-e97b-4f76-a26c-fab8632d85ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_48682946-d466-473d-baf8-a19dc8eef32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d73cd81f-404d-4920-9abc-61ddad70d094" xlink:to="loc_us-gaap_VariableRateDomain_48682946-d466-473d-baf8-a19dc8eef32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7d87a009-ffef-4803-8528-1e8889ca0198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_48682946-d466-473d-baf8-a19dc8eef32d" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7d87a009-ffef-4803-8528-1e8889ca0198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47ac2f32-4d54-4abf-96e0-137444c58a74" xlink:to="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_2b2227e2-f3b3-4866-9d31-9a4a77b16478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:to="loc_us-gaap_PreferredStockMember_2b2227e2-f3b3-4866-9d31-9a4a77b16478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7b2f38ef-9bd9-4207-851e-da54f248ecfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_99f830ae-e6a5-45d3-9225-ef7e56444584" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7b2f38ef-9bd9-4207-851e-da54f248ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4b7f4ae0-77e5-47e0-ad92-4ee58498cb96" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentNumberOfTermLoans_bf3886c7-6dbb-4ea3-b725-c0583c6bbfe8" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentNumberOfTermLoans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentNumberOfTermLoans_bf3886c7-6dbb-4ea3-b725-c0583c6bbfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0bad9548-f02a-4f0f-b53d-1ba3d4c5d0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0bad9548-f02a-4f0f-b53d-1ba3d4c5d0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8814be3d-ddd5-48e5-9fe1-4c92a9b9bada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8814be3d-ddd5-48e5-9fe1-4c92a9b9bada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPrepaymentFee_fac531b9-232a-4f1f-a6ac-5c2d7b199e82" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPrepaymentFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentPrepaymentFee_fac531b9-232a-4f1f-a6ac-5c2d7b199e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_dfdfd825-e293-4905-aab7-c0ee870aceaa" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_dfdfd825-e293-4905-aab7-c0ee870aceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_017569b5-9386-458f-af49-4c383c744310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_017569b5-9386-458f-af49-4c383c744310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7886b05f-8dd7-4f75-a7b1-0721630b4f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7886b05f-8dd7-4f75-a7b1-0721630b4f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5395b9c6-530e-414f-ae11-9210e379a5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5395b9c6-530e-414f-ae11-9210e379a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_5d0ea79a-b26a-4696-a22c-346d7d83df66" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued_5d0ea79a-b26a-4696-a22c-346d7d83df66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_e39e005f-2ce5-48f3-a319-e42b7e110806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_e39e005f-2ce5-48f3-a319-e42b7e110806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_bb0f87be-4145-4433-9b03-73384879d76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_InterestExpenseDebt_bb0f87be-4145-4433-9b03-73384879d76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_397b497a-2ddb-4c42-ac15-b6b5b4bd80a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_397b497a-2ddb-4c42-ac15-b6b5b4bd80a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_28cdafeb-9e78-4f06-95e2-3a34bf3df643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_28cdafeb-9e78-4f06-95e2-3a34bf3df643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44e482c1-2b3d-47c7-80fb-8a8017ac31ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44e482c1-2b3d-47c7-80fb-8a8017ac31ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentVariableRateFloor_2f504c7a-7a6d-4f8b-994e-f00438e6d958" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentVariableRateFloor"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentVariableRateFloor_2f504c7a-7a6d-4f8b-994e-f00438e6d958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_23566b66-a5b3-4782-b614-6de1ea6ae291" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestOnlyPaymentPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod_23566b66-a5b3-4782-b614-6de1ea6ae291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_b47ef558-8dd3-492c-ac44-061a74ec3eba" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_b47ef558-8dd3-492c-ac44-061a74ec3eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_a77b0e1a-0a30-41f1-9312-43ec2aaa1cff" xlink:href="inhibrx-20200930.xsd#inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_a77b0e1a-0a30-41f1-9312-43ec2aaa1cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsAndRightsOutstandingLiability_a758ec9f-78ba-48d6-bee2-90e9d6fde32a" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsAndRightsOutstandingLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_WarrantsAndRightsOutstandingLiability_a758ec9f-78ba-48d6-bee2-90e9d6fde32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsLiability_5989c307-0c6e-4434-a69f-a57f8afad1e2" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_inhibrx_WarrantsLiability_5989c307-0c6e-4434-a69f-a57f8afad1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d5a31346-b8f1-4305-8794-de1faae8a3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d5a31346-b8f1-4305-8794-de1faae8a3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6a763b93-78c0-4f2c-ac95-c7e5cb3c1f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d03345-2292-481e-898b-d88b4479d8db" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6a763b93-78c0-4f2c-ac95-c7e5cb3c1f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dd818f69-c201-4585-8803-0c3bf4425b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dd818f69-c201-4585-8803-0c3bf4425b6c" xlink:to="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09fb29ed-7172-46a1-8204-2a4017f8deae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fe834fa-abdd-4505-a8b5-93684a11b618" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09fb29ed-7172-46a1-8204-2a4017f8deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_3ad39a6c-52b7-49ba-a5bb-09b3804bb339" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09fb29ed-7172-46a1-8204-2a4017f8deae" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_3ad39a6c-52b7-49ba-a5bb-09b3804bb339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2cc649de-952f-4e56-a62f-c0e1081ab854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_721687f9-db97-46f2-b2e8-0c261e070655" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2cc649de-952f-4e56-a62f-c0e1081ab854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d4adeb03-2a5c-4d27-82af-e8310ef0a46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2cc649de-952f-4e56-a62f-c0e1081ab854" xlink:to="loc_us-gaap_SecuredDebtMember_d4adeb03-2a5c-4d27-82af-e8310ef0a46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_65c4d3ea-c33b-42df-9335-f8fc248e92b5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d137765f-60c4-428a-b390-b804c295886b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d137765f-60c4-428a-b390-b804c295886b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8b0216c5-b4a2-44db-90a5-2b9c393bb46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8b0216c5-b4a2-44db-90a5-2b9c393bb46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5fda588e-b14c-46ed-9899-fae000b742e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_LongTermDebt_5fda588e-b14c-46ed-9899-fae000b742e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_aec6de69-f67c-48dc-b31b-a5cd6d552a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_LongTermDebtCurrent_aec6de69-f67c-48dc-b31b-a5cd6d552a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f30a9b05-c40e-48c3-8c2b-7676973a4c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad6b0b47-ea53-46a5-89a4-1672c7a8bbc1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f30a9b05-c40e-48c3-8c2b-7676973a4c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#DEBTFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b0783ecd-e1b8-4137-8d99-b8cc768f7a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b0783ecd-e1b8-4137-8d99-b8cc768f7a0f" xlink:to="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:to="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fd112647-1b8c-4ef5-85ce-b757ecab14f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d68db88a-5fb4-4821-b10f-3e68039d1d53" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fd112647-1b8c-4ef5-85ce-b757ecab14f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_1ce1f3b8-2b2a-4371-ba10-7a63fb210645" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fd112647-1b8c-4ef5-85ce-b757ecab14f0" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_1ce1f3b8-2b2a-4371-ba10-7a63fb210645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ceed4b5a-49e0-486f-be06-0ab3709234ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7aa1e773-f94d-49ff-a35f-a0562ec04ab9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ceed4b5a-49e0-486f-be06-0ab3709234ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_94de080a-b98b-43c6-8335-fb6577ba524d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ceed4b5a-49e0-486f-be06-0ab3709234ea" xlink:to="loc_us-gaap_SecuredDebtMember_94de080a-b98b-43c6-8335-fb6577ba524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4400843a-60fa-44cb-882d-d3f28f3812a3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9e9e7b2d-1675-475c-871d-a94954b1b26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9e9e7b2d-1675-475c-871d-a94954b1b26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f238c031-8e84-46b6-908e-715e9cf8d89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f238c031-8e84-46b6-908e-715e9cf8d89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bfe098e5-6a0d-4943-b049-34ab745d5c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bfe098e5-6a0d-4943-b049-34ab745d5c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7cc9df01-43c4-4881-9e27-68af17f71d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7cc9df01-43c4-4881-9e27-68af17f71d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99318ae3-a4e3-4b25-bed6-84c5d8f05af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_99318ae3-a4e3-4b25-bed6-84c5d8f05af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1f0b4057-a9ac-405f-9475-9867a046ab55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1f0b4057-a9ac-405f-9475-9867a046ab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f0b7829-2b40-4ba6-85b3-b82c24a30727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9f0b7829-2b40-4ba6-85b3-b82c24a30727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ae474ff8-bc5c-4089-b830-a8e656caad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9b3aa4ff-3098-4d81-a0f9-191408a1ef3f" xlink:to="loc_us-gaap_LongTermDebt_ae474ff8-bc5c-4089-b830-a8e656caad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/PPPLOAN" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#PPPLOAN"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/PPPLOAN" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aea36cff-7c43-449d-876d-947488db4d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_b5541527-427e-4965-8d83-faebf1931737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aea36cff-7c43-449d-876d-947488db4d6d" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_b5541527-427e-4965-8d83-faebf1931737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/PPPLOANDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#PPPLOANDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/PPPLOANDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5ab91a36-b376-4ca0-b2ee-006cf279d133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5ab91a36-b376-4ca0-b2ee-006cf279d133" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:to="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_070663ec-4379-4dff-a93c-47946135386c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4a00cc8a-f60f-426f-8cd0-fa6a4987683b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_070663ec-4379-4dff-a93c-47946135386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaycheckProtectionProgramCARESActMember_54a548cb-f584-4cfc-87d2-97fa55d4ba0b" xlink:href="inhibrx-20200930.xsd#inhibrx_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_070663ec-4379-4dff-a93c-47946135386c" xlink:to="loc_inhibrx_PaycheckProtectionProgramCARESActMember_54a548cb-f584-4cfc-87d2-97fa55d4ba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6282c8e6-0042-40f6-96d8-93cb6ca1bb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_fb6eb71c-0498-4c74-baf4-956667c3fbc4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6282c8e6-0042-40f6-96d8-93cb6ca1bb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f16a5697-b3c4-4a85-b22b-3e9dc63c18aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6282c8e6-0042-40f6-96d8-93cb6ca1bb2e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f16a5697-b3c4-4a85-b22b-3e9dc63c18aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_b74ef790-20b0-4b33-851f-4cb068230078" xlink:to="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_d04204c4-aefc-476b-9f21-56ab3b1a65f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_d04204c4-aefc-476b-9f21-56ab3b1a65f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_40ad1907-9010-4a6e-9b83-2043e9fd6f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_ShortTermBorrowings_40ad1907-9010-4a6e-9b83-2043e9fd6f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8a5a1086-e385-49a5-ad24-0ce788ae868a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_19003b91-fdd1-4cdd-a715-508a984ff807" xlink:to="loc_us-gaap_InterestExpenseDebt_8a5a1086-e385-49a5-ad24-0ce788ae868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTES"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_46adf24a-a143-4975-a94a-fbc6ce82fe03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_81ad7e91-c7c0-4090-9988-79c10c5e33cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_46adf24a-a143-4975-a94a-fbc6ce82fe03" xlink:to="loc_us-gaap_LongTermDebtTextBlock_81ad7e91-c7c0-4090-9988-79c10c5e33cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2bdec341-2194-4f5d-b975-e41b3bd75c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_d177894f-6c72-4f78-b24e-c0b9ef3b1555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2bdec341-2194-4f5d-b975-e41b3bd75c6b" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_d177894f-6c72-4f78-b24e-c0b9ef3b1555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4fd11426-8b81-4f70-a16c-c616c45ef8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4fd11426-8b81-4f70-a16c-c616c45ef8c0" xlink:to="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7fd4eabb-f2e8-453e-9f49-3393b7860bea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_e0d3a24b-5194-4733-aa27-2fb698ca3352" xlink:href="inhibrx-20200930.xsd#inhibrx_A2019ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:to="loc_inhibrx_A2019ConvertiblePromissoryNoteMember_e0d3a24b-5194-4733-aa27-2fb698ca3352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_7f839550-cfe7-40a1-9e36-eebbaf10f16c" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_011684bb-9be3-46c9-9421-10e1173e5e72" xlink:to="loc_inhibrx_A2020ConvertiblePromissoryNoteMember_7f839550-cfe7-40a1-9e36-eebbaf10f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b5643df9-55e7-41ba-b5d0-9d3e37d5b828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5de769a0-345c-4580-a7b6-32a18b68f129" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b5643df9-55e7-41ba-b5d0-9d3e37d5b828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a4092c40-1e6b-45ca-8567-d736ce5f867d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b5643df9-55e7-41ba-b5d0-9d3e37d5b828" xlink:to="loc_us-gaap_ConvertibleDebtMember_a4092c40-1e6b-45ca-8567-d736ce5f867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac2dbae3-b75d-4df9-8af2-0dcbc2c9cd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9cc549c9-618e-4214-8eb2-de8daddf6ef6" xlink:to="loc_us-gaap_EquityComponentDomain_ac2dbae3-b75d-4df9-8af2-0dcbc2c9cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5dbe5bcf-9b9c-4d74-b647-3def97c356b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ac2dbae3-b75d-4df9-8af2-0dcbc2c9cd57" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5dbe5bcf-9b9c-4d74-b647-3def97c356b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2f92fcf8-ff13-4873-9dea-68d171c1d866" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e8147ac4-153c-4942-8ca0-903c67da33be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e8147ac4-153c-4942-8ca0-903c67da33be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1cf5836-251b-498f-8c3f-b3438be9d055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1cf5836-251b-498f-8c3f-b3438be9d055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_71f1d36e-00dd-4ce0-8d44-ef589d5e3310" xlink:href="inhibrx-20200930.xsd#inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO_71f1d36e-00dd-4ce0-8d44-ef589d5e3310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_d938492b-6bb7-4277-ac94-bd2a59f85ce3" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice_d938492b-6bb7-4277-ac94-bd2a59f85ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c478c1ea-5dcc-445c-9049-1ca3538cda71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_InterestPayableCurrent_c478c1ea-5dcc-445c-9049-1ca3538cda71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_85cf5e71-b5c2-4a1f-a995-99f2eef03e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_LongTermDebt_85cf5e71-b5c2-4a1f-a995-99f2eef03e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_69b04745-a0d0-4c74-86db-df689c4e4e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_69b04745-a0d0-4c74-86db-df689c4e4e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_073588f4-490b-4c55-a70c-78a8256f737e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_073588f4-490b-4c55-a70c-78a8256f737e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_bf1492ec-2fa9-427f-9b16-bd7d4b00652f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_bf1492ec-2fa9-427f-9b16-bd7d4b00652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_413d7594-1f42-4b1f-81da-e4e478605e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DerivativeLiabilities_413d7594-1f42-4b1f-81da-e4e478605e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ccb07dbb-fea4-4d10-a75e-a6bd5c93fef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ccb07dbb-fea4-4d10-a75e-a6bd5c93fef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ce3638dc-7cbe-45db-88c3-5b29f2639585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ce3638dc-7cbe-45db-88c3-5b29f2639585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtIssuanceCostsNetDerivativeLiability_0e9c382b-fc6c-4770-ae1c-5d9c4526eebd" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtIssuanceCostsNetDerivativeLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_inhibrx_DebtIssuanceCostsNetDerivativeLiability_0e9c382b-fc6c-4770-ae1c-5d9c4526eebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_01cdf9cc-d701-4803-a557-b428f76c2473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_01cdf9cc-d701-4803-a557-b428f76c2473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0beaa3ca-2bcd-40c7-a600-c2d79c66375c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0beaa3ca-2bcd-40c7-a600-c2d79c66375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_659f6366-600b-4b7f-b638-d39e5c08768f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_659f6366-600b-4b7f-b638-d39e5c08768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ab8acf45-5af5-486e-969d-a5fac3dfc56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ad1737b5-f748-4c83-8729-27213c6ad1c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ab8acf45-5af5-486e-969d-a5fac3dfc56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d016d76e-d9e2-4f70-9a1e-9dbc98112828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d016d76e-d9e2-4f70-9a1e-9dbc98112828" xlink:to="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_193c0af4-339a-4700-a007-202199639206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4622699d-56c5-4cd5-a350-d5f8a9acfb3e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_193c0af4-339a-4700-a007-202199639206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a69a1bac-0deb-4b23-8419-3390a500557e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_193c0af4-339a-4700-a007-202199639206" xlink:to="loc_us-gaap_ConvertibleDebtMember_a69a1bac-0deb-4b23-8419-3390a500557e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9cb06e06-242b-4dfb-bf6e-a60f6a360392" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_706957d4-c49a-45ab-bb98-77da9c535a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_706957d4-c49a-45ab-bb98-77da9c535a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3d4c057-92b9-4c66-8228-3e66a687ae10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3d4c057-92b9-4c66-8228-3e66a687ae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6fac5a23-d9d8-4907-ace0-ca73684c3c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3af36a72-4441-4500-bd4b-597a9b37adc5" xlink:to="loc_us-gaap_LongTermDebt_6fac5a23-d9d8-4907-ace0-ca73684c3c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7a73042b-34bd-4726-9c53-ee6235be72a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dec146a5-da1b-47a6-a823-60fece65649a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7a73042b-34bd-4726-9c53-ee6235be72a2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dec146a5-da1b-47a6-a823-60fece65649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b79395de-7f4a-4e5d-b67d-9690536a2d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_a3a0b5b7-8bd2-4016-bb98-264f6495a646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b79395de-7f4a-4e5d-b67d-9690536a2d4d" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_a3a0b5b7-8bd2-4016-bb98-264f6495a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f6d817b4-66d8-4733-9796-7bb1de3e42d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d817b4-66d8-4733-9796-7bb1de3e42d9" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c1d1a39-78fb-4932-a36c-8d17f48effff" xlink:to="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine1PreferredStockMember_248bfcb1-3ee4-4e08-99f8-943dade4c7f0" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine1PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:to="loc_inhibrx_SeriesMezzanine1PreferredStockMember_248bfcb1-3ee4-4e08-99f8-943dade4c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine2PreferredStockMember_c0ee1bdc-b7ba-445a-a00b-4a8690b88eaf" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine2PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9e9adaad-673c-46ab-9ac6-e99ceb198eb7" xlink:to="loc_inhibrx_SeriesMezzanine2PreferredStockMember_c0ee1bdc-b7ba-445a-a00b-4a8690b88eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f1ce4b52-b653-4b81-a9d2-7859d8260b14" xlink:to="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d0b32a64-dc73-455d-aa04-96e81c040576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:to="loc_us-gaap_CommonStockMember_d0b32a64-dc73-455d-aa04-96e81c040576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41063370-d736-44b5-a3ae-1b972f239d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9496c280-6b8f-4bcf-96db-258c6cc5079d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41063370-d736-44b5-a3ae-1b972f239d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2be8e64-bf68-4a9a-832d-0fba0f286807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d98fe136-c311-4f44-b73a-a8f5d37e1c39" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2be8e64-bf68-4a9a-832d-0fba0f286807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_78438a24-b2c1-4538-8425-5330c0aaf2ae" xlink:href="inhibrx-20200930.xsd#inhibrx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a2be8e64-bf68-4a9a-832d-0fba0f286807" xlink:to="loc_inhibrx_WarrantsIssuedUponConsummationOfIPOMember_78438a24-b2c1-4538-8425-5330c0aaf2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_17c931cc-0252-4089-98ac-f1d579ed5874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba30aafc-8141-42a6-8e3d-daba9901f539" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_17c931cc-0252-4089-98ac-f1d579ed5874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_93d11dfa-4764-4324-9ee1-9417c9295307" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_17c931cc-0252-4089-98ac-f1d579ed5874" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_93d11dfa-4764-4324-9ee1-9417c9295307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5e7f44c-6ce9-4afe-b56f-4de0e3919c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_72769f69-93fe-4650-ab2d-b5a2b454491b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5e7f44c-6ce9-4afe-b56f-4de0e3919c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_31450a93-76b2-4514-ae1e-c9cf14911fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d5e7f44c-6ce9-4afe-b56f-4de0e3919c1b" xlink:to="loc_us-gaap_SecuredDebtMember_31450a93-76b2-4514-ae1e-c9cf14911fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_ad29d9db-8786-400d-8665-731ac725a35a" xlink:to="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3c3737a2-3351-44a8-b9a9-0e0dad9a5513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3c3737a2-3351-44a8-b9a9-0e0dad9a5513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_36c08158-f117-416f-8762-5dd8453d85d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_36c08158-f117-416f-8762-5dd8453d85d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_99cefb65-c17f-45c5-8d64-f447c24be097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_99cefb65-c17f-45c5-8d64-f447c24be097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_52211585-84d5-42e6-b4f0-404395525f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_52211585-84d5-42e6-b4f0-404395525f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_94b616c2-31f1-44cd-9dbe-add38ef950b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_94b616c2-31f1-44cd-9dbe-add38ef950b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_02f32813-3f1d-4c27-bf21-b30853ad878f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_02f32813-3f1d-4c27-bf21-b30853ad878f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6f69d70f-c779-4524-8dd3-a9771b54b2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6f69d70f-c779-4524-8dd3-a9771b54b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3b9bb7be-71f6-4211-aa4c-a4334856fa7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_SharePrice_3b9bb7be-71f6-4211-aa4c-a4334856fa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_8c355e64-0301-47ce-bd58-1bbeabbfbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_8c355e64-0301-47ce-bd58-1bbeabbfbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0e403c2-b54d-4b9d-971d-017392e8dd64" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_e0e403c2-b54d-4b9d-971d-017392e8dd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a0a2b664-edfd-4233-8240-e1dec926bddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a0a2b664-edfd-4233-8240-e1dec926bddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ee8f9f6b-0d8e-49b0-a115-f9334c094de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ee8f9f6b-0d8e-49b0-a115-f9334c094de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8371c277-0a68-4ade-b704-c4aa4beac026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8371c277-0a68-4ade-b704-c4aa4beac026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b39c80d-056f-4526-9562-ee62b631dd44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b39c80d-056f-4526-9562-ee62b631dd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_43804640-5f76-4ede-a839-9e271a8dfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_c0a5fc71-9942-4fa8-b789-0527531ba570" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_43804640-5f76-4ede-a839-9e271a8dfa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANS"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ed0e41a-82ce-4158-858e-7f7b14fe0695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b6eb2517-055b-4657-bdd9-c8e038f41703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ed0e41a-82ce-4158-858e-7f7b14fe0695" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b6eb2517-055b-4657-bdd9-c8e038f41703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be2059dc-f701-453c-8efb-f985e0753403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_ee3b13aa-3b9a-484b-9f1a-b418649bdd51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be2059dc-f701-453c-8efb-f985e0753403" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_ee3b13aa-3b9a-484b-9f1a-b418649bdd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dcf41660-45ef-4c49-9522-c63150d1cc7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be2059dc-f701-453c-8efb-f985e0753403" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dcf41660-45ef-4c49-9522-c63150d1cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ce1d0bd9-0335-4564-a154-248c0a0b1a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be2059dc-f701-453c-8efb-f985e0753403" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ce1d0bd9-0335-4564-a154-248c0a0b1a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea07c88-7da2-428b-84e2-6d3996c8e5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea07c88-7da2-428b-84e2-6d3996c8e5d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:to="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f57a5422-ae36-4b6f-af90-904249dde2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_81c1887c-aa33-4e03-8985-542989661781" xlink:to="loc_us-gaap_VestingDomain_f57a5422-ae36-4b6f-af90-904249dde2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a2b7ab52-8761-41b1-a8ea-5c558b227445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f57a5422-ae36-4b6f-af90-904249dde2c4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a2b7ab52-8761-41b1-a8ea-5c558b227445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:to="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67c847ba-19ad-49ae-9043-4e9473f42d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6f3a021b-bafa-4fe5-8a4c-83daece0aa58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67c847ba-19ad-49ae-9043-4e9473f42d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_640c7de8-c155-49d4-9371-778f05de3476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67c847ba-19ad-49ae-9043-4e9473f42d88" xlink:to="loc_us-gaap_EmployeeStockOptionMember_640c7de8-c155-49d4-9371-778f05de3476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2b84779-56f1-4848-a01b-bc4f4a43b92b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationNumberOfPlans_acf908bd-f7a7-4111-8d22-efa07d96b0fb" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_inhibrx_ShareBasedCompensationNumberOfPlans_acf908bd-f7a7-4111-8d22-efa07d96b0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_95b164b9-ab15-4eac-aaad-11883e6c3a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_95b164b9-ab15-4eac-aaad-11883e6c3a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8ac87d7f-33aa-4ed6-8901-c26970d8ff5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8ac87d7f-33aa-4ed6-8901-c26970d8ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_998b6317-841c-44a3-bfd3-7065894a8f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_998b6317-841c-44a3-bfd3-7065894a8f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_69d9ea1d-0552-4bc1-8d67-6d372b4d5cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_69d9ea1d-0552-4bc1-8d67-6d372b4d5cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bedbff-df8b-4524-97c0-12b14f1a98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_04bedbff-df8b-4524-97c0-12b14f1a98f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9d79890b-3617-48d9-83e9-824012961d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d80b80cf-f88b-4631-b649-ffc8900dc055" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9d79890b-3617-48d9-83e9-824012961d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61936c04-ffbd-493f-9275-657b4ae9f72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61936c04-ffbd-493f-9275-657b4ae9f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8c560ab6-6e98-4182-adb6-adfa9a40bce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8c560ab6-6e98-4182-adb6-adfa9a40bce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bd12ba34-229c-4aed-9751-53056ae5be80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bd12ba34-229c-4aed-9751-53056ae5be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_74a47ddc-b77c-41bf-a063-5c14eabc7c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_74a47ddc-b77c-41bf-a063-5c14eabc7c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_53731728-dd60-474a-93f7-ec53a2bddc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_79d6f881-9ffa-4941-8322-7ae838f80090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_53731728-dd60-474a-93f7-ec53a2bddc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c924ac71-e6ea-4bbf-b60d-d8a9f20923a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c924ac71-e6ea-4bbf-b60d-d8a9f20923a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a42436c3-5b9a-4a39-a9d8-bf3c453b6288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a42436c3-5b9a-4a39-a9d8-bf3c453b6288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04f3a438-ae0c-4889-afb2-21462f489adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04f3a438-ae0c-4889-afb2-21462f489adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_445b592e-c363-4f93-96f1-44f87bf3fc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_445b592e-c363-4f93-96f1-44f87bf3fc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_07b91507-7410-48f9-a240-f2de5446d5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_07b91507-7410-48f9-a240-f2de5446d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c082d2b-8221-4066-98c0-59679bd9c1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45fa5608-92a6-46e3-b4d4-7e6e6d2b0699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c082d2b-8221-4066-98c0-59679bd9c1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dfb63408-eaaa-4ebd-abc4-9b3de97de1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dfb63408-eaaa-4ebd-abc4-9b3de97de1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_603f14be-8268-4c1e-9853-1291164a8145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_603f14be-8268-4c1e-9853-1291164a8145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted_8e24f00a-4057-497a-b31f-0e23f1ac61ae" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted_8e24f00a-4057-497a-b31f-0e23f1ac61ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fa36b401-6592-4be2-9d30-037c7700f801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fa36b401-6592-4be2-9d30-037c7700f801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_13180f0d-1e5b-48ad-b31e-cbb61683f05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_13180f0d-1e5b-48ad-b31e-cbb61683f05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted_d88afd45-df83-4f1f-a1c9-9783823298a7" xlink:href="inhibrx-20200930.xsd#inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted_d88afd45-df83-4f1f-a1c9-9783823298a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_bcfba755-3adf-43d2-ba6a-47c12cc531dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79a5442e-f57e-44dc-87ab-654b31190090" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_bcfba755-3adf-43d2-ba6a-47c12cc531dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c3b1d3e-2796-4d12-80cd-95a20e1f6081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c3b1d3e-2796-4d12-80cd-95a20e1f6081" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:to="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b520d69-b294-430d-baea-3fa675dfec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fed0ad57-a0cf-4f1d-af24-e30207c1f494" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b520d69-b294-430d-baea-3fa675dfec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_745262a0-e897-451f-a876-9069a7bd26c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b520d69-b294-430d-baea-3fa675dfec3f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_745262a0-e897-451f-a876-9069a7bd26c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4d0651b5-d5a9-46ec-bbd3-311129500faa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34185745-d7f7-4b02-a71c-88eb0cae6605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34185745-d7f7-4b02-a71c-88eb0cae6605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee6ad9f4-da33-4d97-82ab-5df801639a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee6ad9f4-da33-4d97-82ab-5df801639a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6c74439-740f-4abd-b0bc-66d8217ef026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6c74439-740f-4abd-b0bc-66d8217ef026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc94c15-9a1f-4628-978b-cc2d13ff9e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc94c15-9a1f-4628-978b-cc2d13ff9e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa7355f-8563-4302-be92-39d6c96fc2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb2e7665-29f8-4b79-9a67-801beaf68792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa7355f-8563-4302-be92-39d6c96fc2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07c4cb25-1346-4b2f-a186-82cca1f11bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_07c4cb25-1346-4b2f-a186-82cca1f11bce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b1eaab57-dd55-46b1-958a-0d8660123a54" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0f7e1031-4560-4882-8487-c7b133d6efd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0f7e1031-4560-4882-8487-c7b133d6efd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dbb50a7b-7db8-46cd-b116-2b1f4ad5d023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_303b2fae-b2d5-4fa4-987c-309e54ae16a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dbb50a7b-7db8-46cd-b116-2b1f4ad5d023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:to="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dd548fa-2fa3-48d8-aa11-6e642b38ccdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_799b3d45-818c-45c3-9024-7db92d27b060" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dd548fa-2fa3-48d8-aa11-6e642b38ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5d82cc1d-ad57-4094-b65a-cd0c5109f754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dd548fa-2fa3-48d8-aa11-6e642b38ccdb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5d82cc1d-ad57-4094-b65a-cd0c5109f754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4882659b-c94d-4277-bd0d-b6304fe701ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc028f8a-9962-4712-a9de-16f0ef6f38b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4882659b-c94d-4277-bd0d-b6304fe701ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f330464-6bff-43fa-ae2b-83099342f0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4882659b-c94d-4277-bd0d-b6304fe701ac" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f330464-6bff-43fa-ae2b-83099342f0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUES"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ddfe4dee-4358-470a-b48d-9d9eac83bc84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAndGrantRevenueTextBlock_cfd75f30-23ad-44e6-9003-9c6a82fd5a61" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAndGrantRevenueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ddfe4dee-4358-470a-b48d-9d9eac83bc84" xlink:to="loc_inhibrx_LicenseAndGrantRevenueTextBlock_cfd75f30-23ad-44e6-9003-9c6a82fd5a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_22a5c869-092e-4a2b-ba72-4bfd9cf6a7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_d3ccf9ee-c899-4190-910c-1152a8aeb132" xlink:href="inhibrx-20200930.xsd#inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_22a5c869-092e-4a2b-ba72-4bfd9cf6a7d3" xlink:to="loc_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_d3ccf9ee-c899-4190-910c-1152a8aeb132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESRevenueSummaryDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_8f36ee7f-d9f7-4303-8524-5854c7d3d605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_8f36ee7f-d9f7-4303-8524-5854c7d3d605" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73e02bc1-c0bb-4e7c-9bca-11e4ddb23bfe" xlink:to="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember_ae0e77e2-e1b7-4d80-894b-bf1d409ec8c8" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:to="loc_inhibrx_LicenseAffiliateMember_ae0e77e2-e1b7-4d80-894b-bf1d409ec8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseNonAffiliateMember_c85f862f-d79c-4122-8c11-eddb608bbf9d" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:to="loc_inhibrx_LicenseNonAffiliateMember_c85f862f-d79c-4122-8c11-eddb608bbf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_23a77973-dd68-4afe-9c7a-83248fac6213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1fce6364-f11e-4b9c-a056-ff108b3c5b77" xlink:to="loc_us-gaap_GrantMember_23a77973-dd68-4afe-9c7a-83248fac6213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d602b9aa-761e-4de4-a86f-bf0cedc26ab2" xlink:to="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember_e1ad625a-a8d1-4d94-b504-0baff1d0cf79" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_TranscentaHoldingLtdMember_e1ad625a-a8d1-4d94-b504-0baff1d0cf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_a4bf3cd2-9038-48cb-a8e6-322b8ff76c63" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_a4bf3cd2-9038-48cb-a8e6-322b8ff76c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember_79bf3152-fcce-4b41-ab3e-fa1a93da9506" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_PhylaxisBioScienceLLCMember_79bf3152-fcce-4b41-ab3e-fa1a93da9506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BluebirdBioIncMember_7a421fb8-f11a-4086-bd98-0fb7786837df" xlink:href="inhibrx-20200930.xsd#inhibrx_BluebirdBioIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_BluebirdBioIncMember_7a421fb8-f11a-4086-bd98-0fb7786837df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ChiesiFarmaceuticiSpAMember_aea566b3-ad5b-4461-9bed-1b655604e21b" xlink:href="inhibrx-20200930.xsd#inhibrx_ChiesiFarmaceuticiSpAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_ChiesiFarmaceuticiSpAMember_aea566b3-ad5b-4461-9bed-1b655604e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_9a93e09e-bac1-430b-9df1-22a898b4c103" xlink:href="inhibrx-20200930.xsd#inhibrx_OtherCustomersNotSeparatelyDisclosedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fd3ff5be-04c1-429a-ac57-edc839ea2d2a" xlink:to="loc_inhibrx_OtherCustomersNotSeparatelyDisclosedMember_9a93e09e-bac1-430b-9df1-22a898b4c103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a7ac031d-379d-4923-a681-65b122bed7c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NationalInstitutesOfHealthMember_19b1f3c2-57bb-4756-95cc-66a4a3010529" xlink:href="inhibrx-20200930.xsd#inhibrx_NationalInstitutesOfHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:to="loc_inhibrx_NationalInstitutesOfHealthMember_19b1f3c2-57bb-4756-95cc-66a4a3010529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_ae497f2e-072d-4835-a87c-03bf9803ec19" xlink:href="inhibrx-20200930.xsd#inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:to="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_ae497f2e-072d-4835-a87c-03bf9803ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_8ce92b0b-ee9d-4274-936b-eafc268dcf52" xlink:href="inhibrx-20200930.xsd#inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7925a1cc-dbbe-4032-98d1-4571453b0440" xlink:to="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_8ce92b0b-ee9d-4274-936b-eafc268dcf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aac611d5-200b-44d4-968f-dfabed4bbe24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_058e9fb9-a786-4208-a1c0-67f7605a164e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aac611d5-200b-44d4-968f-dfabed4bbe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8394d94f-5fbf-48f1-86fc-dcf2f24bdda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aac611d5-200b-44d4-968f-dfabed4bbe24" xlink:to="loc_us-gaap_Revenues_8394d94f-5fbf-48f1-86fc-dcf2f24bdda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_2dfea531-006b-41a7-b225-11d341686efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_2dfea531-006b-41a7-b225-11d341686efd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_290bcf25-6386-4d98-b3b0-db2b1aa12241" xlink:to="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember_5e214378-f07b-42de-948b-350b38b4f0dc" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_PhylaxisBioScienceLLCMember_5e214378-f07b-42de-948b-350b38b4f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BluebirdBioIncMember_01475fcc-b481-4c0e-a2c6-8cc5d6055409" xlink:href="inhibrx-20200930.xsd#inhibrx_BluebirdBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_BluebirdBioIncMember_01475fcc-b481-4c0e-a2c6-8cc5d6055409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ChiesiFarmaceuticiSpAMember_33596b16-d2fa-4540-950b-c4fafb2d9e58" xlink:href="inhibrx-20200930.xsd#inhibrx_ChiesiFarmaceuticiSpAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_ChiesiFarmaceuticiSpAMember_33596b16-d2fa-4540-950b-c4fafb2d9e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_60b93b54-34c2-4c13-bc73-64fb0304ddea" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_60b93b54-34c2-4c13-bc73-64fb0304ddea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember_ce7acb9f-8d99-4863-9441-552c96d4cdd1" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_TranscentaHoldingLtdMember_ce7acb9f-8d99-4863-9441-552c96d4cdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CelgeneMember_0e736880-7548-4f6d-8070-149dfeb857ef" xlink:href="inhibrx-20200930.xsd#inhibrx_CelgeneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_66e84279-1ce3-4fda-833d-3b4af3df29fd" xlink:to="loc_inhibrx_CelgeneMember_0e736880-7548-4f6d-8070-149dfeb857ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_76b78ca7-d09c-47ac-8633-d71c46356da5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0388b4f1-a837-467f-b1b9-a31d41b43bbc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_76b78ca7-d09c-47ac-8633-d71c46356da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PhylaxisBioScienceLLCMember_96c8d7ae-e764-4a40-8e56-03a1e1587f76" xlink:href="inhibrx-20200930.xsd#inhibrx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_76b78ca7-d09c-47ac-8633-d71c46356da5" xlink:to="loc_inhibrx_PhylaxisBioScienceLLCMember_96c8d7ae-e764-4a40-8e56-03a1e1587f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_060ae547-8954-4242-9bca-27bf3973af25" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:to="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_a6e35c5b-60a7-43a4-8224-9f89437b99f5" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:to="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_a6e35c5b-60a7-43a4-8224-9f89437b99f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_798253b4-52a9-4acc-8968-eec2be97c9ef" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedMember_b283fd58-1ca0-47c6-9ffa-3582b870b6a6" xlink:to="loc_inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_798253b4-52a9-4acc-8968-eec2be97c9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_b45476d3-807d-4602-865f-963062cf69a7" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cea6b2aa-ef78-46df-8a06-fe197058c055" xlink:to="loc_inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember_b45476d3-807d-4602-865f-963062cf69a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9cbf643d-3d28-4cd2-809f-86b3f3801813" xlink:to="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseNonAffiliateMember_90fbd76e-5f9f-462d-ba5e-c539d37a60e7" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:to="loc_inhibrx_LicenseNonAffiliateMember_90fbd76e-5f9f-462d-ba5e-c539d37a60e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21b2096e-1587-415a-b3bf-ad30a283b789" xlink:to="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_8398dcd2-c522-4332-886c-cc8a23a10f4c" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:to="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_8398dcd2-c522-4332-886c-cc8a23a10f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_16043cfc-4b87-41e4-ade9-7e1cca8151dd" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_LicenseAffiliateMember_aa8e791b-d5e1-4b59-bd8e-4962343aeb83" xlink:to="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_16043cfc-4b87-41e4-ade9-7e1cca8151dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_040ec1c3-bb84-4684-bfd9-2173da8c7b6f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_7a17b4f7-d064-4f55-aa8d-4393ef361fff" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment_7a17b4f7-d064-4f55-aa8d-4393ef361fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_5052b1f9-cb36-47a2-8c0b-c9a5585a7055" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementAdditionalPaymentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable_5052b1f9-cb36-47a2-8c0b-c9a5585a7055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_987d0210-353c-40f7-b79d-80031440170d" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_987d0210-353c-40f7-b79d-80031440170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3bb95a20-dd8a-42c2-befb-713dec7154ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3bb95a20-dd8a-42c2-befb-713dec7154ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_9c43878c-e760-4745-97a3-0b587a3889af" xlink:href="inhibrx-20200930.xsd#inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled_9c43878c-e760-4745-97a3-0b587a3889af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_2324861c-ceff-4eb4-9b98-74cfe5b3e30e" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable_2324861c-ceff-4eb4-9b98-74cfe5b3e30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_9990712f-96f1-47f8-856f-cc98c122f1c1" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable_9990712f-96f1-47f8-856f-cc98c122f1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c9e785a2-b44e-4c85-b19c-87f0d83447cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_EquityMethodInvestments_c9e785a2-b44e-4c85-b19c-87f0d83447cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementPaymentReceivable_98bec887-c1cb-4c61-8a11-34092db8c52c" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementPaymentReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementPaymentReceivable_98bec887-c1cb-4c61-8a11-34092db8c52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfPerformanceObligations_1ce2f400-2011-42bd-8562-26f1902a733d" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_NumberOfPerformanceObligations_1ce2f400-2011-42bd-8562-26f1902a733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RevenueRecognitionNumberOfCompounds_582d0453-338b-4763-b13f-22681c77334a" xlink:href="inhibrx-20200930.xsd#inhibrx_RevenueRecognitionNumberOfCompounds"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_RevenueRecognitionNumberOfCompounds_582d0453-338b-4763-b13f-22681c77334a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f21475c6-acf4-42aa-8fe2-0e26cd08c383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f21475c6-acf4-42aa-8fe2-0e26cd08c383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_609d103f-5e8e-427e-8a07-deb383f725be" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_609d103f-5e8e-427e-8a07-deb383f725be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_d801519f-98d9-486d-a2b1-da0d2c739657" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses_d801519f-98d9-486d-a2b1-da0d2c739657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cf6d70e5-9d82-4a3d-9358-e0bc98ce355a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_Revenues_cf6d70e5-9d82-4a3d-9358-e0bc98ce355a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_fc8d8eca-98cb-4ca9-b568-a4d87aa61cbd" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementMilestonePaymentsReceivable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable_fc8d8eca-98cb-4ca9-b568-a4d87aa61cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_42f02c78-cf56-44ba-b594-47f3d4865bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_42f02c78-cf56-44ba-b594-47f3d4865bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NumberOfLicenseAgreements_7f1237db-91a3-481a-9498-5577788985fa" xlink:href="inhibrx-20200930.xsd#inhibrx_NumberOfLicenseAgreements"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_NumberOfLicenseAgreements_7f1237db-91a3-481a-9498-5577788985fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementExpenseReimbursement_49fe7ca8-9031-4c5b-b6c6-66aba52e2ca8" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementExpenseReimbursement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementExpenseReimbursement_49fe7ca8-9031-4c5b-b6c6-66aba52e2ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d7a3a1ea-50fc-423f-a3b6-34643bab7776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d7a3a1ea-50fc-423f-a3b6-34643bab7776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_59d98e0e-69a2-43b8-9adc-19c9dbd5d8c7" xlink:href="inhibrx-20200930.xsd#inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_59d98e0e-69a2-43b8-9adc-19c9dbd5d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_21acaf73-ba70-4b8c-8885-ebb82790fcf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_21acaf73-ba70-4b8c-8885-ebb82790fcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementForeignTaxWithholding_863c5be6-51ce-49cf-98c5-0822ac6c92b9" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementForeignTaxWithholding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementForeignTaxWithholding_863c5be6-51ce-49cf-98c5-0822ac6c92b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_77e8eb03-8c6c-4829-9b48-b62fa05172d9" xlink:href="inhibrx-20200930.xsd#inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bd38ca5f-ec02-4bca-bfc6-1e86a2b01300" xlink:to="loc_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_77e8eb03-8c6c-4829-9b48-b62fa05172d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#LICENSEANDGRANTREVENUESGovernmentGrantsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_503ba794-255a-4ff3-b75d-ebef493306e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_503ba794-255a-4ff3-b75d-ebef493306e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:to="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fcab63ee-da3b-44b8-ad4f-1267c270656b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1bc76264-f291-4863-9e4e-c974be1b9b58" xlink:to="loc_srt_ProductsAndServicesDomain_fcab63ee-da3b-44b8-ad4f-1267c270656b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_79d2f846-2399-4d86-8f7c-651d3befed19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fcab63ee-da3b-44b8-ad4f-1267c270656b" xlink:to="loc_us-gaap_GrantMember_79d2f846-2399-4d86-8f7c-651d3befed19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:to="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2ebddb0f-0115-468f-bdd5-d40bfcd42440" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_NationalInstitutesOfHealthMember_2dad472d-10f1-4df7-b989-9ce5f8e006d6" xlink:href="inhibrx-20200930.xsd#inhibrx_NationalInstitutesOfHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_NationalInstitutesOfHealthMember_2dad472d-10f1-4df7-b989-9ce5f8e006d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_439f4798-27d5-4e62-b172-7dd8238eda62" xlink:href="inhibrx-20200930.xsd#inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember_439f4798-27d5-4e62-b172-7dd8238eda62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_e2ebaaff-c7ad-4e84-ace9-3fb086e4ffbb" xlink:href="inhibrx-20200930.xsd#inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_e2ebaaff-c7ad-4e84-ace9-3fb086e4ffbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_0dc3d070-ef7a-48db-a463-a64fc8270654" xlink:href="inhibrx-20200930.xsd#inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fd28946-a0f9-40b6-bf3a-8159e6aafc33" xlink:to="loc_inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember_0dc3d070-ef7a-48db-a463-a64fc8270654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f520b28a-e5a1-45cb-b3b0-21b461ffc03d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantValuedAwarded_97ffc188-6af2-452d-ace3-49995b029360" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantValuedAwarded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_inhibrx_GrantValuedAwarded_97ffc188-6af2-452d-ace3-49995b029360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_be278da6-5435-430f-8186-8a60f5029fd7" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor_be278da6-5435-430f-8186-8a60f5029fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_1b5fb786-dffc-4666-85e4-45554490b181" xlink:href="inhibrx-20200930.xsd#inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany_1b5fb786-dffc-4666-85e4-45554490b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_569dcad3-9362-46c5-b10c-d7be5bb4bb81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a4007896-1430-4368-a02d-f172ce80412b" xlink:to="loc_us-gaap_Revenues_569dcad3-9362-46c5-b10c-d7be5bb4bb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a3700d96-91ec-4a15-9875-b563f6ccb609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0e842957-232c-4d6f-8b2c-d1c1c84e3a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a3700d96-91ec-4a15-9875-b563f6ccb609" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0e842957-232c-4d6f-8b2c-d1c1c84e3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7d41c4a4-b250-46da-a4eb-d0281a8dfeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7d41c4a4-b250-46da-a4eb-d0281a8dfeb8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24384ae4-6ef3-43b8-94f1-3ade800e7863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08f634c5-06b7-4014-8741-95b2ce7668d6" xlink:to="loc_us-gaap_RelatedPartyDomain_24384ae4-6ef3-43b8-94f1-3ade800e7863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b29b19d9-3c56-4560-bf92-d4e3b202c1b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_24384ae4-6ef3-43b8-94f1-3ade800e7863" xlink:to="loc_srt_AffiliatedEntityMember_b29b19d9-3c56-4560-bf92-d4e3b202c1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a2e11369-4be9-468e-9163-7458dfcc153b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LAVSummitLimitedMember_1d503d61-1058-4dda-9ae7-9b83f836d9c5" xlink:href="inhibrx-20200930.xsd#inhibrx_LAVSummitLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:to="loc_inhibrx_LAVSummitLimitedMember_1d503d61-1058-4dda-9ae7-9b83f836d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_0ed91f7c-27d4-4ab9-af8b-c78e872eff8d" xlink:href="inhibrx-20200930.xsd#inhibrx_WuXiBiologicsHealthcareVentureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb803665-205c-4927-833b-4b13ddb1dda9" xlink:to="loc_inhibrx_WuXiBiologicsHealthcareVentureMember_0ed91f7c-27d4-4ab9-af8b-c78e872eff8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_69901fa3-7208-43b5-a7cf-b51db96a8819" xlink:to="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TranscentaHoldingLtdMember_77083d2a-9348-419b-94c7-4ce818e198f1" xlink:href="inhibrx-20200930.xsd#inhibrx_TranscentaHoldingLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:to="loc_inhibrx_TranscentaHoldingLtdMember_77083d2a-9348-419b-94c7-4ce818e198f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_f31a755f-d6c7-4467-9ef3-be087d91eb59" xlink:href="inhibrx-20200930.xsd#inhibrx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b7d33cbb-ae7c-471b-bee7-77b75b111731" xlink:to="loc_inhibrx_ElpiscienceBiopharmaceuticalsIncMember_f31a755f-d6c7-4467-9ef3-be087d91eb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_443a8192-3ba6-42f1-9d97-8085b149cf5a" xlink:to="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateMember_4cb491c2-4ba7-441c-9511-99b0043ecc46" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:to="loc_inhibrx_LicenseAffiliateMember_4cb491c2-4ba7-441c-9511-99b0043ecc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_9671915b-50e7-4ae4-b2e8-73eef88c851a" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:to="loc_inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember_9671915b-50e7-4ae4-b2e8-73eef88c851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_ff6a6bab-a3bc-47fc-b7d6-0562bf17d115" xlink:href="inhibrx-20200930.xsd#inhibrx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35854cc1-6b47-4299-9e85-843cd42ba2c9" xlink:to="loc_inhibrx_LicenseAffiliateOX40LicenseAgreementMember_ff6a6bab-a3bc-47fc-b7d6-0562bf17d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_058f1a4c-cb5c-418b-9749-35291a38513b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea6a4a43-341f-4c40-9292-42e0f6b883e7" xlink:to="loc_us-gaap_ClassOfStockDomain_058f1a4c-cb5c-418b-9749-35291a38513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_SeriesMezzanine2PreferredStockMember_5d17cde7-0f84-40b3-9ce9-a17d324338b6" xlink:href="inhibrx-20200930.xsd#inhibrx_SeriesMezzanine2PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_058f1a4c-cb5c-418b-9749-35291a38513b" xlink:to="loc_inhibrx_SeriesMezzanine2PreferredStockMember_5d17cde7-0f84-40b3-9ce9-a17d324338b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_674c8183-8e0a-4578-b700-784dfe8e5893" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RelatedPartyEquityInterestInCompany_9f01e685-a779-4da0-a5d6-0af209a2dcc6" xlink:href="inhibrx-20200930.xsd#inhibrx_RelatedPartyEquityInterestInCompany"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_inhibrx_RelatedPartyEquityInterestInCompany_9f01e685-a779-4da0-a5d6-0af209a2dcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ebb8b647-f682-4b39-98b8-b267829bb95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_Revenues_ebb8b647-f682-4b39-98b8-b267829bb95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_ExpensesReimbursedToDate_b219eab3-115a-4a13-a7d1-8d9b981e65f9" xlink:href="inhibrx-20200930.xsd#inhibrx_ExpensesReimbursedToDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_inhibrx_ExpensesReimbursedToDate_b219eab3-115a-4a13-a7d1-8d9b981e65f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_cf7b41d4-ac38-4de0-bb6d-a7d6c6626c12" xlink:href="inhibrx-20200930.xsd#inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_cf7b41d4-ac38-4de0-bb6d-a7d6c6626c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_bcaa8ea5-0ccc-4383-a8d4-5c8255b2427c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_SharePrice_bcaa8ea5-0ccc-4383-a8d4-5c8255b2427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c16c5816-1ff3-4c45-890c-df9b5a1ba905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6bf051c6-4240-47ab-9f0e-b8b035772f7f" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c16c5816-1ff3-4c45-890c-df9b5a1ba905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9be3d4b-d64d-46e7-8c79-82e8cfd25e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c3ede6ae-761a-4951-81b4-aa5ddd43aa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9be3d4b-d64d-46e7-8c79-82e8cfd25e6e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c3ede6ae-761a-4951-81b4-aa5ddd43aa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf65079e-fe23-488f-8719-51afaf5a4941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_5599fed8-c8ac-49d8-8cc6-035223c1309a" xlink:href="inhibrx-20200930.xsd#inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf65079e-fe23-488f-8719-51afaf5a4941" xlink:to="loc_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_5599fed8-c8ac-49d8-8cc6-035223c1309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8018af23-805e-4202-ab52-a694a9ea3c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf65079e-fe23-488f-8719-51afaf5a4941" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8018af23-805e-4202-ab52-a694a9ea3c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ff15d04a-727f-4123-b2b4-d8cd64971c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ff15d04a-727f-4123-b2b4-d8cd64971c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseSquareFootage_2bb62325-8997-4725-8233-44771f738055" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseSquareFootage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_inhibrx_LesseeOperatingLeaseSquareFootage_2bb62325-8997-4725-8233-44771f738055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d1dd9acc-663c-49bb-b5d4-1d1de561a354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d1dd9acc-663c-49bb-b5d4-1d1de561a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_59428301-17bd-4e39-8315-d072174dc70c" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_59428301-17bd-4e39-8315-d072174dc70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseAnnualEscalations_12a4ce20-ef6a-4bcb-8bea-c5d34f9234cf" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseAnnualEscalations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_inhibrx_LesseeOperatingLeaseAnnualEscalations_12a4ce20-ef6a-4bcb-8bea-c5d34f9234cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseSquareFootageExpansion_e539e924-b727-431f-b4c0-790dfedd0047" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseSquareFootageExpansion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_inhibrx_LesseeOperatingLeaseSquareFootageExpansion_e539e924-b727-431f-b4c0-790dfedd0047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6c7ae39b-d1c3-4685-8c9c-1948049df5cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_us-gaap_OperatingLeaseExpense_6c7ae39b-d1c3-4685-8c9c-1948049df5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fdf2e42f-db0f-405a-a54b-2a16ec28f768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fdf2e42f-db0f-405a-a54b-2a16ec28f768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_54463d4c-a3a4-4fd6-ba01-2af30f805cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d482a58-d02f-47c1-848b-31b06fd0b0f0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_54463d4c-a3a4-4fd6-ba01-2af30f805cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7faa646e-d2c0-47e4-a8ab-603696bd3a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_862cff94-4e6e-4844-bbb8-2f95101e1bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7faa646e-d2c0-47e4-a8ab-603696bd3a57" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_862cff94-4e6e-4844-bbb8-2f95101e1bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_dd8dd7ad-c64f-4ff7-9b1c-553203a0e083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7faa646e-d2c0-47e4-a8ab-603696bd3a57" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_dd8dd7ad-c64f-4ff7-9b1c-553203a0e083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d48dc23-58b6-472d-9985-be5a1c72803a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_dd8dd7ad-c64f-4ff7-9b1c-553203a0e083" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d48dc23-58b6-472d-9985-be5a1c72803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a504daf3-c6fe-4b58-824b-e67d2830ad73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_dd8dd7ad-c64f-4ff7-9b1c-553203a0e083" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a504daf3-c6fe-4b58-824b-e67d2830ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0ce77911-618c-476b-a24c-e7c488a08646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_dd8dd7ad-c64f-4ff7-9b1c-553203a0e083" xlink:to="loc_us-gaap_OperatingLeaseLiability_0ce77911-618c-476b-a24c-e7c488a08646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5c7bd1ee-710c-4481-871d-8742ad3b2d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5c7bd1ee-710c-4481-871d-8742ad3b2d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d8d70880-0bdd-449a-ba4f-d38b987dd8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d8d70880-0bdd-449a-ba4f-d38b987dd8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d5bbef77-a627-4fab-9982-6f66d997a7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d5bbef77-a627-4fab-9982-6f66d997a7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ffe59dc2-af32-4d17-a596-fce38c498d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ffe59dc2-af32-4d17-a596-fce38c498d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34488dc6-47c3-4f29-b6bc-b5586cc16f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34488dc6-47c3-4f29-b6bc-b5586cc16f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_318f5ea0-9340-4849-8670-e2c771ff073e" xlink:href="inhibrx-20200930.xsd#inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_318f5ea0-9340-4849-8670-e2c771ff073e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad465a6c-32b3-46be-af9b-b483a33f731c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad465a6c-32b3-46be-af9b-b483a33f731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27665926-1042-4554-bf28-e34b947fa524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27665926-1042-4554-bf28-e34b947fa524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_116bb154-7d20-4cc8-a38f-1226cd2f54c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_OperatingLeaseLiability_116bb154-7d20-4cc8-a38f-1226cd2f54c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa24211d-552d-4b7a-b513-b797c16cd215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa24211d-552d-4b7a-b513-b797c16cd215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0a63d3e1-e28f-4636-9be2-8541b86d2039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a62c15e-b3af-4ca1-8ff6-387a94bd5782" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0a63d3e1-e28f-4636-9be2-8541b86d2039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/COVID19" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#COVID19"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/COVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_c87fcd33-281e-4e59-80a2-a219dad480d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_55d9ce61-4434-411e-bb64-e58d78420444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_c87fcd33-281e-4e59-80a2-a219dad480d1" xlink:to="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_55d9ce61-4434-411e-bb64-e58d78420444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_312a26b3-be3e-476c-8480-b1c1a05fe435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9a373601-a892-49f7-9859-093d62c861a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_312a26b3-be3e-476c-8480-b1c1a05fe435" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9a373601-a892-49f7-9859-093d62c861a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inhibrx-20200930.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_87e81a51-6626-4bad-af71-220cec0d9a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_87e81a51-6626-4bad-af71-220cec0d9a55" xlink:to="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a6529caf-7765-4cd3-9d40-9d3e9d1c2f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f4874c34-c6ba-45b6-a33b-850fe291240b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a6529caf-7765-4cd3-9d40-9d3e9d1c2f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_63d1ea6e-3e5c-4c99-ae88-eb72b79b2b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a6529caf-7765-4cd3-9d40-9d3e9d1c2f97" xlink:to="loc_us-gaap_SubsequentEventMember_63d1ea6e-3e5c-4c99-ae88-eb72b79b2b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7f890fbd-50a7-4b64-90ff-efb9a2c73b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_0a03db76-bffe-4383-8efe-bdda9891ce50" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7f890fbd-50a7-4b64-90ff-efb9a2c73b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_d311c49b-8737-495a-90b3-9c9fc299f5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7f890fbd-50a7-4b64-90ff-efb9a2c73b54" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_d311c49b-8737-495a-90b3-9c9fc299f5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94379f90-8227-401e-8625-33f248ede893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b9fb90a0-aac6-4443-badf-a12f1ea2a66d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94379f90-8227-401e-8625-33f248ede893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b43f8782-cefc-4d6d-acb0-c192915cd602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_94379f90-8227-401e-8625-33f248ede893" xlink:to="loc_us-gaap_SecuredDebtMember_b43f8782-cefc-4d6d-acb0-c192915cd602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4ee63d05-513e-4550-8ed6-b158f75c2fad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_PaycheckProtectionProgramCARESActMember_d6fe824f-cc82-43dc-9b0d-cade2f6b6a06" xlink:href="inhibrx-20200930.xsd#inhibrx_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:to="loc_inhibrx_PaycheckProtectionProgramCARESActMember_d6fe824f-cc82-43dc-9b0d-cade2f6b6a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d97256-2971-49e3-8e1c-e06ae53eff85" xlink:to="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_b187f447-f628-45a9-9118-04736bb75743" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTranchesBAndCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansTranchesBAndCMember_b187f447-f628-45a9-9118-04736bb75743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTrancheBMember_9cf437d7-3ca8-483a-aff5-40ee14c22399" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansTrancheBMember_9cf437d7-3ca8-483a-aff5-40ee14c22399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansTrancheCMember_e3562a6e-7f42-489a-b681-e3ba141a2c5c" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansTrancheCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansTrancheCMember_e3562a6e-7f42-489a-b681-e3ba141a2c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_A2020OxfordTermLoansFirstTrancheMember_9f7bb47d-5f82-4a00-b1ca-1dd9744346d8" xlink:href="inhibrx-20200930.xsd#inhibrx_A2020OxfordTermLoansFirstTrancheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inhibrx_A2020OxfordTermLoansMember_c51c0a50-659d-4a65-80f3-2f5cdb13eedf" xlink:to="loc_inhibrx_A2020OxfordTermLoansFirstTrancheMember_9f7bb47d-5f82-4a00-b1ca-1dd9744346d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b35f93b0-10ca-4fdd-84bd-d1eb29ab8065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6cb50d17-329e-4796-8e52-d2e2df102a82" xlink:to="loc_us-gaap_VariableRateDomain_b35f93b0-10ca-4fdd-84bd-d1eb29ab8065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2680578c-0664-4125-962a-687b7970e7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b35f93b0-10ca-4fdd-84bd-d1eb29ab8065" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2680578c-0664-4125-962a-687b7970e7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_60f75807-6c83-4923-bf87-3d02048ad8fd" xlink:to="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65dc86ab-62f4-4462-ac4a-50b0b0fa52e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:to="loc_srt_MinimumMember_65dc86ab-62f4-4462-ac4a-50b0b0fa52e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_16818c2e-0a9f-42d0-8baf-5ca1f7424f70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2099003c-7146-4596-8aed-89edd3b0916f" xlink:to="loc_srt_MaximumMember_16818c2e-0a9f-42d0-8baf-5ca1f7424f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_db222e60-1adb-4af7-bb0b-6d3d6d0ed9de" xlink:to="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_a0e88b00-c77c-4a0c-ab3a-0d4b378a4a48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_InterestPayableCurrent_a0e88b00-c77c-4a0c-ab3a-0d4b378a4a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_6660620e-7081-4a3f-922d-e754abfc3d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_6660620e-7081-4a3f-922d-e754abfc3d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8a397eb2-85d8-44c6-a4d7-dc0ead991496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8a397eb2-85d8-44c6-a4d7-dc0ead991496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_933ed5b6-45cb-40b1-b92e-8165d7c7edf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_933ed5b6-45cb-40b1-b92e-8165d7c7edf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestRateFloor_d19d5b7d-aacc-4e22-b1ba-80a0040d3674" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestRateFloor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentInterestRateFloor_d19d5b7d-aacc-4e22-b1ba-80a0040d3674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_40c992a9-310e-4b53-a71f-a950c7eef0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_40c992a9-310e-4b53-a71f-a950c7eef0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_e2edb4d3-e58f-4481-a9cf-db15033babcd" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm_e2edb4d3-e58f-4481-a9cf-db15033babcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_d9d0fa3c-ed81-482f-94d5-9448ea8b7ea0" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod_d9d0fa3c-ed81-482f-94d5-9448ea8b7ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_b0b62002-bc29-4b9b-a080-65aeef2e2788" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm_b0b62002-bc29-4b9b-a080-65aeef2e2788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_30a9febf-c8c8-4685-93cb-c0375578b5fd" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_30a9febf-c8c8-4685-93cb-c0375578b5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inhibrx_DebtInstrumentPrepaymentFee_5c4f8b78-c4fd-451d-a9bd-d603183ac6fa" xlink:href="inhibrx-20200930.xsd#inhibrx_DebtInstrumentPrepaymentFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d074e0bb-cdc3-445f-b0e5-7b7733a095b5" xlink:to="loc_inhibrx_DebtInstrumentPrepaymentFee_5c4f8b78-c4fd-451d-a9bd-d603183ac6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>inhibrx-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:inhibrx="http://inhibrx.namespace.com/20200930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inhibrx-20200930.xsd" xlink:type="simple"/>
    <context id="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idbf3661972cb42c9b5609ea4cbd7cb26_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a502282910747c9aac74a5847fac525_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2815584d6b3449bae058364571557b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied2eec07eda2401383326e716774ff76_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieadc553907f04aea9984cc210e0af52f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i17fce0905feb4ca0a6d436f23bdb5a51_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic597294d6b05480f9b87cfc8e153db62_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id8caa9dd3e98483facac392f2f26d651_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i820a8e2822d74bbd82ecbf86ba928b9c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie34e5f2d63b64f9ab8bdc6574f9e7285_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i000ce15b89d840528ca0541bc84717e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ac975841c0c4eee8d4575323136a11b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f21270f21874db1b0bbfb358bb4a78a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie2d17755e65848568a5814eb7e92fa96_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i603a3e22a39e4c3f84a33bd10c4b7461_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0cb47a5672584355b7d05652419f4135_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifd8c696851984b19adde3434ae473fe3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i846daf89fc2b40ff9276e0309f8bc49b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib15a549f5d7c49ba8413651379bcbb4b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i34b03bb902a94c8785ee943f02414084_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5228ec7bd82b4d18aa5c78ca560be27f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3ab8209e132d4d49885fdd7a39a220b4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia6aba7f28dc64367a0eece71a35d9fb9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idad3866ecff24d2bb1c1621c08c1e65d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide0a954ba6d54755911e36150df70447_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i29ac8459a45944d89bd8d8c502750883_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib43ea9fc9a3749ca8aec69153be4824b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i06e3380af6394476b9fb41f80b54569d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic72f396661b64960a85d478129870552_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0eee8e0a5aa64149a5e9678da896aa09_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief2e22b91c8f4c61bc620f632b4e3aa3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i868602c6c8094dfe8c35ccb6d3bf5389_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8c3d1c7115344cf87b4e8072fb23023_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00e8f3fe84bb4c7c80b0765347fb47fe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia490249b50314ffeb9819be68dddeff5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcfaf63fd5be43bd94a1aa0e5f1b9ed8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59bd56e946e5445bae234daf9abde8e6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i968c5b21c23d497c885a34db4e9dcc82_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93804641103b457fad36e34238434091_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if80eeafcebb44eda80d0e0ab4cb21502_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6437dc22b9a1413a83a988950e6b212f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98b810262bba4b218699272e9d863800_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8ad639b97919472cb19836f0f20c8578_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if5b516dbf8534c51a8a187a321b5ff02_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie17c4099b42e47cdb2c7b8aaaa29181c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9cb446db2851407d98c475b4a9496a9b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic3fd70b3e3724e78bbd68fad24152716_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib639469f8e6f46fe9e906ab1f8a23c3c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if6c148e447dd4a72b3fb1401d56a109a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i832575ad734f4ac68adc394981e0dd95_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3f3ee615da3341d98188126debd31173_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i33fdbec7cbe14bb58d66b46ff6a32efb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5aba2096009b41df80c66bfd01ec2c58_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8ad87a43bcfd47718c0aa0291e455eef_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2c2000034bdf45109c782f320cd6a01d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8dacf172bede47d8a24654bfb96d5b2e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i89f99f3c856b4015a5874dbe44c7d459_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id8760e90a1ba450cadb660bb033f985c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9cf47f3d3e3c429eb534fb4774e9f5cf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i935c025cf0be4f52aa328da8cd08cdbc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73dbd07a8a064245beef5a5cd1785fc5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1fa3b845869d4942a592437637e60ccb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie3d63e6b69ff48ee80954424e39ed256_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iae97d8956ab04cc2adbd33a7853f81d6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i59e35846453d49108af294a83527115a_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i716fae2ef5ce4494a59333e61122850c_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="id7e5ed6c9480459caa6ba643143e71bb_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i55e33ca65d2942a182ef960398078928_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i89b94e216c8747f7a8147b47e4efe7c2_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="ie8dadc7ef039420eaa7b0c92264e86ca_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ifba32dd833574402ada1e36890f6561a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3feb5c4ab8444992aad253b0eb3aac6c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f274e94611f454abf5e4027b0746f28_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31329f709cd646a1985943678e052e84_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6fe512cd41a649b5b6c7acf1a99ef3f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87b2ff8ae24b4a848877e3577572b4fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i678ba84787b74c33aaa1dabda2391b12_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i97607866f6cc41cc94cca89d10cf6bdc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3dbaed7d7d47475091f2e4ab91488da7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i27c38f2ed7fa44b4a81fe1f1eed88df2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica2104115bc94b9fa8ac3b4e7d8a5952_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inhibrx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5f268e0f7dca45f9b9332914738e6f74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac814f782c3b45af984e9c168fd5b2c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9257d69f32004657829030276365dab2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inhibrx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i34eb3903a88c4cf4a2c174b773b1619b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d33748b115443b382ab613199d390b0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i853b5ffb64fa4b6c9270743f860795a1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inhibrx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic48577e54c534c9cb159d018b57d9192_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="id0ac33289ae142bd80d836a856c99abf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67ce0cd624534b4fb3a651217b134e1e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1b460d94a844e52ade7a0f2b9ab1b9f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icf0f30e90da64a8baa297d499a8884ff_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbde3532e59e43b4a2a437f33e108ffd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06bcfbe172b34cf880f671de4e455fd8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5f7d4dd51b19431eb1b4a19269978732_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iced870049b9c4af8a2a71c8e3372f3bd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib34ba14de47a44d4bbeebf803e29fcda_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifd6dd439011c4044a8417377d85ed8ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie5731faed81f4f03a3bb8f76c85c0064_D20200811-20200811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="ie7dd225fb7244d46a1448835a24eedc8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4771026d5c3c40319d148f5c1fcdb3cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i099bcc18560648f6b4af3ed81b2359f0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibc99fb23a741432181c70887a43007ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55cc14d646e5495391d1f2b7134f4a82_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i575d68e93bc24286964f7a4a6a71af6d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f581b24f01849d48dc4babb1fee7e16_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icfa0ca10369144789935f71aa0d4b1c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6863d5d7e63541b0a3f1be858bc15d80_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1492990af4cd4609ab13680229c0d787_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2dbb72e83b64adc8434cf549fd94175_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12196a7c26a24c34983264cd528c02a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec2e8e28f6944a6cad3e341eddbd124d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7a938740c8f41d98cdd5977f98ba01d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73adcaf6ee1947b18f6562d5ec941caf_I20150315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-15</instant>
        </period>
    </context>
    <context id="i1128b89e97354edab268af53bdbb2cfc_I20150315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-15</instant>
        </period>
    </context>
    <context id="i968d197dbe54493980d0c6601895286d_I20150315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-15</instant>
        </period>
    </context>
    <context id="iedc8c75d167c4002ae62b4656fc8dc96_I20150315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-15</instant>
        </period>
    </context>
    <context id="icc18af2d45e5429aa46b9f3c1c60dacf_I20150315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-15</instant>
        </period>
    </context>
    <context id="if717d2bbf6df424fbf967687e556c917_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib7a2211031b8411a97f1eedd40de2aea_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i39bd4629e345403594bc83286802f27d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib431edb342fd4664ae233fef94fbc459_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansTermDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inhibrx:ProfitInterestUnitPIUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-15</startDate>
            <endDate>2015-03-15</endDate>
        </period>
    </context>
    <context id="ia44998013bed488a89c12a2bbbf5d413_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inhibrx:ProfitInterestUnitPIUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75b1864cd5ba4d82ad35132d3bf4651c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a5bfebe16ba4d42b9420939d6abd37e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if576809f1ef74d2dae834e212f4c787a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie8b1c64897a0450b8b676d88f5779c65_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id069de05c44b419a8bc04341e87faf34_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="ifab34d6750ef4bf6b880aa50a8da757b_D20200715-20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="i802d90f694e04e9cbc8a950326d54eca_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i080025cf9ef84898b13a4a46dd987fa0_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i2fc4b9c1f869452c886e27fd8cb739ca_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i2314b9fb755947e4ab7ad70f16e7a771_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inhibrx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c0a3edbbf394e39ac9b8b95852e4df9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i515b22595f7847ed9dff1e886916e38f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iab2815bc314c46819698b119c61f9104_D20200511-20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-11</endDate>
        </period>
    </context>
    <context id="i4662b14824724021a2692a483eecb043_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i41bc12ffbb534f18a23e536d4dde5a2c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i818e609617104ca8b6c8c4969ac1e906_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i26693951deed4303a7da2ddadc8ee05f_I20190520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-20</instant>
        </period>
    </context>
    <context id="ic77d30165eef43de82b4519b6e11aabd_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i5faa4978633f459b997f876d04a34424_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i80dd5d72484a4344aea558884246a977_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i0bbe316909104cd2b78167b976ed7a0b_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i32241f5d4454450aa87c2b3c1c404b87_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i83317f913e354c4c8e1ec68bfd7bd8e5_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i181595e7e07c4d178483c8e330544e15_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i60dcc587e93f4a8496bb9b4c5c8fe5fb_I20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9a4b8eb0b864a8f9f9048637d3d5001_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i654fca3b7c5d415bb115995496918fd5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie28a1239656045f886b00a040931a4d9_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i91870e5d313147eaa4bfc0c02c210fe7_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="if06dc05837124fb486c25738d89fd171_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d02369269bd4bd19d7ac96425d902f6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifd0edf54fa0f44648f71f8021664a663_D20190501-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87def4161b5741d0a3372af759a43214_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c0d84dc7c03423189234b747382592d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b2a8d92980b45cd86a9a0e569b171a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8c0ec15d63b4c9c9db72a0042d9233b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9230559c947e4bdfbd7d8718f81613a0_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e89d479cc1c49dcac81106f1a23036d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i291c0d139a404246b0f7fca420127e86_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iadc0db1dedb64652bed03e473906f250_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a9043b1e7d94f868faef2ed4ddb4eda_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93b90f3cbd93444a8e502d826cbbe51f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia387c26a722e4699b6595d2f733a93c1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1e933df6d96c4e25a0e01262d530c949_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd8eff35edb7419e9932c5f914758304_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1cec1573a81491f8627da20eab3bf7a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i16757954c1044691837622036e587d62_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if6c7d40392014b9993d7e113b2eac17c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iabd02944395c4cd4867b8652d51a714a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i910bafb21fde4c9d995b95ae87cf63a5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i54757ed54df14bceb415fb75f4faf788_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id41c0b142c464e41bb151ae9a392ab96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5230b6435fd4ceb84a6af9831cd457c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92744c9c477a4e4ba89940a3d753b3b3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4373a79ed10e41d296ee0962058ceb18_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifab658b65d2b4e509ba7e6fbedd7ea7f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2ca21b8ec7ba4cbbb974b0a2ed21beea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i120f8c853b1845998a75889f0c5bcfe9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5bf43c32005f4158b0a144b53515e8f4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie739eb4e2f9d498a802def60014528b5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i356cf52c8b484b40b183fa4c374dd895_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45dd132e1b3a439c9b1a6235d9bb85e2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic0911529fc304f48ba356122d24789d2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iefe55a942de0426eba7b59eec3f142f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa06f7d2b0c24a02ae94a2059ca88a36_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib0d8c3a4a6fb430e9f1f76dd0683680a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b8a55eee8e1430987c756c531fd2f92_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifd65ea0d77dd4536bd5211b76ed0f786_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icbd2973e2e9248cd84da19d0ec58f321_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic0f4401ebc2846b4ae91adeae6e806d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib40770b8bf174b6f8619cbc166946dc4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic46e3791b92d409bb00978ee31d2cbf5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f87004b4c11448b93df28c2392164ca_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ieacc3e428d0f429ba6530cfe19d2e300_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6cdcea5a7ee042059428f8230d335a2f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i835a732af4b24c559cab997e0fc7e788_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf8e3ff3da7b46a4ad695b6d2fdeaf72_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i06e44a5c0664414894b59ef342a25530_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6529f0b04b94b0bbe8a4aa98b0cca04_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i67731484d5f24597939db7a05b45c3e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i26a8d9ba96ce4164a0a1f5e705ce4880_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i48d81ecc28084fcdbc1204e113833fc8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i257bc2317ed94a5281a528a81b5b8d35_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie16213d344cb4afaa96412b15c0eedb6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icac09946014a4214af25c0e06ce6c6f6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i48c5f5eb489b4481b39ec65ca48ebfce_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id880884b9ea94b869fb5816f6510e211_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f2e9de97d974ecc9e2ee333fb3c25e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e9b775d892046ed8cff1e30bad6547b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i81510c3679774fff8f396fc3ab77fb74_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i81ebc7d152324a9ea5b0b3b86ab48f78_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifd19c4f689a94a488fadc52fb549283a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib5b52c38a8c44d49a69c3fcc734f8f2d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6ce2eacccd9044d788db421fc7a18c46_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i43aed1ced8c04ca78d779f9c16210fa8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i113089823357421ab17799b937585703_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i822e016bcba04e979cf25eaaedefc7a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5301fb930f5846abbe1ac0d7088d390c_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i6de109f4840c4e22aafdac033f63ff7e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86854d401efc41658a1f7cabc6fbf75f_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="ie2312287da4844f98353e533084710b1_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0f4f3ab77c814395bd909a08f8cdbd8b_I20181220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-20</instant>
        </period>
    </context>
    <context id="if0630b88591a432fb950d54e0c58af38_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic3240262b0c843ab948e2324834e8f4a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementAdditionalProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i65e132a26c12432e9177650608108558_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedProgramOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia9075aabe3384589aa3de96de0cec785_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedProgramTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i91ec1ec2abba44ff94474aa6f6a83271_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inhibrx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15bf51c282994899a1f5ce5fa7ed4e9e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i51e4a311ac19416ebf4f8e8ba3195ba7_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:BluebirdBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6d316a27f564f6c9455708922cd2566_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i47ab1c4748ac4b588b54989d44e542db_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="if7827c4c605f403c95b605cbe15393e7_I20190819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-19</instant>
        </period>
    </context>
    <context id="i0531016c866d4a068e2358c8f73b0f39_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i83c3ddd258264ea38d9e7f8ee2affbb4_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="i75bd7c4152884c68b92109e363fdde3e_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i1f4aef1c0a3941d986e5b4bf56476cf9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia81f4833f5a946919ea5fac5c81bd331_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i530e97d213314faf9adf351089af9dca_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id7a2e84dab1f45e3bb160edd91676c7a_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i3cd4816ef076457ea37eb5b862932984_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24ef54ae4f554e239587b8661dc8a3c4_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="id25843c5c03943bca5950d2498fcf7fc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4443a6f4f1e84d38b14ec1c139ca5267_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i48d4b7b4251d42058175aaa32b17035e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id08c3ccad96d44bea3c92b45810c37f3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a9dc418ead24b64bb8341e1299808f8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ife0bac45fcb24762a17738da0331eeb2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8d67a9e6f56b4ed58267e24b66936168_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9bd3c6489f044c5f983e14ec05aca582_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:TranscentaHoldingLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i2c665a21a67f4bba8893929943f5f8d3_I20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:CelgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-06-30</instant>
        </period>
    </context>
    <context id="iaa0c1f1f0a744b53a8d4ea48cd955591_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ibe47e6db9f494550ba03c3a1ee101b76_I20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="i1e0b1022232b4f71b8972eb5887adc42_D20171001-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia13e3186ca28469286c7cee39c4a772a_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ia36fb85c03c24ea8a91837247d809173_D20180901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c7c69c38154458b921c096178efb2ad_D20180901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie752799339b24161bced2a3798bf9a4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:LAVSummitLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3cf1efa19e3548d48a2df125b2ba8d78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:LAVSummitLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8bd613f072f461db198c9f9f272863d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabfd8187536c4daf96510c57f57bade2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i36cb4e41c5bb48e89203d72ff7e9ad71_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief513a4e2d6b4dff83e12409769524ba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inhibrx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inhibrx:LicenseAffiliatePDL1And41BBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1debe51ec3e946f19e9ced16e42dc5e1_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="id456e841f6ea429782b9752a0983fce5_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inhibrx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inhibrx:SeriesMezzanine2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="iec507b082f8043d7944a7cd34a09a823_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i9382d50f269442c59ff29a8133e54f76_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i29539df2bfdf4e7080d49e945e09a68a_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i434a60e482d64431a96e2d34a17d0b06_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ifb4a4c41e60c471987fc84b082722cf4_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTranchesBAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="ic11ebf603f344bfeb2b655dcddb72921_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="i48109ca4da0c44b1b47c9c968a9d401d_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="i893ad457259b4931a5c0ce26c8fb0c92_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i749adb0c10a241f59042990471fbddfe_D20201112-20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="ie0b6adb629804b27bc064abbdf18bbbb_D20200715-20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="i1dc414bff1c84c9089ef103ad34b6d98_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="i6760108879a84be9ad67b709f7c52557_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="i76849810b9be4460b784e44f45823ceb_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inhibrx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lease">
        <measure>inhibrx:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>inhibrx:segment</measure>
    </unit>
    <unit id="loan">
        <measure>inhibrx:loan</measure>
    </unit>
    <unit id="plan">
        <measure>inhibrx:plan</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>inhibrx:performanceObligation</measure>
    </unit>
    <unit id="compound">
        <measure>inhibrx:compound</measure>
    </unit>
    <unit id="program">
        <measure>inhibrx:program</measure>
    </unit>
    <unit id="license">
        <measure>inhibrx:license</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY18xLTEtMS0xLTc4OA_5be7b270-7ee0-45ca-b6a8-202f82209faa">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY18yLTEtMS0xLTc4OA_20f0d45c-acd4-4066-8577-8955ac584e05">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY18zLTEtMS0xLTc4OA_6ebcfff2-568e-4446-9d92-bc0e9a81af0a">0001739614</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY180LTEtMS0xLTc4OA_2fc9ae49-b572-4d0b-acdb-927b9660b023">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80L2ZyYWc6Nzg4NzZkZjAxNjYxNGM5Yzg5NWFiZmIxODc4NmVjYWQvdGFibGU6MzcyZjgwY2VmZTNkNDJhOTk3NmMyODllYWRmZDg1ZmMvdGFibGVyYW5nZTozNzJmODBjZWZlM2Q0MmE5OTc2YzI4OWVhZGZkODVmY181LTEtMS0xLTc4OA_f0d801b4-c0bb-4fb1-ae18-85cfebdb0705">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifba32dd833574402ada1e36890f6561a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6f274e94611f454abf5e4027b0746f28_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6fe512cd41a649b5b6c7acf1a99ef3f0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ie5731faed81f4f03a3bb8f76c85c0064_D20200811-20200811"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xNDc5L2ZyYWc6N2NjYzIwNDk2MDc0NGYwM2E2MjRkNDJiMzZjNzFjODEvdGFibGU6ZjkxNjViMDk3MjI5NDdkMWE2YzQ5M2IzOWM5YTQxYTkvdGFibGVyYW5nZTpmOTE2NWIwOTcyMjk0N2QxYTZjNDkzYjM5YzlhNDFhOV8xLTEtMS0xLTgzMzI_8ffe4950-368f-4f15-884d-470636e92803"
      unitRef="number">0.5753</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzYzYmQ5MmFlOGY5NDUyNmEwNDBjYTcxMmZhYjM0Y2YvdGFibGVyYW5nZTo3NjNiZDkyYWU4Zjk0NTI2YTA0MGNhNzEyZmFiMzRjZl8zLTEtMS0xLTU5NTQvdGV4dHJlZ2lvbjplMzFlYzliZTljMjY0MDViYTJmYjAwYmFlODk0Y2RmNl8zODQ4MjkwNjk3MjM3_e8640c14-5940-4c27-a35c-f38289dd7ba0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDcyMTc5_b64e29bd-1039-4d06-9183-3bbeadb95a1b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF85MzQ1ODQ4ODU4MTEx_41c825fd-f4e2-46d8-8541-63abf5e91195">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDcyMTgz_cb54caa6-e6c9-44e3-8163-5407a18a22af">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDkxNDE2_1b742a3f-f3c7-4806-b814-8462d9e98026">001-39452</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8xLTAtMS0xLTYyOTU_9f1ae1f5-c59e-47f3-9cd3-89395ae3c79d">INHIBRX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8wLTAtMS0xLTY5Mw_afc7c526-4f2d-4465-9f9e-8849118969d4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8wLTItMS0xLTY5Ng_f0042ac5-c4e9-44a7-bc39-fb789057b30f">82-4257312</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8zLTAtMS0xLTUxNjAvdGV4dHJlZ2lvbjo4MTNjYjdkMGIyMzE0ODUwYjU0MTI5N2U3N2VlMzczZF8zODQ4MjkwNjk3Mjg1_e3651cf1-3314-458b-b1a2-c1a4f0126442">11025 N. Torrey Pines Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8zLTAtMS0xLTUxNjAvdGV4dHJlZ2lvbjo4MTNjYjdkMGIyMzE0ODUwYjU0MTI5N2U3N2VlMzczZF8zODQ4MjkwNjk3Mjk3_e4ed35ef-abfb-472a-ac97-9db428cfcffe">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF80LTAtMS0xLTUxNzQvdGV4dHJlZ2lvbjpmYjlhMDIxMjIyYTU0YWU5YTM4NzVhOGI1YWYzMzBmYl8zODQ4MjkwNjk3MjQ4_22b052a1-34bc-44ee-8aac-f3667497df53">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF80LTAtMS0xLTUxNzQvdGV4dHJlZ2lvbjpmYjlhMDIxMjIyYTU0YWU5YTM4NzVhOGI1YWYzMzBmYl8zODQ4MjkwNjk3Mjc0_12a988a1-7a14-4aa0-923f-58441fbcc55a">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF80LTItMS0xLTEwODU_8f238b09-6e9c-45b0-9dc9-8e80905f5539">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8xMi0xLTEtMS01OTYxL3RleHRyZWdpb246ZGI0ZDVmYjZjN2I3NDcyYWExZjNmZjUyNTQ5NDlmZDVfMzg0ODI5MDY5NzIzOQ_8ed3cde1-9396-4bfe-930f-eb8c3b161bcd">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6ZmJmNWMwODY2YmIwNGZlMThlZmRhMWJkMzJmYjg5YjgvdGFibGVyYW5nZTpmYmY1YzA4NjZiYjA0ZmUxOGVmZGExYmQzMmZiODliOF8xMi0xLTEtMS01OTYxL3RleHRyZWdpb246ZGI0ZDVmYjZjN2I3NDcyYWExZjNmZjUyNTQ5NDlmZDVfMzg0ODI5MDY5NzI1MA_b83eb5ac-9c66-4a61-80fb-88438c5d5e93">795-4220</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6Y2M1ZmFhYzc0NmUxNGQxNWE5OGJlNzFlMmNjZWYyOTcvdGFibGVyYW5nZTpjYzVmYWFjNzQ2ZTE0ZDE1YTk4YmU3MWUyY2NlZjI5N18xLTAtMS0xLTczNQ_aec2ce4e-18cb-48d6-bc52-87a9442afd94">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6Y2M1ZmFhYzc0NmUxNGQxNWE5OGJlNzFlMmNjZWYyOTcvdGFibGVyYW5nZTpjYzVmYWFjNzQ2ZTE0ZDE1YTk4YmU3MWUyY2NlZjI5N180LTItMS0xLTc4MDk_a1c18646-d05f-49f1-b6eb-d09e74f708da">INBX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6Y2M1ZmFhYzc0NmUxNGQxNWE5OGJlNzFlMmNjZWYyOTcvdGFibGVyYW5nZTpjYzVmYWFjNzQ2ZTE0ZDE1YTk4YmU3MWUyY2NlZjI5N18xLTItMS0xLTczOQ_e3c23a23-9ab4-4398-9087-863791ddd175">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDc5MTIz_462db13c-df10-46e9-9a94-54fb28207b6a">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDkxNDE3_2b2163d7-8b9a-4ebf-bf09-de9d2ea5163c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzIwZDIwZDM0MTk2NGUzNmIzMTAxNzVlMGNkYzRiYzYvdGFibGVyYW5nZTo3MjBkMjBkMzQxOTY0ZTM2YjMxMDE3NWUwY2RjNGJjNl8xLTAtMS0xLTgxMzI_17c7a663-8513-4d6b-88fd-09b89b25dbc3">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzIwZDIwZDM0MTk2NGUzNmIzMTAxNzVlMGNkYzRiYzYvdGFibGVyYW5nZTo3MjBkMjBkMzQxOTY0ZTM2YjMxMDE3NWUwY2RjNGJjNl8xLTMtMS0xLTc0Ng_27f8f733-a2cf-4b7c-bf05-47f106c7404d">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGFibGU6NzIwZDIwZDM0MTk2NGUzNmIzMTAxNzVlMGNkYzRiYzYvdGFibGVyYW5nZTo3MjBkMjBkMzQxOTY0ZTM2YjMxMDE3NWUwY2RjNGJjNl8yLTMtMS0xLTc0OA_148f6037-f705-46c9-b654-1bacd479e737">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yMTk5MDIzMjc4ODc1_fa0afa17-9bb8-45e3-ada6-5681d1961c71">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8yNzQ4Nzc5MDkyNjc2_ab952e22-f065-4f06-bfd0-114c269a2c34">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="idbf3661972cb42c9b5609ea4cbd7cb26_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xL2ZyYWc6OWM0MjI4M2UzNjA4NDRhOGEzNTkzMmUzZTg2Y2JlZTQvdGV4dHJlZ2lvbjo5YzQyMjgzZTM2MDg0NGE4YTM1OTMyZTNlODZjYmVlNF8zODQ4MjkwNzE5MjI2_906ef3f6-1499-4b9b-8844-d27c4cb27cae"
      unitRef="shares">37712390</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNS0zLTEtMS0w_7474eb4e-5834-4ca0-8f94-8414f0689703"
      unitRef="usd">127669000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNi01LTEtMS0xMTE_563cb6f1-c70c-4f37-8a74-1ba5f639468d"
      unitRef="usd">11540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNi0zLTEtMS0w_a2852c94-9e11-467e-8e24-fe4a8e3f458b"
      unitRef="usd">681000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNy01LTEtMS0xMTE_4c3fd38c-62cf-44f7-99b9-edb370dabbcc"
      unitRef="usd">199000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNy0zLTEtMS0w_e4ca8fca-d3b6-44fc-a665-a56def7ff585"
      unitRef="usd">283000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfOC01LTEtMS0xMTE_511badd9-d1f5-4f1a-a470-388a7b93a003"
      unitRef="usd">239000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfOC0zLTEtMS0w_a9610077-a2d5-48d8-a444-bd803c1f1c8d"
      unitRef="usd">3217000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfOS01LTEtMS0xMTE_f929582f-d935-4555-b2b6-00aacf821e7d"
      unitRef="usd">3583000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTEtMS0xLTEtNzkx_8a8662e8-67a3-4db0-a97a-6f709a62271a"
      unitRef="usd">131850000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTEtMy0xLTEtNzkx_7da03550-5950-4c76-b6c0-d9983843c414"
      unitRef="usd">15561000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTEtMy0xLTEtMA_3512c135-faf8-4c06-9745-3942051d64fa"
      unitRef="usd">3274000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTItNS0xLTEtMTEx_bb7ad0a8-30a3-4cb0-b6e1-4fd323b37755"
      unitRef="usd">3230000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTItMy0xLTEtMA_4e6b33b6-7ade-4fb1-a0b5-1bc8998825ee"
      unitRef="usd">8185000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTMtNS0xLTEtMTEx_f67a582d-fdc5-4a03-a8a2-3d530ce8560e"
      unitRef="usd">7453000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTMtMy0xLTEtMA_59365a4b-dadf-426c-8e32-7dff4186916a"
      unitRef="usd">245000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTQtNS0xLTEtMTEx_1bb4e793-a7c7-4954-9d9e-23e76bcda727"
      unitRef="usd">245000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTUtMS0xLTEtNzkx_5b95007f-4144-445e-ae26-f34a1d050806"
      unitRef="usd">143554000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTUtMy0xLTEtNzkx_fbb19c65-2f5d-4ab0-98a5-846bfed5cd83"
      unitRef="usd">26489000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTctMy0xLTEtMA_9d1ec870-289a-468e-aaaa-c721e26aa287"
      unitRef="usd">15186000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTgtNS0xLTEtMTEx_fa66f9c4-bbf0-4dad-ad15-9eca4ec3dc20"
      unitRef="usd">3115000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTgtMy0xLTEtMA_87d0034d-2dcb-43eb-9cd2-4af2a3e5ff8a"
      unitRef="usd">11037000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTktNS0xLTEtMTEx_5ab422f3-7442-469f-87d4-a912c2d8ee79"
      unitRef="usd">4832000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMTktMy0xLTEtMA_0e2d4c29-6bd0-4c8c-bcb6-ad5cecb8d80c"
      unitRef="usd">5176000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjAtNS0xLTEtMTEx_9d60f2f1-65fd-4dba-a343-b906d1581b4a"
      unitRef="usd">7939000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjAtMy0xLTEtMA_cfe7f91d-e83b-414e-b116-2ce02f8233c4"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjEtNS0xLTEtMTEx_fb1b4d78-ef45-4a54-b060-67e6053c8897"
      unitRef="usd">3563000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjEtMy0xLTEtMA_ceca362f-19f9-48e1-ab1e-7b47326ca39c"
      unitRef="usd">1463000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItNS0xLTEtMTEx_cb29e51d-e068-4975-99a4-b0dd3b26a1b7"
      unitRef="usd">1105000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItMS0xLTEtOTQ4NQ_b1a5e648-ecc3-46b9-9797-51ae2ced878f"
      unitRef="usd">1875000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItMy0xLTEtOTQ4OQ_d3da89e9-af5a-4a10-8c5a-7cf1339ad89e"
      unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjItMy0xLTEtMA_a24f36c5-59c4-4a2f-bd52-28d0b07082b9"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjMtNS0xLTEtMTEx_25b4f170-01d9-417e-bb72-bffa98930b8a"
      unitRef="usd">16000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtMS0xLTEtNzkx_ecf4fe95-056f-4c5b-9d4c-759a85d9fa03"
      unitRef="usd">34737000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtMy0xLTEtNzkx_f80ae461-6e77-4469-8d52-b9f38a8b7b01"
      unitRef="usd">20570000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtMy0xLTEtMA_65305bb5-5dd1-476c-9ba3-b9d87f002b77"
      unitRef="usd">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjQtNS0xLTEtMA_133ccb66-6f10-464f-907a-8c80686625a8"
      unitRef="usd">30367000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjUtMy0xLTEtMA_9de21aa0-2dc5-4867-aab6-b602b5285b66"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjUtNS0xLTEtMA_b51ce19a-ac8b-471d-baf5-be24ca0008e3"
      unitRef="usd">1916000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjctMS0xLTEtMTUzMDc_54805ad3-82b9-4c81-ae02-e8f35939b9fb"
      unitRef="usd">170000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjctMy0xLTEtMTUzMDc_13bfa51a-685f-4a1a-abf5-b8203109e7cd"
      unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjYtMy0xLTEtMA_46e9af2f-ab45-4995-862b-113c989e7fb6"
      unitRef="usd">9821000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjctNS0xLTEtMTEx_a8e1a7d4-cb1b-4e47-9153-c46d933c2163"
      unitRef="usd">0</us-gaap:SecuredLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjgtMy0xLTEtMA_585c2eb0-d9ce-4897-958a-3f3af513513c"
      unitRef="usd">7097000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMjktNS0xLTEtMTEx_9d4d9bd4-5582-4e1f-ba77-f406a48db6d1"
      unitRef="usd">6698000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzItMS0xLTEtNzkx_05f442c6-3603-4c63-8832-adbb91e57665"
      unitRef="usd">51825000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzItMy0xLTEtNzkx_5253b32e-9e53-44b4-aafb-8e04ebb38c1f"
      unitRef="usd">60551000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtMS0xLTEtNzk0_9cea63d8-67cd-421f-b7a5-4f997a349993"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtMy0xLTEtNzk0_2e7fed83-3827-4f2a-8934-f176631d865d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzczMA_2bb5df64-1b5f-4bab-836e-8353dd1011ea"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzczMA_d532c34b-9b69-4a4a-a7ad-b832054bae0b"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzYzMw_135e2ee9-1747-4362-aae5-503adbbdbd93"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzYyNg_f91ed079-86f2-4ed1-b956-61efe4016262"
      unitRef="shares">25765000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY1Mw_251ffd73-bf0d-438d-b7c9-7aaefc008fef"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY1Mw_ada3dde4-4f6a-4644-ae4c-db51a7a62d98"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY0Ng_7e539d67-fbfc-4948-9724-abbde12b1e92"
      unitRef="shares">12534331</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY0Ng_8489fa48-67ff-4a32-8e7e-6f8177b6f5c7"
      unitRef="shares">12534331</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfNjA0NzMxMzk1MzI4Ng_c962ff0d-5714-4dfa-a43e-85eee0eba731"
      unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzQtMC0xLTEtODU2L3RleHRyZWdpb246NjdiZjkxZDc3OGQ0NGUzMGI4YmQxOWIwN2I2ODkyZjZfMzg0ODI5MDY5NzY2OA_0dbb4621-4eeb-4b7b-a5c0-e94c6b0b3d4c"
      unitRef="usd">87500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtMy0xLTEtMA_1bc1e2a3-6253-43d3-9220-45b884705039"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzMtNS0xLTEtMA_f37a3dd0-b231-46e9-ad2e-eaea50a82e3f"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzQ2Mg_03e09db4-0962-489e-a8aa-a6ff492c8500"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzQ2Mg_a6be608e-4f79-40f8-a7bf-80e2360b7aac"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM3OQ_e727cd30-fdb6-4c9f-a852-6c52954977fb"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4NA_b3e7a1ca-2e95-41a0-ae91-d322dece7390"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_1b7736fd-a90d-48c6-ae03-b7647aa5eb2b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_6ae5ff53-fc56-4980-a466-3ec1634ad022"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_d700027e-21e1-4854-902c-4ec6dd0992ab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMC0xLTEtODU4L3RleHRyZWdpb246YWRhMDNhMzhmOTdhNGNmNWJmNTFlMzM3OTBiMWFkN2JfMzg0ODI5MDY5NzM4OQ_f5f3ec80-08d9-4a6f-91c3-ce67d62d6298"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzUtMS0xLTEtMzIzMw_46bad8ec-8206-4681-914f-29a2ed0e6054"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzUtMy0xLTEtMzIzMw_30b93087-93f5-4c39-9add-5f96586ada9c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU1NA_7f7b0e00-dc75-4745-b108-2d78a901905d"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU1NA_f03edf4f-5738-4fdb-9595-30cd0ee3589c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU2OA_f429b00e-97ef-44f4-b43f-10498e3c9c51"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU4MQ_3600fa5e-a1a6-4d77-a7d6-33bbb28bdf65"
      unitRef="shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzYwMg_8b51a87c-cd39-4076-8276-3265ed1da154"
      unitRef="shares">37710190</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzYwMg_cdd86e22-48dd-4d04-9d69-1fac4da9d8a4"
      unitRef="shares">37710190</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU5NA_af2fb6ea-88eb-4233-870f-ab6552405040"
      unitRef="shares">18154119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMC0xLTEtODYwL3RleHRyZWdpb246ZmI2Mzk4ZjYyODMxNDc5M2IwZjJkZDkzOGI4ZDkzNGNfMzg0ODI5MDY5NzU5NA_bf7db5da-77c2-4680-bd76-804c57c6150a"
      unitRef="shares">18154119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtMy0xLTEtMA_ff897333-046d-41df-a8a6-78b8e598d6a6"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzYtNS0xLTEtMA_c6d1cd14-21c7-4f12-98ad-d00d87a3c866"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctMy0xLTEtMA_98b3ac61-e6dd-4c05-95e9-97dbf1c179b5"
      unitRef="usd">219455000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzctNS0xLTEtMA_9d4a3d73-d49b-4f82-9948-d7c58b8081cd"
      unitRef="usd">-24316000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzgtMy0xLTEtMA_8d327fad-e00f-499f-811a-7ea2aa58bb08"
      unitRef="usd">-127730000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzgtNS0xLTEtMA_4ecf845c-13ae-4869-9202-606142fac776"
      unitRef="usd">-69255000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNDAtMS0xLTEtNzkx_1861ddfb-d851-4cef-883a-533db8614b77"
      unitRef="usd">91729000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfMzktNS0xLTEtMA_39354300-6b56-48b6-a2e7-6b2021de4e0c"
      unitRef="usd">-93569000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNDEtMS0xLTEtNzkx_11a8d184-8465-4a87-871d-4f1d511d6446"
      unitRef="usd">143554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8xOS9mcmFnOjgyNjA5NTVmMGI3MDRhZTg4NzIwM2FkMDdkYjEwY2FkL3RhYmxlOjRkMTVmOTM4NDY1ZjQ4NjBiMWNiMTQ2MWI2NDk5NmJkL3RhYmxlcmFuZ2U6NGQxNWY5Mzg0NjVmNDg2MGIxY2IxNDYxYjY0OTk2YmRfNDEtMy0xLTEtNzkx_e912b660-94ba-4d1b-9a38-126758f2827a"
      unitRef="usd">26489000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i1a502282910747c9aac74a5847fac525_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0xLTEtMS0yMjc_0b4b4f96-baa0-47d3-9fec-c21b41033ce3"
      unitRef="usd">5826000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2815584d6b3449bae058364571557b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0zLTEtMS0yMzM_d347081b-3fd3-4b95-89c3-439cbd472802"
      unitRef="usd">794000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied2eec07eda2401383326e716774ff76_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0xLTEtMS0w_5e361cd5-385d-4a4b-9c73-21af01b240ed"
      unitRef="usd">10032000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieadc553907f04aea9984cc210e0af52f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNS0zLTEtMS0w_480f6a9f-9bf8-4129-b55c-56478524b777"
      unitRef="usd">8826000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17fce0905feb4ca0a6d436f23bdb5a51_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0xLTEtMS0yMjc_e21112d8-7d35-4951-bbaf-d03051fa0ff3"
      unitRef="usd">75000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic597294d6b05480f9b87cfc8e153db62_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0zLTEtMS0yMzM_1aa1d1dd-4bf7-43c6-a49b-cb0c598e04b2"
      unitRef="usd">425000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8caa9dd3e98483facac392f2f26d651_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0xLTEtMS0w_2a5b73bd-4258-4fcf-a67e-04dde1e95bfe"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i820a8e2822d74bbd82ecbf86ba928b9c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0zLTEtMS0w_4bcd2156-ccd1-4877-a356-a88beb07199b"
      unitRef="usd">4122000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0xLTEtMS04MTEy_76a6c765-60f5-4ede-a8f2-173fe8f028ce"
      unitRef="usd">5901000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNi0zLTEtMS04MTEy_e50d4ecf-ff91-4f29-8b61-d1901d19c083"
      unitRef="usd">1219000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNy01LTEtMS04NzA_e1a7c995-00f1-441a-8f48-fd21c726c340"
      unitRef="usd">10112000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfNy03LTEtMS04NzA_da35267e-f81e-4f58-8775-53cb1eb91835"
      unitRef="usd">12948000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0xLTEtMS0yMjc_90b4861a-8018-4059-8e70-cd32fb2f700a"
      unitRef="usd">19837000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0zLTEtMS0yMzM_290ba575-0b92-4b55-8479-4fa2c2a43711"
      unitRef="usd">12785000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0xLTEtMS0w_30517347-bd0e-4de2-9c2f-69a6bcaffe1c"
      unitRef="usd">55827000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfOS0zLTEtMS0w_e0e15fa2-c99b-4a0b-8b7e-8ec6b03014ef"
      unitRef="usd">35624000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMS0xLTEtMjI3_a277f802-5564-4060-8926-a5ebef7645e3"
      unitRef="usd">1622000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMy0xLTEtMjMz_7ad353e6-faee-4a8b-9841-a3fa1f7019c2"
      unitRef="usd">1481000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMS0xLTEtMA_fb5d31cc-5ffc-44f4-9112-f57d96056b73"
      unitRef="usd">4621000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTAtMy0xLTEtMA_b210547b-1193-4954-9ebf-db5f807d4682"
      unitRef="usd">4584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTEtMS0xLTEtODExMg_6cd4429a-156d-4897-84f5-a8838dd4e8c7"
      unitRef="usd">21459000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTEtMy0xLTEtODExMg_36272f16-9d26-4ba3-a968-b5c84706adf3"
      unitRef="usd">14266000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItNS0xLTEtODcw_fd4318cf-2b82-4478-93ed-66ec50ab8622"
      unitRef="usd">60448000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItNy0xLTEtODcw_3beded05-a1d8-4799-84d3-29fe3ef3fb26"
      unitRef="usd">40208000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItMS0xLTEtODExMg_69546b07-e428-47d1-8142-39f304330061"
      unitRef="usd">-15558000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTItMy0xLTEtODExMg_35340932-8c1f-4284-a73f-e5fc504f8f4a"
      unitRef="usd">-13047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTMtNS0xLTEtODcw_8d367e43-9062-4c30-ba0e-8c972c6303df"
      unitRef="usd">-50336000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTMtNy0xLTEtODcw_aafb924e-ee19-45f7-87d6-9a64b8ad1e41"
      unitRef="usd">-27260000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMS0xLTEtMjI3_9066589d-7b3a-4ac5-bd6c-2e4525ce5979"
      unitRef="usd">-4428000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMy0xLTEtMjMz_da041efc-0df5-40c5-aae8-bcc32457abea"
      unitRef="usd">-2670000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMS0xLTEtMA_9725ed85-6f79-419f-98fb-fdbc4ccbb446"
      unitRef="usd">-10284000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTUtMy0xLTEtMA_266f81a7-4649-432c-9d46-a5d3b1878e39"
      unitRef="usd">-3407000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMS0xLTEtMjI3_ce839b07-dec7-4cb6-8b09-3328abd1cb8a"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMy0xLTEtMjMz_4a49e1ab-97a2-4de7-9ee2-5508b79cb2a5"
      unitRef="usd">-70000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMS0xLTEtMA_ae28e9f8-7f8c-44a7-bc04-e0ac12e27c68"
      unitRef="usd">5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMy0xLTEtMA_6d574caa-1700-47a1-b013-6dde7f63b23e"
      unitRef="usd">-54000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMS0xLTEtODYwNg_d27b277c-789f-4087-b3df-d70c33773f29"
      unitRef="usd">24000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtMy0xLTEtODYzMQ_7b53d842-939b-475f-accb-a75f68775c7d"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtNS0xLTEtODYzNQ_ebc9a9e0-2a62-4347-b818-9d2a68add14d"
      unitRef="usd">24000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTYtNy0xLTEtODYzOQ_ab2da79e-497a-4554-b77a-3755462cfb1a"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMS0xLTEtMjI3_1e6dc09d-4103-414f-a073-45ea0cb868b5"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMy0xLTEtMjMz_aa29cefa-66a6-4b07-b204-9e96ab54850a"
      unitRef="usd">-3476000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMS0xLTEtMA_0b472413-798c-426c-8848-db558e630eb2"
      unitRef="usd">2651000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMy0xLTEtMA_d8723d67-34e0-4dee-ad04-2cfd8069dba4"
      unitRef="usd">-3476000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMS0xLTEtODExMg_d6e0d379-142b-481b-af52-2ee62e694858"
      unitRef="usd">-4452000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTctMy0xLTEtODExMg_df8e8397-4936-4a80-8271-a3f8bcf189b7"
      unitRef="usd">-6216000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtNS0xLTEtODcw_fe1f9160-08f6-4990-989e-9d69bb0b24b0"
      unitRef="usd">-7652000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtNy0xLTEtODcw_cec8495c-c175-4871-882d-470b2402f085"
      unitRef="usd">-6937000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtMS0xLTEtODExMg_bf757c5b-c4a1-4434-9579-ac669d44d2fd"
      unitRef="usd">-20010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTgtMy0xLTEtODExMg_34ddd9e0-ca7b-4580-b5a8-cd8478f44ac4"
      unitRef="usd">-19263000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTktNS0xLTEtODcw_2894667c-76fe-41dc-a75f-e611a9718999"
      unitRef="usd">-57988000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMTktNy0xLTEtODcw_f4725b0b-fa1b-4cc4-a1a5-60b40d8d0142"
      unitRef="usd">-34197000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMS0xLTEtMjI3_ab8ec992-567c-467b-9f68-2c53cd9a9b85"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMy0xLTEtMjMz_fc5d129e-e725-492d-8099-d2cdf28e0d78"
      unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMS0xLTEtMA_a742b21e-dffc-4104-a08d-8938542dbc51"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMy0xLTEtMA_a228642e-bf34-41f9-85a4-b7004075f715"
      unitRef="usd">898000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMS0xLTEtMTQwNzQ_c87dbb97-70b1-4ace-9d17-5402d0dd627a"
      unitRef="usd">-487000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMy0xLTEtMTQwNzg_aa75574b-f3f5-465c-8745-e4607c50ce02"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtNS0xLTEtMTQwODI_5d902b45-8b3e-43ce-96d8-18f6292a8a4a"
      unitRef="usd">-487000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtNy0xLTEtMTQwOTI_9eceb72c-38eb-4259-bb44-ff5c9ed97107"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjQtMS0xLTEtMjI3_724e8c64-02ab-4fa4-83e8-a896d08c93cf"
      unitRef="usd">-20497000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjAtMy0xLTEtODExMg_eda1bc13-35ca-4404-97ee-8c94daaab81a"
      unitRef="usd">-20163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjQtNS0xLTEtMjM5_5b58f4ac-a5ef-4628-838f-970004957f8d"
      unitRef="usd">-58475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjQtMy0xLTEtMA_680e4ac1-4283-4a74-9ae5-c51149a95568"
      unitRef="usd">-35095000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMS0xLTEtODExMg_26d28a34-dd36-44ae-8507-4af676e45f55"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjEtMy0xLTEtODExMg_b44d8d68-bb6e-46cd-9c29-955619da89eb"
      unitRef="usdPerShare">-1.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjUtNS0xLTEtODcw_119eeb00-6ec4-44ff-840e-65d5beb920b3"
      unitRef="usdPerShare">-2.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjUtNy0xLTEtODcw_f136fef9-3e83-40be-9bd8-e13be123e1ae"
      unitRef="usdPerShare">-1.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMS0xLTEtMjI3_f3975d95-5031-468d-9923-20c51503c482"
      unitRef="shares">26750000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMy0xLTEtMjMz_49bc19ad-4893-45c1-a97f-2c63c3d14572"
      unitRef="shares">18154000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMS0xLTEtMA_db47ec77-dff0-4074-a735-272a406d8297"
      unitRef="shares">21019000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yMi9mcmFnOjM5Njc2NTU5MGRlYjRiYjA5MjFjY2EwNTJkMWQyOTEyL3RhYmxlOjI2MmUwZjAwNTMwNjQwODM4YWFmOWVmOWYyNjdhMTJiL3RhYmxlcmFuZ2U6MjYyZTBmMDA1MzA2NDA4MzhhYWY5ZWY5ZjI2N2ExMmJfMjYtMy0xLTEtMA_f42fcf58-e09b-4e70-9db2-714afdabe4f5"
      unitRef="shares">18154000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xLTEtMS0zMzgx_89db3911-11cc-4cf2-916f-e63325e8e8c8"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0zLTEtMS0zMzgx_f3562153-4345-475e-8ae2-2208653a4cbd"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie34e5f2d63b64f9ab8bdc6574f9e7285_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi02LTEtMS0zMzgx_4a7a6e31-89c0-4cc1-83b0-bc75a4dce754"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie34e5f2d63b64f9ab8bdc6574f9e7285_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi04LTEtMS0zMzgx_81accdee-fc9a-48ac-bd6b-5119661dddf4"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i000ce15b89d840528ca0541bc84717e8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xMC0xLTEtMzM4MQ_2f7eff0a-0c90-47bc-8a0e-1526d7281c90"
      unitRef="usd">-24316000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ac975841c0c4eee8d4575323136a11b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xMi0xLTEtMzM4MQ_039fd78f-1c88-40d6-98d6-d1d1b4f9f022"
      unitRef="usd">-69255000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMi0xNC0xLTEtMzM4MQ_928aa4e8-96c3-43f8-b8ce-255bacbffb68"
      unitRef="usd">-93569000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1f21270f21874db1b0bbfb358bb4a78a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xMC0xLTEtMzM4MQ_4891b416-c8e5-4c99-a1b4-1afe2fb0af94"
      unitRef="usd">1088000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie2d17755e65848568a5814eb7e92fa96_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xNC0xLTEtMzM4MQ_1f107dbe-fe2d-4cdf-8063-d974c006f64b"
      unitRef="usd">1088000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i603a3e22a39e4c3f84a33bd10c4b7461_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xMi0xLTEtOTUyNg_6d7fffce-180f-434a-bf4b-56a174fa8741"
      unitRef="usd">-20093000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie2d17755e65848568a5814eb7e92fa96_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMy0xNC0xLTEtOTg4MQ_11765ecb-0e01-4877-91f2-8ac7b60c9ef0"
      unitRef="usd">-20093000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i0cb47a5672584355b7d05652419f4135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xLTEtMS05ODYz_c4880ca9-47a5-48f4-ad76-d55f1d08dedc"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i0cb47a5672584355b7d05652419f4135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0zLTEtMS05ODY1_31e9d3bc-6be6-40bc-a706-0407c9717cf9"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifd8c696851984b19adde3434ae473fe3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC02LTEtMS05ODY3_564461e3-f924-4052-8018-7c389d1fe401"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd8c696851984b19adde3434ae473fe3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC04LTEtMS05ODY5_cd0bbff2-8053-4b39-b5fc-9c3418ce48cf"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i846daf89fc2b40ff9276e0309f8bc49b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xMC0xLTEtOTg3MQ_effa46c9-4302-4ecb-b109-2a2e3af31f51"
      unitRef="usd">-23228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib15a549f5d7c49ba8413651379bcbb4b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xMi0xLTEtOTg3MQ_3126f68e-57ba-4bd2-ab46-4e2a09a268ea"
      unitRef="usd">-89348000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cb47a5672584355b7d05652419f4135_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xNC0xLTEtOTg3MQ_1b622775-3760-45ce-a5ae-1131363cb720"
      unitRef="usd">-112574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i34b03bb902a94c8785ee943f02414084_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xMC0xLTEtOTUzMw_e6949e40-afe0-483a-945a-c0c6d2152235"
      unitRef="usd">1259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5228ec7bd82b4d18aa5c78ca560be27f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xNC0xLTEtOTg3OA_92a4f73c-c0c7-46e2-ac67-1c4924a8ddbd"
      unitRef="usd">1259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i3ab8209e132d4d49885fdd7a39a220b4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xMC0xLTEtMzM4MQ_f3129006-134a-45ce-8533-f5ee24a0985c"
      unitRef="usd">2656000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="ia6aba7f28dc64367a0eece71a35d9fb9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNC0xNC0xLTEtMzM4MQ_4663ff81-657d-48eb-b899-13939fe8d573"
      unitRef="usd">2656000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:NetIncomeLoss
      contextRef="idad3866ecff24d2bb1c1621c08c1e65d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNy0xMi0xLTEtOTU0NA_2d84ca93-6e13-4771-a0e3-aef77f39b163"
      unitRef="usd">-17885000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5228ec7bd82b4d18aa5c78ca560be27f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNy0xNC0xLTEtOTg4MQ_c707e825-955e-425e-be71-b574a0ef4064"
      unitRef="usd">-17885000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ide0a954ba6d54755911e36150df70447_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xLTEtMS05ODYz_e58b7ffd-b6a8-4862-9b6a-af80a836aaa5"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ide0a954ba6d54755911e36150df70447_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0zLTEtMS05ODY1_6294b367-1a5e-418a-bc03-09842d66b7d2"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29ac8459a45944d89bd8d8c502750883_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC02LTEtMS05ODY3_a8e53f0e-76a9-4bee-91b7-359db97e2f61"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29ac8459a45944d89bd8d8c502750883_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC04LTEtMS05ODY5_13615504-4ae3-493c-bcaa-40ab692f97f3"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib43ea9fc9a3749ca8aec69153be4824b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xMC0xLTEtOTg3MQ_f9b6356e-4b63-49e3-802c-cffb12b063ad"
      unitRef="usd">-19313000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06e3380af6394476b9fb41f80b54569d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xMi0xLTEtOTg3MQ_6d8bdc0e-d880-41f3-8b5f-932927289dd6"
      unitRef="usd">-107233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide0a954ba6d54755911e36150df70447_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xNC0xLTEtOTg3MQ_58a8c96c-1e8e-4891-83f7-eda5bc48c3a6"
      unitRef="usd">-126544000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xMC0xLTEtOTU4Nw_8d3504e6-dfef-4b7c-a892-7742ae323571"
      unitRef="usd">1303000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xNC0xLTEtOTg3OA_5e9eb465-fefb-4d60-8129-6a8066539e75"
      unitRef="usd">1303000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xMC0xLTEtMzM5OA_c5033f51-69f2-4baf-907d-f22a698a2a60"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xNC0xLTEtMzM5OA_f9496baa-259e-47e4-ba8d-cbe34c5a02a8"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0eee8e0a5aa64149a5e9678da896aa09_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC02LTEtMS0zMzk4_8fa10d64-e0a3-4cd2-addc-cc7415a439a4"
      unitRef="shares">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0eee8e0a5aa64149a5e9678da896aa09_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC04LTEtMS0zMzk4_dbb71fd3-78b2-46ce-a532-ed3bacfd17a7"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xMC0xLTEtMzM5OA_0afdb991-86d3-419b-b548-a4052908bd76"
      unitRef="usd">125862000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOC0xNC0xLTEtMzM5OA_32c56da8-ce6f-4041-8a20-6b3ca254f818"
      unitRef="usd">125863000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xLTEtMS0zMzk4_70722386-b829-4b02-a65d-4fdce46cb5a1"
      unitRef="shares">-12534000</inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0zLTEtMS0zMzk4_f168c028-dbc9-4a9d-a8cf-e53e0516b6c5"
      unitRef="usd">-59507000</inhibrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ief2e22b91c8f4c61bc620f632b4e3aa3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS02LTEtMS0zMzk4_fa64131a-6b8d-4af6-9b5d-9e8692c216ca"
      unitRef="shares">7211000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ief2e22b91c8f4c61bc620f632b4e3aa3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS04LTEtMS0zMzk4_e7366959-f00d-4348-93ca-8cdc00ae0db8"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i868602c6c8094dfe8c35ccb6d3bf5389_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xMC0xLTEtMzM5OA_1163e6f9-2ec6-4c25-8f58-e47dd15b1a03"
      unitRef="usd">59506000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if8c3d1c7115344cf87b4e8072fb23023_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfOS0xNC0xLTEtMzM5OA_af25808f-63d6-4ed4-bb76-dff0a777b7b5"
      unitRef="usd">59507000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i00e8f3fe84bb4c7c80b0765347fb47fe_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTAtNi0xLTEtMzM5OA_c76133d9-2ada-4994-8272-f317feccc4da"
      unitRef="shares">4295000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia490249b50314ffeb9819be68dddeff5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTAtMTAtMS0xLTMzOTg_0c5f2127-ff1e-41b1-8b93-5d29c2f132db"
      unitRef="usd">59393000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ibcfaf63fd5be43bd94a1aa0e5f1b9ed8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTAtMTQtMS0xLTMzOTg_33df8db6-3b0f-4272-b0e6-8a6c789101e2"
      unitRef="usd">59393000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i59bd56e946e5445bae234daf9abde8e6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTItMTAtMS0xLTMzOTg_135a7997-ea7b-4263-9df4-31880c2a73eb"
      unitRef="usd">-5332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i968c5b21c23d497c885a34db4e9dcc82_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTItMTQtMS0xLTMzOTg_fabce598-79c6-4939-b1d1-ac8cd760fbb4"
      unitRef="usd">-5332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i93804641103b457fad36e34238434091_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTMtMTAtMS0xLTMzOTg_a6fc7f47-6f8f-4da1-9670-7cdef44ea019"
      unitRef="usd">-2107000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="if80eeafcebb44eda80d0e0ab4cb21502_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTMtMTQtMS0xLTMzOTg_e8da162d-fec8-4f75-802a-a89f6debabd9"
      unitRef="usd">-2107000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ic72f396661b64960a85d478129870552_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTYtMTAtMS0xLTk2MzM_ed56674c-2281-46a2-91a2-54e95253af55"
      unitRef="usd">139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfMTYtMTQtMS0xLTEwNjY1_fdf9f7d3-4b50-46d1-b977-8411dcad52fa"
      unitRef="usd">139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="i6437dc22b9a1413a83a988950e6b212f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xMi0xLTEtMzM4MQ_df61f425-afa0-49e8-98d6-64baec48db1e"
      unitRef="usd">-20497000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNS0xNC0xLTEtMzM4MQ_803138ef-f49e-472e-82d8-bf6e1ff2a712"
      unitRef="usd">-20497000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xLTEtMS0zMzgx_a2660cc3-ea6d-4739-83a4-88b83b1d14a5"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0zLTEtMS0zMzgx_80ad0c07-7a54-4936-a1fb-b95ca1104203"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98b810262bba4b218699272e9d863800_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi02LTEtMS0zMzgx_ecf26888-5c9a-4114-a6f5-e6170433b7a0"
      unitRef="shares">37710000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98b810262bba4b218699272e9d863800_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi04LTEtMS0zMzgx_df513592-3d04-49ef-8150-0dfb4223bc59"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ad639b97919472cb19836f0f20c8578_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xMC0xLTEtMzM4MQ_d38e7217-cc10-4eef-9885-7053980cbd64"
      unitRef="usd">219455000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5b516dbf8534c51a8a187a321b5ff02_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xMi0xLTEtMzM4MQ_5805f7a3-c5bc-4792-8bb5-d59257c0462a"
      unitRef="usd">-127730000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOmNmZjI0ZmY0YjJkNTQ2ZWJiNDJmZDQyMDgwNzEwNTNkL3RhYmxlcmFuZ2U6Y2ZmMjRmZjRiMmQ1NDZlYmI0MmZkNDIwODA3MTA1M2RfNi0xNC0xLTEtMzM4MQ_39eaacfb-b832-4490-a4e9-030231f2792e"
      unitRef="usd">91729000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xLTEtMS0xNTUxNg_172a94c9-e8d2-40f9-bc9f-3fcbac05ce9c"
      unitRef="shares">10815000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0zLTEtMS0xNTUxNg_7739000a-a3d3-4898-b05d-2c6a23dd7b2f"
      unitRef="usd">47519000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie17c4099b42e47cdb2c7b8aaaa29181c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC02LTEtMS0xNTUxNg_e049f970-835a-49be-918d-af12b8f7725a"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie17c4099b42e47cdb2c7b8aaaa29181c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC04LTEtMS0xNTUxNg_4861f759-4def-41f5-8849-3936b9f08528"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cb446db2851407d98c475b4a9496a9b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xMC0xLTEtMTU1MTY_02075267-2884-4703-9d35-b90643b227a1"
      unitRef="usd">-39790000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3fd70b3e3724e78bbd68fad24152716_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xMi0xLTEtMTU1MTY_8262c800-b762-47d8-aec5-51910439afa0"
      unitRef="usd">-17855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMC0xNC0xLTEtMTU1MTY_c03756a8-2c06-41ee-85ae-454da1476a27"
      unitRef="usd">-57643000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib639469f8e6f46fe9e906ab1f8a23c3c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMS0xMC0xLTEtMTU1MTg_f70d3a04-5930-4e70-bb99-1920735e6d3a"
      unitRef="usd">906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMS0xNC0xLTEtMTU1MTg_307d7590-fd02-41fc-9c6e-5d3752181a61"
      unitRef="usd">906000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMi0xLTEtMS0xNTUyMA_76d89a59-8cb8-4fb6-aba0-b6c52e329a6c"
      unitRef="shares">1719000</inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMi0zLTEtMS0xNTUyMw_9913d92b-0cbe-4dd6-a206-b90b2316e829"
      unitRef="usd">11988000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="if6c148e447dd4a72b3fb1401d56a109a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMy0xMi0xLTEtMTU1MjU_2edabac1-a79c-4ae8-b1c4-0b84162c4749"
      unitRef="usd">-3847000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMy0xNC0xLTEtMTU1MjU_b21f288f-77a8-475b-8e58-c22c81137d91"
      unitRef="usd">-3847000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xLTEtMS0xNTUyNw_7424f1bf-3be3-4919-a1e8-188183ced73f"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0zLTEtMS0xNTUyNw_118d3424-fcc7-4901-b80f-2afa9a6fd93e"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i832575ad734f4ac68adc394981e0dd95_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC02LTEtMS0xNTUyNw_2a0d27a7-cbe1-47d8-8e76-3b3a7ba73c61"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i832575ad734f4ac68adc394981e0dd95_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC04LTEtMS0xNTUyNw_27bb3636-0470-477b-98d7-37b33cd40f23"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3f3ee615da3341d98188126debd31173_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xMC0xLTEtMTU1Mjc_adb97f8d-e7c9-4b38-87cc-ecfb911e902b"
      unitRef="usd">-38884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33fdbec7cbe14bb58d66b46ff6a32efb_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xMi0xLTEtMTU1Mjc_0ab92b25-6ddc-4e24-9451-c347e928fa1f"
      unitRef="usd">-21702000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6d1bc31bd5443db9b44b4c86f6cb247_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNC0xNC0xLTEtMTU1Mjc_d1fadb71-eea4-43fa-b3a1-a1ef0e3f3f78"
      unitRef="usd">-60584000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5aba2096009b41df80c66bfd01ec2c58_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNS0xMC0xLTEtMTU1Mjk_26366a8b-5090-4e47-8513-a2baa6c5a5aa"
      unitRef="usd">925000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNS0xNC0xLTEtMTU1Mjk_1b8a6051-a379-43c2-bb1e-8a92dd5536e9"
      unitRef="usd">925000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i5aba2096009b41df80c66bfd01ec2c58_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNi0xMC0xLTEtMTU1NDE_ecd593b9-ac48-4828-8f5e-b0f505ede70f"
      unitRef="usd">11500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNi0xNC0xLTEtMTU1NDE_7c550501-6fe8-4217-aee5-04ad5253b72a"
      unitRef="usd">11500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:NetIncomeLoss
      contextRef="i8ad87a43bcfd47718c0aa0291e455eef_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNy0xMi0xLTEtMTU1MzE_b42aefeb-3021-44d2-bd71-ed6c73e331b0"
      unitRef="usd">-11085000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i96c67fec0c224753b41a1c57cd4b05b5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfNy0xNC0xLTEtMTU1MzE_770ae365-b4f2-4d6e-948c-4f3cdbb30462"
      unitRef="usd">-11085000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i2c2000034bdf45109c782f320cd6a01d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xLTEtMS0xNTUzMw_a33abb28-d43b-4f99-8ef2-4e21f4b020ec"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i2c2000034bdf45109c782f320cd6a01d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0zLTEtMS0xNTUzMw_101e38a2-a7ed-4ce2-896a-f8d336e4b5c3"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8dacf172bede47d8a24654bfb96d5b2e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC02LTEtMS0xNTUzMw_96a2cb47-7b2f-4e57-a23e-0da33e119872"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8dacf172bede47d8a24654bfb96d5b2e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC04LTEtMS0xNTUzMw_ff5894a1-a0f7-4c86-987e-cc48282fa25e"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89f99f3c856b4015a5874dbe44c7d459_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xMC0xLTEtMTU1MzM_5b3d3584-cce6-4f83-8d18-438d41736e53"
      unitRef="usd">-26459000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8760e90a1ba450cadb660bb033f985c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xMi0xLTEtMTU1MzM_ff848105-bcf8-4695-bc79-11c0f423c1d9"
      unitRef="usd">-32787000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c2000034bdf45109c782f320cd6a01d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOC0xNC0xLTEtMTU1MzM_6477c2fa-36b2-4eb9-82f0-b5b9e75c9ef5"
      unitRef="usd">-59244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9cf47f3d3e3c429eb534fb4774e9f5cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOS0xMC0xLTEtMTU1MzU_016db425-b21c-4657-bd89-4004b5d1d9b5"
      unitRef="usd">1019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfOS0xNC0xLTEtMTU1MzU_b5e7796f-b7c2-4c2e-b21f-7593cd254836"
      unitRef="usd">1019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i935c025cf0be4f52aa328da8cd08cdbc_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTAtMTItMS0xLTE1NTM3_9d51861d-1fae-4582-90f6-2bbd7ff189d1"
      unitRef="usd">-20163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTAtMTQtMS0xLTE1NTM3_c59278cc-ace7-4d54-9d63-164d972be904"
      unitRef="usd">-20163000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMS0xLTEtMTU1Mzk_df7b34c2-59cd-4233-ab4e-8272fbffdf97"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMy0xLTEtMTU1Mzk_79fd2287-8e52-4bed-85f8-0c63429180dc"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1fa3b845869d4942a592437637e60ccb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtNi0xLTEtMTU1Mzk_64cef673-209f-4ce3-9c64-b079b52c04b0"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1fa3b845869d4942a592437637e60ccb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtOC0xLTEtMTU1Mzk_45403cfa-b7bd-45b5-b007-c6fc84d1268b"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3d63e6b69ff48ee80954424e39ed256_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMTAtMS0xLTE1NTM5_7777486c-ebdb-4786-bc0c-baf0a415ef9c"
      unitRef="usd">-25440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae97d8956ab04cc2adbd33a7853f81d6_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMTItMS0xLTE1NTM5_5ec1d201-d2a6-43fc-8914-78510b5ecc41"
      unitRef="usd">-52950000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yNS9mcmFnOjFhNmYzMjIxNGIzNjRkMjE4NjFmNDgyZmMxMGM4OWVkL3RhYmxlOjBkODBjNmYxYzk1MDQ5NThhMmRkMjcwZjNmNzVjOWU2L3RhYmxlcmFuZ2U6MGQ4MGM2ZjFjOTUwNDk1OGEyZGQyNzBmM2Y3NWM5ZTZfMTEtMTQtMS0xLTE1NTM5_ebe5933f-843c-4702-bd09-0139af5674a1"
      unitRef="usd">-78388000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNC0xLTEtMS0zNjc_51deb2b4-bb0f-4fec-aaab-a31b5d6dd1c8"
      unitRef="usd">-58475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNS0xLTEtMS0w_c73b741b-5293-4c78-b32b-fd99dfae55a5"
      unitRef="usd">-35095000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNi0xLTEtMS0zNjc_8eb46c8b-79b1-4ca2-b81c-09a046aaa9ec"
      unitRef="usd">754000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNy0xLTEtMS0w_6755105a-135c-468c-b501-9fe06250e064"
      unitRef="usd">926000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNy0xLTEtMS0zNjc_7899f75a-9361-4573-82be-1d3de0ae6500"
      unitRef="usd">10046000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOC0xLTEtMS0w_5381ab0e-0793-4725-9257-7009ae85358c"
      unitRef="usd">3199000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOC0xLTEtMS0zNjc_407f8931-84d3-46c4-8670-1b08430c95ad"
      unitRef="usd">3650000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOS0xLTEtMS0w_b795f1c4-f60c-4fa9-ae32-21b893cce948"
      unitRef="usd">2850000</us-gaap:ShareBasedCompensation>
    <inhibrx:NoncashOperatingLeaseExpense
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfOS0xLTEtMS0zNjc_ff5e9fa6-0ccb-47c9-98ad-99adf6afc15a"
      unitRef="usd">1020000</inhibrx:NoncashOperatingLeaseExpense>
    <inhibrx:NoncashOperatingLeaseExpense
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMS0xLTEtMA_f69d22fd-9aba-4199-b4a6-a713f36b9c1c"
      unitRef="usd">1089000</inhibrx:NoncashOperatingLeaseExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMS0xLTEtMzY3_48f335c1-5ed8-4f27-bbf2-ab9b7a111436"
      unitRef="usd">2651000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMS0xLTEtMA_bd12f0c5-20d4-4b33-a8e1-5d9842bc6a37"
      unitRef="usd">-3476000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMS0xLTEtODcwMA_53ebeb16-31f0-45d3-883a-45de05be9977"
      unitRef="usd">24000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTAtMy0xLTEtODcwNA_adf31b74-4445-42ef-9eb7-fabbfdb093dd"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMS0xLTEtMTQxMTE_541bf981-4f42-45f4-ae7f-c203704cbb16"
      unitRef="usd">-487000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMy0xLTEtMTQxMTU_347b21a4-45e4-4bd9-aa9b-6ef2cdecdfb2"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTEtMS0xLTEtMzY3_26ee9a50-4298-463f-b78e-94cab55bcf63"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTItMS0xLTEtMA_56dd6107-33c8-4687-9708-3c9a7304b33f"
      unitRef="usd">-69000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTQtMS0xLTEtMzY3_62128632-5d9d-47df-b204-72a7c075a7c3"
      unitRef="usd">482000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTUtMS0xLTEtMA_0ff6d18d-03e5-4716-9114-ba5c061f9201"
      unitRef="usd">1680000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTUtMS0xLTEtMzY3_66920f71-21e7-4d76-9eff-97594b657cdb"
      unitRef="usd">44000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTYtMS0xLTEtMA_faa09047-fdc2-4576-8c3f-eb215cbd2290"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTYtMS0xLTEtMzY3_9eb13f7d-071d-45a8-848e-2e1679bf451b"
      unitRef="usd">-366000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTctMS0xLTEtMA_01962807-bf49-4ea3-84bb-0d2319303813"
      unitRef="usd">848000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTgtMS0xLTEtMzY3_e9f60d56-d810-4c79-a97b-9741c058e624"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTktMS0xLTEtMA_4fb5dfb0-897a-4eec-80fc-bab7983b51d4"
      unitRef="usd">244000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMTktMS0xLTEtMzY3_6a92e611-51fe-4183-8cfc-872d05334603"
      unitRef="usd">11605000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjAtMS0xLTEtMA_b4f48a94-6f29-4498-908e-6e8126d89eca"
      unitRef="usd">-3014000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjAtMS0xLTEtMzY3_c5cf6b54-a75b-4ba5-ae37-0438145e95bd"
      unitRef="usd">6196000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjEtMS0xLTEtMA_e255b91e-4e78-4532-8445-9fc7940bac6d"
      unitRef="usd">1038000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjEtMS0xLTEtMzY3_6fa74411-a530-4d4a-b5ac-ea4de135738b"
      unitRef="usd">995000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjItMS0xLTEtMA_e159dc63-ad1b-49f2-9d33-3a1fc94aa9ac"
      unitRef="usd">746000</us-gaap:OperatingLeasePayments>
    <inhibrx:IncreaseDecreaseContractWithCustomerLiabilityCurrent
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjItMS0xLTEtMzY3_1217ad6e-bfe0-4f44-8255-8811b5fc342c"
      unitRef="usd">-3250000</inhibrx:IncreaseDecreaseContractWithCustomerLiabilityCurrent>
    <inhibrx:IncreaseDecreaseContractWithCustomerLiabilityCurrent
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjMtMS0xLTEtMA_32257a70-f9ef-4cc2-9196-97550e2675cd"
      unitRef="usd">8206000</inhibrx:IncreaseDecreaseContractWithCustomerLiabilityCurrent>
    <inhibrx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjMtMS0xLTEtMzY3_653ece35-662d-4ab5-98ec-e1e9950335bf"
      unitRef="usd">-830000</inhibrx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent>
    <inhibrx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjQtMS0xLTEtMA_afc768eb-51b6-4285-b494-189deef397b4"
      unitRef="usd">1000000</inhibrx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjQtMS0xLTEtMzY3_a4b6ab33-e5bd-41d7-b68b-7e20bfb2716c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjUtMS0xLTEtMA_26deab64-6394-47c9-b9f9-1673ab1879bc"
      unitRef="usd">-363000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjUtMS0xLTEtMzY3_3e094887-b29c-4fa0-bf7d-136175238250"
      unitRef="usd">-32579000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjYtMS0xLTEtMA_1ead2cc9-e653-45ce-97de-a788d466c8e1"
      unitRef="usd">-20137000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjctMS0xLTEtMzY3_8606b4d1-d02b-492c-8638-b1defd6e3f15"
      unitRef="usd">752000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjgtMS0xLTEtMA_bbd877e2-f2c4-4c19-a576-c2716e7345e1"
      unitRef="usd">1475000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjgtMS0xLTEtMzY3_910101ed-65be-4ee6-a217-5f6d0299a02f"
      unitRef="usd">-752000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMjktMS0xLTEtMA_b6ef5f20-739e-4e77-808d-0fa8b2757cf4"
      unitRef="usd">-1475000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMS0xLTEtODcyMw_b779037d-5f43-401b-aaa9-9ed65f28d232"
      unitRef="usd">136850000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMy0xLTEtODcyNw_e32bff17-4fdf-4763-9c7f-a56f27b7caf0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMS0xLTEtODcyMw_2c00cccd-35fb-4f1d-bcf6-995f51c5a9f5"
      unitRef="usd">10558000</inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering>
    <inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMy0xLTEtODcyNw_1d9ed9eb-40be-4df0-a6a8-8cd1b3d143e3"
      unitRef="usd">0</inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering>
    <inhibrx:PaymentsOfStockIssuanceCostsAbandonedIPOAttempt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMS0xLTEtMTMxNjY_c313ec9b-bd35-4950-9517-8766a8b67310"
      unitRef="usd">0</inhibrx:PaymentsOfStockIssuanceCostsAbandonedIPOAttempt>
    <inhibrx:PaymentsOfStockIssuanceCostsAbandonedIPOAttempt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzItMy0xLTEtMTMxNjY_6f09c714-9dd8-4c80-8c5f-a40e0924041d"
      unitRef="usd">1158000</inhibrx:PaymentsOfStockIssuanceCostsAbandonedIPOAttempt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMS0xLTEtMTMxNzQ_1cfe9c59-6ec5-46b1-9669-d99297695e94"
      unitRef="usd">15000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzMtMy0xLTEtMTMxNzQ_3e69a09b-91c5-47e2-83a5-89d91675ae21"
      unitRef="usd">40000000</us-gaap:ProceedsFromConvertibleDebt>
    <inhibrx:PaymentsOfDebtIssuanceCostsConvertibleDebt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtMTMxODI_30decdd9-cd7c-4411-8d72-3c61f06faa00"
      unitRef="usd">0</inhibrx:PaymentsOfDebtIssuanceCostsConvertibleDebt>
    <inhibrx:PaymentsOfDebtIssuanceCostsConvertibleDebt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMy0xLTEtMTMxODI_2675fb08-35f4-4376-be18-3da410d5c4d3"
      unitRef="usd">2470000</inhibrx:PaymentsOfDebtIssuanceCostsConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtMTMxNTQ_7d92b788-3994-4f97-b341-1f0c56a81dee"
      unitRef="usd">9958000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMy0xLTEtMTMxNTQ_57d902c1-f885-46e3-b53e-af131016bce0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inhibrx:PaymentsOfDebtIssuanceCostsSecuredDebt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMS0xLTEtMTMxNTQ_a7023103-19ba-474c-948e-7a1065381379"
      unitRef="usd">86000</inhibrx:PaymentsOfDebtIssuanceCostsSecuredDebt>
    <inhibrx:PaymentsOfDebtIssuanceCostsSecuredDebt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMy0xLTEtMTMxNTQ_8ce5cd7b-c243-49e0-8eae-ac1f7bca267e"
      unitRef="usd">0</inhibrx:PaymentsOfDebtIssuanceCostsSecuredDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzctMS0xLTEtMTMxOTc_6fe57ec8-1561-4cd2-b723-dac302e0c780"
      unitRef="usd">1875000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzctMy0xLTEtMTMxOTc_5dcc704a-160e-411d-9926-082370c637e9"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzgtMS0xLTEtMTMxOTI_b2d96bf9-0fd0-45b3-aae0-180f1f9b8f68"
      unitRef="usd">2183000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzgtMy0xLTEtMTMxOTI_b4757442-9b8f-4d25-8f40-5d38bcae24fa"
      unitRef="usd">4595000</us-gaap:RepaymentsOfSecuredDebt>
    <inhibrx:RepaymentsOfSecuredDebtFinalBalloonPayment
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzktMS0xLTEtMTMxOTI_36f8eb6c-d4ca-4684-89c2-8dc4c0e5351c"
      unitRef="usd">1400000</inhibrx:RepaymentsOfSecuredDebtFinalBalloonPayment>
    <inhibrx:RepaymentsOfSecuredDebtFinalBalloonPayment
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzktMy0xLTEtMTMxOTI_1cb40791-5e33-4092-9bc8-1cdfd462e86f"
      unitRef="usd">0</inhibrx:RepaymentsOfSecuredDebtFinalBalloonPayment>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtODcyMw_4a98a05f-6ecc-4a0f-bf7b-91820a070ce9"
      unitRef="usd">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMy0xLTEtODcyNw_3260933b-a7c8-43a6-8c4b-594a0fde72c0"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzQtMS0xLTEtMzY3_a4a76626-57ed-4200-aaac-8ba2ac6d3aed"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMS0xLTEtMA_7e568b35-dcf0-4432-8875-5b32a0490ada"
      unitRef="usd">12000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <inhibrx:PaymentsOfStockIssuanceCostsConvertiblePreferredStock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzUtMS0xLTEtMzY3_e8331616-fabb-4827-ac52-34c67d10356f"
      unitRef="usd">0</inhibrx:PaymentsOfStockIssuanceCostsConvertiblePreferredStock>
    <inhibrx:PaymentsOfStockIssuanceCostsConvertiblePreferredStock
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfMzYtMS0xLTEtMA_ad53968b-8313-4ffa-b825-aa132fb941d9"
      unitRef="usd">12000</inhibrx:PaymentsOfStockIssuanceCostsConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDEtMS0xLTEtMzY3_3927fdaf-929f-4046-b6e8-5b55f72c259c"
      unitRef="usd">149460000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDItMS0xLTEtMA_de309ff6-aef8-483e-8ed0-505563ea45e5"
      unitRef="usd">43765000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDItMS0xLTEtMzY3_31dd0f80-d046-4fd2-bf32-fdcd8452bd06"
      unitRef="usd">116129000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDMtMS0xLTEtMA_5d9b02f9-1fb3-4edd-aeaa-cf3c503e8308"
      unitRef="usd">22153000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDMtMS0xLTEtMzY3_da0b6ee9-83a5-4153-b5a3-044db581d6a7"
      unitRef="usd">11540000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icd8a35b2ae25448f8fa52a2a75f422e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDQtMS0xLTEtMA_9de4b936-4e74-498f-a7ee-f6788d8e8b86"
      unitRef="usd">2103000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDQtMS0xLTEtOTM3_b06c9e4c-0300-4cc2-9386-3d234e444cb4"
      unitRef="usd">127669000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i73dbd07a8a064245beef5a5cd1785fc5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDQtMy0xLTEtOTM3_2dbdb661-f287-4e9e-8972-952135d9b52d"
      unitRef="usd">24256000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDctMS0xLTEtMzY3_506e1732-a5e3-45f1-b576-ab6ba34d4eb9"
      unitRef="usd">172000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDgtMS0xLTEtMA_992d93dd-95e7-4bd0-94ef-0388178c68f6"
      unitRef="usd">407000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDgtMS0xLTEtMzY3_650af386-e166-4d78-9aec-4e94a0b7d401"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNDktMS0xLTEtMA_68bd038b-1090-46ff-a7af-3481c051091a"
      unitRef="usd">976000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMS0xLTEtMTM1Mzg_2212e7e1-2cac-432a-8927-16d347c7c7d2"
      unitRef="usd">59507000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMy0xLTEtMTM1Mzg_73fbaf5b-f459-486a-9eaf-eb4ba1d4b5d8"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjEtMS0xLTEtMTM1Mzg_a0caf5be-8e2f-4746-972c-b9ba520b4473"
      unitRef="usd">53394000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjEtMy0xLTEtMTM1Mzg_3ab490b9-2879-4341-b43b-3b8a750666a6"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <inhibrx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMS0xLTEtMTM1NTI_cef893a8-0bf4-484a-a283-1aba6b468dce"
      unitRef="usd">4783000</inhibrx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature>
    <inhibrx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMy0xLTEtMTM1NTI_fc768870-2b4b-4090-a20a-a2fa96be467c"
      unitRef="usd">-11500000</inhibrx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMS0xLTEtOTc2Mw_1b3b2099-778e-4043-bfa1-356fc819a1fd"
      unitRef="usd">1752000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjAtMy0xLTEtOTc2Mw_800d3961-139a-425a-8c9e-8ce4fdb99111"
      unitRef="usd">8808000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <inhibrx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMS0xLTEtODc1Nw_c7b44e24-8d23-489a-9604-059b70470234"
      unitRef="usd">735000</inhibrx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred>
    <inhibrx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjItMy0xLTEtODc1Nw_4c95873f-563d-4c37-b67e-9c4c170622c9"
      unitRef="usd">900000</inhibrx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTctMS0xLTEtMzY3_9edbe2f5-b6fc-412a-9f4d-834718e6bbdd"
      unitRef="usd">735000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTgtMS0xLTEtMA_371b5c96-2791-4287-b50f-24d775e5e490"
      unitRef="usd">900000</us-gaap:AmortizationOfDebtDiscountPremium>
    <inhibrx:NonCashEstablishmentOfEquityMethodInvestment
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzItMS0xLTEtMTM1OTY_2d01ec7d-c4cb-4169-95d4-ba7a0a2e443f"
      unitRef="usd">487000</inhibrx:NonCashEstablishmentOfEquityMethodInvestment>
    <inhibrx:NonCashEstablishmentOfEquityMethodInvestment
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzItMy0xLTEtMTM1OTY_4c3e9dd3-da7c-413e-91aa-fe4ff62188eb"
      unitRef="usd">0</inhibrx:NonCashEstablishmentOfEquityMethodInvestment>
    <inhibrx:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzMtMS0xLTEtMTM2MDE_b01968fb-b002-4f58-bc87-86320de58c64"
      unitRef="usd">430000</inhibrx:StockIssuanceCostsIncurredButNotYetPaid>
    <inhibrx:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzMtMy0xLTEtMTM2MDE_785610a2-972a-4a0d-9e1b-9952a1c335de"
      unitRef="usd">597000</inhibrx:StockIssuanceCostsIncurredButNotYetPaid>
    <inhibrx:ReclassificationOfWarrantLiabilitiesToEquity
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTgtMS0xLTEtMzY3_a0578206-0e87-4f42-b365-cd11924eefe0"
      unitRef="usd">139000</inhibrx:ReclassificationOfWarrantLiabilitiesToEquity>
    <inhibrx:ReclassificationOfWarrantLiabilitiesToEquity
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNTktMS0xLTEtMA_c712552b-7ff6-4d6e-adeb-087f32be3005"
      unitRef="usd">0</inhibrx:ReclassificationOfWarrantLiabilitiesToEquity>
    <inhibrx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzUtMS0xLTEtMTM1Nzk_477fd667-6f98-4d36-99cb-c6c4d2bd2c46"
      unitRef="usd">115000</inhibrx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred>
    <inhibrx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNzUtMy0xLTEtMTM1Nzk_1f74b9c7-b63c-45f2-b272-fda47211be4c"
      unitRef="usd">0</inhibrx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred>
    <inhibrx:DebtInstrumentUnamortizedDiscountWarrantLiability
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjUtMS0xLTEtODc0OQ_2ecd0d65-c57c-4088-b4eb-9cb76d0e3397"
      unitRef="usd">115000</inhibrx:DebtInstrumentUnamortizedDiscountWarrantLiability>
    <inhibrx:DebtInstrumentUnamortizedDiscountWarrantLiability
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjUtMy0xLTEtODc1Mw_be7530a2-96c0-4609-a8e6-365546c1704f"
      unitRef="usd">0</inhibrx:DebtInstrumentUnamortizedDiscountWarrantLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjYtMS0xLTEtODc0OQ_f56899f3-0a20-4214-8360-e191b1efa720"
      unitRef="usd">46000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8yOC9mcmFnOmNhODBhZTRhNjJhOTRhNDRhZjdmNGU4MDQxMTkyZDEyL3RhYmxlOjI3OGUzYTM3MDUxZTRlNWViOTRmYzQyNGU5ZjYxOGYzL3RhYmxlcmFuZ2U6Mjc4ZTNhMzcwNTFlNGU1ZWI5NGZjNDI0ZTlmNjE4ZjNfNjYtMy0xLTEtODc1Mw_1ce15ece-9d26-4ba1-804f-6dd90c143df1"
      unitRef="usd">22000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NjUzNg_fe7f7410-ad58-4e84-bae4-3a84dff6f1f4">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inhibrx, Inc. (the &#x201c;Company&#x201d; or &#x201c;Inhibrx&#x201d;) is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines a deep understanding of target biology with innovative protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design highly differentiated therapeutic candidates. The Company&#x2019;s current pipeline is focused on oncology and orphan diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;21, 2020, the Company completed its initial public offering (&#x201c;IPO&#x201d;) in which it sold 8,050,000 shares of common stock at an offering price of $17.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs were $125.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, each of the following occurred in connection with the completion of the IPO:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the conversion of the 2019 Note and the 2020 Notes (each as defined below) into 4,294,603 shares of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the conversion of all outstanding convertible preferred stock into 7,211,086 shares of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,354 shares of the Company&#x2019;s common stock; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the amendment and restatement of the Company&#x2019;s certificate of incorporation, authorizing 120.0 million shares of common stock and 15.0 million shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;11, 2020 the Company effected a&#160;one-for-1.7382&#160;reverse stock split of the Company&#x2019;s common stock (the &#x201c;Reverse Stock Split&#x201d;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion prices of the convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) related to an interim report on the Form 10-Q. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.&#160;All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company&#x2019;s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 19, 2020 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had an accumulated deficit of $127.7 million and cash and cash equivalents of $127.7 million. From its inception and through September&#160;30, 2020, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that existing cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund the Company&#x2019;s operations for at least 12 months from the date of the filing of this Form 10-Q. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#x2019; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The Company&#x2019;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features within convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#x2019;s operating lease, and valuation allowances for the Company&#x2019;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its current loan and security agreement (the &#x201c;2020 Loan Agreement&#x201d;) with Oxford Finance LLC (&#x201c;Oxford&#x201d;) and its former loan and security agreement, as amended (the &#x201c;2015 Loan Agreement&#x201d;), which has been terminated, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense and convertible notes approximate their related fair values due to the short-term nature of these instruments. The Company&#x2019;s derivative instruments and warrants are carried at fair value based on unobservable market inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institution in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#x2019;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of September&#160;30, 2020 and December&#160;31, 2019, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, (&#x201c;WuXi Biologics&#x201d;) pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. The Company does not control the manufacturing processes of the contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations (such as current Good Manufacturing Practices, &#x201c;cGMP&#x201d;), which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company has never declared or paid any dividends on its common stock. The Company currently intends to retain available cash for funding operations; therefore, it does not expect to pay any dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the 2020 Loan Agreement with Oxford, limits, among other things, the Company&#x2019;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#x2019;s common stock will be at the discretion of the Company&#x2019;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#x2019;s board of directors may deem relevant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;machinery and equipment: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b"&gt;three&lt;/span&gt; to five years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;furniture and fixtures: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18"&gt;three&lt;/span&gt; to five years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430"&gt;four&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#x2019;s facilities, which commenced in January 2020. This amendment is accounted for as a separate lease. Leases are reviewed and classified as operating or financing leases at commencement. The Company&#x2019;s existing leases are classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2019, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its condensed consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to exclude from its condensed consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the condensed consolidated statements of operations for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreements are reviewed at inception to determine if they contain a lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 8, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis BioScience, LLC (&#x201c;Phylaxis&#x201d;), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the condensed consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#x2019;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. As of September&#160;30, 2020, the Company&#x2019;s equity method investment has been written down to zero as a result of the allocation of the Company&#x2019;s share of losses of the investee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 5, the convertible promissory note (the &#x201c;2019 Note&#x201d;) issued in May 2019 to DRAGSA 50, LLC, an entity affiliated with Viking Global Investors LP (&#x201c;Viking&#x201d;) and the convertible promissory notes (the &#x201c;2020 Notes&#x201d;) issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#x2019;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 815-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and determined certain of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#x2019;s common stock. As of September&#160;30, 2020, the derivative liabilities no longer exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#x2019;s IPO, the warrants were deemed to be issued for the purchase of common stock and were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the condensed consolidated statements of operations during the three and nine months ended September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific&#160;to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 5). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020 and as of September&#160;30, 2020, the derivative liabilities and warrant liabilities no longer existed. The following table presents the Company&#x2019;s financial liability that was measured at fair value as of December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the completion of the IPO in August 2020, the Company&#x2019;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the nine months ended September 30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of derivative liability on the 2019 Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of derivative liability on the 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of warrant liabilities on the 2020 Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liabilities on the 2019 and 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of warrant liabilities into equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s derivative liabilities categorized in Level 3 of the fair value hierarchy as of December&#160;31, 2019 was determined based upon an independent third-party valuation report which used a lattice model. The valuation report utilized unobservable inputs, including the discount rate, management&#x2019;s assessment of the probability of various underlying events triggering the conversion of the Company&#x2019;s 2019 Note and the 2020 Notes (as discussed in Note 5), such as an IPO, financing, or extraordinary event, and the current valuation of the Company through an independent third-party valuation report. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of September&#160;30, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon Qualified IPO. Additionally, as of September&#160;30, 2020, the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#x2019;s IPO. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs are capitalized, recorded as an offset to the Company&#x2019;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the condensed consolidated balance sheet as a direct deduction from the debt liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal, accounting, and filing fees related directly to the Company&#x2019;s IPO were capitalized as deferred IPO costs to be offset against proceeds upon the consummation of the IPO within stockholders&#x2019; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0&#160;million of IPO costs against the proceeds. As of September&#160;30, 2020 and December&#160;31, 2019, no deferred IPO costs were capitalized on the Company&#x2019;s condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies such as the National Institutes of Health (&#x201c;NIH&#x201d;) and the Congressionally Directed Medical Research Program (&#x201c;CDMRP&#x201d;) funded through the Department of Defense (&#x201c;DoD&#x201d;), as well as from private not-for-profit organizations including Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#x201c;CARB-X&#x201d;). Payments received from customers are included in deferred revenue, allocated between current and non-current, on the condensed consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research, Development, and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;). The Company&#x2019;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has been awarded multiple grants from the NIH, one grant from the CDMRP funded through the DoD, as well as one grant from CARB-X. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the&#160;condensed consolidated&#160;statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#x201c;customer&#x201d; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. Since the Company has concluded that these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;grants do meet the definition of a contribution and are indeed non-reciprocal transactions, the adoption of ASC Topic 606 had no impact on the Company&#x2019;s accounting for grant revenue from governmental agencies or private institutions not considered customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development and Clinical Trial Accruals &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#x2019;s behalf, pursuant to development and consulting agreements in place. The Company&#x2019;s preclinical studies and clinical trials are performed by third party contract research organizations (&#x201c;CROs&#x201d;) and/or clinical investigators. The Company also engages with CDMOs for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#x2019;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The utilization of unused federal and state net operating losses (&#x201c;NOLs&#x201d;) and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended (&#x201c;IRC&#x201d;), a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, the convertible preferred stock, convertible notes, warrants for purchase of common stock, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the three and nine months ended September 30, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following securities that could potentially decrease net loss per share in the future were not included in the determination of diluted loss per share as their effect is anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)  The conversion of the convertible notes into common stock assumes a conversion price of $14.35 per share for the 2019 Note and $12.56 per share for the 2020 Notes, and includes the conversion of the principal balance and all accrued interest as of the stated date (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock-Based Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its condensed consolidated financial condition or results of operations upon adoption. The Company has irrevocably elected not to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act of 2012, as amended (&#x201c;JOBS Act&#x201d;), for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, which includes amendments intended to improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and affects companies that are required to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;include fair value measurement disclosures. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company adopted this guidance as of January 1, 2020, which did not result in a material impact on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard will be effective for the Company on January 1, 2023 or at such time where it is no longer a smaller reporting company. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the potential impact that the adoption of ASU 2019-12 may have on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU 2020-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted, but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the potential impact that the adoption of ASU 2020-01 may have on its condensed consolidated financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 815-40): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i59e35846453d49108af294a83527115a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDY0Nw_e1a76260-72c5-4322-aa12-a744f2631cc1"
      unitRef="shares">8050000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i716fae2ef5ce4494a59333e61122850c_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDY1OQ_826119da-a7f9-458a-a18d-fdfb617ba84a"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i59e35846453d49108af294a83527115a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDYxMQ_f3a3ff75-3422-4a54-a243-d27f738be75e"
      unitRef="usd">125900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="id7e5ed6c9480459caa6ba643143e71bb_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0NzU2Mg_1c771f04-064d-4a32-b7ed-8eec8f9659e1"
      unitRef="shares">4294603</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i55e33ca65d2942a182ef960398078928_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0NzU2Ng_f52b7d97-d81f-49c0-a4fa-ccc8be3fbb1c"
      unitRef="shares">7211086</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0NzU3MA_c2ae56d8-78d5-499a-9800-b7c933ed6611"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDYyNQ_e47d228a-2e15-4488-bc70-b9865daeec4a"
      unitRef="shares">120000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODIwMDYzNQ_b87910b3-fec9-4717-8b74-317186a2ae3c"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjM0Ng_8149dd62-0240-4c84-90db-8d578d6d6536">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) related to an interim report on the Form 10-Q. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.&#160;All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company&#x2019;s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 19, 2020 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <inhibrx:LiquidityPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjQ3Mw_38b20353-8550-4829-bfe6-a8f179fabc5c">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had an accumulated deficit of $127.7 million and cash and cash equivalents of $127.7 million. From its inception and through September&#160;30, 2020, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. &lt;/span&gt;&lt;/div&gt;The Company believes that existing cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund the Company&#x2019;s operations for at least 12 months from the date of the filing of this Form 10-Q. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#x2019; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</inhibrx:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNjA0NzMxNDA0ODkwNA_59f84f40-c6aa-4f8b-a27e-fc6ba92dc2bf"
      unitRef="usd">-127700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNjA0NzMxNDA0ODk0NQ_78cd1816-1e64-410e-b9f3-5face790cac1"
      unitRef="usd">127700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjUxNg_7b251fba-041d-4e2d-94ac-c6ee833491d2">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The Company&#x2019;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features within convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#x2019;s operating lease, and valuation allowances for the Company&#x2019;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjU3Mw_c3c6f19b-1a8e-4ba7-bd43-aa4af4261956">Fair Value of Financial Instruments The Company&#x2019;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its current loan and security agreement (the &#x201c;2020 Loan Agreement&#x201d;) with Oxford Finance LLC (&#x201c;Oxford&#x201d;) and its former loan and security agreement, as amended (the &#x201c;2015 Loan Agreement&#x201d;), which has been terminated, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense and convertible notes approximate their related fair values due to the short-term nature of these instruments. The Company&#x2019;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjU4NQ_5a7caa47-bdac-4829-b959-c9a5c576e6df">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MjY4Nw_bb97d654-aa69-4b5a-b755-5bc4a62c5e77">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institution in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#x2019;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of September&#160;30, 2020 and December&#160;31, 2019, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. &lt;/span&gt;&lt;/div&gt;The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, (&#x201c;WuXi Biologics&#x201d;) pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. The Company does not control the manufacturing processes of the contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations (such as current Good Manufacturing Practices, &#x201c;cGMP&#x201d;), which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.</us-gaap:ConcentrationRiskCreditRisk>
    <inhibrx:CollaborativeArrangementTerm
      contextRef="ie8dadc7ef039420eaa7b0c92264e86ca_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NDQzNA_d02a90ce-fc0b-46f9-93f7-a76e4387083c">P3Y</inhibrx:CollaborativeArrangementTerm>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2Mjc4Mw_5e6e18f5-3041-4199-978b-43ac4ad86799">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company has never declared or paid any dividends on its common stock. The Company currently intends to retain available cash for funding operations; therefore, it does not expect to pay any dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;Additionally, the 2020 Loan Agreement with Oxford, limits, among other things, the Company&#x2019;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#x2019;s common stock will be at the discretion of the Company&#x2019;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#x2019;s board of directors may deem relevant.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2Mjg3OQ_554c6403-eb0c-44cb-b8c4-e09737856e0a">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;machinery and equipment: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b"&gt;three&lt;/span&gt; to five years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;furniture and fixtures: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18"&gt;three&lt;/span&gt; to five years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430"&gt;four&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3feb5c4ab8444992aad253b0eb3aac6c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzY4Nw_ee642007-89a2-453b-946b-dc9eee28913c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i31329f709cd646a1985943678e052e84_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzY4OQ_f8f1089b-dfda-47f7-98ba-8849d3ded290">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i87b2ff8ae24b4a848877e3577572b4fd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDA4OQ_ed40d4ff-1720-4dfa-b21f-589aadb9ede6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzE1OQ_107c25b6-3ec6-499e-95ae-92c374a837cf">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined &lt;/span&gt;&lt;/div&gt;based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its condensed consolidated financial statements.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzE2MQ_cd13de4f-7a33-40b9-b095-7ba7454c67e5">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#x2019;s facilities, which commenced in January 2020. This amendment is accounted for as a separate lease. Leases are reviewed and classified as operating or financing leases at commencement. The Company&#x2019;s existing leases are classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2019, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its condensed consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to exclude from its condensed consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the condensed consolidated statements of operations for all periods presented. &lt;/span&gt;&lt;/div&gt;Agreements are reviewed at inception to determine if they contain a lease.</us-gaap:LesseeLeasesPolicyTextBlock>
    <inhibrx:NumberOfOperatingLeasesHeld
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE3ODAzOA_8d97d483-f415-4376-9bce-a988fc87cbee"
      unitRef="lease">2</inhibrx:NumberOfOperatingLeasesHeld>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NDQ0Ng_2b3f90c0-7c2d-4702-bdca-38632f416f38">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 8, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis BioScience, LLC (&#x201c;Phylaxis&#x201d;), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the condensed consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#x2019;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. As of September&#160;30, 2020, the Company&#x2019;s equity method investment has been written down to zero as a result of the allocation of the Company&#x2019;s share of losses of the investee.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i678ba84787b74c33aaa1dabda2391b12_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE5NjU0MQ_1679b6bd-7996-4565-b4e3-a8d15db70072"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI2Mzg1OQ_bd696a96-0e8c-4146-8cb0-962e3bbcc124"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzIzMg_cb4beb87-3412-4ddd-986c-058242b76acb">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 5, the convertible promissory note (the &#x201c;2019 Note&#x201d;) issued in May 2019 to DRAGSA 50, LLC, an entity affiliated with Viking Global Investors LP (&#x201c;Viking&#x201d;) and the convertible promissory notes (the &#x201c;2020 Notes&#x201d;) issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#x2019;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 815-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and determined certain of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#x2019;s common stock. As of September&#160;30, 2020, the derivative liabilities no longer exist.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <inhibrx:WarrantLiabilitiesPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTU5NDI5MTg3MTE0OTc_9eac04b8-5fd4-48c7-94da-cbddf4cb1bc3">Warrant LiabilitiesAs discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#x2019;s IPO, the warrants were deemed to be issued for the purchase of common stock and were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the condensed consolidated statements of operations during the three and nine months ended September&#160;30, 2020.</inhibrx:WarrantLiabilitiesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzM0MA_b9494d33-6e2c-4945-a47a-3a5f32717f2d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific&#160;to the asset or liability. &lt;/span&gt;&lt;/div&gt;The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 5). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020 and as of September&#160;30, 2020, the derivative liabilities and warrant liabilities no longer existed.Prior to the completion of the IPO in August 2020, the Company&#x2019;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement.The fair value of the Company&#x2019;s derivative liabilities categorized in Level 3 of the fair value hierarchy as of December&#160;31, 2019 was determined based upon an independent third-party valuation report which used a lattice model. The valuation report utilized unobservable inputs, including the discount rate, management&#x2019;s assessment of the probability of various underlying events triggering the conversion of the Company&#x2019;s 2019 Note and the 2020 Notes (as discussed in Note 5), such as an IPO, financing, or extraordinary event, and the current valuation of the Company through an independent third-party valuation report. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of September&#160;30, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon Qualified IPO. Additionally, as of September&#160;30, 2020, the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#x2019;s IPO.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2MzUwNw_7a2d9914-e8b4-4cae-8a6e-a8a6eb483d4e">The following table presents the Company&#x2019;s financial liability that was measured at fair value as of December&#160;31, 2019 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i97607866f6cc41cc94cca89d10cf6bdc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy0xLTEtMS00MTU1_dc8afaca-ec62-4b1a-a9bd-f42d584ae471"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3dbaed7d7d47475091f2e4ab91488da7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy0zLTEtMS00MTU1_f0c45eac-e42d-4972-98c5-f8b5ee348bbe"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i27c38f2ed7fa44b4a81fe1f1eed88df2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy01LTEtMS0w_327cb2ec-c029-49d1-8291-63eac5e206d8"
      unitRef="usd">1916000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOmFkNTY1Y2QzYjQzNTQyYmFiOWZjZDRkMWZiZjEwNmVkL3RhYmxlcmFuZ2U6YWQ1NjVjZDNiNDM1NDJiYWI5ZmNkNGQxZmJmMTA2ZWRfMy03LTEtMS00MTU1_4eea1d9e-0a70-486f-b41e-3b122b9e1929"
      unitRef="usd">1916000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1NA_aad7b531-7d57-49ba-abbc-44e055f1dfbf">The following table provides a &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the nine months ended September 30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of derivative liability on the 2019 Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of derivative liability on the 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of warrant liabilities on the 2020 Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liabilities on the 2019 and 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of warrant liabilities into equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ica2104115bc94b9fa8ac3b4e7d8a5952_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfMi0xLTEtMS0w_7c55e233-ae57-4dd1-8495-8aadc553ac82"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i5f268e0f7dca45f9b9332914738e6f74_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfMy0xLTEtMS0w_cdc4ff4a-ff96-4c10-94d1-1cb157480db3"
      unitRef="usd">900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iac814f782c3b45af984e9c168fd5b2c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNC0xLTEtMS0w_d2b821f6-3993-4aa4-8c8d-a5f0be9adabd"
      unitRef="usd">-1016000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9257d69f32004657829030276365dab2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNS0xLTEtMS0w_fe4cb552-88b3-49ef-9880-53f095f1f8d1"
      unitRef="usd">1916000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i34eb3903a88c4cf4a2c174b773b1619b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNi0xLTEtMS0w_99ba6879-fbe9-4953-bd28-7b2f8ccfa09b"
      unitRef="usd">735000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNy0xLTEtMS05MTgy_1d2cdc84-d62d-4733-963c-2d3a941c636d"
      unitRef="usd">115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d33748b115443b382ab613199d390b0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfNy0xLTEtMS0w_061f5847-ddcd-4728-ab81-28a2d670a069"
      unitRef="usd">2651000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfOS0xLTEtMS05MTg2_4f84f214-9348-4dab-b2f6-63cc828146dc"
      unitRef="usd">-24000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <inhibrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification
      contextRef="iee9278624d524fdeb743b782fe5e64d4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfMTAtMS0xLTEtOTE5MA_c67400e9-f826-4925-bfb5-eeb2eef054b8"
      unitRef="usd">139000</inhibrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i853b5ffb64fa4b6c9270743f860795a1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjc2OTViYmM1ZTk0YTQ5MDA5N2Y1OTZmMWJkYzc0ZWNjL3RhYmxlcmFuZ2U6NzY5NWJiYzVlOTRhNDkwMDk3ZjU5NmYxYmRjNzRlY2NfOC0xLTEtMS0w_83cc2edc-9bac-4a28-877f-2c4f7b09c60c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfOTg5NTYwNDc1ODUxNA_f24ac222-09ce-4288-b759-7375d12de94a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1Mw_5219bd6e-3184-4e26-b40d-f6c720c514bb">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs are capitalized, recorded as an offset to the Company&#x2019;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the condensed consolidated balance sheet as a direct deduction from the debt liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;Legal, accounting, and filing fees related directly to the Company&#x2019;s IPO were capitalized as deferred IPO costs to be offset against proceeds upon the consummation of the IPO within stockholders&#x2019; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0&#160;million of IPO costs against the proceeds. As of September&#160;30, 2020 and December&#160;31, 2019, no deferred IPO costs were capitalized on the Company&#x2019;s condensed consolidated balance sheets.</us-gaap:DeferredChargesPolicyTextBlock>
    <inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering
      contextRef="ic48577e54c534c9cb159d018b57d9192_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI0Nzg0OA_c029622b-63b1-47fc-a90f-9b7dd293c7db"
      unitRef="usd">11000000.0</inhibrx:PaymentsOfStockIssuanceCostsInitialPublicOffering>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1NQ_26e4152a-3acc-42d5-928a-4735d607bd95">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies such as the National Institutes of Health (&#x201c;NIH&#x201d;) and the Congressionally Directed Medical Research Program (&#x201c;CDMRP&#x201d;) funded through the Department of Defense (&#x201c;DoD&#x201d;), as well as from private not-for-profit organizations including Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#x201c;CARB-X&#x201d;). Payments received from customers are included in deferred revenue, allocated between current and non-current, on the condensed consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research, Development, and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;). The Company&#x2019;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has been awarded multiple grants from the NIH, one grant from the CDMRP funded through the DoD, as well as one grant from CARB-X. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the&#160;condensed consolidated&#160;statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#x201c;customer&#x201d; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. Since the Company has concluded that these &lt;/span&gt;&lt;/div&gt;grants do meet the definition of a contribution and are indeed non-reciprocal transactions, the adoption of ASC Topic 606 had no impact on the Company&#x2019;s accounting for grant revenue from governmental agencies or private institutions not considered customers. Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1Ng_7ce4d320-8c6a-4f31-a470-fe946a004193">Research and Development and Clinical Trial Accruals Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#x2019;s behalf, pursuant to development and consulting agreements in place. The Company&#x2019;s preclinical studies and clinical trials are performed by third party contract research organizations (&#x201c;CROs&#x201d;) and/or clinical investigators. The Company also engages with CDMOs for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#x2019;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1Nw_28ec5f78-c081-4c44-9896-e81feb6e46b0">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. &lt;/span&gt;&lt;/div&gt;The utilization of unused federal and state net operating losses (&#x201c;NOLs&#x201d;) and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended (&#x201c;IRC&#x201d;), a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1OA_75d725ec-b527-44ca-a951-dc744ed14f2d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. &lt;/span&gt;&lt;/div&gt;For purposes of the diluted net loss per share calculation, the convertible preferred stock, convertible notes, warrants for purchase of common stock, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the three and nine months ended September 30, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NDE1OQ_3788b7b2-3ede-44ba-bf15-60deacd43d8d">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following securities that could potentially decrease net loss per share in the future were not included in the determination of diluted loss per share as their effect is anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)  The conversion of the convertible notes into common stock assumes a conversion price of $14.35 per share for the 2019 Note and $12.56 per share for the 2020 Notes, and includes the conversion of the principal balance and all accrued interest as of the stated date (see Note 5).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id0ac33289ae142bd80d836a856c99abf_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfMy0xLTEtMS0xMjMyOA_b2475061-a0f4-45f9-b543-8bd5ea02637d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67ce0cd624534b4fb3a651217b134e1e_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfMy0zLTEtMS0xMjMyOA_a06c715e-7265-4293-b86f-818447593ccf"
      unitRef="shares">7211000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib1b460d94a844e52ade7a0f2b9ab1b9f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNC0xLTEtMS0xMjMyOA_fd8e473d-674a-4ff4-81b8-caab9a53c9ba"
      unitRef="shares">2355000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf0f30e90da64a8baa297d499a8884ff_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNC0zLTEtMS0xMjMyOA_ad49c613-bc32-471c-8b98-8e1a5128f04e"
      unitRef="shares">2034000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifbde3532e59e43b4a2a437f33e108ffd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNS0xLTEtMS0xMjMyOA_ff790e6c-9441-4251-84d4-1351d3801306"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i06bcfbe172b34cf880f671de4e455fd8_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNS0zLTEtMS0xMjMyOA_78726cb7-2d72-4b3b-949a-2508a562476f"
      unitRef="shares">2787000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f7d4dd51b19431eb1b4a19269978732_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNi0xLTEtMS0xMjMyOA_27caa30e-c8e6-478d-918d-2d819d1094b3"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iced870049b9c4af8a2a71c8e3372f3bd_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNi0zLTEtMS0xMjMyOA_d7951b6b-bac8-4c87-baf1-7901213a68e9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNy0xLTEtMS0xMjMyOA_a5a6537b-309d-4fee-bc83-c1eb3645377a"
      unitRef="shares">2362000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RhYmxlOjYwNmIxMWJjOGI5YjRmMGY4Y2FiNjNkN2I3Y2E3ZmE3L3RhYmxlcmFuZ2U6NjA2YjExYmM4YjliNGYwZjhjYWI2M2Q3YjdjYTdmYTdfNy0zLTEtMS0xMjMyOA_180553cd-47a4-4f37-8511-13acb63cfb47"
      unitRef="shares">12032000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib34ba14de47a44d4bbeebf803e29fcda_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI1MzM5MA_8fbb0af8-8c35-41fb-9ad8-f298c0f65512"
      unitRef="usdPerShare">14.35</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ifd6dd439011c4044a8417377d85ed8ee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfNTQ5NzU1ODI1MzQyNg_96020c96-a350-41c2-86a7-8d30b490b2ce"
      unitRef="usdPerShare">12.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NzIxMw_69b4ac43-18e8-4691-b300-59b47d07829b">Fair Value of Stock-Based Awards The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NzI0Nw_897820c2-922f-409c-b1a7-f70af61a6092">Other Comprehensive Income The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE2NzI0OA_ca8e20f7-da6d-4c8f-94a9-4cb000024064">Segment Information The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE3ODA0OQ_cc79d5ac-aba6-48a1-8e7e-8dee930f6113"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMjc0ODc3OTE3NTU0OA_f01854f0-b692-4021-8604-f8e9e555a02d">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its condensed consolidated financial condition or results of operations upon adoption. The Company has irrevocably elected not to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act of 2012, as amended (&#x201c;JOBS Act&#x201d;), for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, which includes amendments intended to improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and affects companies that are required to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;include fair value measurement disclosures. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company adopted this guidance as of January 1, 2020, which did not result in a material impact on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard will be effective for the Company on January 1, 2023 or at such time where it is no longer a smaller reporting company. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the potential impact that the adoption of ASU 2019-12 may have on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU 2020-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted, but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the potential impact that the adoption of ASU 2020-01 may have on its condensed consolidated financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 815-40): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMTU5NDI5MTg2MDQzNjI_6de4bdfa-5aec-4720-ad7c-b82b102758ba">OTHER FINANCIAL INFORMATION &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expense and Other Current Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense totaled $0.3 million and $0.5 million for the three months ended September 30, 2020 and 2019, respectively, and $0.8 million and $0.9 million for the nine months ended September 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The amount accrued for research and development expense relates primarily to the Company&#x2019;s increased usage of third-party CROs and CDMOs for preclinical, clinical and development efforts as its therapeutic candidates progress. See Note 1 for further discussion of the components of research and development.</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMjc0ODc3OTA3MTAxMw_d82d5d24-8b0b-46a0-b7db-4607ae26cfd1">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNC0xLTEtMS0w_cbfb8b6f-6683-4b42-b329-53ef960f574e"
      unitRef="usd">2245000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNC0zLTEtMS0w_f7c1bdd8-2005-471f-bb8b-1cb18d76a7ca"
      unitRef="usd">3207000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNi0xLTEtMS0w_6759d638-cda2-4e29-bda0-65b87ea89d6e"
      unitRef="usd">972000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNi0zLTEtMS0w_2e03d537-5efd-4137-ad98-7e41a9199364"
      unitRef="usd">376000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNy0xLTEtMS00Njk1_26b69d08-3415-482d-8e52-934d1645014a"
      unitRef="usd">3217000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmI4MDQ0MGZkZWUzZTRiZDE4ZmRkOGUwMmRkNjdkYzBiL3RhYmxlcmFuZ2U6YjgwNDQwZmRlZTNlNGJkMThmZGQ4ZTAyZGQ2N2RjMGJfNy0zLTEtMS00Njk1_6491d7e0-6ef3-4f35-8582-2fca235f04bf"
      unitRef="usd">3583000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMjc0ODc3OTA3MTAxNA_23d39ee4-224f-4a33-9d5c-a47a52a880be">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7dd225fb7244d46a1448835a24eedc8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNC0xLTEtMS0w_77cce2fe-6213-4c0f-a974-7cde1ffc5606"
      unitRef="usd">5085000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4771026d5c3c40319d148f5c1fcdb3cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNC0zLTEtMS0w_67dc4e88-ba7b-42f3-9e76-dc3eabffff64"
      unitRef="usd">4723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i099bcc18560648f6b4af3ed81b2359f0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNS0xLTEtMS0w_50d53b31-9585-4aaf-9cc7-a79500206553"
      unitRef="usd">441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc99fb23a741432181c70887a43007ec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNS0zLTEtMS0w_782b6c7f-f758-4a04-992e-d1a9f8e9474a"
      unitRef="usd">344000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i55cc14d646e5495391d1f2b7134f4a82_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNi0xLTEtMS0w_f97462a3-2664-49b6-bdbd-1dd000bb3981"
      unitRef="usd">498000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i575d68e93bc24286964f7a4a6a71af6d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNi0zLTEtMS0w_978c011b-a1af-473a-9028-0460404ab895"
      unitRef="usd">317000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f581b24f01849d48dc4babb1fee7e16_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNy0xLTEtMS0w_3b07abd9-03ea-4b4e-932e-8117e5b74c67"
      unitRef="usd">350000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icfa0ca10369144789935f71aa0d4b1c5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfNy0zLTEtMS0w_515fe0b7-045b-4935-b83d-1f7c8741fab6"
      unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOC0xLTEtMS00NjU4_8b3e2925-dc66-4917-8ddd-6260206f3ff3"
      unitRef="usd">6374000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOC0zLTEtMS00NjU4_98710976-b2d5-49fc-b3e5-bbc772dafb93"
      unitRef="usd">5613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOS0xLTEtMS0w_99510fc6-54ff-4001-a2f5-a615ae1deff0"
      unitRef="usd">3100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfOS0zLTEtMS0w_918565d8-143d-4a7a-b862-415960ccd666"
      unitRef="usd">2383000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfMTAtMS0xLTEtNDY1OA_449a655a-67b3-41e3-8c37-521b6587d274"
      unitRef="usd">3274000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOjIyY2UzOTNhZGU5ODRmZjE4ODNlMDgyMWExZTEzM2E4L3RhYmxlcmFuZ2U6MjJjZTM5M2FkZTk4NGZmMTg4M2UwODIxYTFlMTMzYThfMTAtMy0xLTEtNDY1OA_b2520ca5-03d1-4e79-be59-fa013ea7a1e7"
      unitRef="usd">3230000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDQ3MA_b687af23-b87b-4d69-958e-783628790fc6"
      unitRef="usd">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDQ3OQ_1ab0589b-94d8-4a2b-b7e8-eba733448351"
      unitRef="usd">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDM2MA_1ab28182-afe1-4d09-a591-ddef7ba53925"
      unitRef="usd">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfNTQ5NzU1ODE0MDM1MQ_0e2a30c8-45b4-4650-8b42-d193a388e754"
      unitRef="usd">900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RleHRyZWdpb246ODA5NzM0N2Y4MjFjNGE1NmE4YWFjNjhkNjk5YjQwNmJfMjc0ODc3OTA3MTAxNQ_9d6b3746-c25d-4983-9730-876a7054caa2">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <inhibrx:AccruedResearchAndDevelopmentCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNC0xLTEtMS0w_a8f4dd7f-bd8c-46f3-be1c-e26beaa31916"
      unitRef="usd">9866000</inhibrx:AccruedResearchAndDevelopmentCurrent>
    <inhibrx:AccruedResearchAndDevelopmentCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNC0zLTEtMS0w_dc56ddf4-9d62-426a-bf39-aebe47d25852"
      unitRef="usd">3414000</inhibrx:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0xLTEtMS0xMzQzOA_98031ae4-0cec-494b-80f5-da0f15c27c66"
      unitRef="usd">740000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0zLTEtMS0xMzQzOA_29275bb9-b932-4d10-add3-e9db8a4146cf"
      unitRef="usd">813000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0xLTEtMS0w_369f6fd2-fcaa-4058-a47b-b5620654254b"
      unitRef="usd">260000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfNS0zLTEtMS0w_6ff8bcc0-3285-40cb-9582-1891aae709db"
      unitRef="usd">313000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOC0xLTEtMS0w_eb1a7c6b-306f-4dfc-8efd-e28dbb953b65"
      unitRef="usd">171000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOC0zLTEtMS0w_40560a59-a647-40d5-a2f5-cbbabbbfe836"
      unitRef="usd">292000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOS0xLTEtMS00NzM0_064a38cf-ee06-43bc-b66e-22c5d04ea795"
      unitRef="usd">11037000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNy9mcmFnOjgwOTczNDdmODIxYzRhNTZhOGFhYzY4ZDY5OWI0MDZiL3RhYmxlOmYxODhiZjI2YmY0NjQ0MTNhZjg5N2JjN2Y0MDIwZWVlL3RhYmxlcmFuZ2U6ZjE4OGJmMjZiZjQ2NDQxM2FmODk3YmM3ZjQwMjBlZWVfOS0zLTEtMS00NzM2_48356660-b7e2-40b5-ab74-f7f784fc8859"
      unitRef="usd">4832000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTMxOA_fc9539cf-cb49-4bec-9e45-2742dfd0bd8e">DEBT&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding amounts owed pursuant to the 2019 Note, the 2020 Notes, and the PPP Loan (defined below), the Company&#x2019;s debt balance as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following under the 2015 Loan Agreement and the 2020 Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had no outstanding balances under the 2015 Loan Agreement. As of March 31, 2020, the Company had repaid its Oxford Term Loans under the 2015 Loan Agreement in full, including all principal balances, accrued interest, and the $1.4 million final payment. As of December&#160;31, 2019, the Company&#x2019;s outstanding debt balance under the 2015 Loan Agreement consisted of the following (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;15, 2015, the Company entered into the 2015 Loan Agreement, pursuant to which Oxford agreed, subject to certain conditions, to make term loans to the Company in four $5.0 million installments for an aggregate of $20.0 million. The term loans were made on the following dates: (1) Term A: March&#160;31, 2015; (2) Term B: September&#160;9, 2016; (3) Term C: December&#160;22, 2016; and (4) Term D: December&#160;22, 2016. The proceeds from these loans were designated for working capital and general business purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the 2015 Loan Agreement, Oxford had a senior-secured lien on all of the Company&#x2019;s current and future assets, other than its intellectual property. Oxford also had the right to declare the term loan immediately due and payable in an event of default under the 2015 Loan Agreement, which includes, among other things, a material adverse change in the Company&#x2019;s business, operations, or financial condition or a material impairment in the prospect of repayment of the term loan. Throughout the life of the 2015 Loan Agreement, the Company was in compliance with all covenants under the 2015 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each term loan bore interest at the following annual rate: (1) Term A: 8.0%; (2) Term B: 8.6%; (3) Term C: 8.7%; and (4) Term D: 8.7%. The repayment schedule provided for interest-only payments in arrears until May 2016, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date, which was March&#160;31, 2020 (the &#x201c;Maturity Date&#x201d;) for all four term loans. The Company had the option to prepay the outstanding balance of the term loans in full prior to the Maturity Date, subject to a prepayment fee of up to&#160;3.0%. Upon repayment of each term loan, the Company was also required to make a final payment to Oxford equal to&#160;7.0%&#160;of the original principal amount of each term loan. This final payment of $1.4 million was accreted over the life of the 2015 Loan Agreement using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s issuance of its first and second tranches of debt, Oxford also received 33,650 profit interest units (&#x201c;PIUs&#x201d;), which had a per unit value of $3.50, for a total value of $0.1 million. This was recorded as a debt discount and is being amortized using the effective interest method. The PIUs issued to Oxford were converted into 33,889 shares of the Company&#x2019;s common stock in connection with the Company&#x2019;s merger with various affiliated entities in April 2018, in which the Company was the surviving corporation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s interest expense related to the Oxford term loans for the three months ended September 30, 2020 and 2019 was $0 and $0.1 million, respectively, and for the nine months ended September 30, 2020 and 2019 was $0.04 million and $0.6 million, respectively. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company&#x2019;s outstanding debt balance under the 2020 Loan Agreement consisted of the following (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the total future minimum payments, which consist of the future contractual principal and final fee payments, on the Company&#x2019;s debt are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;15, 2020, the Company entered into the 2020 Loan Agreement with Oxford, pursuant to which it received&#160;$10.0 million&#160;in gross proceeds, net of $0.1 million of debt issuance costs (the &#x201c;Term Loan&#x201d;). The outstanding Term Loan will mature on August 1, 2024 (the &#x201c;Maturity Date&#x201d;) and bears interest at a floating per annum rate equal to (1)&#160;8.95%&#160;plus (2) the greater of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii)&#160;1.00%. The repayment schedule provides for interest-only payments beginning on September&#160;1, 2020 and continuing for 24 months thereafter. The interest-only period is followed by 24 months of equal payments of principal and interest. Upon the Maturity Date, a final payment of 7.0% of the original principal amount will be due to Oxford. This final payment of $0.7 million will be accreted over the life of the 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the Term Loan in full prior to the Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company plans to use the proceeds from the Term Loan solely for working capital and to fund its general business requirements. Its obligations under the Loan Agreement are secured by a first priority security interest of substantially all of the Company&#x2019;s assets, other than its intellectual property. The 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#x2019;s operations, that may require prepayment of the outstanding Term Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the debt issuance, the Company issued to Oxford warrants to purchase shares of the Company&#x2019;s capital stock equal to 1.25% of the funded amount, or $125,000. Upon issuance, the warrants were exercisable for preferred stock and were classified as liabilities pursuant to Topic ASC 480 at their fair value of $0.12 million. Upon &lt;/span&gt;&lt;/div&gt;the consummation of the Company&#x2019;s IPO in August 2020, the Company remeasured the warrants and determined a fair value of approximately $0.14 million. The change in fair value was recorded as a change in fair value of warrant liabilities within other income in the Company&#x2019;s condensed consolidated statements of operations. As of September&#160;30, 2020, the warrants are equity-classified and are exercisable for 7,354 shares of common stock of the Company at $17.00 per share.The Company&#x2019;s interest expense related to the Term Loan for the three and nine months ended September 30, 2020 was $0.3 million for each period. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NDQyNA_4f7ef53f-c507-48eb-85dc-b651c8778338"
      unitRef="usd">1400000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTMyMA_98d730ac-e40f-4586-83d8-da9f8536ed65">As of December&#160;31, 2019, the Company&#x2019;s outstanding debt balance under the 2015 Loan Agreement consisted of the following (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company&#x2019;s outstanding debt balance under the 2020 Loan Agreement consisted of the following (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1492990af4cd4609ab13680229c0d787_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfMy0zLTEtMS0w_f8525306-631f-49b3-a7ea-4bc75b5ba7d1"
      unitRef="usd">831000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id2dbb72e83b64adc8434cf549fd94175_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNC0zLTEtMS0w_e6c59945-a0f8-475a-bd90-295c7c202b2f"
      unitRef="usd">893000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i12196a7c26a24c34983264cd528c02a4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNS0zLTEtMS0w_d5441467-8210-4714-8bc6-3fcb8b3d48f8"
      unitRef="usd">930000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iec2e8e28f6944a6cad3e341eddbd124d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNi0zLTEtMS0w_1de62404-0c64-4a9b-ac3a-e09fd2a84941"
      unitRef="usd">930000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfNy0zLTEtMS0w_90be6f6b-b165-4c03-88ea-286fc20bd961"
      unitRef="usd">21000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfOC0xLTEtMS02NTY0_4fc08ef2-950d-4849-9590-8c7d074c3b9b"
      unitRef="usd">3563000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfOS0zLTEtMS0w_47c708be-29c2-437c-a09b-2a495d69fc6d"
      unitRef="usd">3563000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib7a938740c8f41d98cdd5977f98ba01d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjI3MDZiY2IwNTE5NTQzZGE5Y2ExNTViNjA4NmNkYjdiL3RhYmxlcmFuZ2U6MjcwNmJjYjA1MTk1NDNkYTljYTE1NWI2MDg2Y2RiN2JfMTAtMS0xLTEtNjU3NQ_23fbccb2-748a-4185-b6b7-ac7bf6a2b9ae"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <inhibrx:DebtInstrumentNumberOfTermLoans
      contextRef="i73adcaf6ee1947b18f6562d5ec941caf_I20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTExMDI2OA_6dfbd30a-c061-4897-b46d-63aabcd6faeb"
      unitRef="loan">4</inhibrx:DebtInstrumentNumberOfTermLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1128b89e97354edab268af53bdbb2cfc_I20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_0406a27b-a3ad-43c5-b1e1-c10a9fa70856"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i968d197dbe54493980d0c6601895286d_I20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_2080eabf-b369-405a-b4ab-c5482725c50a"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iedc8c75d167c4002ae62b4656fc8dc96_I20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_b5a600a9-8640-4a80-b8b7-bd49da03b093"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icc18af2d45e5429aa46b9f3c1c60dacf_I20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNDgx_ddb5b468-51ac-4e59-bd9d-d6306e7d95fe"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i73adcaf6ee1947b18f6562d5ec941caf_I20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTE3_626ff745-bff1-45c9-9c04-66d0dad0062d"
      unitRef="usd">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if717d2bbf6df424fbf967687e556c917_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTU1Ng_486d5b08-1e51-47fa-a16c-16c1d9743a05"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib7a2211031b8411a97f1eedd40de2aea_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTU3Mg_6b398089-770f-4956-9b93-0645bcedd271"
      unitRef="number">0.086</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i39bd4629e345403594bc83286802f27d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTU4OA_7908fcc8-612b-454d-a5d1-867553088cb9"
      unitRef="number">0.087</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib431edb342fd4664ae233fef94fbc459_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMTYwOA_0dd60c04-b1b7-4d7a-865e-053f783abd3c"
      unitRef="number">0.087</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inhibrx:DebtInstrumentPrepaymentFee
      contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjAyMQ_3d3bf1fc-192b-4eca-84ec-471cdddf03a2"
      unitRef="number">0.030</inhibrx:DebtInstrumentPrepaymentFee>
    <inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue
      contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjEzMg_ddb9098d-eb08-4fcd-9562-c1bb95474903"
      unitRef="number">0.070</inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i6863d5d7e63541b0a3f1be858bc15d80_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjIwOQ_4f7ef53f-c507-48eb-85dc-b651c8778338"
      unitRef="usd">1400000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjQxMA_a6223e19-ebc9-4550-824c-5279a4abc1c3"
      unitRef="shares">33650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjQ0OQ_c8914edf-3764-4b2f-a400-939a38c41380"
      unitRef="usdPerShare">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued
      contextRef="ifb6b604ed84f4ffaa635512e0f3a247d_D20150315-20150315"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjQ3NA_b0611b2d-fbe1-4aa5-9453-0d8602148aca"
      unitRef="usd">100000</inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ia44998013bed488a89c12a2bbbf5d413_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjYyMQ_b1261ee0-c2aa-45f8-a83f-6b9c5c02b589"
      unitRef="shares">33889</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:InterestExpenseDebt
      contextRef="i75b1864cd5ba4d82ad35132d3bf4651c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTEwMTEzMA_6eabc866-a704-4975-aeea-4ee9f1e8af9d"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9a5bfebe16ba4d42b9420939d6abd37e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY1Mw_7ba5b521-899f-42d0-beea-79e009eaeb33"
      unitRef="usd">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="if576809f1ef74d2dae834e212f4c787a_D20200101-20200930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE0ODcwNQ_a42f0a2d-d411-461b-9ade-2a3a68c5fdb5"
      unitRef="usd">40000.00</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie8b1c64897a0450b8b676d88f5779c65_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY2MA_0a55c0f0-0ebc-4167-8277-91c8f8ca75fa"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfMy0xLTEtMS02NjA5_749a47cc-c3cc-4689-aab1-814e84975efa"
      unitRef="usd">10700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNC0xLTEtMS02NjA5_b4b77a21-da19-4908-9db3-7989936e93a6"
      unitRef="usd">879000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNS0xLTEtMS02NjA5_f56f3dc3-d77e-46c2-9457-7b6c9ae9373e"
      unitRef="usd">9821000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNi0xLTEtMS02NjA5_52b12f86-693b-4166-86b9-2d89614fdef1"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOmIwYTYwNGU3ZjZiODRjYWJiY2JhNmU5YTc5YjdjNjcyL3RhYmxlcmFuZ2U6YjBhNjA0ZTdmNmI4NGNhYmJjYmE2ZTlhNzliN2M2NzJfNy0xLTEtMS02NjA5_c0790c89-8124-4259-833e-dedd7366a9eb"
      unitRef="usd">9821000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTExMDI3Nw_7eb074ce-8c2e-4b80-b538-8779e2a87462">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the total future minimum payments, which consist of the future contractual principal and final fee payments, on the Company&#x2019;s debt are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfMy0xLTEtMS0xNTIwNg_fce48a0e-e2a3-45b5-b787-f5d1d800c771"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNC0xLTEtMS0xNTIwNg_f702a611-bb62-4e90-b98d-73c00c9ff438"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNS0xLTEtMS0xNTIwNg_d289a6bf-8cdc-4343-985c-d8df48648fdf"
      unitRef="usd">1667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNi0xLTEtMS0xNTIwNg_191f8b78-d1c5-4604-afaf-d7969ba442f7"
      unitRef="usd">5000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfNy0xLTEtMS0xNTIwNg_c514c17e-2a91-4535-81c9-2b633793c914"
      unitRef="usd">4033000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfOC0xLTEtMS0xNTU2MA_8a1f5f12-5fe5-4732-a303-a09425501b95"
      unitRef="usd">10700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfMTItMS0xLTEtMTUyMTE_554305e7-4b3d-46de-8cef-aa8da61f501e"
      unitRef="usd">879000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="id069de05c44b419a8bc04341e87faf34_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RhYmxlOjk2MmExZjU5NTYwOTQzN2JhMWZhMmYyNGIyZWRjNjEzL3RhYmxlcmFuZ2U6OTYyYTFmNTk1NjA5NDM3YmExZmEyZjI0YjJlZGM2MTNfMTAtMS0xLTEtMTU1NjA_e09acd98-d850-401d-9564-ff3b64d8dfa1"
      unitRef="usd">9821000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY4Ng_2b0b7475-15ec-4f6a-a6ef-6f65198ca208"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDY5NA_97fb80db-e3dc-4eb6-9d73-541bfcb36d5d"
      unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifab34d6750ef4bf6b880aa50a8da757b_D20200715-20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDcwMQ_0b8ebc55-83b4-4a97-814d-7488979918b8"
      unitRef="number">0.0895</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <inhibrx:DebtInstrumentVariableRateFloor
      contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDcwNQ_8f8f2107-fda5-481b-9eca-de16c5b5bc2d"
      unitRef="number">0.0100</inhibrx:DebtInstrumentVariableRateFloor>
    <inhibrx:DebtInstrumentInterestOnlyPaymentPeriod
      contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTEwMTM3Nw_c423847a-2378-493a-9847-1df606017fc1">P24M</inhibrx:DebtInstrumentInterestOnlyPaymentPeriod>
    <inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod
      contextRef="i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfMjc0ODc3OTEwMTE4NQ_12b22213-588e-4643-bbc3-83d686208ad8">P24M</inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod>
    <inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue
      contextRef="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDczNA_01f715ef-804f-4f37-be4c-38dbf9da72a3"
      unitRef="number">0.070</inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="icc1d96b3cea0449e83ebfffd1f7e3760_I20200715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3OTY4OA_07f364c1-80d4-4035-93e4-2045949844b2"
      unitRef="usd">700000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <inhibrx:DebtInstrumentPrepaymentFee
      contextRef="i802d90f694e04e9cbc8a950326d54eca_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTM0Mw_18e58670-759b-4518-9c7f-34f6d07ac317"
      unitRef="number">0.010</inhibrx:DebtInstrumentPrepaymentFee>
    <inhibrx:DebtInstrumentPrepaymentFee
      contextRef="i080025cf9ef84898b13a4a46dd987fa0_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNzY5NjU4MTQxOTM0OQ_f4ddf713-2afb-419a-976f-eb2c77d0301f"
      unitRef="number">0.030</inhibrx:DebtInstrumentPrepaymentFee>
    <inhibrx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued
      contextRef="i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjUxOA_78d8ecf3-72d3-48a9-bb79-f514684a2e50"
      unitRef="number">0.0125</inhibrx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued>
    <inhibrx:WarrantsAndRightsOutstandingLiability
      contextRef="i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjUyOQ_b5e472bd-88ea-4453-a1c0-7e826b657af2"
      unitRef="usd">125000</inhibrx:WarrantsAndRightsOutstandingLiability>
    <inhibrx:WarrantsLiability
      contextRef="i2fc4b9c1f869452c886e27fd8cb739ca_I20200715"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjY1Ng_5e682ef6-b26e-4106-9a35-a1f4fb025f36"
      unitRef="usd">120000</inhibrx:WarrantsLiability>
    <inhibrx:WarrantsLiability
      contextRef="i2314b9fb755947e4ab7ad70f16e7a771_I20200831"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NjY3Mg_1e8eda32-0712-4b82-ac9f-9d448ddb1bbb"
      unitRef="usd">140000</inhibrx:WarrantsLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NzEwMQ_3ccf5b0d-fc3c-4208-aaf4-10c3cc441101"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3NzExMA_d9f755a5-7f08-45b1-ab13-9adcd32ceeaa"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:InterestExpenseDebt
      contextRef="i0c0a3edbbf394e39ac9b8b95852e4df9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDgwMQ_73d3ecf8-3e30-4fa8-9848-55e33b1d3355"
      unitRef="usd">300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i515b22595f7847ed9dff1e886916e38f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80MC9mcmFnOjQxNGFjMGJiYjc5ZTQ2NTNiYTQzYjRjOGZhMzBkYzI5L3RleHRyZWdpb246NDE0YWMwYmJiNzllNDY1M2JhNDNiNGM4ZmEzMGRjMjlfNTQ5NzU1ODE3MDgwMQ_ad7ef048-5e3f-43be-858e-51ff9421f190"
      unitRef="usd">300000</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermDebtTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfMjc0ODc3OTA3MzY4Mg_416de980-6ac7-40eb-92f3-8fb5eb1d999b">PPP LOAN&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;). The CARES Act includes a provision for a Paycheck Protection Program (&#x201c;PPP&#x201d;) administered by the U.S. Small Business Administration (&#x201c;SBA&#x201d;) and further amended by the Paycheck Protection Program Flexibility Act of 2020 (&#x201c;PPP Flexibility Act&#x201d;), which was enacted on June 5, 2020. See Note 11 for further details regarding other provisions of the CARES Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the PPP, the Company was approved for a loan pursuant to the PPP program (the &#x201c;PPP Loan&#x201d;) in the amount of $1.9 million and received the funds on May&#160;11, 2020. The application for these funds required the Company to certify in good faith that current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. The Company was also required to certify that the loan funds would be used to retain workers and maintain payroll or make mortgage payments, lease payments, and utility payments. The PPP Loan has a&#160;two-year&#160;term and bears interest at a rate of 1.0% per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the CARES Act, the Company was eligible to apply for and be granted forgiveness for all or a portion of the PPP Loan. Such forgiveness, if any, would have been determined, subject to limitations, based on the use of loan proceeds for payroll costs, rent and utility costs and provided that only a portion of the use of proceeds are for non-payroll&#160;costs. The unforgiven portion of the PPP Loan was eligible to be repaid by the Company at any time prior to maturity with no prepayment penalty. Loan recipients may elect an eight week or 24 week forgiveness period and the repayment period begins on the date which the amount of forgiveness is determined. In the event that a loan recipient has not applied for forgiveness within 10 months of the end of its covered forgiveness period, the loan recipient must begin making principal and interest payments on that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2020, the Company determined that it would not seek forgiveness of the PPP Loan and would repay the loan in full during the fourth quarter of 2020. As a result, as of September&#160;30, 2020, the full amount of the PPP Loan of $1.9 million was classified as current debt within the Company&#x2019;s condensed consolidated balance sheets. Interest expense related to the PPP loan for the three and nine months ended September&#160;30, 2020 was approximately $4,000 and $7,000, respectively. Interest expense was calculated using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;2, 2020, the Company repaid the loan in full plus all interest accrued during the period outstanding. See Note 12 for further details regarding the repayment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="iab2815bc314c46819698b119c61f9104_D20200511-20200511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTcy_6e667974-0ed0-449c-8c5e-499ab3474127"
      unitRef="usd">1900000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="i4662b14824724021a2692a483eecb043_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTQ5NzU1ODE0MzE4NQ_59be5fec-9d1c-47d3-88e4-1390a49b7959"
      unitRef="usd">1900000</us-gaap:ShortTermBorrowings>
    <us-gaap:InterestExpenseDebt
      contextRef="i41bc12ffbb534f18a23e536d4dde5a2c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTQ5NzU1ODE0MzE1MQ_7822e2eb-352e-4478-968c-42c6e672345f"
      unitRef="usd">4000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i818e609617104ca8b6c8c4969ac1e906_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80My9mcmFnOmI1NTI4MTg2Yjk0YzQxNWQ5MTE2M2IxOWFmMGMxODRjL3RleHRyZWdpb246YjU1MjgxODZiOTRjNDE1ZDkxMTYzYjE5YWYwYzE4NGNfNTQ5NzU1ODE0MzE0OA_b288be38-2048-46c6-ba2e-60caf5f42b67"
      unitRef="usd">7000</us-gaap:InterestExpenseDebt>
    <us-gaap:LongTermDebtTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjU1Ng_be17aaec-ac4e-4320-a9c5-a7fe4ca01a79">CONVERTIBLE PROMISSORY NOTES &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company issued the 2019 Note in the aggregate principal amount of $40.0 million to Viking in a private placement transaction. The 2019 Note began to accrue interest in February 2020 at a rate of 1.5% per month. In April 2020, the Company issued the 2020 Notes in the aggregate principal amount of $15.0 million to Viking and certain other investors in a private placement transaction. Upon issuance, the 2020 Notes accrued interest at a rate of 1.0% per month. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 Note and the 2020 Notes were to mature on the earlier of (1) March&#160;31, 2022; (2) upon the consummation of certain potential settlement events (each as defined in the 2019 Note and the 2020 Notes); or (3) the time at which the balance of the 2019 Note and the 2020 Notes is due and payable upon an Event of Default (the &#x201c;Maturity Date&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion Upon Qualified IPO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 21, 2020, the Company completed a qualified IPO, which was defined as the completion of an IPO with a Company valuation above $400.0&#160;million (&#x201c;Qualified IPO&#x201d;). As defined, a Qualified IPO triggered the automatic conversion and settlement of the aggregate outstanding principal amount plus accrued interest to date under the 2019 Note and the 2020 Notes into shares of the Company&#x2019;s common stock at the lesser of (i) a conversion price equal to 90% of the IPO price per share and (ii) a fixed price based on a specified valuation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the conversion date, accrued interest expense for the 2019 Note and the 2020 Notes was $3.7 million and $0.7 million, respectively for an aggregate total balance of $43.7 million and $15.7 million, respectively. Based on a $400.0&#160;million valuation, the 2019 Note converted at the fixed price of $14.35 per share, resulting in the issuance of 3,046,467 shares of common stock to the holder. Based on a $350.0&#160;million valuation, the 2020 Notes converted at a fixed price of $12.56 per share, resulting in the issuance of 1,248,136 shares of common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion of the 2019 Note and the 2020 Notes were evaluated for contingent beneficial conversion features (&#x201c;BCF&#x201d;) under ASC Topic 470-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt With Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Since the effective conversion prices of both the 2019 Note and the 2020 Notes exceeded the relative fair value of the price per share at the commitment date of the 2019 Note and the 2020 Notes, including the paid-in-kind interest, there was no intrinsic value within the conversion feature. As a result, no additional BCF was recorded upon conversion of the 2019 and the 2020 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the 2019 Note and the 2020 Notes contained alternative conversion options to the Qualified IPO upon the consummation of certain events, each of which had its own conversion prices and terms. For instance, upon a maturity date conversion, upon the election of the holder, the note would have converted and settled into shares of the Company&#x2019;s then-most senior equity securities at the time of such maturity date conversion at the lesser of (i) a conversion price equal to 90% of the price per share to be received by the then-most senior equity securities and (ii) a fixed price based on a specified valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon issuance of each of the 2019 Note and the 2020 Notes and prior to conversion under the IPO, the Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under ASC Topic 815-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Derivatives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to determine if it required bifurcation as a derivative instrument. The Company determined certain settlement features qualified as conversion features not meeting the requirements for separate accounting as embedded derivatives, while others qualified as redemption features meeting the requirements for separate accounting which were accounted for as derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon issuance of the 2019 Note on May&#160;20, 2019, the estimated fair value of the bifurcated compound liability was approximately $0.9 million, which was recorded as a derivative liability with a corresponding reduction to the debt discount on the condensed consolidated balance sheets. The 2019 Note was amended during April 2020 to align the maturity date and certain other provisions with the 2020 Notes. During the second quarter of 2020, the Company assessed the amendment and determined it should be treated as a modification. Since there was no change in the fair value of the embedded conversion options as of the modification date, no change in the carrying amount of the convertible debt instrument was recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon issuance of the 2020 Notes on April&#160;6, 2020, the estimated fair value of the bifurcated compound liability was approximately $0.7 million, which was recorded as a derivative liability with a corresponding reduction to the debt discount on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company engaged a third-party valuation specialist in order to assess the fair value of the derivative liability as of December 31, 2019, which was determined based upon significant inputs not observable in the market, including the discount rate, management&#x2019;s assessment of the probability of various underlying events triggering the conversion of the Company&#x2019;s notes, such as an IPO, financing or extraordinary event, as well as the current valuation of the Company as determined by an independent third-party&#x2019;s valuation report. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability at December 31, 2019 was $1.9 million. Changes in the probability of each embedded redemption feature drove changes in the fair value of the derivative liabilities and had a corresponding impact on the Company&#x2019;s net loss. During the second quarter of 2020, the fair value of the derivative was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined to be zero based upon the expected conversion of the notes via an embedded conversion feature which did not meet the definition of a derivative. Upon conversion of the 2019 Note and the 2020 Notes in August 2020 upon completion of the Company&#x2019;s IPO, the derivative liabilities were extinguished. No additional expense was recorded at extinguishment since the derivative liabilities had already been assessed to have zero value. During the  nine months ended September 30, 2020, the Company recorded other income $2.7 million related to changes in fair value of derivative liabilities in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Discount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to conversion, the Company also evaluated the 2019 Note and the 2020 Notes for BCFs under ASC Topic 470-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt With Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined that the maturity date conversion feature met the definition of a BCF since the embedded conversion option was in-the-money at inception and was fixed and determinable upon execution. Upon issuance of the 2019 Note during the second quarter of 2019, the Company recorded $11.5 million as a debt discount with a corresponding entry to additional paid-in-capital on its condensed consolidated balance sheet to record the BCF the 2019 Note. Additionally, at issuance in May 2019, the Company recorded a debt discount which consisted of $0.9 million related to the establishment of the derivative liability and $2.5 million related to debt issuance costs on the 2019 Note. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon issuance of the 2020 Notes during the second quarter of 2020, the Company recorded $2.7 million as a debt discount with a corresponding entry to additional paid-in-capital on its condensed consolidated balance sheets to record the BCF on the 2020 Notes. Additionally, the Company recorded a debt discount of $0.7 million related to the establishment of the derivative liability on the 2020 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to conversion, the debt discounts were amortized over the life of the notes. Amortization of the debt discount from inception of the 2019 Note until conversion of the Notes upon IPO was $8.7&#160;million. At the time of conversion, the 2019 and the 2020 Notes had unamortized discounts of $6.9&#160;million and $2.7&#160;million, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion of the 2019 Note and the 2020 Notes, the Company remeasured the intrinsic value of the BCFs which resulted in a reversal of the remaining unamortized discounts associated with the BCFs, resulting in a $7.4&#160;million impact to additional paid-in-capital. Additionally, the Company accelerated the unamortized debt discounts related to the debt issuance costs and the derivative liabilities, resulting in a $2.2&#160;million charge to interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2019, the Company&#x2019;s 2019 Note and the 2020 Notes balance, net of discount, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(9,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible note, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i26693951deed4303a7da2ddadc8ee05f_I20190520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0ODkxMA_961abb3c-a5a8-470b-9218-9097ef9e07ad"
      unitRef="usd">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic77d30165eef43de82b4519b6e11aabd_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0OTQ2OA_f557155e-ccfa-4f77-8edf-b02bf4f2cbd6"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5faa4978633f459b997f876d04a34424_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0OTU2Mg_f74abe43-abfa-44b2-8a78-c563ec0e5f45"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5faa4978633f459b997f876d04a34424_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE0OTY4NA_a57d570b-ee23-4457-bd3e-56d335e0f7d3"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjU1OA_710d6bec-2264-4f2c-a6b3-44e616f10ddf"
      unitRef="usd">400000000.0</inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO>
    <inhibrx:DebtInstrumentConvertibleConversionPricePercentageOfSharePrice
      contextRef="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjU3NA_dd4c68ad-4aef-4413-96e6-fc64ecccfd0b"
      unitRef="number">0.90</inhibrx:DebtInstrumentConvertibleConversionPricePercentageOfSharePrice>
    <us-gaap:InterestPayableCurrent
      contextRef="i80dd5d72484a4344aea558884246a977_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQyNA_58385107-51de-4ccc-b029-5587941cba48"
      unitRef="usd">3700000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQzNA_04ab5cd9-ae57-4955-a02b-f01fa3da9b13"
      unitRef="usd">700000</us-gaap:InterestPayableCurrent>
    <us-gaap:LongTermDebt
      contextRef="i80dd5d72484a4344aea558884246a977_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ0NA_e5898ae4-0c52-43b2-b8f1-6fa109a45081"
      unitRef="usd">43700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ1NA_b730835a-c38a-439f-82c1-681946095571"
      unitRef="usd">15700000</us-gaap:LongTermDebt>
    <inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO
      contextRef="i32241f5d4454450aa87c2b3c1c404b87_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfMjc0ODc3OTA5ODk0NQ_1d0c78ee-7437-4f0f-91b1-5f188d6b09ba"
      unitRef="usd">400000000.0</inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i80dd5d72484a4344aea558884246a977_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ2OA_1251761f-9409-493a-92a4-f746b458afc1"
      unitRef="usdPerShare">14.35</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i83317f913e354c4c8e1ec68bfd7bd8e5_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ4Mg_b3aa1d21-5ffc-4abc-85c3-4cbd44608259"
      unitRef="shares">3046467</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO
      contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfMjc0ODc3OTA5ODk2MQ_69540c3b-2284-4276-bba0-13159d6048ff"
      unitRef="usd">350000000.0</inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ4OA_ac839135-fc8a-44f8-b88a-311f6668d1ce"
      unitRef="usdPerShare">12.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i181595e7e07c4d178483c8e330544e15_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODQ5Mg_9900239c-f5e1-4b79-bede-cfb224c2479e"
      unitRef="shares">1248136</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <inhibrx:DebtInstrumentConvertibleConversionPricePercentageOfSharePrice
      contextRef="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjY2NQ_597bcaf5-1abb-4934-a0ad-a364e2487c60"
      unitRef="number">0.90</inhibrx:DebtInstrumentConvertibleConversionPricePercentageOfSharePrice>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i26693951deed4303a7da2ddadc8ee05f_I20190520"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNDkxMA_15e7285e-acc0-4501-a2f7-cebb2b1200ba"
      unitRef="usd">900000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i60dcc587e93f4a8496bb9b4c5c8fe5fb_I20200406"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTU2MQ_40c46354-4ed7-4c56-af4d-dc3e1cd0c3fc"
      unitRef="usd">700000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2NDc4Mw_ed0727d4-4bc4-4a1d-b38b-d0b651dd55d5"
      unitRef="usd">1900000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie9a4b8eb0b864a8f9f9048637d3d5001_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfMjc0ODc3OTEwMTI0MA_ecba16b7-c0a8-45ba-87db-690d2230bd18"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i654fca3b7c5d415bb115995496918fd5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2NDc5OA_bc0b031e-7504-4429-b33d-77315e379cef"
      unitRef="usd">2700000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="ie28a1239656045f886b00a040931a4d9_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODAyOA_ebdc7356-e88b-43f3-8fd8-7d74f27d7620"
      unitRef="usd">11500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <inhibrx:DebtIssuanceCostsNetDerivativeLiability
      contextRef="i91870e5d313147eaa4bfc0c02c210fe7_I20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODI3Mg_8048b6a8-b442-4a2a-9c8f-fdd5ed34e321"
      unitRef="usd">900000</inhibrx:DebtIssuanceCostsNetDerivativeLiability>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i91870e5d313147eaa4bfc0c02c210fe7_I20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODMzNg_77012ac1-fb01-4a2c-b5d7-0b9857a54659"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="if06dc05837124fb486c25738d89fd171_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODQ3Nw_b56179a7-35ad-4cdc-96b8-7a91f19db4b2"
      unitRef="usd">2700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <inhibrx:DebtIssuanceCostsNetDerivativeLiability
      contextRef="i1d02369269bd4bd19d7ac96425d902f6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfODY4NQ_38f6203b-f0d3-428e-bce3-cab873632d06"
      unitRef="usd">700000</inhibrx:DebtIssuanceCostsNetDerivativeLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ifd0edf54fa0f44648f71f8021664a663_D20190501-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUwMA_8b0aff44-9072-4897-8beb-2bc9bce88c2d"
      unitRef="usd">8700000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i80dd5d72484a4344aea558884246a977_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUxMg_05655b6d-2bde-4b4c-9c8d-8db4acc92409"
      unitRef="usd">6900000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i0bbe316909104cd2b78167b976ed7a0b_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUyOQ_27e3ec67-6f6c-40bd-b02b-061bd4a03c2d"
      unitRef="usd">2700000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODUzOQ_cca91103-ad7e-454e-97b9-b7f3734dcb7a"
      unitRef="usd">-7400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if33d72d4f2a94ecb8387aec001faa9cd_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNTQ5NzU1ODE2ODU1Ng_4284da4b-2c80-4763-9293-4f2266854f2e"
      unitRef="usd">2200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RleHRyZWdpb246Nzk0YmRmMWQ3ZmNhNGVhYWFhZmUyY2JhYjQxMWNhYThfNzY5NjU4MTQyMjc0Mw_ae0e5bfc-559b-4dae-801f-1fbfbca8d560">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2019, the Company&#x2019;s 2019 Note and the 2020 Notes balance, net of discount, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(9,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible note, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RhYmxlOmUwOTE4MjdjMGU0MTQ3NTY4ODI0ZGRlYmUzNDBlMWE2L3RhYmxlcmFuZ2U6ZTA5MTgyN2MwZTQxNDc1Njg4MjRkZGViZTM0MGUxYTZfMy0zLTEtMS0w_d142d966-71a6-4801-90a9-6ce61eee5302"
      unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RhYmxlOmUwOTE4MjdjMGU0MTQ3NTY4ODI0ZGRlYmUzNDBlMWE2L3RhYmxlcmFuZ2U6ZTA5MTgyN2MwZTQxNDc1Njg4MjRkZGViZTM0MGUxYTZfNC0zLTEtMS0w_dc02d49d-bd73-4d80-a1e8-c32b7d9a9d33"
      unitRef="usd">9633000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i002ad8c894fe49eaa73e28fe15dbaa17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80Ni9mcmFnOjc5NGJkZjFkN2ZjYTRlYWFhYWZlMmNiYWI0MTFjYWE4L3RhYmxlOmUwOTE4MjdjMGU0MTQ3NTY4ODI0ZGRlYmUzNDBlMWE2L3RhYmxlcmFuZ2U6ZTA5MTgyN2MwZTQxNDc1Njg4MjRkZGViZTM0MGUxYTZfNi0zLTEtMS02ODk3_adf93e28-ff3e-4a90-9018-3266bd3ca0da"
      unitRef="usd">30367000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjc0ODc3OTA5NzYxNQ_b6015395-e5a5-4ba1-8267-eb87635eb2c2">STOCKHOLDERS&#x2019; EQUITY (DEFICIT) &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated Certificate of Incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 21, 2020 upon completion of the IPO, the Company&#x2019;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 15,000,000 shares of preferred stock, each with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to its conversion to common stock in connection with the Company&#x2019;s IPO, the convertible preferred stock was classified as temporary, or mezzanine, equity on the accompanying condensed consolidated balance sheets since the shares contained certain redemption features that were not solely within the control of the Company. The Company had not previously accreted the convertible preferred stock to its redemption value since the shares were not redeemable and redemption was not deemed to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock authorized and issued as of December&#160;31, 2019 consisted of the following (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued and Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Liquidation Preference&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series Mezzanine 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,009.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series Mezzanine 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,465,681&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,235,012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 - 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,480.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,534,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,489.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company issued 1.7 million shares of Series Mezzanine 2 Preferred Stock at a purchase price of $6.98 per share, resulting in net proceeds of approximately $12.0&#160;million, after deducting offering expenses. No shares of Series Mezzanine 1 Preferred Stock and Series Mezzanine 2 Preferred Stock were issued during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the completion of the Company&#x2019;s IPO in August 2020, all of the outstanding shares of convertible preferred stock were converted into 7,211,086 shares of the Company&#x2019;s common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, the Company issued warrants to Oxford concurrently with the 2020 Loan Agreement. Upon the consummation of the Company&#x2019;s IPO in August 2020, the warrants are exercisable for 7,354 shares of common stock of the Company at $17.00 per share. As of September&#160;30, 2020, the warrants are equity-classified and reflected in additional paid-in-capital at $0.14 million. The fair value of the warrants was determined using the Black-Scholes model on the date of conversion. No subsequent remeasurement is required for equity-classified warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM0OA_8879475b-9ab3-43ac-b888-ba7b272fba0a"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM1Mg_05b08e1c-eb2b-4310-baf8-773e2a4a5e81"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM0NA_8009b996-d75d-4e41-896b-f8bffba49f54"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i89b94e216c8747f7a8147b47e4efe7c2_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM0NA_9d8f2385-785e-4c9c-b3ef-faff087d2cd7"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjc0ODc3OTA5Mjg4Mw_d9197884-360f-4ff4-b286-d54cde9d44f3">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock authorized and issued as of December&#160;31, 2019 consisted of the following (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued and Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Liquidation Preference&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series Mezzanine 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,009.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series Mezzanine 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,465,681&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,235,012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 - 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,480.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,534,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,489.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy0xLTEtMS0yMTc5_4d2cec47-22cc-4eda-8586-59d1c3bc9fab"
      unitRef="shares">4299319</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy0zLTEtMS03NzMw_9bd18570-9baf-4ea9-b3b7-819d98c12753"
      unitRef="shares">4299319</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy0zLTEtMS03NzMw_f1d59ac5-8596-47eb-b11a-bb54a661614c"
      unitRef="shares">4299319</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SharePrice
      contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy03LTEtMS03NzMx_9d6784d1-a9df-4b13-a9b4-b88b4fb4c91f"
      unitRef="usdPerShare">6.98</us-gaap:SharePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ibf3ad6f9834e4cbabd456f152ebd36b9_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfMy05LTEtMS0yMTg5_b18db894-1491-4397-b90c-19c8b14c550f"
      unitRef="usd">30009200</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i87def4161b5741d0a3372af759a43214_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC0xLTEtMS0yMTgy_7f11fab1-4c28-4609-bbf8-441e70677f5c"
      unitRef="shares">21465681</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i87def4161b5741d0a3372af759a43214_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC0zLTEtMS03NzMw_9b6e6b89-b45d-4da5-99be-a4e2031a943f"
      unitRef="shares">8235012</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i87def4161b5741d0a3372af759a43214_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC0zLTEtMS03NzMw_d94cc2f3-fd91-4c91-b71f-f4412ab84ee7"
      unitRef="shares">8235012</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SharePrice
      contextRef="i87def4161b5741d0a3372af759a43214_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC03LTEtMS03NzMx_94c4fcd8-9a71-462e-a551-2f1330e50ad8"
      unitRef="usdPerShare">6.98</us-gaap:SharePrice>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i87def4161b5741d0a3372af759a43214_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNC05LTEtMS0yMTkz_e69fb1ac-b913-48ad-93f5-f84fc58e1590"
      unitRef="usd">57480400</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS0xLTEtMS03NzI4_d28138a7-acea-479f-ad0e-b8e49a4cae6b"
      unitRef="shares">25765000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS0zLTEtMS03NzMw_12bdbbf7-b87d-4274-85df-c025b600dc37"
      unitRef="shares">12534331</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS0zLTEtMS03NzMw_5ef45ddb-260e-41da-849c-986ca56766a0"
      unitRef="shares">12534331</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RhYmxlOjQ3NjA2ZTI0NmYyNDQxNGFiNzA4YTZkOTk2YmJiOGVjL3RhYmxlcmFuZ2U6NDc2MDZlMjQ2ZjI0NDE0YWI3MDhhNmQ5OTZiYmI4ZWNfNS05LTEtMS03NzM0_e8282029-6818-44c3-8611-cfc378779dae"
      unitRef="usd">87489600</us-gaap:TemporaryEquityLiquidationPreference>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i4c0d84dc7c03423189234b747382592d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM1Ng_5b6f80d7-fa61-4606-9416-5a294945cf09"
      unitRef="shares">1700000</inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="i87def4161b5741d0a3372af759a43214_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM2Mw_ef51e640-ffda-4921-8bb3-ad2784517aaf"
      unitRef="usdPerShare">6.98</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i4c0d84dc7c03423189234b747382592d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfOTg5NTYwNDY3MzQ4OA_64919482-1d72-4728-a45a-9d82202710fb"
      unitRef="usd">12000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1b2a8d92980b45cd86a9a0e569b171a7_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjE5OTAyMzI3OTAwOQ_94fdb3e4-486b-48c5-83cd-f0d312d69b54"
      unitRef="shares">0</inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ia8c0ec15d63b4c9c9db72a0042d9233b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfMjE5OTAyMzI3OTAwOQ_edb8bd00-62e8-4829-b8c3-09d7ccfd6289"
      unitRef="shares">0</inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9230559c947e4bdfbd7d8718f81613a0_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2MjM2Nw_dffe0366-6c20-4b90-9da1-59fd0482df49"
      unitRef="shares">7211086</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2NDMwNA_3ccf5b0d-fc3c-4208-aaf4-10c3cc441101"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idfe58a3fd21344b0a53d4ea5ec23505a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2NDM0OQ_d9f755a5-7f08-45b1-ab13-9adcd32ceeaa"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV80OS9mcmFnOmYxYmY0MmQxNmIyZDRhOTliMWFhMTY5YTg4M2M0MWNjL3RleHRyZWdpb246ZjFiZjQyZDE2YjJkNGE5OWIxYWExNjlhODgzYzQxY2NfNTQ5NzU1ODE2NDc2Nw_2419e833-7d3c-486c-a98c-f9704cc8a823"
      unitRef="usd">140000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDg5NA_c171f10b-7f19-42ff-a83c-dcf899bc3a2d">EQUITY COMPENSATION PLANS &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;), which provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of September&#160;30, 2020, an aggregate of 3.0 million shares of common stock were reserved for issuance under the 2017 Plan, of which 0.6 million were available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company&#x2019;s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under its 2017 Plan for the nine months ended September 30, 2020 is as follows (in thousands, except for per share data and years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NUMBER OF SHARES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED AVERAGE EXERCISE PRICE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (IN YEARS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGGREGATE INTRINSIC VALUE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#x2019;s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the nine months ended September 30, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NINE MONTHS ENDED SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;97.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;87.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the assumptions used in the option pricing model in the following manner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the IPO, given the absence of a public trading market for the Company&#x2019;s common stock, its board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company&#x2019;s common stock underlying the stock options, such as: contemporaneous valuations performed by independent third-party specialists, its stage of development, including the status of its research and development efforts of its therapeutic candidates and the material risks related to its business and industry, its results of operations and financial condition, including its levels of capital resources, the prices at which its sold shares of its convertible preferred stock, the rights, preferences and privileges of its convertible preferred stock relative to those of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as recently completed mergers and acquisitions of peer companies, the likelihood of achieving a liquidity event for the holders of its common stock or convertible preferred stock, such as an IPO or a sale of the Company given prevailing market conditions, trends and developments in its industry, external market conditions affecting the life sciences and biotechnology sectors, and the lack of liquidity of its common stock, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price. The Company&#x2019;s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;THREE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NINE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of September&#160;30, 2020 and December&#160;31, 2019, the Company had $12.3 million and $12.2 million, respectively, of total unrecognized stock-based compensation expense related to its stock options, which it expected to recognize over a weighted-average period of 2.4 and 2.9 years, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <inhibrx:ShareBasedCompensationNumberOfPlans
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MTkwMw_77f6b857-ac22-4868-8dfd-16b6d0ee6d00"
      unitRef="plan">1</inhibrx:ShareBasedCompensationNumberOfPlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNjU5NzA2OTc3OTA4NQ_b636da48-1509-4824-864a-456171335931"
      unitRef="shares">3000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNjU5NzA2OTc3OTA5Mg_94f861e3-dce3-4198-b40e-6029d7f2e69f"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNzY5NjU4MTQwNTkyNg_a7601782-9629-4029-ad56-42784fc754e2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8e89d479cc1c49dcac81106f1a23036d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNzY5NjU4MTQwNTk0Mw_b6830872-5d06-43d9-83f7-aec990de7e52">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDkwOA_3e00e6c7-cb2f-4a1a-99e7-ad97495d1b34">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDkxNA_29aea8e4-ab94-4076-b32e-bd99fb659586">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under its 2017 Plan for the nine months ended September 30, 2020 is as follows (in thousands, except for per share data and years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NUMBER OF SHARES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED AVERAGE EXERCISE PRICE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (IN YEARS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGGREGATE INTRINSIC VALUE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS0xLTEtMS03Nzk5_4fefaca2-971e-449c-9f82-c701899ed387"
      unitRef="shares">2013000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS0zLTEtMS0w_1437779a-8f60-48ea-aa64-5504499ad271"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i291c0d139a404246b0f7fca420127e86_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS01LTEtMS0w_79f7a89f-5efb-44d1-a742-f8bb6e30d197">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNS03LTEtMS0w_69d29aeb-417a-4c19-87a0-3c45a45157b7"
      unitRef="usd">1261000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNy0xLTEtMS0w_d57572cc-4c59-4f84-a93c-d9469466aca9"
      unitRef="shares">573000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNy0zLTEtMS0w_abfd71ce-1d77-4bb2-af83-06d89ef5df3f"
      unitRef="usdPerShare">12.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNi01LTEtMS05OTcx_86cbaaae-0637-4142-866f-294aef94d965">P9Y7M6D</inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted>
    <inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfNi03LTEtMS05OTc5_98d82ebd-c79c-4950-9379-31a92879c6fb"
      unitRef="usd">3515000</inhibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0xLTEtMS03Nzk5_985f16d4-59dd-4679-824c-e3041cb9bddf"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0zLTEtMS04NDIw_dc1bcc14-29b0-4736-80ce-eb4267a66d2d"
      unitRef="usdPerShare">10.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0xLTEtMS0w_f9be75dc-1d2b-4f1b-924f-f4529c0b1e24"
      unitRef="shares">231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOC0zLTEtMS0w_d8921c51-051b-4f60-8206-3cb41986b2e4"
      unitRef="usdPerShare">11.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtMS0xLTEtNzc5OQ_5b18f653-a8c0-4d10-9442-0c12d1d7e287"
      unitRef="shares">2355000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOS0zLTEtMS0w_dde2eccc-9d2f-495b-b796-83dbe819b898"
      unitRef="usdPerShare">11.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOS01LTEtMS0w_7c43871a-1561-4397-a903-a297cb0ac447">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfOS03LTEtMS0w_4511823b-0127-4800-8411-78dad40288de"
      unitRef="usd">16184000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtMS0xLTEtMA_77f8c1a2-abd7-4c5f-b061-9b02b1270563"
      unitRef="shares">864000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtMy0xLTEtMA_ddaa99d2-d398-4916-b3da-ca28e0dee2dc"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtNS0xLTEtMA_5f41a61e-39b9-49a0-885d-64bfdf86c166">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjgyMjY0NjQ4YTA5NDQ3YmZiZDcyNWI2MDVmNmFiN2I4L3RhYmxlcmFuZ2U6ODIyNjQ2NDhhMDk0NDdiZmJkNzI1YjYwNWY2YWI3YjhfMTAtNy0xLTEtMA_d42301cb-35d7-4fc9-b563-c6552dce42d6"
      unitRef="usd">6200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfMjc0ODc3OTA4MDkxNQ_5705342d-3561-4078-a938-4c565e44eeb0">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the nine months ended September 30, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NINE MONTHS ENDED SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;97.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;87.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNC03LTEtMS0w_c122f316-000d-4243-a752-7595f698eba5"
      unitRef="number">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNC05LTEtMS0w_d47401fc-9943-4e21-9cce-148a018d002b"
      unitRef="number">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNS03LTEtMS0w_8e926ca3-704e-45b1-8cc4-f0ed08548642"
      unitRef="number">0.9778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNS05LTEtMS0w_0ce87f13-a8d8-4c28-9afa-b21d598ce442"
      unitRef="number">0.8743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNi03LTEtMS0w_14da663a-cb68-44d6-ba8b-535f4fa99a91"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNi05LTEtMS0w_8decbe8c-8410-46ed-95d2-4db8c3c8b0dc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNy03LTEtMS0w_cf0d9173-bef1-4e40-9422-dc71cb129d4c">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfNy05LTEtMS0w_e9ac9ed8-90a8-44b5-9ae3-d60455576d66">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfOS03LTEtMS0w_706a1319-c284-4e8b-b594-0b99a1eeff69"
      unitRef="usdPerShare">9.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOmU0ZWFhZWE4MDQ5ODQ5Y2Q4MTcxNGY5NzhhZGUzMTU5L3RhYmxlcmFuZ2U6ZTRlYWFlYTgwNDk4NDljZDgxNzE0Zjk3OGFkZTMxNTlfOS05LTEtMS0w_967006cb-3e92-408e-bfd9-ed33494f8705"
      unitRef="usdPerShare">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNzY5NjU4MTQwNTkwOA_6da5268c-df5d-4a15-b187-a1bed27dc9b7">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;THREE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NINE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a9043b1e7d94f868faef2ed4ddb4eda_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC0xLTEtMS0w_08ae7fad-e983-4f00-976a-49271031e4c8"
      unitRef="usd">1103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i93b90f3cbd93444a8e502d826cbbe51f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC0zLTEtMS0w_782eb724-4f6b-4dbd-b53b-addeea02f35b"
      unitRef="usd">877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia387c26a722e4699b6595d2f733a93c1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC01LTEtMS0w_25261637-3c19-4179-8b05-0e1a3f804158"
      unitRef="usd">3149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e933df6d96c4e25a0e01262d530c949_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNC03LTEtMS0w_592e767e-9196-41b4-a455-7536f5b2b9e6"
      unitRef="usd">2449000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd8eff35edb7419e9932c5f914758304_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS0xLTEtMS0w_23e65c89-b5d4-4b78-8b38-f2158ee8af89"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1cec1573a81491f8627da20eab3bf7a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS0zLTEtMS0w_5bbc6725-8cec-42c4-a9e0-7cebf887ecf8"
      unitRef="usd">142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16757954c1044691837622036e587d62_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS01LTEtMS0w_52e48ea3-888c-47e9-a4ad-462669a4dbd8"
      unitRef="usd">501000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6c7d40392014b9993d7e113b2eac17c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS03LTEtMS0w_220af98e-e51a-497f-b468-135c36c152f8"
      unitRef="usd">401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iabd02944395c4cd4867b8652d51a714a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNS0xLTEtMS04NDI5_4d7b1a6c-63a6-4b6f-bbca-733235a6ba4a"
      unitRef="usd">1303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i910bafb21fde4c9d995b95ae87cf63a5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNi0zLTEtMS01MDA_a11f5507-11f9-4214-a70a-fb6ce8326e7b"
      unitRef="usd">1019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNi01LTEtMS01MjE_0c2dcd08-f84f-4da7-aab3-5a38a23fc7ee"
      unitRef="usd">3650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iadc0db1dedb64652bed03e473906f250_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RhYmxlOjU4OWM2ZDRiZDFiMDRjZTliODZlZjBkYzNhNGZmMGZjL3RhYmxlcmFuZ2U6NTg5YzZkNGJkMWIwNGNlOWI4NmVmMGRjM2E0ZmYwZmNfNi03LTEtMS0w_5eb0e1e5-4944-4b9e-87b8-3796393d11be"
      unitRef="usd">2850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i54757ed54df14bceb415fb75f4faf788_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE0OQ_71750d84-e43b-4c8a-8ac7-f3889f44c273"
      unitRef="usd">12300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id41c0b142c464e41bb151ae9a392ab96_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE1OQ_caa7fa58-c473-4e50-833d-b5de55da4c29"
      unitRef="usd">12200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icdfa6c61bb394b2bb3e6c0cfad1b9a4f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE5Nw_5d5e80f2-eacd-4961-95f8-d65e87de32ec">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib5230b6435fd4ceb84a6af9831cd457c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81Mi9mcmFnOjQ4YmU5MmVjYzRlYTQwNTRiMmM1NDliNTM0YmIwODhhL3RleHRyZWdpb246NDhiZTkyZWNjNGVhNDA1NGIyYzU0OWI1MzRiYjA4OGFfNTQ5NzU1ODE0NzE5Mw_d2becc01-0f39-44be-b3e2-13a0f286234b">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <inhibrx:LicenseAndGrantRevenueTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDE0Nw_b0b011f6-0664-4209-9736-84d993f9c222">LICENSE AND GRANT REVENUES &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total revenue recorded in the Company&#x2019;s condensed consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;THREE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NINE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transcenta Holding, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elpiscience Biopharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phylaxis BioScience, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;bluebird bio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chiesi Farmaceutici S.p.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license revenues from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;National Institutes of Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combating Antibiotic Resistant Bacteria Accelerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Congressionally Directed Medical Research Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Phylaxis Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis BioScience, LLC (&#x201c;Phylaxis&#x201d;). In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement (collectively the &#x201c;Phylaxis Agreements&#x201d;), pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. Upon closing, the Company received a $2.5&#160;million nonrefundable, upfront payment from Phylaxis under the Master Services Agreement (&#x201c;MSA&#x201d;). The Company is also entitled to an additional $2.5&#160;million payable within 180 days from closing under the MSA. Upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company&#x2019;s intellectual property and know-how and is entitled to receive an additional 5% based on the achievement of certain milestones. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0&#160;million and $175.0&#160;million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the fair value of the equity interest in Phylaxis, the Company engaged a third-party valuation specialist. The valuation report utilized a market approach to establish the total equity value of Phylaxis using inputs not observable in the market, including the discount rate. The fair value of the equity interest was $0.5&#160;million, which has been accounted for under the equity method. The fair value of the equity interest upon the execution of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the agreements has been included in the transaction price, along with the $5.0&#160;million of payments due pursuant to the MSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the transfer of the exclusive licenses for, and performance of, development services to modify the first and second compounds as one performance obligation and allocated the transaction price evenly between the two compounds. Revenue related to the performance obligation will be recognized over time as services are performed, based on the Company&#x2019;s progress to satisfy the performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020, the Company has recognized $0.8&#160;million of revenue related to this performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;bluebird&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2018, the Company entered into a License Agreement with bluebird bio, Inc. (&#x201c;bluebird&#x201d;) whereby the Company granted bluebird the exclusive, worldwide rights to develop, manufacture, and commercialize certain cell therapy products containing binders. In January 2019, the Company received a non-refundable upfront fee of $7.0 million from bluebird for this exclusive license. As part of the Company&#x2019;s performance obligations to bluebird, it transferred certain know-how to bluebird, the completion of which occurred in March&#160;2019. As a result, the Company recognized the $7.0 million upfront payment as license fee revenue during March 2019 upon completion of all performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also entitled to receive specified development milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Option and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a separate Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide development licenses to develop binders and cell therapy products containing sdAbs directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. The Company also granted to bluebird an option to acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which bluebird exercises its option, bluebird will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions for each option bluebird chooses to exercise. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the effective date of the agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company will reassess its performance obligations and transaction price accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the total transaction price of the contract at execution was $0.4 million for the transfer of the two exclusive development licenses. The Company recognized $0.4 million of revenue related to this agreement at the point in time in which the exclusive development licenses were transferred to bluebird, which occurred upon execution of the agreement in June 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chiesi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company entered into an Option Agreement (as amended by the First Amendment to Option Agreement, dated August 19, 2019, the &#x201c;Chiesi Option Agreement&#x201d;) with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019. If Chiesi chooses to exercise its option under the Chiesi Option Agreement, then Chiesi must pay the Company a one-time, non-refundable fee of $12.5 million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, the Company may be entitled to receive specified milestone payments of up to $122.5 million, as well as royalties on future product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified one performance obligation as of the effective date of this agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#x2019;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company&#x2019;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#x2019;s delivery to Chiesi of the finalized minutes from the definitive parallel EMA-HTA scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company has determined that the option to grant a license in the future is not a material right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $10.0 million upfront payment has been allocated to the single performance obligation. Revenue will be recognized over time as services are performed during the option period, based on the Company&#x2019;s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the three months ended September 30, 2020 and 2019, the Company recognized $2.0 million and $0.8 million, respectively, in revenue related to this agreement. During the nine months ended September 30, 2020 and 2019, the Company recognized $5.8 million and $0.8 million, respectively, in revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Elpiscience&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company has entered into two different License Agreements with Elpiscience Biopharmaceuticals, Inc. (&#x201c;Elpiscience&#x201d;). Each agreement is a standalone license of a distinct and differentiated protein therapeutic candidate with a separate biological target, providing a unique benefit. Neither the license nor the asset is reliant upon the other. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PD-L1 and 4-1BB Program &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a License Agreement (the &#x201c;PD-L1 and 4-1BB License Agreement&#x201d;) with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#x2019;s bi-specific therapeutic candidate designed to target PD-L1 and 4-1BB (also referred to as &#x201c;INBRX-105&#x201d;). This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as to manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-105, including process development and manufacturing data and information necessary to develop INBRX-105. In the PD-L1 and 4-1BB License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-105 for its development in China, Hong Kong, Macau and Taiwan. The Company is eligible to receive specified developmental and commercial milestone payments of up to an aggregate of $100.0 million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the PD-L1 and 4-1BB License Agreement, the Company is entitled to reimbursement for certain toxicology study costs and chemistry, manufacturing and controls (&#x201c;CMC&#x201d;) costs. Elpiscience paid the Company $3.0 million in March 2018 for certain costs in relation to the development of INBRX-105. The payment received in advance of the work to be completed was recorded to other current liabilities upon receipt and, since the Company was acting as an agent on behalf of Elpiscience, the Company recorded it as a contra-expense against research and development as the relevant work was completed. During the three and nine months ended September 30, 2019, the Company derecognized approximately $0  and $0.7 million of liabilities related to this agreement, respectively. As of September&#160;30, 2019, the Company had completed all relevant work on this program and had no remaining liabilities related to the reimbursement under the PD-L1 and 4-1BB License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OX40 Program &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into a separate License Agreement (the &#x201c;OX40 License Agreement&#x201d;) with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#x2019;s multivalent protein therapeutic directed to the biological target OX40 (also referred to as &#x201c;INBRX-106&#x201d;). This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-106, including process development and manufacturing data and information necessary to develop INBRX-106. In the OX40 License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-106 for its development in Mainland China, Hong Kong Macau and Taiwan. The Company is eligible to receive certain developmental and commercial milestones of up to an aggregate of $100.0 million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company achieved a milestone under the contract for $2.0&#160;million, which was received during September 2020. The Company recognized revenue of $2.0&#160;million during the three and nine months ended September 30, 2020 related to this agreement. No revenue was recognized related to this agreement during the three and nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the OX40 License Agreement, the Company is entitled to reimbursement for certain toxicology study costs and CMC costs. Elpiscience paid the Company $3.4 million in August 2018 for certain costs incurred in relation to the development and production of INBRX-106. The payment received in advance of the work to be completed was recorded to other current liabilities upon receipt and since the Company was acting as an agent on behalf of Elpiscience, the Company recorded it as a contra-expense against research and development as the relevant work was completed. As of September&#160;30, 2020, the Company has $0.2 million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. As of September&#160;30, 2020 and December 31, 2019, the Company had no liabilities outstanding related to this agreement. During the three and nine months ended September 30, 2020, the Company received $0 and $0.2 million in reimbursements for expenses already incurred, respectively. During the three and nine months ended September 30, 2019, the Company derecognized approximately $0.1 million and $1.3 million of liabilities related to this reimbursement, respectively. Additional reimbursements of $0.1 million related to multi-year stability studies are expected to be recognized and paid upon completion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transcenta&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, the Company entered into a License Agreement with Transcenta Holding, Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), (&#x201c;Transcenta&#x201d;) (the &#x201c;Transcenta License Agreement&#x201d;), whereby the Company granted Transcenta exclusive, non-transferable rights to develop, manufacture, and sell its products containing the Company&#x2019;s protein therapeutic candidate, designed to target DR5 (also referred to as &#x201c;INBRX-109&#x201d;), or a derivative thereof, within mainland China, Hong Kong, Macau and Taiwan and agreed to provide Transcenta with the intellectual property and materials, including assays and cell lines, necessary to develop the therapeutic candidate. In addition, pursuant to the Transcenta License Agreement, the Transcenta License Agreement granted the Company a royalty-free, worldwide, non-exclusive research license to intellectual property created by Transcenta that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incorporates intellectual property licensed to Transcenta. In June 2019, the Company achieved a milestone under the contract for $1.0 million, which was received during August 2019, net of $0.1 million in foreign tax withholding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Transcenta License Agreement, the Company is also eligible to receive certain developmental and commercial milestone payments of up to an aggregate of approximately $100.0 million, as well as percentage tiered royalties on future product sales with rates ranging between the high single-digits to the low teens. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2012, the Company entered into a Development and Option agreement with Celgene whereby the Company granted Celgene an option to exclusively license certain intellectual property rights relating to the Company&#x2019;s CD47 checkpoint inhibitor . Upon grant of the Development and Option agreement, Celgene made a non-refundable upfront option payment for the exclusive license. In June 2013, Celgene opted to exercise its right to license the intellectual property rights associated with the Company&#x2019;s CD47 therapeutic. The Company is also eligible to receive certain developmental and commercial milestones of an aggregate of $934.1 million, assuming the achievement of all potential milestones in the agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens. The Company is obligated to pay 2% of future amounts received under the Development and Option Agreement to advisors who assisted the Company with the negotiation and other matters in connection with the Development and Option agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue was recognized in accordance with the Company&#x2019;s stated methodology discussed in Note 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NIH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During August 2017, the Company was awarded a grant by the NIH in the amount of $1.0 million for the continued development of multi-specific antibodies for the treatment of Pseudomonas aeruginosa infection, all of which has been recognized as revenue upon completion in June 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from this NIH grant was based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue was recognized when the Company incurred these covered expenses related to the grant&#x2019;s continued progression. The Company submitted invoices to the NIH for only those expenses which had been incurred by the Company in each period, resulting in reimbursement in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CARB-X Subaward Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During July 2017, the Company was awarded a grant by Boston University in the amount of approximately $4.6 million. The program, Combating Antibiotic Resistant Bacteria Accelerator (&#x201c;CARB-X&#x201d;), is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. The Company received this award in relation to its program aimed at the development of novel antimicrobial therapeutics using multiple mechanisms of action to circumvent the development of resistance, and in the case of this grant, specifically for pseudomonas. The payment structure of this grant was a cost share, where 70% of costs were reimbursed by the sponsor, or Boston University, and the remaining 30% of costs are covered by the Company. The work under this grant began in October 2017 and was discontinued during the third quarter of 2019 based on the uncertainty within the applicable regulatory environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from this grant was based upon internal costs incurred by the Company that were specifically covered by the grant as well as certain specified overhead expenses. Revenue was recognized when the Company incurred these covered expenses related to the grant&#x2019;s continued progression. The Company submitted invoices to Boston University for only those expenses which had been incurred by the Company in each period, resulting in reimbursement in arrears. Prior to discontinuation of the work on this grant, $4.0 million in revenue was recognized, all of which has been received in cash from Boston University. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CDMRP funded through the DoD &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During September 2018, the Company was awarded a grant by the CDMRP funded through the DoD by the U.S. Army Medical Research Acquisition Activity in the amount of approximately $0.3 million for the continued development of multi-specific antibodies for the treatment against Acinetobacter baumannii infection by circumventing development of bacterial resistance. The work under this grant began in December 2018 and was completed in September 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from this grant is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant&#x2019;s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. As of September&#160;30, 2020, $0.3 million in revenue has been recognized under this grant, $0.2&#160;million of which has been received in cash from the DoD.&lt;/span&gt;&lt;/div&gt;</inhibrx:LicenseAndGrantRevenueTextBlock>
    <inhibrx:ScheduleOfLicenseAndGrantRevenueTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDMwNA_828099be-6c44-48f3-abeb-3b1b02ad1946">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total revenue recorded in the Company&#x2019;s condensed consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;THREE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NINE MONTHS ENDED&lt;br/&gt;SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transcenta Holding, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elpiscience Biopharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phylaxis BioScience, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;bluebird bio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chiesi Farmaceutici S.p.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license revenues from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;National Institutes of Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combating Antibiotic Resistant Bacteria Accelerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Congressionally Directed Medical Research Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inhibrx:ScheduleOfLicenseAndGrantRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i92744c9c477a4e4ba89940a3d753b3b3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS0xLTEtMS0w_7ed00c99-b243-4a88-9219-49f9d7d0bdc9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4373a79ed10e41d296ee0962058ceb18_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS0zLTEtMS0w_bb95535e-678f-49af-b377-171cf3f151ff"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifab658b65d2b4e509ba7e6fbedd7ea7f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS01LTEtMS0w_c431438f-b6fa-49b7-8e97-0cd9a041432d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ca21b8ec7ba4cbbb974b0a2ed21beea_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNS03LTEtMS0w_2fadd8bb-b480-4ee3-b94e-dad4b7f6145c"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i120f8c853b1845998a75889f0c5bcfe9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0xLTEtMS0w_d336bdd3-a93d-4393-bd84-fe7d5c5aecd2"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bf43c32005f4158b0a144b53515e8f4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0zLTEtMS0w_378d5d54-6a2e-4921-8d6d-ad8daf9bfb43"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie739eb4e2f9d498a802def60014528b5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi01LTEtMS0w_aaf609ab-8c71-428e-9eb4-83fd168eb8df"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i356cf52c8b484b40b183fa4c374dd895_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi03LTEtMS0w_a1adad45-19b9-4ec8-b8aa-3c67da17f99c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45dd132e1b3a439c9b1a6235d9bb85e2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0xLTEtMS04MTg3_ef79e3ea-0fb5-4513-9e9d-e0c972cc698e"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0911529fc304f48ba356122d24789d2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi0zLTEtMS04MTg3_5ce002d6-672d-4457-82e1-4b50444a0e05"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefe55a942de0426eba7b59eec3f142f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi01LTEtMS03ODgw_f99fb79b-a996-4eb1-bfce-0d16834a4b26"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa06f7d2b0c24a02ae94a2059ca88a36_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfNi03LTEtMS03ODgy_a2649741-f998-4e33-9ae8-f840d17649fe"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0d8c3a4a6fb430e9f1f76dd0683680a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC0xLTEtMS0xMDE4NA_b909b037-8c61-48fc-b50f-ea70f8591d75"
      unitRef="usd">809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b8a55eee8e1430987c756c531fd2f92_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC0zLTEtMS0xMDE4NA_93cec983-d635-4604-9c5e-16476891b769"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd65ea0d77dd4536bd5211b76ed0f786_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC01LTEtMS0xMDE4NA_6290d890-2a4c-48d1-af4e-427f10ba80c7"
      unitRef="usd">809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbd2973e2e9248cd84da19d0ec58f321_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOC03LTEtMS0xMDE4NA_780aa69a-506a-4741-a242-7ad0d34a2b76"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0f4401ebc2846b4ae91adeae6e806d4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS0xLTEtMS0w_06fc1d23-72d4-4a14-81ae-dae51a7edd61"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib40770b8bf174b6f8619cbc166946dc4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS0zLTEtMS0w_f6607a99-2426-42f5-9a90-695ff1d87a66"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic46e3791b92d409bb00978ee31d2cbf5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS01LTEtMS0w_80906745-972d-4941-94ab-84433846b362"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f87004b4c11448b93df28c2392164ca_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfOS03LTEtMS0w_5a29e00a-9fc0-47a9-9e3e-f5ccbc204c23"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieacc3e428d0f429ba6530cfe19d2e300_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtMS0xLTEtMA_31420796-72fa-4aad-a337-30388df63011"
      unitRef="usd">1967000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cdcea5a7ee042059428f8230d335a2f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtMy0xLTEtMA_56dab255-fdcf-418d-908f-442de8081187"
      unitRef="usd">794000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i835a732af4b24c559cab997e0fc7e788_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtNS0xLTEtMA_5362c046-6018-4da2-b4b2-f6e0a8c1ade2"
      unitRef="usd">5773000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf8e3ff3da7b46a4ad695b6d2fdeaf72_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTAtNy0xLTEtMA_c2f0a8b9-5326-42ac-83ef-9c8220d3702d"
      unitRef="usd">794000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06e44a5c0664414894b59ef342a25530_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtMS0xLTEtMA_56bd66b8-05ee-4d93-8a12-1a80e9b415d0"
      unitRef="usd">1050000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6529f0b04b94b0bbe8a4aa98b0cca04_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtMy0xLTEtMA_f04ec5f3-0fc0-49a8-b989-3c7037eea362"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67731484d5f24597939db7a05b45c3e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtNS0xLTEtMA_e350832c-7299-4f7f-98d6-5765a0091e87"
      unitRef="usd">1050000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26a8d9ba96ce4164a0a1f5e705ce4880_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTEtNy0xLTEtMA_8008aac5-20cf-4489-b320-45635551f1c8"
      unitRef="usd">32000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48d81ecc28084fcdbc1204e113833fc8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItMS0xLTEtODE4Nw_a34b8360-27ac-48fe-a691-20e3ec498450"
      unitRef="usd">3826000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i257bc2317ed94a5281a528a81b5b8d35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItMy0xLTEtODE4Nw_3d7cbc52-fe14-49bf-a926-55201e1a6452"
      unitRef="usd">794000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie16213d344cb4afaa96412b15c0eedb6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItNS0xLTEtNzg4NA_f560baa5-e330-42c8-9742-c62540e4c629"
      unitRef="usd">8032000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icac09946014a4214af25c0e06ce6c6f6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTItNy0xLTEtNzg4Ng_3865e8b9-d3a7-4cae-ab71-2be2773d5d46"
      unitRef="usd">7826000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48c5f5eb489b4481b39ec65ca48ebfce_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtMS0xLTEtMA_4ddfe3c8-020f-4b35-8b3e-5e6adf863d13"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id880884b9ea94b869fb5816f6510e211_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtMy0xLTEtMA_0b700b75-a149-4e2b-a100-ad005d4c5bcb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f2e9de97d974ecc9e2ee333fb3c25e3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtNS0xLTEtMA_9ee09f2a-294b-4dc2-aa71-f264fd5d9b5b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e9b775d892046ed8cff1e30bad6547b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTQtNy0xLTEtMA_9a441bd2-501f-4dd2-968d-cc4dc6ecb066"
      unitRef="usd">880000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81510c3679774fff8f396fc3ab77fb74_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtMS0xLTEtMA_fd205bf2-ee38-4374-8b87-a728c626f2fa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81ebc7d152324a9ea5b0b3b86ab48f78_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtMy0xLTEtMA_5fdf76ae-2939-4167-b6cb-ef486825a7d6"
      unitRef="usd">364000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd19c4f689a94a488fadc52fb549283a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtNS0xLTEtMA_d1e80d79-5d4a-4ee9-b631-ed5269210b77"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5b52c38a8c44d49a69c3fcc734f8f2d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTUtNy0xLTEtMA_84630c09-d13c-45fe-9315-ed1a5098a639"
      unitRef="usd">3096000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ce2eacccd9044d788db421fc7a18c46_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtMS0xLTEtMA_67a474e7-dd9b-44e7-8934-7b3bcbaac3e6"
      unitRef="usd">75000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43aed1ced8c04ca78d779f9c16210fa8_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtMy0xLTEtMA_e892ccfb-1249-4d35-a7aa-69605ea7d352"
      unitRef="usd">61000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i113089823357421ab17799b937585703_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtNS0xLTEtMA_168f754d-dd79-4557-bdac-e3f8f1e102aa"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i822e016bcba04e979cf25eaaedefc7a6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTYtNy0xLTEtMA_ed7b3c90-996c-4587-9258-00868d17f0d0"
      unitRef="usd">146000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17fce0905feb4ca0a6d436f23bdb5a51_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctMS0xLTEtODE4Nw_7eb9d612-0da9-4523-b64c-b364fdfe22d8"
      unitRef="usd">75000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic597294d6b05480f9b87cfc8e153db62_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctMy0xLTEtODE4Nw_0287522c-4f93-4fb6-b84c-9c57e928ab15"
      unitRef="usd">425000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8caa9dd3e98483facac392f2f26d651_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctNS0xLTEtNzg4OA_867034bb-1903-4507-8a38-2f96e0ed4a7c"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i820a8e2822d74bbd82ecbf86ba928b9c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTctNy0xLTEtNzg5MA_f008466e-350a-4211-b77a-196542d906a1"
      unitRef="usd">4122000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtMS0xLTEtODE4Nw_4e48fa0c-09df-4abb-a14a-c5512e89447d"
      unitRef="usd">5901000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtMy0xLTEtODE4Nw_2015ffa5-2b9e-43d4-8745-1248c9fd4620"
      unitRef="usd">1219000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtNS0xLTEtNzg4OA_4023e3cb-dbef-42cf-bcbc-e671579b527d"
      unitRef="usd">10112000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RhYmxlOjQ0ODE1YTE2MWE4ODRkMDk4MDc5OGEwMzViOWQwZTMzL3RhYmxlcmFuZ2U6NDQ4MTVhMTYxYTg4NGQwOTgwNzk4YTAzNWI5ZDBlMzNfMTgtNy0xLTEtNzg5MA_9098492e-8a80-4fff-b83d-7aa4b524b6df"
      unitRef="usd">12948000</us-gaap:Revenues>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i5301fb930f5846abbe1ac0d7088d390c_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY2OA_612532a7-37b6-499d-9897-970806cc16ec"
      unitRef="usd">2500000</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inhibrx:CollaborativeArrangementAdditionalPaymentReceivable
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY3NQ_220be591-7ede-4f3d-bbe2-68c13d497daf"
      unitRef="usd">2500000</inhibrx:CollaborativeArrangementAdditionalPaymentReceivable>
    <inhibrx:CollaborativeArrangementAdditionalPaymentReceivablePeriod
      contextRef="i6de109f4840c4e22aafdac033f63ff7e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDE3Nw_b3bc01df-a4cc-47e7-84b6-fc4d31063fa5">P180D</inhibrx:CollaborativeArrangementAdditionalPaymentReceivablePeriod>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i678ba84787b74c33aaa1dabda2391b12_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY5MA_37037b3d-aa98-44d9-8994-a02c9c9f6049"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inhibrx:EquityMethodInvestmentAdditionalOwnershipEntitled
      contextRef="i678ba84787b74c33aaa1dabda2391b12_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY5NA_dd2f6739-0bec-42e0-82da-e318a39d26ab"
      unitRef="number">0.05</inhibrx:EquityMethodInvestmentAdditionalOwnershipEntitled>
    <inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTY5OA_9f2d3f88-0884-49e6-8549-3fdb2633e396"
      unitRef="usd">225000000.0</inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inhibrx:CollaborativeArrangementCommercializationMilestoneReceivable
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTcwNg_16689415-2bc8-4ca7-9bd7-de74c8e14b60"
      unitRef="usd">175000000.0</inhibrx:CollaborativeArrangementCommercializationMilestoneReceivable>
    <us-gaap:EquityMethodInvestments
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTcxNA_ceabf088-c9be-4a62-98b0-6988b0af7e28"
      unitRef="usd">500000</us-gaap:EquityMethodInvestments>
    <inhibrx:CollaborativeArrangementPaymentReceivable
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTcyNg_ae02d6c3-bfaf-4fbc-9ba7-f4ce86bbfd35"
      unitRef="usd">5000000.0</inhibrx:CollaborativeArrangementPaymentReceivable>
    <inhibrx:NumberOfPerformanceObligations
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NzczOA_be6f9313-2e1b-4a15-8c94-9cf7ea949655"
      unitRef="performanceobligation">1</inhibrx:NumberOfPerformanceObligations>
    <inhibrx:RevenueRecognitionNumberOfCompounds
      contextRef="i5067bf55c43b41a3a073d8ca0504a9cf_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1Nzc0Ng_371ea12d-662e-4fcf-b153-a4efe96097fe"
      unitRef="compound">2</inhibrx:RevenueRecognitionNumberOfCompounds>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ib0d8c3a4a6fb430e9f1f76dd0683680a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTczOA_1374a2b4-29ad-4188-b81d-b47730dea939"
      unitRef="usd">800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ifd65ea0d77dd4536bd5211b76ed0f786_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTczOA_80367917-f905-47a6-bcb1-9706ebd35543"
      unitRef="usd">800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i86854d401efc41658a1f7cabc6fbf75f_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMDg4NQ_5ea82066-907b-493c-9bfc-f04cfabf977e"
      unitRef="usd">7000000.0</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie2312287da4844f98353e533084710b1_D20190301-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMTEyNg_e3263c6e-a38a-4310-a40d-e5c7407fba5e"
      unitRef="usd">7000000.0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="i0f4f3ab77c814395bd909a08f8cdbd8b_I20181220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMTM0Mg_5ae63757-ba2f-4ba0-8d23-cda57a378427"
      unitRef="usd">51500000</inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="if0630b88591a432fb950d54e0c58af38_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI1NA_57f76f32-bf5d-4b61-9ddb-f2772f88c85c"
      unitRef="program">2</inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="ic3240262b0c843ab948e2324834e8f4a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI1Mg_d61e0df7-d9f7-4c4e-8f7e-b6b960504bd2"
      unitRef="program">8</inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i65e132a26c12432e9177650608108558_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMjQyNQ_a147fc77-4daa-4852-8efd-becce7e775ca"
      unitRef="usd">200000</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="ia9075aabe3384589aa3de96de0cec785_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMjQyNQ_b98a36cd-8385-4015-baee-437cebe4c7a0"
      unitRef="usd">200000</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="if0630b88591a432fb950d54e0c58af38_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MTQ3NQ_48374c26-afeb-4e55-8906-91bf8803a1ca"
      unitRef="program">2</inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i91ec1ec2abba44ff94474aa6f6a83271_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMjQ4NQ_c49599b3-78c9-4cfc-82c1-b0f13023f000"
      unitRef="usd">400000</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="i15bf51c282994899a1f5ce5fa7ed4e9e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzMzE5NA_c98df41a-794e-4d04-9517-16f28b4187b2"
      unitRef="usd">51500000</inhibrx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inhibrx:NumberOfPerformanceObligations
      contextRef="if0630b88591a432fb950d54e0c58af38_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMxMw_3481b11c-2831-4273-b057-6d35852059fd"
      unitRef="performanceobligation">1</inhibrx:NumberOfPerformanceObligations>
    <inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="if0630b88591a432fb950d54e0c58af38_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI2MA_848d77e1-b692-4144-8b26-6bd5262de192"
      unitRef="program">2</inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="ic3240262b0c843ab948e2324834e8f4a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI2Ng_8ab1b579-1cf8-4aec-b009-15e4eb6c38cd"
      unitRef="program">8</inhibrx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i91ec1ec2abba44ff94474aa6f6a83271_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzNDUyNQ_662bd949-276f-46f7-9d13-2dddc63afc8d"
      unitRef="usd">400000</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inhibrx:CollaborativeAgreementExclusiveDevelopmentLicenses
      contextRef="i15bf51c282994899a1f5ce5fa7ed4e9e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI3NA_73035365-f503-49da-a605-ed3edd00ca84"
      unitRef="license">2</inhibrx:CollaborativeAgreementExclusiveDevelopmentLicenses>
    <us-gaap:Revenues
      contextRef="i51e4a311ac19416ebf4f8e8ba3195ba7_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzNDYxMg_03b6d8e1-07ee-42ef-852b-3e197ed56485"
      unitRef="usd">400000</us-gaap:Revenues>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="if6d316a27f564f6c9455708922cd2566_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzOTk3Ng_e5c66099-9a2d-42a5-903a-2439528c5766"
      unitRef="usd">10000000.0</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inhibrx:CollaborativeArrangementAdditionalPaymentReceivable
      contextRef="i47ab1c4748ac4b588b54989d44e542db_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc0NQ_48f5b1fe-ab27-42f6-9d71-5418c655edf4"
      unitRef="usd">12500000</inhibrx:CollaborativeArrangementAdditionalPaymentReceivable>
    <inhibrx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="i47ab1c4748ac4b588b54989d44e542db_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAzNTcyNA_63bd12a0-4a3f-4dbf-83eb-110586835b7b"
      unitRef="usd">122500000</inhibrx:CollaborativeArrangementMilestonePaymentsReceivable>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1Nzc1NA_6b66b8da-c7b5-480c-a377-73395cdb62d9">The Company has identified one performance obligation as of the effective date of this agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#x2019;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company&#x2019;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#x2019;s delivery to Chiesi of the finalized minutes from the definitive parallel EMA-HTA scientific advice meeting conducted following completion of such Phase I Clinical Trial.</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <inhibrx:NumberOfPerformanceObligations
      contextRef="if7827c4c605f403c95b605cbe15393e7_I20190819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMxOQ_f7daf4c3-15e0-407a-aee3-56bcff666b82"
      unitRef="performanceobligation">1</inhibrx:NumberOfPerformanceObligations>
    <inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="if6d316a27f564f6c9455708922cd2566_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc1Mg_65b10ce3-2dff-47e3-8de3-b5d7f9eaa166"
      unitRef="usd">10000000.0</inhibrx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ieacc3e428d0f429ba6530cfe19d2e300_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc2Nw_3ad27990-af0b-4746-9125-2bebdc8ed547"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i6cdcea5a7ee042059428f8230d335a2f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc4MQ_5fd9598b-0e58-4de2-9439-d5486b80b9ed"
      unitRef="usd">800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i835a732af4b24c559cab997e0fc7e788_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc4NQ_15df77a7-bf72-41e5-8b66-20fe77adc6ee"
      unitRef="usd">5800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="iaf8e3ff3da7b46a4ad695b6d2fdeaf72_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTc5NA_045bf867-0b70-42c9-ac82-8764dfbf8abd"
      unitRef="usd">800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <inhibrx:NumberOfLicenseAgreements
      contextRef="i0531016c866d4a068e2358c8f73b0f39_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDI5NA_6734d2a2-788a-40e9-8998-dbe72c105974"
      unitRef="program">2</inhibrx:NumberOfLicenseAgreements>
    <inhibrx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="i83c3ddd258264ea38d9e7f8ee2affbb4_I20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxOTY2Mg_8d05aefe-3945-40ca-b656-953ea6495ceb"
      unitRef="usd">100000000.0</inhibrx:CollaborativeArrangementMilestonePaymentsReceivable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i75bd7c4152884c68b92109e363fdde3e_I20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMDM4MA_73a129c4-95ae-41c2-a239-bb63e4be8721"
      unitRef="usd">3000000.0</us-gaap:ContractWithCustomerLiability>
    <inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="i1f4aef1c0a3941d986e5b4bf56476cf9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTgxNA_9e2b13a4-0d1f-4d70-8aaf-f8e1e09d8562"
      unitRef="usd">0</inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="ia81f4833f5a946919ea5fac5c81bd331_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTgxOQ_7b4cfda1-ebf8-4769-9a18-ce43b2bf5331"
      unitRef="usd">700000</inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i530e97d213314faf9adf351089af9dca_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjE5OTAyMzM0Mjg1Ng_4c9a057b-2465-4e74-a8e4-d7af43bde217"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <inhibrx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="id7a2e84dab1f45e3bb160edd91676c7a_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMjA1Mg_a4e1c8c0-1758-4690-8fe3-5dff457860c7"
      unitRef="usd">100000000.0</inhibrx:CollaborativeArrangementMilestonePaymentsReceivable>
    <us-gaap:Revenues
      contextRef="i3cd4816ef076457ea37eb5b862932984_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTgzMw_ec6f095e-d206-46c3-8818-10182d64a575"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie739eb4e2f9d498a802def60014528b5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg0Mg_010cc48a-574e-4a63-a6c6-de3d63c1603d"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i120f8c853b1845998a75889f0c5bcfe9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg0Mg_441c9d75-0273-49cc-8c92-1b41f4539e8e"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bf43c32005f4158b0a144b53515e8f4_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MTQ2NQ_017ad484-b671-4e96-a443-a35c05dbbc92"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i356cf52c8b484b40b183fa4c374dd895_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MTQ2NQ_8df9bfc4-341f-471b-b68f-8e4ccea310d0"
      unitRef="usd">0</us-gaap:Revenues>
    <inhibrx:CollaborativeArrangementExpenseReimbursement
      contextRef="i24ef54ae4f554e239587b8661dc8a3c4_D20180801-20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMjczMg_68e2d5e0-e479-41d4-b1a4-19573f539819"
      unitRef="usd">3400000</inhibrx:CollaborativeArrangementExpenseReimbursement>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAyMzE2NA_28842dcd-0b35-4649-bd92-ba898fd0df5b"
      unitRef="usd">200000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4443a6f4f1e84d38b14ec1c139ca5267_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMzOQ_b7697360-cc3f-4cd5-9630-747fe4d4afe7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjc0ODc3OTE1NTMzOQ_f25256e4-3aa6-4a4d-a3f4-190ffd028575"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <inhibrx:CollaborativeArrangementExpenseReimbursement
      contextRef="i48d4b7b4251d42058175aaa32b17035e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg2Mg_100312a3-6985-4c85-b18e-2ca62fd53738"
      unitRef="usd">0</inhibrx:CollaborativeArrangementExpenseReimbursement>
    <inhibrx:CollaborativeArrangementExpenseReimbursement
      contextRef="id08c3ccad96d44bea3c92b45810c37f3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg2Nw_b8a7d68e-970e-4831-9797-3e6d58f58850"
      unitRef="usd">200000</inhibrx:CollaborativeArrangementExpenseReimbursement>
    <inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="i3a9dc418ead24b64bb8341e1299808f8_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg4MA_c4d57adc-28ba-4e19-85ac-5da2bf2c3978"
      unitRef="usd">100000</inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="ife0bac45fcb24762a17738da0331eeb2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg4NA_1f96c3fe-173d-4e21-a176-49443e7f6ec8"
      unitRef="usd">1300000</inhibrx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inhibrx:CollaborativeArrangementAdditionalPaymentReceivable
      contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg5Mw_21318be1-b33f-4ce1-9bfa-4770613b6646"
      unitRef="usd">100000</inhibrx:CollaborativeArrangementAdditionalPaymentReceivable>
    <us-gaap:Revenues
      contextRef="i8d67a9e6f56b4ed58267e24b66936168_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxMTk4OA_bc728cb8-fa5a-44ea-84d3-b5ba6c219e4f"
      unitRef="usd">1000000.0</us-gaap:Revenues>
    <inhibrx:CollaborativeArrangementForeignTaxWithholding
      contextRef="i8d67a9e6f56b4ed58267e24b66936168_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxMjAzOQ_dffd129a-e130-4914-a876-d788cdb0e86e"
      unitRef="usd">100000</inhibrx:CollaborativeArrangementForeignTaxWithholding>
    <inhibrx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="i9bd3c6489f044c5f983e14ec05aca582_I20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNjA0NzMxNDAxMjI0Ng_4786d37e-d776-45d1-9f9e-8043b8d890ec"
      unitRef="usd">100000000.0</inhibrx:CollaborativeArrangementMilestonePaymentsReceivable>
    <inhibrx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="i2c665a21a67f4bba8893929943f5f8d3_I20130630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMTg0NDY_4d93cf5c-6c07-4fae-8b3f-abe56e9ef591"
      unitRef="usd">934100000</inhibrx:CollaborativeArrangementMilestonePaymentsReceivable>
    <inhibrx:CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay
      contextRef="i2c665a21a67f4bba8893929943f5f8d3_I20130630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNzY5NjU4MTQ4MDMwMQ_5506b78c-ed46-4583-b6d4-d55f54e5ae27"
      unitRef="number">0.02</inhibrx:CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay>
    <inhibrx:GrantValuedAwarded
      contextRef="iaa0c1f1f0a744b53a8d4ea48cd955591_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMTk0ODE_47ffdd12-7764-494a-94f0-11ab5ea565b0"
      unitRef="usd">1000000.0</inhibrx:GrantValuedAwarded>
    <inhibrx:GrantValuedAwarded
      contextRef="ibe47e6db9f494550ba03c3a1ee101b76_I20170731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjA2MDQ_4cf6c4e9-551f-4ab8-9f56-e8fe246581fa"
      unitRef="usd">4600000</inhibrx:GrantValuedAwarded>
    <inhibrx:GrantAwardedPaymentStructurePercentageReimbursedBySponsor
      contextRef="ibe47e6db9f494550ba03c3a1ee101b76_I20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjExNjI_79529fcc-bf05-4779-bb14-47f4657426bd"
      unitRef="number">0.70</inhibrx:GrantAwardedPaymentStructurePercentageReimbursedBySponsor>
    <inhibrx:GrantAwardedPaymentStructurePercentageCoveredByCompany
      contextRef="ibe47e6db9f494550ba03c3a1ee101b76_I20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjEyNDY_91727c77-4203-4c98-96a0-8f20929b4f6c"
      unitRef="number">0.30</inhibrx:GrantAwardedPaymentStructurePercentageCoveredByCompany>
    <us-gaap:Revenues
      contextRef="i1e0b1022232b4f71b8972eb5887adc42_D20171001-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjE5Mjc_acd59cd6-59a0-4d94-af26-99a0a7c4ba7d"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <inhibrx:GrantValuedAwarded
      contextRef="ia13e3186ca28469286c7cee39c4a772a_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfMjIyMzM_58023eec-9f55-490d-8433-66f4415ec3dd"
      unitRef="usd">300000</inhibrx:GrantValuedAwarded>
    <us-gaap:Revenues
      contextRef="ia36fb85c03c24ea8a91837247d809173_D20180901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTg5OQ_69df0616-e37a-4bb7-bea6-f505704739dd"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c7c69c38154458b921c096178efb2ad_D20180901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81NS9mcmFnOmJmMTdjODJiZmRmNTRhMTdiOGY4Yjc2ZGFkMmZiYWExL3RleHRyZWdpb246YmYxN2M4MmJmZGY1NGExN2I4ZjhiNzZkYWQyZmJhYTFfNTQ5NzU1ODIyNTkwOA_ec4b6d7a-3758-4c57-a2f2-e341dfea102e"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4MA_191f978e-7e52-40ee-b42b-1888c3563346">RELATED PARTY TRANSACTIONS &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company&#x2019;s Board of Directors or a committee thereof pursuant to policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LAV Summit Limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LAV Summit Limited (&#x201c;LAV SL&#x201d;), a limited company, is a principal shareholder owning more than 5% of the Company&#x2019;s outstanding equity interest as of September&#160;30, 2020 and December&#160;31, 2019. Due to this equity ownership, LAV SL is considered a related party. Moreover, Judith Li, a former member of the Company&#x2019;s board of directors, is a Partner at LAV SL&#x2019;s General Partner, Lilly Asia Ventures (&#x201c;LAV&#x201d;), a biomedical venture capital firm. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, the Company entered into the Transcenta License Agreement. LAV, through one of its funds, holds a significant equity ownership position in Transcenta. During the three and nine months ended September 30, 2019, the Company recorded revenue of $0 and $1.0&#160;million related to this agreement. During the three and nine months ended September 30, 2020, the Company recorded no revenue related to this agreement. See Note 8 for further discussion of this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into the PD-L1 and 4-1BB License Agreement with Elpiscience. LAV, through one of its funds, holds a significant equity ownership position in Elpiscience and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identifies Elpiscience as a related party. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred for which Elpiscience has paid the Company $4.7 million to date as of September&#160;30, 2020 and December&#160;31, 2019. During the three and nine months ended September 30, 2020 and 2019, the Company recorded no revenue related to this agreement. See Note 8 for further discussion of this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into the OX40 License Agreement with Elpiscience. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred for which Elpiscience has paid the Company approximately $5.1 million and $4.9 million to date as of September&#160;30, 2020 and December&#160;31, 2019, respectively. During the three and nine months ended September 30, 2020, the Company recorded $2.0&#160;million of revenue related to this agreement. During the three and nine months ended September 30, 2019, the Company recorded no revenue related to this agreement. See Note 8 for further discussion of this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WuXi Biologics Healthcare Venture&lt;/span&gt;&lt;/div&gt;WuXi Biologics Healthcare Venture (&#x201c;WuXi Bio HV&#x201d;) is a corporate venture arm of WuXi Biologics, with whom the Company has an existing Exclusivity Agreement. In January 2019, WuXi Bio HV purchased 1.7 million shares of the Company&#x2019;s Series Mezzanine 2 Preferred Stock at a purchase price of $6.98 per share, for a purchase price of $12.0 million. These shares converted to common stock upon the consummation of the Company&#x2019;s IPO in August 2020. See Note 6 for further discussion of Preferred Stock transactions.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <inhibrx:RelatedPartyEquityInterestInCompany
      contextRef="ie752799339b24161bced2a3798bf9a4d_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzQyMw_4da1f390-b24a-4243-9981-91c041c53669"
      unitRef="number">0.05</inhibrx:RelatedPartyEquityInterestInCompany>
    <inhibrx:RelatedPartyEquityInterestInCompany
      contextRef="i3cf1efa19e3548d48a2df125b2ba8d78_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzQyMw_9673b8f2-6be7-47d8-bde7-cc63642c7509"
      unitRef="number">0.05</inhibrx:RelatedPartyEquityInterestInCompany>
    <us-gaap:Revenues
      contextRef="i4373a79ed10e41d296ee0962058ceb18_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1Njg3OA_73f16ea5-e3ad-4ddd-bd16-ff1e99c3a409"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ca21b8ec7ba4cbbb974b0a2ed21beea_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1Njg4Ng_a0616272-8aaf-4e8d-bc18-571e4cefb853"
      unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifab658b65d2b4e509ba7e6fbedd7ea7f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mw_5e8ece35-518d-412b-88fb-779ce818065d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92744c9c477a4e4ba89940a3d753b3b3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mw_9db28a13-1a28-49fe-8433-832978aca804"
      unitRef="usd">0</us-gaap:Revenues>
    <inhibrx:ExpensesReimbursedToDate
      contextRef="if8bd613f072f461db198c9f9f272863d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMTczMg_55ac770f-15ef-4e58-8bbb-22be30ccb562"
      unitRef="usd">4700000</inhibrx:ExpensesReimbursedToDate>
    <inhibrx:ExpensesReimbursedToDate
      contextRef="iabfd8187536c4daf96510c57f57bade2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMTczMg_56fc0241-8503-4b4d-9106-62e047fdf880"
      unitRef="usd">4700000</inhibrx:ExpensesReimbursedToDate>
    <us-gaap:Revenues
      contextRef="i36cb4e41c5bb48e89203d72ff7e9ad71_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_25f0f351-fb56-4e28-91e5-2f482ab44aca"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia81f4833f5a946919ea5fac5c81bd331_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_783dbcec-6a1c-44de-8af4-736b33f637ec"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f4aef1c0a3941d986e5b4bf56476cf9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_db611474-33ab-4661-a533-8e458f3aae15"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief513a4e2d6b4dff83e12409769524ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM4Mg_f425d0b3-56d4-471a-bab2-b2ad6336e537"
      unitRef="usd">0</us-gaap:Revenues>
    <inhibrx:ExpensesReimbursedToDate
      contextRef="id25843c5c03943bca5950d2498fcf7fc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE0NTg3Mg_3cbca1e8-4ed6-4bfb-88aa-1fa12bd6474d"
      unitRef="usd">5100000</inhibrx:ExpensesReimbursedToDate>
    <inhibrx:ExpensesReimbursedToDate
      contextRef="i4443a6f4f1e84d38b14ec1c139ca5267_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjMyNQ_83ce0898-090e-49e1-895b-92ad26764422"
      unitRef="usd">4900000</inhibrx:ExpensesReimbursedToDate>
    <us-gaap:Revenues
      contextRef="i48d4b7b4251d42058175aaa32b17035e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1NzAxNA_41ad8471-8a50-4d75-ad20-98f88c0e1c35"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id08c3ccad96d44bea3c92b45810c37f3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1NzAxNA_f34f627b-4d36-4c30-8c3e-65806bc69c4b"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife0bac45fcb24762a17738da0331eeb2_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM5Mg_3c8e9f48-451d-4a78-8c33-9efa35292541"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a9dc418ead24b64bb8341e1299808f8_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfMjc0ODc3OTA4NzM5Mg_b9f15e22-a36f-4925-8c95-59f882bfaa52"
      unitRef="usd">0</us-gaap:Revenues>
    <inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1debe51ec3e946f19e9ced16e42dc5e1_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1MDU2Ng_c24a0bbb-1303-40fe-b12a-65bbe3049fc2"
      unitRef="shares">1700000</inhibrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="id456e841f6ea429782b9752a0983fce5_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1NzAwNg_0b23ae3c-1c58-4d0a-bc52-05a56b69a150"
      unitRef="usdPerShare">6.98</us-gaap:SharePrice>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1debe51ec3e946f19e9ced16e42dc5e1_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV81OC9mcmFnOjM5ZjkwNzM2MzZlOTRjMTdhNDYyODM5MDNhOTE4MjVkL3RleHRyZWdpb246MzlmOTA3MzYzNmU5NGMxN2E0NjI4MzkwM2E5MTgyNWRfNTQ5NzU1ODE1MDgxNw_2b646a99-10a8-413a-95e6-395ac288c13d"
      unitRef="usd">12000000.0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU0NA_49395d05-5ebc-44fd-b97f-c90e10cb1d2c">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company entered into a seven-year lease agreement for approximately 34,000 square feet as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company executed an amendment to its lease agreement to expand its facilities by approximately 9,000 square feet and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset and operating lease liability as of September&#160;30, 2020 and December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2020 and 2019, the Company recognized operating lease expense of $0.8&#160;million and $0.6&#160;million, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized operating lease expense of $2.3&#160;million and $1.7&#160;million, respectively. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s operating lease had a remaining term of 4.8 and 5.5 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% and 8.0% as of September&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental payments under operating leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (3 months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s condensed consolidated balance sheets, condensed consolidated statements of operations, or condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU2MQ_92c97c9c-ed04-4deb-a943-45c0a8026ce2">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <inhibrx:LesseeOperatingLeaseSquareFootage
      contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMTE0_4459481e-dd36-4258-ad88-89a6ad3f3bab"
      unitRef="sqft">34000</inhibrx:LesseeOperatingLeaseSquareFootage>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU3Ng_15406a38-0f61-4555-a043-3bd99303d94f">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <inhibrx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth
      contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMzE4_6f95ff40-e878-43fc-84ec-badfd1681b7c"
      unitRef="usd">100000</inhibrx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth>
    <inhibrx:LesseeOperatingLeaseAnnualEscalations
      contextRef="iec507b082f8043d7944a7cd34a09a823_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMzM2_18e6e481-1083-4df7-9922-c906165262ec"
      unitRef="number">0.02</inhibrx:LesseeOperatingLeaseAnnualEscalations>
    <inhibrx:LesseeOperatingLeaseSquareFootageExpansion
      contextRef="i9382d50f269442c59ff29a8133e54f76_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNjUx_fc63a6ff-6ebd-41ea-8b7e-3e595a67fdaa"
      unitRef="sqft">9000</inhibrx:LesseeOperatingLeaseSquareFootageExpansion>
    <inhibrx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth
      contextRef="i9382d50f269442c59ff29a8133e54f76_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfODMx_566a078b-080a-48be-80fd-cb63f1473fd8"
      unitRef="usd">30000</inhibrx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth>
    <inhibrx:LesseeOperatingLeaseAnnualEscalations
      contextRef="i9382d50f269442c59ff29a8133e54f76_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfODQ5_1a34c3ea-bf0d-423c-8bdb-60ad087923c1"
      unitRef="number">0.02</inhibrx:LesseeOperatingLeaseAnnualEscalations>
    <inhibrx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU0NQ_5fdec110-6589-49df-b137-8484b74ba083">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset and operating lease liability as of September&#160;30, 2020 and December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inhibrx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfMi0xLTEtMS01MzYz_f6bb3754-b251-4220-8f3f-d86694b08454"
      unitRef="usd">8185000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfMi0zLTEtMS01Mzc5_d6f48d8c-8694-49a7-89cd-7e3ca479b03e"
      unitRef="usd">7453000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNS0xLTEtMS01MzY2_ff3ca329-ade2-4dc1-85dc-dfebb4cf24e3"
      unitRef="usd">1463000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNS0zLTEtMS01Mzg1_9d0a76a7-8c7a-465b-9a7a-68903ce71eff"
      unitRef="usd">1105000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNi0xLTEtMS01MzY2_a0280763-ed36-48b7-b0a2-140e59d87aee"
      unitRef="usd">7097000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfNi0zLTEtMS01Mzg1_325ec6c6-c6c7-4a9c-b0d2-c57c33dbc586"
      unitRef="usd">6698000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfOS0xLTEtMS04NDMz_92d2c090-a252-4940-92a2-44b25d1d4221"
      unitRef="usd">8560000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOmZlODZhZmQ4YzIxMDRiZTM5MjNmZDU2ZDZhODNlZDA0L3RhYmxlcmFuZ2U6ZmU4NmFmZDhjMjEwNGJlMzkyM2ZkNTZkNmE4M2VkMDRfOS0zLTEtMS04NDMz_d3dcdf5d-0522-4d97-b2e0-aa77a31bc1e3"
      unitRef="usd">7803000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjAzMg_d26581f4-bebf-4c19-989d-158335575b44"
      unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8f766f450c354532a6fbb4a74cb7f8b3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjA0MQ_567a773e-f854-4f2f-af74-daa3eb5353d8"
      unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjA0NQ_0612b8fe-89ed-4c2c-bcda-1dea689b6831"
      unitRef="usd">2300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2d59ffa9fdc644e1b30b90191a53b21a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0NjA0OQ_e5cf5da9-a2c8-4186-8976-ec7a517e9d8f"
      unitRef="usd">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0MTU4MQ_417b043d-c8bb-4af6-b267-9fe335875691">P4Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0MTU4NQ_675ae60b-a150-48ed-8900-5c73532a23a5">P5Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfNTQ5NzU1ODE0MTU5Mg_b0aab395-5369-4d4e-b2ab-83f81d87dcb8"
      unitRef="number">0.082</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMTk2Mg_bd1e8f36-72f3-492d-816b-edcbf3a58186"
      unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RleHRyZWdpb246ZjA0Yzc0MThmMjU4NDA4YzgwMzg2NGNkNWVjM2I0NWZfMjc0ODc3OTA3NjU0Ng_ef75d4ed-250a-41d4-bbee-d68cd45d5518">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental payments under operating leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;AS OF SEPTEMBER 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (3 months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMy0yLTEtMS0w_d4f55dd1-5335-413f-ba0e-d81a3fe921a9"
      unitRef="usd">522000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNC0yLTEtMS0w_621a97c0-29ee-4970-a3dd-cb8e214ff2ad"
      unitRef="usd">2119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNS0yLTEtMS0w_d2cbc6af-a02a-484b-96ec-e7699c133094"
      unitRef="usd">2161000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNi0yLTEtMS0w_116f0f6b-eece-408e-9783-55ed2c54cc64"
      unitRef="usd">2203000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfNy0yLTEtMS0w_9430be79-1984-4f66-8309-31fe52ee8179"
      unitRef="usd">2247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <inhibrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfOC0yLTEtMS0w_acdd707b-e160-4650-b153-14969177fa5f"
      unitRef="usd">1137000</inhibrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTAtMS0xLTEtODQ1Nw_4c4c8ec1-e0f2-486d-9ef0-a5211d44b000"
      unitRef="usd">10389000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTAtMi0xLTEtMA_81d89591-581b-43b3-b67b-70b45b4b8046"
      unitRef="usd">1829000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTItMS0xLTEtODQ1Nw_86d04d80-ffd9-423a-ab29-688e7d6ac22f"
      unitRef="usd">8560000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTItMi0xLTEtMA_5d7b6e28-e4ec-4e44-8de0-82e9177daa01"
      unitRef="usd">1463000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV82NC9mcmFnOmYwNGM3NDE4ZjI1ODQwOGM4MDM4NjRjZDVlYzNiNDVmL3RhYmxlOjNhOGI2ZDg0MzI2NzQ5ZGQ4ZDBkYmM3MTAzYmNiMDY0L3RhYmxlcmFuZ2U6M2E4YjZkODQzMjY3NDlkZDhkMGRiYzcxMDNiY2IwNjRfMTQtMS0xLTEtODQ1Nw_71b30faa-7e33-4f7c-be30-324c8f388dc6"
      unitRef="usd">7097000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83MC9mcmFnOmUwOTI3YmM1YjJlMDRjZmY5ZGU2YzY0NGQ0YTFkZmU3L3RleHRyZWdpb246ZTA5MjdiYzViMmUwNGNmZjlkZTZjNjQ0ZDRhMWRmZTdfNzY5NjU4MTM5NzA4Ng_bd9a0f2a-aa85-44d2-9803-f39772f79f71">COVID-19&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19 outbreak&#x201d;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The continued spread of the COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#x2019;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&#x2019;s therapeutic candidates and the conduct of future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the FDA which could result in delays in meetings, reviews and approvals, including with respect to any of the Company&#x2019;s therapeutic candidates. For example, as a result of the COVID-19 pandemic patient travel restrictions, the Company temporarily suspended patient enrollment for its trial for INBRX-101 during the second and third quarters of 2020. Additionally, while the potential economic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#x2019;s ability to access capital, which could negatively impact the Company&#x2019;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or future clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#x2019;s business, financial condition, results of operations and prospects, and those of the third parties relied upon by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CARES Act&lt;/span&gt;&lt;/div&gt;On March 27, 2020, the U.S. federal government enacted the CARES Act, which includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;The CARES Act also includes provisions for PPP loans administered by the SBA. The Company applied for and received PPP funds. See Note 4 and Note 12 for further discussion of the Company&#x2019;s PPP loan. The Company will continue to examine and evaluate any impacts the CARES Act and associated subsequent legislation may have on its business and taxes.</us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTA4NDg3Nw_e69f67a6-6e0e-4da8-bb68-a1b4b7fe079f">SUBSEQUENT EVENTS &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the unaudited condensed consolidated financial statements as of September&#160;30, 2020, the Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these condensed consolidated financial statements, other than disclosures related to those outlined below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PPP Loan Repayment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, after receiving proceeds from its IPO, the Company repaid its PPP Loan in full. As of the repayment date, the Company had accrued approximately $7,400 of interest, for a total repayment of $1.9&#160;million. As discussed in Note 4, there were no prepayment penalties associated with the payment of the loan prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to the 2020 Loan Agreement with Oxford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 12, 2020, the Company entered into the First Amendment to the 2020 Loan Agreement with Oxford (the &#x201c;2020 Loan Amendment&#x201d;). The 2020 Loan Amendment provides for two additional tranches of term loans in an aggregate principal amount of up to $40.0&#160;million, as follows: (a) the second tranche in an aggregate principal amount of $20.0&#160;million, funded upon the closing of the 2020 Loan Amendment (&#x201c;Tranche B&#x201d;), and (b) the third tranche in an aggregate principal amount of $20.0&#160;million to fund on or before September 30, 2021, subject to the initiation of a registration-enabling trial for the Company&#x2019;s therapeutic candidate, INBRX-109, in chondrosarcoma, pursuant to the terms of the 2020 Loan Amendment (&#x201c;Tranche C&#x201d;). Tranche B and Tranche C are in addition to the first tranche of term loans in an aggregate principal amount of $10.0&#160;million, which was funded on July 15, 2020. In accordance with the 2020 Loan Amendment, the Company paid a one-time first amendment fee of $0.7&#160;million. The terms of the first tranche under the 2020 Loan Agreement were modified to align with Tranche B pursuant to the 2020 Loan Amendment.&lt;/span&gt;&lt;/div&gt;The outstanding term loan will mature on November 1, 2025 (the &#x201c;Amended Maturity Date&#x201d;) and bears interest at a floating per annum rate equal to the greater of (1)&#160;7.96%&#160;and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii)&#160;7.80%. The repayment schedule provides for interest-only payments until January 1, 2024. Upon funding of Tranche C, the interest-only payments may be extended by 12 months to January 1, 2025. The interest-only period is followed by 23 months of equal payments of principal and interest, or if the interest-only period is extended, by 11 months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:InterestPayableCurrent
      contextRef="i29539df2bfdf4e7080d49e945e09a68a_I20201031"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfNTQ5NzU1ODE2MTI4Ng_20846723-e2f0-4563-ab0e-f3f1a57140ff"
      unitRef="usd">7400</us-gaap:InterestPayableCurrent>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i434a60e482d64431a96e2d34a17d0b06_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfNTQ5NzU1ODE2MTMxNA_516278aa-8821-48ee-a41b-4ccc850b1ce9"
      unitRef="usd">1900000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifb4a4c41e60c471987fc84b082722cf4_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjE5OTAyMzI4ODQ1OA_5604152a-eaaa-4d69-b983-f01f3d4a0883"
      unitRef="usd">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic11ebf603f344bfeb2b655dcddb72921_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTM5Ng_76e367d9-3e33-45f8-b584-3c72b785bd77"
      unitRef="usd">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i48109ca4da0c44b1b47c9c968a9d401d_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQxMQ_acfce076-50ab-478d-b20d-ab74dd2da748"
      unitRef="usd">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i893ad457259b4931a5c0ce26c8fb0c92_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjE5OTAyMzI4ODQ0Mw_bcce83f1-bd04-4ce4-8b08-2d51b553f5a2"
      unitRef="usd">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i749adb0c10a241f59042990471fbddfe_D20201112-20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQyNg_a1c04360-6b03-4e1c-943e-216d9ca5b687"
      unitRef="usd">700000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <inhibrx:DebtInstrumentInterestRateFloor
      contextRef="i893ad457259b4931a5c0ce26c8fb0c92_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQ3NA_f413b1dd-84da-403d-941b-c04185c0a91a"
      unitRef="number">0.0796</inhibrx:DebtInstrumentInterestRateFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie0b6adb629804b27bc064abbdf18bbbb_D20200715-20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQ4MQ_23919aac-e05c-4dc4-9a8b-33a4b81f6119"
      unitRef="number">0.0780</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <inhibrx:DebtInstrumentInterestOnlyPaymentsExtendedTerm
      contextRef="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTUyNw_9f8fb70b-483c-46e1-be5c-bc2c0f2bb017">P12M</inhibrx:DebtInstrumentInterestOnlyPaymentsExtendedTerm>
    <inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod
      contextRef="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTUwNw_5e5352a9-f9db-4f25-84b0-2f500e2af6f9">P23M</inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod>
    <inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm
      contextRef="i6d79283b3fcb4eda83f4be2ec35b57ae_D20201112-20201112"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTU0Nw_38751572-cb22-4870-b6f4-e9b86c875708">P11M</inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm>
    <inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue
      contextRef="i1dc414bff1c84c9089ef103ad34b6d98_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMTQ4OA_69c1746b-b96a-479e-9102-3597e47226bb"
      unitRef="number">0.090</inhibrx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue>
    <inhibrx:DebtInstrumentPrepaymentFee
      contextRef="i6760108879a84be9ad67b709f7c52557_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMjMxMQ_a6fbe717-0b3c-467b-8547-abc509dfaa5e"
      unitRef="number">0.010</inhibrx:DebtInstrumentPrepaymentFee>
    <inhibrx:DebtInstrumentPrepaymentFee
      contextRef="i76849810b9be4460b784e44f45823ceb_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV83My9mcmFnOjMzNWY4NWViMDMzODRhM2U4NzljODI3YmRiZmJkNGYzL3RleHRyZWdpb246MzM1Zjg1ZWIwMzM4NGEzZTg3OWM4MjdiZGJmYmQ0ZjNfMjc0ODc3OTEwMjMxNw_8a3b6bea-8799-42fc-9cd8-6ba6711b2539"
      unitRef="number">0.030</inhibrx:DebtInstrumentPrepaymentFee>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610465864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INHIBRX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4257312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11025 N. Torrey Pines Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">795-4220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INBX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,712,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334609936408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 127,669,000<span></span>
</td>
<td class="nump">$ 11,540,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">681,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivables from related parties</a></td>
<td class="nump">283,000<span></span>
</td>
<td class="nump">239,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,217,000<span></span>
</td>
<td class="nump">3,583,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">131,850,000<span></span>
</td>
<td class="nump">15,561,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,274,000<span></span>
</td>
<td class="nump">3,230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">8,185,000<span></span>
</td>
<td class="nump">7,453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,554,000<span></span>
</td>
<td class="nump">26,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,186,000<span></span>
</td>
<td class="nump">3,115,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,037,000<span></span>
</td>
<td class="nump">4,832,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">5,176,000<span></span>
</td>
<td class="nump">7,939,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,563,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,463,000<span></span>
</td>
<td class="nump">1,105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Paycheck Protection Program loan</a></td>
<td class="nump">1,875,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,737,000<span></span>
</td>
<td class="nump">20,570,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, net of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,367,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,916,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current portion of deferred revenue</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-term debt, net of current portion and including final payment fee</a></td>
<td class="nump">9,821,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">7,097,000<span></span>
</td>
<td class="nump">6,698,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">51,825,000<span></span>
</td>
<td class="nump">60,551,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.0001 par value; no and 25,765,000 shares authorized at September&#160;30, 2020 and December&#160;31, 2019, respectively; no and 12,534,331 shares issued and outstanding at September&#160;30, 2020 and December&#160;31, 2019 respectively; liquidation preferences of $0 and $87.5 million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,507,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 15,000,000 and no shares authorized at September&#160;30, 2020 and December&#160;31, 2019; no shares issued or outstanding.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 and 65,000,000 shares authorized as of September&#160;30, 2020 and December&#160;31, 2019, respectively; 37,710,190 and 18,154,119 issued and outstanding as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">219,455,000<span></span>
</td>
<td class="num">(24,316,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(127,730,000)<span></span>
</td>
<td class="num">(69,255,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">91,729,000<span></span>
</td>
<td class="num">(93,569,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 143,554,000<span></span>
</td>
<td class="nump">$ 26,489,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334530484616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,765,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Issuance of Mezzanine Preferred Stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,534,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,534,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preferences</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 87,489,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">37,710,190<span></span>
</td>
<td class="nump">18,154,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">37,710,190<span></span>
</td>
<td class="nump">18,154,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610237272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 5,901<span></span>
</td>
<td class="nump">$ 1,219<span></span>
</td>
<td class="nump">$ 10,112<span></span>
</td>
<td class="nump">$ 12,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,837<span></span>
</td>
<td class="nump">12,785<span></span>
</td>
<td class="nump">55,827<span></span>
</td>
<td class="nump">35,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,459<span></span>
</td>
<td class="nump">14,266<span></span>
</td>
<td class="nump">60,448<span></span>
</td>
<td class="nump">40,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,558)<span></span>
</td>
<td class="num">(13,047)<span></span>
</td>
<td class="num">(50,336)<span></span>
</td>
<td class="num">(27,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(4,428)<span></span>
</td>
<td class="num">(2,670)<span></span>
</td>
<td class="num">(10,284)<span></span>
</td>
<td class="num">(3,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,476)<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
<td class="num">(3,476)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(4,452)<span></span>
</td>
<td class="num">(6,216)<span></span>
</td>
<td class="num">(7,652)<span></span>
</td>
<td class="num">(6,937)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income tax expense</a></td>
<td class="num">(20,010)<span></span>
</td>
<td class="num">(19,263)<span></span>
</td>
<td class="num">(57,988)<span></span>
</td>
<td class="num">(34,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,497)<span></span>
</td>
<td class="num">$ (20,163)<span></span>
</td>
<td class="num">$ (58,475)<span></span>
</td>
<td class="num">$ (35,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to Inhibrx, Inc., basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.78)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding, basic and diluted (in shares)</a></td>
<td class="nump">26,750<span></span>
</td>
<td class="nump">18,154<span></span>
</td>
<td class="nump">21,019<span></span>
</td>
<td class="nump">18,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 5,826<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 10,032<span></span>
</td>
<td class="nump">$ 8,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 4,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334520464632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>2019 and 2020 Notes</div></th>
<th class="th"><div>2019 Convertible Note</div></th>
<th class="th"><div>2020 Convertible Note</div></th>
<th class="th"><div>COMMON STOCK</div></th>
<th class="th">
<div>COMMON STOCK </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th">
<div>COMMON STOCK </div>
<div>2019 and 2020 Notes</div>
</th>
<th class="th"><div>ADDITIONAL PAID-IN CAPITAL</div></th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>2019 and 2020 Notes</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>2019 Convertible Note</div>
</th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>2020 Convertible Note</div>
</th>
<th class="th"><div>ACCUMULATED DEFICIT</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2018</a></td>
<td class="nump">10,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Dec. 31, 2018</a></td>
<td class="nump">$ 47,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Mezzanine Preferred Stock (in shares)</a></td>
<td class="nump">1,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Mezzanine Preferred Stock</a></td>
<td class="nump">$ 11,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Mar. 31, 2019</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Mar. 31, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(57,643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,847)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="num">$ (60,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,702)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2018</a></td>
<td class="nump">10,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Dec. 31, 2018</a></td>
<td class="nump">$ 47,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Sep. 30, 2019</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Sep. 30, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(57,643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="num">$ (78,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2018</a></td>
<td class="nump">10,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Dec. 31, 2018</a></td>
<td class="nump">$ 47,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Dec. 31, 2019</a></td>
<td class="nump">12,534,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Dec. 31, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (57,643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,855)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">18,154,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">$ (93,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,255)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Mar. 31, 2019</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Mar. 31, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Jun. 30, 2019</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Jun. 30, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="num">(60,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,085)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="num">$ (59,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,787)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Sep. 30, 2019</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Sep. 30, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,163)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="num">$ (78,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2019</a></td>
<td class="nump">12,534,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Dec. 31, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Mar. 31, 2020</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Mar. 31, 2020</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">18,154,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (93,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,093)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">$ (112,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2019</a></td>
<td class="nump">12,534,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Dec. 31, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Sep. 30, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Sep. 30, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">18,154,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (93,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">37,710,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 91,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Mar. 31, 2020</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Mar. 31, 2020</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Jun. 30, 2020</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Jun. 30, 2020</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="num">(112,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,885)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="num">$ (126,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of preferred shares (in shares)</a></td>
<td class="num">(12,534,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of preferred shares</a></td>
<td class="num">$ (59,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Sep. 30, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Sep. 30, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of shares upon exercise of stock options</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares in IPO, net of issuance costs</a></td>
<td class="nump">125,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,211,000<span></span>
</td>
<td class="nump">4,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="nump">$ 59,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,506<span></span>
</td>
<td class="nump">$ 59,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,332)<span></span>
</td>
<td class="num">$ (2,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,332)<span></span>
</td>
<td class="num">$ (2,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liabilities to equity</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,497)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">37,710,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 91,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (127,730)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334535415448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,497)<span></span>
</td>
<td class="num">$ (20,093)<span></span>
</td>
<td class="num">$ (20,163)<span></span>
</td>
<td class="num">$ (3,847)<span></span>
</td>
<td class="num">$ (58,475)<span></span>
</td>
<td class="num">$ (35,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,046<span></span>
</td>
<td class="nump">3,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NoncashOperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,651)<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="num">(1,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="num">(848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,605<span></span>
</td>
<td class="num">(3,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,196<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(995)<span></span>
</td>
<td class="num">(746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,250)<span></span>
</td>
<td class="nump">8,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent', window );">Deferred revenue, non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(830)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,579)<span></span>
</td>
<td class="num">(20,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(752)<span></span>
</td>
<td class="num">(1,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(752)<span></span>
</td>
<td class="num">(1,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering', window );">Costs associated with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,558)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt', window );">Deferred offering costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt', window );">Costs associated with the issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt', window );">Payment of fees associated with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of principal on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,183)<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment', window );">Final payment on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock', window );">Costs associated with the issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,460<span></span>
</td>
<td class="nump">43,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,129<span></span>
</td>
<td class="nump">22,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,103<span></span>
</td>
<td class="nump">11,540<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">$ 2,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 127,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,669<span></span>
</td>
<td class="nump">24,256<span></span>
</td>
<td class="nump">$ 11,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,507<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of the 2019 Note and the 2020 Notes to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,394<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature', window );">Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,783<span></span>
</td>
<td class="num">(11,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">8,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount related to derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(735)<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NonCashEstablishmentOfEquityMethodInvestment', window );">Non-cash equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_StockIssuanceCostsIncurredButNotYetPaid', window );">Initial public offering costs included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity', window );">Reclassification of warrant liabilities to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability', window );">Debt discount related to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Payable for purchase of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Beneficial Conversion Feature Discount (Reversal) Of Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Unamortized Discount, Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Contract With Customer, Liability, Non-Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_NonCashEstablishmentOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash Establishment Of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_NonCashEstablishmentOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Noncash Investing And Financing Items, Derivative Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Debt Issuance Costs, Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Debt Issuance Costs, Secured Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Stock Issuance Costs, Abandoned IPO Attempt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Stock Issuance Costs, Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Stock Issuance Costs, Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ReclassificationOfWarrantLiabilitiesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrant Liabilities To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ReclassificationOfWarrantLiabilitiesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Secured Debt, Final Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334528322632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc. (the &#8220;Company&#8221; or &#8220;Inhibrx&#8221;) is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines a deep understanding of target biology with innovative protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design highly differentiated therapeutic candidates. The Company&#8217;s current pipeline is focused on oncology and orphan diseases. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;21, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) in which it sold 8,050,000 shares of common stock at an offering price of $17.00 per share. Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs were $125.9&#160;million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of the following occurred in connection with the completion of the IPO:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of the 2019 Note and the 2020 Notes (each as defined below) into 4,294,603 shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of all outstanding convertible preferred stock into 7,211,086 shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,354 shares of the Company&#8217;s common stock; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amendment and restatement of the Company&#8217;s certificate of incorporation, authorizing 120.0 million shares of common stock and 15.0 million shares of preferred stock.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2020 the Company effected a&#160;one-for-1.7382&#160;reverse stock split of the Company&#8217;s common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion prices of the convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) related to an interim report on the Form 10-Q. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.&#160;All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company&#8217;s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 19, 2020 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had an accumulated deficit of $127.7 million and cash and cash equivalents of $127.7 million. From its inception and through September&#160;30, 2020, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that existing cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date of the filing of this Form 10-Q. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features within convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease, and valuation allowances for the Company&#8217;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its current loan and security agreement (the &#8220;2020 Loan Agreement&#8221;) with Oxford Finance LLC (&#8220;Oxford&#8221;) and its former loan and security agreement, as amended (the &#8220;2015 Loan Agreement&#8221;), which has been terminated, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense and convertible notes approximate their related fair values due to the short-term nature of these instruments. The Company&#8217;s derivative instruments and warrants are carried at fair value based on unobservable market inputs. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institution in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of September&#160;30, 2020 and December&#160;31, 2019, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, (&#8220;WuXi Biologics&#8221;) pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. The Company does not control the manufacturing processes of the contract development and manufacturing organizations (&#8220;CDMOs&#8221;) with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations (such as current Good Manufacturing Practices, &#8220;cGMP&#8221;), which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has never declared or paid any dividends on its common stock. The Company currently intends to retain available cash for funding operations; therefore, it does not expect to pay any dividends in the foreseeable future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the 2020 Loan Agreement with Oxford, limits, among other things, the Company&#8217;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">machinery and equipment: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture and fixtures: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18">three</span> to five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430">four</span> to five years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its condensed consolidated financial statements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#8217;s facilities, which commenced in January 2020. This amendment is accounted for as a separate lease. Leases are reviewed and classified as operating or financing leases at commencement. The Company&#8217;s existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its condensed consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its condensed consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the condensed consolidated statements of operations for all periods presented. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements are reviewed at inception to determine if they contain a lease. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 8, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis BioScience, LLC (&#8220;Phylaxis&#8221;), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the condensed consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. As of September&#160;30, 2020, the Company&#8217;s equity method investment has been written down to zero as a result of the allocation of the Company&#8217;s share of losses of the investee.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, the convertible promissory note (the &#8220;2019 Note&#8221;) issued in May 2019 to DRAGSA 50, LLC, an entity affiliated with Viking Global Investors LP (&#8220;Viking&#8221;) and the convertible promissory notes (the &#8220;2020 Notes&#8221;) issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#8217;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determined certain of the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock. As of September&#160;30, 2020, the derivative liabilities no longer exist.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#8217;s IPO, the warrants were deemed to be issued for the purchase of common stock and were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the condensed consolidated statements of operations during the three and nine months ended September&#160;30, 2020. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific&#160;to the asset or liability. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 5). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020 and as of September&#160;30, 2020, the derivative liabilities and warrant liabilities no longer existed. The following table presents the Company&#8217;s financial liability that was measured at fair value as of December&#160;31, 2019 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO in August 2020, the Company&#8217;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the nine months ended September 30, 2020 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2019 Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of warrant liabilities on the 2020 Loan Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities on the 2019 and 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s derivative liabilities categorized in Level 3 of the fair value hierarchy as of December&#160;31, 2019 was determined based upon an independent third-party valuation report which used a lattice model. The valuation report utilized unobservable inputs, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s 2019 Note and the 2020 Notes (as discussed in Note 5), such as an IPO, financing, or extraordinary event, and the current valuation of the Company through an independent third-party valuation report. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of September&#160;30, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon Qualified IPO. Additionally, as of September&#160;30, 2020, the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#8217;s IPO. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the condensed consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal, accounting, and filing fees related directly to the Company&#8217;s IPO were capitalized as deferred IPO costs to be offset against proceeds upon the consummation of the IPO within stockholders&#8217; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0&#160;million of IPO costs against the proceeds. As of September&#160;30, 2020 and December&#160;31, 2019, no deferred IPO costs were capitalized on the Company&#8217;s condensed consolidated balance sheets. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies such as the National Institutes of Health (&#8220;NIH&#8221;) and the Congressionally Directed Medical Research Program (&#8220;CDMRP&#8221;) funded through the Department of Defense (&#8220;DoD&#8221;), as well as from private not-for-profit organizations including Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#8220;CARB-X&#8221;). Payments received from customers are included in deferred revenue, allocated between current and non-current, on the condensed consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;). The Company&#8217;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has been awarded multiple grants from the NIH, one grant from the CDMRP funded through the DoD, as well as one grant from CARB-X. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the&#160;condensed consolidated&#160;statements of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#8220;customer&#8221; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. Since the Company has concluded that these </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grants do meet the definition of a contribution and are indeed non-reciprocal transactions, the adoption of ASC Topic 606 had no impact on the Company&#8217;s accounting for grant revenue from governmental agencies or private institutions not considered customers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development and Clinical Trial Accruals </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed by third party contract research organizations (&#8220;CROs&#8221;) and/or clinical investigators. The Company also engages with CDMOs for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of unused federal and state net operating losses (&#8220;NOLs&#8221;) and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended (&#8220;IRC&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, the convertible preferred stock, convertible notes, warrants for purchase of common stock, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the three and nine months ended September 30, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities that could potentially decrease net loss per share in the future were not included in the determination of diluted loss per share as their effect is anti-dilutive (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  The conversion of the convertible notes into common stock assumes a conversion price of $14.35 per share for the 2019 Note and $12.56 per share for the 2020 Notes, and includes the conversion of the principal balance and all accrued interest as of the stated date (see Note 5).</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its condensed consolidated financial condition or results of operations upon adoption. The Company has irrevocably elected not to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act of 2012, as amended (&#8220;JOBS Act&#8221;), for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, which includes amendments intended to improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and affects companies that are required to </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include fair value measurement disclosures. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company adopted this guidance as of January 1, 2020, which did not result in a material impact on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard will be effective for the Company on January 1, 2023 or at such time where it is no longer a smaller reporting company. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the potential impact that the adoption of ASU 2019-12 may have on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted, but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the potential impact that the adoption of ASU 2020-01 may have on its condensed consolidated financial statements and related disclosures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Subtopic 470-20) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 815-40): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529498120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $0.3 million and $0.5 million for the three months ended September 30, 2020 and 2019, respectively, and $0.8 million and $0.9 million for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The amount accrued for research and development expense relates primarily to the Company&#8217;s increased usage of third-party CROs and CDMOs for preclinical, clinical and development efforts as its therapeutic candidates progress. See Note 1 for further discussion of the components of research and development.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529775208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts owed pursuant to the 2019 Note, the 2020 Notes, and the PPP Loan (defined below), the Company&#8217;s debt balance as of September&#160;30, 2020 and December&#160;31, 2019 consisted of the following under the 2015 Loan Agreement and the 2020 Loan Agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had no outstanding balances under the 2015 Loan Agreement. As of March 31, 2020, the Company had repaid its Oxford Term Loans under the 2015 Loan Agreement in full, including all principal balances, accrued interest, and the $1.4 million final payment. As of December&#160;31, 2019, the Company&#8217;s outstanding debt balance under the 2015 Loan Agreement consisted of the following (in thousands).</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;15, 2015, the Company entered into the 2015 Loan Agreement, pursuant to which Oxford agreed, subject to certain conditions, to make term loans to the Company in four $5.0 million installments for an aggregate of $20.0 million. The term loans were made on the following dates: (1) Term A: March&#160;31, 2015; (2) Term B: September&#160;9, 2016; (3) Term C: December&#160;22, 2016; and (4) Term D: December&#160;22, 2016. The proceeds from these loans were designated for working capital and general business purposes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2015 Loan Agreement, Oxford had a senior-secured lien on all of the Company&#8217;s current and future assets, other than its intellectual property. Oxford also had the right to declare the term loan immediately due and payable in an event of default under the 2015 Loan Agreement, which includes, among other things, a material adverse change in the Company&#8217;s business, operations, or financial condition or a material impairment in the prospect of repayment of the term loan. Throughout the life of the 2015 Loan Agreement, the Company was in compliance with all covenants under the 2015 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each term loan bore interest at the following annual rate: (1) Term A: 8.0%; (2) Term B: 8.6%; (3) Term C: 8.7%; and (4) Term D: 8.7%. The repayment schedule provided for interest-only payments in arrears until May 2016, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date, which was March&#160;31, 2020 (the &#8220;Maturity Date&#8221;) for all four term loans. The Company had the option to prepay the outstanding balance of the term loans in full prior to the Maturity Date, subject to a prepayment fee of up to&#160;3.0%. Upon repayment of each term loan, the Company was also required to make a final payment to Oxford equal to&#160;7.0%&#160;of the original principal amount of each term loan. This final payment of $1.4 million was accreted over the life of the 2015 Loan Agreement using the effective interest method. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s issuance of its first and second tranches of debt, Oxford also received 33,650 profit interest units (&#8220;PIUs&#8221;), which had a per unit value of $3.50, for a total value of $0.1 million. This was recorded as a debt discount and is being amortized using the effective interest method. The PIUs issued to Oxford were converted into 33,889 shares of the Company&#8217;s common stock in connection with the Company&#8217;s merger with various affiliated entities in April 2018, in which the Company was the surviving corporation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest expense related to the Oxford term loans for the three months ended September 30, 2020 and 2019 was $0 and $0.1 million, respectively, and for the nine months ended September 30, 2020 and 2019 was $0.04 million and $0.6 million, respectively. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company&#8217;s outstanding debt balance under the 2020 Loan Agreement consisted of the following (in thousands).</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the total future minimum payments, which consist of the future contractual principal and final fee payments, on the Company&#8217;s debt are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;15, 2020, the Company entered into the 2020 Loan Agreement with Oxford, pursuant to which it received&#160;$10.0 million&#160;in gross proceeds, net of $0.1 million of debt issuance costs (the &#8220;Term Loan&#8221;). The outstanding Term Loan will mature on August 1, 2024 (the &#8220;Maturity Date&#8221;) and bears interest at a floating per annum rate equal to (1)&#160;8.95%&#160;plus (2) the greater of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii)&#160;1.00%. The repayment schedule provides for interest-only payments beginning on September&#160;1, 2020 and continuing for 24 months thereafter. The interest-only period is followed by 24 months of equal payments of principal and interest. Upon the Maturity Date, a final payment of 7.0% of the original principal amount will be due to Oxford. This final payment of $0.7 million will be accreted over the life of the 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the Term Loan in full prior to the Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to use the proceeds from the Term Loan solely for working capital and to fund its general business requirements. Its obligations under the Loan Agreement are secured by a first priority security interest of substantially all of the Company&#8217;s assets, other than its intellectual property. The 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding Term Loan. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance, the Company issued to Oxford warrants to purchase shares of the Company&#8217;s capital stock equal to 1.25% of the funded amount, or $125,000. Upon issuance, the warrants were exercisable for preferred stock and were classified as liabilities pursuant to Topic ASC 480 at their fair value of $0.12 million. Upon </span></div>the consummation of the Company&#8217;s IPO in August 2020, the Company remeasured the warrants and determined a fair value of approximately $0.14 million. The change in fair value was recorded as a change in fair value of warrant liabilities within other income in the Company&#8217;s condensed consolidated statements of operations. As of September&#160;30, 2020, the warrants are equity-classified and are exercisable for 7,354 shares of common stock of the Company at $17.00 per share.The Company&#8217;s interest expense related to the Term Loan for the three and nine months ended September 30, 2020 was $0.3 million for each period. Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529491192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP LOAN<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">PPP LOAN</a></td>
<td class="text">PPP LOAN<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;). The CARES Act includes a provision for a Paycheck Protection Program (&#8220;PPP&#8221;) administered by the U.S. Small Business Administration (&#8220;SBA&#8221;) and further amended by the Paycheck Protection Program Flexibility Act of 2020 (&#8220;PPP Flexibility Act&#8221;), which was enacted on June 5, 2020. See Note 11 for further details regarding other provisions of the CARES Act.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PPP, the Company was approved for a loan pursuant to the PPP program (the &#8220;PPP Loan&#8221;) in the amount of $1.9 million and received the funds on May&#160;11, 2020. The application for these funds required the Company to certify in good faith that current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. The Company was also required to certify that the loan funds would be used to retain workers and maintain payroll or make mortgage payments, lease payments, and utility payments. The PPP Loan has a&#160;two-year&#160;term and bears interest at a rate of 1.0% per annum. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CARES Act, the Company was eligible to apply for and be granted forgiveness for all or a portion of the PPP Loan. Such forgiveness, if any, would have been determined, subject to limitations, based on the use of loan proceeds for payroll costs, rent and utility costs and provided that only a portion of the use of proceeds are for non-payroll&#160;costs. The unforgiven portion of the PPP Loan was eligible to be repaid by the Company at any time prior to maturity with no prepayment penalty. Loan recipients may elect an eight week or 24 week forgiveness period and the repayment period begins on the date which the amount of forgiveness is determined. In the event that a loan recipient has not applied for forgiveness within 10 months of the end of its covered forgiveness period, the loan recipient must begin making principal and interest payments on that date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, the Company determined that it would not seek forgiveness of the PPP Loan and would repay the loan in full during the fourth quarter of 2020. As a result, as of September&#160;30, 2020, the full amount of the PPP Loan of $1.9 million was classified as current debt within the Company&#8217;s condensed consolidated balance sheets. Interest expense related to the PPP loan for the three and nine months ended September&#160;30, 2020 was approximately $4,000 and $7,000, respectively. Interest expense was calculated using the effective interest method. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;2, 2020, the Company repaid the loan in full plus all interest accrued during the period outstanding. See Note 12 for further details regarding the repayment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529775208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONVERTIBLE PROMISSORY NOTES</a></td>
<td class="text">CONVERTIBLE PROMISSORY NOTES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company issued the 2019 Note in the aggregate principal amount of $40.0 million to Viking in a private placement transaction. The 2019 Note began to accrue interest in February 2020 at a rate of 1.5% per month. In April 2020, the Company issued the 2020 Notes in the aggregate principal amount of $15.0 million to Viking and certain other investors in a private placement transaction. Upon issuance, the 2020 Notes accrued interest at a rate of 1.0% per month. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Note and the 2020 Notes were to mature on the earlier of (1) March&#160;31, 2022; (2) upon the consummation of certain potential settlement events (each as defined in the 2019 Note and the 2020 Notes); or (3) the time at which the balance of the 2019 Note and the 2020 Notes is due and payable upon an Event of Default (the &#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Upon Qualified IPO</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company completed a qualified IPO, which was defined as the completion of an IPO with a Company valuation above $400.0&#160;million (&#8220;Qualified IPO&#8221;). As defined, a Qualified IPO triggered the automatic conversion and settlement of the aggregate outstanding principal amount plus accrued interest to date under the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock at the lesser of (i) a conversion price equal to 90% of the IPO price per share and (ii) a fixed price based on a specified valuation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the conversion date, accrued interest expense for the 2019 Note and the 2020 Notes was $3.7 million and $0.7 million, respectively for an aggregate total balance of $43.7 million and $15.7 million, respectively. Based on a $400.0&#160;million valuation, the 2019 Note converted at the fixed price of $14.35 per share, resulting in the issuance of 3,046,467 shares of common stock to the holder. Based on a $350.0&#160;million valuation, the 2020 Notes converted at a fixed price of $12.56 per share, resulting in the issuance of 1,248,136 shares of common stock to the holders.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of the 2019 Note and the 2020 Notes were evaluated for contingent beneficial conversion features (&#8220;BCF&#8221;) under ASC Topic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt With Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the effective conversion prices of both the 2019 Note and the 2020 Notes exceeded the relative fair value of the price per share at the commitment date of the 2019 Note and the 2020 Notes, including the paid-in-kind interest, there was no intrinsic value within the conversion feature. As a result, no additional BCF was recorded upon conversion of the 2019 and the 2020 Notes.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2019 Note and the 2020 Notes contained alternative conversion options to the Qualified IPO upon the consummation of certain events, each of which had its own conversion prices and terms. For instance, upon a maturity date conversion, upon the election of the holder, the note would have converted and settled into shares of the Company&#8217;s then-most senior equity securities at the time of such maturity date conversion at the lesser of (i) a conversion price equal to 90% of the price per share to be received by the then-most senior equity securities and (ii) a fixed price based on a specified valuation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of each of the 2019 Note and the 2020 Notes and prior to conversion under the IPO, the Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under ASC Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine if it required bifurcation as a derivative instrument. The Company determined certain settlement features qualified as conversion features not meeting the requirements for separate accounting as embedded derivatives, while others qualified as redemption features meeting the requirements for separate accounting which were accounted for as derivative instruments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2019 Note on May&#160;20, 2019, the estimated fair value of the bifurcated compound liability was approximately $0.9 million, which was recorded as a derivative liability with a corresponding reduction to the debt discount on the condensed consolidated balance sheets. The 2019 Note was amended during April 2020 to align the maturity date and certain other provisions with the 2020 Notes. During the second quarter of 2020, the Company assessed the amendment and determined it should be treated as a modification. Since there was no change in the fair value of the embedded conversion options as of the modification date, no change in the carrying amount of the convertible debt instrument was recognized.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2020 Notes on April&#160;6, 2020, the estimated fair value of the bifurcated compound liability was approximately $0.7 million, which was recorded as a derivative liability with a corresponding reduction to the debt discount on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company engaged a third-party valuation specialist in order to assess the fair value of the derivative liability as of December 31, 2019, which was determined based upon significant inputs not observable in the market, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s notes, such as an IPO, financing or extraordinary event, as well as the current valuation of the Company as determined by an independent third-party&#8217;s valuation report. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability at December 31, 2019 was $1.9 million. Changes in the probability of each embedded redemption feature drove changes in the fair value of the derivative liabilities and had a corresponding impact on the Company&#8217;s net loss. During the second quarter of 2020, the fair value of the derivative was </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined to be zero based upon the expected conversion of the notes via an embedded conversion feature which did not meet the definition of a derivative. Upon conversion of the 2019 Note and the 2020 Notes in August 2020 upon completion of the Company&#8217;s IPO, the derivative liabilities were extinguished. No additional expense was recorded at extinguishment since the derivative liabilities had already been assessed to have zero value. During the  nine months ended September 30, 2020, the Company recorded other income $2.7 million related to changes in fair value of derivative liabilities in the condensed consolidated statements of operations. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Discount </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to conversion, the Company also evaluated the 2019 Note and the 2020 Notes for BCFs under ASC Topic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt With Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined that the maturity date conversion feature met the definition of a BCF since the embedded conversion option was in-the-money at inception and was fixed and determinable upon execution. Upon issuance of the 2019 Note during the second quarter of 2019, the Company recorded $11.5 million as a debt discount with a corresponding entry to additional paid-in-capital on its condensed consolidated balance sheet to record the BCF the 2019 Note. Additionally, at issuance in May 2019, the Company recorded a debt discount which consisted of $0.9 million related to the establishment of the derivative liability and $2.5 million related to debt issuance costs on the 2019 Note. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2020 Notes during the second quarter of 2020, the Company recorded $2.7 million as a debt discount with a corresponding entry to additional paid-in-capital on its condensed consolidated balance sheets to record the BCF on the 2020 Notes. Additionally, the Company recorded a debt discount of $0.7 million related to the establishment of the derivative liability on the 2020 Notes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to conversion, the debt discounts were amortized over the life of the notes. Amortization of the debt discount from inception of the 2019 Note until conversion of the Notes upon IPO was $8.7&#160;million. At the time of conversion, the 2019 and the 2020 Notes had unamortized discounts of $6.9&#160;million and $2.7&#160;million, respectively.   </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the 2019 Note and the 2020 Notes, the Company remeasured the intrinsic value of the BCFs which resulted in a reversal of the remaining unamortized discounts associated with the BCFs, resulting in a $7.4&#160;million impact to additional paid-in-capital. Additionally, the Company accelerated the unamortized debt discounts related to the debt issuance costs and the derivative liabilities, resulting in a $2.2&#160;million charge to interest expense.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company&#8217;s 2019 Note and the 2020 Notes balance, net of discount, consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529510696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY (DEFICIT) <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020 upon completion of the IPO, the Company&#8217;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 15,000,000 shares of preferred stock, each with a par value of $0.0001 per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to its conversion to common stock in connection with the Company&#8217;s IPO, the convertible preferred stock was classified as temporary, or mezzanine, equity on the accompanying condensed consolidated balance sheets since the shares contained certain redemption features that were not solely within the control of the Company. The Company had not previously accreted the convertible preferred stock to its redemption value since the shares were not redeemable and redemption was not deemed to be probable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock authorized and issued as of December&#160;31, 2019 consisted of the following (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.485%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Liquidation Preference</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Mezzanine 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,009.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Mezzanine 2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,465,681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,235,012</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,480.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,765,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,534,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,489.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company issued 1.7 million shares of Series Mezzanine 2 Preferred Stock at a purchase price of $6.98 per share, resulting in net proceeds of approximately $12.0&#160;million, after deducting offering expenses. No shares of Series Mezzanine 1 Preferred Stock and Series Mezzanine 2 Preferred Stock were issued during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the Company&#8217;s IPO in August 2020, all of the outstanding shares of convertible preferred stock were converted into 7,211,086 shares of the Company&#8217;s common stock.  </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, the Company issued warrants to Oxford concurrently with the 2020 Loan Agreement. Upon the consummation of the Company&#8217;s IPO in August 2020, the warrants are exercisable for 7,354 shares of common stock of the Company at $17.00 per share. As of September&#160;30, 2020, the warrants are equity-classified and reflected in additional paid-in-capital at $0.14 million. The fair value of the warrants was determined using the Black-Scholes model on the date of conversion. No subsequent remeasurement is required for equity-classified warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334530257096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY COMPENSATION PLANS</a></td>
<td class="text">EQUITY COMPENSATION PLANS <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of September&#160;30, 2020, an aggregate of 3.0 million shares of common stock were reserved for issuance under the 2017 Plan, of which 0.6 million were available. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2017 Plan for the nine months ended September 30, 2020 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF SHARES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE EXERCISE PRICE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (IN YEARS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGGREGATE INTRINSIC VALUE</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and exercisable as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, given the absence of a public trading market for the Company&#8217;s common stock, its board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company&#8217;s common stock underlying the stock options, such as: contemporaneous valuations performed by independent third-party specialists, its stage of development, including the status of its research and development efforts of its therapeutic candidates and the material risks related to its business and industry, its results of operations and financial condition, including its levels of capital resources, the prices at which its sold shares of its convertible preferred stock, the rights, preferences and privileges of its convertible preferred stock relative to those of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as recently completed mergers and acquisitions of peer companies, the likelihood of achieving a liquidity event for the holders of its common stock or convertible preferred stock, such as an IPO or a sale of the Company given prevailing market conditions, trends and developments in its industry, external market conditions affecting the life sciences and biotechnology sectors, and the lack of liquidity of its common stock, among other factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price. The Company&#8217;s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of September&#160;30, 2020 and December&#160;31, 2019, the Company had $12.3 million and $12.2 million, respectively, of total unrecognized stock-based compensation expense related to its stock options, which it expected to recognize over a weighted-average period of 2.4 and 2.9 years, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529564664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LicenseAndGrantRevenueTextBlock', window );">LICENSE AND GRANT REVENUES</a></td>
<td class="text">LICENSE AND GRANT REVENUES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s condensed consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from affiliates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcenta Holding, Ltd.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elpiscience Biopharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from affiliates</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from non-affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bluebird bio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license revenues from non-affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from non-affiliates</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Institutes of Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combating Antibiotic Resistant Bacteria Accelerator</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phylaxis Agreements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis BioScience, LLC (&#8220;Phylaxis&#8221;). In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement (collectively the &#8220;Phylaxis Agreements&#8221;), pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. Upon closing, the Company received a $2.5&#160;million nonrefundable, upfront payment from Phylaxis under the Master Services Agreement (&#8220;MSA&#8221;). The Company is also entitled to an additional $2.5&#160;million payable within 180 days from closing under the MSA. Upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company&#8217;s intellectual property and know-how and is entitled to receive an additional 5% based on the achievement of certain milestones. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0&#160;million and $175.0&#160;million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the fair value of the equity interest in Phylaxis, the Company engaged a third-party valuation specialist. The valuation report utilized a market approach to establish the total equity value of Phylaxis using inputs not observable in the market, including the discount rate. The fair value of the equity interest was $0.5&#160;million, which has been accounted for under the equity method. The fair value of the equity interest upon the execution of </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the agreements has been included in the transaction price, along with the $5.0&#160;million of payments due pursuant to the MSA.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the transfer of the exclusive licenses for, and performance of, development services to modify the first and second compounds as one performance obligation and allocated the transaction price evenly between the two compounds. Revenue related to the performance obligation will be recognized over time as services are performed, based on the Company&#8217;s progress to satisfy the performance obligation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, the Company has recognized $0.8&#160;million of revenue related to this performance obligation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bluebird</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2018, the Company entered into a License Agreement with bluebird bio, Inc. (&#8220;bluebird&#8221;) whereby the Company granted bluebird the exclusive, worldwide rights to develop, manufacture, and commercialize certain cell therapy products containing binders. In January 2019, the Company received a non-refundable upfront fee of $7.0 million from bluebird for this exclusive license. As part of the Company&#8217;s performance obligations to bluebird, it transferred certain know-how to bluebird, the completion of which occurred in March&#160;2019. As a result, the Company recognized the $7.0 million upfront payment as license fee revenue during March 2019 upon completion of all performance obligations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to receive specified development milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Option and License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a separate Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide development licenses to develop binders and cell therapy products containing sdAbs directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. The Company also granted to bluebird an option to acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which bluebird exercises its option, bluebird will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions for each option bluebird chooses to exercise. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company will reassess its performance obligations and transaction price accordingly.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the total transaction price of the contract at execution was $0.4 million for the transfer of the two exclusive development licenses. The Company recognized $0.4 million of revenue related to this agreement at the point in time in which the exclusive development licenses were transferred to bluebird, which occurred upon execution of the agreement in June 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chiesi</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into an Option Agreement (as amended by the First Amendment to Option Agreement, dated August 19, 2019, the &#8220;Chiesi Option Agreement&#8221;) with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019. If Chiesi chooses to exercise its option under the Chiesi Option Agreement, then Chiesi must pay the Company a one-time, non-refundable fee of $12.5 million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, the Company may be entitled to receive specified milestone payments of up to $122.5 million, as well as royalties on future product sales.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified one performance obligation as of the effective date of this agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#8217;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration (&#8220;FDA&#8221;) scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive parallel EMA-HTA scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company has determined that the option to grant a license in the future is not a material right.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $10.0 million upfront payment has been allocated to the single performance obligation. Revenue will be recognized over time as services are performed during the option period, based on the Company&#8217;s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the three months ended September 30, 2020 and 2019, the Company recognized $2.0 million and $0.8 million, respectively, in revenue related to this agreement. During the nine months ended September 30, 2020 and 2019, the Company recognized $5.8 million and $0.8 million, respectively, in revenue related to this agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elpiscience</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has entered into two different License Agreements with Elpiscience Biopharmaceuticals, Inc. (&#8220;Elpiscience&#8221;). Each agreement is a standalone license of a distinct and differentiated protein therapeutic candidate with a separate biological target, providing a unique benefit. Neither the license nor the asset is reliant upon the other. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PD-L1 and 4-1BB Program </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a License Agreement (the &#8220;PD-L1 and 4-1BB License Agreement&#8221;) with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s bi-specific therapeutic candidate designed to target PD-L1 and 4-1BB (also referred to as &#8220;INBRX-105&#8221;). This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as to manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-105, including process development and manufacturing data and information necessary to develop INBRX-105. In the PD-L1 and 4-1BB License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-105 for its development in China, Hong Kong, Macau and Taiwan. The Company is eligible to receive specified developmental and commercial milestone payments of up to an aggregate of $100.0 million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PD-L1 and 4-1BB License Agreement, the Company is entitled to reimbursement for certain toxicology study costs and chemistry, manufacturing and controls (&#8220;CMC&#8221;) costs. Elpiscience paid the Company $3.0 million in March 2018 for certain costs in relation to the development of INBRX-105. The payment received in advance of the work to be completed was recorded to other current liabilities upon receipt and, since the Company was acting as an agent on behalf of Elpiscience, the Company recorded it as a contra-expense against research and development as the relevant work was completed. During the three and nine months ended September 30, 2019, the Company derecognized approximately $0  and $0.7 million of liabilities related to this agreement, respectively. As of September&#160;30, 2019, the Company had completed all relevant work on this program and had no remaining liabilities related to the reimbursement under the PD-L1 and 4-1BB License Agreement. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OX40 Program </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into a separate License Agreement (the &#8220;OX40 License Agreement&#8221;) with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s multivalent protein therapeutic directed to the biological target OX40 (also referred to as &#8220;INBRX-106&#8221;). This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-106, including process development and manufacturing data and information necessary to develop INBRX-106. In the OX40 License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-106 for its development in Mainland China, Hong Kong Macau and Taiwan. The Company is eligible to receive certain developmental and commercial milestones of up to an aggregate of $100.0 million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company achieved a milestone under the contract for $2.0&#160;million, which was received during September 2020. The Company recognized revenue of $2.0&#160;million during the three and nine months ended September 30, 2020 related to this agreement. No revenue was recognized related to this agreement during the three and nine months ended September 30, 2019.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OX40 License Agreement, the Company is entitled to reimbursement for certain toxicology study costs and CMC costs. Elpiscience paid the Company $3.4 million in August 2018 for certain costs incurred in relation to the development and production of INBRX-106. The payment received in advance of the work to be completed was recorded to other current liabilities upon receipt and since the Company was acting as an agent on behalf of Elpiscience, the Company recorded it as a contra-expense against research and development as the relevant work was completed. As of September&#160;30, 2020, the Company has $0.2 million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. As of September&#160;30, 2020 and December 31, 2019, the Company had no liabilities outstanding related to this agreement. During the three and nine months ended September 30, 2020, the Company received $0 and $0.2 million in reimbursements for expenses already incurred, respectively. During the three and nine months ended September 30, 2019, the Company derecognized approximately $0.1 million and $1.3 million of liabilities related to this reimbursement, respectively. Additional reimbursements of $0.1 million related to multi-year stability studies are expected to be recognized and paid upon completion.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transcenta</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company entered into a License Agreement with Transcenta Holding, Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), (&#8220;Transcenta&#8221;) (the &#8220;Transcenta License Agreement&#8221;), whereby the Company granted Transcenta exclusive, non-transferable rights to develop, manufacture, and sell its products containing the Company&#8217;s protein therapeutic candidate, designed to target DR5 (also referred to as &#8220;INBRX-109&#8221;), or a derivative thereof, within mainland China, Hong Kong, Macau and Taiwan and agreed to provide Transcenta with the intellectual property and materials, including assays and cell lines, necessary to develop the therapeutic candidate. In addition, pursuant to the Transcenta License Agreement, the Transcenta License Agreement granted the Company a royalty-free, worldwide, non-exclusive research license to intellectual property created by Transcenta that </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporates intellectual property licensed to Transcenta. In June 2019, the Company achieved a milestone under the contract for $1.0 million, which was received during August 2019, net of $0.1 million in foreign tax withholding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Transcenta License Agreement, the Company is also eligible to receive certain developmental and commercial milestone payments of up to an aggregate of approximately $100.0 million, as well as percentage tiered royalties on future product sales with rates ranging between the high single-digits to the low teens. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2012, the Company entered into a Development and Option agreement with Celgene whereby the Company granted Celgene an option to exclusively license certain intellectual property rights relating to the Company&#8217;s CD47 checkpoint inhibitor . Upon grant of the Development and Option agreement, Celgene made a non-refundable upfront option payment for the exclusive license. In June 2013, Celgene opted to exercise its right to license the intellectual property rights associated with the Company&#8217;s CD47 therapeutic. The Company is also eligible to receive certain developmental and commercial milestones of an aggregate of $934.1 million, assuming the achievement of all potential milestones in the agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens. The Company is obligated to pay 2% of future amounts received under the Development and Option Agreement to advisors who assisted the Company with the negotiation and other matters in connection with the Development and Option agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was recognized in accordance with the Company&#8217;s stated methodology discussed in Note 1.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NIH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2017, the Company was awarded a grant by the NIH in the amount of $1.0 million for the continued development of multi-specific antibodies for the treatment of Pseudomonas aeruginosa infection, all of which has been recognized as revenue upon completion in June 2019.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this NIH grant was based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue was recognized when the Company incurred these covered expenses related to the grant&#8217;s continued progression. The Company submitted invoices to the NIH for only those expenses which had been incurred by the Company in each period, resulting in reimbursement in arrears. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CARB-X Subaward Agreement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July 2017, the Company was awarded a grant by Boston University in the amount of approximately $4.6 million. The program, Combating Antibiotic Resistant Bacteria Accelerator (&#8220;CARB-X&#8221;), is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. The Company received this award in relation to its program aimed at the development of novel antimicrobial therapeutics using multiple mechanisms of action to circumvent the development of resistance, and in the case of this grant, specifically for pseudomonas. The payment structure of this grant was a cost share, where 70% of costs were reimbursed by the sponsor, or Boston University, and the remaining 30% of costs are covered by the Company. The work under this grant began in October 2017 and was discontinued during the third quarter of 2019 based on the uncertainty within the applicable regulatory environment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this grant was based upon internal costs incurred by the Company that were specifically covered by the grant as well as certain specified overhead expenses. Revenue was recognized when the Company incurred these covered expenses related to the grant&#8217;s continued progression. The Company submitted invoices to Boston University for only those expenses which had been incurred by the Company in each period, resulting in reimbursement in arrears. Prior to discontinuation of the work on this grant, $4.0 million in revenue was recognized, all of which has been received in cash from Boston University. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CDMRP funded through the DoD </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2018, the Company was awarded a grant by the CDMRP funded through the DoD by the U.S. Army Medical Research Acquisition Activity in the amount of approximately $0.3 million for the continued development of multi-specific antibodies for the treatment against Acinetobacter baumannii infection by circumventing development of bacterial resistance. The work under this grant began in December 2018 and was completed in September 2020. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this grant is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant&#8217;s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. As of September&#160;30, 2020, $0.3 million in revenue has been recognized under this grant, $0.2&#160;million of which has been received in cash from the DoD.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LicenseAndGrantRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LicenseAndGrantRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529703928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company&#8217;s Board of Directors or a committee thereof pursuant to policy.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LAV Summit Limited </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LAV Summit Limited (&#8220;LAV SL&#8221;), a limited company, is a principal shareholder owning more than 5% of the Company&#8217;s outstanding equity interest as of September&#160;30, 2020 and December&#160;31, 2019. Due to this equity ownership, LAV SL is considered a related party. Moreover, Judith Li, a former member of the Company&#8217;s board of directors, is a Partner at LAV SL&#8217;s General Partner, Lilly Asia Ventures (&#8220;LAV&#8221;), a biomedical venture capital firm. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company entered into the Transcenta License Agreement. LAV, through one of its funds, holds a significant equity ownership position in Transcenta. During the three and nine months ended September 30, 2019, the Company recorded revenue of $0 and $1.0&#160;million related to this agreement. During the three and nine months ended September 30, 2020, the Company recorded no revenue related to this agreement. See Note 8 for further discussion of this agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into the PD-L1 and 4-1BB License Agreement with Elpiscience. LAV, through one of its funds, holds a significant equity ownership position in Elpiscience and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identifies Elpiscience as a related party. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred for which Elpiscience has paid the Company $4.7 million to date as of September&#160;30, 2020 and December&#160;31, 2019. During the three and nine months ended September 30, 2020 and 2019, the Company recorded no revenue related to this agreement. See Note 8 for further discussion of this agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into the OX40 License Agreement with Elpiscience. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred for which Elpiscience has paid the Company approximately $5.1 million and $4.9 million to date as of September&#160;30, 2020 and December&#160;31, 2019, respectively. During the three and nine months ended September 30, 2020, the Company recorded $2.0&#160;million of revenue related to this agreement. During the three and nine months ended September 30, 2019, the Company recorded no revenue related to this agreement. See Note 8 for further discussion of this agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics Healthcare Venture</span></div>WuXi Biologics Healthcare Venture (&#8220;WuXi Bio HV&#8221;) is a corporate venture arm of WuXi Biologics, with whom the Company has an existing Exclusivity Agreement. In January 2019, WuXi Bio HV purchased 1.7 million shares of the Company&#8217;s Series Mezzanine 2 Preferred Stock at a purchase price of $6.98 per share, for a purchase price of $12.0 million. These shares converted to common stock upon the consummation of the Company&#8217;s IPO in August 2020. See Note 6 for further discussion of Preferred Stock transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529491192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a seven-year lease agreement for approximately 34,000 square feet as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company executed an amendment to its lease agreement to expand its facilities by approximately 9,000 square feet and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset and operating lease liability as of September&#160;30, 2020 and December&#160;31, 2019 are as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020 and 2019, the Company recognized operating lease expense of $0.8&#160;million and $0.6&#160;million, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized operating lease expense of $2.3&#160;million and $1.7&#160;million, respectively. As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s operating lease had a remaining term of 4.8 and 5.5 years, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% and 8.0% as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating leases are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (3 months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s condensed consolidated balance sheets, condensed consolidated statements of operations, or condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529654696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock', window );">COVID-19</a></td>
<td class="text">COVID-19<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of the COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&#8217;s therapeutic candidates and the conduct of future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the FDA which could result in delays in meetings, reviews and approvals, including with respect to any of the Company&#8217;s therapeutic candidates. For example, as a result of the COVID-19 pandemic patient travel restrictions, the Company temporarily suspended patient enrollment for its trial for INBRX-101 during the second and third quarters of 2020. Additionally, while the potential economic </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or future clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s business, financial condition, results of operations and prospects, and those of the third parties relied upon by the Company.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act</span></div>On March 27, 2020, the U.S. federal government enacted the CARES Act, which includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;The CARES Act also includes provisions for PPP loans administered by the SBA. The Company applied for and received PPP funds. See Note 4 and Note 12 for further discussion of the Company&#8217;s PPP loan. The Company will continue to examine and evaluate any impacts the CARES Act and associated subsequent legislation may have on its business and taxes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=114868817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529726872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the unaudited condensed consolidated financial statements as of September&#160;30, 2020, the Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these condensed consolidated financial statements, other than disclosures related to those outlined below. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Loan Repayment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after receiving proceeds from its IPO, the Company repaid its PPP Loan in full. As of the repayment date, the Company had accrued approximately $7,400 of interest, for a total repayment of $1.9&#160;million. As discussed in Note 4, there were no prepayment penalties associated with the payment of the loan prior to maturity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the 2020 Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, the Company entered into the First Amendment to the 2020 Loan Agreement with Oxford (the &#8220;2020 Loan Amendment&#8221;). The 2020 Loan Amendment provides for two additional tranches of term loans in an aggregate principal amount of up to $40.0&#160;million, as follows: (a) the second tranche in an aggregate principal amount of $20.0&#160;million, funded upon the closing of the 2020 Loan Amendment (&#8220;Tranche B&#8221;), and (b) the third tranche in an aggregate principal amount of $20.0&#160;million to fund on or before September 30, 2021, subject to the initiation of a registration-enabling trial for the Company&#8217;s therapeutic candidate, INBRX-109, in chondrosarcoma, pursuant to the terms of the 2020 Loan Amendment (&#8220;Tranche C&#8221;). Tranche B and Tranche C are in addition to the first tranche of term loans in an aggregate principal amount of $10.0&#160;million, which was funded on July 15, 2020. In accordance with the 2020 Loan Amendment, the Company paid a one-time first amendment fee of $0.7&#160;million. The terms of the first tranche under the 2020 Loan Agreement were modified to align with Tranche B pursuant to the 2020 Loan Amendment.</span></div>The outstanding term loan will mature on November 1, 2025 (the &#8220;Amended Maturity Date&#8221;) and bears interest at a floating per annum rate equal to the greater of (1)&#160;7.96%&#160;and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in&#160;The Wall Street Journal&#160;on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii)&#160;7.80%. The repayment schedule provides for interest-only payments until January 1, 2024. Upon funding of Tranche C, the interest-only payments may be extended by 12 months to January 1, 2025. The interest-only period is followed by 23 months of equal payments of principal and interest, or if the interest-only period is extended, by 11 months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536667656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) related to an interim report on the Form 10-Q. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.&#160;All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2019, which are included in the Company&#8217;s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 19, 2020 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had an accumulated deficit of $127.7 million and cash and cash equivalents of $127.7 million. From its inception and through September&#160;30, 2020, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div>The Company believes that existing cash and cash equivalents, including the net proceeds from the IPO, will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date of the filing of this Form 10-Q. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features within convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease, and valuation allowances for the Company&#8217;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments The Company&#8217;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its current loan and security agreement (the &#8220;2020 Loan Agreement&#8221;) with Oxford Finance LLC (&#8220;Oxford&#8221;) and its former loan and security agreement, as amended (the &#8220;2015 Loan Agreement&#8221;), which has been terminated, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense and convertible notes approximate their related fair values due to the short-term nature of these instruments. The Company&#8217;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institution in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of September&#160;30, 2020 and December&#160;31, 2019, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div>The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, (&#8220;WuXi Biologics&#8221;) pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. The Company does not control the manufacturing processes of the contract development and manufacturing organizations (&#8220;CDMOs&#8221;) with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations (such as current Good Manufacturing Practices, &#8220;cGMP&#8221;), which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Dividends</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company has never declared or paid any dividends on its common stock. The Company currently intends to retain available cash for funding operations; therefore, it does not expect to pay any dividends in the foreseeable future. </span></div>Additionally, the 2020 Loan Agreement with Oxford, limits, among other things, the Company&#8217;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">machinery and equipment: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk3ODY_3aaea0d6-2041-47be-af95-c28f02e6343b">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture and fixtures: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4Mjk_215f6a94-828c-4630-b431-8345b1d72e18">three</span> to five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVlOTFiOWE5MGY4MDQwNzdiMjM3NTg0MTYwYjkzNzBhL3NlYzplZTkxYjlhOTBmODA0MDc3YjIzNzU4NDE2MGI5MzcwYV8zNC9mcmFnOmRhY2UzYjhjMjI0ZTQyMDJhMGY5Mzk2ZjhmZmMzNTNiL3RleHRyZWdpb246ZGFjZTNiOGMyMjRlNDIwMmEwZjkzOTZmOGZmYzM1M2JfMTk4NzQ_95c778cb-f266-4b1c-8eec-2fbec5f12430">four</span> to five years.</span></div>Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined </span></div>based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its condensed consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#8217;s facilities, which commenced in January 2020. This amendment is accounted for as a separate lease. Leases are reviewed and classified as operating or financing leases at commencement. The Company&#8217;s existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its condensed consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its condensed consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the condensed consolidated statements of operations for all periods presented. </span></div>Agreements are reviewed at inception to determine if they contain a lease.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 8, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis BioScience, LLC (&#8220;Phylaxis&#8221;), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the condensed consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. As of September&#160;30, 2020, the Company&#8217;s equity method investment has been written down to zero as a result of the allocation of the Company&#8217;s share of losses of the investee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, the convertible promissory note (the &#8220;2019 Note&#8221;) issued in May 2019 to DRAGSA 50, LLC, an entity affiliated with Viking Global Investors LP (&#8220;Viking&#8221;) and the convertible promissory notes (the &#8220;2020 Notes&#8221;) issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#8217;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determined certain of the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock. As of September&#160;30, 2020, the derivative liabilities no longer exist.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_WarrantLiabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text">Warrant LiabilitiesAs discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#8217;s IPO, the warrants were deemed to be issued for the purchase of common stock and were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the condensed consolidated statements of operations during the three and nine months ended September&#160;30, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific&#160;to the asset or liability. </span></div>The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 5). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020 and as of September&#160;30, 2020, the derivative liabilities and warrant liabilities no longer existed.Prior to the completion of the IPO in August 2020, the Company&#8217;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement.The fair value of the Company&#8217;s derivative liabilities categorized in Level 3 of the fair value hierarchy as of December&#160;31, 2019 was determined based upon an independent third-party valuation report which used a lattice model. The valuation report utilized unobservable inputs, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s 2019 Note and the 2020 Notes (as discussed in Note 5), such as an IPO, financing, or extraordinary event, and the current valuation of the Company through an independent third-party valuation report. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of September&#160;30, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon Qualified IPO. Additionally, as of September&#160;30, 2020, the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#8217;s IPO.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the condensed consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss.</span></div>Legal, accounting, and filing fees related directly to the Company&#8217;s IPO were capitalized as deferred IPO costs to be offset against proceeds upon the consummation of the IPO within stockholders&#8217; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0&#160;million of IPO costs against the proceeds. As of September&#160;30, 2020 and December&#160;31, 2019, no deferred IPO costs were capitalized on the Company&#8217;s condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies such as the National Institutes of Health (&#8220;NIH&#8221;) and the Congressionally Directed Medical Research Program (&#8220;CDMRP&#8221;) funded through the Department of Defense (&#8220;DoD&#8221;), as well as from private not-for-profit organizations including Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#8220;CARB-X&#8221;). Payments received from customers are included in deferred revenue, allocated between current and non-current, on the condensed consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;). The Company&#8217;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has been awarded multiple grants from the NIH, one grant from the CDMRP funded through the DoD, as well as one grant from CARB-X. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the&#160;condensed consolidated&#160;statements of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#8220;customer&#8221; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. Since the Company has concluded that these </span></div>grants do meet the definition of a contribution and are indeed non-reciprocal transactions, the adoption of ASC Topic 606 had no impact on the Company&#8217;s accounting for grant revenue from governmental agencies or private institutions not considered customers. Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development and Clinical Trial Accrurals</a></td>
<td class="text">Research and Development and Clinical Trial Accruals Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed by third party contract research organizations (&#8220;CROs&#8221;) and/or clinical investigators. The Company also engages with CDMOs for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div>The utilization of unused federal and state net operating losses (&#8220;NOLs&#8221;) and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended (&#8220;IRC&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div>For purposes of the diluted net loss per share calculation, the convertible preferred stock, convertible notes, warrants for purchase of common stock, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the three and nine months ended September 30, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Fair Value of Stock-Based Awards</a></td>
<td class="text">Fair Value of Stock-Based Awards The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income</a></td>
<td class="text">Other Comprehensive Income The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its condensed consolidated financial condition or results of operations upon adoption. The Company has irrevocably elected not to take advantage of the extended transition period afforded by the Jumpstart Our Business Startups Act of 2012, as amended (&#8220;JOBS Act&#8221;), for the implementation of new or revised accounting standards and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, which includes amendments intended to improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements and affects companies that are required to </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include fair value measurement disclosures. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The Company adopted this guidance as of January 1, 2020, which did not result in a material impact on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard will be effective for the Company on January 1, 2023 or at such time where it is no longer a smaller reporting company. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the potential impact that the adoption of ASU 2019-12 may have on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted, but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the potential impact that the adoption of ASU 2020-01 may have on its condensed consolidated financial statements and related disclosures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Subtopic 470-20) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 815-40): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_WarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_WarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21459-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529724632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Financial Liabilities Measured at Fair Value</a></td>
<td class="text">The following table presents the Company&#8217;s financial liability that was measured at fair value as of December&#160;31, 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LEVEL 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Notes Measured at Fair Value Using Level 3 Unobservable Inputs</a></td>
<td class="text">The following table provides a <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the nine months ended September 30, 2020 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2019 Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of warrant liabilities on the 2020 Loan Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities on the 2019 and 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities that could potentially decrease net loss per share in the future were not included in the determination of diluted loss per share as their effect is anti-dilutive (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  The conversion of the convertible notes into common stock assumes a conversion price of $14.35 per share for the 2019 Note and $12.56 per share for the 2020 Notes, and includes the conversion of the principal balance and all accrued interest as of the stated date (see Note 5).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334528252520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536278184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text">As of December&#160;31, 2019, the Company&#8217;s outstanding debt balance under the 2015 Loan Agreement consisted of the following (in thousands).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company&#8217;s outstanding debt balance under the 2020 Loan Agreement consisted of the following (in thousands).</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the total future minimum payments, which consist of the future contractual principal and final fee payments, on the Company&#8217;s debt are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529751576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company&#8217;s 2019 Note and the 2020 Notes balance, net of discount, consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529724072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Temporary Equity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock authorized and issued as of December&#160;31, 2019 consisted of the following (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.485%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Liquidation Preference</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Mezzanine 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,009.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series Mezzanine 2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,465,681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,235,012</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,480.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,765,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,534,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,489.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334529740936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2017 Plan for the nine months ended September 30, 2020 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF SHARES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE EXERCISE PRICE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM (IN YEARS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGGREGATE INTRINSIC VALUE</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and exercisable as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334530264376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock', window );">Schedule of License and Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s condensed consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THREE MONTHS ENDED<br/>SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NINE MONTHS ENDED<br/>SEPTEMBER 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from affiliates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcenta Holding, Ltd.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elpiscience Biopharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from affiliates</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from non-affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bluebird bio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license revenues from non-affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from non-affiliates</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Institutes of Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combating Antibiotic Resistant Bacteria Accelerator</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of License And Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536391464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock', window );">Schedule of Operating Lease, by Balance Sheet Location</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset and operating lease liability as of September&#160;30, 2020 and December&#160;31, 2019 are as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Maturity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating leases are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AS OF SEPTEMBER 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (3 months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset And Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536238728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Conversion of outstanding warrants to purchase convertible preferred stock into common stock (in shares)</a></td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000.0<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="nump">7,211,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="nump">7,211,086<span></span>
</td>
<td class="nump">7,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember', window );">2019 and 2020 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember', window );">2019 and 2020 Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of shares of common stock after conversion (in shares)</a></td>
<td class="nump">4,294,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="nump">$ 125.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334537007624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>lease </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.5753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (127,730,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (69,255,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,540,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NumberOfOperatingLeasesHeld', window );">Number of operating leases held | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,916,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering', window );">Costs associated with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">$ 10,558,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliates | WuXi Biologics Healthcare Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_NumberOfOperatingLeasesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_NumberOfOperatingLeasesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Stock Issuance Costs, Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_WuXiBiologicsHealthcareVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_WuXiBiologicsHealthcareVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610933736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Liabilities at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,916,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">LEVEL 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">LEVEL 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">LEVEL 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,916,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536219496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=inhibrx_WarrantAndDerivativeLiabilitiesMember', window );">Warrant And Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,916<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeMember', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Establishment of liabilities</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification', window );">Reclassification of liabilities into equity</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Establishment of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Establishment of liabilities</a></td>
<td class="nump">735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember', window );">2019 and 2020 Notes | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liabilities</a></td>
<td class="num">$ (2,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=inhibrx_WarrantAndDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=inhibrx_WarrantAndDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2019And2020ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610224472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">2,362,000<span></span>
</td>
<td class="nump">12,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,211,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">2,355,000<span></span>
</td>
<td class="nump">2,034,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,787,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610471272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Outside research and development services</a></td>
<td class="nump">$ 2,245<span></span>
</td>
<td class="nump">$ 3,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,217<span></span>
</td>
<td class="nump">$ 3,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334535419864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,383)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334528114616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 9,866<span></span>
</td>
<td class="nump">$ 3,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 11,037<span></span>
</td>
<td class="nump">$ 4,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610381208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion, including debt discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,563)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember', window );">2015 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Add: debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion, including debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, including debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermAMember', window );">Term A | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermBMember', window );">Term B | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermCMember', window );">Term C | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermDMember', window );">Term D | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334524243464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 15, 2015 </div>
<div>USD ($) </div>
<div>loan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,958,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember', window );">Warrants Issued Concurrently With 2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued', window );">Common or preferred stock warrants issued as a percent of funded amount</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_WarrantsAndRightsOutstandingLiability', window );">Warrants issued, amount</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember', window );">Warrants Issued Concurrently With 2020 Loan Agreement | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_WarrantsLiability', window );">Warrants liability</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember', window );">2015 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentNumberOfTermLoans', window );">Number of term loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Periodic payment terms, final payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember', window );">2015 Loan Agreement | Secured Debt | Profit Interest Unit (PIU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Award issued, per unit value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued', window );">Value of awards issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Awards converted to common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermAMember', window );">Term A | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermBMember', window );">Term B | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermCMember', window );">Term C | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermDMember', window );">Term D | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Periodic payment terms, final payment amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentVariableRateFloor', window );">Variable rate floor</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod', window );">Interest-only payment period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod', window );">Equal payments of principal and interest period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Warrants Issued Upon Consummation of IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable for shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percentage Of Funded Amount Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Equal Payments Of Principal And Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentInterestOnlyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest-Only Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentInterestOnlyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentNumberOfTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Term Loans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentNumberOfTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentVariableRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Floor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentVariableRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Value Of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_WarrantsAndRightsOutstandingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_WarrantsAndRightsOutstandingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inhibrx_ProfitInterestUnitPIUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inhibrx_ProfitInterestUnitPIUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2015OxfordTermLoansTermDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedUponConsummationOfIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedUponConsummationOfIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610364168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion, including debt discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,563)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Add: debt discount</a></td>
<td class="num">(879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">9,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion, including debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, including debt discount</a></td>
<td class="nump">$ 9,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610275976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Future Minimum Payments (Details) - 2020 Loan Agreement - Secured Debt<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">4,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total future minimum payments</a></td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount</a></td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 9,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610211544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP LOAN (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_PaycheckProtectionProgramCARESActMember', window );">PPP Loan | Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the Paycheck Protection Program loan</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334522759544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">16 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>May 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO', window );">Company valuation</a></td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Other income related to changes in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,476,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,651,000<span></span>
</td>
<td class="num">$ (3,476,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="num">$ (7,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice', window );">Conversion price, as a percentage of stock price</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Other income related to changes in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Charge of amortized debt issuance costs to interest expense</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO', window );">Company valuation</a></td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,332,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,332,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note monthly interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expense</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of shares of common stock after conversion (in shares)</a></td>
<td class="nump">3,046,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of bifurcated compound liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtIssuanceCostsNetDerivativeLiability', window );">Debt discount related to derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,107,000)<span></span>
</td>
<td class="nump">2,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,107,000)<span></span>
</td>
<td class="nump">2,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note monthly interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO', window );">Company valuation</a></td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest expense</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of shares of common stock after conversion (in shares)</a></td>
<td class="nump">1,248,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of bifurcated compound liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature (reversal of unamortized BCF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtIssuanceCostsNetDerivativeLiability', window );">Debt discount related to derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Price, Percentage Of Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtIssuanceCostsNetDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtIssuanceCostsNetDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Qualified Company Valuation For Initial Public Offering (IPO)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2019ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610444632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES - Notes Balance, Net of Discount (Details) - Convertible Debt<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts</a></td>
<td class="nump">9,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 30,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334531564648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000.0<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,534,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,534,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,534,000<span></span>
</td>
<td class="nump">12,534,331<span></span>
</td>
<td class="nump">12,534,000<span></span>
</td>
<td class="nump">12,534,000<span></span>
</td>
<td class="nump">12,534,000<span></span>
</td>
<td class="nump">10,815,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,489,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liabilities to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedUponConsummationOfIPOMember', window );">Warrants Issued Upon Consummation of IPO | 2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable for shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="nump">7,211,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liabilities to equity</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine1PreferredStockMember', window );">Series Mezzanine 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,299,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,299,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,299,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,009,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine2PreferredStockMember', window );">Series Mezzanine 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,465,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,235,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,235,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,480,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedUponConsummationOfIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inhibrx_WarrantsIssuedUponConsummationOfIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536466072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Narrative (Details)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ShareBasedCompensationNumberOfPlans', window );">Number of share-based compensation plans | plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available shares reserved for issuance (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Cliff Vesting | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ShareBasedCompensationNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation, Number Of Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ShareBasedCompensationNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536123848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>NUMBER OF SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">2,355<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">10.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">11.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">11.17<span></span>
</td>
<td class="nump">$ 10.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Granted</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Vested and exercisable</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE</a></td>
<td class="nump">$ 16,184<span></span>
</td>
<td class="nump">$ 1,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted', window );">AGGREGATE INTRINSIC VALUE, Granted</a></td>
<td class="nump">3,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE, Vested and exercisable</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value, Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term, Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610062248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (in dollars per share)</a></td>
<td class="nump">$ 9.33<span></span>
</td>
<td class="nump">$ 9.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">2.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.78%<span></span>
</td>
<td class="nump">87.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334610738184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details) - Employee Stock Option - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,303<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 3,650<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">3,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334530372632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES - Revenue Summary (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,901,000<span></span>
</td>
<td class="nump">$ 1,219,000<span></span>
</td>
<td class="nump">$ 10,112,000<span></span>
</td>
<td class="nump">$ 12,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember', window );">License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember', window );">License fee revenue, affiliates | Transcenta Holding, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember', window );">License fee revenue, affiliates | Elpiscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,826,000<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="nump">8,032,000<span></span>
</td>
<td class="nump">7,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">809,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | bluebird bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | Chiesi Farmaceutici S.p.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967,000<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="nump">5,773,000<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | Other license revenues from non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">4,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Combating Antibiotic Resistant Bacteria Accelerator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">364,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,096,000<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_ChiesiFarmaceuticiSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_ChiesiFarmaceuticiSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_OtherCustomersNotSeparatelyDisclosedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_OtherCustomersNotSeparatelyDisclosedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334517852888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)<br></strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>performanceObligation </div>
<div>compound</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>performanceObligation </div>
<div>program </div>
<div>license</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 19, 2019 </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Dec. 20, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,901,000<span></span>
</td>
<td class="nump">$ 1,219,000<span></span>
</td>
<td class="nump">$ 10,112,000<span></span>
</td>
<td class="nump">$ 12,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Revenue, Performance Obligation, Description of Timing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has identified one performance obligation as of the effective date of this agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#8217;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration (&#8220;FDA&#8221;) scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive parallel EMA-HTA scientific advice meeting conducted following completion of such Phase I Clinical Trial.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,826,000<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="nump">$ 8,032,000<span></span>
</td>
<td class="nump">7,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember', window );">License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inhibrx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled', window );">Additional equity interest percentage entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable', window );">Additional payable due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod', window );">Additional payment receivable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable', window );">Development milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable', window );">Commercialization milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementPaymentReceivable', window );">Payments due pursuant to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_RevenueRecognitionNumberOfCompounds', window );">Number of compounds | compound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">809,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember', window );">bluebird bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable', window );">Development milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses', window );">Exclusive development license | license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember', window );">bluebird bio, Inc. | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember', window );">bluebird bio, Inc. | Initial Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement', window );">Number of programs related to collaborative agreement | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember', window );">bluebird bio, Inc. | Initial Programs, Program 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember', window );">bluebird bio, Inc. | Initial Programs, Program 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember', window );">bluebird bio, Inc. | Additional Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement', window );">Number of programs related to collaborative agreement | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ChiesiFarmaceuticiSpAMember', window );">Chiesi Farmaceutici S.p.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable', window );">Additional payable due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ChiesiFarmaceuticiSpAMember', window );">Chiesi Farmaceutici S.p.A. | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="nump">$ 5,773,000<span></span>
</td>
<td class="nump">794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_NumberOfLicenseAgreements', window );">License agreements | program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience | License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience | PD-L1 and 4-1BB License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Liabilities related to reimbursement of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod', window );">Liabilities derecognized from agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience | OX40 License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable', window );">Additional payable due from agreement</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementExpenseReimbursement', window );">Reimbursement expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Liabilities related to reimbursement of agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod', window );">Liabilities derecognized from agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Receivable for expenses incurred, not yet reimbursed</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember', window );">Transcenta Holding, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember', window );">Transcenta Holding, Ltd. | License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementForeignTaxWithholding', window );">Foreign tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_CelgeneMember', window );">Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay', window );">Percentage due to advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Exclusive Development Licenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number Of Related Programs To Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementAdditionalPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementAdditionalPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Payment Receivable Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Commercialization Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementExpenseReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expense Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementExpenseReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementForeignTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Foreign Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementForeignTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Nonrefundable Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay Advisors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Derecognized During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Ownership Entitled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_RevenueRecognitionNumberOfCompounds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Number Of Compounds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_RevenueRecognitionNumberOfCompounds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inhibrx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inhibrx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_BluebirdBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementInitialProgramsAuthorizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementInitialProgramsAuthorizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_ChiesiFarmaceuticiSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_ChiesiFarmaceuticiSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateOX40LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateOX40LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334619921272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES - Government Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 5,901,000<span></span>
</td>
<td class="nump">$ 1,219,000<span></span>
</td>
<td class="nump">$ 10,112,000<span></span>
</td>
<td class="nump">$ 12,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inhibrx_NationalInstitutesOfHealthMember', window );">National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_GrantValuedAwarded', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember', window );">Combating Antibiotic Resistant Bacteria Accelerator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_GrantValuedAwarded', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor', window );">Cost share, percentage reimbursed by sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany', window );">Cost share, percentage covered by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember', window );">Congressionally Directed Medical Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_GrantValuedAwarded', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">4,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Combating Antibiotic Resistant Bacteria Accelerator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">364,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,096,000<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program, Cash from DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Awarded, Payment Structure, Percentage Covered By Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Awarded, Payment Structure, Percentage Reimbursed By Sponsor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_GrantValuedAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant, Valued Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_GrantValuedAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334520360872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,901,000<span></span>
</td>
<td class="nump">$ 1,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,112,000<span></span>
</td>
<td class="nump">$ 12,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine2PreferredStockMember', window );">Series Mezzanine 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember', window );">License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember', window );">Transcenta Holding, Ltd. | License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience | License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience | PD-L1 and 4-1BB License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ExpensesReimbursedToDate', window );">Reimbursement for related party transaction expenses incurred to date</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience | OX40 License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_ExpensesReimbursedToDate', window );">Reimbursement for related party transaction expenses incurred to date</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliates | LAV Summit Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_RelatedPartyEquityInterestInCompany', window );">Ownership interest, more than</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliates | WuXi Biologics Healthcare Venture | Series Mezzanine 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_ExpensesReimbursedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses Reimbursed To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_ExpensesReimbursedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_RelatedPartyEquityInterestInCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party , Equity Interest In Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_RelatedPartyEquityInterestInCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=inhibrx_SeriesMezzanine2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_TranscentaHoldingLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inhibrx_ElpiscienceBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateOX40LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inhibrx_LicenseAffiliateOX40LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_LAVSummitLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_LAVSummitLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inhibrx_WuXiBiologicsHealthcareVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inhibrx_WuXiBiologicsHealthcareVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334517836328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LesseeOperatingLeaseSquareFootage', window );">Square footage of lease agreement (in sq feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth', window );">Initial base rent per month | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LesseeOperatingLeaseAnnualEscalations', window );">Annual escalations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LesseeOperatingLeaseSquareFootageExpansion', window );">Square footage of lease extension agreement (in sq feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | $</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining term of operating lease</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LesseeOperatingLeaseAnnualEscalations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Escalations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LesseeOperatingLeaseAnnualEscalations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Initial Base Rent Expense Per Month</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LesseeOperatingLeaseSquareFootage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Square Footage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LesseeOperatingLeaseSquareFootage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LesseeOperatingLeaseSquareFootageExpansion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Square Footage Expansion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LesseeOperatingLeaseSquareFootageExpansion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334535989432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 8,185<span></span>
</td>
<td class="nump">$ 7,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">7,097<span></span>
</td>
<td class="nump">6,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">$ 8,560<span></span>
</td>
<td class="nump">$ 7,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334536339160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (3 months)</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">10,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">8,560<span></span>
</td>
<td class="nump">$ 7,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">$ 7,097<span></span>
</td>
<td class="nump">$ 6,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140334517820296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2020</div></th>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod', window );">Equal payments of principal and interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2020 Loan Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2020 Loan Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2020 Loan Agreement | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentInterestRateFloor', window );">Annual interest rate, floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | First Tranche | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Secured Debt | 2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Payment for debt restructuring costs</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Secured Debt | 2020 Loan Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Secured Debt | 2020 Loan Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Secured Debt | Second and Third Tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Secured Debt | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Secured Debt | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan aggregate amount</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm', window );">Interest only payments, extended term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod', window );">Equal payments of principal and interest period</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm', window );">Equal payments of principal and interest, extended term</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Notes Payable, Other Payables | PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Equal Payments Of Principal And Interest, Extended Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Equal Payments Of Principal And Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Only Payments, Extended Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Floor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inhibrx_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inhibrx_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inhibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansTranchesBAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansTranchesBAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_A2020OxfordTermLoansTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inhibrx_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inhibrx_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M3JY/H&"6X*W)BDMW[G#!*K+2Z!GNTP>RE^--P6[OXL3"U:JP2M-GM;8%TZ6
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MO,105G,U^DT6]F^,.\)YKB$\4O,G6SH.>30\Y+TK2V&:AATH1+D20-RL%<"
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M'8,-67XBE!,M"GO+W@@-=W8[3.&SBDHC .M;(?3SQ%S<ZP^UQ6]02P,$%
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MKMQ:B>+S%OX6%HXG'IF> ]UW/+[7>G[/CK]-]((:@;2HA<],(I!M=T-HWSB
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MS![K7PW[DI5E-JU?/B2QV,)5!N+[^RPKEV^J'R);_:+AX=]02P,$%     @
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M!UY#A]?0]C74\YH?2IL*68.+IVN9M"VU #U?37!,Y[/+Z?/QE )A\9R<PFY
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M@"8I33W$C>BBL.K^UG)L4X3S/%TE==:'"YG@HQ$X96G4%H7E=IBP._[FG:V
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MSNH?K.<G\R?>&$%LYZ9=AQ\L[ 8:W8J 2Y^?9[^A/<^>!NH'7:-;-ZY?K>\
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M]C702@A&2:?A/T"'!?8G)><_!&7I/VDPW"UR;T:DI;G&RHE"%K-[%VRV)+I
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MHK"^JGRH,J3!?X#9<\#LU[CZ>0BH]%XS0+!&QQ#7+A0@4P_V3K2JOA:%M+0
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M7IRC$3RQ4GO)O\3%LU.XII1>-+ASF(67BD(\5%3Z H[6EIS1P2W$+X-6PGI
M28WY*,T2M5+;V6W['+SA(\D2+7=Z?KJX^^V1UD4I[EZ FSYX6G;@\+6O4\)W
M0[J0EH-WSX\&(S:BJB-.],!##X\\P4\_HTKQ)W9&/KG_Z"A054)4V7TBJJ,?
MK$K9%OBM18\"5%#H( ^%TH,^D7@TQIA(/?W*I5)QB:XY"V]K;3_]/2'Z:#EJ
M#Z".EUR:U?B6.!SI6ALLONDCMGM:KEJN$6)TB<D<=:=-7(^D3H+8D@L#3;$5
M[V :A D6GWX.$S/A)BZ#CKRQ7N7,0&G$8RD )>]$L48E[_&1::Z#A(KR9,U]
M>I?/VNVV,M],Q]*ZFG)WX%N$0</*?,QQJN/1[&.N CD.8@@4(4]7VQZ#%*4"
M+GH 6,>WS"QIU&2Y68!'Y0U0/Y"#3!OF(__&T+3'QEM+31<^"93,\) !!*[9
MS3)Q@-$EIJFA%19OU@B4YRJW TLAR9_+LIB_A1>Q>'G%1H4,?$:GADJ%,8"$
M12D[8BA./^*7#47E*M'@KX2Y<![,GT/VZ&N>2*[3<[0QO.36'^'7@5B30L%$
MCG(>F_8/DMF_Z*F#,\0Z:<.G_H<+/CUY.AO0Z44L\&.=",^F7X<RSC3(I-U4
M:9#.\Z0H4PUR,>VF!X*;EM5:299VA\E'5THA/3AO,RE6(SY'9\ZW7WD3U4>#
M2^RXLWG?#>?/!)#\" 4*TF#4HEXY&ODQS>710'*:9\RSM.+]B^ESC>9%2>:3
M*V4M1Q$T#5J&O+ ?*;GE+P>+YT!*W"0>-JG5I8B'Z")"_% IDR(C571-7E#O
M$<6S^%4LFDH+&6C T+&I4,QP?03+-WV)!G[Y&>&8NP^$@ 2[VRRPL'^Z]+85
M/;/W3I)&()RCPC457B!+JWI<=.0'K8Y(C HW*-P$OP! 2BRS1$+.R,I-Q&.0
MCN)&]_[;X,)LHC0:$_5;4W4WM;E@R8?*M$A@HE&N"I2.X&NL4_.0;<,-^KQH
M$OKRY0D\E=P3@MU@W*S+40J=,2(M=44(](Q4Z[Y)"ZE6W@-I"-+12-FJ_$;1
M#GJ-?*@)- 3>=76E8[IOG9^>C-.NL(EGO^W@G5ND.Y3W,HN5=<8NF#-C(SI(
M&>K!F9)?!!69<&00A] L=:'0%[1QF0N9@U)J%ZL4N;^D<4R4N\AZ;9G$&_52
MC^Y-A_HPL.,9/[ZBA?I>!R.D/+,%1L>VP*V&_37W;D*;#;<$&-62VIJGX=F0
MD;U:QEDB=E:&ZZ3@4$!,R86#;_(M'*'8>UH@C+M$PURV*C@O15 = 9T\(]UX
MM";X\A5>*=RM!"UVRM$ZECD>0"#I(N%-&29!U##/_HG4$FZ5U19U!Q83./&N
M#G79'T;%@ EPW^#(C*QD3=>$E@T.E,>1">%PGF.,O0<D\5M@A#+^HL0]X)!8
M#%P/%%46R#W^&RP#XQQ8/.;#LM7OL_0RQJ'Q)$5D\NV* STUL:XTYX<V6N*
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M=V]R:W-H965T<R]S:&5E=#@N>&ULO599;]LX$/XK R$/"2#$NGP%M@''L=$
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MT  @X"/?:WP*U3M-MVJM=,>"+2+30[3W]W0FQV);*D1G*WW//33_VA@2+U+
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MC%1X3A2\*^*E_R273W*:*&\/DNV&-"0A[SU*BR/:^[>_O!B-!J\_D9>T>Q*
M3<7/AJ^/^T@F!+C@EL/!^\=2)GJF8=?'NUMQB^Q;SH'*8N0]V$G!"+\3Y;!:
MBM^;.WO!NE7#4?C3.YWW!)=#;3IHI1V<6LE]D,G21T5.S8.BLFS6Y5&PJ:5L
M;=-E=68/,ML6N4+/YT@<[U>Y1+_!01&E0ND'<FTC[B$H=4&AU5N'150P:\65
M)\L-B8XLC6GK$FVBV"/&&3;8A<3>\OC@&3)R>/':DA=1)P*E&7VG9*(UB;(V
M9+X^AN4-FZ G\DM1C$B9ERBU()B<XC^EVN-#6:4CS3)F^A&&^ 7$!F*J,REL
MKB+OU"I4[/<@M'$RV=U;]XAZ!,VR2H!F/>\/RJ+#<?^B2@!:<SBH'_3 ET@E
M8CS)$PM%8M4A<\;!\$:9'4[6Q $2M\CKBZO:\DXJ5N;W.F9X%W!I^.@T/<D0
M/.F/SVJG\Y$HVM!M:$<)I+1\W!M,SGN3\XM&7K1R %&E/0N3(,7:&H_/=FI<
MN;FELEQ7>-0_.]];X6%O-'G1&X[/]U+8>KQOY,T^6,@=0'F#H"J%'1)((RK<
MJ<J  A'!>$/N3'&[L!6(7%U_**$CU.?E_;7X:G*@PN1B<$*8QS3J-\*HZS9.
MW'*3O,W)GU;TQ;TF\[D/S68^?];*D%TQ17M]WD#U&"D5![ J5")9X$SJ@L-8
M=8RU G8EU*;:,8K%H<L^=V0/L8R2)8,;2Y8Z/M'9">A!7;V<.3B&ZC(S]!@P
M:.$OKQ2!N<ZZ0! <SS A0^[T:+N,8TW^0YP0"Q9:J,@49#>WMBU9L:Y\'X%B
M@D)>^D7+J4X@&7ZDW(+JJ=TKK2B'I&]9"79ELAM&$^(=4KC=89YE%YY(] 03
M"3SWG7(AX5_P"[/*-F0,:TD&] 6&,WB<.A!1+-_[/0>B[LYQKO?W:G6JP3"X
MP!>>!X&,/+$RRR2&'@\M\*J:8;Q/6\*S["0U 'BK,@U-T7)(+:LBTH]B$7*3
M61"DV"6,WZ;^?]79ND6!3Z=419%".&,Q??)Z[*'Q'VN'+3),2I4!?S8!F=P5
MI QT;MA:TP>F6$TF5J,@G]+@+\T<;E3F3@6Z./AB>'8R/.N)FW2J8JK+NLZ\
MMNVE$T F@)('31X<;@#*KLZ26^3X#;N9X$90J;.IL:(<1^4)/4,Q(%981%QM
MJF?+(@J,D. CKNN<:J%8DJF^AY0>J835(TW#*U4;J&FKM!O[!&I#I$JY$A&#
M4BE/ ]1RK,HE#S$@.<0!>9 "=I>^JG6U3(O!V'FVZIP-.U7*P%*?_=/G!M9-
MX!R>AK[(/'R#S^R&/&VGARFG[%YCTD83T*EONFO-J P6.1ZQ@!*Q2 (8/S&\
MRSPOS",+ %L#D7M9$Z]Z;JB:0#?B#6%^;, ZXFO&<W(X<NF1+N!S3-T[UC;R
MXV^%SC$QT)AQVB0Z9HU+CL@W3+8[A;+R<!N'%?" T^KIG(?]1,^]_#:DK0_6
M\,"#MMQ&V(JU3N;%TV- $92E; $D,PJN3V(2 &EM.=:0BK[XL[A9"*@INV"8
M!Q*Z0K')[-[4Q,C$*$!716/J)A\M)&A5R?36HUZE^X8^*:M^T3PFC 9KLB-9
M%$]<1-5]14TEG*:)ER-:)W&5+O-,_U#QUI2N\,V4MRKGS:GV3T[JB__KI*X:
M1S:7<Q[@T1J*^ 28XIH#.+<VI+6_N:J@VN?;EES8:)9/@O=HO\B4(ES)$)XT
M;PJJ3/7-E<F+14EQTF2D0H[IFS'93.F.D"] =%ERQ7?EN@RV\E'!Z9;*#/92
MUE3MR-O2'/81R6FI-QX]2#3C96B+">=FN T*UPGE6>M,M4N0,D^RF?50"F2^
ME<]TA@B1&&(@C^B<\#2>%4_^I!XM7JDDJ6Y1EL@.*%P'JGV@Z+CSB8X"AU<Y
MH1?=V]71KI2KA14J-T5HJ/O&UZT'UT_NPQK?^^*::[VZI^QXFLE+!27K+5'$
M!=T'16TA>VE8,CDBVMWJTO!95%716LR4$XFQ^X/R3GTZB>Y9Z0]5F&;.,QP]
MT@U$!U%G%5]'N+2DJ&Y"WM)=OK9B'5<T)JB#A-/5'5Q#O8"=/SF(Z_J>D!Z&
MJ:UYS[?)KQ6)W1(M/]X_$K%9:F 7@/US:UPL+Y':P.H:>[BH;364;SF(4R*A
M=WQ/"(;*&MW4^(&(X\,1;25!1EPU]:^ /"NX5[D+-3#8=&-:J5E>K\--2AR.
M&K=1/.?[LQMYWLZI+8;HG6T ,Z,+_!$B#"8C+G8>F\-K(@;*N_71HT,V$FL:
M$\>SZ4$$%*/]^ESQT_<K6PB^6X1!<>L@619$NJ4"Z.:ASI/M9(9S36<G6(6I
M,5.,>[3/?THZTPH_)S;95WU3KQXQ6FX9$=NNC'?#3?>U5Y5;A\-A_ZR^W?1,
MHTD7-E(,) ;:C6M56'G]$\E<TQ4JJ>OL7CR#)'F-6$ER<,NZOKBLSDDP")(?
M2T_H;6_VZBKO6L1 1]J J5!YS5IS1;.H M5#0$J V-G6Z&YXU'!G0Y*GH:72
MD;'.ECVD8>9S9/29*&]%D!9H_(^";#=$N?) /<RT([U70'T -Z+BSP5P@SI;
M :ZE0FA F$(P=?R@G'H(MR\8VE6K%<-"OZI%Q=H&S0J3-I!BK=AI@D\V--YP
M(T-)Q&_*B%&]J!V#H]L7:EV;MMR5<M-;9K5UM=GD^O-&[802V/IVY \PAFX2
MI$K2]Q/\LNY]<I#''<37N;\]]B]?Z2Z93J;$G86;$OIV#F7[9OO0W0UF&MI?
MC=XDO/-&0XK#B_ZD\D+@B#M+9U>FRRA2";7<8&5+MW;>=7)]$\R4+MU,!-8M
M&?5'E25@%<6<[T.[K^/*=W@;IK1-!&YGTP\XT6/Z3)0EF-=KHS3S99,D9D7*
M'C&#P:P%@?;X%:B"N/T@WM]<WWRZNOE2SQ5WW?>NAV(RZ T& _%MNUL/Q='+
MWOEX?!Q8AK]+H +V2AX29QN?7XA-WXTY;7SG*%7P'WVSBD 2HOW7CZJGU9>W
M+OUWENKE_IM?G^!^Y+=(U Q; 7)G!Z+PWZ;R_SB3\S>8IL8YD_*?"Y!35= "
M?#XST#G\0P=47VE[]Q]02P,$%     @ *8%M4=X/?=4"!@  20X  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&ULK5=M4^,V$/XK.RG3N9LQCNTD)%R!
MF0"Y.:9'DQ*N-YU./RBV$FNP)9\D$[A?WUW),0D$VD[[ 6+)N\\^N]H7^62M
M])W).;?P4!;2G'9R:ZL/W:Y)<UXR$ZJ*2WRS5+ID%I=ZU365YBQS2F713:+H
MJ%LR(3MG)VYOIL].5&T+(?E,@ZG+DNG'<UZH]6DG[FPV;L0JM[31/3NIV(K/
MN?U2S32NNBU*)DHNC5 2-%^>=L;QA_,^R3N!WP1?FZUG($\62MW1XBH[[41$
MB!<\M83 \.>>7_"B(""D\:W![+0F27'[>8/^T?F.OBR8X1>J^"HRFY]V1AW(
M^)+5A;U1ZT^\\6= >*DJC/L/:R_;0XMI;:PJ&V5<ET+Z7_;0Q&%+812]HI T
M"HGC[0TYEI?,LK,3K=:@21K1Z,&YZK21G)!T*'.K\:U /7LVOYU>_/QI^OER
M<C/_\8=1$@]_@LFO7ZYN?X=WEY./5Q=7M^]/NA8MD7PW;5#//6KR"NHQ7"MI
M<P,3F?%L5[^+#%N:R8;F>?(FX)Q7(?2B )(HB=[ Z[5N]QQ>[Q6\R;=:V$?X
M8[PP5F-F_/D&9K_%[#O,_O\<RO^."F,L$PPT,)G!#3>665Q<<&W%4J2X +6$
M*YDJ72G-7#5,)8SK%>87)+&/*M05[J>JK KN1%#'YARN9M/ /5S@*R8?&Q(&
MTEU\L8._9@;8%BN]8645L-KF2HOO'.(D"J+(_8')&0H1$G(H$0)S/[USRO%@
MCQ3VH"77&B&=8 "<I3E6C\V!0<4TW+.B=LP.HA!58ZBX]OHA^B+OB?ZBX#!K
M@>;.XDP+I8FGL.BD$W0M"'=VF F*EI1->W&&]X6IC5^Z9?,9>1>NM&#&8$ I
M8@8L+RF8^C$ 9%/R[]^9Q-1 -WWJ$B$$96GJ[0FY(@L9]DL$P">C"I&YD"]8
MP63*P74) T;0@I2;8**PQ?9-:L@/G_"T,C3O_%IR9FN2LCFSL.::@U06$)T7
MC\YK(3?N68W]JTF;)@PAW#XM(&>9TT;W[X6J#2*@ YJ[Q/B;$#4'LD7-'_ +
M=UJ.)(HCC,!\"K::%&Z2H/<^)Q=D4"U(>#<[GM-HD]?GM3"F]@>&?E_RE)<+
MS+*>JZGXV)V#,.1>$Y:E*G .TF&]<W'#("",P6-]2'EEO0\.N<U6K"-52VO>
M?X#Q'*8?X7)R,;D^G]R0&6=E[AT?/U%K=JX:=@@WK2U6H,S(M-N&&<=$SRC=
M4[?P2C!>K31?45%_%IAJF:]G7R2<0CU'/<2^WJ0DQ- /DN/CH(=4GIZ0V1 .
MZ6<$!W 4'M-/CZKX.$Q>@B34B/I'@^!H%,,H2'I8\W'BU0]],!N4P3#HCZ*P
M#[?*L@*203 \<@T"VTDPZ/6#7B]&V1&)'8='<%EK<IJB_\BQ+_BF].*L=IK<
MYESC<(A3MR@H!$^M9P_YYTT$:P6[4*W3'*\,F$048VI%SH/V: /JBWA_('Z8
M#I)3::B4\\S9816N'@3>/:C6#N(DC#9L F!+BS#H2ITZ?;5$ O3 'RIJ B:$
M7]1;I..7I#%/_H%OKL": &5/P772I9_[/L8XM6T3Y&9TASB&]G;-EW-G3Q^E
M&&VF%H)A#(JVWZBM_-X>)6_T7'*C$<!-(;$-#(,DCH-H=+2%L7?V;0T"ZA=N
MY:/SE6G-L%QA;" 3!N]PQJ'C:6!-]?:FV7JC@Q2F#WC5=AT\K9&MM$V;=7IN
M4']6#.. 58K-2]H0OE2J;<'N<OUOPTAR+07J ?R!ZU08USJ1#8:E-^B_-J%W
M#5'F'\1#G+C;\W;<I.#S?-AGV\VWP^UIZ)KWDB[R/I(LRP3YB-5?,9$="GF8
MLDI0-R#K41CW-W7BY\^2B:W[P(Y)&@49#B!=N@E8FTTZGQ<LO3N<ISE..H-Y
MG?%B,W2SYLKS=#GPM58O#++',T&Z)6>FUNZ$\)1Q ]VBW*-POG1Q0R?<=P_M
M;EWO2ZY7[B.&<A"G@K_IM[OM=]+8?QX\B?N/K&NF5T(:*/@25:-P..B ]A\N
M?F%5Y3X6%LKBIX=[S/%;CVL2P/=+A5G<+,A ^_5X]A=02P,$%     @ *8%M
M49^U<<+*"P  Y!T  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK5G;
M<MLX$OT5E'=F*ZF29=U\R;5*MAE'56/'*SF9G=K:!XB$)$PH@@%(.YZOW],-
M\";+F=FM?;!%$4"C<;K[=#?T]L'8KVZC5"&^;]/,O3O8%$7^^NC(Q1NUE:YO
M<I5A9&7L5A;X:M='+K=*)KQHFQZ-!H.3HZW4V<'[M_SNUKY_:\HBU9FZM<*5
MVZVTC^<J-0_O#H8'U8NY7F\*>G'T_FTNUVJABL_YK<6WHUI*HK<J<]IDPJK5
MNX/I\/7YA.;SA"]:/;C6LZ"3+(WY2E]FR;N# 2FD4A47)$'BXUY=J#0E05#C
M6Y!Y4&])"]O/E?0/?':<92F=NC#IKSHI-N\.S@Y$HE:R3(NY>?BHPGF.25YL
M4L?_Q8.?.QD?B+ATA=F&Q=!@JS/_*;\''%H+S@;/+!B%!2/6VV_$6E[*0KY_
M:\V#L#0;TNB!C\JKH9S.R"B+PF)48UWQ/OK'Y]G=;^+BT_5M=+.8WLT^W8C;
M7Z8WB[='!<33I*,XB#KWHD;/B'HEKDU6;)R(LD0EW?5'4*O6;53I=C[ZH<"%
MROMB/.B)T6 T^(&\<7W6,<L;/R=O(ZTZ)!LFXE8^PK4*,;569FO%S_^:+EUA
MX2?__L%FDWJS"6\V^7\ ^T-1%)>O72YC]>X @>>4O5<'S\L7B\+$7\4LBW$F
M>+RX364F[C9*7)AM+K-'L9%.F$P)U\(CQAA"37*HY%C1$P663 $,C"EDEHBY
M<H4L\&4T&)Z*:)NGYE&IGKC4%B%F+$^Z,)E#0$C &7TK=?&XJ\@+$OOWOYV-
M1H,W+(C>\O?AFY<]\;#1\4;DUMSK1#D!UF$]M'.EA"!A5D+7 AV?U.2DM.N!
M(V ^'1=!WS)KO?!3Y8.T"6;2L(%<Z]\'#/QH7TP=;0/O*]1VB3F5"](Z(==K
MJ]; @>:,^P,$99H2:(PFKP266WK!6SXHJT2P6L+GJ<]2 EI_O!J('JWW& SZ
M)[5L%B+OI4[E,E7]8.)/?' Q)6(CI-LVADG,.M-_0*..:6/C"H?1E"U9F#T
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MHQ2RPM)!__3XP+-\]:4P.?^.MS1%8;;\N%%H]"Q-P/C*("[#%]J@_F'W_7\
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MU#BN0JQ12;*F,E]!XBLQ"0;=J"DO,RH)W@9HT&954GYM ZM,]C'\IF(_D7-
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M,<%OP-X8:FA+W(=5?#B0B_6#S7((53=!EUJ 1=>=#/C7^^(HI\)51L/84@/
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M&:#/E(VX%+F.N,H(R@W^:-Q*KV8*\*?+]<A_^6EOT-]]X<382-@ _!,%1][
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MOYT,LCXYZ@>Y:7_$KBH;T0W,YL!@!)!C$<QO).UU:UJ1FJ66_Q*O"U'#B&H
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MXTDGGDNV-]Z4X1/7W'AOBG"9"]3:T@*\7Q@Z%<8;,M!\\SS_-U!+ P04
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MIY1J@QJL;<05^53QP#'Q@W=Y09U@EXMM,]TU,%NF'SS_HMTY>&Q;OW5WL*"
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M[Q$Y5'U-UXJ1I;L:-]+01>O$/?W9H+(&M+^5TAP5>T#[KS3Y%U!+ P04
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M-_0PHG8)M+Y2I'DW<07JI[;W#U!+ P04    "  I@6U1GDA'<B@#   ^!@
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MF4[PQWU_\@.Z=X-1,!S[D_[=$$;?_.$83B9BFJ ^O:P:\L/2U=G&YG5AT_O
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M$-%X^XF?,R'V F"](@!E >A- ((5 4X6X+P)<)R*@'H64#\U@YL%N*<&-+*
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MRHH^G>3G,QY0Z^34.K74;"T^PRN-;Q]<,B7U=,8#Y@]XG>:\3FMYE0J(OZB
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MM8!KB)O(M;\@;&.[@L_TW>E.OX:.6VC@IGCN&;QK0@7Z3L($OJ"QE* D(BQ
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M2[2[;1^J/GC!"58!I[;9;+]?_YE+( %"J;K=EP3,.3-S9IPQD_&>LA\\P%B
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MBD"N\D#T,X$8X(;&(N!@&?O8;^$ONOE.!U^522DSHQ\R<Z5W&GS NTM@:!=
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M%]L#[':@>&;/@ NN](G2WJ[UH1^$F:#?+SE7KP-SK"S_1HS_ 5!+ P04
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M%RHQ(^D+U$-B33@5^=\*Y0FL?$TW7>0[>_ZU4'W;6M4=UH_ZW4E\>_]'?/L
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M_MI8?B'9QKQ3=,ND9(GYN%8UAG+=0/V^9$QN+_1K2KN7]R[_!U!+ P04
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MYM4%T@:8YVLA]/O&3M/N99C^!5!+ P04    "  I@6U176*/ =<"  #5"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RU5EUOVC 4_2M741]:J6T^
M2/BH *F%5:O4#U36[6':@PD7$C6)F6U**^W'[]I),PHD19WZ0GSM>\X]/C:V
MNRLN'F6$J. Y33+9LR*E%F>V+<,(4R9/^0(S&IEQD3)%H9C;<B&030TH36S/
M<9IVRN+,ZG=-WTCTNWRIDCC#D0"Y3%,F7BXPX:N>Y5JO'??Q/%*ZP^YW%VR.
M8U0/BY&@R"Y9IG&*F8QY!@)G/>O</;MT#<!D?(]Q)=?:H*<RX?Q1!U?3GN5H
M19A@J#0%H\\3#C!)-!/I^%V06F5-#5QOO[)?FLG39"9,XH G/^*IBGI6VX(I
MSM@R4?=\]16+"06:+^2)-+^PRG,#JA@NI>)I :8XC;/\RYX+(]8 ;J,"X!4
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M!YG?B&23??+UF B11-GEFE'I1R4@WR\3F:J*&_45V>YKU(O_ U!+ P04
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MC=$5WZ&D8:0,LVE,I6G?YW5)VPT<%FZ&#J3%BQ-V(.*'QB?A7T)1Z%Q8?_?
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M;@GV29(N$,_7E/*/0>J@_*-A]#]02P,$%     @ *8%M460X+K(I P  BPD
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M3#/VQ>T0,DZQO'EK MLIQ#L?(].F\7I7&>^4ZUQX[S<S#G[%807(=*R#9%>
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MIKN'476;97I/[QP%/,M*.=-EW'F.:UKRRSAXACN9:>\PTUZ3#(,_^RA+D,#
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M$;120=M5,#L4]%)!WW4)=R@8I8(Q5,$L%<RA"E:I8 U5L$L%>ZB"4RHX0_.
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MHN$H6%%V//MFM#S#*G9:<E.)G(*QVA*<R0PZNET7;$1L;B,VP8COBUB/T9U
M$R3@Y!B-2>+%=),77M$"/5)6"2YED R/\[@BK(I;;]SP%:W<!%&?K0NZH,1'
M$5N!-2Q#T79TQ 39F"G3)8L%R;>_R'=34ERE"7*K4O 8O:RHMT+L6AI5YE@F
M$^+&[#(O(GT6:A!M\GL@(?$S*R<2Q,30Y8J2A"(_BUEH^6A1$2\S0R._,OU"
M@P!YK&:C;,+0ARP,2)+DXJ6![YMF>9H[0V(V8<QE'S%/ DK8%ORUKL3&3\7<
M?$09LQ\@4V%QOG+W@B!ZJ=P*W"3EX46>E\5\#C[0CW7M?__#5K'U2\)"#=A4
MQ:]<N!JGF,<TIFR%;U@*\IET\PG@7RQHS(S?Y5]<HTN6/^HQR4<N?\P&VGND
M!0L[H'^QP-D$9"F?ZSA:YU_YA'U)\VP^G3R<H*N(P05/T3C.EFCD,P6:I&6U
M_X&/I2J_7(U'^2?\RT>4>+18/AYR?9Y(ACDDY=/$\N-G'I]N,76\1 U(M8*3
MC.6R*T[N!(OU;PIVX\9N$)  36:C3U\?1W]7'"< EEM;8+# &[;:?BT(J0#Q
M&(51^,E=+&A V8J&&,/>CF(?$(\Y6Z^<M]& TZ(!S5;--@VTY2Q';[. TP)W
M6]$D)" QMS-L(URLB'VXLG^R!R4:U_;Z^(!2C57AE_JV9)?Z]6GGN6EG6R*X
MF^E2Q.RS-9/8PCN"S7A%Y8@U,-Z[U6O@_F#4=$&C!XX_'LOU='H)3:8H +%^
M2$D6=1V&"[NR,J4AXV-6E')F9RL^=9>RC%_V&,/*B:+\"_)+5%\8+HM&OD]Y
MP&P%DDX7$>>(-&!<P'@G)AYA,R=U&Q[+Z/-:4 .&N>%GEI!@!'Q(E( %)V"8
M%-C ,5EDH>_. Q9NMF$,SX;<N*\=6YQ+W,9UU0#N857@M0KC=6W9L/&Y0ZQZ
M)47-L2V)I4T_I8UEH$L"WE6\ATMY-HJEFGM75-+23@YL%MM%)0SU1P74JS#4
MCVL[@#5EY7N:[SU:[DIG3L("Y=1US9V 9!6&9%9GKMG=3GD)612]>WNGM>G"
M@KT3F*Z^VZ[^LC35V"!#3@@ 5V',O2NF(<G7^2:+D\P-\[T0O-S;VV9X4@1P
MJS"8WF;K.<GW8/*M:X+^AX8VZ"[+L1K9ZW!08+0*8[1PL.K0<Y> ;OUE:;"Q
MPCN\$&"NVC_%%,R5MVTP5(';JG- ?*()#-=@#"\[+_S&CI9AOG>,29!W"D0'
M8V=5R<I3K0WIMJ2BG)9R9K=<,Q"!_!H,T;T%=*G?]+#=#/LFD6L%,<S4##35
MC%.PAP:SQSS(R)S&/IK3Z!A=AQZTS=9JG=Q#:N5J O8U&/;WKG>^:NU^K 6A
MK2;07X/1_PW$/=8D'( -R1UR-T2R&8"@"PVFB\D/+\B2O'U9"Z4\T61@V'VV
M.=;:Y- !RYH@!PTFA_92?C,@:X(3M$,J\#5!%!I<X+\3(/^JM<M^\#;0!67H
M,&7T(>U8;V.\+EGI-WJ;,W;!N%]D*A&1C3:3R,$3(JA'AZE'NHZO>;>5S=-=
M<>(+'FP)\-?5 UJTNF /'=XZ[(W2X](@L$::KM0._WH(XQU+XK'>WDATE,2Z
M8!$=9I&:@^72J-_@S?QMMQ7<Z<Y'!\9Z^T"P YQUP14ZS!6#%O5Q]0EA:!T)
M1M"M0UK?@BQT> /Q$^O;[FBQ=N1%\(,.\\.>>5&!^ T!^89R0'DQ!/(:,/+N
MGY?2X-"\& *:C7WK<I:76CMJ  \8 F^-0ZK6#0&^QF#P?2]L,]H0;'?DJO9\
M!0S!Y:GIE<LXP"-92CV*'DXV)R-H+V4(Z#3,0\J.0%>CIQFS[]TR*0TVGPR!
MBB9#0*H!0^K/-H\GI=T&)X/=8T-@J]'37'_'VN&[T3XG[:@=3('#)EQZSW9W
MG0F\[9R8[5(<J^!LF0)\31A\N^^B-V_C3 &[YB%5Q*9 :!.NB-^KKV:V6^KR
M8U^)H+0!)Y$S9(*S?H/-J1$D8<(DT=NI,]L='.R8EB3F-C=(GVR0&#0L2Y/$
MW&NP&;-@'+/GY#?8T*3H/$/+J_:\W"%1C"DHQASVO(XK7HZ V/W"A+K]Y6KH
M%9F"(LU(!#^9,#_5,M8%9\.@3+"/>4A'!)8@'>MM_9X+JTTR4HRZ&2KXS>IO
M^PRU-0-M-:=$4)\%4U]S<=R-/TUQ_M">_@E?7&P7RTA>QC3'%$QG'1+368+I
M+)CI>N'<:A-)*]^](M-^D1DHTHQ.D)4%D]6^%=>#)2$O!:R9+<$B%LPB4^K.
M&>*DK.ZJ5Q,QH>MY%B=%KEGU"M7/WZQVLZ@UD;TB]U;[E$(#@Q349L&-IWJ0
M/JG53\VM02*-K7U*T8JM+6)!?M>>5(6IKXD)W_^K*_L!@6 FZY!.+BS!7Q:\
M>_K9'=V%)=DI2>ECF-RT7Z[YE+!@0OMM3'AC2QYLDA*<1' WBJ&V9J"M9J2"
MX&R8X/:%O=_L=E^M!_9LP7PVW%J[;^ ;^;'A-Y7L_K^VVP^V:M*C)[O_(5F)
M"-0IM 5AVC!AO@>*7]B]='C3+S+M%[FUVP<U73,@2-6&2?4M$&]+CF2D=X5$
M3H/R)UC8AEGX7CQ0R%];J=8CHJ&7Q3'Q>9\C1:\D%2F5/>ET8;<I5)6N5<GI
MC@SV^N6: 0M&MGO>FN*DD3\%C+Y&@4_#Y3&:IC[4++4%;=J'=.1CUUX)@?=_
M^R+@H]T^\>E#0$&M=L^K(!T9>-/.U!&\YQS2\8\C6,IYVS-?5TXG*^W<8Q+!
MUELTO2+3?I'9 (^:DR%8TH%9\BIB<+,,4>K^0"\T7:V*A2*=EC9-0@62(ZC-
MZ7F$F 1+$D(M+D>0A'-(+W$X OX=&/[W!88GIXWSCJ:#$RZ@V8&A^4Z\GL%K
M;?XDLO],DRB6<>=3:0RK]05ZHNSVRDYKOZ6R)O$R_[&G!'E1%J;%:]C;J]L?
ME!KE/ZNS<_T"?[[&DNLW^/,WV?4I_CPK?M-%#%O\JM7,C9>4Y3(@"^:"<L*W
MGW'Q0U'%'VFTR7_A91ZE:;3./ZZ(RXH++L"^7T116OW!!]C^7-?Y_P%02P,$
M%     @ *8%M40>=CF3S!   -1D  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3 N>&ULS5E;;Z,X%/XK5K0/LU*W8$-N51HI#6F::AI533O[[( 3T #.VDXS
ME>;'KR$4:#$&3?.0/C1 SO?YW'S.P1D=*/O)?4($^!6%,;_N^$+LK@R#NSZ)
M,+^D.Q++;S:415C(6[8U^(X1[*6@*#20:?:," =Q9SQ*GSVR\8CN11C$Y)$!
MOH\BS-YN2$@/UQW8>7_P%&Q]D3PPQJ,=WI(5$2^[1R;OC)S%"R(2\X#&@)'-
M=6<"K^XM,P&D$C\"<N"E:Y"8LJ;T9W*S\*X[9J(1"8DK$@HL/U[)E(1APB3U
M^"\C[>1K)L#R]3O[;6J\-&:-.9G2\-_ $_YU9] !'MG@?2B>Z.&.9 9U$SZ7
MACS]#PZ9K-D![IX+&F5@J4$4Q,=/_"MS1 F 8 T 90#4%F!E *LMP,X =EM
M-P-TVP)Z&:#7%M#/ /VV@$$&&+0%##/ L"T FN^12U/2.(8\S1<'"SP>,7H
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MP&U6 -P"X!X"G J 5P"\8RTT"D#C6 O- M \ #A^!:!5 %J'%KP*@%\ _$-
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M/E=X+Z1<#<#_:K79-92!\J;9_P]02P,$%     @ *8%M4;>.VAO1 @  -@<
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MD<]L]QU5]02:+V%$F"?85;&.!9)"2)958*4@P[1\P[?*AP. V[X \"J ]UF
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M_T&QGRA>V3-YQ94^X>TPUQ]A(,P"_7S#N7J=F&.^_:R;_ M02P,$%     @
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MPZ_GISA#-56+-AC!SG[ *:G9O)WU:#:BF=79/\SR_, 6[-Z:XK]02P,$%
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M+GAM;%!+ 0(4 Q0    ( "F!;5'D^'R"[0   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "F!;5&97)PC$ 8
M )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ *8%M4<<IV&=F!0  EQ8  !@              ("!# @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "F!;5&D.:FRUP8
M %L=   8              " @:@-  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  I@6U1.U(=I'T#  "T#0  &               @(&U
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ *8%M4=50
MS&8*!@  3AD  !@              ("!:!@  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( "F!;5$9MH)]=0L  -U0   8
M  " @:@>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  I
M@6U1*L@W87T*  "5,@  &               @(%3*@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ *8%M4=.:V45P*@  @X<  !@
M         ("!!C4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( "F!;5&+#^@(! 0  -\)   8              " @:Q?  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  I@6U1E3A\QPX+  !>'P
M&               @('F8P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ *8%M45O&I4AR!@  ' \  !D              ("!*F\  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  I@6U12J23KA@,
M  #>)@  &0              @('3=0  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( "F!;5'>#WW5 @8  $D.   9              "
M@2*"  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ *8%M
M49^U<<+*"P  Y!T  !D              ("!6X@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  I@6U1#0BC1VD8   Z80  &0
M        @(%<E   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( "F!;5%V5SM!804  #H/   9              " @?RL  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ *8%M479VVL$U"   _Q0
M !D              ("!E+(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  I@6U1"WWB 60%  !##   &0              @($ NP
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "F!;5%O.#H0
M^P0  "\,   9              " @9O   !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ *8%M4654H_8U*@  ZXT  !D
M ("!S<4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  I
M@6U1N->P9$4%   P#0  &0              @($Y\   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "F!;5&R[[8<Z@,  -P)   9
M          " @;7U  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ *8%M48&M"HZ2 P  -PD  !D              ("!UOD  'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  I@6U1$ 5>-;0"  !V
M!0  &0              @(&?_0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    ( "F!;5&>2$=R* ,  #X&   9              " @8H
M 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ *8%M43?6
M-&(K!0  IPL  !D              ("!Z0,! 'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    "  I@6U1/6V?2@$$  "G"   &0
M    @(%+"0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M "F!;5&'@"98GP,  &,(   9              " @8,- 0!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ *8%M44K.4S,9!   N0\  !D
M             ("!61$! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  I@6U12!H>>M4$  "6%   &0              @(&I%0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "F!;5'66YHLP (
M !X)   9              " @;4: 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ *8%M46**57H3!   2A   !D              ("!
MK!T! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  I@6U1
M!%IRU>@#  !=$   &0              @('V(0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( "F!;5%8E$LHHP(  "0&   9
M      " @14F 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ *8%M45]^QX;K P  %A   !D              ("![R@! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  I@6U1TXOV\L("   N!P
M&0              @($1+0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( "F!;5&!>/M"* ,  %(,   9              " @0HP 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ *8%M45NM4)Q8
M!P  R"<  !D              ("!:3,! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  I@6U1">R[[K,"  #C!P  &0
M@('X.@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( "F!
M;5&<AHK5F@(  !@'   9              " @>(] 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ *8%M45UBCP'7 @  U0D  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( "F!;5$1Q)&@4P0  '00   9
M  " @4I8 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M*8%M460X+K(I P  BPD  !D              ("!U%P! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  I@6U1Z#LM>#P#  #D"@  &0
M            @($T8 $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( "F!;5'Q>.S" @8  '8B   9              " @:=C 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ *8%M43P%;*M\#
MNDL  !D              ("!X&D! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  I@6U1!YV.9/,$   U&0  &0              @(&3
M=@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( "F!;5%[
MF&T%R 4  -@<   9              " @;U[ 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ *8%M4=(2/B0#!   =0X  !D
M     ("!O($! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M  !"#0  #0              @ &^D0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( "F!;5&7BKL<P    !,"   +              "  464 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( "F!;5'G#4G\=@0  +,D   /              "
M 2Z5 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  I@6U1O '6P> !  #L
M(   &@              @ '1F0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  I@6U1%-1QY- !  "M(   $P              @ 'I
LFP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /P _ # 1  #JG0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>303</ContextCount>
  <ElementCount>410</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2109102 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2114103 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2120104 - Disclosure - PPP LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/PPPLOAN</Role>
      <ShortName>PPP LOAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - CONVERTIBLE PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - EQUITY COMPENSATION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS</Role>
      <ShortName>EQUITY COMPENSATION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - LICENSE AND GRANT REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES</Role>
      <ShortName>LICENSE AND GRANT REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2142110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - COVID-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/COVID19</Role>
      <ShortName>COVID-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/DEBT</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - EQUITY COMPENSATION PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables</Role>
      <ShortName>EQUITY COMPENSATION PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - LICENSE AND GRANT REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables</Role>
      <ShortName>LICENSE AND GRANT REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails</Role>
      <ShortName>DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails</Role>
      <ShortName>DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - DEBT - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails</Role>
      <ShortName>DEBT - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - PPP LOAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/PPPLOANDetails</Role>
      <ShortName>PPP LOAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/PPPLOAN</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Notes Balance, Net of Discount (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES - Notes Balance, Net of Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - EQUITY COMPENSATION PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - EQUITY COMPENSATION PLANS - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails</Role>
      <ShortName>LICENSE AND GRANT REVENUES - Revenue Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails</Role>
      <ShortName>LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails</Role>
      <ShortName>LICENSE AND GRANT REVENUES - Government Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inhibrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="inhibrx-20200930.htm">inhibrx-20200930.htm</File>
    <File>exhibit1011-firstamend.htm</File>
    <File>exhibit311.htm</File>
    <File>exhibit312.htm</File>
    <File>exhibit321.htm</File>
    <File>exhibit322.htm</File>
    <File>inhibrx-20200930.xsd</File>
    <File>inhibrx-20200930_cal.xml</File>
    <File>inhibrx-20200930_def.xml</File>
    <File>inhibrx-20200930_lab.xml</File>
    <File>inhibrx-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "inhibrx-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 303,
   "dts": {
    "calculationLink": {
     "local": [
      "inhibrx-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inhibrx-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "inhibrx-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inhibrx-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inhibrx-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "inhibrx-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 522,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 9
   },
   "keyCustom": 74,
   "keyStandard": 336,
   "memberCustom": 41,
   "memberStandard": 31,
   "nsprefix": "inhibrx",
   "nsuri": "http://inhibrx.namespace.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://inhibrx.namespace.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120104 - Disclosure - PPP LOAN",
     "role": "http://inhibrx.namespace.com/role/PPPLOAN",
     "shortName": "PPP LOAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - CONVERTIBLE PROMISSORY NOTES",
     "role": "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES",
     "shortName": "CONVERTIBLE PROMISSORY NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - EQUITY COMPENSATION PLANS",
     "role": "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS",
     "shortName": "EQUITY COMPENSATION PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:LicenseAndGrantRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - LICENSE AND GRANT REVENUES",
     "role": "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES",
     "shortName": "LICENSE AND GRANT REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:LicenseAndGrantRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - COVID-19",
     "role": "http://inhibrx.namespace.com/role/COVID19",
     "shortName": "COVID-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "role": "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - DEBT (Tables)",
     "role": "http://inhibrx.namespace.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Tables)",
     "role": "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables",
     "shortName": "CONVERTIBLE PROMISSORY NOTES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "role": "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - EQUITY COMPENSATION PLANS (Tables)",
     "role": "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables",
     "shortName": "EQUITY COMPENSATION PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - LICENSE AND GRANT REVENUES (Tables)",
     "role": "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables",
     "shortName": "LICENSE AND GRANT REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i89b94e216c8747f7a8147b47e4efe7c2_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i89b94e216c8747f7a8147b47e4efe7c2_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "inhibrx:NumberOfOperatingLeasesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Liabilities at Fair Value (Details)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i97607866f6cc41cc94cca89d10cf6bdc_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9257d69f32004657829030276365dab2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ica2104115bc94b9fa8ac3b4e7d8a5952_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)",
     "role": "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)",
     "role": "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:AccruedResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)",
     "role": "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:AccruedResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details)",
     "role": "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
     "shortName": "DEBT - Outstanding Debt Balance 2015 Loan Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ib7a938740c8f41d98cdd5977f98ba01d_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - DEBT - Narrative (Details)",
     "role": "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
     "shortName": "DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i7f48b6f3d1bb40d981c9d05fcdb64060_I20200715",
      "decimals": "INF",
      "lang": "en-US",
      "name": "inhibrx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)",
     "role": "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
     "shortName": "DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "id069de05c44b419a8bc04341e87faf34_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "id069de05c44b419a8bc04341e87faf34_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - DEBT - Future Minimum Payments (Details)",
     "role": "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
     "shortName": "DEBT - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "id069de05c44b419a8bc04341e87faf34_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromShortTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - PPP LOAN (Details)",
     "role": "http://inhibrx.namespace.com/role/PPPLOANDetails",
     "shortName": "PPP LOAN (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "iab2815bc314c46819698b119c61f9104_D20200511-20200511",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromShortTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i89b94e216c8747f7a8147b47e4efe7c2_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:QualifiedCompanyValuationForInitialPublicOfferingIPO",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Narrative (Details)",
     "role": "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
     "shortName": "CONVERTIBLE PROMISSORY NOTES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i3894c29c607640ecb0416a55ad4bb599_D20200821-20200821",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i002ad8c894fe49eaa73e28fe15dbaa17_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Notes Balance, Net of Discount (Details)",
     "role": "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
     "shortName": "CONVERTIBLE PROMISSORY NOTES - Notes Balance, Net of Discount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i002ad8c894fe49eaa73e28fe15dbaa17_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i89b94e216c8747f7a8147b47e4efe7c2_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details)",
     "role": "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i89b94e216c8747f7a8147b47e4efe7c2_I20200821",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - EQUITY COMPENSATION PLANS - Narrative (Details)",
     "role": "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i7b6fdbbcb0c3430aa47340c75d0dbad3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - EQUITY COMPENSATION PLANS - Stock Option Activity (Details)",
     "role": "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)",
     "role": "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "iabd02944395c4cd4867b8652d51a714a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)",
     "role": "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "iabd02944395c4cd4867b8652d51a714a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)",
     "role": "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
     "shortName": "LICENSE AND GRANT REVENUES - Revenue Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inhibrx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i06e44a5c0664414894b59ef342a25530_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)",
     "role": "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
     "shortName": "LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfTiming",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "icd8a35b2ae25448f8fa52a2a75f422e0_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "role": "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i4e883e4dde0f46b3a92c80f458c3bca9_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)",
     "role": "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
     "shortName": "LICENSE AND GRANT REVENUES - Government Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "iaa0c1f1f0a744b53a8d4ea48cd955591_I20170831",
      "decimals": "INF",
      "lang": "en-US",
      "name": "inhibrx:GrantValuedAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if8bd613f072f461db198c9f9f272863d_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "inhibrx:ExpensesReimbursedToDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "iec507b082f8043d7944a7cd34a09a823_I20170930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "iec507b082f8043d7944a7cd34a09a823_I20170930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)",
     "role": "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details)",
     "role": "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Liability Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "ie5cdb018b33a425fba18e1e8ce8b8bd9_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i373c8870a27246cc9bc37042ebcb4e3d_D20200715-20200715",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inhibrx:DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i893ad457259b4931a5c0ce26c8fb0c92_I20200715",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "i9a427e8353f84ac6a632f7e62c74166a_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109102 - Disclosure - OTHER FINANCIAL INFORMATION",
     "role": "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114103 - Disclosure - DEBT",
     "role": "http://inhibrx.namespace.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inhibrx-20200930.htm",
      "contextRef": "if5d7e1ecff2f44c1bf17b51fb9212e3b_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "inhibrx_A2015OxfordTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 Oxford Term Loans",
        "label": "2015 Oxford Term Loans [Member]",
        "terseLabel": "2015 Loan Agreement"
       }
      }
     },
     "localname": "A2015OxfordTermLoansMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2015OxfordTermLoansTermAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 Oxford Term Loans, Term A",
        "label": "2015 Oxford Term Loans, Term A [Member]",
        "terseLabel": "Term A"
       }
      }
     },
     "localname": "A2015OxfordTermLoansTermAMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2015OxfordTermLoansTermBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 Oxford Term Loans, Term B",
        "label": "2015 Oxford Term Loans, Term B [Member]",
        "terseLabel": "Term B"
       }
      }
     },
     "localname": "A2015OxfordTermLoansTermBMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2015OxfordTermLoansTermCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 Oxford Term Loans, Term C",
        "label": "2015 Oxford Term Loans, Term C [Member]",
        "terseLabel": "Term C"
       }
      }
     },
     "localname": "A2015OxfordTermLoansTermCMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2015OxfordTermLoansTermDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 Oxford Term Loans, Term D",
        "label": "2015 Oxford Term Loans, Term D [Member]",
        "terseLabel": "Term D"
       }
      }
     },
     "localname": "A2015OxfordTermLoansTermDMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2019And2020ConvertiblePromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 And 2020 Convertible Promissory Notes",
        "label": "2019 And 2020 Convertible Promissory Notes [Member]",
        "terseLabel": "2019 and 2020 Notes"
       }
      }
     },
     "localname": "A2019And2020ConvertiblePromissoryNotesMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2019ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Convertible Promissory Note",
        "label": "2019 Convertible Promissory Note [Member]",
        "terseLabel": "2019 Convertible Note"
       }
      }
     },
     "localname": "A2019ConvertiblePromissoryNoteMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2020ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Convertible Promissory Note",
        "label": "2020 Convertible Promissory Note [Member]",
        "terseLabel": "2020 Convertible Note"
       }
      }
     },
     "localname": "A2020ConvertiblePromissoryNoteMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2020OxfordTermLoansFirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Oxford Term Loans, First Tranche",
        "label": "2020 Oxford Term Loans, First Tranche [Member]",
        "terseLabel": "First Tranche"
       }
      }
     },
     "localname": "A2020OxfordTermLoansFirstTrancheMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2020OxfordTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Oxford Term Loans",
        "label": "2020 Oxford Term Loans [Member]",
        "terseLabel": "2020 Loan Agreement"
       }
      }
     },
     "localname": "A2020OxfordTermLoansMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2020OxfordTermLoansTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Oxford Term Loans, Tranche B",
        "label": "2020 Oxford Term Loans, Tranche B [Member]",
        "terseLabel": "Tranche B"
       }
      }
     },
     "localname": "A2020OxfordTermLoansTrancheBMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2020OxfordTermLoansTrancheCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Oxford Term Loans, Tranche C",
        "label": "2020 Oxford Term Loans, Tranche C [Member]",
        "terseLabel": "Tranche C"
       }
      }
     },
     "localname": "A2020OxfordTermLoansTrancheCMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_A2020OxfordTermLoansTranchesBAndCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Oxford Term Loans, Tranches B And C",
        "label": "2020 Oxford Term Loans, Tranches B And C [Member]",
        "terseLabel": "Second and Third Tranches"
       }
      }
     },
     "localname": "A2020OxfordTermLoansTranchesBAndCMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Research And Development, Current",
        "label": "Accrued Research And Development, Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_BluebirdBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bluebird Bio, Inc.",
        "label": "Bluebird Bio, Inc. [Member]",
        "terseLabel": "bluebird bio, Inc."
       }
      }
     },
     "localname": "BluebirdBioIncMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boston University - Combating Antibiotic Resistant Bacteria Accelerator",
        "label": "Boston University - Combating Antibiotic Resistant Bacteria Accelerator [Member]",
        "terseLabel": "Combating Antibiotic Resistant Bacteria Accelerator"
       }
      }
     },
     "localname": "BostonUniversityCombatingAntibioticResistantBacteriaAcceleratorMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_CelgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celgene",
        "label": "Celgene [Member]",
        "terseLabel": "Celgene"
       }
      }
     },
     "localname": "CelgeneMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_ChiesiFarmaceuticiSpAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chiesi Farmaceutici S.p.A.",
        "label": "Chiesi Farmaceutici S.p.A. [Member]",
        "terseLabel": "Chiesi Farmaceutici S.p.A."
       }
      }
     },
     "localname": "ChiesiFarmaceuticiSpAMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Percentage Of Funded Amount Issued",
        "label": "Class of Warrant or Right, Percentage Of Funded Amount Issued",
        "terseLabel": "Common or preferred stock warrants issued as a percent of funded amount"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentageOfFundedAmountIssued",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_CollaborativeAgreementExclusiveDevelopmentLicenses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Exclusive Development Licenses",
        "label": "Collaborative Agreement, Exclusive Development Licenses",
        "terseLabel": "Exclusive development license"
       }
      }
     },
     "localname": "CollaborativeAgreementExclusiveDevelopmentLicenses",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Number Of Related Programs To Agreement",
        "label": "Collaborative Agreement, Number Of Related Programs To Agreement",
        "terseLabel": "Number of programs related to collaborative agreement"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberOfRelatedProgramsToAgreement",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_CollaborativeArrangementAdditionalPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Payment Receivable",
        "label": "Collaborative Arrangement, Additional Payment Receivable",
        "terseLabel": "Additional payable due from agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalPaymentReceivable",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementAdditionalPaymentReceivablePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Payment Receivable Period",
        "label": "Collaborative Arrangement, Additional Payment Receivable Period",
        "terseLabel": "Additional payment receivable period"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalPaymentReceivablePeriod",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_CollaborativeArrangementCommercializationMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Commercialization Milestone Receivable",
        "label": "Collaborative Arrangement, Commercialization Milestone Receivable",
        "terseLabel": "Commercialization milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementCommercializationMilestoneReceivable",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementDevelopmentMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Development Milestone Receivable",
        "label": "Collaborative Arrangement, Development Milestone Receivable",
        "terseLabel": "Development milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementDevelopmentMilestoneReceivable",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementExpenseReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Expense Reimbursement",
        "label": "Collaborative Arrangement, Expense Reimbursement",
        "terseLabel": "Reimbursement expenses"
       }
      }
     },
     "localname": "CollaborativeArrangementExpenseReimbursement",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementForeignTaxWithholding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Foreign Tax Withholding",
        "label": "Collaborative Arrangement, Foreign Tax Withholding",
        "terseLabel": "Foreign tax withholding"
       }
      }
     },
     "localname": "CollaborativeArrangementForeignTaxWithholding",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payments Receivable",
        "label": "Collaborative Arrangement, Milestone Payments Receivable",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentsReceivable",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementNonrefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Nonrefundable Upfront Payment",
        "label": "Collaborative Arrangement, Nonrefundable Upfront Payment",
        "terseLabel": "Nonrefundable, upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementNonrefundableUpfrontPayment",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Payment Receivable",
        "label": "Collaborative Arrangement, Payment Receivable",
        "terseLabel": "Payments due pursuant to agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentReceivable",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay Advisors",
        "label": "Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay",
        "terseLabel": "Percentage due to advisors"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "inhibrx_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaborative arrangement, term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Congressionally Directed Medical Research Program, Cash From Department Of Defense",
        "label": "Congressionally Directed Medical Research Program, Cash From Department Of Defense [Member]",
        "terseLabel": "Congressionally Directed Medical Research Program, Cash from DoD"
       }
      }
     },
     "localname": "CongressionallyDirectedMedicalResearchProgramCashFromDepartmentOfDefenseMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_ContractWithCustomerLiabilityDerecognizedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Liability, Derecognized During Period",
        "label": "Contract With Customer, Liability, Derecognized During Period",
        "terseLabel": "Liabilities derecognized from agreements"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDerecognizedDuringPeriod",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_DebtInstrumentConvertibleConversionPricePercentageOfSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Price, Percentage Of Share Price",
        "label": "Debt Instrument, Convertible, Conversion Price, Percentage Of Share Price",
        "terseLabel": "Conversion price, as a percentage of stock price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPricePercentageOfSharePrice",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Equal Payments Of Principal And Interest, Extended Term",
        "label": "Debt Instrument, Equal Payments Of Principal And Interest, Extended Term",
        "terseLabel": "Equal payments of principal and interest, extended term"
       }
      }
     },
     "localname": "DebtInstrumentEqualPaymentsOfPrincipalAndInterestExtendedTerm",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Equal Payments Of Principal And Interest Period",
        "label": "Debt Instrument, Equal Payments Of Principal And Interest Period",
        "terseLabel": "Equal payments of principal and interest period"
       }
      }
     },
     "localname": "DebtInstrumentEqualPaymentsOfPrincipalAndInterestPeriod",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_DebtInstrumentInterestOnlyPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest-Only Payment Period",
        "label": "Debt Instrument, Interest-Only Payment Period",
        "terseLabel": "Interest-only payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentPeriod",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_DebtInstrumentInterestOnlyPaymentsExtendedTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Only Payments, Extended Term",
        "label": "Debt Instrument, Interest Only Payments, Extended Term",
        "terseLabel": "Interest only payments, extended term"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentsExtendedTerm",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_DebtInstrumentInterestRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Floor",
        "label": "Debt Instrument, Interest Rate, Floor",
        "terseLabel": "Annual interest rate, floor"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloor",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_DebtInstrumentNumberOfTermLoans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Number Of Term Loans",
        "label": "Debt Instrument, Number Of Term Loans",
        "terseLabel": "Number of term loans"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfTermLoans",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value",
        "terseLabel": "Percentage of principal amount for final payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_DebtInstrumentPrepaymentFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee",
        "label": "Debt Instrument, Prepayment Fee",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFee",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Beneficial Conversion Feature Discount (Reversal) Of Beneficial Conversion Feature",
        "label": "Debt Instrument, Unamortized Discount, Beneficial Conversion Feature (Reversal) Of Beneficial Conversion Feature",
        "terseLabel": "Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_DebtInstrumentUnamortizedDiscountWarrantLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Unamortized Discount, Warrant Liability",
        "label": "Debt Instrument, Unamortized Discount, Warrant Liability",
        "negatedTerseLabel": "Debt discount related to warrant liabilities"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountWarrantLiability",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_DebtInstrumentVariableRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Floor",
        "label": "Debt Instrument, Variable Rate, Floor",
        "terseLabel": "Variable rate floor"
       }
      }
     },
     "localname": "DebtInstrumentVariableRateFloor",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_DebtIssuanceCostsNetDerivativeLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Derivative Liability",
        "label": "Debt Issuance Costs, Net, Derivative Liability",
        "terseLabel": "Debt discount related to derivative liability"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDerivativeLiability",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Department of Defense - Congressionally Directed Medical Research Program",
        "label": "Department of Defense - Congressionally Directed Medical Research Program [Member]",
        "terseLabel": "Congressionally Directed Medical Research Program"
       }
      }
     },
     "localname": "DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_ElpiscienceBiopharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Elpiscience Biopharmaceuticals, Inc.",
        "label": "Elpiscience Biopharmaceuticals, Inc. [Member]",
        "terseLabel": "Elpiscience"
       }
      }
     },
     "localname": "ElpiscienceBiopharmaceuticalsIncMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_EquityMethodInvestmentAdditionalOwnershipEntitled": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Additional Ownership Entitled",
        "label": "Equity Method Investment, Additional Ownership Entitled",
        "terseLabel": "Additional equity interest percentage entitled to receive"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalOwnershipEntitled",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_ExpensesReimbursedToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses Reimbursed To Date",
        "label": "Expenses Reimbursed To Date",
        "terseLabel": "Reimbursement for related party transaction expenses incurred to date"
       }
      }
     },
     "localname": "ExpensesReimbursedToDate",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification",
        "negatedTerseLabel": "Reclassification of liabilities into equity"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_GrantAwardedPaymentStructurePercentageCoveredByCompany": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Awarded, Payment Structure, Percentage Covered By Company",
        "label": "Grant Awarded, Payment Structure, Percentage Covered By Company",
        "terseLabel": "Cost share, percentage covered by company"
       }
      }
     },
     "localname": "GrantAwardedPaymentStructurePercentageCoveredByCompany",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "inhibrx_GrantAwardedPaymentStructurePercentageReimbursedBySponsor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Awarded, Payment Structure, Percentage Reimbursed By Sponsor",
        "label": "Grant Awarded, Payment Structure, Percentage Reimbursed By Sponsor",
        "terseLabel": "Cost share, percentage reimbursed by sponsor"
       }
      }
     },
     "localname": "GrantAwardedPaymentStructurePercentageReimbursedBySponsor",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "inhibrx_GrantValuedAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant, Valued Awarded",
        "label": "Grant, Valued Awarded",
        "terseLabel": "Grant award"
       }
      }
     },
     "localname": "GrantValuedAwarded",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_IncreaseDecreaseContractWithCustomerLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) Contract With Customer, Liability, Current",
        "label": "Increase (Decrease) Contract With Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseContractWithCustomerLiabilityCurrent",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) Contract With Customer, Liability, Non-Current",
        "label": "Increase (Decrease) Contract With Customer, Liability, Non-Current",
        "terseLabel": "Deferred revenue, non-current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseContractWithCustomerLiabilityNonCurrent",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_LAVSummitLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "LAV Summit Limited",
        "label": "LAV Summit Limited [Member]",
        "terseLabel": "LAV Summit Limited"
       }
      }
     },
     "localname": "LAVSummitLimitedMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LesseeOperatingLeaseAnnualEscalations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Escalations",
        "label": "Lessee, Operating Lease, Annual Escalations",
        "terseLabel": "Annual escalations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualEscalations",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Initial Base Rent Expense Per Month",
        "label": "Lessee, Operating Lease, Initial Base Rent Expense Per Month",
        "terseLabel": "Initial base rent per month"
       }
      }
     },
     "localname": "LesseeOperatingLeaseInitialBaseRentExpensePerMonth",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_LesseeOperatingLeaseSquareFootage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Square Footage",
        "label": "Lessee, Operating Lease, Square Footage",
        "terseLabel": "Square footage of lease agreement (in sq feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSquareFootage",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "inhibrx_LesseeOperatingLeaseSquareFootageExpansion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Square Footage Expansion",
        "label": "Lessee, Operating Lease, Square Footage Expansion",
        "terseLabel": "Square footage of lease extension agreement (in sq feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSquareFootageExpansion",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "inhibrx_LicenseAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License, Affiliate",
        "label": "License, Affiliate [Member]",
        "terseLabel": "License fee revenue, affiliates"
       }
      }
     },
     "localname": "LicenseAffiliateMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAffiliateOX40LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License, Affiliate - OX40 License Agreement",
        "label": "License, Affiliate - OX40 License Agreement [Member]",
        "terseLabel": "OX40 License Agreement"
       }
      }
     },
     "localname": "LicenseAffiliateOX40LicenseAgreementMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAffiliatePDL1And41BBLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License, Affiliate - PD-L1 And 4-1BB License Agreement",
        "label": "License, Affiliate - PD-L1 And 4-1BB License Agreement [Member]",
        "terseLabel": "PD-L1 and 4-1BB License Agreement"
       }
      }
     },
     "localname": "LicenseAffiliatePDL1And41BBLicenseAgreementMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAgreementAdditionalProgramsAuthorizedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Additional Programs Authorized",
        "label": "License Agreement, Additional Programs Authorized [Member]",
        "terseLabel": "Additional Programs"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalProgramsAuthorizedMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAgreementInitialProgramsAuthorizedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Initial Programs Authorized",
        "label": "License Agreement, Initial Programs Authorized [Member]",
        "terseLabel": "Initial Programs"
       }
      }
     },
     "localname": "LicenseAgreementInitialProgramsAuthorizedMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Initial Programs Authorized, Program One",
        "label": "License Agreement, Initial Programs Authorized, Program One [Member]",
        "terseLabel": "Initial Programs, Program 1"
       }
      }
     },
     "localname": "LicenseAgreementInitialProgramsAuthorizedProgramOneMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Initial Programs Authorized, Program Two",
        "label": "License Agreement, Initial Programs Authorized, Program Two [Member]",
        "terseLabel": "Initial Programs, Program 2"
       }
      }
     },
     "localname": "LicenseAgreementInitialProgramsAuthorizedProgramTwoMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LicenseAndGrantRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License And Grant Revenue",
        "label": "License And Grant Revenue [Text Block]",
        "terseLabel": "LICENSE AND GRANT REVENUES"
       }
      }
     },
     "localname": "LicenseAndGrantRevenueTextBlock",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inhibrx_LicenseNonAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License, Non-Affiliate",
        "label": "License, Non-Affiliate [Member]",
        "terseLabel": "License fee revenue, non-affiliates"
       }
      }
     },
     "localname": "LicenseNonAffiliateMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidity",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inhibrx_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "National Institutes Of Health",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institutes of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_NonCashEstablishmentOfEquityMethodInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash Establishment Of Equity Method Investment",
        "label": "Non-cash Establishment Of Equity Method Investment",
        "negatedTerseLabel": "Non-cash equity method investment"
       }
      }
     },
     "localname": "NonCashEstablishmentOfEquityMethodInvestment",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Operating Lease Expense",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of License Agreements",
        "label": "Number Of License Agreements",
        "terseLabel": "License agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_NumberOfOperatingLeasesHeld": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Operating Leases Held",
        "label": "Number Of Operating Leases Held",
        "terseLabel": "Number of operating leases held"
       }
      }
     },
     "localname": "NumberOfOperatingLeasesHeld",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Performance Obligations",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_OtherCustomersNotSeparatelyDisclosedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Customers, Not Separately Disclosed",
        "label": "Other Customers, Not Separately Disclosed [Member]",
        "terseLabel": "Other license revenues from non-affiliates"
       }
      }
     },
     "localname": "OtherCustomersNotSeparatelyDisclosedMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Noncash Investing And Financing Items, Derivative Liabilities Incurred",
        "label": "Other Noncash Investing And Financing Items, Derivative Liabilities Incurred",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred",
        "label": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOANDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_PaymentsOfDebtIssuanceCostsConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments of Debt Issuance Costs, Convertible Debt",
        "label": "Payments of Debt Issuance Costs, Convertible Debt",
        "negatedLabel": "Costs associated with the issuance of convertible notes"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCostsConvertibleDebt",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_PaymentsOfDebtIssuanceCostsSecuredDebt": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments of Debt Issuance Costs, Secured Debt",
        "label": "Payments of Debt Issuance Costs, Secured Debt",
        "negatedLabel": "Payment of fees associated with debt"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCostsSecuredDebt",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_PaymentsOfStockIssuanceCostsAbandonedIPOAttempt": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Stock Issuance Costs, Abandoned IPO Attempt",
        "label": "Payments Of Stock Issuance Costs, Abandoned IPO Attempt",
        "negatedTerseLabel": "Deferred offering costs paid"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsAbandonedIPOAttempt",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_PaymentsOfStockIssuanceCostsConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Stock Issuance Costs, Convertible Preferred Stock",
        "label": "Payments Of Stock Issuance Costs, Convertible Preferred Stock",
        "negatedTerseLabel": "Costs associated with the issuance of preferred stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsConvertiblePreferredStock",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_PaymentsOfStockIssuanceCostsInitialPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments of Stock Issuance Costs, Initial Public Offering",
        "label": "Payments of Stock Issuance Costs, Initial Public Offering",
        "negatedTerseLabel": "Costs associated with initial public offering",
        "terseLabel": "Costs associated with initial public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsInitialPublicOffering",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_PhylaxisBioScienceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phylaxis BioScience, LLC",
        "label": "Phylaxis BioScience, LLC [Member]",
        "terseLabel": "Phylaxis BioScience, LLC"
       }
      }
     },
     "localname": "PhylaxisBioScienceLLCMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_ProfitInterestUnitPIUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Interest Unit (PIU)",
        "label": "Profit Interest Unit (PIU) [Member]",
        "terseLabel": "Profit Interest Unit (PIU)"
       }
      }
     },
     "localname": "ProfitInterestUnitPIUMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_QualifiedCompanyValuationForInitialPublicOfferingIPO": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Qualified Company Valuation For Initial Public Offering (IPO)",
        "label": "Qualified Company Valuation For Initial Public Offering (IPO)",
        "terseLabel": "Company valuation"
       }
      }
     },
     "localname": "QualifiedCompanyValuationForInitialPublicOfferingIPO",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_ReclassificationOfWarrantLiabilitiesToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Of Warrant Liabilities To Equity",
        "label": "Reclassification Of Warrant Liabilities To Equity",
        "terseLabel": "Reclassification of warrant liabilities to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilitiesToEquity",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_RelatedPartyEquityInterestInCompany": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party , Equity Interest In Company",
        "label": "Related Party , Equity Interest In Company",
        "terseLabel": "Ownership interest, more than"
       }
      }
     },
     "localname": "RelatedPartyEquityInterestInCompany",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inhibrx_RepaymentsOfSecuredDebtFinalBalloonPayment": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Secured Debt, Final Balloon Payment",
        "label": "Repayments Of Secured Debt, Final Balloon Payment",
        "negatedTerseLabel": "Final payment on debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebtFinalBalloonPayment",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_RevenueRecognitionNumberOfCompounds": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Number Of Compounds",
        "label": "Revenue Recognition, Number Of Compounds",
        "terseLabel": "Number of compounds"
       }
      }
     },
     "localname": "RevenueRecognitionNumberOfCompounds",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Asset And Operating Lease Liability",
        "label": "Right-Of-Use Asset And Operating Lease Liability [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease, by Balance Sheet Location"
       }
      }
     },
     "localname": "RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inhibrx_ScheduleOfLicenseAndGrantRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of License And Grant Revenue",
        "label": "Schedule Of License And Grant Revenue [Table Text Block]",
        "terseLabel": "Schedule of License and Grant Revenue"
       }
      }
     },
     "localname": "ScheduleOfLicenseAndGrantRevenueTableTextBlock",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inhibrx_SeriesMezzanine1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series Mezzanine 1 Preferred Stock",
        "label": "Series Mezzanine 1 Preferred Stock [Member]",
        "terseLabel": "Series Mezzanine 1"
       }
      }
     },
     "localname": "SeriesMezzanine1PreferredStockMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_SeriesMezzanine2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series Mezzanine 2 Preferred Stock",
        "label": "Series Mezzanine 2 Preferred Stock [Member]",
        "terseLabel": "Series Mezzanine 2"
       }
      }
     },
     "localname": "SeriesMezzanine2PreferredStockMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Value Of Shares Issued",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Value Of Shares Issued",
        "terseLabel": "Value of awards issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValueOfSharesIssued",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value, Granted",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value, Granted",
        "terseLabel": "AGGREGATE INTRINSIC VALUE, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term, Granted",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term, Granted",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inhibrx_ShareBasedCompensationNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation, Number Of Plans",
        "label": "Share-Based Compensation, Number Of Plans",
        "terseLabel": "Number of share-based compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberOfPlans",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inhibrx_StockIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance Costs Incurred But Not Yet Paid",
        "label": "Stock Issuance Costs Incurred But Not Yet Paid",
        "terseLabel": "Initial public offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "StockIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of preferred shares (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "inhibrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "verboseLabel": "Issuance of Mezzanine Preferred Stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inhibrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of preferred shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_TranscentaHoldingLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transcenta Holding, Ltd.",
        "label": "Transcenta Holding, Ltd. [Member]",
        "terseLabel": "Transcenta Holding, Ltd."
       }
      }
     },
     "localname": "TranscentaHoldingLtdMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_WarrantAndDerivativeLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant And Derivative Liabilities",
        "label": "Warrant And Derivative Liabilities [Member]",
        "terseLabel": "Warrant And Derivative Liabilities"
       }
      }
     },
     "localname": "WarrantAndDerivativeLiabilitiesMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_WarrantLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant Liabilities",
        "label": "Warrant Liabilities [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesPolicyTextBlock",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inhibrx_WarrantsAndRightsOutstandingLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants And Rights Outstanding, Liability",
        "label": "Warrants And Rights Outstanding, Liability",
        "terseLabel": "Warrants issued, amount"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingLiability",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Issued Concurrently With 2020 Loan Agreement",
        "label": "Warrants Issued Concurrently With 2020 Loan Agreement [Member]",
        "terseLabel": "Warrants Issued Concurrently With 2020 Loan Agreement"
       }
      }
     },
     "localname": "WarrantsIssuedConcurrentlyWith2020LoanAgreementMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_WarrantsIssuedUponConsummationOfIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Issued Upon Consummation Of IPO",
        "label": "Warrants Issued Upon Consummation Of IPO [Member]",
        "terseLabel": "Warrants Issued Upon Consummation of IPO"
       }
      }
     },
     "localname": "WarrantsIssuedUponConsummationOfIPOMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inhibrx_WarrantsLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Liability",
        "label": "Warrants Liability",
        "terseLabel": "Warrants liability"
       }
      }
     },
     "localname": "WarrantsLiability",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inhibrx_WuXiBiologicsHealthcareVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "WuXi Biologics Healthcare Venture",
        "label": "WuXi Biologics Healthcare Venture [Member]",
        "terseLabel": "WuXi Biologics Healthcare Venture"
       }
      }
     },
     "localname": "WuXiBiologicsHealthcareVentureMember",
     "nsuri": "http://inhibrx.namespace.com/20200930",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r230",
      "r339",
      "r340",
      "r342",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliates"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r58",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r169",
      "r218",
      "r221",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r393",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r393",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r169",
      "r218",
      "r221",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r218",
      "r220",
      "r358",
      "r392",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r218",
      "r220",
      "r358",
      "r392",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r222",
      "r232",
      "r233",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r393",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r222",
      "r232",
      "r233",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r393",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r27",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r45"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r182"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r28",
      "r264"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL",
        "verboseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r204",
      "r209",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Beneficial conversion feature (reversal of unamortized BCF)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r234",
      "r236",
      "r267",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r194",
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Reclassification of warrant liabilities to equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r236",
      "r257",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r70",
      "r84",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "negatedTerseLabel": "Debt discount related to derivative liabilities",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r67",
      "r84",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Charge of amortized debt issuance costs to interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r84",
      "r323"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of debt discount and non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r149",
      "r159",
      "r165",
      "r176",
      "r286",
      "r288",
      "r312",
      "r371",
      "r382"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r55",
      "r99",
      "r176",
      "r286",
      "r288",
      "r312"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r237",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "negatedTerseLabel": "Payable for purchase of fixed assets"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r35",
      "r86"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r87",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r86",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r313"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r97",
      "r99",
      "r121",
      "r122",
      "r123",
      "r125",
      "r127",
      "r131",
      "r132",
      "r133",
      "r176",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r211",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Conversion of outstanding warrants to purchase convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants exercisable for shares of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r189",
      "r375",
      "r388"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "COMMON STOCK",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 120,000,000 and 65,000,000 shares authorized as of September\u00a030, 2020 and December\u00a031, 2019, respectively; 37,710,190 and 18,154,119 issued and outstanding as of September\u00a030, 2020 and December\u00a031, 2019, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r136",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r213",
      "r215",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Receivable for expenses incurred, not yet reimbursed"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r213",
      "r214",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Liabilities related to reimbursement of agreement"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r213",
      "r214",
      "r219"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r213",
      "r214",
      "r219"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Non-current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized related to performance obligation"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "verboseLabel": "Awards converted to common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes, net of discount"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of the 2019 Note and the 2020 Notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Issuance of shares of common stock after conversion (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r372",
      "r373",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails",
      "http://inhibrx.namespace.com/role/PPPLOANDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r21",
      "r195",
      "r373",
      "r381"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total long-term debt",
        "totalLabel": "Total future minimum payments",
        "verboseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan aggregate amount",
        "verboseLabel": "Note aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Annual interest rate",
        "verboseLabel": "Note monthly interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails",
      "http://inhibrx.namespace.com/role/PPPLOANDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Periodic payment terms, final payment amount"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r104",
      "r205",
      "r206",
      "r207",
      "r208",
      "r321",
      "r322",
      "r324",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r196",
      "r323"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount",
        "negatedTerseLabel": "Add: debt discount",
        "terseLabel": "Unamortized debt discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r40",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r146"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Change in fair value of derivative liabilities",
        "terseLabel": "Change in fair value of derivative liabilities",
        "verboseLabel": "Other income related to changes in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r56",
      "r57",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative [Member]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r106",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY COMPENSATION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r26",
      "r101",
      "r340"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Receivables from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to Inhibrx, Inc., basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of bifurcated compound liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r130",
      "r177",
      "r204",
      "r209",
      "r261",
      "r262",
      "r263",
      "r279",
      "r280",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r36",
      "r150",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r36",
      "r79",
      "r94",
      "r175",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r84",
      "r201"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r300",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of Financial Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r301",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r229",
      "r231",
      "r301",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "LEVEL 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r229",
      "r231",
      "r301",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "LEVEL 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r301",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "LEVEL 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Notes Measured at Fair Value Using Level 3 Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value of liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Establishment of liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r94",
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r180",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r105",
      "r149",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r64",
      "r84",
      "r147",
      "r173",
      "r376",
      "r389"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r119",
      "r120",
      "r148",
      "r273",
      "r281",
      "r282",
      "r391"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r94",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r70",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Debt interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/PPPLOANDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r78",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest expense",
        "verboseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (3 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining term of operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r99",
      "r160",
      "r176",
      "r287",
      "r288",
      "r289",
      "r312"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r99",
      "r176",
      "r312",
      "r374",
      "r386"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock, and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r99",
      "r176",
      "r287",
      "r288",
      "r289",
      "r312"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License fee revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r197",
      "r373",
      "r384"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total debt",
        "verboseLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion, including debt discount",
        "verboseLabel": "Current portion of long-term debt, net of discount"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r107",
      "r191"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r107",
      "r191"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r107",
      "r191"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r107",
      "r191"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, including debt discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "CONVERTIBLE PROMISSORY NOTES"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNotesBalanceNetofDiscountDetails",
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r65",
      "r85",
      "r99",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r124",
      "r149",
      "r158",
      "r161",
      "r164",
      "r166",
      "r176",
      "r312",
      "r377",
      "r390"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes Payable, Other Payables"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOANDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Current portion of lease liability",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r328",
      "r332"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r108",
      "r142",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r45"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r45"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtRestructuringCosts": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.",
        "label": "Payments of Debt Restructuring Costs",
        "terseLabel": "Payment for debt restructuring costs"
       }
      }
     },
     "localname": "PaymentsOfDebtRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 15,000,000 and no shares authorized at September\u00a030, 2020 and December\u00a031, 2019; no shares issued or outstanding."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Outside research and development services"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from the issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from the issuance of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from the issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from the Paycheck Protection Program loan"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://inhibrx.namespace.com/role/PPPLOANDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r260"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r181"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r183",
      "r387"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r94",
      "r183",
      "r403",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r230",
      "r339",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r230",
      "r339",
      "r342",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r338",
      "r340",
      "r343",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayment of principal on debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "terseLabel": "Repayment of loan"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r270",
      "r406"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r94",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development and Clinical Trial Accrurals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r209",
      "r264",
      "r385",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r177",
      "r261",
      "r262",
      "r263",
      "r279",
      "r280",
      "r397",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "ACCUMULATED DEFICIT"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Revenue, Performance Obligation, Description of Timing"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r63",
      "r99",
      "r144",
      "r145",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r176",
      "r312",
      "r378"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r333",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, proceeds received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r48",
      "r104",
      "r205",
      "r206",
      "r207",
      "r208",
      "r321",
      "r322",
      "r324",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r236",
      "r256",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r39",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r102",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r237",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOANDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2015LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt, net of current portion and including final payment fee"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Award issued, per unit value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "AGGREGATE INTRINSIC VALUE"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r243",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "NUMBER OF SHARES"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "WEIGHTED AVERAGE EXERCISE PRICE"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "AGGREGATE INTRINSIC VALUE, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Cliff Vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r94",
      "r237",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Fair Value of Stock-Based Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r251",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r18",
      "r372",
      "r383"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Paycheck Protection Program loan",
        "verboseLabel": "PPP loan"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets",
      "http://inhibrx.namespace.com/role/PPPLOANDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOANDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short-term Debt [Text Block]",
        "terseLabel": "PPP LOAN"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOAN"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOANDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/PPPLOANDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r97",
      "r99",
      "r121",
      "r122",
      "r123",
      "r125",
      "r127",
      "r131",
      "r132",
      "r133",
      "r176",
      "r204",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r130",
      "r177",
      "r204",
      "r209",
      "r261",
      "r262",
      "r263",
      "r279",
      "r280",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CONVERTIBLEPROMISSORYNOTESNarrativeDetails",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r130",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r204",
      "r205",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of convertible securities (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r204",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of shares in IPO (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r204",
      "r209",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of convertible securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares in IPO, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of shares upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r30",
      "r31",
      "r99",
      "r172",
      "r176",
      "r312"
     ],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r99",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r176",
      "r177",
      "r209",
      "r261",
      "r262",
      "r263",
      "r279",
      "r280",
      "r284",
      "r285",
      "r290",
      "r312",
      "r314",
      "r315",
      "r319",
      "r398",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r209",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r320",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r320",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r320",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r320",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "OTHER FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/OTHERFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r13",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Convertible preferred stock, $0.0001 par value; no and 25,765,000 shares authorized at September\u00a030, 2020 and December\u00a031, 2019, respectively; no and 12,534,331 shares issued and outstanding at September\u00a030, 2020 and December\u00a031, 2019 respectively; liquidation preferences of $0 and $87.5 million at September\u00a030, 2020 and December\u00a031, 2019, respectively."
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r50",
      "r99",
      "r176",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance, preferred stock",
        "periodStartLabel": "Beginning balance, preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Convertible preferred stock, liquidation preferences"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "verboseLabel": "Issuance of Mezzanine Preferred Stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance, preferred stock (in shares)",
        "periodStartLabel": "Beginning balance, preferred stock (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Mezzanine Preferred Stock",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://inhibrx.namespace.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r13",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Temporary Equity"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/COVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/DEBTNarrativeDetails",
      "http://inhibrx.namespace.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock",
        "verboseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.namespace.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://inhibrx.namespace.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e34017-109320"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r409": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r411": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r412": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r413": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/subtopic&trid=114868817"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001739614-20-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739614-20-000014-xbrl.zip
M4$L#!!0    ( "F!;5%:,I@OB"4  %=- 0 :    97AH:6)I=#$P,3$M9FER
M<W1A;65N9"YH=&WM/6U3VTC2WY]?,4_V;@^JA+$-A)#L;94!Y\(^+%#&>]G]
M=#66QO9L9,FKD2"^7_]T]\SHQ9:-(00+4&HWL2UI--/3[]W3_=/_GEZ>]/^X
MZK)Q//'9U6_'YV<G[,W.[N[GO9/=W=/^*?O4__6<[3>:+=:/>*!D+,. ^[N[
MW8LW[,TXCJ?O=W=O;V\;MWN-,!KM]GN[.-3^KA^&2C2\V'OS\T_X"_PMN/?S
M__STOSL[[#1TDXD(8N9&@L?"8XF2P8A]]H3ZPG9VS%TGX706R=$X9NUFN\D^
MA]$7></U]5C&OOC9CO/3KO[^TRZ]Y*=!Z,U^_LF3-TQZ_WPCQ?Z[=VYKOWW0
M/CS<?]=V^9Y[Y VY>[BWWV[OO3O\3PLFN0NWZV=4///%/]],9+ S%OC^]X?M
M:?SA5GKQ^'VKV?S[&[KOYY^&81##RR)X6']<&",67^,=[LM1\)Y6\N8;'K*7
MW= /H_<_-.G/![RR,^03Z<_>_Z,O)T*Q"W'+>N&$!_]P%&S9CA*1'.H;E?RO
M@"7 :NCKK5D>C./+0-CEMMJXQN[7L1S(F+6:C5:K.-E%6/%H!. :A'$<3N!Y
M>$%N%2YLD8@VM(R/9[WK/NO\VKTXA?_[K'_)SB\[%ZQS<<JNNR>_]<[Z?[#.
MOWK=+EY>NBFK5_AGHF(YG.F?9.#!@M_OO9U^_ZW;+UUS_]/9-9M?>!RR\Y '
MC <>NQ9N$LEXQCJC2 @BQ:UX+!7[\8=W[7;S@P7#)C:L ]/Q-%4_Q23*(4AP
M:'W89@ 3PEY@4C( $'+%PB&["&_$9" BUFH[FCL!^$05H/=11BIF*0S9*?#7
M*@#288,9H1Z?A,#J+W__>-D[!1R]Z%R<=-GY^8G#.#L5/K_ED6"^G$B4"[[D
M ^DCHKKA9,J#&;N5\1C&@4T82A=N#%T2(!SXU-X>[$L$ES]R&0WY5W8= W+'
M#NOXXBN\.I+<8?^62,>2,^#\K7VV9;;L\NLPC+QLLK#- "$?QHZXS_B(*$0&
M3"7NF+E\REV8E%.%#3_)IMD9581J'(;4< XX*"(%FZAPB\* 7;MCX26^8*U&
M"_D1W84\*<>& /*>&,+0'AL(/[S=9F'$0K@SNI5* )),>03X@#\(&&(8A1,6
MPR)H//Q7!JZ?>*A/Z$V%'YB,5;IKN+?<3(YM"0X;RJNPD7I&%=@^(E/$?N'&
M\D;X,[V=E0&1J@",D$4 E,XN/IT=]WYWX,-)H\#!W#":AA%'=7D5SVHUVP>&
M:_7#*!(S=@6O5#!3[CGL.@$N"/*EZ;!SSGY!2G?828<=M9M[ARGOVN2.',.D
MP]M*H.UVXV4H;Y\_=7O=SC5L]!QG=YB%-N&>9:]C?B.*.DH\!M1R111S8'TK
M=#Z'>1H12:?Y)?%GK'5@]1GDDJA%",!#E4RG/CV"?#S/CB>A)X<2?EW@P]5A
M&@4!4P5$9=,D4@F'"0"L;L<2)%!A,Z=1>",!\'@YW7*[GSXL1Z%,XR[P&(\'
MP%&(P2"X 0DFRO#OP"-C76E1&0Y__.'@B'C["R,3"R$G!2*N?YYX0*E0,B+L
M)+1.X4G 5@0H(((2C:1 6OF=*[D7B";=/(2ZU*2GDL&?($SM0Z6[I$3,AB0(
M](.T72]CJRXN/SNLC_L%2G_70>2%A2N DA&0!O  N@DP%>7 Y1L1 )@UE+B%
M+RKE >Y:"EXMAHD?L5$8>O3UAOL)'_BB^!;-D"+A"CF-];B>^"OA[@S?K\D0
M)3<.C+:*^R4(;WWAC9 #KHED]EF<,"+#$&X(;Q7LY;OE>SGE'JJK.[X8ZFVZ
M:RMW6N\VMI>MQN8XZ(<"I%K-Q@&"X81/90S ^B\R3**L1&7D-TAB%H1Q3F19
MZT*-N>]KAJL10TVUPLLF@@?P&L5&\"TP5#M!M%TD^>5*Q^(FKN7]>U;8T*X<
M-ESC'@)+:3?:6WQ["4N7*J54K>(0-0,&Q*0/&8,1[@2)H0W&AQ'RHVWXAK87
M(/CC#ZVWS0^+?V]PWPD\GG"->?4^08:,=[WYN7/#I6]<1IO4]!J,/<9^/UO$
M688U6W(I0EVOH2,1-0/QYBR8O*.)Q"Y8*^(&1;*O_8W(_/\,07DC/T;()OR+
M'MUHTGD=.]0<OCL<&DF WE/2M>&_$8P^PN]\$B8 4IA,'Z3#K]+WD>&<HBX
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M37\:24P!"!=CEC#>6$?%0=N;H$H:AZ##;VE-"E3"8$7 DKUM'#"=!D#%P&Z
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M'D29M4'W. 9=;8#5!EC5L)<4Y9/: *L-L-H JPKL:@.L-L!J ZPVP*H&N-H
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MDD%]1#>18?<810IT+0_"C]N7$:DOSRP:B(WO6M7F^_)L@ZPHHRA7-OYK%/1
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MN5*A(2[QW&RJ//I-Q)U?_R6/^Z;H]$]02P,$%     @ *8%M44Y1:Y(H!0
M=1,   X   !E>&AI8FET,S(Q+FAT;>U8;6_;-A#^OE]Q=; T!:Q7.XXMNP$\
MVT4#I'$6J^CZ:: ERB(BB2I)Q_%^_8Z4E#C-DB8%UI=A06!(XMWQ[KF'QR-'
M+Z;S2?CQ? :IRC,X?__;Z<D$6I;C?.A,'&<:3N%M^.X4NK;K02A((9EBO""9
MX\S.6M!*E2H#Q]EL-O:F8W.Q<L(+1YOJ.AGGDMJQBEO'(_T%?RF)CW\9O; L
MF/)HG=-"020H432&M63%"C[$5%Z"9=52$UYN!5NE"GS7=^$#%Y?LBE3CBJF,
M'C=V1D[U/G+,)*,EC[?'HYA= 8M?MQ@Y.NH.W'Z/>&[<3?PEZ0W\I-M/NEU_
M.8A)_&?'1R\=E*^4I-IF]'4K9X654NU <.27:KAAL4H#SW5_;1FYXU'""X6S
M"52N'F]L?.U8,[>BU\HB&5L5@8&@52DUPQ'/N CV7/,WU"-60G*6;8.7(<NI
MA#.Z@0N>D^)E6V+:+$D%2RI!R?ZB& 4&9%XW=81H)V,%;2+V?!WF[#IE2Z:@
MX]O>75\?\SC"E%#QG5R>S"["DS<GDW%X,C]#2E\LWH_/0@CGX/7AO;VP)S8L
M9A,SZG4.W;;.PW@!X^G\/)Q-=S7T2",Z<'LP?P/AVQDLQA>_C<]F"VO^Q^GL
M(XPGH1[Q7==_2CKO@/,X"7(B5LC!)5>*Y\' /BS_?1YT_Q'4DP(B7A0TTLL?
M-DREH%(*G]9$8##9%@0MN5# $S@ID#+BNHT/D0T'6FQ_K^_[[G#"\Y(46_/F
M#5\!6GK#10Z>:_T."1>[)H$6,=:%!2T5S9=4[.]Y/7?8<=NF%K2!2$A8AA(W
MOBQHM!98GC!H4L0PNXY24JPH5I$\9U)JO_%?2\98<B"E@J*WN_Y=F!@:]S"
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M52!H1G1Z[MWHW%9( [Y[JT*6&-Y:W5=Y\!Q_Y[>ZD#)78\=_ U!+ P04
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M!RBXCM: R>3K<3 !# *]N8EB?I9C4<H:;?(I&LPTDT P]-X$%IT0&M#J>$F
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M%DB.D>-D7Y(WOX:T1$6D)4R4E@243/8P8@$\(\\<,9&TLO@UI"4K(JWH!6?
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M06SW!KB2VX>R+GDI+)!#1E!B(: EK>2=#2Q&S]81H,KB:3$,21LC22U!4EF
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MP-4)>Y/HRVVFQ^FNO?[#*?@RZ9MZ]IU6^_SA_]DC'3JH-?%C;;?7\=W_\\>
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MV5'MUH@@[7$^8RB F[L<<KP@]O/1SGBFSL7>=CM!-O/!TT@8,119S%<6Q^#
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M.:W*6;  F8SPAV A$$Q(M#\GX3N4ZG$N?U&J55"J(!@%*G'(.&D0M]PBJVQ
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M_0%VW/%D)'+68L15GH.>HD>>$L<)9LQ'MK8NFIK>+ %;^NX/A8A6EH@2U40
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M5XU+Z5Y?I?%]* JW?MP;M+-&O.['3C7K_9^G[3 \O.";B6^-I8ZOOF(=W +
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M(L$S(JJI]1RF:Q<0UQ#$<\A4*2!^7A!?Z\?K%5914X&,$!%Q"G^X"$AV0G%
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M-:@H^"\L7:0T"TLGC6.TR4?PKWD,5N. ([:.>T>)P"7JLF(L/1UUB1J(6=*
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M7-O@<EV0>]?C/B=<O,T]KG;Y;^3U%^IU74=_(AW'6EM. Y?.6^JD50;^HQK
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M*^UV[YH+6-KMWJ_=KC<N$DEM\"%U:S645X+;:'7EA:5A"8A4VNTN#UOH K8
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M'E-O^ P6.L!D6I3+>V<V?.[6#>:F?N%3WF.99)C2U1;XIJNK E-?H-#^EMI
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MXY>^<[?J_.)]/YR:MA_77=<AJ=[P./1;;M3OA]2#KFSA/6'2T )(-?+:#C&
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MN (.1:IU0O62@O$KPZ&6&*E_Q=#RF!RJ0,L*0\ON+ \37EM,HT:PQC#$@_?
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M*S?3E&. >8L4K!$D"A:5-HGKS8XLD_3N=2M"8XQI#QM\JC2L8$X&S?36A<6
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M4DC]93 ,OC3Q&6PPV*VE586@>YN/IN3PM:SFQ=_F6 PV$*40F:P"C(.2 RK
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M^ZLJX#JOU"_$[K$ISN1T7-;' N-*/;7&MA:*U;?-G[K #B[,5UM(![8"1G2
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MLH#4A]X3M&K,+LS*ZP4P9UQ(8]U,;/K$:F+;$1Z6J39Y>)T% \>V.AR /[[
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MP2:C?.7/P29=^=M5CZ5L,^7LAQY[]6]Q\&-W7MO8\*:/O?.:I+^ASFE5!R_
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M9UE(9!KG)*76V2L+E<J?O$@V&*4/&S0> ?/S]>D?$O/;;YT_SYQM_!"I6S(
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MBH>$IB8E/,XH 0(>D B^3W20I"R3\^ER L%S"F).L"CF2E/!TSB4(N8TY"+
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MO6]D<XY-3N!]F"("\S<,!J G3C$\?SPZ!U7Q<K/6)0?ER#8"7V*5?>P"P,!
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M43)RXF,/!A;L_,#<LC8D.ICG_%;Z<KIKH:M"XJ6NK$7.HSV8@NFP0+XX0!@
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M&G_H]\!"<8-W_5ZG,C#WPV=O1S %:XKC"<4Q;YX<4X--SG.!B(@M9$.FD<[
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M:I66O4.,"^8N<N'$:4GFR,<1_# =)^U^V%\!?;,_J:(E\V*H%O[;3N1W.A[
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MUA3TC0.8M0O!MT)$+)M=N .HXZ*Q,-&=SVH%IIF<GC2^=,9T3-N-FSD5R^R
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MD!,<3'1%-Z\+;I8@L]%('1Y@!=W()FGJ!9CR^)>RD?=@<T$U10S5TBFJ)#:
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M1F9[6)2=*M_N[WW8:7[>.MC=;S8^_+75_'R?EI6W/WQZL#QH+6)?*44%SPV
MB_?,>BYS021HP15M<5GX4[O=6*G8^NX;']HPJA5PJZ8[Z RN]TW.X85F-+P7
MUAE,I&%,<RJ"T40"?DCK90S*J;MY)K=$2"=H4<>3RC>)T[PT[L?SXL?!MXN]
MB^,<]IR1(N:/4QJ5N432!8=(9C*'8:LZC%^][G7]-<X',KKH\329ZT9<^L*:
MG-O(-;'P[73.V[U+[S<:VZ" [1#T;[SH;?2AVT-0NHTBPCV[1?Z(MXWN-,7_
M3C>*GZ9_DW__<Z-Q<=JRI_%X\'O+@=!'M1Y_T"I/W,I.J>4-2V<IM6$:I%/&
M(8#8L!SOJ%O[H&R- P9![&(3O^[!??O%Y^4<%-_>:F7#2^@Q>S=<N)AW?[\]
MM-!19:VA8FD*%V%&6$#?_^[=NU[_W2CVX:K.,9?%./[E^ZEY]@6,XRVZ?U#L
MJ=1-FF5.<XF(P"J>+W D,Z[!:<M 4S,F% .5Q>:<5<[)A9ARZE/$NE^N09+L
ML52GCNIEA*K<$AOQ]\5N6#H!FP_16]'6/DFF^9O+*S;?5MQ<XPA344+T7;?:
M,4@& OD^VNEK.3PH^Y6=Q*-.F1'/P!"$/\!CD\B 5XTR3)7+ XTEC]%)FQ/@
MKN0P"9RN)GFV$]WJ&EW[1=^]+7C=[U'#K)C5!=JR=]*%'P^FM:Z-OA)\VZX:
M?5_531M1^;5'Q3'9M/(K+BL]:=![*9_&S7'1BSO-^MPG<?]-]U<\*3SY\@EE
MW^!N%=RN\K; Z=;M.-IA%1" 6?_FA],/G0VCEX.?'D,Z""S6MC:<ZODQGC48
MF3.P-1J3L[ZY?JUU06<V(\8PQ0V%__C,8ANTB[X]#W/]VED+U8WZ,Q;J@^$O
M_?%W7)SJ_(^\-*#[>2@ [,!XC??_=MD\.=9Y!CI/4J0R"@HWIA%K)[)8R!2K
MM_/H.[YZ'7JC/HHYJ[,>:^-[,9]57^N;Y$)ZJ1S/E;7$<N6LMI(0G 6B*<.@
M]M=RL21R@<&Q,9ED6.84"8=!&IA32+( ?HZW2F'G<Q]#<>#8S!<+VVZ%D S]
M4PVN@BY:RH**3'#E^YV:Z?ZD(!)'-U=2S.V28F8E9>?'>:M?U"XD.7EA8C(=
M/_MVL;]US#S&L# YLH8&Q#712"D/8N)4SI6 Q6+\U6N"KPA(7)?!K%$T/S)<
M&@NE1L^C@73>&Z0SAS^3O@9G=-)X]!_3$:W2^L"3GV@SZ+5'P^M_,L=NN4J.
M]4R6#,UF9JSVYVE_TM7PQ"/3]_H;2CF;?^KVA;X<O/K7]'O"2]8G=8'YN/[M
M0WBRMR\6 9RB7K$'_TQ^6[P*AJ.79BR-TWY$L/^Z_3 C!\LT92D %KZ-X)=2
M0_3K>4L\-QA\:W!W)AA,E'/4>!=S;F/6ON:F."8T1&(L[:NG[I#]V9YZ-VI[
M\$&C"5JX$H-/O78;G-"(L,O4,_NY\?5'<^N8*NVU]!QIHSB89WF&#*.PN9U2
MP61""9FM1L_LK4;*[NE?WN*4%!Z(KKS+(C83N\6/8S/CL.1=TCKC,:4>E!VU
M!]?TTXXWG'32!H=()],EZ:A5;ZC-U":@P^-W)Z:;DM,G:*4,[L@+'RS;S.[8
M]WD)!AMG]F[2]7B=F)>$N?1NK4:;7U)OZOUWC<__L_5IY_,=V$M_UZGXNK/[
M_G\.=K8;6W_O?-IZO]/8^7\[G][N?MYI?/BT^W9G/3.3F?FTL[>UV]QMOF^\
MW0=38^OMP9>MOQH'.Y_V&G_L-AN'.UN?/O_S!4_8UOOWGW;>;QWL-'9A>G:;
MGW??-O[>^NO+M!#= CF5#@:#U]\\-^LKIZ]<3^QZ8E?KRI= ]5EC[XH^#_A9
M5[@E'H$(]"JIQYJD[WJJG$72JN]]@E'&46KK7QSU+PNOSGTC*26OSLGEWMDA
M;L;?'FR)YO9'=M@Y:AUMV\OFUUVZM_UWI]EYUVK273[+J[._O7L)OZ--N-_>
M]C?<W':MH\Y_OC5_[I+#L\.+YM=#&GEV#L].9[A!OXEC'GS05E.D<N(13_1M
M05)D<TRD4MXQF;]Z33<P84_=_FO)^-B>%BE^':X6L?U?V?%P6:C$[OKF]ZA[
MNA]0TB<$PZ_IC;S;@JG5)WZJ=&K5DUE_-416-)<7QX2S/,^51C)D&''I-=(Z
MXT@(#%BI(D<-B4=_F^K)NR,N&3PN<H]%WFDUL&+NV1%5Q&)'F-(<<\HS@T,>
MK.8 !33W,IO+%?34Q_FW(L4GW]&M+GS^=I*]<.#[';K&BKM@!1EC1:Y"KJ4*
M2/A@P)2*[:-S3E&0QF2>@60H,*74YI4\@:7J,[^V7GXCZV6EW;M=@*-6=]"R
M?\<TS[6;MQ@NL3$N9<K%$W: )))KQ"U12.8:(V:YT%P0D1O );)!LZL,W4MJ
MP[R$)L^I7,&[>P6SEK"MUH/A;&[ ZE[I.M/0]KCXE59ML%OF3K[O]P:#-7(M
M@ER7XP#5Q;$3N<BIM0!:0B$>)$=:Q<)EQ3/X7Z:M5K'GUH-#4\O7/>_!6WN5
M3;0E:M;YA#&D!V+7XL&DP4+8M0XH/1ZD30)*V@27$^LC46V.N#$4Z2 9PIF3
MRH-(A-AW.Q+5BM\/U![)5%O:4[;'RRB^)2IT,Y'!W:V5.X:"2E-TO==OW^NM
M<4!([!_8'\<RLT9K[6&#,]COA%,DLRP@JKCV07&G,A&#0MFC!(5^'Z-BW0!\
MD<#.([A!=VZ%\5#,F0[KC*%E[2,M C*L!C+B6$DGJ3<@Z[D"9TD)C!3+%6)$
M*RKALRRRW[,-09;)J'@)V4J5U7R_,,Z<%UZ'<>Z 7S]]O^?TX'0AANQZL=9X
MV=:XM  N[;^=22Y24@22.8Z$<@[Q#"!)4FZ19Y@3:Y1Q#IR=5!Q%__U(L><E
M.B)_\+Y>Y1C.O'=<5<Q:H1A.A5SK,,X3H%L5QH'Q[UX<.UAN:PD'7\Y@Q'.6
M(8FM1]YPFN4ZRQQU*3=(/%9NT!)AVV]SCY=PE/BNUP^^]0(/$_]8\=/$<N%&
M_0F>KRW2^UFD%\=!&9\+9Q%QU" >B$&*\H "%U19;(BG_-5K.J=/^94BQ!6*
MN:]0S&]]D/B;&*%S8&MMACZ^&0HFJ(0EMH(@+$B$M R#@XTSQ*R)=)Z9H3XR
M4Y'-I0K\/>-IXE+>8Z4#H7?%M:MUFU=Y;-:%F_<-H-Z3D7E=N+DJL+]WL!4A
M/UFSS9]6['\\%H;(D F&8GM9Q!W!2'%.$;:$.@(F 2U*-YEX,/BO6&W2.O#Z
MV]N\]P.\=0'F"D#=?KT TSE/O;46*1>Y5Y4PR.0J0Y(YXR511BI96+CY.LCZ
M_/ERCU%&^10)<^LRRB7?\;4R2LN9S(E&1&0$<:9RI!4&*X>JW!JL+>=@ULA-
MM@QEE&M+8KE>;H&<N=5RF=;%D ]!ETDQ)!>$2,H,BC7YB$N,D>2$H%PZ[3BF
M4CH/]D2V0>35UJ3/9U"L]"GE73=O;$]1-E:KMS=_U&A1.2^E)UNR&C-8%=<;
MQ8?%UZS[N3-?+5LPZ6G2\>X/C8^+?X5 ;'5C3XK43?J@%S_:F0C'.I+TH$C2
MWE9L[B@MT11IX_)8:!F0P6!X*8.I 8S$(F-@;F4/1L-'WGGK8]7UL>J+"#'=
M#H+KR--C0N/E&!J=TUHI1Y%C2B*N2.Q+X32RFDJ/G??4V93@)W_# O35J]7\
MW6-/"P/!=2&I%>W\]LNAH#FQDD3@1&?$(Z:, BC0X#9*X5#&37!!9I9DV:O7
M^6:^+N-<VQZ_=U#J=AC:JEJ7KX-6#\.?FBG"*</$&L1$]-*"5<B 8X9L)@18
M(9Y3!_B3;8!L+)$IDJ)6_TIMGU[7NA_6X7%E6T2CM#\:]3W4B#NB._"KT"WZ
M<[VU<VI\G)HIN\9H$#.T8N>Q-VV0#?39GO;:\-P]6&AXQ;)U66S,'*_K])QO
M7]OHN368?WVK^[W7_@XWU8UN"N#$7U4-I:<Z4*=.TR7.--JM[T7/^_CI3&_J
M><W68!3PU//4I+JX'!X+*]6./==BE+$5.[[ <QO]^-S-QN=:-^RIOMF^7-C6
M8-):NSY5 S"OXN2B=NK6YH>G/=?HP=Y(WU;M@\]3)NQT!^Q:I^XPR9J-,4_X
MY66C9^VH/]M!])>U+YRK!NIULA'7"_4Q&(PZQ6?K[H;U[H8?CT6.!0-\!NB.
MYYDXEY'$3,906R8\Y]X;O!K=#:/<7I0N!M*%CP&2.EYYV!"P*\QE?3/&/NK5
MSI[T;Q\W;I_JAUAV@[\.@>9!R4;<*1>^W2YW#.RGP:A=-.N>'6GMR0LU5XQ(
M$7E1X8Y]7^NSN.(]$S.V*?&=6_#-\5N6K__-$UUYYRDEV2;F^:IT-8R#5<^V
M_G?LE/BLWNMLF[;Y[MU\^_I)15:M9D.[YFYSI[&WWSSXG\^-'5#5VXW/.Q\.
M=E+O2(#;1=K:+1"V7$I,^457WK?SPO+)SHTG_@N^\%UBW5/'E%=O]3M-[ T=
MTWXQVJ]W\XU@__L(W1^CK@8/'\SSNS1X77=%O,T&^=0:?$.A[_UT3..7&B6K
M<N5+8USKECE24X$BZX+.;$:,88H;"O_QF<4V:$>,TCS<4C/.'^U4X1UXY>EX
MH!9"BM+\#H1YMY3E3R#*X],#M-(9]9TO^.CKN].CKSMQ7&(?_O^0?N1[!_9'
M\_VA:/X\/3UZ_^7GWL$7,7M\<'0 S_CZ#IYS<M'<_@;C:I\=;9_\:/[<P4=G
MW]C^^W??C@[V?C0/VJ'YMI;S:@FE@9$,@00ZQ"EG2.>"HEPH$3(EO='BU6N\
MR1^K_\<#SPZ>9?O\XRG*!]:84\<<[2QVACCO3,8S08UWF'F>,X6S0 6>Z8^V
MQIR5PQPQJ=OC.<<D6*04P WWE"!E(^T]EQH3Z3"F!GR/3;PD97M+BSF_V/9=
MIKJ!.W/LEN>#D].]M=W[<CC>?B.[MY+DO\>"O-9""VNA>K67](IF5C.48^X1
M%X8@:2U' 8/I(067&:>O7JM\,Y?+D3:SM&KH_OG#:]A9=M-W#3N/ CL3XQ=;
M+_- (C./BXD>5"*E@T:&$B>4M)Y'V)'Y)E^2PH&EA9UUY/?.UJ]K?6\YWW6-
MRY9O7\_TNRK6ZCKRNYP6\&[SW1V;;3R%BMHNA7RMH!964*V:74RXTUG&-+(F
MD[%5?8:,E@8))@(/6BFMR)(UYEA:%;4."C^G9;R&HY6%HXF]+&$]C9<V4K%@
MQ#/OD!*.(NZ,M,Q*@V.A[1J.EM!B7N5X\=#W.VL[^:67?-_+'G[JDN^;E,[*
MEW#_*A5S6<^!"-@IDC-D?""(>Q[)DBE%SN;$&D*5XZ!BLDTL?T4%]\O<:?<R
M]=8[;25VVL28\TI;Y9U$"NOH6QJ!E/8,N0QS(42>N4B5<,^=MHX'WK8!*PZ0
MQM6RM[6M<S_WX+?CT/C-B%V7I2W2+<09J=7Y=0V1TI?;>NC'^NCW8.[Z11IH
MBN,UQYDFC"ADJ>1@ZTF#C% <8:.4)E'T,_7JM=ID#SY]6S[*^#6N_?:X1IU0
M(6@5G,TX]\0P$&RPEXD6S%"B;XF8KG%MM7!M8EFK+,<XBR1 7E'$L?3(!*>0
M=XQQQ8/,L8BX)I>_W_ CV/'WY!5Z;@*-BA?#^1A^A$L*WHHK-!JM@E/G&OZ<
M@DHC\5"DCW6WZ_N+$E(\T12D.\YC4YH_*:ET+6;>-ZK4^T8\3AE'^XM7>H[E
M>E>RA%1+57 !E?Q#_?D5=]-41(U1S*?Z6:[QE\W/FXV#OM>#4?^R2--HV%'_
M>\%'TNH.AOU1:J\9%QCVG[?#AAZFGP[AO>*3.^G'"94;%ZWA:4.G*'9D*X+/
MX*M(LY*^F&).2M=,1&R64&A%)&4<N)\DJBV!E&R/?"2YF4= U6YU8HEKX[0U
M&/;Z$2(;!>%-W,Z^SD;E]%!/2T[!0M4"81C3YT22K*NY[A7[5G591: _>V&K
MX,[2C9-1"T D,M]$T#^/'YZ/#"Q!^[(Q[&M7DE_I;BMR8I6;8  0U=7MR\&L
MA ]\NWC0^#>%_*5_]A/EC07K ?003"\,T0YJ]%ZI+ADF8U#2CVVD;073TPNM
M=GQ2?)5TN_H41F.DG,)6MX@/QHTY&(4 *!FW!JQ'Q_OA+'U8\%/L8273EXZV
MS&":EBN.?C0L]VWMV3-+5N,J<AI$JV';O?1)&MU@S#-T=9)*&2E>9M!PH_Z8
M[NQ_1RV8C/@:!6%8-69XOAVUTPI/;VSX/LK);>]TT6JWDR79ZA8BJ\_/XY)'
MFC:8<1@OJ![XM@TR4IM+W0'+8!@?4IN'^KQ'KL?^F*VM+IC%N'H7W2FQ-QYF
M(7*<?8<IBP*RZG!490$L 1@=U 5^.B,PDM<E%1#%I@>KT(BI$@T05^NG=O2I
M'C2Z/I+7G>O6Y"Z#M!E=#P;;[0WA*M!;H+WZ25#;,.9XUW,=F?4N:S\" 8E"
M$!54KY2#V?6.MELIETFBIB2@?+T\\D&>P^:*%_S9]U'(OOL)"U9TI6J_*@4&
M3WZBS:#7ABU][4_FB-I5#H5G,AQI/C-CM3]/^Q,6C1/P","^^(9T@,'^J=L7
M^G+PZE_3[PDO69_4!>;C^K</X<G>OE@$\%][_20=?X*?XOOQ*AB.7IJQ-$[[
MT3O_KY;W*AX<*QPDYCC/#66YD!S\+Z-8CO5Q#MLTZ47 Q\C,'2V^__Z7?CUO
MB6=V1N$P$^5</#R33E&X+]'<& Q_T89(C*5]-49YMQ5/SCS6CCBE:1X(SQC3
MTKDL2))3(S4S[ 'K_ER0&T_FE@1N*]@<\Y?.,;WK&GI,NIKH#@LP]IWS=N_2
M^P)CP8]%U2> I'VX4:]?YT4<M.#;5FC!CPNNT8W&Q2GX(.9R8\[#P:#0[=++
M+,^$2HNB(B8MW -X<O(XP:D'7Z<P%4K6^/%;3%S2:=NBYN> FBD)4 O5TAK.
M*(V:;5&S*,J.3[ZPJZ(JZ?>B#@%C)'I,O6[:,F#=P/U'Y[ 5+DY;]O0*O>34
MJR^+87&C#'T &Z]?>1"['_8W&B>@V0J;'I26CW.8[/;"2$\F>N'S][^!B5N9
MF+.^1UWA;B3I,STPT^*M)B)537I:^5:_<39R)\FWC,( ZS^ !>A'<[+&T]LS
M9_!K&&*Z:# :_S/HXJ;P*N/@1AJ:B<YQW8NYR@-ZVQLT"J"]G!#N3K'_#D8@
M"GKP9Q$H[9P#/'=];S1(#]#%=@-C.MJL!4-I"VYW'AD_H[-PVNH[!,X*F*P#
MD)X6@-%@.-@HMVRY7QQ81.W>>9R=68)BN&8X&E2;',QYK_MQ/-%<FOPJ>O2]
M_G!\'?RRK\\][!P+IGW7M5P"CVH;QKGJPU"21Q3O6EC^,+EI+2,81(.]H#%V
MH\&P?[E1/7_4+A[3@W<NWSY>%V!;=^/KQ6ERR2RJOTK\<3N.-_W6ZO,(R_%V
MO5'?5FY?Z=CH8;G_TASUP+HL'9GRY> !*2H8]^PY*$;?[U<DS!ME^ 1V -RS
M^#(*>3%&N/]W</U.[G2K1F4'%MNG-_"3']6E/WE/U2L/JO"9:?6&WIYV89^?
M7(XG<;P H.2[O4[\HG'BNS"1[8V:Z!6N3"E3.N[1^+MIYZ?F B??<Q!!+[YH
MN9/'SN 4BRWL39"6=N&#MOTP@7S_Q/>+"=(6_,-!^2;1=?>P+6MWBD-LM[Z!
M@W_:*WQ';4];_GM<80W?P*]='!\L='>"'J>PA/$)<Z8/%,+-RUEN/AA=A*]X
M.5AENCV[KTM8@Y]'OZ^&8).5@='W)Y[&9.ND)6NE_U22#G:8[T<M=>4F#9TB
M9]7FG)[Y>./I=1\44+@Q7O?(.1R'/IFJN3(%;C$\H1=W<85\FRN@;3Z/0*7\
M[Z@,DLR#W:2"[H'0H)?'L._*\%7E_)51D7*MTMZ9LA_&=YRCHV)X-5$S:]@?
M<VPGXZ>[10ZCJJQV9QDLBK9'.\+E\%07FW_RW?1K7I'^*<63$*8<0AEV2R-)
MU/?/1=.^4YJ*GWW_.[SV-<=Y[7;/IK_MAT]C"OOBR.YM#]3=2V5L;_X\%,VS
M+WPOW?_;Q?[6<>:TH)FTR,$Z(:Z)0.!9Y4@3<+IH[JPR^6HPMM_:T"#B_[17
MDJR^U(>U,M3&ITQ_),4)9A5 Y>"??RYJ7#\%_[E2FY*I^]"?<[%)Z/VXNF]D
MU2:;.;\OS??-%.!T/=C5&BR_TVU?#!'ZBI*6'_S/IYUIUO+_-OU_O;Z>N?R>
M%,<K.CU7.-UOF9W'8X+^?=B0GX?;_+>8N#MQES_&W*S:Q#Q,HAY%G%9MRF9D
MZ254BWRZ)EBY:*;@G2'E=\TYOOL$K'!"\DPB,M<*<V:(SUW,/LUDT#Y0[[AS
MAGNGRRA&?DV!Q4)=2\OXA7?SPQMEY\7?I,7H%[[_=8\>;7]J'6V_:^UM?SH[
M.FBW]K>/VD=G;[X=_FR>-M\?=?;>'YW-YA;#V,7ASZ-OS??_^;;W=?>B^;[9
MWO^ZRYN=O^'Z3V=[= <?=0XOCCK-R-?[8T)9)K7/@W;(*\D0#Q@CE6<:<45S
M@AGQW,I7K\D&_/V1DHL7L4*6N:)B#7TO$/H4,PH'9HU3C'.NI1>8.DDS:XP7
M))0U&/DU-1@1^M;X]O3X]G-2$R:I-SGE &V9B<0R#AG!# +Q]%YC&I@PD9+Q
ML>C(U^BV1K?E>O,%T$TSF5N:Z9Q2SS.E3"8B'U/(&=.*67)+A=G:L'MVX"-C
MX*."9B1C.8)U4XB37"%IL$#8$\UBBB(18-BQ#<+5&OK6T/?2H8]XQ9@+F5.9
MY9X*C3TF-*-.,&P55[>0!JRA[]FA;\(#(!3U>99[I(C* /H,1YH+@7+!LB ,
M-<IGKU[3#;XZT/<2^/G>%]EV1;:;Z[2ZK<&PG]+\KHUHO[0> U=QRSH) LC^
M?_:^O*F-)-OWJRC\[HV8&T'ZYK[TO' $;>@>SS/@A9X>]S]$KB!;($:+,?[T
M[V16E3;$(B.,L"MZ!H.6JJS,LR^_(V)PBA,3C6'4BV0(5T(SS.\0BVN%TT,+
MI_<S 3?*HA1>&W!# WBE3FFPRYA&B8)!%J.V29N<E,";,2&@'0WR(&R;B(^>
M",6L!@.<)"VI"I;B:!US2=DVCK01;#N-(PGGO%14( T'ASCU8%.8B)'RT26M
M5?0IQ\GYO2$X6K;=8+8E4@EE!/<$<RX-T4Q)2C&346@5)+U#@*1EVX=GVVD4
M1-#(=;0,::V!;54TX K8@+BD4AJ;X\' M@+?>P)NR[8;S+9)>A4X9@:8DCL#
M-G(NPR?,T6@]4?X.SGW+M@_/ME,/'F2J349'% 7)N6B5D.-2(\*$9Q(,)YJU
M+=\HMEU3V5#%?6;#??7#_J@!M;FAS> ;PRAU_P [SQW$X]P\T#S04PG-WG$7
MOS4RNXX->B3I?L>=625IY0*FAG-FA.<^<"V5TU+0 *)#$=Y6(VV\W&^"([#^
M5^*(!^6(E1Y)9B7B3H+L=]XBQ1AEPDH'!ERN2&+KKDA: U<]C<Q6*U];^;I"
MR1/!SB9'20J1>Q.,$<X(&[7R"5A4W"%4U<K71Y2OW4D4B^SM;!]90I(06"'X
MUR!."4=688N2DSYJ1F54+HO74A7?BM=6O+;B]4'%ZSW'LK;B]='%*YF(UX^[
M1]C3X /6*&F>$ ]6(6L=0\(R;2E+7L68RZZDN'>"KQ6OK7AMQ>MMT8'[C9EM
MQ>NCB]>9NJ[H<"11(&YX+ITP$6GE-&+*2&98(,3%7->E?R#9>H>1!S?"Z&X.
M)LUR3-/;,4JW"SK9^W@^BAF*L#I(AK<ZV1PJQ6([T<^^1?);Q,S#E9_8T/FO
M%>2&X$JH& 0/L"[GH^-$)*?*F/2DM#YZM=0:$RN(BSOA-^UG!+8,RU,FKPQ+
MW'WV_8SAM-\??8BC*;K31,+(IREAOAW3Z?"M@'60@YU=G*>J'+P]4D0)'#1'
MD3.'N-<6:>L52DQKDS&XJ (:(_3YU6!B!YB@E\DDT]@JM!,X\=B17"0B>>1@
MVA-!;#26&6J=D9EVB"&4D99V-I5V"-".MU8E*S3R8"\@'@5&FK'<0!:B$,$"
M\9A".U>+?AK:V<HXFN<54&KO<JM@:Y74V?AL,-GS6_-HBRB@"RBH#2+G# AN
MOS.Y?*>?(=UMYZ(>T(0:,.#IE(''&I/\8%1<X=O]UA_4+^7//=&!KNLB:+$/
M!E004>-$4;0^@!4E"3(B:10DO*Y"9#1Z,*">\T4;HXC FZC$"<HP6-A,I,!!
M6VIN9<[@,^(#%U6%Q8R97<F^EDHVCTKV+HXRQKSW<%(X,9,'^48$3$\1819H
M1TO*N,M48JY023Z]X;S(>W[5//T6<.X7!5WJVB^VPR(RD(V^?EA$?H3*WKYM
M2H$0S]H)$S_!A(EKSX/#:NM7LEO+OH/#> 68J="S?GZCRKD'EF[W[*3K!E]^
M>0WJ!,RK[;-0QE6^R]C8X[@IB+C[[VM5</K/T[W#\/%@YY_=OT[?G8(:.(&_
MNP=PSP\?/?WK]]\^[9W^U?WPY^Z7157PX?3#EWVZQ_?@&G_]_@'4P"[\_8K_
M]?&DN__UKT\?_GQ[^=?I/T\^',XAXL*S@#JX.'+884*21%A*CCC%!AG%)-(\
M&,.2\932Q:DC5BKBX=:.:,TI51:\9P..?0"/RU(1%Q%T7[]ZN;O_?K>SO;_3
M^?W=]OYAY]WNOW;W_]A]W[EV4/SU,U)NO_O\:G'$8-Q+HYQ7G OBP SR3$2E
MHM+$^F</A>?<T. 4S_D::LP,W9)D)LF]B_WM(TTU-@9L$NES$% GAJR+#C%'
M'*;@E1@NGP9(\^$<R'*-DCP^A05.)D=6ON*@HH3BT@W"=$;H55CV/-BB<B+/
M2BBR.(UY3$6LX/3G9T.TN,X_(OIPN]@G@>O\H^$!MW#)3PTN^:G!M+;(MO=%
MMFVAMUOH[18N><6)E,NWH7;6.BG&B7V>!OW3/(6JV^OFD6YW(:][ <K<A>Y6
M+<)J%_DT%ODS  (=#N#+60+:SC_ZO;SLK<[K47A^G^[.'PZS;=DS_CB=VX:"
MV^6-YTI9'KFSVAB.+0M*, ?_K=C<ER>?!SL\64PQUK&VX<;4YGUCH*VNS7N+
M#W9VR8=#N.:?N_Q@Y]VGO9U/L$8O#G[?O=C[^B]8]]N+OP[WOEZIS=MYR_<.
M_P7W^/#EP^$QW__][<7!X3$\VR?^X7#[Z_Z?K\1?.[_V]KXNP!JI&##VQB!'
M.4/<:HT,S<"3)IF@ G;!FSPIJ![=O#%=VVL"6WA"(FCMU<<;)('67S_,F6)6
MF1@(CIP$:F2,V$B*A?;1$;UB]ULK@-8K@*8 3<X9(9B(2"J=0.S8A!Q3"A%%
M?&*)"))2*X V00"U-M"*Z#762:'A_X&Z7(1HG%51)A=#4-&J53O$6A&T7A$T
M!9ORG!'.0/HXF3)JC5-(1Z,0]L%8S.$]&EH1U(J@#7FX%400]982IZ-7SG+O
M0-<J[K"E,<#+,=IU=E&U<NC;Y- ,>E8"*M3.(<<U1CQ&AISA$04;N%-)$BY\
M:?'?*)#9'R2.?"/+[?;.NT/?C6<^=G[M]L]/+#"%C^.RP.%6Y]69OQ+=NA..
MWY*]^ %Q_ C%27LM&#A>7!BCK1*YC0=[X7R*9IU03ZT8^A8QU)T)"07&I N!
M(6M80)P9$$.Y$RM%%807-OI <[OF&L30#5!ZC]3,_E2Y=OT1%.$29YX!.XJ4
MA\Z W4 X=^"K$Q%UXFT$Y5'Y=1I!84H'$01'$@R[/ "2(!UD0#;H8)-QR7&V
M-O>EY=@-UK-1,1,=CS29P$'+:DQ#3!)CL!RI=F*=F#0MWWX;WT[##M;"T1CK
MD/:*($YU1/GTD&8I$*FCTR&U>O;'YUHFI$^">@UN'W<<@Y',$KCK3'%P!XU8
MT4EO%>UZ&7;JGUMBLRLN$#'.@'_N-7+:6L2\5,$2E8SQFZAHUU1S4G$>?4[%
MAGOK%<AU[QZ57G> WK];K>ECBZL'2*R*$ BCD3AFP3?T)H/^4B:"<4Z+2%M?
M_O%%U@28>>_PF!W%I$QDT2*<G$!<$ 9VA@DH8F\4]5X:'==D9ZS$&T]HSL;/
MRNP>&T($-<DSS!/7SH*Q0B@-E"MM FUC !L1 ZCX7/B(P>&32"H:$.="(0UR
M&G$G<)YYCR,6ZTYCMIS^@W!Z3%$(:S@-$7,JH[/*"1.C9XEPFG ;.GA\=F]"
M!^Q@Y_CB"+R-Y)1QR)H\+3<Z@ESR$>$</&#<<D=EJ]9;9E\&KFJQ3"I0AST%
MO4!M--Q2+(RW6ELFV[* QV=V-L/LET>62FX4)PBX7@.S,[#A;2QHU<#O"MY,
M<;VE 0_+[#](T<"ZFL_@N-!Z&M V;(-NE%C+"?-[]W"UU[C#-7Z&MK4W)Y<]
M^Z4[S!4^[ZMBGZW.Z]<OVRGVUQH2#@?MF>56YB0SCB:1I&0(&"Q0J?%=9KBU
MUL*]K86#EY.(WY>]G5V^OWWDP&ASF"FDO209;<DC)W!"T2J<M# D*/'LA<;W
MGA6T>>7,3Y4]UV_F,Z>M$#%&'0EPI]'**R&]8"0%FDP;O7M<GOVZP+.&^>B-
M9BA()A"7F"/C141$<B6U(4[)'[D5\ZGR[4-T#F5@9XN#4B%PD:LQ!27Y_&/
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M!=Y&SJ]1=Y=@;MN(:9">(9=LRIWO'LQML+D3]U%+YU)@XMF+VSTRX+J)1Q]
M<<VF-)L0ZA,P@>><A)#=@Q+8F/!# JW=Z.0OP"_#'&BKHWC#3*I5@A@<B$*V
M9S[+HZVYP,ALXO6T'[JIRA.G[F!814V&( BKX$F5A,TAQ6LY;>9.?;"#CXM
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M!&&*6^HXHL8&Q(G6R&D2D.-*,1Q 3^3I 2O-?)$B6AR4"H$+)ET0E("3(V/
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M%=+/$J".XE^WM%QYO@#2>PLV;Y&U2P'[OB5G%:WW+'*J TZ<&F>E8-BG2$P
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M:]3>-XJ5FYT(QHQ0RY T&E2CAQ^.Z(BHMY*F()AB>FEAX*IU@0%KS[RWP<C
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M(&3XI?/^J(P]F".HQIZ8LN<=;9_)7+_:/IB$>BL;:.L;C*!,]C,6T (/U9,
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M\4]=BTMXXD;SN1:G5UER12'HV\]J6:X5,_\3#TI\-DA8/"'8L#A$=8W#P;R
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M<B4K43:.'!U>_E"Q:%NW'D_A]?=+Q(4IM7U[D*5%7"#'-8Z6Y$5QPG"L@^Q
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M<((('A?[W82LBCM$,4)%T32:Z#OT343:)(U1%TC@'1E/? .#WCUJ7I1S8U?
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M$I_Z8#0V@'[?89/?<FLX[8+80S2=Y(C(FU50KK+6MVBP8+7J;&'506/5,M*
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MX2FP9J^H4#*Z4E_G=SEXG20YSW^*UDSQ9GI;-6<9S)1$+VRK=C1J5!F0S9I
M[@A*_9SC".W/LTX_?E D:;+$9&4NK2?HLFP*NIAI[ 4(DR+0;I*D#1F48H4@
M1S*B"-^Y_Z=<FKE,5JQ V4 [6?!=CF&1\J^I2,)13]/J$CMR9*Y,YC_!7OWV
MC.P5L!K$+Z;E$4J2Q"3'LP1B^O="F"O<4GTFO(4/-'$_YXN_9\I+24?R<*SN
MT)@3ES!#/\-)Q[0DM20E'402?-[A\<+R7Q:2Y5D6^TBD74L=I$C;A"A6+6L^
MFW'=J8LJHI,L4E<4<)@Y!+8NG;J@^'=3U$CGT(Y:]<M#Y$YM=;.'OZQ+*&G
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MF^)P1RU.5+[NRL77(9;.E[AIN7A]M;^ZOD(8P'_F-=UW!O>3;[WDFU['F[(
MC[FW\0_ZQ:(B4^F_@GR._OY9T^ZE;A NMOBBI0"K>O+B6 1G[W7PJ&]NE%B.
MGX^_Q]Z VU06\'B?>L9!<4IPSG:+VR(TXR.0Y,P(G'C/5;$/[C5<6";^X$.Y
M]CX&4391)-!(FDL',BIZ':*?98&#=(R-3(G8#RY1>@?4S '\?]MY0D\+%CZQ
M#@@3,@-,Z@8LLA,6\(K@7V%QYW3_+&RXJO!]CB5.9"NVZTC18(>9D/D77QX@
MR>) #_?LR]_],<1F-29JU9#K-5I5W_)PK0";@D9'SR6(L,]XIFGX%B$8.90"
M+5TN.&^H+(?2IQG.F)MFQ<9(=KX?PN%JN-1S3]9S/[_P15TJLQ^+!SMAFE$M
MT$,<66MN]TXL5E\+$O#.6/GX:'#1><SEF*S!Z. 8WIXN3!Z%_D'L3 </:\*^
M>D&(T;5PS!&CT5++ M/7N"F.#75,D*3,XNG8'7:1O1XWR1'2>C\Q'D391*:Q
M.>;503 PH[_"*QP>P8.#+5[!2JF+,#.;4E()LT?T:'3N\U[N?,Y4WQON*"<K
MWB]!\=88Y5V25T: ZQ\N2F3W&))8&)G3R=TY;T>.JA/QIWHAVR*_A5"$^!^2
MER#PF8H*==)I83YO65]HF1^/T%3\,W25IMO/4L@ MT'U*9&'G<@FJA[;; QM
M&^SYW[_X[K^?//TLA +ZSS_$?_Z>?3W]\>F%_O@1Z8]AEV-'4<Q,S.0RX*Y.
MS?IE5AYO5H)IM0P@1T7,1S[,DT06C9G9TLZSB0ALL+\OT_=XTQ>GC$B>.P8J
M'$&JN3\P7IP"O!#7AM_NJWRIN":2I-Q(7D 1P&U1[FX(:87/Z'SS"F"E,3F:
MF=&E;%=/./T5O+VF3<RLJE>$<[8Z4#,B(?[I(XR>8CR,XNI;=G0V]% UW9L%
ML!@T3")@R:5?4'J*!156\D.YNJRIQUM35=[7THLPR'L(W6!TT(SE]41^E3,+
MB6NUH*1*<*_Y3DCCL6,FN<S$C!#A_4U5=M(=P7Y<N#GW0MC]:C2'LKHMHZ#6
M;1Y^[I'9O:R/QUL?Z80@H\UU0)BA'GTG_&M?-^:L3U.'KX7@3CIA-8,.,N'+
M##W^J< ;Q)T'6O4>6_6;8,>WQRY$:CFUXE!O,K>PC"V]473M8'XK[28_'"^S
M^'BSZ+85: 2@C$G_YD*Z[KZ"H)_F5Y<^];N7U.^"@(SKIBJ;R_P\WOR4.Q'D
M&6GM2!\C]Y=U4EWWQQ%:S.NB6!6KBWC*SQ!Z'L"*B\T3C)GNG+90,_D]$7B!
M:(-;$>NB.@LXPA>Q9P^UK#ZX:N#]GT%*YUW7+,M<.4<([%<U&YCP">A(YD#5
MDFS4XFYU3!!5JA#?"ODH/9#BFARYJ("K!&&9.9#5(MY@HD@)I+4\B_6X2D_I
M/VJ 4DD9L2#R;):T6WS9]IO%]2H\5@G< 1-%M(NOO[QFC/17/1G',&4((:C\
MO;C>%/62"ZM?O;C&_[D>!JQ1RRG()D1)FWJ1]X=M(S0Q!"\K6HJS)@$7E"T>
M9+C*V)C*Z5H"*R4P]9@S53PJ=Y%RX'-DP4+IT+1$&E)A@UM)&G60-!/8^BD<
M!RL)R<P)*DRA:KQ[.,MJY?UUWV*T\&B$3#]_=-7;H3 ?C':$PGF@E#L!UCWE
MF&DU<RWB?0&0=^@6IM3YIL\)"5L47*09W,-ZX6D#F3)#4ZN_ASU5M#NL@AP-
M\E>+KR-HT,K@X=)V/4(_\M&$:@ B+2$DQLQF# 3'P@K7+FLM5T^ _A90ERP?
ML-YX88M3FEGC0@)YT:N>A6E^&#XX10%C.^?=UJ.!DVW(T&#>@[\(%O@CA_T^
M?R2LW$&:FR:P<EBH:'&D_JE^IQZY"+(E9ZZ1?VDQD@B]>;947[(X%+KG,R7"
M2*I0V50?0PI<":^3LT K\U5[&@C9XA/8EB$F*%;)!L0))\&):[=IM82L%_58
M.L[HG,7.=:5O+2&C;<#DWHWTFX72:_"Z">VX ,YXDZ=->[R32UY9M,UY>=$_
M:,+"E B_O%CTKB<NE5)$(,D^VZZN8QN.[[D(#UL5I!I'#_?T<VYK4.*J5(B.
M=9K6TYV"5XN_-'>TXC*F@L #>Q)VQJT;TB^2?0>GK&<L 3NF?&[T$34^Y$\/
M3XMJ?E[/^S]R)/(^X&7=4;:0883A)8LC7R%^G8TG>@PCJT7R!@(!,-6,IDJ!
M6TE=,1^,_0-QM99#/UV?C([FS-_EY:E6XX##^%WP6,GAIN\2#)QN'LQ13<)?
M6O.7#E'2^Q([M)26U+X;G]QL:OU!$\663*<8INI.?3\'[!^5<ILT,J9T$:]9
M3AT/_,KTZW;N72TTT''(V >?+HQ>$9,\$=/HZN5#AS,G%T3;243;;R^(M@NB
M[6,YKSG:BK T.#_>P3KAZ Z!O2=QO0/8$8> H[ /3\'E+ K%K!$DF.5PT#2[
M<-'8!N#YE4;D$!DSH%F1C>R]8OR#_=5^7#N^1EZ;>UCQ R5BF KV!HV;OE]S
MT, )3!B:.39POM5;Q5L(0HT93JGN3$B +1')LQ]!^&^:/,U9#1)4-"').1U)
M8(%=>_E?S[]\\O1/"SIQ"AI+3U,*0H%/SX)78AW+[KQLE(\@B>/CVJR.XZ#>
MS9[C6>&(?>7B]1 *],LB#=A'.:&I>)L216D'7=+II]7Y-,,UETYJW2/&PW<L
M0BE+-+8([LDEI>I2.0I-4,ER8:+XF+0SA3D560BZ*SA<#@.>8W/ERY:4EI\<
MFB<DN.SC7]Y]X(9@_ABCOQQN,77+IHV*=R7E%>?LS/GGS;Z3"9B8FQ AD"N*
MZ6%+ UZY1%C6!1"KLNHU36K!$[@LMDVU J0$R4BYH63>Q)0%FV-E,NXED2QU
M8K-BGTXG/2\$(Y#Y=5$6(FP^7#BL"6Y?68=?=-ND5:.E@3B/4/<?P>I6S!>.
ME :G8(@TR5(-/L4Y#ZRUKN@L!@DLQU[GVHF/2+=&!&T!*VV4&[)(8FY.L0;,
M'CEQ>HOQ"6]SZQ')0@EU%%'$ XH46K5#MR9;HK"80'W@NL:5IF)T^L\O\+BP
MLS0)X->QHHV;.^ITVI82WL4>N:0I5W:%\4MJFA=G*L5)Z5X2<:PP2N&)5C+:
M&AF&8'9-K+:&F1\9.O1-\[+FO)M[\*O%5W-SQNDA/<\R>1)T&?L])_S]_(24
MFZR)^X'=&]FONB6UR.&L+@X0ZV;*N7$QXS4-2E02G];O==MPS"*E]HY]$6T%
MYT2GL$FX2:47LH_K#",L#1\!*RJLUS+X.6C,(GK3 JOF#';_FZT1:P@RA$K(
M-V$WX.#EV)R3BN2VQ8+>NOR!DB#<XS$2&HW'?,)'BS9R\LHE-VIS>NMG'54N
M"M-U JN4:7DP^R.B#)ZPTU_*EWBL<(^"O1LU'M/@"5WXYIXG'$[\#J9H*'0$
M][@*UN><T-E%_J *W7J+O_;A"B @ <]0&"30DE@%(9C MKFC"2&#_/*'X.U0
M2>&SJ\^LHD!?_(_?N=\@[;]70OG,M=/@1M\VN>_GC%H76F]UGZ(_2)V8G"2
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M0M=->F@3L#G2+8-=CI)OOE1?)OR=/8?1EU%UR%>% &%FK^ [AZF8436=!!L
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MM0XK)'J7X#)@$="0/J%L$HDP.> ^23%&C(UF]7WY:[0WDHFR?DB9E8B:"X$
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MVGE1.,MW1"ATQKVI4PSD91DF; !O? -=XTUDLT=I0?MPJ!VC1?-$TF^G?T_
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MJ2':A6._"G%>U7,;:PB"T& 7H5H<^4H_-IP1(\BG5=]'<&LA*F=,*5N]"]$
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M#Y?VJ:>9YC%.R @^:"*3:UZ+-UM;2/:!]EK9Q*H^F ^<[^1V=-W/CLI8#!?
M>&=C<E.[7>_S14I;F]TH]H$R9F.[#O[YY>Q/Z+15/1C[K;6OQ8U<2E:J2B!Z
MFZHRJ5(',]WM=T1DX '+!>YA4)YP>V'V"\L6>MWS.T( HRC$*.B+"C6<#3"I
MR8,V(V\&)K$$8JU/[*1%J/&-YCBL_P9-\5QRR#J,7>1 ?[ZM4"83U%+= 'D8
M2Z,NZ .1XQ(\RW5/_$! 1=#<T4N8D(Z['5MQK<BM6FKY!/$#5K.]E 0X-C^T
ML0=#H%<?KJ5,__IR]O-XPQ1?7#6DLAEC\R@NHL(U5+#%A,HLW<@O6H/L@_JF
M5RZXE(8I>5)N2B6*BXK!'?>,A1Z.U2L"Y#AP'@D;8NM&]MP>W@9QGM (D&&C
ME=JNPIW"FKL)SWY;R^U%,LM=I)A$?;Y70SR4#0Y;BGW7TN%I2"+VTW)\EB"K
MZ.14GBB GPN6CQ-OF[ =S@2H"91:*5SM?.%DZV;$)F!B^21&Y2[<+*S<GK$!
M,B!5=UMN>RF@)OO#M3;@_['&)!A]AF;T08R/,*MF\.=!^T3.9>ZD*7\%,O-7
M@]3P<8I=*B :3M 32:18)A_-D*#\31@7V#@=MAT;*/<KQ4RHLDXFE3#(NQ]W
M'\]5RJ-5RC^>JY3G*N6)5"G3_ 7BGD/D)6_#V7,CMBV"24H2[^2^-L2LPEYD
MA[1!8HX9.W& DM2RFA]0>U7OJ"4*(+YPSG;[K0!M4YHDB3[#7V[K;1^?W.7#
M+'%G\!('-QI]Q#S)<P*AS<^<3RQCJ**SX&;+TX%) E)Y"CV=W /@5BOTT@PM
M=DF&7>N^W)T2?MYZLK.11\H:4'\8?@,):K1/6JN?#UC=$BU\5U#7'LJUT0.A
M1\@28)RA\MCA#8&(=L$)(4<N+"/2FB/9.!R&[A9YPN]1&R9Y'^GRE^7I,)FZ
M+D7)@/LZW9=%9MAK'DH><618*>T?0ZT06/Q]S_!^]2IZUFT=_%!9E]/\G*^/
M'\DP.J4U]]S+B5V6[/8'],%?QB3H8&TPU(I2+<9<-S0NKK %KDL*G<)PUW%9
MMITZJ../6^ZTZ^)O$Q-KWG!'[R%^I%T\6RV4SALWKR'TV93=V+0640?"UDW3
M)B8P N%&7\\1-(K:>UR+_>BJWK% Q\2ZWF_[7?!A-J,/FSR%-ROOM?JS]ZA\
MU2']9EP!JF3?6Z33+A;[SDU1&+9UV]Q4(DZ5LFFZ9L^)M4"DRYHT++4%,MY?
M2SRX.^(PS396B[W(<A"@=UEWM-9U\.+<@=%0EF.D]=5*E!KP$26=98N8SP-9
MD>BEZ6\&\-:"DM# +HYMO[&LWRY*M^3 F52@;4JH)GACVU9R_<G;C8[T29R]
MWRI"%"/9U>BW5VWU\07DRM!: $.V77>/(^$ZZ\]^6*4SZP=5X1/Q@*(!'MBR
M+(!W!(B*"<;)<%85_,!3)83&%EMDJ1#)ME )S>$*N)]FU.%(SSMV7.M>!"(<
M8JP:VY+GR?W ^U!/2R'7'^#<9'_RON0JON_%SP(_);9QD4<26YRG[P/JN^Z)
M3S!XA!7SHHUYL>-&]![BW%$AK ^_ZU<4+E!\-WK-\\1]V'W')'T4*O@F1PZ3
MJ9?MXK:]'RM$_]+65#RD$K:4F07A-6YLYX>,3 .%I]XU1T4$R[,$,WH6>?W5
M1%Y'VUO-]B8E@Y/PO%^L8GL6>M7'UV+"*V%9"4UR$. %;-YYT&/D+C') H^@
MZTH!B_;C(+4(-YWH-Y\.H1!^"NWZ9!/_Z;.VO)SD8G'9G;%DKB'ABEP3'J79
M'+":(G[#6O$Y,EHPJC.0.?8I](U95&<^>BA8_D=AN&E6CD%[:4[A>)R;2MXP
M!DOXS@&-LA*D5>C\J:MMO,-TNN/!>> :*<Q0V\1/)/O]7-*XCH--0&4/+C);
M)3WMXEIVZX9.OZWD?^*RR%EE5,5&UM7Q%9O22=&:C5D"::U'@D^:X5MVEB0&
MTM3WPPEF9*\.GFJ$4S)_X$S>1&)&8BD4W#T#N)$@<F:]\+GW8M@W501O&S#"
M(CIS1>+JT\7[?<=ZV;%,;R :)XRL7N,?QA8L9\.!(=S[9/C$AD[V/A\(,5O#
MNUPR7TF.X%_;QXS%YLL^L/VBXVPWL,<%SDL(G5E!#KL]>:,)>,/_9IWV%'@+
MWD"F>@#BH0TK\L MBLQB  +5L*W;@_+).0V:\/O6I%5<;S>C1AN8#G:*D]K4
ME'-,%;)WM.+3C=M#=$GI<"9_NL]<#$]*T<B%[2H$9;-5 OL$%3M15;A%E+RB
M_8+7J._83LE;] \X5,+37?::T>9*#;^(R/LDEE:RU7VU7KD';4V.B  1BULE
M'9.7/,--CL)-OCC#3<YPDX_%Z,Z],-8<.,Q,HG?HI#(N4;\'\#S,0<?YUZCL
MF[ 1#7(9]Z-&Z5\K*WW$(=2+">B*87<%7(Z.!*;HZ:G',.E3MDX$$3WNV7?"
M"1E&EK#.:TL!U82M!G4J]Z;V-6+E^CU"TM]R:?XPTB,QA/[[;I9CA*!"<TA,
MB(*M)(H=@KT"B>PPTX536";(3,.-:BE1 2-1.TI/O*W8?9?N%B_$&*>+M0*1
M1PL_BAY=]-QU,HT9D=Q2--6*_*/TR[SG1"?R1-KP(I65\0YX14D;J!^>D^#H
MC9)J"HD5N^=WL=4>/;X&RU='/>'+]&![1Q*Q"9?>U$+%3D^V;OM]Q(P#,[ [
ML/,?;SYHC*TZU]\ B/:""*U;DA:1[((6[\V9OJU*ND>8I$TK,;>'VW;U)EF(
MJ2_)&[1>,8*@%F!3N3[T.^D5NR, 4_!4P\#!CY/ 4!^ R<$;]#30\JNSF"&9
MNT'8(-G#A1MKR .'6R[>7LY>,YK([Z]A]U':"Y7D-R3.H.Z%%L4\%D"QW(4S
M4]9@NLJ<;5=5R#I@2_!UQ_Y(J"%15_E<0D[[Y4G8L9\C\$-ZS*Q3<B3(C$.7
M L$HX-M'(-C$U FC>YST]VJC.W[MQ_72\3ZJ.VN>B^^8'EZXVJ:T5G19&Y/P
M,Q)\784HL"4Z C"^AX<B!IEEL'FD@(V D-OAB@FT3>24\8E'F%&'L$>?^X!C
MA!<BOIODAK6!2NWV<2C^_VC_X..[)Q+H$"V:2J-EWH;20_8[\,)&J&458RG)
M 3N3I/*"P[BC9J]@R[MJ)SW>B4#KJ.[K?4IX>!+&*A/]4G:I87_.ZDB7SP0)
M$PT\M<R0$U4C?9:.:O2%$L^ .^"LY&4USZ@!G6',C>%/<9W)?3BMZZYO%]RE
M:K ^+XC^.3X(&=(Y')":N&'6U$F_E,,;+@EK&T.B['+V)GD0V=\C3X*N.-75
M3DM;??(3O"I-4K*.C]]E8CP+98HJR-5"AD3P<"U:-)WSE5^R'JD#11ROD&5$
M'@<<,\;:+=E1"?\LHU<8_T5AO$NNXR])S!>SYS^]1(5)<LEA&^PI218>MN//
MR<Z60+D& UA;@9LMYS'5[',B\G03D;^SY,9O>2[\&+PU"@H]'41>]^!V6%@.
M]N+:Z)QQ<&/NF2"/E4S(%8 QCWG;$ILLZ"QQ:\KZP)&\\N^(<:JTH])(+%Q8
MZ0^8D3/=LR&F7J.RQ(@S;D+U. .Q5V3U]<1<,6D6HP9L>T?6K,PO:8H=@G-8
MD8\BI-G5TD>_H+P8#YXO9]^A&H?EZOF=M-6H7FM3J0[:<N#L@@C=CP]9/SN0
MBI@6X=)G6&@7CL)1F[ZUUWW8E)Y86)6H[79'FJ_5U5">M&$;-O2H:46(8=@W
M^H^IHY';K)MQ)\\Z$:#U<,_++'(=T5[V).$Q>@F'9^DB+]?#8/T?VCCA*"XW
M' $H'3>UVF?P@I@><4XZ[#(5_>/^]#<7.SWRH'T6WM-9%IP4\6G&M@_6+S8_
M%ZRC)G;B!35&-J!)IG+#_1WI:=.:\)^7MXA7&BHKY;1&GK#L40Z>=@*-RN7:
MR0@7E41BEQP<<#\_KU+O*CI:=$,F[2!.PKD^>[^4F2Z5T(B/]LBE&/<L&:;W
M6(5^-(]'*:F(BK"T][LJK)D=I"Z]/SI\6/BN9//H"% #E^H9$*+ <B!=17L?
MD(B1,QG+;!"(TQ/YNYY;W!^H.7YYKCF>:XXGDJ+Y^0CYI\8/PM04PRZV^1KE
M"3UCUS8W?'#OQ<N)YE,9CK*C8Y5>5\C)LLOKIW0V5O9M%B#DY.=B3;:-04^]
M<<0IARBHKSF 0+ AI8+P7LM6NEL\^#1$S*T/W'(VRTW;\&DMA)4F +?F)NSU
M_DAK9&02M[K2:00D[K2,RP G)1W'!((CMX;_ O&6$$!0ZM-*#BF9+9V-9<-*
M5I%@6>E!O2,23L@U51!O2#4T#RCW?  .:&+]_$TL:PF1_))6#+033UUGC=C#
ME3UPAH;4?MZMLX1]OIJINS_RZ EYIR= U-5KYW9<ZDG??4)7"+='2[)UFFT,
MBYF^DJ_G5&_DGUG/UT8T]+8Z1#*]6$FUC7O?=F\56&E9]##U [!Y @,O/&']
M1!-^<3PWZN#+8%>CU"5Y9%EF4VE8)8F=^M1QE,?FI!B"#2(@VI<3N1Y$1H2"
MX%B8;L7UTTKT[Z0>8"XLE3H$F(XMU)1T:Z4@&)(R"(-U,Y$VF.]K8-$W%7S<
MFZ;6"(D),*FNTFNJKZM$_R8I+6C1+NOV/I%:PLMT8-LN&5<]#)5_$!WZPJ)<
M2&QVQREJI.5$# [8C+!Y\)FDWS3A[EFR5+ ']^;LHGL6/UTJR4@=4([5+-$E
MMY\JF;NF'O.+K+3/JDDYT>9D=F[VZQ)LB5$_7G/?%-%\_^VUE2X&A<M8ETCP
MS7UU;.W&_&C,@_9A"T;9KUZ^ZE@*P D#>?I\Z9(LMYV(1D]-OM$^7'5#_YA>
MW7HDI+6W\(>2 ^SAW1+^X\F7G*KU:HK$%ZQ_A0WV\=LVR3^P/AHS1:N* >4O
M6ZHT@YKP" ]$Z;1+55DM*;+03 >'2K6SEMW^IA^ODR?*,<7H=&C!6H[ $S%W
MRAXH57<M_2WW7<0D#9*;S+&^7G-&I6J@Z,X*Z93S"<]'YTU9BUA"0WB)L/DP
MC9%4R)'/1NS:TR<B9<#XAIV3]TWSJTWK.G'"Q9WX[^7LOZ6A!'TMW*JCFT:A
M/468P)TT$:\2>?F8"_8IPAWMLK9;TLOW.D[1M1F(S1[SF]AK<TNQT$Y7:&)(
MOC9\V @TR0 4JPJRG[PAEMX_#YZD2[+6D?_5Y\^H!& J'#%B<'O ?>,DUN^W
ME4I:J- #K3_N#9(UK-7-96W$K.'0<E MMA'E^D$]IB%]Z)@LHJVU:EW?U(HB
MTYWE#%M<GJXSY]M@A&:O@()[[J:2WD&$N-_03W\"$(_?[YKSUE=??_5Y,:9T
M_>=RM[B]^+E\%T8;7Z:+Z803,7._3DB=O]M37%)"A%PI@ ?7V)(70Q[WQ!M1
M(6C+PHQAX<F>!HMS3FK-(K.)PC0C!C94KRD-N&%G8G+'-1$/13)>_#I7WA(_
MQ3LS7B2GESZO\1<14F%\L!2@X$:RY/BJMV7SZM VJ$.U.UY05Y][@T8_A]89
MH:+T767YL=V!7#FMM)3F5_P#/U9T7-E2P].10?IS>U^AI.(<C."@5%SW<N]5
M)QQS7!Y1V:AXSV55+FG741]7\E73C4VMNA58<[97Q/UZ"65D<#?R7-R^,@0+
M'4Y@@D%S5M]-C58!4$938!]=:=)U2\1E!FN6MZ#-JLIGN$'K1^_%CTE4DNU2
M%Z.YI@0T'%%14(I*Y8C1Y0!N7DJXW+:4.YF0>G5".6:^$.>24=-OQBW1PV5B
M6>4FTBI25HC2=./MB#R[=$@8=)F&9'SLY.5E/:JU<P&'R,J[MS 1!7WUUF(/
M.@PS^596%&#=#I:)<3MCPF*3FV(.H!/6(<SOLHA2(=%W.XE#[T\U>1V &Q@
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M;-O>J=7H1HL95;Z*KP[0+N1: J?<QX<&Q=,0;JY+X.D;WJH\*B1WM':',=4
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MI=,FBX6(!#2-B_B7,3ZV&GA^[I)QYXL>G-NRYM.8:,NH=%8J[QDQ5T<6:XR
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MT.J"GCW4BC4RKW)5]W#<G-X2AJOL&&50[08K5'D1Q\;T),SJF^EU_@CI:64
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MB\^?/7W"+Q'6^9J>CK5IR0^AY40J#%7WJ06+>7\(>70IL_[/E0]H=;'I2[+
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M!KKT?<1%T>[Z)/SW]]6\VQ-"Y^IS;/"K3XM$=ZX,$0[+2!+-*2S[FB&T,\G
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M1\?1Y$Y42[()8J_B:1"[1$I?R=W![;C+A0I,/DUWU@$"TM'EX@O[WDH/&L0
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M31#J[S,TN7*_S;B$,\$41]6.0QDB!PAH+&#EQIP2_ /6VDTX)=QWJ4_D"\:
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M?G>_TY7_ZAX,#G;XC7K!?NMK>S*_YFPX-X1=**S (Q<K\-3&"JP(<'R[=?8
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M'9[>K0]/[PS3:"'_,YE?3W_^?U!+ P04    "  I@6U16/'0X$ 5   9Y@
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M?S>J\6=QST)&_%< @PHC_LIKZ+#2>HP%V'Y<@;WR7,8;=C@E<]8;FAG"S8]
MA?&V%@0STD5T":D58+?(>-7(\$TR$!7&)'HM1%.RW7A&U,;IP=ZA1]4UK'T,
M>07>#GG&?P1@.[H>9&[S= ^3 _+41I5+#?"C?$/CM_[T #\5;YJ-;?XZ7$T=
M6":< KX"#(!@_2OQ%ZT '/H2T\0V#PU]W9_8;@<4A#,4O$F"A5+8%(Z(^P3B
M/XC67L6[K5ZS$^UT $4RZ288E"FA-GCYGFO)S>GA9U6PHX?RQ@D83&N!F\4S
MSEU(%4:X[:QA95GAI=+.*U]=>_><%?'\N9&I, _1W;LCS#"BUJ+AVFW^A@Q/
MW+0<7;2=NAKS 9?WJF^>RL79E3D3W@3$QPFW/.:SQ M7^7>I<U $A<I9[0@[
M_'VC0T3]US K[X&GHY"%]ER>@"'W59*ZY8!]BR@#H"&A\$\40W5>@%,F9K]L
M,)5 H4!4E53& ?8A1"!/HM*PCAKDT54>>'5CYA%>K=>F>"D+!$8PJBYQD=-$
MCN-Y;K1X)8J='X7*BSMV4-ER/_"DPO9;O \BJ@>'Y4-8E>"&NN$[RMPY1\.B
M,25>5]8+/71ZJ'T\8I7582#H(H>G3QP_!O4.JU'R."<;3H60INGQRNFC"W:*
M,M!@\$!3%,H/?#'Q?&)!Q$*$RC9AC, <@D@&4 %G'LV(V4^#7(5Y2JL]-VR;
MA'*.;-NF]IR9H);&>/()"3^)@<H5/8?MO@Z+WM";S>-JGSD0J:<1,8>=%\L)
MF.A?7@?WT2C2JS-E4"E0L-DN*D$LNU99,'5#2L#VKY #HHP#W,Z+CUT;BV0W
M9ZFJ,%8EUD8^C[@?(I[.VV;@5MGAQCV/YBQ>_JXM"M#1IE?.-I.B:!2IB0VI
M-R-^K-O@._UA[U%N0*4@*IC*0_TO_)=6\;:9+3 5QA8I%RS(M0/+Y>X. :@P
M'C[I]XEB#"C7DC#FT5=^@6FVP+)A51CEMI.)EX[I.J^1K\D(WG+#*^&.P.Y3
M7GUIX_"G=&^$]YYDE#)+XU-X=V438XA+>M)JDT.*9YC[4/%4CD)G(6PJN^66
M@QB,)TKC32K:.(=A31'-P<UV QZ%-9;\.N.PN)\>\);!]=-KHB)ZB/:_(P&/
M@16+MZ-LF&_QVPRPW7S-*@271?<VD?\*J![GS3/Z(3+!5/ +8Z"&V0/^\T_D
M$A?KVPM4/L!\L"J,4K+OR)H0)F?'9?G 51CK!"]7D%G3:*]E;8ZW-_Y%;TMH
MF)GH/TH8Z<T[RE.7\FF)*.T%4JI644OQ")/E-* ,2W<*BB%1>3HD&YJ)+9 R
M^Z%;X"I/P6Z-+E&_I-Z<HB5K!/["H[S7)E\AL @F%4S,X?)=W&05[_=&0YAX
MZR<*U@/S(%2@*B@+?7N\5QG$&4P=8IDS<(]@'$L%T2F85%XHPFV6SZQSP*JP
M&,8+1'%S]U;56'>'CJQ+,1>L BH>[_M"K",R%Y9X,6/^7>,,:(5WD@]7/T9@
ME;J.Y]&"59,$W$]/\79=4&QFCO1DF6A46+G;TOF"*.$<%97J ;C3#ZZH6 \;
MED3DV7S=/!*Y'9&9QPU:\>B8V'V9+) ;7M_-1$P/#HI#LXRJQP_F0N%B6UH"
M(-T8E ,I46@]E!EW"65^E!X7SZL/0:M@+/X9((?,2*C*R'WE&BA(=CUZ,#;K
M#<U4R99#IFXSW:'.QP9,,7(ZS$+A_07I45!.Z)_N*]/6XW8=EU<SPSIN="P3
MVR:(<BZ&,?' S!5>\,4)_.R2:;Y2[[KN88,C6(&0)4[W"(P_>S+6K]]X ,T&
M*/X WSEZ=+TIPU1T.O7<52#DZ;F6V",%!D:\(L)7/_A'LNFYA(_Y;@+8#RNR
M>2E3]N9T_PT=+AC<)6@+&%CRI^!L?9;ZB//8^9"J:[[3QI7HPSK%-&6A4W>"
M=G8Z:D?LDJ3 JA#BE [7HZ#\*^;9/;8;3^#)N2WFI,&,Q+OEX-!YF"<L^5MD
M#2794"*0CG8"V,:!3;PV9)2ILY0.H.XRB@M;N]6"]-!0 J% 6>SP_22;*K[Y
M[&+*%F35<8&\(]'Y$IA^>C@<E?7$N;X#O9>Y#D5F :M@%H>+5P>]$-8DWM@B
M&%9*OY^Q82P%46%,AU*NS35D7A,/$;$;,Q_3;QC1KA>D!^9E4"E<ZA4M?:"6
MTOV''->?Y<>A@CZDA6Q=CX(W=2?HA2<."\^Q9?M7!;$HG#[DZV\(RX]OW461
MF\H;!3(L++*>=CLA^F3R[)UH8V$?H<KK:N^D4_&:T#X&=0._[1V3A/INM'I(
M0=+)0I=0>_%ISHV8XFA__C[-]@@@-8Q.%'=QWE'OP/STJ'";NT=@V0.9\&MG
M"+-XT7+G6&S&(?-BF!3V*+O5LW4S<"+JG7BA(Y"<."^"1/G>D,,ME>6;,94*
ML8\M8_1<'V( 1BQ1PGWKHDD*-847U*$6J?"T7S/P(<#^AGV>>:3/6%YXA>=@
M]R1QL7/'*JV6M&;Y[ NEY& JC$TT+\3'A!BHUAA<-A#%SFMTVWQ6>TT1#"J,
M.--U-[&+P8E!)+\)U;J8O]4#\].JE"''G$D>*A\T'$]987L AAW<H/4=DB$?
M6[Z(?T5:U&J,.N.&E7$Q06YP%72LT)F\DQ[P^W<XW;<?%^:]1#$'I"(GQTM<
M*'+*RTE43K@[S@KLG:@\-XFW6FPNY85!9UX]F1=:!3-PJ/P<%8EXK#O"ZU,V
M0TP?8%DO"E6RLU"IJP)I&CWP7(IG@6MSMA]7,^JMBTF%5X<4E\+6$<S[G(*T
MQ<+F,10%=\=#*)NK>'QC9>S\$%MTJ;=L\YA+[,OQTTLSK@<9%V*?F(H*RZWP
M936%[A4H@$^)7?NBU6DSZ_T>1R!403N*;&@,\+/XZC3;(PEL"FR#R YR-:;(
MM<%:V;VAV? !W2K/<<F<>%0N^?$B'1-U^-_"'<"^GY'VRB!44/?U02U,9Q[$
M2#"/FT[<[*:6-# %.EL.>*%"WDPNUU-A5T$',B_&824N@<M&HX3[2ZN^M<L5
M[=HJR37E#K4<[R#(@%,D>=[9113DB14I&Y<&V[["..[DB?92S5D74D*Q69!W
MH_(H$C]H7U.\[Y)9"[Q$GW[Y?U!+ P04    "  I@6U1;/M'ZPX@   P4@$
M&    &EN:&EB<G@M,C R,# Y,S!?8V%L+GAM;.5]6UN;N9+N_?H5F<SM5D?G
M0S^KUSP$2 _/$& #66MZW_C1H91XEK$9VR2=^?6[9&S"R6!LR3:9BZ8#F$^O
MJMY/=9"J]-=_^_.B]^8K#$?=0?^WM^P7^O8-].,@=?N??WO[Z?P#L6__[6]_
M^<M?_X60_WQ_>OAF;Q"O+J _?K,[!#^&].9;=_SES3\2C/[Y)@\'%V_^,1C^
ML_O5$_*WR1_M#BZ_#[N?OXS?<,KI_=\.?Q49:.!&DA2U)-)D3YQTG,@8)<1
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M$:^.(=744(T8)T.X]-VT_^=EL=K(WN/Q%QC>G3$$D8-RE@B=/*YRVA*$(U
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MH)I804WI[1.B3-+2-H6UM2:P5:5QU6CXH$GN)M1=\QS4XW!^'TX:<2:7'(1
M@A4"!:,174+&9,%HBD%''YLTQGD:UG99U$:\JJB9#9K5Z1UY4X>C59 X9Y3V
MQG21Z56RHP]O&[SQL#1E7G-&').LE)A$X@3C)",%+*74<]ZF=?H\1*LN2OO(
MA\%W@&E;Q$>FK)4/1F9'4M"&2,HD\3HXXC+.MA05I]2D4.Y99-L4 -9AS/UU
MJ:YR*H> <V>,\U0QX2)L0$LTKOC%AI"(T(%RZQTHU>0T[].PMLF0M6%+1;74
MNY/B&@X:V RC$4K&]S[ #TQH5Y6&E$C6@A*IN27!9468"2)H+E(637R>IV%M
M4]%V&ZI45$NUTY133*<P GQ:Z1^U5W;N!A-';(9,6&%9TA[Q!(TD=OBO*"GA
MWEEE Q@!? 'OYB5C;M.MN'79T$SR[9W@O?WWYTMZMI,_K>:N/@12:7^H/'BE
MW;-;#Z@ZVX9[8N7QQU?CT=CW2Q^X<ECWO>^5,[R<,G4X\/V=ST. U?.%2PQ4
M58:K3+)2C',XZ'^^Z<S!/ 2(BI(@A<?5@Y;.>DD3Q4$Y=!!\;'.3V&T0JU_Z
M$,8'_=%X>#59MOQP^+V<++\H]]YT@F"E<00C-/.$%DVYTED9B'51"4-%#J9)
MW/84J&V*7Y9FP\.K'"IIH>)E(+<1?<(W<I(AA)L[M4Z&<-&]NIB8O7M5 R6Q
M!-FP+%4DW.$7"=03E\J%6UY+RVPRM,WNUHJX7QCOM,T(-Z)76V6NQXMYF2GH
ML+59/!QJ@S;O_D1;6#V@C&H*2 99DB?>E3I698B508'Q-&;>I#U+3:MW^UD_
M+BOM2,9TDM$2#//16^<8$WBN& '(02DA$PU- NO'X6RMI7L) ^XO114D7\W&
MW<8R"]B4!6$#%X3JC'.ST9! (R,<@[CDD[+F?@5K?0IL8>ZMB?Z7D?EZS$NE
M8I!''U75/*RE5.,I.\3IF@+,.0.MQ=@N,LF*LOYP-;X:PL=NOWMQ=3&KSEU=
MLD\^MJH<%Y] )0?ER?C)QZ"%\)$(GW!Y2982BP$5>J\R6TFYH:E)6[#%H]C5
M3-='/YZ>YK_=5.)DV.W'[J7OG<*%[Z*,A^6"Y!$J]P_PPTZ(U@4+#LULZ1;I
M8L8U7 .ARFM'<U(\LM9V;AG@V^0456/=4T:RN7:;N%//H#[H%Y@?!E?#CLP"
MHO8<3;XIL:6AQ#'N"&3G8N 8>+KF/O?":+?))=L&]BVIQ\U0[@B-S?DWZ'V%
MCX/^^,NHHX44@7E+*&?E;AV.X+/CQ++@HO Y:M%DRWTEU-NTS;H=%%Q)KYM;
M_<Z14M")P3G/I2-)(T)<J1/QT28B,Y5,E-L\H$GO]>7@;M.N[G:0;SE-;I!U
MWP8=7)&-+G=P&L],N9(SXZ*-7YP%X%I:&MLT#EP&[ N;=_]O8=P+M=@^:W)R
M<G)XO+-L:>_LKZM%H8_"J12B3Y^]6D!^[R&U)]XR1;%[?/3W_=/S@_>'^R>G
MQQ\/SLZ.3_\X.CY?NK_6$P^L)I=%03>7T4JG4YY][!KDU? DR_Q!*R5D7S#
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M7V1E9BYX;6SLO5MW6SF2)OK>OR)/SNM!)>Z76ET]2[Y5>XW3\MC.RN[SPA4
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MB PD&N<85SH%-&34M&DUV>(&9X\2GLL*=A^$3J#H=="UJW"@@S)$)8@G**,
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M)BVG57BD=R<5P\BK+K8("<DU21[;&_E1L;!?/39HSG6C$OGD8O9Q/!G^"_,
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M\L;KI#FFI3$LB&28<$B4K]-LH$G.R8/O?= Q [:1\P%Z'RAM':_E]QF #*=
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MC3<.Z@5WL#41.$@&17CFG$<GG2X6F_CY#[ .[Z#N^9ZJ:; WW)I%O@FN'[H
M;RO%;5ISM8O4^RS ,\6"4"60PE1BFCPO%HLR+#FI4=A2;F3$/48V;%^ UX0,
MVPC[4 5X=?"[DT&Q#*XPG1(M7)%3'@M7B @6[);55X^I &\K#>U2@+>-> ]5
M@!=,#&0=%5:4)>M6U"+![!5+R8&4(!VL!L".J0!O3PIT*]Y;=X$&&6?O__/Y
MVQ<O7Y^\?OKRY-7+UR].W_XZSUW:-6?LUL_K+.MK,\0K>5NHJ_B+S *\=CX
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M,3.DVCM&%V4D_="%+K3^[ ?1^BYB;1#QJ7&HV2(.]2W?6"<027#%4LW^T76
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M<%;%H&CSJZTBR]QD"H8EAR9%E4113697[H3VB(G6J:+6T*OC_.W+:E<=7=&
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M,3#&L:BE+\XFJ5VC^].U>!XW*;H4]AH2[!V7/;EL.SJ_CC@M=>4K_4<'/"*
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M'"<6%?=&0?:N30.2.S =,REVD'J#9M1KH9U>S*8S&.7AZ,/ %ANRXX4E5P?
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MTI1.,<-3'VQKB^N%B,.J=@-'.T?4:U0=DA0BB[B3!RN)U/@EY.0(9T8DC_9
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MK%/E/:CD-QWON0E9."-\YDUV@]:7HAO1/'-SI3]-]>C(KD#=%X;?//^5:=\
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ML/-.K[Z/9C?],]$$^?[53[_Y"-?SDCD^>S>.2Y19,&^4RB3I@DUJ-$1+L"Q
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M8R\BB$DHN50K1J1^2EDDH2>",*$1Q9*G-BO&Z>[&1ONU<RRK1 0_B%K('R_
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MQ",,<424D1/P!(=IR&AJ="_0H4QC(Y*M>R/65H[+H3+;U@X\ #VSU<;X4>J
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M'_B*:3P*481]M8VE"&(O%# @,@UC[!.46*4</]G;V#BF$@_F$BYU#0XM89?
MS%UHS=C%&6 ]$\M>F.8:O%^UJ_(D>!T#-H^ TE_<YFZ'[QB^>43WTU&<QQYJ
MMVF=:,RV?#YW2N2L+//B5=]#:VSX)"4B9-B#<:@K5(D(P539*1"ETB-QXB.)
MK4ZW3#H=&YUHD=\4]]:BVFV:C+ VVY*Z1K!G?MD#;R-OA6/+7:@1H'8;4-?
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MZ*) ,RUC%V_$/L!MO#Z=8!O:Q]- >"NW:BRYA;"+^Z83E._EK+&"M*-GYBA
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M&E"F<S-+S*,XELC(\'G3ZACG:%8N,D9FH*G<4;^DEE7%-K"=GJ>MP1A@>K;
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M,2\6^M:4+L\V%7$8\D2?TC&F3&*!8DB9IPL.(4)DE*286*7R.=K3V-:2E:!
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M<'D^FY&B!,^*BRORM>3>H5\/0VMUO(/>M\FKU8)4ZP6V=0=;RNL$U=O?:P
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MR^@7HJ_R5JN"6B[*C(O&+2&84-WQV_E6MM!IF/@HUMG0)-&7;%$H( UY EE
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M'^?@O5+>SJ+A^Z.\^>@=[8GR]EIUG=47R]6Z-_VG8JYN5NJIG'(1,Y22Q*S
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M5"]]FAR!"1KK.2-RV,"/F_T'42#'VSKVTU5S\_C9U5Q>25NDS3[4)K"];A>
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M,8D3ZG.>-XA68Z.-C1%@:P78F '6=H =0_S.NH89RW;R>;,1ZIFS:GO UB
M08<!ZWA*.<S(^1UJ'GP$!SH#'6@DPQV<#@JTPSGK,/(&/98=%*+]4]QA']ZU
MMVM5[N%.+?5B^63;HMSR6?&U^A0^J%(LBVI7Y%8_%$]&LZG*DI32&$&AA( X
MQQ@RG""(&,:,2(I1DOKU>?62/[:I\WY=+6/' +"U8 )V;+"+T]H*WXZP?D/D
MYJ3W"'S/,V)@S#NTC>V$7-@6LGXJ#-Q.MA,^AZUENSVF8^"2E8\?9XL_/AL;
MS8\W\V]-^M!<?BSF1KK]6:R*;]4QYP]%*6:+\F6I-DOC-!591G1DZ) IB%,1
MPYSA#,HH4S%'.5+4:Q/W4H7&QI1?7IZ?9]7^.YN!4CPJ^5*7+)XOYM!:"(JU
MB=7^@EX;"=C&2L]0Z*5#ZA@I'7"@^@ZDVF&PMDQ 8PVX>34H&X/ UB*P-:F7
MR$HH?(-&8R_5:=A@;2 $#V*YH9[;>:^I>LP_B]7C^Q?C2C^IY6:#?7/>22NA
MN:0PC9GQ5[.804YE"K7"$1<\,[_F7K3L('1LU-NH!6R*>N,32:65^:5<EWOS
MWF0ZC[SS/E-0//O?:JK4!7\8?<%:X5<MW((?K/*!*/"6TWFY0^\Z.2-Q9./)
M_=[NW3O4_[R8!UV;CVKUJ9BKFY5Z*J<"T3C1U+B%7'&(M2*0(4&@1@G),.9Q
MGGI5MCDE:&S$L]435(J"WZVJH-*U0Q./H]BZT4P(Q'JFEFY@=>KET89$Z%8>
M1V4-WLFCS>)CC3Q:K^_I%$EY)C'YEZI@U#HG>:] ]O5WM11%J>Z6A5#3E"N4
MB"B%+,\,X>3&]3%K40JE>0O-@A2EG! OPAE.][%Q6*5Y<\I$VB*!RQ(\JV6=
MG1/ZP$G 5\"1%\<YL'U3K<,!E=+UA$J-P/9PR@0<=#!8XP J( 8\O1)^] 8]
MU1)0_7&==@D_+MZG8'I0H>L.U+JAN&WO8):HMHZ:K9LTS1&/HUR997N<VO_D
M*<QUI"'7J:8D5YP*S[VF$Y+&-N=L%+5+=5M1SG?#Z!2BKEM# 7#J?1-HK6/=
M&,9H":M&I5;/D'L]9Z (NZMS2MC ^S=G;#[<J3EW0X@*DTV*:,%G:IM$6A$0
MFJ81R2(L8LAQGMDHG[)%$6E5?!*EBM$<R>XE)ULDCXTY=E*AGZV"0=Q6]W%P
MXY=>T.V9;PX**NZHO?Y'!7M@%\\;J_YJ+K8)?\,BC Z8M%=E='E MQS65T7E
M=WROCXNE\:?F#^R[C4;:A&V;M\%IFA!I2^9B^Q^2YC975<-8)@GB/!$T]>H]
MXR5];$36* E6['L5:V_4],M>],._G;QZ1[7WG8L371&J&@L5UD9W\,]AL/;+
M".T-\X$R/P-B[YWDV0D[AV1.O^<.FK39R>3]Y,QN#[F@3N?-7"R>U-5<-N<Q
MRYU#3&F2"IU!Q".[A\TI9 G.H-*2)RK%D11^]2%:Q8UM)JC+5A:5NN G56O[
M\U\[5/0\C;";WQH.MYZYOH:LUK3*VUGKVD]E""=8@A<!/2UQ^(*@9ZT_6AST
M_%W=W,XK"]OM=VWNL2OQ3PNVZ?U$A$PCG6,HB8P@UB2%-FL;1K%B>4Y$GL9.
M.]'G18V-1JRBP.H'KKXN547E?@Y."ZINGF,8K'JFC@JF6DE0-;2HU.QX>J@%
M,C\', QT WE[QR$,Y]&=!\/!?6MYR*"^VGEC]ATSASLNV*#GYPN'\?T=DTT!
M]ZNR?'FJMT\LI8NZ%.(3FNI<8T2R",:4$+.^3S*8IRJ#,DU5&JLLQUGNO1_?
MBZICH^VU<L &]SOLMO<SGF[^XCA&J><)(T"QQVUG"K!C\ 1LQOZA;>R[[9KW
M.BS!-\G[T7;X/?%>43^Z!=ZOQ&X3S><7.UO=ZDUMN"_J:[5]-HT2BC#B"4Q$
M&D,<B\1\,22'$>8T$SI3:>)5]?NDI+'1?*VHW<I=;,H:EHVN?JQ_&EPWT@X"
M6<^<NT5K6P3RRSFTO'GR+!(A:>ZTL$%9ZJS-^R1S_@;_9A_7\U6Q^O&QF*GZ
MZ5/&28PCQF":)+:*"8W,JEW'4&2:IECP*$;(M<O'_L/'Q@2U?L J"&H-W?MZ
M' #7_LE?"D?/7[D'$EXM/$Z9?$'OCH-'#M:TXY0QN]TZ3EX3+KSVL5B657]I
M\;BINJHCFZ260T7RJIVQ^6C3E$(A-,9"ZA@+IX_63^S8/N=*0]"H>'GTZ C.
MW8-OEZ'W)H$XLUC:!31@7.X(LI?'Z"Y#^$WC=7M(]QN^.XU3QU#>D0>^>5CO
MM)$N(;Z6N[MG%W8^]'_\YA'11Y6OUO/)_'800B>BO?4I^G9KCZ68!3_Q_EFM
M[)G[N^7B6R&5?/?CMU+)F_EF[;$];&]/NQ;S%_.[YH^+^7:W6RL6T9P@R&/)
M(499#*F*"6121-(L-21E7CU PZ@U-L_E2OZ?EW)5IYBO%F"I['MB??&Y6@$S
MK-5O[<]5G8P7&]<LYCOABVW9$L]<A4"C[!CN&'SL^HZ-F!&IZIBL3;+!YY]^
MJX?GYYV R=:R*G^WL0ULC>N%,\/B'30"$T:S8<,U0=$\B.V$?7HWSK]ZLE4[
M_L7J6E>;NBKO%^6JO)I+.\?8AO+EE"5I$F49AS)&&<2"99!2%,-$(4P02G,5
M>54Z<14\.MX68JFV=4Z,&R0;5:M4J)UR4T8;93S\)J7,CZ2=A\6-AOL NV>B
MW5790EV?D"C+EZH>7Z5Y!?A&]W DZHM62)ITECTH$?HBLD]UWO=W"YV].BFF
MA/&,I7UMK+S9.S:;+1;S9B-N2G.&$V%CWI%->LU%9)Q4E,,D3V*.59;32'DT
MR/37P.E3>X.^EU93L#D?.J\HSB_\XS$*;L&UP* .?H+T5H-&[8K%)J &N5%]
MG:[0&\A^<;9^P!XHUA8.=.^XFS]N#K$WCX<.&G_S-W8_!M?A"=WFA$^%L.Z7
MF66JD@--V=<']7WUSECTW].(Q$)BAF&L;;1"40VIS&*898(@Q9,\\DM9/B-O
M;.[LIYOWUY^_7(.KSQ_ +_=7GQ_ _?4_KC__=OW%CX_.P>S&] '!ZYG>&TV!
M4;4NT0(:9<'O5EU0Z>NY;W(.0S\B#XCE0.Q]$M-P+.T(B@,UGWO2H'SL:-8^
M";O>%C2<?*1VZS1+A8ATAJ&(-8/8-NS+F=*VQ'4N\X2@S/;16:S8[**0\1'1
M7GR\4:#?^&(5/WC>B2]>7JS:8RPN"NQ>B/#;!F^/E9_N/33;@M@ X==CTL<0
M8FU!Q3&,VO:$K@<X=FK//)AG7'TORJEM5)+PG$&*4@FQC%)(=2QAH@EB+.)I
MQK'?V8LC4L;F->X51)H JRCXW:KJ6WCU**AN''0Q5#W332>4.IPW:$$A[%&!
M8X(&SO)OL?4P0;_MXJX11C%C95GH0C3!S'\RF_&_6M=Z-C3SL*@[%4ZS6!D2
ML)TZ-(T@CE);6\[\1' 6I4+9[1.O[H ^PL?&&/NZVY#^'[7V8+95WVYZURU%
M?<-A'N/B&G7L!^W>XXY[0-]JT"@.=C0'#PMPW3?0OI''?@ ?+/88"O@.L4=_
MY)RBCQZ/'3C^Z&_P802RPS,Z;K)O<WT>%E=2%E8>F]VQPCBJ[]ES8=:5C7"[
MPZGD5!")14QSF*0JACC/!.3(+(U9I@G-DCC*A?+:;??5X/\G\T?W$7+<>.\3
M][YWX%]GJ&VU!U9]FXW6&##9\%QM0\"=^*[P!=V2]U9BV+WYKA@=;-)W?E!/
M'0O.E)#^ARIMR>BZODUU>'9A?]44CV9\IJZ^?EU66^<W\]6RF)>%J,[=3D4N
ME8I2#)$B*<24:\A2F<*<Y#$G6B*!/-?L;V3)V%CZZI=?[J]_N7JX!C>?'^YO
M/G^Y>0_^<?7IM^L)J&VL4G;4UJ[ #0YZ>V-< Q)_@O>@]Z#'Q04;-KT/=MZ9
M;:&.1?7K"=A!90(VN( -,'7)AP&[(?0]N(/V1NC-F'%U2NA[S+S[)O2N4,<5
MS*SZ0)0\;D!386Z:("E%E&BHDRR#6"81I&DNH!!QAG6N!&5.AU+]Q(YM%GQ8
M5$UH5POQWPW!B5TB[)80[#8 CJN2X+ ..*EL)HO=.K?79S#U7WEX011TN>$F
M>=@UAA<:!PL+O[O#%D,WDIXL.;)9DW_\:S$SC+F8JWLE5/'-<N8415&>ZAC#
M/(D8Q"I+((O-@D 0EJ;,K \4=@JWA%!F;&QVH#-X6BN]R1->;K0/4]7;:=#<
MPOA##47/#-A2X_MP@#:F@/NW&)@PU==##]#;%V._<*""U6;W0?:"4NU.8D91
MN=T'$-="[E[/])ORRN7*B'VQ!\R>V7+UX[-Y':NT"8R0T)%*H$QI##%2"N8R
MUU!$C. X(B06L<LT=DK ^*:FK8[ *NF5@G(2QO:))00XO4\6GK@X4\LYXUL<
M87/KCA-L_K7O )]\]B <<<ZR]7=_]KIN"VQ+%XOY%[MFK"..FNH\R1"#FBH*
M<1QKF)O5-52)P(@D<9+$7K4:]P6,[UNV^M6KY@GX7]%?HBA"QL%<@F]6W;\!
M%$<3\SO[ORHB2-+-/ZNN8R5@+ZO'Q;+XEPT9UGW[S'A7M5S^_=\0B?Z61!-0
M5>.ISHT:%M[Y$[)_0G1B7-G21E8,F<]^_ TDV21#T031^B:43U"*)PA14%1;
M(-5O%R^K<F5^J!)T@PC^BU]PX.#E<0L#7/)*],Y@U=OPI7X;*NTFP7<73]D?
M<C5_(&/0=?LI"_=7Z">OZ[86O]L>[;*/7)_:KH_[<O,1&"](WMS=7JW,5_*\
MFD9*RT1F.90ZYQ#3.($4L02F*.9Q0A*&%.]P&-=3#:?7?_@3N1^45DM[C'&A
MS0^68T1U^/V9%:>_A2##XK; [@/E84CF;O>LJ-5]K[[ !&ST!\8 T%C0+^A^
MB^<>P1]HO1QZ$+Q7R1TA=%@8^SYYT+5P1[/WE[]='],Q9:0^*?QI,?^Z;>,M
M)"<IS2"-D(*8X\0XRH1!I/,TDBPE6!*O9(Y#&6/SE:UN];D"69TKL&7"C-=I
M]%[::.RS+;9AO"?K;19S,7NI/%/]JK*#5KZY%T>@=W,S+P2T[ZVEIDC %M/Z
MK,9G\QG5> 9,(3B-1-#-_2-BAMUV/VWGP89XRZ7^I<T_-'/6QZ(4;/9?BBT_
MFM^44T9S;E;-&"8)EA!CCFPZK89QFA$F.,YCY%2\JD7&V#ABK2:H]01645!I
MZE[P_!2<[=]]()!Z_NX[X.-5!OT, A=40S_UY,&*HI\Q;;<V^KE+N[D!=\N%
M4$J6'XU::X_C51F1J<X5DAG/8*Z)65'&+(,\S[2!T:PI,REUFCH=O7*6.+;/
M?ZTPL$,'5H^J"EA5;G53M\YO^C\/N9LS$!3(OM>'KS"\V<%OM[)0./? &9N0
MSL)YH8.Z#LX8[#L2[C=VS"]Y+%19?&3+)_.RO*P*47QYOFHJV7/*,D,Q!&JL
M*<3(%CO.L@PJE J&$4X5<=IW<Y U-IZI506[NH(O?WG^RY5C"-L%7K<X5"#0
M^@YLG\2K8[.%-N \$S'" #A4GH7_B^>?0'$>$9?\B):G#)O^<-Z<@^P&AUNZ
M^7"[*[[W]4)[JGF>,BXRF'&6F&5:'$.NB8)*Y5$D28S2#$^_J25?N/IM1Z3X
MO,N[LGI\E??B-L;!F!V/\*Q+#?OY;L>@-F\I4HDM1A!)!'&$-.0"*1C')*:Q
M$!G6F<>6RZ5X#[^M\DF5Y5_!'O23G7C9J]K.EP/NYAY?^+[V/'GMQ\C6Z/W*
M5B_+P.626I (Z?X>$S.HP]MBY[Z+VW9IUS: S7/N5?4%S+]^,?.V#9BIC&8\
MUY!FV'87RRT31RE,E**4H#QG>>K7$O"XH+&YL[6NFQ=[HRVHU?7M%7@"W?/Q
MLU"8]4P(7>'JT%"P'8N+FPN>>/S C0;;C3QL.GCF^HZ;;&RFFNV\NV4AU)U:
M5@<WIFG.L624P@RIS-8SXI#3*(<9D](V"L69VRF)<X+&1@I63^M]-;EISU97
M\*R6==X9^*F8 VFS@)?E]K<_>^ZNG<+<<8LM ))][[,U(#8I796:P.A9'P0.
MN,=V!HJ@&VVG9 V[VW;&XH,MMW/7=Z.-35OS7Q6S3<EL#."?Q>KQM_F"EVI9
M);S?S)]?5N5]T^NJJ$($]S9$9_.:WK&R*-?%=W[\PHKYIT59WE0.N:WH>,V6
M<W-9.96ISG2,4XBX6;;@1.60HDS A$4\C^(LY4FR7KNX,=%@NG=8#/4>P+,G
M%FPU%VU J)-MJQ7HMJB.'Y4-]QZX<>.XQG88LK4VK[-F=\P&?QB[P:[AH+8<
MO#9] C;&@\KZR::"V8\)L B GRP&/X,U"O;]6>,0CLL''[J0D\-PR@\ZVPP^
M)OO3U_ *='2C7XPZ__-BM+O^9O[S4!V-5 01+ B#6J7$K*MQ!FDN!4S-$ALA
M@J(D<5I7MPD9G?N\T1%42H+?*S5]"P4?@]/1.[X0I+X]8U]\_'WB%@""^L/'
MY SK"[=8>N 'MUW;[9M?4\?:I;Y;S KQ8]O!0QN;>)QD$%&&(>8401YE9ADM
ME::91#A/G#:*'>6-C0EL_7W+M0[KOD[PNM%!0-#Z#J\UFF[Q,@OG2EOP>_/_
M+LUFO/G"$:&0U'%.Y* LXFC_/J&XWM:]H?S-O%PMJ]WU>OXSJUU*4Q(W?&);
M;><<:ZB02'/CS,2:>#5E/2)C;!SR13PJ^5+'DE[O1X&MYF4W'^,8Q&Z<<B%P
M?7L883#SYI$65$)RQS$Q@_)%BYW['-%VZ<!E5.O2UCLOP.WJ42T?'MF\*397
M-84R"R/#9\5"_E,57Q]M\;EO:LF^JNJ/']A*;=9C4XUR1)+4GK])[9%U16">
MI B22*0JCHSV?DFWH[%L;!Q8&=F<0)]4>PXO\V+5Q.Z";$>,!?F^"Z^^Y9O2
M-^E?7HBU1N?5'%'A U8&H&V9UAHC&P*L49J -4Z@ :IIYV>A MO8Y AJL_8U
M_J.HU1K<N#]'[=:^QC18+=?>%+RPK]F[Q7*Y^*/:6D$B$S&1"FH2FZD\(BFD
M26QH0DFJ(B$2%2>=NIIM98QM4C4C9-QD\=^V.>#*%F*Q7:*7BZ]+]@1F"S;O
MV-=L!]0HD0FB*H>(4 (QCF+((X$AXR01L99("N67WGHAK,.DM][=W04"T-49
MN B4WJ?E5TWA>N@#=VAV+UW@=L2\30^X0SM/=H [<FG0GK8W\V^J7+UJ-GG%
M#;TSL9JF,4:<$@SC+%,VJ=VP*)69^8].&&$9,S_X4*F_"F-CVJH%JYXM_FA.
MUA5KU4.WMVT;%C<NZ1?LGJGF3+O;C1$[[6[![VL[ H:!NH,X0 ?<-BW&T G7
M 27'CK@N3^K&B@_JZ7FQ9,L?M6?[GBV7/ZR<)WMTXF9]HN*N/F-QM5HM"_ZR
MLJ&OAX4ML[&8KPQ0YOE?;VQ91:-D.8TSGC".,,PCSB%.K)L4DPPBK=,L2U"D
M*)T^5_[QEQ5;KMRX,[RB/I_[OKK]??GOU-=B;O<B &<S>Q+69JVNZXA5::Q^
M_-K# &?4>+Q,1S#FYG/%!!'(D&)09['((\98',MF@*_GCFE\8QC>M;(][@K6
ME29'.[)N,^O;CE7/,^_&N":$-@%K^T!MX 1L3 2-C6#72-OFZ+698&-GN(FY
MOS$(.7'WH.6@$WM_*.]/_#U*NKBJ<14**YOFF8F,9<+,["YB0B#.201S21,H
M5*:2#.E$^*V)3L@9W<+G58WCIFIQ4TC8;MO4O_'<JSF%L1L-!T"N9RY]70JX
M5K+76L#'<.BI)/ K46]5&?B8O2T%@H]>WI$>S"KE:B[M_UG&^L9F-AI^M5H3
M5[.MG&4*9Y)"XQYJB--,0JJ8@34F9HF0BRA%D1=9N$@='778=;PMZ"CL#VJK
MMR=9."'N2!VA<>R;2-805C_LJ#P!;+5UT )O37JA%)1FG 0/2SH^6!Q0D-?-
MW0CIUJSAF V1?%+,?-+K,P+3&!OWA"<&YCR1$,<20YIFYI\TEPG1.DXUFJYL
MVS\W"CHAQXMT-M)ZW+DQ#[/I )M#88NUWF!F%=\<$O/LMGX*9C?>"0!>STRS
MT1!4*NZ<G@K'*V=0",DDIT0-RAUG[-UGBW.7=S_34\C"K+!NE_4:ZU>U>ES(
M.K2JU,[1VG<_#B]>7U9GEF*,%1<&\9RD&<1419!)%$.9<9%GF*<Z]?)K0BHW
M-O=GJZX9KW5>4FT>6"MN%@>[9\RKW*9CMZVO[WX.*=@KX+BA_48#V_=.^%N,
M::>S4Z'!#WWF*IA^@Y_5"HWLL3->P65<7O!N6UQ^JI($4T$2R&VZ%4[,"%--
M<ZAC21);/307V&<6."YF;'R^W\$@>-FU'83=2/9RW'JFR_WB:]??UY -58;M
M$):^*K'M2'JS8FR'UK;58SMR=;<ZPY]?;''-6_W:@2W_KF9R*O,DHS%+H: I
MAX8:8L@XYS#+$ZY41G2JO.H,M\@:&V'4JAY9@Y;@T:CK5S.W#>-VM@B,7,^4
MT8!VJ\'>BK0$?P\*FE^AX4#@#51HN"N(WM6&'6!QJ#;<]I1!JPT[F+-?;=CE
MEF[.U\U<+.VS/JCZ_V_F5Z+R,,J=ON6(9")2.88DPM3F9Q/(HY3 *(^5I"S*
MN<H[U,1UD>WTW@]?)'>M*%AZ]I'WPMW-00L&XS#<NU87_+16^&=[0FJ#:,B&
M[UT@"NFZ.<D=U)'S06+?K?.Z-\19_D_%7-VLU%,YI;G,TEA'$,?:E@>*.*1$
M8)BA7!$4:RF55WF@$W+&YMSMG40'OUM-0:7J12?XM\"Z44P N'IFE4Y(77AN
M_P"'_L[N;T6]X?G] WO;S_ ?7MY#$O7K9*T[5@4V,,=$D-1@FB0:8LWL,5Z9
M0((4M<G3"?>KQ^NMP=AXY/UB_DTM5X5-H-S+BCW:4GZ^J/(!XG22U=WDCW62
M7P5H(]\(0O$D3? D2=!>\M=!%_DN0O=DS@HSBK(^\EV#H<S'4+6G_U_U8_Y7
MGOTE!4_%;%9U"[W<4,^V]?YOO!N-]_H>]TSP#IG#^WG"M0T#906WP3=8TN]1
M)<:3T]N&D5?*;NN#.NY@6S)\7,S,'64M<HH4(2G+%63:)N/&YB>:*PT)IV;9
M:[Q1FL4^R2V'(L:6U_)@9=3S0J/GO_];'J/L;U5BW>H'^$DJ78ABY5LVY1!<
MQQW>BR#K>Y]V1[G_6&^X]DU"IQ$)NGEZ*&78+="35AYL9)Z^LML^PVLG=IWP
M?V_K2LP6B^644103JBA4=G,2"Y';#C 2)C+!D<1("^ZUUW!&WMA<R:OY_,5P
M1-'H"99&T8D]M+Q8^H7-S^'LMM\0$+UA5ZB3S;DE<%]!^#$\A'Z[#P&A'&@'
MXC)(O?<A' %RV(LX]Z1!]R,<S=K?DW"]K6-2R+;+PM5<'O$?-$4ZSC"%@D4*
MXDQ(F*=9 JGF6FC**$&ICW-V3N X7;6=9A03($ZO\JN5:GB_[NPHN7EY(;'O
MF<5W5*TPK14,F%;B"$70!)-S,H=--7%$X"#IQ/6^KAT!KZ0T;U+YWOQXNWQ8
M_#&?DCPF.,()%(+D$.>,PSQ+<A@G.9(<:R5RX=<,\$#&V-R_6DW0Z#D!5E.;
M;FIU]6T"> AH.UT$@JEGANB$4(>^?R<QN+CEW^&3!^[V=]*TPT9_IR_MV*C@
MZ7FV^*'4O9I5/::VI++N5XN-TR&2/(9Q3A#$2 I(LYS".%8)1X0@DGIM19Z5
M.#8*N!)B:6/S8K=VJOIN?_9M6W 6;#?_(2B$?=-#HRM<ULJ"3[LN7*-OP(X%
MKM $[5EP5NBP70M<,3CH6^!\XX6= =_]V/SX]T(MS8,>?WQ2WPPJWXMR2K3*
M8B93R".:0JQI!)E*L%GTQ#)!0DK"B0_CN(D=&^ULRR.#C;*5"_[YZA_@=ZNQ
M9TJ$(_IN%!0>TYYYZ!(XN_>K<T*GEV9S[9+?IE.<$QHGV[RYW1TB"'ZW5,]U
MF>:/2DUY3G+,&8)9FL40$X(A1XK8DC5))E6J6))U#X"_DC4V#MHJ![1R='9<
M(.T2Z^X,U-!Q[AW0/H8$[9+H=F?PWBJR[0CBA3'MH[!XQ[-?/^4-8]E'S6F/
M8Q^_I1N)_I,MJWKUVSH.48852;&$6.2Y\=\(AXQA E%&2<QCDJ),^E#G@82Q
M$>9:0=^"&*<A=*/*BX#IF2 WF)PO?N&(B1\37H3-0/SG@9$WY9VTWX'H#N\=
ME-Y.JKY/:J<O[+92_47-C8<YNYK+*_E4S M;'=FF-E[789\IC9!"4G.(*!:V
M?6]BVV+DD&1<1 13@C,GG]!1WMAHKE&W6C^Q5PK[+4G/P>RV%@T(7L]4N(O;
M:UW!]9F HO<:U!&5D(O/<R('774ZVK^_W'2]K9N+5/7LJ7K_;#H!?3&>F%B]
M+-6=,F^9F6F^JGM5//$7\QG+=S^^/"_FY6(Y)2SB*8HMV40,8D41I'%"H=)Y
MFE"4:\6\5J&=-1D;%[U?E*LZB[[J@-<H#I8;S6VMF++6W<_QZ#Y8;D[;($/0
M-Z-5_=P:(R:;OG$;.R9@:PG8F@+>_0!?AAT3/Z=QD+$9R+GL<8R\G=&+<75P
M6KO+&-2YO1B*?2?X\@=V<Y:OYJM"%K,7.TU^4:(I/5.7I5'RHS'<]L5[J5_S
M6[W?';L^XC E$4:(9@B:F2RWLUP"F<P11$)Q3%"4FS_ZN-1!M!K;9+=K%"@W
M5@'5F%7W45+K=O&;MJ_5YG5C:_<*XV$&VLVI'WSX>IXH7XW<UB!P_6KD=FRR
MY_/65EF"KBN>3YK37^'6"4&!#KF:"*/8H&N.H%CNKTS"/KQK5N#U]P<SS92%
M%5*W)9U&,LD51QI2%7&S-,D49,0L4CB--8^PB@7S3 L\%#(V(FZRWJZ_@ZVF
M3==CW[3 (XBV4V0HG'IFO"X0=<@+/(W!Q8F!1QX]<&;@:>,.4P-;KNT8!&7%
M_-.B+&_G=77,NZ4MN;;Z<6>&>663C)^MBSFE0N819AKFD4X@)HDPG[\24$12
M"AZE:9S+#M62W*0[O>_#UTNRB@/SNLNB?%Z4;&8G<UU\MR?\RU+Y-FMP' C'
M:&DX7 <*,1B%P4]6Y9\MI!\J2(NUB[16'U3Z@XT! 0.I7H %C:>Z21XVK.J%
MQD%TU>_N;D'6O:/TU=&(NDW-!^,TS;_6Y%BWK_FL_JC^5$XQ36C"<PF1EF;]
MF6H*.1<"YCD7<<*ET%BZ->6^2 ^?#V^8MMU6+]M@T'YMOZI__8O-;:FAN\V!
MJ[H@M_>B\K+18I%.8YQ%,$UD##&6PHY6#%.E42PUQ5G.?<+AO8_5FY>]N;#+
MV&7#Y180[WT0>IZI#FNVU-]&;0.HC6A<X&T',V-)?86C5W#92/B%P7L?D8%"
MX+V-C'< _")$'8+?W9X_:.#[(@CV@]Z7/:SCH:FZ1,_"2)Z;=_?#XLFX-=.4
MDBA5B$.:)&9*0G$"&<H(U"F.94:8CK13LENKE+%-.4T5F(V6X/=:3\^S"<<1
M=5O07(Q3WW$0;XC\3SVU01#TI--10<.>;FJS]>!$4^O%H4I(WZX>U7);^/^J
M6N)/5<(8YC&!)!4*8F:6%CRC"L9FD4&0P$*R,%6DCXH?:6"DTA7,%W/8:-LI
M(.(Z!&X$$A+1-ZTI78.[U1M<M6,;H*YT*U+]EI8^+OJ-JTNWXG&^P'3[[=WX
MZE6,Y6HN-V&6SVHUC522ICS*H'%>,H@SX[GP-.,PXYF0%%'-8Z\&W&W"QN:[
M;$*'-AU3K16=@+GR[#?4BG"F,&<193#*M)D&5"Y@GDH&<:0I)2S7R!X?<R_<
M$PSA0?J&#H&P&\N'PJUG:E^K.6D"VNNB.PURGUN0\Z9S%TA"<GBKO$&)V\7R
M?;9VNJ=C__-%=2!+V"#(S=P(^FJ+?/Q:U5F>)B06"9<:\B32$ NL(.-20DU2
MS:G.4>;6[,E%V-@H>E=7Z^$\+Q?"*.O9Z[P-73?R"(59S^2Q#]=:4?![K6K
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M &8A"W..$IQD1@W!+.<=&S_<+V8K?3[ZNJ;S&0.%OG'1>R>F-0"S1=/X;[8
MI#XR*K476*4@5HW5&5OJXO1-/1++HPA36YGYA!XLX)EYMO7]J]XEE<R@%1HH
MJ8$2&RBYJ] M/]C:.84>,![(*72$M;57:(F8@5=H.N*@7J&EFKM>H>WC/9L
M5ZFDF[RUG-&4YA3*0"0Z%"V >49#&)$HXC0.!2%616_?C6[%\P-4(/BAYP"7
MU#-_#YZ9Y]<;$L_$6\OE(1/MH,).&\Z^FV#8QK&'=-MK 'OP0_95(YL1MB&I
MGQ;\(UF):1Q&E*52PBP/<I@D 85YBA&4),4YSW,:$:, TE.3C,U):^3L1FL#
M)2K0LIK7B3P*Z>EWV150OJ]N^F!D51GR' @7%(4\.O1@]2#/*=<M!7GVLST#
ML]I ]::\6[DIR8!1A-,T2" +B(!)S$-]3QSH8WD:QD&8"V2T5SL[T]A>_&U.
M1[O!LJQ[<1Q3LP7<"5*>W_PM2*V07NI7G(7":6C-T<F&C8$YI_->L,K9!_J=
MZK3#/8K9"UVK%X__**JU"\LH00+G4/ \ADF@2]#C.(<TRQ.<T#0,I%'A^7,3
MC8T9-O)55QFR6&YRQ5^);F:QTFVV25UDO>4.?9Q3;W=7!>#&OL-9&Y@=S[A
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MTJJ(A9 0(<(CBFC&0Z-ZU.Y$&MNA1MNG:+FI *E^K!VP50%>M[J!8J/<Y8U
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M53^(K::6GL^PWPE#+VFTEO;M42E5;NJ&1AV-;L!6V?J7VNZ[__;N@1H$T*(
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M.22<5H4Z.MFP=:'.Z;Q7&>KL W9$R\5L^D699O[P7"Q$W1!7AY-%0C$ #(*
MPR13I)#GA$&>IED<1XB$7)APZZ'!QT:GE7R@$K#I'VWV_A\$[O0K?RD<GM]R
M"R2,W^U3*F]?Y[)]GTO!_O6I^/5OZK'Z558_[+[!!X<<Y*4]I4S[GI[\C),=
M4GVJ/MEVL)]REM& Z+3V6*K755D78B24/Q0%,@VR-(A3JX[1YR8<VRO<O87J
MW"?K2XF;]EJYV(IO?\5L;(D\3.(PUDV56*H3*)(,Y@E.H40HYP11%D;</O#.
MI3VNV.OJ9M<X'@V!<T18P!5O<)'"1/ 8DC /89I%(LQPGD78.GC.O1F&;EXU
MI 5Z'3%<A.G 1PWMG3CHB.OMQ.$H,!Y/'O;GO.8)Q%$$SIQ$''^NYVJL'IO(
M3C6\*C,\QRR044*@H%+GVP=J">9YI&-W1901J;/JK);@0[.,;]T]4O>QN@?M
M_GVR>A9+L'HF"_#^H3[Y^8<M8,@WE^+JF63\0VK/1*<@<TH_!R<:EG-.Z;I'
M-"<_W/-26+/5!U(*?E>\Z..H*@CL]D^RY#_4/.Q93!:;QLP(4T0C!H74L:@4
M"YAGJ8 ,BSSGF!,>6I6ALYA[=$PTGTD)_B[*U:E%^&+$S3C&$XZ>F:>2&E(M
M-GAHJEB_*^7;R Z4\.>3>.WO=^U!<WJU:S']L+>Z]KCL7>CV&*(?>WTFL^7?
MR7PM.L>37P4IUVK#,5D\ZH@_'1VH9)F5/Q<%+<6R*AE\OWA=K]2O%23JJ4J\
M;7P%2\(TXP+#-(T5S44Y@7F8IA!'+(RQ#'*16I4R\B'DV/CPO9@Z5.-;L5);
ME59/G1VE<0 5$.!G67>]^J5L&H.NTJ#2VO)*Q,O7P(Q[KVU<SR2]M=E-]S)F
M:U=E[(V2H-+RYH ]P<[WPV?@CD^+N%P!O,@YZ%+A$^G=-<7K7%=??.[(G*WG
MU8^/:F_UN5CJQ7*JW.TT"5 (499F,$EE""DB.<Q%%C.<<I($]$HKT6&)Q[8L
M^:$OG7NZT1[\H?4'#0"6)PO^OT*#KV*7?S'^*9>T7M^):ZYMI^TTTH7NB-#_
MK*O>:1MX7 +/3-QO/=RI3$N6RS<ESNU+L5ZLIBF*,AQ%!%*A<Z$RED,<<PXY
M#_6^2G FK9:R4Y.-;16JVQK,-['KW#I'X"2T69RF 9<)Y!$/E)<0*0<A#B(H
M)(H9SW,1)='TEUC28FAPNY/ZO"=3F,Z-R^<982KRD"OO*X)(QLKSTG!2FB+(
M0A(0CF,:Y*%-;**SK^L X8GUUU6N5XI8P,ML,7M9O[1]YBPWYB<Q-G--7"'G
MV:MXGYER WX[V7;8>N$W0<'EFGUROD&76Q/-=U=*HV<N3:)[/TFY/3A*D2 T
MBS@,4MW^(R0)Q&DL8(A2E*C_Z>2Y?FESQZ8<VX+73>!RDQIW%&S#&Q*G$/J^
M&#F*7J?K0SE0\MLYO/RDNQV=]4H);N=0.)[2=O9)^^CI3XO5;/5VR[GZTI7-
M?[[,%B*<(BZ2*,YT_!F-8((8A7D8*Z^%X"1@L8AR;I3!=G*6L9%-+2AH1+QI
M?P!:6'UW:!Y=?1S8TRSC#"[/Q-(;*:OHZ[-(7!"&?7SLP>*QSZK7#<P^_V%W
MKW\TC3.:*9>CZDRJ7O\@D#!/> SC-(R4/\)(F.:7OO[1/]7K_^//XO+7/[K@
M];>"ZYJO_RFDG+S^D<?7/[K^ZQ_9O/Y1S]=_4]ZP6*R6A*U^GZV>[];EJG@1
MR_90\&V*L6 YPQ)RGB7ZUBB .4,"4L4#>1"C6#"K^(63LXV-#KHG^DLQ)[KP
MYZI0/\Y>Z%I-7X49*<>:/"U%]1?+,JTGD3?;C#C#TS-?M'*"/Y6@H)5T>VGR
MYK" J@DD3@NDGIQPV *H)KKO%3@U>JBO<_%)C?8T6SS]MBS^5.,7+Z]D\38-
M218BQI13D0L&DQ@%D"#.82JYQ(3'-,+$SKTX.,_8&*59-EM902TL:*2U=2\.
M0VOJ8%P,V# NABU6/1R,DTA<[&(<'GU@)^.DBOMNQNF/]^WW>+#.8G4+6?UN
M\JKO$,M/?XDEFY5"AZR$/ I1JD@B"V"29PABAC',,0XDBSAB@=WAIZT$8Z./
M S6)UZ_% HA&X&VWXZ+6Q+9WI*V%#$],?>+N^P#U1%G9)O"C_DBC ]@HX;(A
M94_\W#:JM!5BX :6/3':;VS9=R"?)=ZKZ0TJO(<<921.8913M5U3)*D8DRK?
MBH6!VKN%5&*C0UL?POT3D.G9 N\^"H ;FO8TU5[;8)Y9V*[<=\/+UZKH;FA0
M'P7=W1MVE/7<71C84SEW.PLXJ^9N..T(B[G; =:OEKOE'+T/4MLQ']IEHY*G
MR;^D:B46 <,PY?I&A4L*<Q2D,,-JEZ/#&2.46AZEGIIO;,MM]_7<R%N_Y=;'
MIB=Q-CXX=86>_Z/38\!Y2&4UQ,7Q^>G)*8<^0371_\ 9JM%C_?8(7T19"C%Y
M%;I*PN+IBR"EN%\HTB)SG1K[J-;GIN6VXKNOQ6+U/,4\"3(9AE#&(84)YACJ
MND$PQ'G.4DI(CJUZ/=F+,#8":J0%.DL<Z**#NK<>>-&BVGF!/:QAYKS[Q=@S
M3=7"WX"-^*"2_P:TN&L5@-8!-$IH=PY\'01_.U_;KQT&\JB]V,/::>X/I8%K
MW&/P01W@_LKONKD7C-2S='558$$]6Y4G0EAB&6 !,[5V*->5(IAS0F&<YR3%
MG(LDM')=WXT^MG6B$@YHZ7H5>'J/G)DSVAL/SYQN#H5]O>1#*CNMD?QN@F'K
M(A_2;:\6\L$/73U[_,NFS4+,XXQ(&L,@CE)=%8Y#P@+=NX<J!S>+LR2TNGWS
M(>38N,-7B8LO?9MH>/EFF)':M>WMF1NO:>IKYGKOV6*DZ=U?KM-ZQ"?2'I.X
M]^?J>5(Q^\=ZQF>KM]TNBF$:!#Q,&4PQBM5J(@*(A?H.4$YX(-(XSK%1O;]S
M$XUM1=C(:;G'/8:CX4F" W1\GQ>T(EIUF+0#RW+;[P"TH3;W9[]5]COU,]J;
M[,>/#3'LKON,(GM[ZW.?[^>3/XHVS7TBJSLFP77^WC201"8Y4WMI3(@B0IQ"
MPEFL_@AE&HE08)9/%^))1YO_,/>NCTQG]-W-Z^_NWJ3^OK\;:>L@BYE:B%[)
M7+M,]O4LC@%MYJ5>@MLP1+F54(/5R'@Z =K:/SR#@DL7[]A4@WII9_3==;3.
M?;R?KW0W)Z4:\'>B"]6N)LO'V=/SZD&HKXU:/Y[$1'Y>+[C@=:F!^E)[FB,>
M)%@*&$N&8((X@SC+"0QIBN(\Y"1 5@%>/608FX=U5[R\Z B0Y5Y_B#]KK4HP
MJZ-(2 F(OO1A#?'(2C= *N7L7(X^MC-SW3Q;Q/=EM99>8]O(K\U2:7 #MCJ
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M$D81S6%"8@1QR"4D,DA9%N8QCZT",(]/-;;UIQ$/S+<2_[O=W<\)6,V.:=R
MY7F-Z AY UK0?)REG$?#Y0')B=D&/?4XK_7N48;!$_81')\6*\4ZRM>:SW4<
M(EF\39.8XE"2#*:YKOZ'=5AV$L4P9DF$4L3S3!JE[QP>?FQT4$L(*A%!(Z-Y
M1,<!^$Y3P.6@>'[MK?"PBO XKO8%81X'!ATLUN.X0MV CQ.?ZMF!N9BKOQ;:
M>_@E.@'#MYS/M%=*YDVT\#8*8IJE(6&8(=UR.8%)FJKEGJ,(1D2M_RG&1'D!
M5AV8[648VXN_%16\DK=J>\/7 F@3;^]Q+9O[]K",V9;3,]Z>.>6=]-U$N!O0
ML4*;!+=5P3_ZEJV5_5IAJ-;*KJUAWU6Y/XXF795[C#YL5^7^ZN]U5;Y@J)[I
M@.*I'N]5=^E;/#T4\QE[J__LG'VF7&TC>0P15DMV$F0$4AZH]49@*1GB),-6
M=>J-9AW;"M,(K=O"Z,(XYL>8=EB;[3F=(^AYS6C!VPA\ VIAP1_-?[VTT;&"
MR6GVG-'$PZ;#V6"QE]]F]7#?&J-_WC*F&\;K"9;%0OW(ZJO[([2$HRBG3-%2
M'"%%2T1"H@O;$X*22"(BX]RH4E]? <;&4'I5T&4'-CJ ]TK8EAJU-(<9<_D$
MV3.)*=&/@SL,H?5%SVT)4DL9!BY$V@^A_7*D/<?IZ8BU84J=T*6'HJS</LOS
M:).A1O16;<1]'_+72NSED-H&(J=N@<F\PWH%%DCL.04VSQY[+;I&_:)^^H__
MU?Z+^D/7T_F/__7_ 5!+ P04    "  I@6U1V[83OLNN  #<^ < &    &EN
M:&EB<G@M,C R,# Y,S!?<')E+GAM;.R]:9>;.7(N^/W^BIJ^7R>ZL"\^MN])
M2:6VSJ@DC:1RV_<+#Y: DM-,4B:9527_^@F0N:],\D6^D&;<QZ549HJ(Y4$@
M(A"(^.?_]>?)[*??<;F:+N;_\A?^5_:7GW">%GDZ__(O?_GM\VMP?_E?__H_
M_L<__Q\ __'BX]N?7BW2Z0G.US^]7&)88_[IC^GZ^*>_9US]XZ>R7)S\]/?%
M\A_3WP/ OV[^T<O%UV_+Z9?C]4^""7;SI\M_D@59%%9!3D:!LB6 5UZ 2DEA
MBHQA,?_GEW]*+(=D0P2K7 0ED@>71 !A@E",>9=9V7SH;#K_QS_5_\2PPI^(
MN?EJ\]=_^<OQ>OWUGW[^^8\__OCKGW$Y^^MB^>5GP9C\^?RW_W+VZW_>^OT_
MY.:WN??^Y\U/+WYU-;WK%^EC^<__\>O;3^D83P),YZMUF*>ZP&KZ3ZO--]\N
M4EAO9/XH73_=^QOU;W#^:U"_!5R Y'_]<Y7_\J__XZ>?MN)8+F;X$<M/]<_?
M/KZY6'(Z/Y[&Y9]_G8<37'T-"?^:%B<_U]_Z^>6",$'T;O[]^MM7_)>_K*8G
M7V=X_KWC)99_^<O9)T#5+?.2U87_Y_;?_GRY_M<EK@@R&W[?TC?./J(NM"<M
M^.<:YQFW3)XO,UND:[\TJR)>7/S+68@XVWQWDG$ZV7SJ45RMER&M)]HZ$[+2
M@-$0^&)AX (/D!S/&%CTJ&ZP7NE>$>$;C:PP_?7+XO>?Z8-_KK*H7VR$ HR?
MZ>-_WEIT*Z+]J#_?AI_I=R<81<K%,M#&%%!&9R*>UK8\61^DS]&G 8B_NN9U
MVJ\J^&B9?EHL,R[)FIPO&I;IFK)O(_GL-W[^&I;T09".I[-\_J^K61E";^O%
M /+;*H?(_<M/Q'7!Y1+SVZUN[F5NP]F:;"QN?G,(O?_?IV%)GSC[]A&_+I;K
MB<E%16(8BC8:5(D60BH*4L[*D?$T7MH!(7!C^9W0(/I'PR%2[008'W Y7>1?
MYOD5G<X3Q7D,ED<2" MT;&H'(7L&W#@OI$T"K1D0%M<6WPD4LG]0["_13B#Q
M>1GFJVD5_#FL8^8&BX2(FB3B D),G@3D5(Y8O _&#7E>W%A_)V"H_H%QD%Q'
MQL8O\_5T_>WU=(;O3D\B+B?62EE8"%#(HR9AT$$84'*2#6KNK?%Q$$MQ<]V=
ML*#[Q<)!<NP" Q_QR[0*8;Y^1Z[WA#C-COX'R<AJWY*"$((&%AEA.*(2L0R&
M@^MK[X0%TSL6#I!G%WAX0]'_DLS91O"?2/[X<G$Z7R^_O5QDG#CK;5 4:W,R
M:*"\LT!"DL $CPXU2S[%P>#Q("D[H<7VCI;AI-T%>#Z'/]]D$M^T3+?IC3.K
MF+-P26;RH85(H&0QX$/A)"G,-G+K1 B#P>8>(G8"C.L=,$-(N NH'.5,*EB=
M_?%V.D<^4=YXI6T"D21QDE 3WFV&X(PKR1KZV1".Z;T$[ 01WSM$#I5LI_ 0
M$ZE]X88PCEY+PGBPX"QI-UH7-5%ALQGN\+F#@-V27NS[P\?31-L3/E[2E^^7
MGQ=_S"=H,01FB'!>%"A../<8(T1N?'#":N?RT.BX7'XW;'2<$1U"K#TA8^-,
MO5]^6"Y^G\X33IA&'LG,43B&#E00Y(BG8, 5G:7E(9LRN/&X0<-N&.DX3SJ8
M@'L"RH?%:AUF_WOZ=>-R<RFE9\J"9=80%VQS4 K2LI,F<,90RZ%A<HV"W4#2
M<=YT(.&.#)%J 8^6&#9T>Y;0Y%S Y&3)>XH,R)LBH1A%H@@V!^D' ,75-7>#
M0<=9TKT%.++BZ\7\[,/Q8GZ1T3.L6"8-!!W(KG&#$(-/P!&33LSZ9(?(B-U<
M=S< =)P:/4B0(X/@$Z;3)0&8B_AYNI[A1&GO. 51P! Y*"T+>)XY6%ET81P]
M%C$ "&ZNNQL(.LZ)'B3(D4'P>1EJ&=2G;R=Q,9M8ZV/)SD-)1+U2*8-/(D$)
M**5-RMHPA!FXMNANZN\XR;F_"#LQ +_\F8[#_ N>Y?)Y+C)X4-EFPJXC7U?$
M#"F%PI+1.FD^H!&XNO9N2.@X>WFP0+L(&5Z>+JNXMO>]%=BD@]/51&04O%[U
M1<8B*.G(O9$>00O+M?04(HLAJL<>HF$W@'2?NQQ P%T Y<V</HW$,?T=7X5U
M.&-K$HQ6IF@Z_3B2<!C))4CRB&P(I0AE4XYJ,*#<3<-NM5K=)S$'$' 70*FE
M \N788U?%LMODZ28*"8@L%)/R%H2'7FFB"EJ,H<J.AZ&RV%>6WHW6'2?O]Q?
MG%V@X=-)F,U>G*ZF<URM)@J9X\@T%%02E/ >?*3CT21#=M"E'"P;# W7EMX-
M#=UG*O<79Q=H^.4$EU_H$/S;<O''^OCEXN1KF!.HG98Y6@LL\%0S* H""0:\
MLYED(J/&(4I]'R!A-W1TGZ(\7+Q]H.3/RT+$;:WJ1 7AI= <>,( RC(+,;,$
M$GF(BBF7!JD&OV_]W?#1<>YR$,%V 8Y/QSB;G4/;!^LD=P8PU=I$Q S.4?25
M0O8EHV):#)'&OKWR;H#H.)=YH#"[@ (1?E)KS!;I'Y^.26ZK]Z?K^BZM)F@F
M*5F5$M8W+V3K5'84:N6@( ?'R(?*VL3A',^'*-D-*AUG/ <6]MC78-NXZO5T
ME<+L/S$LS]]!D*'SVM=2,W0D'NXEN=:)PO(BB\G*9U.&N">];_W=8-)Q9G00
MP8X,CJ,3G.?Z$N+U+'R92*69M<F!QEIBQDF1OC[6Y0(Y%JEE*4,X'=<6W0T&
M':=%]Q=A'V<*4;X,LS?SC'_^7_AM$I,5=/9EB(+7EY2,073D2T<?3(Q2<RF&
M>(EZY^*[8:'_#.@!(NWDP=FE47M-WUE-C+/<HRQ@;4:R:U4@];R3&(1-))HB
MALAZWK/\;N\0.TYX#B'6KI"Q#::V3'"9LL3(H/C,0/F$$$R)(+QFT:#5R(:X
M5KV7@-W0T7'><QC1#H:/?_[YEB#?TC<.;$9!QG"^PDQ?K!:S::Z-1UZ$6>VI
M03$9KE?7V7A"IXI'/WC(-A9/X^+ 'A>G*_@2PM?)IDRS N1]>3V=TV)30LEB
MF]6X %]B0>2$'*+BM3!/:' <)=BHDM3&ILCT[5UXO@E+6,4-+,[6W.Y$G*U7
MY]^YN26?0MR^=N=\C:/5BF1[P:K*0I8D$Y S;>M#&0E.:(3-V]U:E&9B$U:O
MDS%._XQFF#@W2 /(?,23ZCKU9Q':!1->*(59*K#*$!,ZE5JL0/+03(D2:W;X
MCDO^H8!S@YIQ\7.(>N]$RB&R[@ P+\/J^&B>ZQ^__-?I]/<P(V961^N78;G\
M-IU_^?<P.\6)X#XF1W)!*6A#Z4!;*YL$0M)AS%)R,=T1'!T.H)VHZP%0!Z%@
MT5HE'>#L**7Z.GCU$1,22W&&[W!]7OK HD9R%"5@()'1GLQDKSV#C$PD)T).
MY0Y/>@#[] !1XS0&:H>JP130 9A>G>)K$ME'G%5']$-8KJ=X+JP))A6\8@)\
MT)EB!RLI=HA8WVQP+54P_*Y$SN%@>HBH<1H*M0/38 KH $P?EO@U3/,O?WZM
M(0X9WO?K8PINK\ILXIG6QJD"N: &97T&SRP'0P%99D9&D^Y( QV.J1UH&Z<E
M43MH#:V.#A!VG?A@K!&F<,"B ]G:G,CES **56BDE.[.4NR!G?%QFA<U/-WV
M%O'^^%BLPVP@"[3XBLOUMP^S0.*8Y^KU?:TQ+IW0$R=-%);$P)2BH[E6A 9/
M'I^6A:6H@PMXQ^/?(4S/_43UX!L-$L(-)OD.K,Q[XB34PO.W&%;XL38N?E]^
M(Q-:Q34A&UE\K?F@'5! %:X@1!U!LMI'P_A2^!U-T@Z'T8-4]> 6#8*CX63?
M Y N#]QWBWDZ/W.-XU%:1C:YD'BLM! <6C#"!:&2MEHW<:OOI*8'IV<8X!PL
MZPX LZ5_(GU1JG;:D$J[^B2*0]#%@[1"NNA"D:Y-%+]9O@>/9L"TXI.DV8$/
M\W8:XG0VK7$@G:.;ZK'CQ8R$OJIGZOK;A6B"4L%&CK63$Z.8D'OP(@F0DF41
M"=S.WU%]=3A*=B5P7-^F^?5&$SUU8(.N\'4SKBBN]G!0K'8[%D";*I-=51)*
M93$YP_Q=[7,&15Q75R!M(' _S@[11P?(.D^<?@C?:M;T(L9D.D<7-6!MF4N$
M5Z>.)4B)BU!$+:IO8L?N)J<;1!VD['M2U@=(O@_\+$]IU5LRFMC T9/!!D,>
M BAN14UC!<A6!Q6S0RWOJ%P?!$)W4S3NV=<.10/(OP,@O5S,-]+X^W1]_/)T
MM5Z<X/*<JV\7J=%<D(AW8(K)H!S)S+%:I9^D#,8(SVV3&I%=B!LWW&\$K\&U
MT@'2WB[F7S[C\N05QHLK0ILL<S4F52S&V@=+0E"9D=757F1FO(AM_/;;M(P;
M_3?"T:$RWQLVO^,R+IKD(&]M@\*=X\(BH*IY#12.Y.,H-L[6H6?1N+LF-0R=
MA-S++#7+'#2"TX":Z, @?3I>+-=U=[Q8+)>+/XBMU22YDI2V'K+QM#DRJRV9
M; %=<G)"*.M5D[#N#EK&&?_0&$&'RKP#V&RRJW<X?@JY\W'35X,DHKB(%$'(
MVMV1V\C0J]SF.O\>>L:9!]':  T@^PX@= <'@DDL9"!!9Z1-4(AXSWT&*76A
M<"*:<-?[T1;YI''F0K1VA Z3> >Y< H)R*E:3^,,S[VZ=XLUGN<Q)D%+54K2
MD%@%/O,U[M092O0ZF.!2*4W*L1^AJYOHOUU6<DC-=&"<7N%R^GNHC<2N2._*
M/:)R/%A>,QH>%>T;J^IDE00%!9G:D#AK5 KY,%W=Y ': 6U(S70 M >3'%?8
MRHC"U[??1@9.(JL= !*%%5KS5(0.N:0FM6T[TM=-XJ"IA1M<4QT <-.#E5:]
MDB29:"V=\6C!N:)K3UX&D6D%AEO'8Z8]I=L$@+=IZ2:%T Y8AVJ@ Q#=DQ.Y
MLBLD"0>KUIVICJ8NY&BR(,$(IG00J&1JXID]2EDW&89V !M6.QW [8K4)DXP
MQ[2H35$$G?<L9_!9(YCDDA-.B*R:7/5=H:&;+,.S%!T\2>)=Q(PG)]/UR>:E
MW[R^LZ\[ >>ILL)-BM([K&UU:J)$N-JZCX$(7!,G%$[?U7IY"*_J7IJZR3RT
M]*2&T4@'EN@SGM1!K<MO6_&</R0].JGE%4?K]7(:3]<U /Z\^+!1P,21:+1V
M#%#5KN6UGVB,QD L4<3H$O'>Y!KYR92.,_?R68'85GL=P/.&K&((R+/G% R[
M>EE>1\$:0VA1'H56CO;8':-4#\?>'G6@PT_,?%9D'2#X#F#SX7S=C72VK^(9
M%IY=3>"5.I8C<PF>!P\:O64A<XSRCK[C@SS4O$G+N"5YAZCV]HO,@^3< 52N
M]#0]HS]D5A1M&"V\J]V0"P2T"3)]$S%[[>(=4[V'<:FN$C)NSGU D!PDX0X0
M<I3SIL@^S#Z$:7XS?QF^3LFWGX@HDDX$=.2\AA&:UT> '(PO.=1*5&/;M,ZY
MFYYQ4^<#XF4(>7< FX^X#M,YYE_"<EXK)(Y2.CTYW71%>(5EFJ:U.QZ35B@-
M)LM4364 KR6#$)/0Q@1SI3O>D AZG+1QT^$#@FE@+72 J]L.WR2:@$FH#$D%
M33M#1@@V$"^VN!RL=,@;-;J[2<JXV>X!<7.@E#M(&ST6)M04/4,F/ 169X*@
M)/'(J"$Z[YA/P9;2))AZC+"1ALZ/E8X\7#F#@6V<-J?;S,0QKJ>)O)AK/ W8
M\_3Z*L_9 /4!_IZS&ZI5WDFC!' F JA"KK>3=.HQK1.ABLZ]-A=8S]$-]48>
MC"3^?KE9-V\BC@^XW,RKF"3B,V:5P!I5,[1(,B@A [J2K744A*@FZ?(=Z?L.
M^J<^!46/9"L'T5('#MD-MK:348Y.U\>+Y?2_,4]"(E=#8P8NI $5F237LI@Z
MPE%[7QL889/F!X_0]1V\9A\0; =II5>0O5FM3HD5"E$B5R07D4.M@:68.##E
MP/IH:T:%'-?GL&I7:1HW&3$.N/;01A<OL^YDYNIDIRB3\0X1F*@]TS PB+1'
MP/#,A TV"=FDFNHQPL9-4HP#LGWUTI\)>SNE/_)&7=MK!"2/>6*9CBES!L[Z
MFN2CKWQ( 6A7"2<*"<R)9\#:G<2-F]QX;KP=KI\.,'?]@NI>CU-DGW-]A!U$
MC;9E?>Z/7-0&2UPJI>@O36*CW<@;M\*O.>X:Z*@[Y-UR/\G5=#$'#CK79__:
M97"*=E0,9+E+,$':.^;*#8VXO6*"9H6 SXRT@W32*<+.?% =).:2 SAT'BC0
M(294D2!<LDPEXWB;KOGWDS1N5> HR-I#%YVBZJK3Z82@HUX&*,90>!,]!Q=H
MNT24B2ON=.:M^IT_1->XQ7ZCX&M?K70 LBLE(?>>]T%&;IE,P!0G<7E9($9=
MF^2Z[(J1P;?):NQ V\@%@,W1-K1Z^D+<K7-?(S*K"NV69"BFT:IF ;,!CK1U
M8K#9E]857WLY8NWN0)\380>IHT=DG9W[D1F.M8[$,VY!B20A:F7!,6]"\=;*
M-BW\[J%G-T1]O_G^(=30(YJNGO+!,V7KVS:N!/$2123Y. J!@U*F)F9X:A(T
M/D34;KCZ?E/]@RGD^QM&>R';U:*</<&DGPY9H7'/"HVK,W;A:Z#*C#=S(@4O
M%KQ 9,Y>,"\*&%F!XTVA,RX%\#*CEQ&Y=4T2CO?0<WA-XMD'?M[T2A&)!5M<
M!(_U#9R39&Z--$"A+@].IEI)U[34Y//.36N:N5!#:/YV4>+>8A[Q:%LMUW6:
M3CY-:PHE</G[-.'1G]/5I+;1C;(D<"7R.EK04[SJ/:#4&+GF2NI=/"3Z_"L0
MH;_=A,=]!'12;K.',A<#2K8/9&S*(+<<K%XM3L)T/LG(34)&IZFN+4Y]IE/;
M(P(:.EQEB,Z:73K&/ 4>MZD8!R/#*/8V2@Z4<@?^\5LBG<[S7_$DXG+BO94B
M"0-2H:M] AE$%244G9SS]#^-3;I87:-B=(@<JM5;M<G[BK@#?/QM&>;K,]+)
MJS>\[A-M@P"%T8/76=-?I4M>,;2N2=W*%1K&*;)KAXU]Q=L!,B[.6PHC\ U]
MN9I$;[2J1?8\Y#J"K<XV5CF ]!&52"7FW"3%?)N43HHQ]W=%!I)R!SCYB+_C
M_!0O)W;%I#1/B4&.&$ 9KR$*FR'4D:&<MH_(31)Y-PGIQ%W=4[&WWN4=(.6.
M4#+A].'"E ".["HH08=DY(9#4EZZPJ5,;0HYS@D8%Q6'J?$>3#Q)IAU@X:(]
MV=EDZDMI<)[(AAH-P=1)?2%[<*%D$!XECRZ;U'BJP4V*.CEGAK$AP\B] P!]
M)#40 <?DJ[VB/3!;; 8-GW$UB5B\2RE"B;H.9) .0A$)> ZHN&2831,0/4C5
MN&9G(,W?LC]#J:$#3/T-YR2C&?%RE$^F\VF53VTZ?,Z.%M6=*PG(3R]DJ!.)
M+# &@6OO'0O.IB:O?Q^A:UP#U0970ZJB V3=$M(DE*2<UJG.;,CU(4(!'Z6&
M)+VWQ8@B0I.B_5N4C/OLJ UZ#A-W!XT(+AC87HF\7:SHV.>Y6,X\B. (\M9&
MB)YSB"&$&*7**-HZ1I>T=/)4;6"7:$]9]P"7.AUF2SY9S%M;*1KM220%N%::
MI%/G9WL;P.1HH[&N.-GDW'J8K$Z>H@T$HN$TT,%Q]69.GX6K]9:A,V[>+>:+
M\ZWR#HFG(NI@=@Y,2C*I1F(]?3-X4VQTK!C%FEPD[$+<R*[V@&!8--9,!VC;
MB.LJ#]>8F^B(S 95Y\JZ.OTH1@B("3+Y -$XC%FV\90>)&MDI[L=P@;41@?8
M>AVFRTT1]E'^?TY7ZVW5V]_#LM[)K"9<VYBQBLAF\C&%IV->"A(6US%1@(JZ
M-$E$/DC5R YY.V0-IXNG \MO@37'+[6:[7.#F5%_"]-Y]1W?SR^_5XVQQL(4
M.9.@-\],:C&M9^15<)1"D2$F9\.WP-BCE(WK?S7$V; ZZ<"(W6^-)4E)%NG!
M"$MB*K'.""SDP1;,,DFK8V[BV1]V+#9[[]\05,/HH(-8\3+*?4WRVPYB."6F
M+JMZ7V!9+''[>Y_#G[CZ=3I?+*?K;^?.)\GV^J=LNQ_\BNOC!?WD=]P:]]5$
MJ=H9*))W@)&<!>\#.-IY-1U,GD*B'YF&);O/PF,G#2Z&B6)[Q48WVX98/MOV
M+W".95H;IKH20B*Z4YWAS!4'QZ*"5(PNGAMI8I,^LO?0TTG?BR'A>)C,.SB^
M=]L/*0EALE$D&:5 A43Q.G/DDV3G8M99Y-C$3QS.RK5O<M'"R@VACW[B$?)N
MKZ2QM;4N)ZN =HLG&ZO)-2G) ;+"H]6B^BU-W,.K5'32QF(8[.POWP[.L/.&
M[N</TE^$U335F_OI['1=V_"1*$PAM =I* 1G*H*SR@+QE;0FX>C<Y%'W(W1U
MTJ=B&  -J8,.SK:_X_3+,=%]]#MYB%_PW6DM<WY?-JQ=>?5YDTLF25ZU)1J7
M9%>5BF1<N?4@C$K.VFB)Y19(VX_<7GI7#(/ 9U#9]_UN]\I8^^L]9,)=;>?/
MIW]<8WVX)[[[$?.,KX$'D-;P+=T?&D$0<]($6'+D?!U)0:=WU%*"L#K7])^/
M;0IO=J)NX$?%SG.5@JP-_^I%H%>R5KU0M.101!Y"++J)_]?3H^+A4?'($^.G
M"+V#$_R"^K-YF(N3KXMYW=J;QY,LQ9HL52!T[9<;D8&KHUF#U8Q"[HRFS4']
M(%6= &H/==^'G(-EWP&0;O!P]G*.Q5(\Q=+ (VTGQ>O<5%$<>2J"&87:&=$D
M/W8G-9T YW!MWSEY]!#1=X"?*UUCSEY+BL2Y#.C!L(0D$@J(HO4.#/=.DOL;
M;6J"G5N4]#!\]"#MWM^@9P]1=X"5>^8=GK^_9EYKY258$2@ZTD:#0^-!R105
MTD&/H<FA]2!5/<PF'1)#PZF@ SS=''EXQ@4F&5&G!-H547M5:=H5>C.]S&2O
MO-.\24+L;G)ZF%8Z)((&$'H'T'F%<?UF3F'$Z:9G43W*427'/%J(1"Y!OJ;O
MT!I SE"@UFBPR;7W;5(Z>;MXN*=\H)2[P\F[<()G6RB8%'1]7)"LK%UAO8?@
MF80B2TC(2C []>PY$"V7!(WK[!RJZ =QLZ?41T3/669N<B08]T?S7'5Y+>.V
M.)FN5HOEMW>+-9Y;4"694+H64')>*Y)JG5,F"\JLR20Q:8V^<95\9VYRG[5[
M L^^VEX\D^A[@=6]3)TWK>%9E3K>P7A)Q[#4!9RF\%3FN)DC$E"4I\+ID37'
M/;?:P6A(4?<!GP?VQ!E/*=B$M9]%B=6+RZ% "(%D*# $RY.6]HG6Z-$UQ_64
M6\%G6%%WX!)=^(<O9V&U.LO/;XY\Z[G@.0@0U?U7W&OPV3M@QO+,*)+,MDG_
MH'LIZN3%ZX IYX-DW@%XKM)_MK]42(1Q4X?[;;JKZ0B!60W99V=-$-&W0<UM
M4CI)-!^FXYM)P\,$W@-D[KNJ/C]]':8L+0.LCR=580B120FH#/<I)A-2DQ?V
MC] U+I@.5?NMU/-P.N@ 4G?4YJBB8Q E@8F!]IBB/1:*$\"TD3IYB](T&22V
M9X?$]B_L!SRT]I-R!SAY,T]+#"M\A=L_W\QOC []N)C-7B^6?X1EGEAA%(6+
MM+\V&5#F _F)6@.:0MRRS&5HDA%Z"I&=G'![ N)V17@;[72 O$='(@LKA7/:
M@\E&TL8DZ3FN/,04B^*ACJIM4B0TR*CJEK,(&D'BJ2.KGZ*?O?'V%9?31:WK
M6ZY;H.YE6"Z_$3-')XO3>:V@GYU6WCXLEAM]KM?+:3Q=UW/B\^+=8IX6\S61
M-=N\M=R^*R/?53$6=,Q@K)7;8;;!Q @<M=7>&&]UDVJ X5D9-[LU%K*?&P.C
M[X7SU,W-'5Z]W>VDK5>GRRJ![7J;C;]UCU<DD/=7*VL_8:)?74]Q-9&Q<!)!
M 9Y< I68 X]:030Y%<FE"?Y&D/)@.FU0XL;-DC0']O@*[2#GNQOSFSX?C_.N
M#<\JY00BB0A*DP*"K@WZ2DP*$V;/=JFB;T';N,%39UANH,[O!LK;??P._]C\
M:#5A,N9"G(+4TH(*U1]#E< JE$7[8$I4C0SP!1'C=AWH#)R'*&AO%!+ZXZ)1
MB/; 'KSD,G,F29@D5R[K"&':9B1-!I9B8!&)?^V:) GV(7;<K@2CA7*#Z_%[
M2"=PET)13$ VCH,R)H%/Y*+KC?R8M;E-$GV0=$*S%@;]I!.>HI\#0ZA?YKG7
M9(+W(ODZ'X/)H*J(%3C#+21,4BB3+ M-NFV,E$QHUE[A>TXF/ 4#G>R$V^*^
M_:;QFL1U<=%8 9()DKBA_SAK,F 47GB5M7%-7D(\D<Y.RI1;728,IZ,.'( '
MAWM'GY0H@D-(PM4Y>8FVE"/7FWG/;!9H59,'$X=/6W\^ SD@&IXR=_TIJAD]
M=7JY-6_*:A]3/TETMABC'#!6>\UQC^!-E4(4++*,+,M&KYB'(+^WZX)V !Y!
MW=U _;(I\NKSXI['=9M='<.F&\=);8FW0<%')%&MIFL\&UJZ#3,_8EI\F6\^
M91-Q3@RK(TRC!=KP"91S$6)*"J0J7.62A=1- K/6C/5VZ=!N>W0%D0Y<D8<2
M+)N?O?^Z:5KZRY^X3%,229V2Z$D#9 ^R) 9#\=O[PZP2!IZ+\(PU.PB>0FEO
MMP^-;7XS)?:+TIM9:V=23LX$T+H>6@HE1"41C(K:2>:"X$T>C7Z?%P[/CL=#
MU-4O"&_DHH-(A3:5!)%9(<<I%?"A&'".T[%0'V&*)EFQ[_(281R3N)^R^D7@
MSE42.;B M4I":0,J2T6N"<6P08EL+)=!ZR;77<]0$/.,EPXCF<UAU=LOF'<L
MDQ %E<-2V[L2X)24'EQT KQS)4IAE1+/[H4. ^5GO&<8Q_P.J]P.D+Q+3'F%
MT?JV]>_3]?&E'%YC6)\N<>*"CRKP #([!"4"@RB4! Q*^QQBB:Q)7\VA&!BW
MRW1O:83!5?Z=0/UL'-EV]T^$C04CKT^I,Z\WA+K.4,P@M/*<(;,ECH;I:Y2.
MW*&Z-_3NK\4.8'I]Q(!@(6B!""';1,0;!\&1O'B.7M87D>3IMX#@TT<X\!_B
M#FU_Z7< G0<O ,F+CDD("3[7-DHZUSIS8RE>+ RQ&!]YDTNPP^]F?XB[K<%T
MTTDIRD!W=58Q$=!$8 $U^1 YU.9>%IA4R:,FG[G->,QGO)KE/\3ETPCZ'A3I
MXXR2"*OCU[/%'ZOK+ TX'N)B@><<^7 W5\./<;A8Z*)/?RV2+H;P8DJ@$)LL
M(SCA%(CBG--<$Y[:-E>X@Z@!'+[ZF1^6B]^G)+X7WWXCV;^9OS\?-WJ4UM/?
M-\F%"S$DP;0,7$)FNI!?ZSP$"L(@B>CJV%%=V@RN?CJIG?0).!1+=[B)+776
M@2]YW1$NW&=K*89"5<=2N40N<:G]P9,J(M;U>YDDUPQ+K57^8"#R%/GW 9X=
M9777D-D+^4D>E*]!>\FE5FB73<UB(&<AYY2TJ8[QN&;N(?+'K=M[?K@^M\8[
MP/DKI)73=,,$?3W#C7;G^>BDNL3_O?G^A+N<?8X&A*MM'[5'<%Y;D*8X[7CR
M"5,+%.]"W/=B4H<#S:T&T0-KL -47J7]?7D]G8=Y(LF]7*S6J\U$OU6JKV96
M$V-3HDU?B\!-S8R:0H(S"I*+=<L[94N;DM ="?Q>+&@S=#;19 <(/1]]>KU*
M=5)$$D;Y"$YNTJU<0%0"(89HO4DR!='DO+^;G'$+BSM WP!:ZJ#+0TU$D2 O
M!/>V9LK.)LI/C-$6"[,0A8QU@K.%P&.&7')DF0=C[%-ZFS^TUK@EO2/":7!%
M=&# 7N%R^CMQ\3O^+4SG-41[/[_\'@F;=@D&HCJ"5K1!5"F;QZX<1%*!29^<
M<$V>PCU*V;BEO!V8M6%U]W0P^BT8Y_BE)E8_#X;)UV&ZW!0I75Z1OR]G5^&K
MB47-"G>&;+73H% :\#%X4#$;:P-S6C:I97B0JG%K>CO XG ZZ\ H7N:K7I.L
MMY=$O^+Z>$%"_1W/BC8FS!(W=3J*(8<!5.;$GK6%+'UT4A=I]<W^28.]27^<
MNG$+=CL Y/ Z[,= 7IK[3V&&[PO)F82W_O9A%K9#6;]6[B9!&>0R65#"UWN!
M&*KX--A$<15'J5V;*^G=R!NW#K<#A#;08C\0O7VC?R':L]JV*]E:[KG.##@F
M"2JD0KXS[<$B)<F3A922:V1'=R1QW)+:#J#:2)M]'/4W.#M*VU341TQ(KG1M
M^2^+5$(K)/>%)3HEM ;G69U)1&+33DB#35S.78CKK2O(,,!X%'\':JEG0_GJ
M%*O+\A%G=:4/8;EYCL$=9D41')08,SG.%,4YI6/M]&2\"ZQ8;%(_NR-]O?7V
M>"88'JZK0Y'8"(0?EO@U3/.K,XK.LEM'\_Q^?8S+H]4*R7OF,@=N4(%,=<>9
M&N 9VG&9I1*\82JT>5:P'[F]]==X)H@.KLF>;>>&IYJ?/5U6I9QQ%YC0V@H.
MWGK:C\DR\,D*\-X'I;6QC0*A'>GKK4?&,P'S<%WUC,1S!^5#^+;Q3I*(R17-
MP)7:'9_5PJ?,-&3G.=?*&RF:S/1[E++>.F(\LP.YCWYZC5N6IT3'-,3I;%L/
M=6;C+R^J+G\V08/.R$0,9I*A8AEIBS$$ZU+)04:F^#/9Q*<1WEOWC.>#:ROM
M=H#FZU>IM"6WV=D@BO1,D>.,G$0HG">OA#.P.4D=LM<A-,D,W4U.;STPFB!O
M $V,?RJ?7]3?E%G-CU4);5Z!GZ[6BQ-<GN^:;R^W;LA$Q<!M$!&082#I*4,'
M0:8C04M?'[$I;6X$V@]64NQ#0V\M*@9%VK,IIX.2G2?Q2*[P.9NHF9"..,S;
M!AS1@W/6@=.TV=!QGZ-KA<%+,GKK)#$^#/=440<G[*/AUU7OP2,WICXH(B#5
M%LN*0^2Q@#29?(K,E5"M;K9W)K*[3A'C1,W[JJT#2.Y^KS71/ ;!I2=C[WVM
MU P0=+8@K9=UB+?TLLG(S-U)_%YJ;)_YC<R3-+<_)A>TWUIB<ELR<K<@:9L%
MDJ4!GY0BUU@6\ XM,.,3<J9S2,_YA/4!4CN93O%,3UB'TED'EO(\#/N\.$K_
M=3I=XK52D:-YOJP684Z6@+3!7 D<5#3DD>1$^,DQ%9&D\+[)N_+=2>SRI=9@
M8%D\B^;&#[&?+L^)9EPDKBR(VFZ88C<-(:@$&()E4@8M69,,^.XD=OE,JQ4T
M&VFNWT/\XM79'8(TQ![Y/>0(Q4 ^N@T)7,J2]B(711'K23[G ^T'2!W7T7SN
M0WPHG?5PB"\7"3%ORI%K0S_BB\(Y8BG,/IS&V32]+T17;:*55/8<BP&I,=)V
MXR1'^@X(C,($6X*U3<+OG2GL\@@?#"HWC_ F>NL@.7GNF[PO%XV"*V^;-[EW
M,UARIB,F)> Q&E"R/L[5@0'/11+GJ;B;SZP?3$L^F8 NS^>A<?<\ZAG?@]R%
MSZ,8YGDQ)S%_>'^TII/G*_D\N79_0P$D/CIE@B>9!E& I\"BC"AN6<>]07C'
M\EWF><: X*&J&1^ =QGX&^VB)]ID[TE>X"CZ I6+ Q^C R-5M#XP7T*3JML'
M:.KR^?5S'+Z'Z*:KX[92?VTOW>2L>.:4H "+N4R&7!D+P8<((E.PQ:3)0NB]
M3-QC*W?YI+J]=1M4(5T4=-_EM)(5K],=,&]8DL'D@+1=;*PC\H) </7EHW)2
M,7)=(P]-6N8\2EF73ZF?,[C87T]]6[FK7'&60C)2@[?UA801%J*R&;PTD?,<
MK4M^& OW5&0]]YOH$:S;OHKHSK)].EXLU^0(GFR-M$XU^T0[Q=?.*\I;\,D[
M*";F[ S%0*E)?OE>BKI\X?P<EFQ_O720I_N(7R_#GJN&F GDU=-T6-U-46]J
M<M3 :V&M$L*RV&2NY3WT=/DFN16XAM#)^ 'GN6F^AYLJO-F+,)LM%O,SZSV1
M=8O(**!X3J<_.DX1-3>UGX\)Q83*_Q/.R=U7'KF\ZID/RT8:&1]R=UKG.X<1
M5Z<R4I@#N3*G0A#@G&/$%T8F F.J_:7#_A.DV\WL&?,8/5A1'1RG=T<X5P+L
M#^>$;=B=..\$1AD@<\-H?WD.T7M?@QZM.4,369-RJB?2.?+ GR["U&&4V%70
M>CO/?3^31F8K X5.V13R:Y,@)C6="=%*9QFWUCO[A+-Y+R)&GMO3T7W$,'KJ
MY\3>7;036S+]GQ(@PJ8\QUD(FFMPDEF1A%"2-^G0N3N)N\'T1[FT:*2Z#BJK
M*EOU_VO5XN]AAIL&/"2Q:2+LUQ\<S?/U;USYS>WTX=LO&LZ&;_WR9SH.\R_X
MD?;1+Z5@;5DEF/$LD8.C'6FBL%R[\PE(P4EM2$0\-IF5_KQLCGNAUZRBJV.L
M?.\[::)S+MQ;!=&(.D7'(L4 7$)@.KE<E-&QR7N8@Z@>]W*Q3YP_29,'CA$D
M"2S7'8#7,5M;;030% B RIX1\XJ8-]RAX#XKW:2FHCUXF]U*=@K>IVBREVFO
MIU^_SC:B#+-S4;Z9E\7R9*O,"Z$FHC%( T'5XR2C L<UJY=CI>B<C!5-KL=W
MI&_<J\QF<&RAG0YR8.=#8^ML]]J6'TNF\"'7W@5U2K*OSR.])E\E84J.)>US
MDZND&W2,/-*RA:YO/9_>7_!=X*;V,/\<_L35.0=*6<1@R-J*PFMFC4$(*"!P
MQTH4,EC6)-:_3<K(KTF?!3T'B;\# )U+YFQBS>7;KGF^(QM1IW#-%JO3)5ZF
M0:*Q3GH%247:,%ER<,EJ<"H[;9/@VC4+- XA?-S2BZ;NVK/ILP?\;I*ZJ\W0
MN$TR]^BD-NT[R_5BYA,A#2^UN"3BICM^TN #*R LA4[*6I]8DQ9ACU(V[N'Z
MO$"YB=)!M=8!#&LMP"53%WR\F9.P3NL^WS+()]DK%Y4JH+.*H'1*=#R$ K'>
MAUGA/+(FSTAW)7#<,WM44#;180=WEYOJS@LF?IN'[:1-O)BI^0+G6*9I2G[2
M!?NO,:Q)L!^Q_CW,WI<'?JFFJ&0*AH..R$!%\IQ]*@@\DU\5)$M%WJBK?/">
MLSG!XS[1&@7D?8*A \O]<?KEF+RPWU:X:2_]/J[#M+Y9FY_?(+Q>+*^WO+SH
M]3:1WME<%9%YK;>WA8%W.=8V;T45[E3@32JB#J!YW*ND4>W[<VFZ Y-_T0+N
M/B&_H>AC=3D)\DJ/N#?;OG%Y0D&L#UDJ*%A(U)N^,UIX,*F0-Z:PEC@^P:@/
M0-*XUT.CFNWG5F@'AOGZ0/!Z;IT?41^6>#(]/9F(5#L?*0:2#ASRPPJ'D'P"
M[@Q/6FLA=9/+_T<I&_<J:%0C.ZS6QB^VNC+1>7.WM5J'.)NNCK>YF[N'1DZ*
MEX&.B!H;U*&Z1A=PY/= DE&K$DV4X2FO<Y^R]KC7/J/:R&8JZ@>%=_7YV%KW
M%Z?K=XOU?^+F(F.2'09-$H.(Y(BK(@5X1;%J[;*0E; RX%,"LAV7'3>E.BKV
M6BBF S_R(Z996*VF%.N=6?2S@<U7_(O/B^T6FRBG<V("P1:+Y%^0=??<<6"U
M@%$SQ;)_"NB>LO:X3]U&15XS%74 O]V\WMO\7KB\Y%QD9*66Y]:'I0(%67F?
M023):;_9X'4</(:YGYZ1G\Q]!Q',0+KL +N/)MINL/IM@CX5$3T#HU-U21))
ME[X!.3*K.,\ZW>PD=%@6]28!(S^CZSLM>I"VQG<@+X6\F3RP&?&8IS5?>X^C
M8F2*OM@ZFU1I4*H^.ZCNLE$E9UF4<SZUN=;?C<"17]>->WO:0HE#8_2??[ZE
MF;?TC<V/-C^I__@CEI_JG[]]?'.QS-F6_"OM05Q]#0G_FA8GVZ7>?_S;T;LW
M__OH\YOW[X[>O?KTVZ^_'GW\S_>O/[WYV[LWK]^\/'KW^>CER_>_O?O\YMW?
M/KQ_^^;EFU\^76=P-3WY.L,=S.A^:_U\R=]-SL^6O ;#MKSBGVL""+D=!XY>
M6WX)\[.4SLO%?+683?-VI\WSARM,OB]GT ^SB_*6RZ(6)QEG0040/-<'GTZ"
M+TQ#<11RFV+)^VPR37 0Z@^>7G<($5>LQSQ_FGZ9;WS]^?IL/B59F@_T>:GZ
M^:3Q%[/-B\9HH@T%P87 :D<57JO0%"#:S%&@=VTJZ)^;T7%K:)Y_9]P:QM<S
ML ;SPKLY2\[E\9QGRL6:(Y\M=_/>U1FCD&M6&U\P"@9!244AHC06.'IIC S*
MVB:C3;HX8UZ$U73UOMS8O-^V_[W<P-8%X;)A8*U"4)K$$[/.)+*(1D14Q3<Y
MAW<C[T>PYT]!X4U[WD")'>1"WD[_ZW1*D<HM/A)ZS3?#;+2B_P1KP$LG0)82
M8Z+@)8NR@UU];)UQBQK'0]6@\N^@)."W%;XOOU"@?4+B64T0=>&*G(^H>&V-
M$ JXB!R$19]L5"D8T<*472=CW&+"\4W6 4KI %*OPW3Y[V%VBE<$=)D(7&TW
MS"2D%#+G=49A[5;DI(4@L$"TW"2FR?::)H5^.U$W;DG?^  <7H4=X/+L9?7-
MIA<W[#<Z#*PH![8.%E:"3'>P#NMD&8LF<HH>FUC G:@;MUQO?%P.K\(><+F8
M)ZSSKZOL/DY7_WA)-$S7]:L)ALA%= ZB,\2*4K6R*S("C^9!9!,RDTW0>#]-
MXU;B=8#!@=35 ?(V)3;'BQFI;+4M9[BYE0(F83A#0,<-J%1\;? CH7!3VU (
M^F&;C@R/439N4=[X*!Q6=1U@\=X9K;<"=7*&12P2R,-0=>"Z)V_8)&#D#;,@
MF8^RR6/\70D<MV1O?&0V460' 'US\I6\XDT%[/+5=/5UL7FV]78Q__)V^COF
MS0.86ZZ(\-GPX Q8GR0=")I<$=J*0(X(\UK;(DR3E]+[$#MNQ=_XP&VNX Y
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MMPY@N.'A15B1H[LXJ09\*[ZO9S)]LRGZF/Z.]5KS/ '*E' ^T"8K+)-MKSW
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M![[ %4?[G /:_XZ9),$QU*"DSN"%W#2H"KHH-$ZUB4EOD?(CN)Z'(.Q Y70
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MZ[]N1$!*+Q2+%CPCTZN(L3HO"4$7:1D7//.[9?M/KK;:_:66@+&O)G<LM!I
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M!I/M<5+...$598O*U-T1,D' XBB'\"EN:O+%*%W1]TF9UI\=IMI'<+*'G!M
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M9U_/YC\MV&$\IN)CA&3K&CS')*#6%H(2KE@3A;(CU6GLI*<;H$[B96!(R3<
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MN<Y439>0'Z[XQ=A::, -OMOH B_>S%?KV?IRG5=GY3\R7JR_; TQ]X%3EBA
MV_H\:[4!KV,=%XH*)>-,BSY7-T]];SJ\C*3BQ8CR;@ _SQ?DS>>_S\E\+U>S
M]?<7BZ^!6)Q_?C9?S\)L03'B!PH9Z^K=]7,RZ'DYPV>435[D9?W)-[&C\K8(
M"BJLH&/II*Y[-B(P&8IW3.;(^X!L$**FNQ0Z#A*/K[D&X/JR!ISK*M&S4LOJ
MYJO\8C$G*:]6FV-9 ]'E9O#K;SG5Z[+KP2SOEXO/2_RZY=K%[$6@F#1GOVD7
M4^"EH7_%$H5Q*1;=IQ)\&*JFNYDZ#F GT%T##_X#!-!O;]H<$:/A/&F"(:LY
M>B+>C2N0"GTX*=*)&*7C;$@F)IYQW49F,SDZ&C@9VW+HU;F3OCY_%= E%/)!
MA8,SA6Q,+*((%5*ZN[M^T)K]B0MWIX/ O1EF>^CC%)MRML5D.$^W9$_*OO9]
M!^ZS/O2KH[?N[,?_)$V,J634D@-CY.$51PM!U"FX/$G%C:LS\T:T#"?;S:,8
MQ>U10@A.@3+T2VW= \&M3.BB#6:<%:M_Y6Z>/E@]1C=/#PRT5_TH/ OD;308
M66.J^E 9*+N@M$,$CLB%4%T6V(]9_7A2G3Q]P/!X]6,?S31;_6A,=I0Y>N Q
M2U EU:I@F4 &A46F(GPGO_(+53_V4FNGZL<^,F[@9NFQ.AJ=!5?2.BC,DFD7
M*8-7+H#4+$@75&%W]^.,6IUTY/K'7HKL49W41ZH- &1G50WCRNH28YWMPD%%
ME@%%-.!BU+5]5RO6Z^)[W^JD(Q<W'@*)@^78 !8>JZ.14GL3N($D"H(BRL$3
MHB&J@B6(Y+/NT_=W:'72D4L9#T'&4%)M " =*W@-"UX&K4"J* CVG"*T:"48
M50*33*64L0=6!JR6/G*YXR&P&4'6#2#HD<Z!F"W&X NX5(?F."/)<2H.6HOH
M35(QI3XSUP[LQCAR^>,A2!E(I@V@XT6^^)SG-YLELI7&.096*T<R,0D<LPRX
M\JGDX+3-?6JD?_KA+=8P'N1D]I;<Q-GLCVN!5_]S.5M__RVOORS2F_D?>;5Y
M5+W_NSG?U$TQZ6I$S0&=M*",+1!X?;*2/"D>E RARU3E3@GO(83^>GVG>]Z\
M'$W;$Z/Z(3ZNZPU,L"ZBA<1J=S_9:"#3+"%9'I61VB3L,LZK$VX?)V6ZS/QX
M4%B,HI<&W.5CUQ#>1)<L9LC6T E%RBQ<U@:81)ZY=O45_]0O=X;49H\;GCZB
M;: @H2YV."NWS/G5"3(,LU86G*?D00DEKN8;"1N*]%9B$:-,%-Q)S:_7%K"'
M?QQ.7PV [K[P<+>\;A(5-$$@0BZV;O5*E+(@,U R]Y9I%YD>9Y% /SJG?4(;
M !EWEP2,J*8&'.3UW*WK$I W];D;+[:5EZMGE^0YEK-_W[1W!>%D2=I1!H:,
M/$8TX$M!D-J)X"P+!OLXS9Z?GWAKU9A0>& >VAAZ.278;7_G["9Q1Y.ECCH
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M3&IK1;'EB!6L;WN-0QAM16@S=:O[*:H!BW6;GU?_<SE;?W]3GYSS:OUF?MT
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M.DE5O) JEAT!]VC183.RPV)L-PF,%%8/? )2&YS6J6Z3K*7/7B@(Y&B"DKQ
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MC!XI=-Z?SQ>7JVW=*$2Q(2B;0)?JMB%;5DXBU'F#ME93F^1VA,_C58>)R0>
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M:70Q,#$Q+69I<G-T86UE;F0N:'1M4$L! A0#%     @ *8%M46:C2#RV!P
MI"0   X              ( !P"4  &5X:&EB:70S,3$N:'1M4$L! A0#%
M  @ *8%M4<WKA8^Y!P  KB0   X              ( !HBT  &5X:&EB:70S
M,3(N:'1M4$L! A0#%     @ *8%M44Y1:Y(H!0  =1,   X
M ( !AS4  &5X:&EB:70S,C$N:'1M4$L! A0#%     @ *8%M4> K/?8N!0
M<A,   X              ( !VSH  &5X:&EB:70S,C(N:'1M4$L! A0#%
M  @ *8%M4=<XL<3O> , AOD> !0              ( !-4   &EN:&EB<G@M
M,C R,# Y,S N:'1M4$L! A0#%     @ *8%M45CQT.! %0  &>8  !0
M         ( !5KD# &EN:&EB<G@M,C R,# Y,S N>'-D4$L! A0#%     @
M*8%M46S[1^L.(   ,%(! !@              ( !R,X# &EN:&EB<G@M,C R
M,# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( "F!;5'01I?""'H  !%*!0 8
M          "  0SO P!I;FAI8G)X+3(P,C P.3,P7V1E9BYX;6Q02P$"% ,4
M    "  I@6U1+A:D)=KX  #=;0H &               @ %*:00 :6YH:6)R
M>"TR,#(P,#DS,%]L86(N>&UL4$L! A0#%     @ *8%M4=NV$[[+K@  W/@'
M !@              ( !6F(% &EN:&EB<G@M,C R,# Y,S!?<')E+GAM;%!+
4!08     "P + -0"  !;$08    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
